1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	5	amod
4	drug2	drug2	NN	_	5	compound
5	administration	administration	NN	_	6	nsubj
6	decreased	decrease	VBD	_	1	dep
7	the	the	DT	_	9	det
8	mean	mean	NN	_	9	compound
9	AUC	auc	NN	_	6	dobj
10	of	of	IN	_	12	case
11	total	total	JJ	_	12	amod
12	drug3	drug3	NN	_	9	nmod
13	approximately	approximately	RB	_	14	advmod
14	55	55	CD	_	15	nummod
15	%	%	NN	_	6	nmod:npmod
16	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	incremental	incremental	JJ	_	4	amod
3	LDL-C	ldl-c	NN	_	4	compound
4	reduction	reduction	NN	_	13	nsubjpass
5	due	due	JJ	_	4	amod
6	to	to	TO	_	7	mark
7	adding	add	VBG	_	5	advcl
8	drug1	drug1	NN	_	7	dobj
9	to	to	TO	_	10	case
10	drug2	drug2	NN	_	7	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	reduced	reduce	VBN	_	0	ROOT
14	by	by	IN	_	16	case
15	this	this	DT	_	16	det
16	interaction	interaction	NN	_	13	nmod
17	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	safety	safety	NN	_	15	nsubjpass
5	and	and	CC	_	4	cc
6	effectiveness	effectiveness	NN	_	4	conj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	administered	administer	VBN	_	8	acl
10	with	with	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	established	establish	VBN	_	1	appos
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	cholesterol	cholesterol	NN	_	5	compound
5	excretion	excretion	NN	_	3	dobj
6	into	into	IN	_	8	case
7	the	the	DT	_	8	det
8	bile	bile	NN	_	3	nmod
9	,	,	,	_	3	punct
10	leading	lead	VBG	_	3	advcl
11	to	to	TO	_	12	case
12	cholelithiasis	cholelithiasis	NN	_	10	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	preclinical	preclinical	JJ	_	4	amod
4	study	study	NN	_	9	nmod
5	in	in	IN	_	6	case
6	dogs	dog	NNS	_	4	nmod
7	,	,	,	_	9	punct
8	drug1	drug1	NN	_	9	nsubj
9	increased	increase	VBD	_	0	ROOT
10	cholesterol	cholesterol	NN	_	9	dobj
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	gallbladder	gallbladder	NN	_	14	compound
14	bile	bile	NN	_	9	nmod
15	.	.	.	_	9	punct

1	Co-administration	co-administration	NN	_	8	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	recommended	recommend	VBN	_	14	csubjpass
9	until	until	IN	_	10	case
10	use	use	NN	_	8	nmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	is	be	VBZ	_	14	auxpass
14	studied	study	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	11	nmod
7	,	,	,	_	11	punct
8	concomitant	concomitant	JJ	_	10	amod
9	drug2	drug2	NN	_	10	compound
10	administration	administration	NN	_	11	nsubj
11	increased	increase	VBD	_	1	dep
12	total	total	JJ	_	14	amod
13	drug3	drug3	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	approximately	approximately	RB	_	16	advmod
16	1.5-fold	1.5-fold	RB	_	11	advmod
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	11	nmod
7	,	,	,	_	11	punct
8	concomitant	concomitant	JJ	_	10	amod
9	drug2	drug2	NN	_	10	compound
10	administration	administration	NN	_	11	nsubj
11	increased	increase	VBD	_	1	dep
12	total	total	JJ	_	14	amod
13	drug3	drug3	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	approximately	approximately	RB	_	16	advmod
16	1.7-fold	1.7-fold	RB	_	11	advmod
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	No	no	DT	_	7	neg
4	clinically	clinically	RB	_	5	advmod
5	significant	significant	JJ	_	7	amod
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	interactions	interaction	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	seen	see	VBN	_	1	appos
10	when	when	WRB	_	13	advmod
11	drug2	drug2	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	co-administered	co-administer	VBN	_	9	advcl
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	,	,	,	_	15	punct
17	drug4	drug4	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug5	drug5	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug6	drug6	NN	_	15	conj
22	,	,	,	_	15	punct
23	or	or	CC	_	15	cc
24	drug7	drug7	NN	_	15	conj
25	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	6	det
4	total	total	JJ	_	6	amod
5	drug2	drug2	NN	_	6	compound
6	level	level	NN	_	7	nsubj
7	increased	increase	VBD	_	1	appos
8	12-fold	12-fold	RB	_	7	advmod
9	in	in	IN	_	13	case
10	one	one	CD	_	13	nummod
11	renal	renal	JJ	_	13	amod
12	transplant	transplant	NN	_	13	compound
13	patient	patient	NN	_	7	nmod
14	receiving	receive	VBG	_	13	acl
15	multiple	multiple	JJ	_	16	amod
16	medications	medication	NNS	_	14	dobj
17	,	,	,	_	16	punct
18	including	include	VBG	_	19	case
19	drug3	drug3	NN	_	16	nmod
20	.	.	.	_	1	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	who	who	WP	_	3	nsubj
3	take	take	VBP	_	1	acl:relcl
4	both	both	DT	_	5	cc:preconj
5	drug1	drug1	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	should	should	MD	_	11	aux
9	be	be	VB	_	11	auxpass
10	carefully	carefully	RB	_	11	advmod
11	monitored	monitor	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Carcinogenesis	carcinogenesis	NN	_	16	nsubjpass
2	,	,	,	_	1	punct
3	Mutagenesis	mutagenesis	NN	_	1	conj
4	,	,	,	_	1	punct
5	Impairment	impairment	NN	_	1	appos
6	of	of	IN	_	12	case
7	Fertility	fertility	NN	_	12	compound
8	A	a	NN	_	12	compound
9	104-week	104-week	JJ	_	12	amod
10	dietary	dietary	JJ	_	12	amod
11	carcinogenicity	carcinogenicity	NN	_	12	compound
12	study	study	NN	_	5	nmod
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	5	nmod
15	was	be	VBD	_	16	auxpass
16	conducted	conduct	VBN	_	0	ROOT
17	in	in	IN	_	18	case
18	rats	rat	NNS	_	16	nmod
19	at	at	IN	_	20	case
20	doses	dose	NNS	_	18	nmod
21	up	up	RB	_	23	advmod
22	to	to	TO	_	23	dep
23	1500	1500	CD	_	24	nummod
24	mg/kg/day	mg/kg/day	NN	_	20	dep
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	males	male	NNS	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	and	and	CC	_	20	cc
29	500	500	CD	_	30	nummod
30	mg/kg/day	mg/kg/day	NN	_	20	conj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	females	female	NNS	_	30	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	-LRB-	-lrb-	-LRB-	_	40	punct
35	~	~	RB	_	37	advmod
36	20	20	CD	_	37	compound
37	times	time	NNS	_	40	nummod
38	the	the	DT	_	40	det
39	human	human	JJ	_	40	amod
40	exposure	exposure	NN	_	18	appos
41	at	at	IN	_	43	case
42	10	10	CD	_	43	nummod
43	mg	mg	NN	_	40	nmod
44	daily	daily	JJ	_	40	amod
45	based	base	VBN	_	47	case
46	on	on	IN	_	47	case
47	AUC0-24hr	auc0-24hr	NN	_	44	advcl
48	for	for	IN	_	50	case
49	total	total	JJ	_	50	amod
50	drug2	drug2	NN	_	47	nmod
51	-RRB-	-rrb-	-RRB-	_	40	punct
52	.	.	.	_	16	punct

1	A	a	DT	_	5	det
2	104-week	104-week	JJ	_	5	amod
3	dietary	dietary	JJ	_	5	amod
4	carcinogenicity	carcinogenicity	NN	_	5	compound
5	study	study	NN	_	10	nsubjpass
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	was	be	VBD	_	10	auxpass
9	also	also	RB	_	10	advmod
10	conducted	conduct	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	mice	mouse	NNS	_	10	nmod
13	at	at	IN	_	14	case
14	doses	dose	NNS	_	10	nmod
15	up	up	RB	_	17	advmod
16	to	to	TO	_	17	dep
17	500	500	CD	_	18	nummod
18	mg/kg/day	mg/kg/day	NN	_	14	dep
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	>	>	JJR	_	22	dep
21	150	150	CD	_	22	compound
22	times	time	NNS	_	18	dep
23	the	the	DT	_	25	det
24	human	human	JJ	_	25	amod
25	exposure	exposure	NN	_	22	dep
26	at	at	IN	_	28	case
27	10	10	CD	_	28	nummod
28	mg	mg	NN	_	25	nmod
29	daily	daily	JJ	_	25	amod
30	based	base	VBN	_	32	case
31	on	on	IN	_	32	case
32	AUC0-24hr	auc0-24hr	NN	_	29	advcl
33	for	for	IN	_	35	case
34	total	total	JJ	_	35	amod
35	drug2	drug2	NN	_	32	nmod
36	-RRB-	-rrb-	-RRB-	_	22	punct
37	.	.	.	_	10	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	6	neg
4	statistically	statistically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	increases	increase	NNS	_	2	nsubj
7	in	in	IN	_	9	case
8	tumor	tumor	NN	_	9	compound
9	incidences	incidence	NNS	_	6	nmod
10	in	in	IN	_	12	case
11	drug-treated	drug-treated	JJ	_	12	amod
12	rats	rat	NNS	_	9	nmod
13	or	or	CC	_	12	cc
14	mice	mouse	NNS	_	12	conj
15	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	evidence	evidence	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	mutagenicity	mutagenicity	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	6	advmod
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	microbial	microbial	JJ	_	12	amod
12	mutagenicity	mutagenicity	NN	_	6	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	Ames	Ames	NNP	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	test	test	NN	_	12	amod
17	with	with	IN	_	19	case
18	Salmonella	salmonella	FW	_	19	compound
19	typhimurium	typhimurium	FW	_	16	nmod
20	and	and	CC	_	19	cc
21	Escherichia	escherichia	FW	_	22	compound
22	coli	coli	FW	_	19	conj
23	with	with	IN	_	27	nmod
24	or	or	CC	_	23	cc
25	without	without	IN	_	23	conj
26	metabolic	metabolic	JJ	_	27	amod
27	activation	activation	NN	_	16	nmod
28	.	.	.	_	6	punct

1	No	no	DT	_	2	neg
2	evidence	evidence	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	clastogenicity	clastogenicity	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	6	advmod
9	in	in	IN	_	13	case
10	a	a	DT	_	13	det
11	chromosomal	chromosomal	JJ	_	13	amod
12	aberration	aberration	NN	_	13	compound
13	assay	assay	NN	_	6	nmod
14	in	in	IN	_	18	case
15	human	human	JJ	_	18	amod
16	peripheral	peripheral	JJ	_	18	amod
17	blood	blood	NN	_	18	compound
18	lymphocytes	lymphocyte	NNS	_	13	nmod
19	with	with	IN	_	23	nmod
20	or	or	CC	_	19	cc
21	without	without	IN	_	19	conj
22	metabolic	metabolic	JJ	_	23	amod
23	activation	activation	NN	_	18	nmod
24	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	5	nmod
3	,	,	,	_	5	punct
4	there	there	EX	_	5	expl
5	was	be	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	evidence	evidence	NN	_	5	nsubj
8	of	of	IN	_	9	case
9	genotoxicity	genotoxicity	NN	_	7	nmod
10	in	in	IN	_	16	case
11	the	the	DT	_	16	det
12	in	in	FW	_	16	amod
13	vivo	vivo	FW	_	12	dep
14	mouse	mouse	NN	_	16	compound
15	micronucleus	micronucleus	NN	_	16	compound
16	test	test	NN	_	7	nmod
17	.	.	.	_	5	punct

1	In	in	IN	_	7	case
2	oral	oral	JJ	_	7	amod
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	gavage	gavage	NN	_	2	dep
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	fertility	fertility	NN	_	7	compound
7	studies	study	NNS	_	15	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	conducted	conduct	VBN	_	9	acl
11	in	in	IN	_	12	case
12	rats	rat	NNS	_	10	nmod
13	,	,	,	_	15	punct
14	there	there	EX	_	15	expl
15	was	be	VBD	_	0	ROOT
16	no	no	DT	_	17	neg
17	evidence	evidence	NN	_	15	nsubj
18	of	of	IN	_	20	case
19	reproductive	reproductive	JJ	_	20	amod
20	toxicity	toxicity	NN	_	17	nmod
21	at	at	IN	_	22	case
22	doses	dose	NNS	_	20	nmod
23	up	up	RB	_	25	advmod
24	to	to	TO	_	25	dep
25	1000	1000	CD	_	26	nummod
26	mg/kg/day	mg/kg/day	NN	_	22	dep
27	in	in	IN	_	31	case
28	male	male	JJ	_	31	amod
29	or	or	CC	_	28	cc
30	female	female	JJ	_	28	conj
31	rats	rat	NNS	_	26	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	~	~	NN	_	31	dep
34	7	7	CD	_	35	compound
35	times	time	NNS	_	38	nummod
36	the	the	DT	_	38	det
37	human	human	JJ	_	38	amod
38	exposure	exposure	NN	_	33	dep
39	at	at	IN	_	41	case
40	10	10	CD	_	41	nummod
41	mg	mg	NN	_	38	nmod
42	daily	daily	JJ	_	41	advmod
43	based	base	VBN	_	45	case
44	on	on	IN	_	45	case
45	AUC0-24hr	auc0-24hr	NN	_	38	nmod
46	for	for	IN	_	48	case
47	total	total	JJ	_	48	amod
48	drug2	drug2	NN	_	45	nmod
49	-RRB-	-rrb-	-RRB-	_	33	punct
50	.	.	.	_	15	punct

1	Pregnancy	Pregnancy	NNP	_	3	compound
2	Pregnancy	Pregnancy	NNP	_	3	compound
3	Category	Category	NNP	_	0	ROOT
4	:	:	:	_	3	punct
5	C	c	NN	_	3	dep
6	There	there	EX	_	7	expl
7	are	be	VBP	_	5	acl:relcl
8	no	no	DT	_	12	neg
9	adequate	adequate	JJ	_	12	amod
10	and	and	CC	_	9	cc
11	well-controlled	well-controlled	JJ	_	9	conj
12	studies	study	NNS	_	7	nsubj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	in	in	IN	_	17	case
16	pregnant	pregnant	JJ	_	17	amod
17	women	woman	NNS	_	12	nmod
18	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	during	during	IN	_	6	case
6	pregnancy	pregnancy	NN	_	4	nmod
7	only	only	RB	_	12	advmod
8	if	if	IN	_	12	mark
9	the	the	DT	_	11	det
10	potential	potential	JJ	_	11	amod
11	benefit	benefit	NN	_	12	nsubj
12	justifies	justify	VBZ	_	4	advcl
13	the	the	DT	_	14	det
14	risk	risk	NN	_	12	dobj
15	to	to	TO	_	17	case
16	the	the	DT	_	17	det
17	fetus	fetus	NN	_	12	nmod
18	.	.	.	_	4	punct

1	In	in	IN	_	8	case
2	oral	oral	JJ	_	8	amod
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	gavage	gavage	NN	_	2	dep
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	embryo-fetal	embryo-fetal	JJ	_	8	amod
7	development	development	NN	_	8	compound
8	studies	study	NNS	_	20	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	conducted	conduct	VBN	_	10	acl
12	in	in	IN	_	13	case
13	rats	rat	NNS	_	11	nmod
14	and	and	CC	_	13	cc
15	rabbits	rabbit	NNS	_	13	conj
16	during	during	IN	_	17	case
17	organogenesis	organogenesis	NN	_	11	nmod
18	,	,	,	_	20	punct
19	there	there	EX	_	20	expl
20	was	be	VBD	_	0	ROOT
21	no	no	DT	_	22	neg
22	evidence	evidence	NN	_	20	nsubj
23	of	of	IN	_	25	case
24	embryolethal	embryolethal	JJ	_	25	amod
25	effects	effect	NNS	_	22	nmod
26	at	at	IN	_	28	case
27	the	the	DT	_	28	det
28	doses	dose	NNS	_	25	nmod
29	tested	test	VBN	_	28	acl
30	-LRB-	-lrb-	-LRB-	_	36	punct
31	250	250	CD	_	36	nummod
32	,	,	,	_	36	punct
33	500	500	CD	_	36	nummod
34	,	,	,	_	36	punct
35	1000	1000	CD	_	36	nummod
36	mg/kg/day	mg/kg/day	NN	_	28	appos
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	.	.	.	_	20	punct

1	In	in	IN	_	2	case
2	rats	rat	NNS	_	27	nmod
3	,	,	,	_	27	punct
4	increased	increase	VBD	_	5	amod
5	incidences	incidence	NNS	_	27	nsubjpass
6	of	of	IN	_	10	case
7	common	common	JJ	_	10	amod
8	fetal	fetal	JJ	_	10	amod
9	skeletal	skeletal	JJ	_	10	amod
10	findings	finding	NNS	_	5	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	extra	extra	JJ	_	13	amod
13	pair	pair	NN	_	10	dep
14	of	of	IN	_	16	case
15	thoracic	thoracic	JJ	_	16	amod
16	ribs	rib	NNS	_	13	nmod
17	,	,	,	_	13	punct
18	unossified	unossified	JJ	_	21	amod
19	cervical	cervical	JJ	_	21	amod
20	vertebral	vertebral	JJ	_	21	amod
21	centra	centra	NNS	_	13	appos
22	,	,	,	_	13	punct
23	shortened	shorten	VBD	_	24	amod
24	ribs	rib	NNS	_	13	appos
25	-RRB-	-rrb-	-RRB-	_	13	punct
26	were	be	VBD	_	27	auxpass
27	observed	observe	VBN	_	0	ROOT
28	at	at	IN	_	30	case
29	1000	1000	CD	_	30	nummod
30	mg/kg/day	mg/kg/day	NN	_	27	nmod
31	-LRB-	-lrb-	-LRB-	_	37	punct
32	~	~	CD	_	34	compound
33	10	10	CD	_	34	compound
34	times	time	NNS	_	37	nummod
35	the	the	DT	_	37	det
36	human	human	JJ	_	37	amod
37	exposure	exposure	NN	_	30	appos
38	at	at	IN	_	40	case
39	10	10	CD	_	40	nummod
40	mg	mg	NN	_	37	nmod
41	daily	daily	JJ	_	37	amod
42	based	base	VBN	_	44	case
43	on	on	IN	_	44	case
44	AUC0-24hr	auc0-24hr	NN	_	41	advcl
45	for	for	IN	_	47	case
46	total	total	JJ	_	47	amod
47	drug1	drug1	NN	_	44	nmod
48	-RRB-	-rrb-	-RRB-	_	37	punct
49	.	.	.	_	27	punct

1	In	in	IN	_	2	case
2	rabbits	rabbit	NNS	_	15	nmod
3	treated	treat	VBN	_	2	acl
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	15	punct
7	an	a	DT	_	9	det
8	increased	increase	VBN	_	9	amod
9	incidence	incidence	NN	_	15	nsubjpass
10	of	of	IN	_	13	case
11	extra	extra	JJ	_	13	amod
12	thoracic	thoracic	JJ	_	13	amod
13	ribs	rib	NNS	_	9	nmod
14	was	be	VBD	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	at	at	IN	_	18	case
17	1000	1000	CD	_	18	nummod
18	mg/kg/day	mg/kg/day	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	24	punct
20	150	150	CD	_	21	compound
21	times	time	NNS	_	24	nummod
22	the	the	DT	_	24	det
23	human	human	JJ	_	24	amod
24	exposure	exposure	NN	_	18	appos
25	at	at	IN	_	27	case
26	10	10	CD	_	27	nummod
27	mg	mg	NN	_	24	nmod
28	daily	daily	JJ	_	24	amod
29	based	base	VBN	_	31	case
30	on	on	IN	_	31	case
31	AUC0-24hr	auc0-24hr	NN	_	28	advcl
32	for	for	IN	_	34	case
33	total	total	JJ	_	34	amod
34	drug2	drug2	NN	_	31	nmod
35	-RRB-	-rrb-	-RRB-	_	24	punct
36	.	.	.	_	15	punct

1	drug1	drug1	NN	_	2	nsubj
2	crossed	cross	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	placenta	placenta	NN	_	2	dobj
5	when	when	WRB	_	11	advmod
6	pregnant	pregnant	JJ	_	7	amod
7	rats	rat	NNS	_	11	nsubjpass
8	and	and	CC	_	7	cc
9	rabbits	rabbit	NNS	_	7	conj
10	were	be	VBD	_	11	auxpass
11	given	give	VBN	_	2	advcl
12	multiple	multiple	JJ	_	14	amod
13	oral	oral	JJ	_	14	amod
14	doses	dose	NNS	_	11	dobj
15	.	.	.	_	2	punct

1	Multiple	multiple	JJ	_	3	amod
2	dose	dose	NN	_	3	compound
3	studies	study	NNS	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	given	give	VBN	_	5	acl
7	in	in	IN	_	8	case
8	combination	combination	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug3	drug3	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	in	in	IN	_	15	case
15	rats	rat	NNS	_	10	nmod
16	and	and	CC	_	15	cc
17	rabbits	rabbit	NNS	_	15	conj
18	during	during	IN	_	20	case
19	organogenesis	organogenesis	NN	_	20	compound
20	result	result	NN	_	3	nmod
21	in	in	IN	_	23	case
22	higher	higher	JJR	_	23	amod
23	drug4	drug4	NN	_	20	nmod
24	and	and	CC	_	23	cc
25	statin	statin	NN	_	26	compound
26	exposures	exposure	NNS	_	23	conj
27	.	.	.	_	3	punct

1	Reproductive	Reproductive	NNP	_	2	compound
2	findings	finding	NNS	_	3	nsubj
3	occur	occur	VBP	_	0	ROOT
4	at	at	IN	_	6	case
5	lower	lower	JJR	_	6	amod
6	doses	dose	NNS	_	3	nmod
7	in	in	IN	_	9	case
8	combination	combination	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod
10	compared	compare	VBN	_	12	case
11	to	to	TO	_	12	case
12	monotherapy	monotherapy	NN	_	3	advcl
13	.	.	.	_	3	punct

1	All	all	DT	_	2	det
2	drug1	drug1	NN	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	contraindicated	contraindicate	VBN	_	0	ROOT
5	in	in	IN	_	9	case
6	pregnant	pregnant	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	nursing	nursing	NN	_	6	conj
9	women	woman	NNS	_	4	nmod
10	.	.	.	_	4	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	15	advcl
5	with	with	IN	_	7	case
6	an	a	DT	_	7	det
7	drug2	drug2	NN	_	4	nmod
8	in	in	IN	_	10	case
9	a	a	DT	_	10	det
10	woman	woman	NN	_	7	nmod
11	of	of	IN	_	13	case
12	childbearing	childbearing	JJ	_	13	amod
13	potential	potential	NN	_	10	nmod
14	,	,	,	_	15	punct
15	refer	refer	VBP	_	0	ROOT
16	to	to	TO	_	19	case
17	the	the	DT	_	19	det
18	pregnancy	pregnancy	NN	_	19	compound
19	category	category	NN	_	15	nmod
20	and	and	CC	_	19	cc
21	package	package	NN	_	22	compound
22	labeling	labeling	NN	_	19	conj
23	for	for	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	15	nmod
26	.	.	.	_	15	punct

1	Labor	labor	NN	_	16	nsubj
2	and	and	CC	_	1	cc
3	Delivery	delivery	NN	_	1	conj
4	The	the	DT	_	5	det
5	effects	effect	NNS	_	1	dep
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	on	on	IN	_	9	case
9	labor	labor	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	delivery	delivery	NN	_	9	conj
12	in	in	IN	_	14	case
13	pregnant	pregnant	JJ	_	14	amod
14	women	woman	NNS	_	9	nmod
15	are	be	VBP	_	16	cop
16	unknown	unknown	JJ	_	0	ROOT
17	.	.	.	_	16	punct

1	Nursing	Nursing	NNP	_	2	compound
2	Mothers	Mothers	NNP	_	17	nsubj
3	In	in	IN	_	5	case
4	rat	rat	NN	_	5	compound
5	studies	study	NNS	_	2	nmod
6	,	,	,	_	2	punct
7	exposure	exposure	NN	_	2	appos
8	to	to	TO	_	10	case
9	total	total	JJ	_	10	amod
10	drug1	drug1	NN	_	7	nmod
11	in	in	IN	_	13	case
12	nursing	nursing	NN	_	13	compound
13	pups	pup	NNS	_	10	nmod
14	was	be	VBD	_	17	cop
15	up	up	RB	_	17	advmod
16	to	to	TO	_	17	case
17	half	half	NN	_	0	ROOT
18	of	of	IN	_	19	case
19	that	that	DT	_	17	nmod
20	observed	observe	VBN	_	19	acl
21	in	in	IN	_	23	case
22	maternal	maternal	JJ	_	23	amod
23	plasma	plasma	NN	_	20	nmod
24	.	.	.	_	17	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	whether	whether	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	excreted	excrete	VBN	_	4	ccomp
9	into	into	IN	_	12	case
10	human	human	JJ	_	12	amod
11	breast	breast	NN	_	12	compound
12	milk	milk	NN	_	8	nmod
13	;	;	:	_	4	punct

1	therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	nursing	nursing	NN	_	10	compound
10	mothers	mother	NNS	_	7	nmod
11	unless	unless	IN	_	15	mark
12	the	the	DT	_	14	det
13	potential	potential	JJ	_	14	amod
14	benefit	benefit	NN	_	15	nsubj
15	justifies	justify	VBZ	_	7	advcl
16	the	the	DT	_	18	det
17	potential	potential	JJ	_	18	amod
18	risk	risk	NN	_	15	dobj
19	to	to	TO	_	21	case
20	the	the	DT	_	21	det
21	infant	infant	NN	_	18	nmod
22	.	.	.	_	7	punct

1	Pediatric	Pediatric	NNP	_	4	compound
2	Use	Use	NNP	_	4	compound
3	The	The	NNP	_	4	compound
4	pharmacokinetics	pharmacokinetic	NNS	_	17	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	in	in	IN	_	8	case
8	adolescents	adolescent	NNS	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	13	punct
10	10	10	CD	_	12	compound
11	to	to	TO	_	12	dep
12	18	18	CD	_	13	nummod
13	years	year	NNS	_	4	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	shown	show	VBN	_	0	ROOT
18	to	to	TO	_	20	mark
19	be	be	VB	_	20	cop
20	similar	similar	JJ	_	17	xcomp
21	to	to	TO	_	22	case
22	that	that	DT	_	20	nmod
23	in	in	IN	_	24	case
24	adults	adult	NNS	_	22	nmod
25	.	.	.	_	17	punct

1	Treatment	treatment	NN	_	2	compound
2	experience	experience	NN	_	10	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	pediatric	pediatric	JJ	_	8	amod
8	population	population	NN	_	2	nmod
9	is	be	VBZ	_	10	auxpass
10	limited	limit	VBN	_	0	ROOT
11	to	to	TO	_	13	case
12	4	4	CD	_	13	nummod
13	patients	patient	NNS	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	18	punct
15	9	9	CD	_	17	compound
16	to	to	TO	_	17	dep
17	17	17	CD	_	18	nummod
18	years	year	NNS	_	13	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	sitosterolemia	sitosterolemia	NN	_	23	compound
23	study	study	NN	_	13	nmod
24	and	and	CC	_	13	cc
25	5	5	CD	_	26	nummod
26	patients	patient	NNS	_	13	conj
27	-LRB-	-lrb-	-LRB-	_	31	punct
28	11	11	CD	_	30	compound
29	to	to	TO	_	30	dep
30	17	17	CD	_	31	nummod
31	years	year	NNS	_	26	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	in	in	IN	_	36	case
34	the	the	DT	_	36	det
35	HoFH	hofh	NN	_	36	compound
36	study	study	NN	_	26	nmod
37	.	.	.	_	10	punct

1	Treatment	treatment	NN	_	13	nsubjpass
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	5	case
5	children	child	NNS	_	1	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	<	<	JJR	_	9	dep
8	10	10	CD	_	9	nummod
9	years	year	NNS	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	is	be	VBZ	_	13	auxpass
12	not	not	RB	_	13	neg
13	recommended	recommend	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Geriatric	Geriatric	NNP	_	2	compound
2	Use	Use	NNP	_	0	ROOT
3	Of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	patients	patient	NNS	_	2	nmod
6	who	who	WP	_	7	nsubj
7	received	receive	VBD	_	5	acl:relcl
8	drug1	drug1	NN	_	7	dobj
9	in	in	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	studies	study	NNS	_	7	nmod
12	,	,	,	_	2	punct
13	948	948	CD	_	15	nsubj
14	were	be	VBD	_	15	cop
15	65	65	CD	_	2	acl:relcl
16	and	and	CC	_	15	cc
17	older	older	JJR	_	15	conj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	this	this	DT	_	20	nsubj
20	included	include	VBD	_	15	dep
21	206	206	CD	_	20	dobj
22	who	who	WP	_	24	nsubj
23	were	be	VBD	_	24	cop
24	75	75	CD	_	21	acl:relcl
25	and	and	CC	_	24	cc
26	older	older	JJR	_	24	conj
27	-RRB-	-rrb-	-RRB-	_	20	punct
28	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effectiveness	effectiveness	NN	_	8	nsubj
3	and	and	CC	_	2	cc
4	safety	safety	NN	_	2	conj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	were	be	VBD	_	8	cop
8	similar	similar	JJ	_	0	ROOT
9	between	between	IN	_	11	case
10	these	these	DT	_	11	det
11	patients	patient	NNS	_	8	nmod
12	and	and	CC	_	11	cc
13	younger	younger	JJR	_	14	amod
14	subjects	subject	NNS	_	11	conj
15	.	.	.	_	8	punct

1	Greater	Greater	NNP	_	2	compound
2	sensitivity	sensitivity	NN	_	10	nsubjpass
3	of	of	IN	_	6	case
4	some	some	DT	_	6	det
5	older	older	JJR	_	6	amod
6	individuals	individual	NNS	_	2	nmod
7	can	can	MD	_	10	aux
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	ruled	rule	VBN	_	0	ROOT
11	out	out	RP	_	10	compound:prt
12	.	.	.	_	10	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Although	although	IN	_	10	mark
6	drug2	drug2	NN	_	10	nsubj
7	does	do	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	itself	itself	PRP	_	10	nsubj
10	cause	cause	VB	_	19	advcl
11	orthostatic	orthostatic	JJ	_	12	amod
12	hypotension	hypotension	NN	_	10	dobj
13	,	,	,	_	19	punct
14	its	its	PRP$	_	15	nmod:poss
15	administration	administration	NN	_	19	nsubj
16	to	to	TO	_	17	case
17	patients	patient	NNS	_	15	nmod
18	already	already	RB	_	19	advmod
19	receiving	receive	VBG	_	1	dep
20	drug3	drug3	NN	_	19	dobj
21	can	can	MD	_	22	aux
22	result	result	VB	_	19	dep
23	in	in	IN	_	26	case
24	profound	profound	JJ	_	26	amod
25	orthostatic	orthostatic	JJ	_	26	amod
26	effects	effect	NNS	_	22	nmod
27	.	.	.	_	1	punct

1	If	if	IN	_	8	mark
2	at	at	IN	_	5	case
3	all	all	DT	_	5	det
4	possible	possible	JJ	_	5	amod
5	drug1	drug1	NN	_	8	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	discontinued	discontinue	VBN	_	0	ROOT
9	well	well	RB	_	8	advmod
10	before	before	IN	_	13	mark
11	drug2	drug2	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	begun	begin	VBN	_	8	advcl
14	.	.	.	_	8	punct

1	Where	where	WRB	_	5	advmod
2	this	this	DT	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	possible	possible	JJ	_	11	advcl
6	,	,	,	_	11	punct
7	drug1	drug1	NN	_	8	compound
8	therapy	therapy	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	started	start	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	hospital	hospital	NN	_	11	nmod
15	and	and	CC	_	11	cc
16	the	the	DT	_	17	det
17	patient	patient	NN	_	19	nsubj
18	should	should	MD	_	19	aux
19	remain	remain	VB	_	11	conj
20	institutionalized	institutionalized	JJ	_	19	xcomp
21	until	until	IN	_	28	mark
22	severe	severe	JJ	_	24	amod
23	orthostatic	orthostatic	JJ	_	24	amod
24	effects	effect	NNS	_	28	nsubj
25	are	be	VBP	_	28	cop
26	no	no	RB	_	27	neg
27	longer	longer	RB	_	28	advmod
28	present	present	JJ	_	19	advcl
29	or	or	CC	_	28	cc
30	the	the	DT	_	31	det
31	patient	patient	NN	_	33	nsubj
32	has	have	VBZ	_	33	aux
33	learned	learn	VBN	_	28	conj
34	to	to	TO	_	35	mark
35	avoid	avoid	VB	_	33	xcomp
36	activities	activity	NNS	_	35	dobj
37	that	that	WDT	_	38	nsubj
38	provoke	provoke	VBP	_	36	acl:relcl
39	them	they	PRP	_	38	dobj
40	.	.	.	_	11	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	21	nmod
4	in	in	IN	_	5	case
5	which	which	WDT	_	10	nmod
6	34	34	CD	_	8	nummod
7	different	different	JJ	_	8	amod
8	drugs	drug	NNS	_	10	nsubjpass
9	were	be	VBD	_	10	auxpass
10	tested	test	VBN	_	3	acl:relcl
11	,	,	,	_	21	punct
12	therapeutically	therapeutically	RB	_	13	advmod
13	relevant	relevant	JJ	_	14	amod
14	concentrations	concentration	NNS	_	21	nsubj
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug2	drug2	NN	_	16	conj
19	and	and	CC	_	16	cc
20	drug3	drug3	NN	_	16	conj
21	displaced	displace	VBD	_	0	ROOT
22	protein-bound	protein-bound	JJ	_	23	amod
23	drug4	drug4	NN	_	21	dobj
24	in	in	IN	_	27	case
25	fresh	fresh	JJ	_	27	amod
26	human	human	JJ	_	27	amod
27	serum	serum	NN	_	21	nmod
28	to	to	TO	_	33	case
29	a	a	DT	_	33	det
30	small	small	JJ	_	33	amod
31	but	but	CC	_	30	cc
32	significant	significant	JJ	_	30	conj
33	extent	extent	NN	_	21	nmod
34	.	.	.	_	21	punct

1	Because	because	IN	_	6	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	6	det
4	extremely	extremely	RB	_	5	advmod
5	high	high	JJ	_	6	amod
6	binding	binding	NN	_	19	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	to	to	TO	_	11	case
10	plasma	plasma	NN	_	11	compound
11	proteins	protein	NNS	_	6	nmod
12	,	,	,	_	19	punct
13	these	these	DT	_	15	det
14	small	small	JJ	_	15	amod
15	decreases	decrease	NNS	_	19	nsubj
16	in	in	IN	_	17	case
17	binding	binding	NN	_	15	nmod
18	could	could	MD	_	19	aux
19	cause	cause	VB	_	0	ROOT
20	substantial	substantial	JJ	_	21	amod
21	increases	increase	NNS	_	19	dobj
22	in	in	IN	_	25	case
23	free	free	JJ	_	25	amod
24	drug	drug	NN	_	25	compound
25	levels	level	NNS	_	21	nmod
26	in	in	IN	_	27	case
27	plasma	plasma	NN	_	25	nmod
28	which	which	WDT	_	30	nsubj
29	could	could	MD	_	30	aux
30	result	result	VB	_	21	acl:relcl
31	in	in	IN	_	32	case
32	potentiation	potentiation	NN	_	30	nmod
33	of	of	IN	_	35	case
34	drug	drug	NN	_	35	compound
35	toxicity	toxicity	NN	_	32	nmod
36	.	.	.	_	19	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	8	mark
8	administering	administer	VBG	_	6	advcl
9	drug1	drug1	NN	_	8	dobj
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	drug2	drug2	NN	_	12	compound
12	injection	injection	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	to	to	TO	_	15	case
15	patients	patient	NNS	_	8	nmod
16	receiving	receive	VBG	_	15	acl
17	these	these	DT	_	19	det
18	other	other	JJ	_	19	amod
19	agents	agent	NNS	_	16	dobj
20	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	change	change	NN	_	2	nsubj
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	plasma	plasma	NN	_	8	compound
8	kinetics	kinetics	NNS	_	2	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	when	when	WRB	_	12	advmod
12	coadministered	coadminister	VBN	_	2	advcl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	2	punct

1	However	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	the	the	DT	_	5	det
4	plasma	plasma	NN	_	5	compound
5	clearance	clearance	NN	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	was	be	VBD	_	10	auxpass
9	slightly	slightly	RB	_	10	advmod
10	increased	increase	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	An	a	DT	_	2	det
2	increase	increase	NN	_	9	nsubjpass
3	in	in	IN	_	5	case
4	intracellular	intracellular	JJ	_	5	amod
5	levels	level	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	was	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	in	in	FW	_	11	compound
11	vitro	vitro	FW	_	9	advmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	presence	presence	NN	_	9	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	9	punct

1	drug1	drug1	NN	_	2	nsubj
2	antagonize	antagonize	VBP	_	0	ROOT
3	the	the	DT	_	5	det
4	uricosuric	uricosuric	JJ	_	5	amod
5	action	action	NN	_	2	dobj
6	of	of	IN	_	8	case
7	.	.	.	_	8	punct
8	drugs	drug	NNS	_	5	nmod
9	used	use	VBN	_	8	acl
10	to	to	TO	_	11	mark
11	treat	treat	VB	_	9	xcomp
12	gout	gout	NN	_	11	dobj
13	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	compound
2	AND	and	CC	_	1	cc
3	OTHER	other	NN	_	1	conj
4	drug2	drug2	NN	_	6	nsubj
5	WILL	will	MD	_	6	aux
6	BE	be	VB	_	0	ROOT
7	ADDITIVE	ADDITIVE	NNP	_	6	dobj
8	TO	to	TO	_	9	mark
9	drug3	drug3	VB	_	7	acl
10	AND	and	CC	_	9	cc
11	MAY	MAY	NNP	_	14	compound
12	INCREASE	INCREASE	NNP	_	14	compound
13	PLASMA	PLASMA	NNP	_	14	compound
14	CONCENTRATIONS	CONCENTRATIONS	NNPS	_	9	conj
15	OF	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	TO	to	TO	_	19	case
18	TOXIC	TOXIC	NNP	_	19	compound
19	LEVELS	LEVELS	NNP	_	16	nmod
20	.	.	.	_	6	punct

1	Drugs	drug	NNS	_	9	nsubj
2	and	and	CC	_	1	cc
3	foods	food	NNS	_	1	conj
4	that	that	WDT	_	5	nsubj
5	raise	raise	VBP	_	1	acl:relcl
6	urine	urine	NN	_	7	compound
7	pH	ph	NN	_	5	dobj
8	will	will	MD	_	9	aux
9	increase	increase	VB	_	0	ROOT
10	renal	renal	JJ	_	11	amod
11	clearance	clearance	NN	_	9	dobj
12	and	and	CC	_	11	cc
13	urinary	urinary	JJ	_	14	amod
14	excretion	excretion	NN	_	11	conj
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	11	nmod
17	,	,	,	_	9	punct
18	thus	thus	RB	_	19	advmod
19	lowering	lower	VBG	_	9	advcl
20	plasma	plasma	NN	_	21	compound
21	levels	level	NNS	_	19	dobj
22	;	;	:	_	9	punct

1	acidifying	acidify	VBG	_	2	amod
2	drugs	drug	NNS	_	6	nsubj
3	or	or	CC	_	2	cc
4	foods	food	NNS	_	2	conj
5	will	will	MD	_	6	aux
6	decrease	decrease	VB	_	0	ROOT
7	urinary	urinary	JJ	_	8	amod
8	excretion	excretion	NN	_	6	dobj
9	and	and	CC	_	8	cc
10	increase	increase	NN	_	12	compound
11	plasma	plasma	NN	_	12	compound
12	levels	level	NNS	_	8	conj
13	.	.	.	_	6	punct

1	drug1	drug1	NN	_	7	nsubj
2	given	give	VBN	_	1	acl
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	may	may	MD	_	7	aux
7	predispose	predispose	VB	_	0	ROOT
8	to	to	TO	_	10	case
9	systemic	systemic	JJ	_	10	amod
10	bleeding	bleeding	NN	_	7	nmod
11	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypoglycemic	hypoglycemic	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	9	case
8	oral	oral	JJ	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	sulfonylurea	sulfonylurea	NN	_	13	compound
13	class	class	NN	_	9	nmod
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	competes	compete	VBZ	_	0	ROOT
3	with	with	IN	_	5	case
4	a	a	DT	_	5	det
5	number	number	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	for	for	IN	_	11	case
9	protein	protein	NN	_	11	compound
10	binding	binding	NN	_	11	compound
11	sites	site	NNS	_	7	nmod
12	,	,	,	_	5	punct
13	notably	notably	RB	_	14	advmod
14	drug2	drug2	NN	_	5	appos
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug5	drug5	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug6	drug6	NN	_	14	conj
23	,	,	,	_	14	punct
24	drug7	drug7	NN	_	14	conj
25	,	,	,	_	14	punct
26	drug8	drug8	NN	_	14	conj
27	,	,	,	_	14	punct
28	drug9	drug9	NN	_	14	conj
29	,	,	,	_	14	punct
30	drug10	drug10	NN	_	14	conj
31	,	,	,	_	14	punct
32	and	and	CC	_	14	cc
33	possibly	possibly	RB	_	34	advmod
34	drug11	drug11	NN	_	14	conj
35	.	.	.	_	2	punct

1	Drug	drug	NN	_	6	compound
2	/	/	:	_	6	punct
3	Laboratory	Laboratory	NNP	_	6	compound
4	Test	Test	NNP	_	6	compound
5	Interactions	interaction	NNS	_	6	compound
6	drug1	drug1	NN	_	7	nsubj
7	competes	compete	VBZ	_	0	ROOT
8	with	with	IN	_	10	case
9	thyroid	thyroid	NN	_	10	compound
10	hormone	hormone	NN	_	7	nmod
11	for	for	IN	_	12	case
12	binding	bind	VBG	_	7	nmod
13	to	to	TO	_	15	case
14	plasma	plasma	NN	_	15	compound
15	proteins	protein	NNS	_	12	nmod
16	,	,	,	_	15	punct
17	which	which	WDT	_	20	nsubjpass
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	reflected	reflect	VBN	_	15	acl:relcl
21	in	in	IN	_	26	case
22	a	a	DT	_	26	det
23	depressed	depressed	JJ	_	26	amod
24	plasma	plasma	NN	_	26	compound
25	T4	t4	NN	_	26	compound
26	value	value	NN	_	20	nmod
27	in	in	IN	_	29	case
28	some	some	DT	_	29	det
29	patients	patient	NNS	_	26	nmod
30	;	;	:	_	7	punct

1	thyroid	thyroid	NN	_	2	compound
2	function	function	NN	_	7	nsubj
3	and	and	CC	_	2	cc
4	basal	basal	JJ	_	5	amod
5	metabolism	metabolism	NN	_	2	conj
6	are	be	VBP	_	7	cop
7	unaffected	unaffected	JJ	_	0	ROOT
8	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	elderly	elderly	JJ	_	3	amod
3	patients	patient	NNS	_	21	nmod
4	concurrently	concurrently	RB	_	5	advmod
5	receiving	receive	VBG	_	3	acl
6	certain	certain	JJ	_	7	amod
7	drug1	drug1	NN	_	5	dobj
8	,	,	,	_	21	punct
9	primarily	primarily	RB	_	10	advmod
10	drug2	drug2	NN	_	21	nsubjpass
11	,	,	,	_	10	punct
12	an	a	DT	_	14	det
13	increased	increase	VBN	_	14	amod
14	incidence	incidence	NN	_	10	appos
15	of	of	IN	_	16	case
16	thrombopenia	thrombopenia	NN	_	14	nmod
17	with	with	IN	_	18	case
18	purpura	purpura	NN	_	14	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	reported	report	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	It	it	PRP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	prolong	prolong	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	8	dobj
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	who	who	WP	_	16	nsubj
15	are	be	VBP	_	16	aux
16	receiving	receive	VBG	_	13	acl:relcl
17	the	the	DT	_	19	det
18	drug2	drug2	NN	_	19	compound
19	drug3	drug3	NN	_	16	dobj
20	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	kept	keep	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	mind	mind	NN	_	5	nmod
8	when	when	WRB	_	11	advmod
9	drug1	drug1	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	given	give	VBN	_	5	advcl
12	to	to	TO	_	13	case
13	patients	patient	NNS	_	11	nmod
14	already	already	RB	_	17	advmod
15	on	on	IN	_	17	case
16	anticoagulant	anticoagulant	JJ	_	17	amod
17	therapy	therapy	NN	_	11	nmod
18	,	,	,	_	5	punct
19	and	and	CC	_	5	cc
20	the	the	DT	_	22	det
21	coagulation	coagulation	NN	_	22	compound
22	time	time	NN	_	25	nsubjpass
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	reassessed	reassess	VBN	_	5	conj
26	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	inhibit	inhibit	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	At	at	IN	_	4	case
2	a	a	DT	_	4	det
3	1.6-g	1.6-g	JJ	_	4	amod
4	dose	dose	NN	_	7	nmod
5	,	,	,	_	7	punct
6	drug1	drug1	NN	_	7	nsubj
7	produced	produce	VBD	_	0	ROOT
8	a	a	DT	_	12	det
9	slight	slight	JJ	_	12	amod
10	but	but	CC	_	9	cc
11	significant	significant	JJ	_	9	conj
12	increase	increase	NN	_	7	dobj
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	half-life	half-life	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	but	but	CC	_	7	cc
19	did	do	VBD	_	21	aux
20	not	not	RB	_	21	neg
21	produce	produce	VB	_	7	conj
22	a	a	DT	_	24	det
23	corresponding	corresponding	JJ	_	24	amod
24	decrease	decrease	NN	_	21	dobj
25	in	in	IN	_	29	case
26	the	the	DT	_	29	det
27	metabolic	metabolic	JJ	_	29	amod
28	clearance	clearance	NN	_	29	compound
29	rate	rate	NN	_	24	nmod
30	.	.	.	_	7	punct

1	When	when	WRB	_	2	advmod
2	administering	administer	VBG	_	10	advcl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	concurrently	concurrently	RB	_	2	advmod
6	,	,	,	_	10	punct
7	one	one	CD	_	10	nsubj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	cop
10	alert	alert	JJ	_	0	ROOT
11	for	for	IN	_	15	case
12	possible	possible	JJ	_	15	amod
13	excessive	excessive	JJ	_	15	amod
14	drug1	drug1	NN	_	15	compound
15	effect	effect	NN	_	10	nmod
16	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubj
2	can	can	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	displace	displace	VB	_	0	ROOT
5	drug2	drug2	NN	_	4	dobj
6	from	from	IN	_	9	case
7	plasma	plasma	NN	_	9	compound
8	protein-binding	protein-binding	JJ	_	9	amod
9	sites	site	NNS	_	4	nmod
10	,	,	,	_	4	punct
11	thus	thus	RB	_	12	advmod
12	increasing	increase	VBG	_	4	advcl
13	free	free	JJ	_	15	amod
14	drug3	drug3	NN	_	15	compound
15	concentrations	concentration	NNS	_	12	dobj
16	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	presence	presence	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	interfere	interfere	VB	_	0	ROOT
7	with	with	IN	_	13	case
8	the	the	DT	_	13	det
9	Jaff	Jaff	NNP	_	13	compound
10	alkaline	alkaline	NN	_	13	compound
11	picrate	picrate	NN	_	13	compound
12	reaction	reaction	NN	_	13	compound
13	assay	assay	NN	_	6	nmod
14	for	for	IN	_	15	case
15	creatinine	creatinine	NN	_	13	nmod
16	,	,	,	_	6	punct
17	resulting	result	VBG	_	6	advcl
18	in	in	IN	_	19	case
19	overestimations	overestimation	NNS	_	17	nmod
20	of	of	IN	_	23	case
21	about	about	IN	_	22	advmod
22	10	10	CD	_	23	nummod
23	%	%	NN	_	19	nmod
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	range	range	NN	_	17	nmod
27	of	of	IN	_	29	case
28	normal	normal	JJ	_	29	amod
29	values	value	NNS	_	26	nmod
30	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	9	nsubj
4	listed	list	VBN	_	3	acl
5	below	below	RB	_	4	advmod
6	are	be	VBP	_	9	cop
7	potentially	potentially	RB	_	9	advmod
8	clinically	clinically	RB	_	9	advmod
9	important	important	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Mutual	mutual	JJ	_	2	amod
2	inhibition	inhibition	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	metabolism	metabolism	NN	_	2	nmod
5	occurs	occur	VBZ	_	0	ROOT
6	with	with	IN	_	8	case
7	concurrent	concurrent	JJ	_	8	amod
8	use	use	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	;	;	:	_	5	punct

1	therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	possible	possible	JJ	_	0	ROOT
6	that	that	IN	_	20	mark
7	adverse	adverse	JJ	_	8	amod
8	events	event	NNS	_	20	nsubj
9	associated	associate	VBN	_	8	acl
10	with	with	IN	_	13	case
11	the	the	DT	_	13	det
12	individual	individual	JJ	_	13	amod
13	use	use	NN	_	9	nmod
14	of	of	IN	_	16	case
15	either	either	CC	_	16	det
16	drug	drug	NN	_	13	nmod
17	may	may	MD	_	20	aux
18	be	be	VB	_	20	cop
19	more	more	RBR	_	20	advmod
20	apt	apt	JJ	_	5	ccomp
21	to	to	TO	_	22	mark
22	occur	occur	VB	_	20	xcomp
23	.	.	.	_	5	punct

1	convulsions	convulsion	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	concurrent	concurrent	JJ	_	7	amod
7	use	use	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	15	nsubj
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	hepatic	hepatic	JJ	_	5	amod
5	enzymes	enzyme	NNS	_	3	dobj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	drug3	drug3	NN	_	8	conj
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	clearance	clearance	NN	_	15	dobj
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	and	and	CC	_	15	cc
21	may	may	MD	_	22	aux
22	require	require	VB	_	15	conj
23	increased	increase	VBN	_	22	ccomp
24	in	in	IN	_	26	case
25	drug5	drug5	NN	_	26	compound
26	dose	dose	NN	_	23	nmod
27	to	to	TO	_	28	mark
28	achieve	achieve	VB	_	23	xcomp
29	the	the	DT	_	31	det
30	desired	desire	VBN	_	31	amod
31	response	response	NN	_	28	dobj
32	.	.	.	_	15	punct

1	Drugs	drug	NNS	_	8	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	inhibit	inhibit	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	8	cc
14	thus	thus	RB	_	15	advmod
15	decrease	decrease	VB	_	8	conj
16	its	its	PRP$	_	17	nmod:poss
17	clearance	clearance	NN	_	15	dobj
18	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	titrated	titrate	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	avoid	avoid	VB	_	9	xcomp
12	steroid	steroid	NN	_	13	compound
13	toxicity	toxicity	NN	_	11	dobj
14	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	clearance	clearance	NN	_	3	dobj
6	of	of	IN	_	10	case
7	chronic	chronic	JJ	_	10	amod
8	high	high	JJ	_	10	amod
9	dose	dose	NN	_	10	compound
10	drug2	drug2	NN	_	5	nmod
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	decreased	decrease	VBN	_	8	amod
6	drug1	drug1	NN	_	8	compound
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	3	nmod
9	or	or	CC	_	3	cc
10	increase	increase	VB	_	3	conj
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	when	when	WRB	_	19	advmod
17	drug3	drug3	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	withdrawn	withdraw	VBN	_	10	advcl
20	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	cautiously	cautiously	RB	_	4	advmod
6	in	in	IN	_	7	case
7	conjunction	conjunction	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	suffering	suffer	VBG	_	11	acl
13	from	from	IN	_	14	case
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	12	nmod
15	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	is	be	VBZ	_	9	cop
9	variable	variable	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	reports	report	NNS	_	2	nsubj
4	of	of	IN	_	10	case
5	enhanced	enhance	VBN	_	10	amod
6	as	as	RB	_	5	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	diminished	diminished	JJ	_	5	conj
10	effects	effect	NNS	_	3	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	2	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	coagulation	coagulation	NN	_	4	compound
4	indices	index	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	maintain	maintain	VB	_	7	xcomp
10	the	the	DT	_	13	det
11	desired	desire	VBN	_	13	amod
12	anticoagulant	anticoagulant	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	.	.	.	_	7	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	generally	generally	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	treated	treat	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	action	action	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	potentiated	potentiate	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	anesthesia	anesthesia	NN	_	7	nmod
10	,	,	,	_	9	punct
11	other	other	JJ	_	12	amod
12	drug2	drug2	NN	_	9	conj
13	and	and	CC	_	9	cc
14	drug3	drug3	NN	_	9	conj
15	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	24	nmod
4	,	,	,	_	24	punct
5	the	the	DT	_	7	det
6	concurrent	concurrent	JJ	_	7	amod
7	administration	administration	NN	_	24	nsubjpass
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	drug1	drug1	NN	_	11	compound
11	inhaler	inhaler	NN	_	7	nmod
12	and	and	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	conj
15	commonly	commonly	RB	_	16	advmod
16	used	use	VBN	_	11	acl
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	treatment	treatment	NN	_	16	nmod
20	of	of	IN	_	21	case
21	asthma	asthma	NN	_	19	nmod
22	was	be	VBD	_	24	auxpass
23	not	not	RB	_	24	neg
24	associated	associate	VBN	_	0	ROOT
25	with	with	IN	_	29	case
26	any	any	DT	_	29	det
27	unusual	unusual	JJ	_	29	amod
28	adverse	adverse	JJ	_	29	amod
29	events	event	NNS	_	24	nmod
30	.	.	.	_	24	punct

1	However	however	RB	_	14	advmod
2	,	,	,	_	14	punct
3	drug1	drug1	NN	_	14	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	potent	potent	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	11	case
9	cytochrome	cytochrome	NN	_	11	compound
10	P450	p450	NN	_	11	compound
11	3A4	3a4	NN	_	7	nmod
12	,	,	,	_	3	punct
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	plasma	plasma	NN	_	16	compound
16	levels	level	NNS	_	14	dobj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	during	during	IN	_	21	case
20	concomitant	concomitant	JJ	_	21	amod
21	dosing	dosing	NN	_	14	nmod
22	.	.	.	_	14	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	13	nsubjpass
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	conj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	performed	perform	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Drugs	drug	NNS	_	6	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	potentiate	potentiate	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	release	release	NN	_	6	dobj
9	of	of	IN	_	10	case
10	neutrophils	neutrophil	NNS	_	8	nmod
11	;	;	:	_	6	punct

1	patients	patient	NNS	_	7	nsubj
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	should	should	MD	_	7	aux
7	have	have	VB	_	0	ROOT
8	more	more	RBR	_	9	advmod
9	frequent	frequent	JJ	_	10	amod
10	monitoring	monitoring	NN	_	7	dobj
11	of	of	IN	_	13	case
12	neutrophil	neutrophil	NN	_	13	compound
13	counts	count	NNS	_	10	nmod
14	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	0	ROOT
5	sensitivity	sensitivity	NN	_	4	dobj
6	to	to	TO	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug3	drug3	NN	_	5	nmod
9	.	.	.	_	4	punct

1	Dosage	dosage	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	have	have	VB	_	0	ROOT
7	to	to	TO	_	9	mark
8	be	be	VB	_	9	auxpass
9	decreased	decrease	VBN	_	6	xcomp
10	in	in	IN	_	13	mark
11	order	order	NN	_	10	mwe
12	to	to	TO	_	13	mark
13	maintain	maintain	VB	_	9	advcl
14	desired	desire	VBN	_	16	amod
15	prothrombin	prothrombin	NN	_	16	compound
16	time	time	NN	_	13	dobj
17	.	.	.	_	6	punct

1	Patients	patient	NNS	_	6	nsubj
2	receiving	receive	VBG	_	1	acl
3	oral	oral	JJ	_	5	amod
4	anticoagulant	anticoagulant	JJ	_	5	amod
5	therapy	therapy	NN	_	2	dobj
6	require	require	VBP	_	0	ROOT
7	close	close	JJ	_	8	amod
8	monitoring	monitoring	NN	_	6	dobj
9	,	,	,	_	8	punct
10	especially	especially	RB	_	11	advmod
11	when	when	WRB	_	14	advmod
12	drug1	drug1	NN	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	started	start	VBN	_	8	acl:relcl
15	or	or	CC	_	14	cc
16	stopped	stop	VBN	_	14	conj
17	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	5	det
4	multidose	multidose	JJ	_	5	amod
5	study	study	NN	_	25	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	5	punct
9	given	give	VBN	_	5	acl
10	as	as	IN	_	15	case
11	5	5	CD	_	14	compound
12	or	or	CC	_	11	cc
13	10	10	CD	_	11	conj
14	mg	mg	NN	_	15	amod
15	BID	BID	NNP	_	9	nmod
16	in	in	IN	_	19	case
17	15	15	CD	_	19	nummod
18	healthy	healthy	JJ	_	19	amod
19	subjects	subject	NNS	_	9	nmod
20	concurrently	concurrently	RB	_	21	advmod
21	treated	treat	VBN	_	19	acl
22	with	with	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	,	,	,	_	5	punct
25	resulted	result	VBD	_	1	dep
26	in	in	IN	_	29	case
27	a	a	DT	_	29	det
28	mean	mean	JJ	_	29	amod
29	increase	increase	NN	_	25	nmod
30	in	in	IN	_	32	case
31	drug4	drug4	NN	_	32	compound
32	half-life	half-life	NN	_	29	nmod
33	from	from	IN	_	37	case
34	26	26	CD	_	36	compound
35	to	to	TO	_	36	dep
36	48	48	CD	_	37	nummod
37	hours	hour	NNS	_	29	nmod
38	and	and	CC	_	37	cc
39	AUC	auc	NN	_	37	conj
40	from	from	IN	_	41	case
41	4.55	4.55	CD	_	29	nmod
42	to	to	TO	_	43	dep
43	12.08	12.08	CD	_	41	nmod
44	ng	ng	NN	_	46	compound
45	*	*	SYM	_	46	dep
46	hr/mL	hr/ml	NN	_	43	dep
47	:	:	:	_	25	punct
48	similar	similar	JJ	_	49	amod
49	increases	increase	NNS	_	57	nsubjpass
50	in	in	IN	_	52	case
51	drug5	drug5	NN	_	52	compound
52	half-life	half-life	NN	_	49	nmod
53	and	and	CC	_	52	cc
54	AUC	auc	NN	_	52	conj
55	were	be	VBD	_	57	auxpass
56	also	also	RB	_	57	advmod
57	detected	detect	VBN	_	25	parataxis
58	.	.	.	_	57	punct

1	Microscopic	microscopic	JJ	_	2	amod
2	hematuria	hematuria	NN	_	14	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	9/15	9/15	CD	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	and	and	CC	_	2	cc
7	gingival	gingival	JJ	_	8	amod
8	bleeding	bleeding	NN	_	2	conj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	1/15	1/15	CD	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	were	be	VBD	_	14	auxpass
13	also	also	RB	_	14	advmod
14	observed	observe	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	A	a	DT	_	3	nsubj
2	5.5-fold	5.5-fold	RB	_	3	advmod
3	decrease	decrease	VB	_	0	ROOT
4	in	in	IN	_	8	case
5	the	the	DT	_	8	det
6	mean	mean	NN	_	8	compound
7	drug1	drug1	NN	_	8	compound
8	dose	dose	NN	_	3	nmod
9	from	from	IN	_	11	case
10	6.13	6.13	CD	_	11	nummod
11	mg/day	mg/day	NN	_	3	nmod
12	to	to	TO	_	14	case
13	1.13	1.13	CD	_	14	nummod
14	mg/day	mg/day	NN	_	11	nmod
15	-LRB-	-lrb-	-LRB-	_	19	punct
16	approximately	approximately	RB	_	17	advmod
17	80-85	80-85	CD	_	18	dep
18	%	%	NN	_	19	dep
19	reduction	reduction	NN	_	11	dep
20	of	of	IN	_	22	case
21	drug2	drug2	NN	_	22	compound
22	dose	dose	NN	_	19	nmod
23	-RRB-	-rrb-	-RRB-	_	19	punct
24	,	,	,	_	3	punct
25	was	be	VBD	_	26	cop
26	necessary	necessary	JJ	_	3	dep
27	to	to	TO	_	28	mark
28	maintain	maintain	VB	_	26	xcomp
29	a	a	DT	_	31	det
30	target	target	NN	_	31	compound
31	INR	inr	NN	_	28	dobj
32	of	of	IN	_	33	case
33	1.5	1.5	CD	_	31	nmod
34	.	.	.	_	3	punct

1	When	when	WRB	_	5	advmod
2	drug1	drug1	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	initiated	initiate	VBN	_	25	advcl
6	in	in	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	already	already	RB	_	10	advmod
10	receiving	receive	VBG	_	8	acl
11	treatment	treatment	NN	_	10	dobj
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	10	nmod
14	,	,	,	_	25	punct
15	the	the	DT	_	16	det
16	INR	inr	NN	_	25	nsubjpass
17	or	or	CC	_	16	cc
18	prothrombin	prothrombin	NN	_	19	compound
19	time	time	NN	_	16	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	PT	pt	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	monitored	monitor	VBN	_	0	ROOT
26	closely	closely	RB	_	25	advmod
27	and	and	CC	_	25	cc
28	the	the	DT	_	29	det
29	dose	dose	NN	_	44	nsubjpass
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	adjusted	adjust	VBN	_	29	acl
33	as	as	RB	_	34	advmod
34	necessary	necessary	JJ	_	32	xcomp
35	until	until	IN	_	39	case
36	a	a	DT	_	39	det
37	stable	stable	JJ	_	39	amod
38	target	target	NN	_	39	compound
39	INR	inr	NN	_	34	nmod
40	or	or	CC	_	39	cc
41	PT	pt	NN	_	39	conj
42	has	have	VBZ	_	44	aux
43	been	be	VBN	_	44	auxpass
44	achieved	achieve	VBN	_	25	conj
45	.	.	.	_	25	punct

1	Furthermore	furthermore	RB	_	26	advmod
2	,	,	,	_	26	punct
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	26	nmod
5	receiving	receive	VBG	_	4	acl
6	both	both	CC	_	7	cc:preconj
7	drugs	drug	NNS	_	5	dobj
8	,	,	,	_	26	punct
9	careful	careful	JJ	_	10	amod
10	monitoring	monitoring	NN	_	26	nsubjpass
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	INR	inr	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	PT	pt	NN	_	13	conj
16	,	,	,	_	10	punct
17	and	and	CC	_	10	cc
18	adjustment	adjustment	NN	_	10	conj
19	of	of	IN	_	22	case
20	the	the	DT	_	22	det
21	drug1	drug1	NN	_	22	compound
22	dosage	dosage	NN	_	18	nmod
23	if	if	IN	_	24	mark
24	indicated	indicate	VBN	_	10	dep
25	are	be	VBP	_	26	auxpass
26	recommended	recommend	VBN	_	0	ROOT
27	when	when	WRB	_	32	advmod
28	the	the	DT	_	30	det
29	drug2	drug2	NN	_	30	compound
30	dose	dose	NN	_	32	nsubjpass
31	is	be	VBZ	_	32	auxpass
32	changed	change	VBN	_	26	advcl
33	or	or	CC	_	32	cc
34	discontinued	discontinue	VBN	_	32	conj
35	.	.	.	_	26	punct

1	Patients	patient	NNS	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	be	be	VB	_	5	auxpass
4	closely	closely	RB	_	5	advmod
5	monitored	monitor	VBN	_	0	ROOT
6	for	for	IN	_	7	case
7	signs	sign	NNS	_	5	nmod
8	and	and	CC	_	7	cc
9	symptoms	symptom	NNS	_	7	conj
10	of	of	IN	_	12	case
11	occult	occult	NN	_	12	compound
12	bleeding	bleeding	NN	_	7	nmod
13	.	.	.	_	5	punct

1	Oral	oral	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	metabolism	metabolism	NN	_	5	dobj
8	of	of	IN	_	10	case
9	oral	oral	JJ	_	10	amod
10	drug3	drug3	NN	_	7	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	16	nsubj
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	In	in	IN	_	5	case
5	patients	patient	NNS	_	1	nmod
6	with	with	IN	_	7	case
7	edema	edema	NN	_	5	nmod
8	,	,	,	_	1	punct
9	concomitant	concomitant	JJ	_	10	amod
10	administration	administration	NN	_	1	appos
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	may	may	MD	_	16	aux
16	increase	increase	VB	_	0	ROOT
17	the	the	DT	_	18	det
18	edema	edema	NN	_	16	dobj
19	.	.	.	_	16	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	test	test	NN	_	3	compound
3	interactions	interaction	NNS	_	6	nsubj
4	drug1	drug1	NN	_	3	dep
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	0	ROOT
7	levels	level	NNS	_	6	dobj
8	of	of	IN	_	10	case
9	thyroxine-binding	thyroxine-binding	JJ	_	10	amod
10	globulin	globulin	NN	_	7	nmod
11	,	,	,	_	6	punct
12	resulting	result	VBG	_	6	conj
13	in	in	IN	_	18	case
14	decreased	decrease	VBN	_	18	amod
15	total	total	JJ	_	18	amod
16	T4	t4	NN	_	18	compound
17	serum	serum	NN	_	18	compound
18	levels	level	NNS	_	12	nmod
19	and	and	CC	_	6	cc
20	increased	increase	VBD	_	22	amod
21	resin	resin	NN	_	22	compound
22	uptake	uptake	NN	_	6	conj
23	of	of	IN	_	24	case
24	T3	t3	NN	_	22	nmod
25	and	and	CC	_	24	cc
26	T4	t4	NN	_	24	conj
27	.	.	.	_	6	punct

1	Free	Free	NNP	_	4	compound
2	thyroid	thyroid	NN	_	4	compound
3	hormone	hormone	NN	_	4	compound
4	levels	level	NNS	_	5	nsubj
5	remain	remain	VBP	_	0	ROOT
6	unchanged	unchanged	JJ	_	5	xcomp
7	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	13	nmod
3	,	,	,	_	13	punct
4	a	a	DT	_	5	det
5	decrease	decrease	NN	_	13	nsubj
6	in	in	IN	_	7	case
7	PBI	pbi	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	radioactive	radioactive	JJ	_	11	amod
10	iodine	iodine	NN	_	11	compound
11	uptake	uptake	NN	_	7	conj
12	may	may	MD	_	13	aux
13	occur	occur	VB	_	0	ROOT
14	.	.	.	_	13	punct

1	The	the	DT	_	3	det
2	following	follow	VBG	_	3	amod
3	agents	agent	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	0	ROOT
6	certain	certain	JJ	_	7	amod
7	actions	action	NNS	_	5	dobj
8	or	or	CC	_	7	cc
9	side	side	JJ	_	10	amod
10	effects	effect	NNS	_	7	conj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	:	:	:	_	5	punct
14	drug2	drug2	NN	_	5	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	e.g.	e.g.	FW	_	20	dep
19	,	,	,	_	20	punct
20	drug4	drug4	NN	_	16	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	14	punct
23	drug5	drug5	NN	_	14	conj
24	,	,	,	_	14	punct
25	drug6	drug6	NN	_	14	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	e.g.	e.g.	FW	_	29	dep
28	,	,	,	_	29	punct
29	drug7	drug7	NN	_	25	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	14	punct
32	drug8	drug8	NN	_	14	conj
33	,	,	,	_	14	punct
34	drug9	drug9	NN	_	14	conj
35	,	,	,	_	14	punct
36	drug10	drug10	NN	_	14	conj
37	-LRB-	-lrb-	-LRB-	_	40	punct
38	e.g.	e.g.	FW	_	40	dep
39	,	,	,	_	40	punct
40	drug11	drug11	NN	_	36	dep
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	,	,	,	_	14	punct
43	drug12	drug12	NN	_	14	conj
44	and	and	CC	_	14	cc
45	drug13	drug13	NN	_	14	conj
46	,	,	,	_	14	punct
47	drug14	drug14	NN	_	14	conj
48	,	,	,	_	14	punct
49	drug15	drug15	NN	_	14	conj
50	,	,	,	_	14	punct
51	and	and	CC	_	14	cc
52	other	other	JJ	_	53	amod
53	drugs	drug	NNS	_	54	nsubj
54	having	have	VBG	_	14	conj
55	anticholinergic	anticholinergic	JJ	_	56	amod
56	activity	activity	NN	_	54	dobj
57	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	antagonize	antagonize	VBP	_	0	ROOT
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	2	punct

1	drug1	drug1	NN	_	11	nsubj
2	in	in	IN	_	4	case
3	the	the	DT	_	4	det
4	presence	presence	NN	_	1	nmod
5	of	of	IN	_	8	case
6	increased	increase	VBN	_	8	amod
7	intraocular	intraocular	JJ	_	8	amod
8	pressure	pressure	NN	_	4	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	cop
11	hazardous	hazardous	JJ	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	taken	take	VBN	_	11	advcl
14	concurrently	concurrently	RB	_	13	advmod
15	with	with	IN	_	16	case
16	agents	agent	NNS	_	13	nmod
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug2	drug2	NN	_	16	nmod
20	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	affect	affect	VB	_	0	ROOT
4	gastrointestinal	gastrointestinal	JJ	_	5	amod
5	absorption	absorption	NN	_	3	dobj
6	of	of	IN	_	8	case
7	various	various	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	13	mark
11	as	as	IN	_	10	mwe
12	slowly	slowly	RB	_	13	advmod
13	dissolving	dissolve	VBG	_	8	acl
14	dosage	dosage	JJ	_	15	amod
15	forms	form	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	;	;	:	_	3	punct

1	increased	increase	VBN	_	4	amod
2	serum	serum	NN	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	concentrations	concentration	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	that	that	WDT	_	9	nsubj
9	alter	alter	VBP	_	7	acl:relcl
10	gastrointestinal	gastrointestinal	JJ	_	11	amod
11	motility	motility	NN	_	9	dobj
12	,	,	,	_	11	punct
13	such	such	JJ	_	15	case
14	as	as	IN	_	13	mwe
15	drug2	drug2	NN	_	11	nmod
16	.	.	.	_	3	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	interfere	interfere	VB	_	18	advcl
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	18	punct
11	simultaneous	simultaneous	JJ	_	12	amod
12	use	use	NN	_	18	nsubjpass
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	drugs	drug	NNS	_	12	nmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	avoided	avoid	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	The	the	DT	_	3	det
2	inhibiting	inhibiting	JJ	_	3	amod
3	effects	effect	NNS	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	on	on	IN	_	10	case
7	gastric	gastric	JJ	_	10	amod
8	hydrochloric	hydrochloric	JJ	_	10	amod
9	acid	acid	NN	_	10	compound
10	secretion	secretion	NN	_	3	nmod
11	are	be	VBP	_	12	auxpass
12	antagonized	antagonize	VBN	_	0	ROOT
13	by	by	IN	_	14	case
14	agents	agent	NNS	_	12	nmod
15	used	use	VBN	_	14	acl
16	to	to	TO	_	17	mark
17	treat	treat	VB	_	15	xcomp
18	achlorhydria	achlorhydria	NN	_	17	dobj
19	and	and	CC	_	18	cc
20	those	those	DT	_	18	conj
21	used	use	VBN	_	20	acl
22	to	to	TO	_	23	mark
23	test	test	VB	_	21	xcomp
24	gastric	gastric	JJ	_	25	amod
25	secretion	secretion	NN	_	23	dobj
26	.	.	.	_	12	punct

1	Since	since	IN	_	7	mark
2	drug1	drug1	NN	_	7	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	may	may	MD	_	7	aux
7	interact	interact	VB	_	22	advcl
8	with	with	IN	_	11	case
9	concurrently	concurrently	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drug3	drug3	NN	_	7	nmod
12	,	,	,	_	22	punct
13	periodic	periodic	JJ	_	16	amod
14	serum	serum	NN	_	16	compound
15	level	level	NN	_	16	compound
16	determinations	determination	NNS	_	22	nsubj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	drugs	drug	NNS	_	16	nmod
20	may	may	MD	_	22	aux
21	be	be	VB	_	22	cop
22	necessary	necessary	JJ	_	0	ROOT
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	eg	eg	FW	_	25	compound
25	drug4	drug4	NN	_	27	nsubj
26	may	may	MD	_	27	aux
27	increase	increase	VB	_	22	ccomp
28	the	the	DT	_	30	det
29	plasma	plasma	NN	_	30	compound
30	concentrations	concentration	NNS	_	27	dobj
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	30	nmod
33	and	and	CC	_	32	cc
34	drug6	drug6	NN	_	32	conj
35	-RRB-	-rrb-	-RRB-	_	27	punct
36	.	.	.	_	22	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	13	nsubj
4	and	and	CC	_	3	cc
5	probably	probably	RB	_	7	advmod
6	other	other	JJ	_	7	amod
7	drug3	drug3	NN	_	3	conj
8	given	give	VBN	_	3	acl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug4	drug4	NN	_	8	nmod
12	can	can	MD	_	13	aux
13	cause	cause	VB	_	1	appos
14	unusually	unusually	RB	_	15	advmod
15	large	large	JJ	_	18	amod
16	or	or	CC	_	15	cc
17	prolonged	prolonged	JJ	_	15	conj
18	losses	loss	NNS	_	13	dobj
19	of	of	IN	_	20	case
20	fluid	fluid	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	electrolytes	electrolyte	NNS	_	20	conj
23	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	When	when	WRB	_	8	advmod
5	drug2	drug2	NN	_	6	compound
6	Tablets	tablet	NNS	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	16	advcl
9	with	with	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug3	drug3	NN	_	8	nmod
12	,	,	,	_	16	punct
13	care	care	NN	_	16	nsubjpass
14	must	must	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	taken	take	VBN	_	2	dep
17	,	,	,	_	16	punct
18	especially	especially	RB	_	21	advmod
19	during	during	IN	_	21	case
20	initial	initial	JJ	_	21	amod
21	therapy	therapy	NN	_	16	nmod
22	.	.	.	_	2	punct

1	Dosage	dosage	NN	_	2	compound
2	adjustments	adjustment	NNS	_	8	nsubj
3	of	of	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	necessary	necessary	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	:	:	:	_	1	punct
8	The	the	DT	_	10	det
9	hypotensive	hypotensive	JJ	_	10	amod
10	effects	effect	NNS	_	16	nsubjpass
11	of	of	IN	_	13	case
12	these	these	DT	_	13	det
13	drugs	drug	NNS	_	10	nmod
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	potentiated	potentiate	VBN	_	1	dep
17	by	by	IN	_	20	case
18	the	the	DT	_	20	det
19	volume	volume	NN	_	20	compound
20	contraction	contraction	NN	_	16	nmod
21	that	that	WDT	_	24	nsubjpass
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	associated	associate	VBN	_	20	acl:relcl
25	with	with	IN	_	27	case
26	drug4	drug4	NN	_	27	compound
27	therapy	therapy	NN	_	24	nmod
28	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	8	dep
4	-	-	:	_	8	punct
5	induced	induce	VBN	_	6	amod
6	hypokalemia	hypokalemia	NN	_	8	nsubj
7	can	can	MD	_	8	aux
8	increase	increase	VB	_	1	dep
9	the	the	DT	_	10	det
10	sensitivity	sensitivity	NN	_	8	dobj
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	myocardium	myocardium	NN	_	10	nmod
14	to	to	TO	_	15	case
15	drug3	drug3	NN	_	10	nmod
16	.	.	.	_	1	punct

1	Serious	serious	JJ	_	2	amod
2	arrhythmias	arrhythmia	NNS	_	4	nsubj
3	can	can	MD	_	4	aux
4	result	result	VB	_	0	ROOT
5	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	May	May	NNP	_	6	nsubj
6	increase	increase	VB	_	1	dep
7	the	the	DT	_	8	det
8	risk	risk	NN	_	6	dobj
9	of	of	IN	_	10	case
10	hypokalemia	hypokalemia	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	increase	increase	NN	_	13	compound
13	salt	salt	NN	_	10	conj
14	and	and	CC	_	10	cc
15	water	water	NN	_	16	compound
16	retention	retention	NN	_	10	conj
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Serum	serum	NN	_	5	compound
4	drug2	drug2	NN	_	5	compound
5	levels	level	NNS	_	7	nsubj
6	may	may	MD	_	7	aux
7	increase	increase	VB	_	1	parataxis
8	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	compound
4	-	-	:	_	6	punct
5	induced	induce	VBN	_	6	amod
6	hypokalemia	hypokalemia	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	enhance	enhance	VB	_	1	dep
9	neuromuscular	neuromuscular	JJ	_	11	amod
10	blocking	blocking	NN	_	11	compound
11	effects	effect	NNS	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug4	drug4	NN	_	13	nmod
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	the	the	DT	_	22	det
20	most	most	RBS	_	21	advmod
21	serious	serious	JJ	_	22	amod
22	effect	effect	NN	_	26	nsubj
23	would	would	MD	_	26	aux
24	be	be	VB	_	26	cop
25	respiratory	respiratory	JJ	_	26	amod
26	depression	depression	NN	_	8	ccomp
27	which	which	WDT	_	29	nsubj
28	could	could	MD	_	29	aux
29	proceed	proceed	VB	_	26	acl:relcl
30	to	to	TO	_	31	case
31	apnea	apnea	NN	_	29	nmod
32	.	.	.	_	1	punct

1	Accordingly	accordingly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubj
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	cop
6	advisable	advisable	JJ	_	0	ROOT
7	to	to	TO	_	8	mark
8	discontinue	discontinue	VB	_	6	xcomp
9	drug1	drug1	NN	_	10	compound
10	Tablets	tablet	NNS	_	8	dobj
11	three	three	CD	_	12	nummod
12	days	day	NNS	_	8	nmod
13	before	before	IN	_	12	case
14	elective	elective	JJ	_	15	amod
15	surgery	surgery	NN	_	12	dep
16	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	Other	other	JJ	_	4	amod
4	drug2	drug2	NN	_	1	conj
5	:	:	:	_	1	punct
6	May	May	NNP	_	7	nsubj
7	decrease	decrease	VB	_	1	dep
8	the	the	DT	_	10	det
9	antihypertensive	antihypertensive	JJ	_	10	amod
10	effects	effect	NNS	_	7	dobj
11	of	of	IN	_	13	case
12	drug3	drug3	NN	_	13	compound
13	Tablets	tablet	NNS	_	10	nmod
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	decrease	decrease	VB	_	1	dep
6	arterial	arterial	JJ	_	7	amod
7	responsiveness	responsiveness	NN	_	5	dobj
8	to	to	TO	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	,	,	,	_	5	punct
11	but	but	CC	_	5	cc
12	this	this	DT	_	13	det
13	diminution	diminution	NN	_	16	nsubj
14	is	be	VBZ	_	16	cop
15	not	not	RB	_	16	neg
16	sufficient	sufficient	JJ	_	5	conj
17	to	to	TO	_	18	mark
18	preclude	preclude	VB	_	16	xcomp
19	effectiveness	effectiveness	NN	_	18	dobj
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	pressor	pressor	NN	_	23	compound
23	agent	agent	NN	_	19	nmod
24	for	for	IN	_	26	case
25	therapeutic	therapeutic	JJ	_	26	amod
26	use	use	NN	_	18	nmod
27	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Efficacy	efficacy	NN	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	decreased	decrease	VBN	_	1	appos
7	due	due	JJ	_	11	case
8	to	to	TO	_	11	case
9	urinary	urinary	JJ	_	11	amod
10	alkalizing	alkalize	VBG	_	11	amod
11	effect	effect	NN	_	6	advcl
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	12	nsubj
4	,	,	,	_	3	punct
5	as	as	RB	_	3	cc
6	well	well	RB	_	5	mwe
7	as	as	IN	_	5	mwe
8	other	other	JJ	_	9	amod
9	drug3	drug3	NN	_	3	conj
10	,	,	,	_	3	punct
11	may	may	MD	_	12	aux
12	affect	affect	VB	_	1	dep
13	the	the	DT	_	15	det
14	hypoprothrombinemic	hypoprothrombinemic	JJ	_	15	amod
15	response	response	NN	_	12	dobj
16	to	to	TO	_	17	case
17	drug4	drug4	NN	_	15	nmod
18	;	;	:	_	12	punct

1	dosage	dosage	NN	_	2	compound
2	adjustments	adjustment	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	necessary	necessary	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	Coadministration	coadministration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	resulted	result	VBD	_	0	ROOT
7	in	in	IN	_	11	case
8	increased	increase	VBN	_	11	amod
9	plasma	plasma	NN	_	11	compound
10	drug3	drug3	NN	_	11	compound
11	concentrations	concentration	NNS	_	6	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	57	57	CD	_	14	nummod
14	%	%	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	11	punct
17	increased	increase	VBN	_	21	amod
18	plasma	plasma	NN	_	21	compound
19	bismuth	bismuth	NN	_	21	compound
20	trough	trough	NN	_	21	compound
21	concentrations	concentration	NNS	_	11	conj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	48	48	CD	_	24	nummod
24	%	%	NN	_	21	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	11	punct
27	and	and	CC	_	11	cc
28	increased	increase	VBD	_	31	amod
29	drug4	drug4	NN	_	31	compound
30	plasma	plasma	NN	_	31	compound
31	concentrations	concentration	NNS	_	11	conj
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	31	31	CD	_	34	nummod
34	%	%	NN	_	31	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	.	.	.	_	6	punct

1	Coadministration	coadministration	NN	_	4	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	results	result	VBZ	_	0	ROOT
5	in	in	IN	_	8	case
6	a	a	DT	_	8	det
7	slight	slight	JJ	_	8	amod
8	decrease	decrease	NN	_	4	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	rate	rate	NN	_	8	nmod
12	of	of	IN	_	14	case
13	drug2	drug2	NN	_	14	compound
14	absorption	absorption	NN	_	11	nmod
15	that	that	WDT	_	18	nsubj
16	is	be	VBZ	_	18	cop
17	clinically	clinically	RB	_	18	advmod
18	unimportant	unimportant	JJ	_	11	acl:relcl
19	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	12	nsubj
2	with	with	IN	_	5	case
3	a	a	DT	_	5	det
4	high	high	JJ	_	5	amod
5	dose	dose	NN	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	170	170	CD	_	10	nummod
10	mEq	meq	NN	_	5	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	results	result	VBZ	_	0	ROOT
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	28	28	CD	_	16	compound
16	%	%	NN	_	17	amod
17	decrease	decrease	NN	_	12	nmod
18	in	in	IN	_	20	case
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	17	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	and	and	CC	_	12	cc
24	may	may	MD	_	25	aux
25	decrease	decrease	VB	_	12	conj
26	plasma	plasma	NN	_	27	compound
27	concentrations	concentration	NNS	_	25	dobj
28	of	of	IN	_	29	case
29	bismuth	bismuth	NN	_	27	nmod
30	from	from	IN	_	31	case
31	drug3	drug3	NN	_	25	nmod
32	.	.	.	_	12	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	clinically	clinically	RB	_	5	advmod
5	insignificant	insignificant	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	For	for	IN	_	2	case
2	information	information	NN	_	10	nmod
3	on	on	IN	_	5	case
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	2	nmod
6	associated	associate	VBN	_	5	acl
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	,	,	,	_	10	punct
10	refer	refer	VBP	_	0	ROOT
11	to	to	TO	_	15	case
12	the	the	DT	_	15	det
13	drug2	drug2	NN	_	15	compound
14	package	package	NN	_	15	compound
15	insert	insert	NN	_	10	nmod
16	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	other	other	JJ	_	12	amod
11	local	local	JJ	_	12	amod
12	drug2	drug2	NN	_	9	dobj
13	or	or	CC	_	12	cc
14	agents	agent	NNS	_	12	conj
15	structurally	structurally	RB	_	16	advmod
16	related	related	JJ	_	8	amod
17	to	to	TO	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	,	,	,	_	4	punct
20	since	since	IN	_	28	mark
21	the	the	DT	_	23	det
22	toxic	toxic	JJ	_	23	amod
23	effects	effect	NNS	_	28	nsubj
24	of	of	IN	_	26	case
25	these	these	DT	_	26	det
26	drugs	drug	NNS	_	23	nmod
27	are	be	VBP	_	28	cop
28	additive	additive	JJ	_	4	advcl
29	.	.	.	_	4	punct

1	Cytochrome	cytochrome	NN	_	2	compound
2	P4501A2	p4501a2	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	involved	involve	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	formation	formation	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	4	punct
11	the	the	DT	_	13	det
12	major	major	JJ	_	13	amod
13	metabolite	metabolite	NN	_	4	dobj
14	.	.	.	_	4	punct

1	In	in	FW	_	2	compound
2	vivo	vivo	FW	_	10	advmod
3	,	,	,	_	10	punct
4	the	the	DT	_	6	det
5	plasma	plasma	NN	_	6	compound
6	clearance	clearance	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	reduced	reduce	VBN	_	0	ROOT
11	by	by	IN	_	13	case
12	70	70	CD	_	13	nummod
13	%	%	NN	_	10	nmod
14	during	during	IN	_	15	case
15	coadministration	coadministration	NN	_	10	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	25	25	CD	_	20	compound
20	mg	mg	NN	_	21	amod
21	bid	bid	NN	_	17	dep
22	for	for	IN	_	24	case
23	2	2	CD	_	24	nummod
24	days	day	NNS	_	21	nmod
25	-RRB-	-rrb-	-RRB-	_	21	punct
26	,	,	,	_	17	punct
27	a	a	DT	_	32	det
28	selective	selective	JJ	_	32	amod
29	and	and	CC	_	28	cc
30	potent	potent	JJ	_	28	conj
31	CYP1A2	cyp1a2	NN	_	32	compound
32	inhibitor	inhibitor	NN	_	17	appos
33	.	.	.	_	10	punct

1	Thus	thus	RB	_	20	advmod
2	strong	strong	JJ	_	3	amod
3	inhibitors	inhibitor	NNS	_	20	nsubj
4	of	of	IN	_	6	case
5	cytochrome	cytochrome	NN	_	6	compound
6	P4501A2	p4501a2	NN	_	3	nmod
7	,	,	,	_	3	punct
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug1	drug1	NN	_	3	nmod
11	,	,	,	_	3	punct
12	given	give	VBN	_	3	acl
13	concomitantly	concomitantly	RB	_	12	advmod
14	during	during	IN	_	15	case
15	administration	administration	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	3	punct
19	can	can	MD	_	20	aux
20	interact	interact	VB	_	0	ROOT
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	leading	lead	VBG	_	22	acl
24	to	to	TO	_	28	case
25	increased	increase	VBN	_	28	amod
26	drug4	drug4	NN	_	28	compound
27	plasma	plasma	NN	_	28	compound
28	levels	level	NNS	_	23	nmod
29	.	.	.	_	20	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	9	advmod
6	CYP1A2	cyp1a2	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	coadministered	coadminister	VBN	_	4	advcl
10	.	.	.	_	4	punct

1	Possible	possible	JJ	_	2	amod
2	interactions	interaction	NNS	_	21	nsubj
3	with	with	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	known	know	VBN	_	4	acl
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	metabolized	metabolize	VBN	_	5	xcomp
9	by	by	IN	_	10	case
10	CYP1A2	cyp1a2	NN	_	8	nmod
11	via	via	IN	_	13	case
12	competitive	competitive	JJ	_	13	amod
13	inhibition	inhibition	NN	_	8	nmod
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	drug1	drug1	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	may	may	MD	_	21	aux
20	also	also	RB	_	21	advmod
21	occur	occur	VB	_	0	ROOT
22	.	.	.	_	21	punct

1	Coadministration	coadministration	NN	_	28	nsubj
2	of	of	IN	_	7	case
3	a	a	DT	_	7	det
4	selective	selective	JJ	_	7	amod
5	and	and	CC	_	4	cc
6	potent	potent	JJ	_	4	conj
7	inhibitor	inhibitor	NN	_	1	nmod
8	of	of	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	,	,	,	_	9	punct
11	drug1	drug1	NN	_	15	compound
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	100	100	CD	_	14	compound
14	mg	mg	NN	_	15	amod
15	bid	bid	NN	_	9	appos
16	for	for	IN	_	18	case
17	2	2	CD	_	18	nummod
18	days	day	NNS	_	15	nmod
19	with	with	IN	_	21	case
20	drug2	drug2	NN	_	21	compound
21	infusion	infusion	NN	_	18	nmod
22	administered	administer	VBN	_	21	acl
23	1	1	CD	_	24	nummod
24	hour	hour	NN	_	22	nmod
25	after	after	IN	_	24	case
26	drug3	drug3	NN	_	24	dep
27	-RRB-	-rrb-	-RRB-	_	1	punct
28	caused	cause	VBD	_	0	ROOT
29	a	a	DT	_	32	det
30	15	15	CD	_	31	compound
31	%	%	NN	_	32	amod
32	reduction	reduction	NN	_	28	dobj
33	in	in	IN	_	36	case
34	in-vivo	in-vivo	JJ	_	36	amod
35	plasma	plasma	NN	_	36	compound
36	clearance	clearance	NN	_	32	nmod
37	of	of	IN	_	38	case
38	drug4	drug4	NN	_	36	nmod
39	.	.	.	_	28	punct

1	Additives	additive	NNS	_	4	nsubj
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	cop
4	incompatible	incompatible	JJ	_	0	ROOT
5	;	;	:	_	4	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	are	be	VBP	_	5	cop
5	incompatible	incompatible	JJ	_	0	ROOT
6	with	with	IN	_	8	case
7	drug3	drug3	NN	_	8	compound
8	solution	solution	NN	_	5	nmod
9	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	7	case
6	parenteral	parenteral	JJ	_	7	amod
7	solutions	solution	NNS	_	2	nmod
8	containing	contain	VBG	_	7	acl
9	drug2	drug2	NN	_	8	dobj
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	avoided	avoid	VBN	_	0	ROOT
13	,	,	,	_	12	punct
14	except	except	IN	_	20	mark
15	where	where	WRB	_	20	advmod
16	compatibility	compatibility	NN	_	20	nsubjpass
17	has	have	VBZ	_	20	aux
18	been	be	VBN	_	20	auxpass
19	previously	previously	RB	_	20	advmod
20	established	establish	VBN	_	12	advcl
21	.	.	.	_	12	punct

1	Precipitation	precipitation	NN	_	5	nsubj
2	or	or	CC	_	1	cc
3	haze	haze	NN	_	1	conj
4	may	may	MD	_	5	aux
5	result	result	VB	_	0	ROOT
6	from	from	IN	_	9	case
7	sodium	sodium	NN	_	9	compound
8	bicarbonate-calcium	bicarbonate-calcium	NN	_	9	compound
9	admixtures	admixture	NNS	_	5	nmod
10	.	.	.	_	5	punct

1	NOTE	note	VB	_	0	ROOT
2	:	:	:	_	1	punct
3	Do	do	VBP	_	5	aux
4	not	not	RB	_	5	neg
5	use	use	VB	_	1	dep
6	the	the	DT	_	7	det
7	injection	injection	NN	_	5	dobj
8	if	if	IN	_	10	mark
9	it	it	PRP	_	10	nsubj
10	contains	contain	VBZ	_	5	advcl
11	precipitate	precipitate	NN	_	10	dobj
12	.	.	.	_	1	punct

1	Additives	additive	NNS	_	4	nsubj
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	cop
4	incompatible	incompatible	JJ	_	0	ROOT
5	.	.	.	_	4	punct

1	Consult	consult	VB	_	6	dep
2	with	with	IN	_	3	case
3	pharmacist	pharmacist	NN	_	1	nmod
4	,	,	,	_	6	punct
5	if	if	IN	_	6	mark
6	available	available	JJ	_	0	ROOT
7	.	.	.	_	6	punct

1	When	when	WRB	_	5	advmod
2	introducing	introduce	VBG	_	5	advcl
3	additives	additive	NNS	_	2	dobj
4	,	,	,	_	5	punct
5	use	use	VBP	_	0	ROOT
6	aseptic	aseptic	JJ	_	7	amod
7	technique	technique	NN	_	5	dobj
8	,	,	,	_	5	punct
9	mix	mix	NN	_	8	root
10	thoroughly	thoroughly	RB	_	9	advmod
11	and	and	CC	_	9	cc
12	do	do	VB	_	14	aux
13	not	not	RB	_	14	neg
14	store	store	NN	_	9	conj
15	.	.	.	_	9	punct

1	Drug-Drug	Drug-Drug	NNP	_	3	compound
2	Interactions	interaction	NNS	_	3	compound
3	Effect	effect	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	Metabolism	metabolism	NN	_	3	nmod
12	of	of	IN	_	14	case
13	Other	other	JJ	_	14	amod
14	Drugs	drug	NNS	_	11	nmod
15	:	:	:	_	3	punct
16	drug3	drug3	NN	_	19	nsubjpass
17	is	be	VBZ	_	19	auxpass
18	primarily	primarily	RB	_	19	advmod
19	metabolized	metabolize	VBN	_	3	dep
20	through	through	IN	_	21	case
21	hydrolysis	hydrolysis	NN	_	19	nmod
22	by	by	IN	_	23	case
23	esterases	esterase	NNS	_	19	nmod
24	.	.	.	_	3	punct

1	Minimal	minimal	JJ	_	2	amod
2	metabolism	metabolism	NN	_	3	nsubj
3	occurs	occur	VBZ	_	0	ROOT
4	via	via	IN	_	9	case
5	the	the	DT	_	9	det
6	major	major	JJ	_	9	amod
7	cytochrome	cytochrome	NN	_	9	compound
8	P450	p450	NN	_	9	compound
9	isoenzymes	isoenzyme	NNS	_	3	nmod
10	.	.	.	_	3	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	studies	study	NNS	_	20	advcl
6	,	,	,	_	20	punct
7	no	no	DT	_	10	neg
8	pharmacokinetic	pharmacokinetic	JJ	_	10	amod
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	20	nsubjpass
11	with	with	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	metabolized	metabolize	VBN	_	12	acl
14	by	by	IN	_	18	case
15	the	the	DT	_	18	det
16	following	follow	VBG	_	18	amod
17	isoenzyme	isoenzyme	NN	_	18	compound
18	systems	system	NNS	_	13	nmod
19	are	be	VBP	_	20	auxpass
20	expected	expect	VBN	_	0	ROOT
21	:	:	:	_	20	punct
22	CYP1A2	cyp1a2	NN	_	20	dep
23	,	,	,	_	22	punct
24	CYP2D6	cyp2d6	NN	_	22	conj
25	,	,	,	_	22	punct
26	CYP3A4/5	cyp3a4/5	NN	_	22	conj
27	,	,	,	_	22	punct
28	CYP2E1	cyp2e1	NN	_	22	conj
29	,	,	,	_	22	punct
30	CYP2C9	cyp2c9	NN	_	22	conj
31	,	,	,	_	22	punct
32	CYP2C8	cyp2c8	NN	_	22	conj
33	,	,	,	_	22	punct
34	or	or	CC	_	22	cc
35	CYP2C19	cyp2c19	NN	_	22	conj
36	.	.	.	_	20	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug3	drug3	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug4	drug4	NN	_	7	conj
14	,	,	,	_	7	punct
15	or	or	CC	_	7	cc
16	drug5	drug5	NN	_	7	conj
17	in	in	IN	_	18	case
18	studies	study	NNS	_	5	nmod
19	in	in	IN	_	21	case
20	healthy	healthy	JJ	_	21	amod
21	volunteers	volunteer	NNS	_	18	nmod
22	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	elevation	elevation	NN	_	11	nsubjpass
3	of	of	IN	_	5	case
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	2	nmod
6	induced	induce	VBN	_	5	acl
7	by	by	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	affected	affect	VBN	_	0	ROOT
12	by	by	IN	_	13	case
13	administration	administration	NN	_	11	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	11	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	1	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	Metabolism	metabolism	NN	_	1	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	:	:	:	_	1	punct
11	Drugs	drug	NNS	_	20	nsubjpass
12	that	that	WDT	_	13	nsubj
13	induce	induce	VBP	_	11	acl:relcl
14	or	or	CC	_	13	cc
15	inhibit	inhibit	VBP	_	13	conj
16	CYP450	cyp450	NN	_	17	compound
17	metabolism	metabolism	NN	_	13	dobj
18	are	be	VBP	_	20	auxpass
19	not	not	RB	_	20	neg
20	expected	expect	VBN	_	1	dep
21	to	to	TO	_	22	mark
22	alter	alter	VB	_	20	xcomp
23	the	the	DT	_	24	det
24	metabolism	metabolism	NN	_	22	dobj
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	.	.	.	_	20	punct

1	Single	single	JJ	_	4	amod
2	dose	dose	NN	_	4	compound
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	studies	study	NNS	_	5	nsubj
5	demonstrated	demonstrate	VBD	_	0	ROOT
6	that	that	IN	_	14	mark
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	14	nsubjpass
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	is	be	VBZ	_	14	auxpass
12	not	not	RB	_	14	neg
13	significantly	significantly	RB	_	14	advmod
14	affected	affect	VBN	_	5	ccomp
15	by	by	IN	_	17	case
16	concurrent	concurrent	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	,	,	,	_	19	punct
23	drug4	drug4	NN	_	19	conj
24	,	,	,	_	19	punct
25	or	or	CC	_	19	cc
26	drug5	drug5	NN	_	19	conj
27	.	.	.	_	5	punct

1	Population	Population	NNP	_	3	compound
2	PK	pk	NN	_	3	compound
3	analysis	analysis	NN	_	10	nsubj
4	with	with	IN	_	6	case
5	a	a	DT	_	6	det
6	database	database	NN	_	3	nmod
7	of	of	IN	_	9	case
8	625	625	CD	_	9	nummod
9	patients	patient	NNS	_	6	nmod
10	showed	show	VBD	_	0	ROOT
11	that	that	IN	_	18	mark
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	18	nsubjpass
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	were	be	VBD	_	18	auxpass
17	not	not	RB	_	18	neg
18	influenced	influence	VBN	_	10	ccomp
19	by	by	IN	_	22	case
20	commonly	commonly	RB	_	21	advmod
21	prescribed	prescribe	VBN	_	22	amod
22	medications	medication	NNS	_	18	nmod
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	drug2	drug2	NN	_	22	nmod
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	n	n	NN	_	25	dep
28	=	=	JJ	_	27	amod
29	77	77	CD	_	28	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	,	,	,	_	25	punct
32	drug3	drug3	NN	_	25	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	n	n	NN	_	32	dep
35	=	=	JJ	_	34	amod
36	72	72	CD	_	35	dep
37	-RRB-	-rrb-	-RRB-	_	34	punct
38	,	,	,	_	25	punct
39	drug4	drug4	NN	_	25	conj
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	n	n	NN	_	39	dep
42	=	=	JJ	_	41	amod
43	75	75	CD	_	42	dep
44	-RRB-	-rrb-	-RRB-	_	41	punct
45	,	,	,	_	25	punct
46	drug5	drug5	NN	_	25	conj
47	-LRB-	-lrb-	-LRB-	_	48	punct
48	n	n	NN	_	46	dep
49	=	=	JJ	_	48	amod
50	21	21	CD	_	49	dep
51	-RRB-	-rrb-	-RRB-	_	48	punct
52	,	,	,	_	25	punct
53	drug6	drug6	NN	_	25	conj
54	-LRB-	-lrb-	-LRB-	_	55	punct
55	n	n	NN	_	53	dep
56	=	=	JJ	_	55	amod
57	79	79	CD	_	56	dep
58	-RRB-	-rrb-	-RRB-	_	55	punct
59	,	,	,	_	25	punct
60	drug7	drug7	NN	_	25	conj
61	-LRB-	-lrb-	-LRB-	_	62	punct
62	n	n	NN	_	60	dep
63	=	=	JJ	_	62	amod
64	70	70	CD	_	63	dep
65	-RRB-	-rrb-	-RRB-	_	62	punct
66	,	,	,	_	25	punct
67	drug8	drug8	NN	_	25	conj
68	-LRB-	-lrb-	-LRB-	_	69	punct
69	n	n	NN	_	67	dep
70	=	=	JJ	_	69	amod
71	177	177	CD	_	70	dep
72	-RRB-	-rrb-	-RRB-	_	69	punct
73	,	,	,	_	25	punct
74	drug9	drug9	NN	_	25	conj
75	-LRB-	-lrb-	-LRB-	_	76	punct
76	n	n	NN	_	74	dep
77	=	=	JJ	_	76	amod
78	35	35	CD	_	77	dep
79	-RRB-	-rrb-	-RRB-	_	76	punct
80	,	,	,	_	25	punct
81	and	and	CC	_	25	cc
82	drug10	drug10	NN	_	25	conj
83	-LRB-	-lrb-	-LRB-	_	84	punct
84	n	n	NN	_	82	dep
85	=	=	JJ	_	84	amod
86	15	15	CD	_	85	dep
87	-RRB-	-rrb-	-RRB-	_	84	punct
88	.	.	.	_	10	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Because	because	IN	_	8	case
6	of	of	IN	_	5	mwe
7	their	they	PRP$	_	8	nmod:poss
8	mechanism	mechanism	NN	_	13	nmod
9	of	of	IN	_	10	case
10	action	action	NN	_	8	nmod
11	,	,	,	_	13	punct
12	drug2	drug2	NN	_	13	nsubj
13	have	have	VBP	_	1	dep
14	the	the	DT	_	15	det
15	potential	potential	JJ	_	13	dobj
16	to	to	TO	_	17	mark
17	interfere	interfere	VB	_	15	acl
18	with	with	IN	_	20	case
19	the	the	DT	_	20	det
20	activity	activity	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	1	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	Other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	3	conj
7	:	:	:	_	1	punct
8	A	a	DT	_	10	det
9	synergistic	synergistic	JJ	_	10	amod
10	effect	effect	NN	_	13	nsubjpass
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	expected	expect	VBN	_	1	parataxis
14	when	when	WRB	_	17	advmod
15	drug3	drug3	NN	_	17	nsubjpass
16	are	be	VBP	_	17	auxpass
17	given	give	VBN	_	13	advcl
18	concurrently	concurrently	RB	_	17	advmod
19	with	with	IN	_	20	case
20	drug4	drug4	NN	_	17	nmod
21	,	,	,	_	20	punct
22	similar	similar	JJ	_	23	amod
23	drug5	drug5	NN	_	20	conj
24	or	or	CC	_	20	cc
25	drug6	drug6	NN	_	20	conj
26	such	such	JJ	_	28	case
27	as	as	IN	_	26	mwe
28	drug7	drug7	NN	_	25	nmod
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	Reports	report	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug2	drug2	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	diminish	diminish	VB	_	3	ccomp
8	the	the	DT	_	10	det
9	antihypertensive	antihypertensive	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	15	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	1000	1000	CD	_	10	nummod
9	mg	mg	NN	_	10	compound
10	TID	tid	NN	_	6	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	to	to	TO	_	14	case
13	healthy	healthy	JJ	_	14	amod
14	volunteers	volunteer	NNS	_	4	nmod
15	tended	tend	VBD	_	1	dep
16	to	to	TO	_	17	mark
17	increase	increase	VB	_	15	xcomp
18	the	the	DT	_	19	det
19	AUC	auc	NN	_	17	dobj
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	10	10	CD	_	22	nummod
22	%	%	NN	_	19	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	and	and	CC	_	19	cc
25	Cmax	cmax	NN	_	19	conj
26	-LRB-	-lrb-	-LRB-	_	28	punct
27	24	24	CD	_	28	nummod
28	%	%	NN	_	25	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	19	nmod
32	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	;	;	:	_	9	punct

1	however	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	as	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug1	drug1	NN	_	17	nmod
7	,	,	,	_	17	punct
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	is	be	VBZ	_	17	auxpass
15	not	not	RB	_	17	neg
16	generally	generally	RB	_	17	advmod
17	recommended	recommend	VBN	_	0	ROOT
18	because	because	IN	_	21	case
19	of	of	IN	_	18	mwe
20	the	the	DT	_	21	det
21	potential	potential	NN	_	17	nmod
22	for	for	IN	_	25	case
23	increased	increase	VBN	_	25	amod
24	adverse	adverse	JJ	_	25	amod
25	effects	effect	NNS	_	21	nmod
26	.	.	.	_	17	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubj
3	of	of	IN	_	5	case
4	low-dose	low-dose	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	result	result	VB	_	0	ROOT
10	in	in	IN	_	13	case
11	an	a	DT	_	13	det
12	increased	increase	VBN	_	13	amod
13	rate	rate	NN	_	9	nmod
14	of	of	IN	_	16	case
15	GI	gi	NN	_	16	compound
16	ulceration	ulceration	NN	_	13	nmod
17	or	or	CC	_	16	cc
18	other	other	JJ	_	19	amod
19	complications	complication	NNS	_	16	conj
20	,	,	,	_	13	punct
21	compared	compare	VBN	_	23	case
22	to	to	TO	_	23	case
23	use	use	VB	_	13	acl
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	alone	alone	RB	_	25	advmod
27	.	.	.	_	9	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	not	not	RB	_	5	neg
4	a	a	DT	_	5	det
5	substitute	substitute	NN	_	0	ROOT
6	for	for	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	for	for	IN	_	10	case
9	cardiovascular	cardiovascular	JJ	_	10	amod
10	prophylaxis	prophylaxis	NN	_	7	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Pretreatment	pretreatment	NN	_	10	nsubj
4	for	for	IN	_	6	case
5	four	four	CD	_	6	nummod
6	days	day	NNS	_	3	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	3	nmod
9	significantly	significantly	RB	_	10	advmod
10	increased	increase	VBD	_	1	dep
11	the	the	DT	_	12	det
12	clearance	clearance	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	by	by	IN	_	17	case
16	50	50	CD	_	17	nummod
17	%	%	NN	_	10	nmod
18	.	.	.	_	1	punct

1	This	this	DT	_	2	nsubj
2	resulted	result	VBD	_	0	ROOT
3	in	in	IN	_	5	case
4	a	a	DT	_	5	det
5	decrease	decrease	NN	_	2	nmod
6	in	in	IN	_	7	case
7	t1/2	t1/2	NN	_	5	nmod
8	,	,	,	_	5	punct
9	from	from	IN	_	11	case
10	19.2	19.2	CD	_	11	nummod
11	hours	hour	NNS	_	5	nmod
12	to	to	TO	_	14	case
13	12.5	12.5	CD	_	14	nummod
14	hours	hour	NNS	_	11	nmod
15	,	,	,	_	5	punct
16	and	and	CC	_	5	cc
17	a	a	DT	_	20	det
18	35	35	CD	_	19	compound
19	%	%	NN	_	20	amod
20	reduction	reduction	NN	_	5	conj
21	in	in	IN	_	22	case
22	AUC	auc	NN	_	20	nmod
23	.	.	.	_	2	punct

1	This	this	DT	_	2	nsubj
2	suggests	suggest	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	existence	existence	NN	_	2	dobj
5	of	of	IN	_	8	case
6	a	a	DT	_	8	det
7	recirculation	recirculation	NN	_	8	compound
8	pathway	pathway	NN	_	4	nmod
9	for	for	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	gastrointestinal	gastrointestinal	JJ	_	14	amod
14	tract	tract	NN	_	8	nmod
15	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	10	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	established	establish	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	12	nsubj
5	of	of	IN	_	9	case
6	200	200	CD	_	7	compound
7	mg	mg	NN	_	9	amod
8	drug2	drug2	NN	_	9	compound
9	QID	qid	NN	_	4	nmod
10	did	do	VBD	_	12	aux
11	not	not	RB	_	12	neg
12	alter	alter	VB	_	1	dep
13	the	the	DT	_	15	det
14	single-dose	single-dose	JJ	_	15	amod
15	pharmacokinetics	pharmacokinetic	NNS	_	12	dobj
16	of	of	IN	_	19	case
17	30	30	CD	_	19	nummod
18	mg	mg	NN	_	19	compound
19	drug3	drug3	NN	_	15	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	15	15	CD	_	5	nummod
5	mg	mg	NN	_	13	nsubj
6	once	once	RB	_	7	advmod
7	daily	daily	RB	_	5	advmod
8	for	for	IN	_	10	case
9	7	7	CD	_	10	nummod
10	days	day	NNS	_	5	nmod
11	did	do	VBD	_	13	aux
12	not	not	RB	_	13	neg
13	alter	alter	VB	_	1	dep
14	the	the	DT	_	17	det
15	plasma	plasma	NN	_	17	compound
16	concentration	concentration	NN	_	17	compound
17	profile	profile	NN	_	13	dobj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	after	after	IN	_	22	case
21	b-acetyldigoxin	b-acetyldigoxin	NN	_	22	compound
22	administration	administration	NN	_	13	nmod
23	for	for	IN	_	25	case
24	7	7	CD	_	25	nummod
25	days	day	NNS	_	13	nmod
26	at	at	IN	_	28	case
27	clinical	clinical	JJ	_	28	amod
28	doses	dose	NNS	_	13	nmod
29	.	.	.	_	1	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	testing	testing	NN	_	4	nsubj
4	found	find	VBD	_	0	ROOT
5	no	no	DT	_	9	neg
6	protein	protein	NN	_	9	compound
7	binding	binding	NN	_	9	compound
8	drug	drug	NN	_	9	compound
9	interaction	interaction	NN	_	4	dobj
10	between	between	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	13	nsubj
5	,	,	,	_	4	punct
6	as	as	RB	_	4	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	post-marketing	post-marketing	JJ	_	10	amod
10	observations	observation	NNS	_	4	conj
11	,	,	,	_	4	punct
12	have	have	VBP	_	13	aux
13	shown	show	VBN	_	1	appos
14	that	that	IN	_	17	mark
15	drug2	drug2	NN	_	17	nsubj
16	can	can	MD	_	17	aux
17	reduce	reduce	VB	_	13	ccomp
18	the	the	DT	_	20	det
19	natriuretic	natriuretic	JJ	_	20	amod
20	effect	effect	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	in	in	IN	_	27	case
26	some	some	DT	_	27	det
27	patients	patient	NNS	_	20	nmod
28	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	.	.	.	_	5	punct

1	Studies	study	NNS	_	9	nsubj
2	with	with	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	agents	agent	NNS	_	1	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	have	have	VBP	_	9	aux
8	not	not	RB	_	9	neg
9	demonstrated	demonstrate	VBN	_	0	ROOT
10	a	a	DT	_	11	det
11	reduction	reduction	NN	_	9	dobj
12	in	in	IN	_	14	case
13	natriuretic	natriuretic	JJ	_	14	amod
14	effect	effect	NN	_	11	nmod
15	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	single	single	JJ	_	7	amod
4	and	and	CC	_	3	cc
5	multiple	multiple	JJ	_	3	conj
6	dose	dose	NN	_	7	compound
7	pharmacodynamics	pharmacodynamic	NNS	_	12	nsubjpass
8	and	and	CC	_	7	cc
9	pharmacokinetics	pharmacokinetic	NNS	_	7	conj
10	are	be	VBP	_	12	auxpass
11	not	not	RB	_	12	neg
12	affected	affect	VBN	_	1	dep
13	by	by	IN	_	15	case
14	multiple	multiple	JJ	_	15	amod
15	doses	dose	NNS	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	1	punct

1	Nevertheless	nevertheless	RB	_	14	advmod
2	,	,	,	_	14	punct
3	during	during	IN	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	therapy	therapy	NN	_	14	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	14	punct
11	patients	patient	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	closely	closely	RB	_	14	advmod
16	for	for	IN	_	17	case
17	signs	sign	NNS	_	14	nmod
18	of	of	IN	_	21	case
19	declining	decline	VBG	_	21	amod
20	renal	renal	JJ	_	21	amod
21	function	function	NN	_	17	nmod
22	,	,	,	_	14	punct
23	as	as	RB	_	14	cc
24	well	well	RB	_	23	mwe
25	as	as	IN	_	23	mwe
26	to	to	TO	_	27	mark
27	assure	assure	VB	_	14	conj
28	diuretic	diuretic	JJ	_	29	amod
29	efficacy	efficacy	NN	_	27	dobj
30	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	trials	trial	NNS	_	9	nmod
6	,	,	,	_	9	punct
7	drug2	drug2	NN	_	9	nsubj
8	have	have	VBP	_	9	aux
9	produced	produce	VBN	_	1	appos
10	an	a	DT	_	11	det
11	elevation	elevation	NN	_	9	dobj
12	of	of	IN	_	15	case
13	plasma	plasma	NN	_	15	compound
14	drug3	drug3	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	and	and	CC	_	11	cc
17	a	a	DT	_	18	det
18	reduction	reduction	NN	_	11	conj
19	in	in	IN	_	22	case
20	renal	renal	JJ	_	22	amod
21	drug4	drug4	NN	_	22	compound
22	clearance	clearance	NN	_	18	nmod
23	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	9	nmod
4	conducted	conduct	VBN	_	3	acl
5	in	in	IN	_	7	case
6	healthy	healthy	JJ	_	7	amod
7	subjects	subject	NNS	_	4	nmod
8	,	,	,	_	9	punct
9	mean	mean	VB	_	0	ROOT
10	pre-dose	pre-dose	JJ	_	12	amod
11	drug1	drug1	NN	_	12	compound
12	concentration	concentration	NN	_	16	nsubjpass
13	and	and	CC	_	12	cc
14	AUC	auc	NN	_	12	conj
15	were	be	VBD	_	16	auxpass
16	increased	increase	VBN	_	9	ccomp
17	by	by	IN	_	19	case
18	21	21	CD	_	19	nummod
19	%	%	NN	_	16	nmod
20	in	in	IN	_	21	case
21	subjects	subject	NNS	_	16	nmod
22	receiving	receive	VBG	_	21	acl
23	drug2	drug2	NN	_	24	compound
24	doses	dose	NNS	_	22	dobj
25	ranging	range	VBG	_	24	acl
26	from	from	IN	_	27	case
27	804	804	CD	_	25	nmod
28	to	to	TO	_	29	dep
29	1072	1072	CD	_	27	nmod
30	mg	mg	NN	_	31	compound
31	BID	BID	NNP	_	29	dobj
32	with	with	IN	_	36	case
33	drug3	drug3	NN	_	36	compound
34	15	15	CD	_	35	compound
35	mg	mg	NN	_	36	amod
36	QD	qd	NN	_	31	nmod
37	as	as	IN	_	38	mark
38	compared	compare	VBN	_	16	advcl
39	to	to	TO	_	40	case
40	subjects	subject	NNS	_	38	nmod
41	receiving	receive	VBG	_	40	acl
42	drug4	drug4	NN	_	41	dobj
43	alone	alone	RB	_	41	advmod
44	.	.	.	_	9	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	by	by	IN	_	13	case
13	drug1	drug1	NN	_	7	nmod
14	.	.	.	_	5	punct

1	Patients	patient	NNS	_	8	nsubjpass
2	on	on	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	treatment	treatment	NN	_	1	nmod
5	should	should	MD	_	8	aux
6	be	be	VB	_	8	auxpass
7	closely	closely	RB	_	8	advmod
8	monitored	monitor	VBN	_	0	ROOT
9	when	when	WRB	_	12	advmod
10	drug2	drug2	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	introduced	introduce	VBN	_	8	advcl
13	or	or	CC	_	12	cc
14	withdrawn	withdraw	VBN	_	12	conj
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	study	study	NN	_	13	nmod:tmod
5	in	in	IN	_	8	case
6	13	13	CD	_	8	nummod
7	rheumatoid	rheumatoid	JJ	_	8	amod
8	arthritis	arthritis	NN	_	13	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	RA	ra	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	patients	patient	NNS	_	13	nsubj
13	evaluated	evaluate	VBD	_	1	appos
14	the	the	DT	_	15	det
15	effects	effect	NNS	_	13	dobj
16	of	of	IN	_	18	case
17	multiple	multiple	JJ	_	18	amod
18	doses	dose	NNS	_	15	nmod
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	on	on	IN	_	23	case
22	the	the	DT	_	23	det
23	pharmacokinetics	pharmacokinetic	NNS	_	15	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	taken	take	VBN	_	23	acl
27	once	once	RB	_	28	advmod
28	weekly	weekly	RB	_	26	advmod
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	have	have	VB	_	0	ROOT
5	a	a	DT	_	7	det
6	significant	significant	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
11	of	of	IN	_	13	case
12	single	single	JJ	_	13	amod
13	doses	dose	NNS	_	10	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	4	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	7	advmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	displace	displace	VB	_	0	ROOT
8	drug2	drug2	NN	_	7	dobj
9	from	from	IN	_	14	case
10	its	its	PRP$	_	14	nmod:poss
11	human	human	JJ	_	14	amod
12	serum	serum	NN	_	14	compound
13	binding	binding	NN	_	14	compound
14	sites	site	NNS	_	7	nmod
15	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Anticoagulant	anticoagulant	JJ	_	4	amod
4	activity	activity	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	1	dep
8	,	,	,	_	7	punct
9	particularly	particularly	RB	_	14	advmod
10	in	in	IN	_	14	case
11	the	the	DT	_	14	det
12	first	first	JJ	_	14	amod
13	few	few	JJ	_	14	amod
14	days	day	NNS	_	7	nmod
15	after	after	IN	_	16	mark
16	initiating	initiate	VBG	_	14	acl
17	or	or	CC	_	16	cc
18	changing	change	VBG	_	16	conj
19	drug2	drug2	NN	_	20	compound
20	therapy	therapy	NN	_	16	dobj
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	receiving	receive	VBG	_	22	acl
24	drug3	drug3	NN	_	23	dobj
25	or	or	CC	_	24	cc
26	similar	similar	JJ	_	24	conj
27	agents	agent	NNS	_	24	dep
28	,	,	,	_	7	punct
29	since	since	IN	_	36	mark
30	these	these	DT	_	31	det
31	patients	patient	NNS	_	36	nsubj
32	are	be	VBP	_	36	cop
33	at	at	IN	_	36	case
34	an	a	DT	_	36	det
35	increased	increase	VBN	_	36	amod
36	risk	risk	NN	_	7	advcl
37	of	of	IN	_	38	case
38	bleeding	bleeding	NN	_	36	nmod
39	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	8	case
6	the	the	DT	_	8	det
7	anticoagulant	anticoagulant	JJ	_	8	amod
8	effect	effect	NN	_	2	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	was	be	VBD	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	in	in	IN	_	15	case
14	a	a	DT	_	15	det
15	group	group	NN	_	12	nmod
16	of	of	IN	_	18	case
17	healthy	healthy	JJ	_	18	amod
18	subjects	subject	NNS	_	15	nmod
19	receiving	receive	VBG	_	18	acl
20	daily	daily	JJ	_	21	amod
21	doses	dose	NNS	_	19	dobj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	that	that	WDT	_	25	nsubj
25	produced	produce	VBD	_	21	acl:relcl
26	an	a	DT	_	27	det
27	INR	inr	NN	_	25	dobj
28	-LRB-	-lrb-	-LRB-	_	31	punct
29	International	International	NNP	_	31	compound
30	Normalized	Normalized	NNP	_	31	compound
31	Ratio	Ratio	NNP	_	27	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	between	between	IN	_	34	case
34	1.2	1.2	CD	_	27	nmod
35	and	and	CC	_	34	cc
36	1.8	1.8	CD	_	34	conj
37	.	.	.	_	12	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	subjects	subject	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	alter	alter	VB	_	0	ROOT
9	drug2	drug2	NN	_	10	compound
10	pharmacokinetics	pharmacokinetic	NNS	_	8	dobj
11	and	and	CC	_	10	cc
12	the	the	DT	_	15	det
13	average	average	JJ	_	15	amod
14	anticoagulant	anticoagulant	JJ	_	15	amod
15	effect	effect	NN	_	10	conj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	as	as	IN	_	19	mark
19	determined	determine	VBN	_	8	advcl
20	by	by	IN	_	22	case
21	prothrombin	prothrombin	NN	_	22	compound
22	time	time	NN	_	19	nmod
23	.	.	.	_	8	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	one	one	CD	_	4	nummod
4	subject	subject	NN	_	5	nsubj
5	showed	show	VBD	_	0	ROOT
6	an	a	DT	_	7	det
7	increase	increase	NN	_	5	dobj
8	in	in	IN	_	9	case
9	INR	inr	NN	_	7	nmod
10	from	from	IN	_	11	case
11	1.5	1.5	CD	_	7	nmod
12	to	to	TO	_	13	case
13	2.1	2.1	CD	_	11	nmod
14	.	.	.	_	5	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	6	dobj
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	since	since	IN	_	15	mark
11	patients	patient	NNS	_	15	nsubj
12	on	on	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	may	may	MD	_	15	aux
15	experience	experience	VB	_	6	advcl
16	changes	change	NNS	_	15	dobj
17	in	in	IN	_	18	case
18	INR	inr	NN	_	16	nmod
19	and	and	CC	_	16	cc
20	an	a	DT	_	22	det
21	increased	increase	VBN	_	22	amod
22	risk	risk	NN	_	16	conj
23	of	of	IN	_	24	mark
24	bleeding	bleed	VBG	_	22	acl
25	complications	complication	NNS	_	24	dobj
26	when	when	WRB	_	31	advmod
27	a	a	DT	_	29	det
28	new	new	JJ	_	29	amod
29	medication	medication	NN	_	31	nsubjpass
30	is	be	VBZ	_	31	auxpass
31	introduced	introduce	VBN	_	24	advcl
32	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	inhibit	inhibit	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	10	nsubj
2	,	,	,	_	1	punct
3	given	give	VBN	_	1	acl
4	at	at	IN	_	8	case
5	a	a	DT	_	8	det
6	common	common	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	dosage	dosage	NN	_	3	nmod
9	,	,	,	_	1	punct
10	increased	increase	VBD	_	0	ROOT
11	the	the	DT	_	13	det
12	drug2	drug2	NN	_	13	compound
13	half-life	half-life	NN	_	10	dobj
14	by	by	IN	_	16	case
15	51	51	CD	_	16	nummod
16	%	%	NN	_	10	nmod
17	and	and	CC	_	10	cc
18	decreased	decrease	VBD	_	10	conj
19	the	the	DT	_	23	det
20	drug3	drug3	NN	_	23	compound
21	metabolic	metabolic	JJ	_	23	amod
22	clearance	clearance	NN	_	23	compound
23	rate	rate	NN	_	18	dobj
24	by	by	IN	_	26	case
25	30	30	CD	_	26	nummod
26	%	%	NN	_	18	nmod
27	.	.	.	_	10	punct

1	When	when	WRB	_	2	advmod
2	administering	administer	VBG	_	10	advcl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	concurrently	concurrently	RB	_	2	advmod
6	,	,	,	_	10	punct
7	one	one	CD	_	10	nsubj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	cop
10	alert	alert	JJ	_	0	ROOT
11	for	for	IN	_	15	case
12	possible	possible	JJ	_	15	amod
13	excessive	excessive	JJ	_	15	amod
14	drug1	drug1	NN	_	15	compound
15	effect	effect	NN	_	10	nmod
16	.	.	.	_	10	punct

1	Excessive	excessive	JJ	_	3	amod
2	glucocorticoid	glucocorticoid	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubj
4	will	will	MD	_	5	aux
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	growth-promoting	growth-promoting	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	5	punct

1	Patients	patient	NNS	_	6	nsubj
2	with	with	IN	_	4	case
3	ACTH	acth	NN	_	4	compound
4	deficiency	deficiency	NN	_	1	nmod
5	should	should	MD	_	6	aux
6	have	have	VB	_	0	ROOT
7	their	they	PRP$	_	8	nmod:poss
8	drug1	drug1	NN	_	6	dobj
9	-	-	:	_	8	punct
10	replacement	replacement	NN	_	11	compound
11	dose	dose	NN	_	8	dep
12	carefully	carefully	RB	_	13	advmod
13	adjusted	adjust	VBN	_	11	acl
14	to	to	TO	_	15	mark
15	avoid	avoid	VB	_	13	xcomp
16	an	a	DT	_	18	det
17	inhibitory	inhibitory	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	on	on	IN	_	20	case
20	growth	growth	NN	_	18	nmod
21	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	17	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	2	nmod
7	with	with	IN	_	10	case
8	chronic	chronic	JJ	_	10	amod
9	renal	renal	JJ	_	10	amod
10	insufficiency	insufficiency	NN	_	6	nmod
11	receiving	receive	VBG	_	10	acl
12	glucocorticoid	glucocorticoid	NN	_	13	compound
13	therapy	therapy	NN	_	11	dobj
14	has	have	VBZ	_	17	aux
15	not	not	RB	_	17	neg
16	been	be	VBN	_	17	auxpass
17	evaluated	evaluate	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Concomitant	concomitant	JJ	_	3	amod
2	glucocorticoid	glucocorticoid	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	growth-promoting	growth-promoting	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	5	punct

1	If	if	IN	_	5	mark
2	drug1	drug1	NN	_	3	compound
3	replacement	replacement	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	required	require	VBN	_	13	advcl
6	,	,	,	_	13	punct
7	the	the	DT	_	9	det
8	drug2	drug2	NN	_	9	compound
9	dose	dose	NN	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	carefully	carefully	RB	_	13	advmod
13	adjusted	adjust	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	controlled	controlled	JJ	_	8	amod
8	studies	study	NNS	_	4	nmod
9	of	of	IN	_	12	case
10	drug1	drug1	NN	_	12	compound
11	s	s	NNS	_	12	compound
12	interaction	interaction	NN	_	8	nmod
13	with	with	IN	_	14	case
14	drugs	drug	NNS	_	12	nmod
15	commonly	commonly	RB	_	16	advmod
16	used	use	VBN	_	14	acl
17	in	in	IN	_	21	case
18	chronic	chronic	JJ	_	21	amod
19	renal	renal	JJ	_	21	amod
20	insufficiency	insufficiency	NN	_	21	compound
21	patients	patient	NNS	_	16	nmod
22	.	.	.	_	2	punct

1	Limited	limited	JJ	_	3	amod
2	published	publish	VBN	_	3	amod
3	data	datum	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	7	compound
7	treatment	treatment	NN	_	8	nsubj
8	increases	increase	VBZ	_	4	ccomp
9	cytochrome	cytochrome	NN	_	10	compound
10	P450	p450	NN	_	14	nsubj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	CP450	cp450	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	mediated	mediate	VBD	_	8	ccomp
15	drug2	drug2	JJ	_	16	amod
16	clearance	clearance	NN	_	14	dobj
17	in	in	IN	_	18	case
18	man	man	NN	_	14	nmod
19	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	drug1	drug1	NN	_	6	compound
6	administration	administration	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	alter	alter	VB	_	3	ccomp
9	the	the	DT	_	10	det
10	clearance	clearance	NN	_	8	dobj
11	of	of	IN	_	12	case
12	compounds	compound	NNS	_	10	nmod
13	known	know	VBN	_	12	acl
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	auxpass
16	metabolized	metabolize	VBN	_	13	xcomp
17	by	by	IN	_	20	case
18	CP450	cp450	NN	_	20	compound
19	liver	liver	NN	_	20	compound
20	enzymes	enzyme	NNS	_	16	nmod
21	-LRB-	-lrb-	-LRB-	_	24	punct
22	e.g.	e.g.	FW	_	24	dep
23	,	,	,	_	24	punct
24	drug2	drug2	NN	_	20	dep
25	,	,	,	_	24	punct
26	drug3	drug3	NN	_	24	conj
27	,	,	,	_	24	punct
28	drug4	drug4	NN	_	24	conj
29	,	,	,	_	24	punct
30	drug5	drug5	NN	_	24	appos
31	-RRB-	-rrb-	-RRB-	_	24	punct
32	.	.	.	_	3	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	advisable	advisable	JJ	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	nmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drugs	drug	NNS	_	10	nmod
14	known	know	VBN	_	13	acl
15	to	to	TO	_	17	mark
16	be	be	VB	_	17	auxpass
17	metabolized	metabolize	VBN	_	14	xcomp
18	by	by	IN	_	21	case
19	CP450	cp450	NN	_	21	compound
20	liver	liver	NN	_	21	compound
21	enzymes	enzyme	NNS	_	17	nmod
22	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	other	other	JJ	_	7	amod
6	addictive	addictive	JJ	_	7	amod
7	medications	medication	NNS	_	3	nmod
8	,	,	,	_	3	punct
9	in	in	IN	_	13	mark
10	that	that	IN	_	13	mark
11	it	it	PRP	_	13	nsubj
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	3	advcl
14	the	the	DT	_	15	det
15	likelyhood	likelyhood	NN	_	13	dobj
16	of	of	IN	_	17	case
17	addiction	addiction	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	abuse	abuse	NN	_	17	conj
20	.	.	.	_	3	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	4	conj
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	0	ROOT
10	the	the	DT	_	13	det
11	CNS	cns	NN	_	13	compound
12	depressant	depressant	NN	_	13	compound
13	effects	effect	NNS	_	9	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	or	or	CC	_	15	cc
17	these	these	DT	_	19	det
18	other	other	JJ	_	19	amod
19	medications	medication	NNS	_	15	conj
20	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effectiveness	effectiveness	NN	_	3	dobj
6	of	of	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	,	,	,	_	8	punct
10	certain	certain	JJ	_	11	amod
11	drug3	drug3	NN	_	8	conj
12	,	,	,	_	8	punct
13	drug4	drug4	NN	_	8	conj
14	,	,	,	_	8	punct
15	drug5	drug5	NN	_	8	conj
16	,	,	,	_	8	punct
17	drug6	drug6	NN	_	8	conj
18	,	,	,	_	8	punct
19	drug7	drug7	NN	_	8	conj
20	,	,	,	_	8	punct
21	and	and	CC	_	8	cc
22	drug8	drug8	NN	_	8	conj
23	.	.	.	_	3	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	drug1	drug1	NN	_	5	dobj
7	with	with	IN	_	8	case
8	compounds	compound	NNS	_	5	nmod
9	that	that	WDT	_	11	nsubjpass
10	are	be	VBP	_	11	auxpass
11	metabolized/eliminated	metabolized/eliminated	VBN	_	8	acl:relcl
12	predominantly	predominantly	RB	_	11	advmod
13	by	by	IN	_	16	case
14	the	the	DT	_	16	det
15	UGT1A1	ugt1a1	NN	_	16	compound
16	pathway	pathway	NN	_	11	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	e.g.	e.g.	FW	_	19	dep
19	drug2	drug2	NN	_	16	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	.	.	.	_	3	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	treatment	treatment	NN	_	5	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	resulted	result	VBD	_	0	ROOT
6	in	in	IN	_	10	case
7	a	a	DT	_	10	det
8	21	21	CD	_	9	compound
9	%	%	NN	_	10	amod
10	increase	increase	NN	_	5	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	AUC	auc	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	5	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	drug1	drug1	NN	_	5	dobj
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	CYP2B6	cyp2b6	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	CYP2C8	cyp2c8	NN	_	3	conj
6	in	in	FW	_	7	compound
7	vitro	vitro	FW	_	2	advmod
8	with	with	IN	_	10	case
9	Ki	ki	NN	_	10	compound
10	values	value	NNS	_	2	nmod
11	of	of	IN	_	12	case
12	6	6	CD	_	10	nmod
13	and	and	CC	_	12	cc
14	1-2	1-2	CD	_	12	conj
15	?	?	.	_	2	punct
16	M	m	NN	_	2	dep
17	,	,	,	_	16	punct
18	respectively	respectively	RB	_	16	advmod
19	.	.	.	_	2	punct

1	Systemic	systemic	JJ	_	2	amod
2	exposure	exposure	NN	_	10	nsubjpass
3	to	to	TO	_	4	case
4	substrates	substrate	NNS	_	2	nmod
5	of	of	IN	_	6	case
6	CYP2B6	cyp2b6	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	CYP2C8	cyp2c8	NN	_	6	conj
9	is	be	VBZ	_	10	auxpass
10	expected	expect	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	increase	increase	VB	_	10	xcomp
13	when	when	WRB	_	14	advmod
14	co-administered	co-administer	VBN	_	12	advcl
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	.	.	.	_	10	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	substrates	substrate	NNS	_	5	dobj
7	of	of	IN	_	8	case
8	CYP2B6	cyp2b6	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	CYP2C8	cyp2c8	NN	_	8	conj
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	5	nmod
13	.	.	.	_	3	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	9	advcl
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	9	punct
7	drug2	drug2	NN	_	9	nsubj
8	may	may	MD	_	9	aux
9	enhance	enhance	VB	_	0	ROOT
10	or	or	CC	_	9	cc
11	precipitate	precipitate	VB	_	9	conj
12	bradycardia	bradycardia	NN	_	9	dobj
13	,	,	,	_	12	punct
14	A.V.	A.V.	NNP	_	12	appos

1	block	block	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	arrhythmia	arrhythmia	NN	_	1	conj
4	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	23	nsubj
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	that	that	WDT	_	6	nsubj
6	stimulate	stimulate	VBP	_	4	acl:relcl
7	alpha-adrenergic	alpha-adrenergic	JJ	_	8	amod
8	receptors	receptor	NNS	_	6	dobj
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	e.g.	e.g.	FW	_	12	dep
11	,	,	,	_	12	punct
12	drug1	drug1	NN	_	2	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug3	drug3	NN	_	12	conj
17	,	,	,	_	12	punct
18	drug4	drug4	NN	_	12	conj
19	or	or	CC	_	12	cc
20	drug5	drug5	NN	_	12	conj
21	-RRB-	-rrb-	-RRB-	_	12	punct
22	may	may	MD	_	23	aux
23	enhance	enhance	VB	_	0	ROOT
24	or	or	CC	_	23	cc
25	potentiate	potentiate	VB	_	23	conj
26	the	the	DT	_	28	det
27	pressor	pressor	JJ	_	28	amod
28	effects	effect	NNS	_	23	dobj
29	of	of	IN	_	30	case
30	drug6	drug6	NN	_	28	nmod
31	.	.	.	_	23	punct
32	Therefore	therefore	RB	_	37	advmod
33	,	,	,	_	37	punct
34	caution	caution	NN	_	37	nsubjpass
35	should	should	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	used	use	VBN	_	23	parataxis
38	when	when	WRB	_	41	advmod
39	drug7	drug7	NN	_	41	nsubjpass
40	is	be	VBZ	_	41	auxpass
41	administered	administer	VBN	_	37	advcl
42	concomitantly	concomitantly	RB	_	41	advmod
43	with	with	IN	_	44	case
44	agents	agent	NNS	_	41	nmod
45	that	that	WDT	_	46	nsubj
46	cause	cause	VBP	_	44	acl:relcl
47	vasoconstriction	vasoconstriction	NN	_	46	dobj
48	.	.	.	_	23	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	concomitantly	concomitantly	RB	_	8	advmod
8	treated	treat	VBN	_	6	acl
9	with	with	IN	_	12	case
10	salt-retaining	salt-retaining	JJ	_	12	amod
11	steroid	steroid	NN	_	12	compound
12	therapy	therapy	NN	_	8	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	i.e.	i.e.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug2	drug2	NN	_	12	dep
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	4	punct
19	with	with	IN	_	23	nmod
20	or	or	CC	_	23	cc
21	without	without	IN	_	23	conj
22	salt	salt	NN	_	23	compound
23	supplementation	supplementation	NN	_	4	nmod
24	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	potential	potential	NN	_	9	nsubjpass
3	for	for	IN	_	5	case
4	supine	supine	NN	_	5	compound
5	hypertension	hypertension	NN	_	2	nmod
6	should	should	MD	_	9	aux
7	be	be	VB	_	9	auxpass
8	carefully	carefully	RB	_	9	advmod
9	monitored	monitor	VBN	_	0	ROOT
10	in	in	IN	_	12	case
11	these	these	DT	_	12	det
12	patients	patient	NNS	_	9	nmod
13	and	and	CC	_	9	cc
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	minimized	minimize	VBN	_	9	conj
17	by	by	IN	_	19	mark
18	either	either	CC	_	19	cc:preconj
19	reducing	reduce	VBG	_	16	advcl
20	the	the	DT	_	21	det
21	dose	dose	NN	_	19	dobj
22	of	of	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	or	or	CC	_	19	cc
25	decreasing	decrease	VBG	_	19	conj
26	the	the	DT	_	28	det
27	salt	salt	NN	_	28	compound
28	intake	intake	NN	_	25	dobj
29	prior	prior	RB	_	25	advmod
30	to	to	TO	_	31	case
31	initiation	initiation	NN	_	29	nmod
32	of	of	IN	_	33	case
33	treatment	treatment	NN	_	31	nmod
34	with	with	IN	_	31	nmod
35	.	.	.	_	9	punct

1	drug1	drug1	NN	_	15	dep
2	.	.	.	_	1	punct
3	drug2	drug2	NN	_	15	nsubj
4	,	,	,	_	3	punct
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug3	drug3	NN	_	3	nmod
8	,	,	,	_	7	punct
9	drug4	drug4	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug5	drug5	NN	_	7	conj
13	,	,	,	_	3	punct
14	can	can	MD	_	15	aux
15	antagonize	antagonize	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	effects	effect	NNS	_	15	dobj
18	of	of	IN	_	19	case
19	drug6	drug6	NN	_	17	nmod
20	.	.	.	_	15	punct
21	Potential	potential	JJ	_	15	dep
22	for	for	IN	_	24	case
23	Drug	drug	NN	_	24	compound
24	Interactions	interaction	NNS	_	21	nmod
25	:	:	:	_	15	punct
26	It	it	PRP	_	27	nsubj
27	appears	appear	VBZ	_	15	parataxis
28	possible	possible	JJ	_	27	xcomp
29	,	,	,	_	27	punct
30	although	although	IN	_	32	mark
31	there	there	EX	_	32	expl
32	is	be	VBZ	_	27	advcl
33	no	no	DT	_	36	neg
34	supporting	support	VBG	_	36	amod
35	experimental	experimental	JJ	_	36	amod
36	evidence	evidence	NN	_	32	nsubj
37	,	,	,	_	32	punct
38	that	that	IN	_	50	mark
39	the	the	DT	_	42	det
40	high	high	JJ	_	42	amod
41	renal	renal	JJ	_	42	amod
42	clearance	clearance	NN	_	50	nsubj
43	of	of	IN	_	44	case
44	drug7	drug7	NN	_	42	nmod
45	-LRB-	-lrb-	-LRB-	_	47	punct
46	a	a	DT	_	47	det
47	base	base	NN	_	44	appos
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	is	be	VBZ	_	50	cop
50	due	due	JJ	_	32	ccomp
51	to	to	TO	_	54	case
52	active	active	JJ	_	54	amod
53	tubular	tubular	JJ	_	54	amod
54	secretion	secretion	NN	_	50	nmod
55	by	by	IN	_	58	case
56	the	the	DT	_	58	det
57	base-secreting	base-secreting	JJ	_	58	amod
58	system	system	NN	_	54	nmod
59	also	also	RB	_	60	advmod
60	responsible	responsible	JJ	_	54	amod
61	for	for	IN	_	63	case
62	the	the	DT	_	63	det
63	secretion	secretion	NN	_	60	nmod
64	of	of	IN	_	66	case
65	such	such	JJ	_	66	amod
66	drugs	drug	NNS	_	63	nmod
67	as	as	IN	_	68	case
68	drug8	drug8	NN	_	66	nmod
69	,	,	,	_	68	punct
70	drug9	drug9	NN	_	68	conj
71	,	,	,	_	68	punct
72	drug10	drug10	NN	_	68	conj
73	,	,	,	_	68	punct
74	drug11	drug11	NN	_	68	conj
75	,	,	,	_	68	punct
76	drug12	drug12	NN	_	68	conj
77	,	,	,	_	68	punct
78	drug13	drug13	NN	_	68	conj
79	,	,	,	_	68	punct
80	and	and	CC	_	68	cc
81	drug14	drug14	NN	_	68	conj
82	.	.	.	_	15	punct

1	Thus	thus	RB	_	6	advmod
2	there	there	EX	_	6	expl
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	a	a	DT	_	6	det
6	potential	potential	NN	_	0	ROOT
7	for	for	IN	_	9	case
8	drug-drug	drug-drug	JJ	_	9	amod
9	interactions	interaction	NNS	_	6	nmod
10	with	with	IN	_	12	case
11	these	these	DT	_	12	det
12	drugs	drug	NNS	_	9	nmod
13	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	enhance	enhance	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	sedative	sedative	NN	_	9	compound
9	activity	activity	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	11	punct
17	and	and	CC	_	11	cc
18	drug5	drug5	NN	_	11	conj
19	.	.	.	_	4	punct

1	Peripheral	peripheral	JJ	_	2	amod
2	Neuropathy	neuropathy	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Medications	medication	NNS	_	14	nsubjpass
5	known	know	VBN	_	4	acl
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	associated	associate	VBN	_	5	xcomp
9	with	with	IN	_	11	case
10	peripheral	peripheral	JJ	_	11	amod
11	neuropathy	neuropathy	NN	_	8	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	used	use	VBN	_	2	appos
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	drug1	drug1	NN	_	19	dobj
21	.	.	.	_	2	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	7	case
5	10	10	CD	_	7	nummod
6	healthy	healthy	JJ	_	7	amod
7	women	woman	NNS	_	2	nmod
8	,	,	,	_	7	punct
9	the	the	DT	_	11	det
10	pharmacokinetic	pharmacokinetic	JJ	_	11	amod
11	profiles	profile	NNS	_	33	nsubjpass
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	following	follow	VBG	_	17	case
17	administration	administration	NN	_	11	nmod
18	of	of	IN	_	21	case
19	a	a	DT	_	21	det
20	single	single	JJ	_	21	amod
21	dose	dose	NN	_	17	nmod
22	containing	contain	VBG	_	21	acl
23	1.0	1.0	CD	_	24	nummod
24	mg	mg	NN	_	22	dobj
25	of	of	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	and	and	CC	_	24	cc
28	75	75	CD	_	29	nummod
29	g	g	NN	_	24	conj
30	of	of	IN	_	31	case
31	drug5	drug5	NN	_	29	nmod
32	were	be	VBD	_	33	auxpass
33	studied	study	VBN	_	7	acl:relcl
34	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	4	nsubj
3	were	be	VBD	_	4	cop
4	similar	similar	JJ	_	0	ROOT
5	with	with	IN	_	4	dep
6	and	and	CC	_	5	dep
7	without	without	IN	_	8	case
8	coadministration	coadministration	NN	_	6	conj
9	of	of	IN	_	12	case
10	drug1	drug1	NN	_	12	compound
11	200	200	CD	_	12	nummod
12	mg/day	mg/day	NN	_	8	nmod
13	to	to	TO	_	15	case
14	steady-state	steady-state	JJ	_	15	amod
15	levels	level	NNS	_	8	nmod
16	.	.	.	_	4	punct

1	Important	important	JJ	_	2	amod
2	Non	non	NN	_	0	ROOT
3	-	-	:	_	2	punct
4	drug1	drug1	NN	_	7	compound
5	Drug	drug	NN	_	7	compound
6	Interactions	interaction	NNS	_	7	compound
7	Drugs	drug	NNS	_	2	dep
8	That	that	WDT	_	9	nsubj
9	Interfere	interfere	VBP	_	7	acl:relcl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	:	:	:	_	2	punct
13	Concomitant	concomitant	JJ	_	14	amod
14	use	use	NN	_	2	dep
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug4	drug4	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug5	drug5	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug6	drug6	NN	_	16	conj
23	,	,	,	_	16	punct
24	drug7	drug7	NN	_	16	conj
25	,	,	,	_	16	punct
26	drug8	drug8	NN	_	16	conj
27	,	,	,	_	16	punct
28	drug9	drug9	NN	_	16	conj
29	,	,	,	_	16	punct
30	drug10	drug10	NN	_	16	conj
31	,	,	,	_	16	punct
32	or	or	CC	_	16	cc
33	certain	certain	JJ	_	35	amod
34	herbal	herbal	JJ	_	35	amod
35	supplements	supplement	NNS	_	16	conj
36	such	such	JJ	_	38	case
37	as	as	IN	_	36	mwe
38	St.	St.	NNP	_	35	nmod

1	drug1	drug1	NN	_	5	nsubj
2	with	with	IN	_	3	case
3	drug2	drug2	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	reduce	reduce	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	effectiveness	effectiveness	NN	_	5	dobj
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	contraception	contraception	NN	_	7	nmod
11	and	and	CC	_	7	cc
12	up	up	RB	_	14	advmod
13	to	to	TO	_	14	dep
14	one	one	CD	_	15	nummod
15	month	month	NN	_	7	conj
16	after	after	IN	_	15	case
17	discontinuation	discontinuation	NN	_	15	dep
18	of	of	IN	_	21	case
19	these	these	DT	_	21	det
20	concomitant	concomitant	JJ	_	21	amod
21	therapies	therapy	NNS	_	17	nmod
22	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	women	woman	NNS	_	14	nsubj
4	requiring	require	VBG	_	3	acl
5	treatment	treatment	NN	_	4	dobj
6	with	with	IN	_	7	case
7	one	one	CD	_	5	nmod
8	or	or	CC	_	7	cc
9	more	more	JJR	_	7	conj
10	of	of	IN	_	12	case
11	these	these	DT	_	12	det
12	drugs	drug	NNS	_	7	nmod
13	must	must	MD	_	14	aux
14	use	use	VB	_	0	ROOT
15	two	two	CD	_	21	nummod
16	OTHER	other	JJ	_	21	amod
17	effective	effective	JJ	_	21	amod
18	or	or	CC	_	17	cc
19	highly	highly	RB	_	20	advmod
20	effective	effective	JJ	_	17	conj
21	methods	method	NNS	_	14	dobj
22	of	of	IN	_	23	case
23	contraception	contraception	NN	_	21	nmod
24	or	or	CC	_	23	cc
25	abstain	abstain	NN	_	23	conj
26	from	from	IN	_	29	case
27	heterosexual	heterosexual	JJ	_	29	amod
28	sexual	sexual	JJ	_	29	amod
29	contact	contact	NN	_	14	nmod
30	while	while	IN	_	31	mark
31	taking	take	VBG	_	14	advcl
32	drug1	drug1	NN	_	31	dobj
33	.	.	.	_	14	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	and	and	CC	_	7	cc
11	other	other	JJ	_	12	amod
12	drug4	drug4	NN	_	7	conj
13	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	increase	increase	VBP	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	reduce	reduce	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	antihypertensive	antihypertensive	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	and	and	CC	_	8	cc
14	drug5	drug5	NN	_	8	conj
15	.	.	.	_	3	punct

1	Interactions	interaction	NNS	_	11	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	conj
7	have	have	VBP	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	fully	fully	RB	_	11	advmod
11	evaluated	evaluate	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Drugs	drug	NNS	_	19	nsubjpass
2	which	which	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	potentiate	potentiate	VB	_	1	acl:relcl
5	the	the	DT	_	7	det
6	myeloproliferative	myeloproliferative	JJ	_	7	amod
7	effects	effect	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	9	punct
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug2	drug2	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	1	punct
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	used	use	VBN	_	0	ROOT
20	with	with	IN	_	21	case
21	caution	caution	NN	_	19	nmod
22	.	.	.	_	19	punct

1	The	the	DT	_	4	det
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	binding	binding	NN	_	12	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	to	to	TO	_	10	case
8	human	human	JJ	_	10	amod
9	plasma	plasma	NN	_	10	compound
10	proteins	protein	NNS	_	4	nmod
11	is	be	VBZ	_	12	aux
12	unaffected	unaffected	JJ	_	0	ROOT
13	by	by	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	drug3	drug3	NN	_	20	nsubj
18	does	do	VBZ	_	20	aux
19	not	not	RB	_	20	neg
20	alter	alter	VB	_	12	conj
21	the	the	DT	_	23	det
22	prothrombin	prothrombin	NN	_	23	compound
23	time	time	NN	_	20	dobj
24	of	of	IN	_	26	case
25	normal	normal	JJ	_	26	amod
26	volunteers	volunteer	NNS	_	23	nmod
27	.	.	.	_	12	punct

1	However	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	increased	increase	VBD	_	5	amod
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	bleeding	bleeding	NN	_	5	conj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	on	on	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	drug1	drug1	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	18	compound
18	therapy	therapy	NN	_	15	conj
19	.	.	.	_	10	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	administering	administer	VBG	_	6	advcl
9	drug1	drug1	NN	_	8	dobj
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	8	nmod
12	on	on	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	adult	adult	JJ	_	4	amod
3	diabetic	diabetic	JJ	_	4	amod
4	patients	patient	NNS	_	13	nmod
5	under	under	IN	_	6	case
6	treatment	treatment	NN	_	4	nmod
7	with	with	IN	_	9	case
8	either	either	CC	_	9	cc:preconj
9	drug1	drug1	NN	_	6	nmod
10	or	or	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	there	there	EX	_	13	expl
13	is	be	VBZ	_	0	ROOT
14	no	no	DT	_	15	neg
15	change	change	NN	_	13	nsubj
16	in	in	IN	_	19	case
17	the	the	DT	_	19	det
18	clinical	clinical	JJ	_	19	amod
19	effects	effect	NNS	_	13	nmod
20	of	of	IN	_	22	case
21	either	either	CC	_	22	cc:preconj
22	drug3	drug3	NN	_	19	nmod
23	or	or	CC	_	22	cc
24	the	the	DT	_	25	det
25	drug4	drug4	NN	_	22	conj
26	.	.	.	_	13	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	other	other	JJ	_	4	amod
4	drug2	drug2	NN	_	1	conj
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	reduce	reduce	VB	_	7	xcomp
10	the	the	DT	_	12	det
11	tubular	tubular	JJ	_	12	amod
12	secretion	secretion	NN	_	9	dobj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	in	in	IN	_	18	case
16	an	a	DT	_	18	det
17	animal	animal	NN	_	18	compound
18	model	model	NN	_	9	nmod
19	,	,	,	_	9	punct
20	possibly	possibly	RB	_	21	advmod
21	enhancing	enhance	VBG	_	9	advcl
22	the	the	DT	_	23	det
23	toxicity	toxicity	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	.	.	.	_	7	punct

1	Laboratory	Laboratory	NNP	_	2	compound
2	Tests	Tests	NNP	_	0	ROOT
3	Because	because	IN	_	11	mark
4	serious	serious	JJ	_	7	amod
5	GI	gi	NN	_	7	compound
6	tract	tract	NN	_	7	compound
7	ulceration	ulceration	NN	_	11	nsubj
8	and	and	CC	_	7	cc
9	bleeding	bleeding	NN	_	7	conj
10	can	can	MD	_	11	aux
11	occur	occur	VB	_	2	acl
12	without	without	IN	_	13	mark
13	warning	warn	VBG	_	11	advcl
14	symptoms	symptom	NNS	_	13	dobj
15	,	,	,	_	2	punct
16	physicians	physician	NNS	_	18	nsubj
17	should	should	MD	_	18	aux
18	follow	follow	VB	_	2	acl:relcl
19	chronically	chronically	RB	_	20	advmod
20	treated	treat	VBN	_	21	amod
21	patients	patient	NNS	_	18	dobj
22	for	for	IN	_	24	case
23	the	the	DT	_	24	det
24	signs	sign	NNS	_	21	nmod
25	and	and	CC	_	24	cc
26	symptoms	symptom	NNS	_	24	conj
27	of	of	IN	_	28	case
28	ulceration	ulceration	NN	_	24	nmod
29	and	and	CC	_	28	cc
30	bleeding	bleeding	NN	_	28	conj
31	and	and	CC	_	18	cc
32	should	should	MD	_	33	aux
33	inform	inform	VB	_	18	conj
34	them	they	PRP	_	33	dobj
35	of	of	IN	_	37	case
36	the	the	DT	_	37	det
37	importance	importance	NN	_	33	nmod
38	of	of	IN	_	40	case
39	this	this	DT	_	40	det
40	follow-up	follow-up	NN	_	37	nmod
41	.	.	.	_	2	punct

1	An	a	DT	_	2	det
2	inhibitor	inhibitor	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	CYP2C8	cyp2c8	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	4	nmod
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	may	may	MD	_	11	aux
11	increase	increase	VB	_	0	ROOT
12	the	the	DT	_	13	det
13	AUC	auc	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	an	a	DT	_	18	det
18	inducer	inducer	NN	_	13	conj
19	of	of	IN	_	20	case
20	CYP2C8	cyp2c8	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	24	punct
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug3	drug3	NN	_	20	nmod
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	may	may	MD	_	27	aux
27	decrease	decrease	VB	_	11	dep
28	the	the	DT	_	29	det
29	AUC	auc	NN	_	27	dobj
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	if	if	IN	_	5	mark
4	an	a	DT	_	5	det
5	inhibitor	inhibitor	NN	_	12	nsubjpass
6	or	or	CC	_	5	cc
7	an	a	DT	_	8	det
8	inducer	inducer	NN	_	5	conj
9	of	of	IN	_	10	case
10	CYP2C8	cyp2c8	NN	_	5	nmod
11	is	be	VBZ	_	12	auxpass
12	started	start	VBN	_	0	ROOT
13	or	or	CC	_	12	cc
14	stopped	stop	VBN	_	12	conj
15	during	during	IN	_	16	case
16	treatment	treatment	NN	_	12	nmod
17	with	with	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	,	,	,	_	12	punct
20	changes	change	NNS	_	26	nsubjpass
21	in	in	IN	_	23	case
22	diabetes	diabetes	NN	_	23	compound
23	treatment	treatment	NN	_	20	nmod
24	may	may	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	needed	need	VBN	_	12	parataxis
27	based	base	VBN	_	26	dep
28	upon	upon	IN	_	30	case
29	clinical	clinical	JJ	_	30	amod
30	response	response	NN	_	27	nmod
31	.	.	.	_	12	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	properties	property	NNS	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	altered	alter	VBN	_	0	ROOT
8	by	by	IN	_	10	case
9	the	the	DT	_	10	det
10	addition	addition	NN	_	7	nmod
11	of	of	IN	_	13	case
12	either	either	CC	_	13	cc:preconj
13	drug2	drug2	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	or	or	CC	_	13	cc
17	the	the	DT	_	18	det
18	combination	combination	NN	_	13	conj
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	drug5	drug5	NN	_	20	conj
23	.	.	.	_	7	punct

1	No	no	DT	_	4	neg
2	clinically	clinically	RB	_	3	advmod
3	significant	significant	JJ	_	4	amod
4	changes	change	NNS	_	11	nsubjpass
5	to	to	TO	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	drug2	drug2	NN	_	9	compound
9	pharmacokinetics	pharmacokinetic	NNS	_	6	conj
10	were	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	following	follow	VBG	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	administration	administration	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	11	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	8	case
6	the	the	DT	_	8	det
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	properties	property	NNS	_	2	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreases	decrease	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	elimination	elimination	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	causing	cause	VBG	_	4	acl
8	an	a	DT	_	9	det
9	increase	increase	NN	_	7	dobj
10	in	in	IN	_	12	case
11	overall	overall	JJ	_	12	amod
12	exposure	exposure	NN	_	9	nmod
13	.	.	.	_	2	punct
14	The	the	DT	_	15	det
15	addition	addition	NN	_	18	nsubj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	has	have	VBZ	_	2	parataxis
19	no	no	DT	_	22	neg
20	clinically	clinically	RB	_	21	advmod
21	significant	significant	JJ	_	22	amod
22	effect	effect	NN	_	18	dobj
23	on	on	IN	_	26	case
24	the	the	DT	_	26	det
25	pharmacokinetic	pharmacokinetic	JJ	_	26	amod
26	properties	property	NNS	_	18	nmod
27	of	of	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	.	.	.	_	2	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	0	ROOT
4	of	of	IN	_	7	case
5	11	11	CD	_	7	nummod
6	HIV-infected	hiv-infected	JJ	_	7	amod
7	patients	patient	NNS	_	3	nmod
8	receiving	receive	VBG	_	7	acl
9	drug1	drug1	NN	_	8	dobj
10	-	-	:	_	12	punct
11	maintenance	maintenance	NN	_	12	compound
12	therapy	therapy	NN	_	3	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	40	40	CD	_	15	nummod
15	mg	mg	NN	_	12	appos
16	and	and	CC	_	15	cc
17	90	90	CD	_	18	nummod
18	mg	mg	NN	_	15	conj
19	daily	daily	JJ	_	15	amod
20	-RRB-	-rrb-	-RRB-	_	15	punct
21	with	with	IN	_	23	case
22	600	600	CD	_	23	nummod
23	mg	mg	NN	_	12	nmod
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	twice	twice	RB	_	27	advmod
27	daily	daily	RB	_	12	advmod
28	-LRB-	-lrb-	-LRB-	_	33	punct
29	twice	twice	RB	_	33	dep
30	the	the	DT	_	33	det
31	currently	currently	RB	_	32	advmod
32	recommended	recommend	VBN	_	33	amod
33	dose	dose	NN	_	12	dep
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	,	,	,	_	12	punct
36	oral	oral	JJ	_	38	amod
37	drug3	drug3	NN	_	38	compound
38	clearance	clearance	NN	_	39	nsubj
39	increased	increase	VBD	_	12	acl:relcl
40	22	22	CD	_	41	nummod
41	%	%	NN	_	39	dobj
42	-LRB-	-lrb-	-LRB-	_	45	punct
43	90	90	CD	_	44	compound
44	%	%	NN	_	45	amod
45	CI	ci	NN	_	41	dep
46	6	6	CD	_	45	amod
47	%	%	NN	_	46	dep
48	to	to	TO	_	50	case
49	42	42	CD	_	50	nummod
50	%	%	NN	_	47	nmod
51	-RRB-	-rrb-	-RRB-	_	45	punct
52	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	alteration	alteration	NN	_	5	nsubj
3	will	will	MD	_	5	aux
4	not	not	RB	_	5	neg
5	result	result	VB	_	0	ROOT
6	in	in	IN	_	10	case
7	a	a	DT	_	10	det
8	drug1	drug1	NN	_	10	compound
9	dose	dose	NN	_	10	compound
10	modification	modification	NN	_	5	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	majority	majority	NN	_	10	nmod
14	of	of	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	;	;	:	_	5	punct

1	however	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	an	a	DT	_	6	det
4	increased	increase	VBN	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	dose	dose	NN	_	9	nsubjpass
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	in	in	IN	_	13	case
11	a	a	DT	_	13	det
12	small	small	JJ	_	13	amod
13	number	number	NN	_	9	nmod
14	of	of	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	.	.	.	_	9	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	6	advmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	drug3	drug3	NN	_	12	compound
12	USP	usp	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	because	because	IN	_	17	mark
15	they	they	PRP	_	17	nsubj
16	may	may	MD	_	17	aux
17	have	have	VB	_	6	advcl
18	additive	additive	JJ	_	19	amod
19	effects	effect	NNS	_	17	dobj
20	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	27	csubjpass
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	4	nmod
9	being	be	VBG	_	10	auxpass
10	treated	treat	VBN	_	8	acl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	4	punct
16	since	since	IN	_	18	case
17	the	the	DT	_	18	det
18	action	action	NN	_	4	nmod
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	on	on	IN	_	24	case
22	the	the	DT	_	24	det
23	vascular	vascular	JJ	_	24	amod
24	system	system	NN	_	18	nmod
25	may	may	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	potentiated	potentiate	VBN	_	0	ROOT
28	.	.	.	_	27	punct

1	A	a	DT	_	2	det
2	study	study	NN	_	6	nsubj
3	published	publish	VBN	_	2	acl
4	in	in	IN	_	5	case
5	2002	2002	CD	_	3	nmod
6	found	find	VBD	_	0	ROOT
7	that	that	IN	_	9	mark
8	drug1	drug1	NN	_	9	nsubj
9	causes	cause	VBZ	_	6	ccomp
10	a	a	DT	_	13	det
11	statistically	statistically	RB	_	12	advmod
12	significant	significant	JJ	_	13	amod
13	increase	increase	NN	_	9	dobj
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	clearance	clearance	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	1984	1984	CD	_	13	nmod
3	,	,	,	_	13	punct
4	Drs	Drs	NNP	_	5	compound
5	Rimmer	Rimmer	NNP	_	13	nsubj
6	and	and	CC	_	5	cc
7	Richens	Richens	NNP	_	5	conj
8	at	at	IN	_	10	case
9	the	the	DT	_	10	det
10	University	University	NNP	_	5	nmod
11	of	of	IN	_	12	case
12	Wales	Wales	NNP	_	10	nmod
13	reported	report	VBD	_	0	ROOT
14	that	that	IN	_	19	mark
15	administering	administer	VBG	_	19	csubj
16	drug1	drug1	NN	_	15	dobj
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	15	nmod
19	lowered	lower	VBD	_	13	ccomp
20	the	the	DT	_	23	det
21	serum	serum	NN	_	23	compound
22	drug3	drug3	NN	_	23	compound
23	concentration	concentration	NN	_	19	dobj
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	23	nmod
26	with	with	IN	_	28	case
27	treatment-resistant	treatment-resistant	JJ	_	28	amod
28	epilepsy	epilepsy	NN	_	25	nmod
29	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	concentration	concentration	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	falls	fall	VBZ	_	0	ROOT
6	to	to	TO	_	8	case
7	23	23	CD	_	8	nummod
8	%	%	NN	_	5	nmod
9	within	within	IN	_	11	case
10	five	five	CD	_	11	nummod
11	weeks	week	NNS	_	5	nmod
12	,	,	,	_	5	punct
13	according	accord	VBG	_	16	case
14	to	to	TO	_	13	mwe
15	an	a	DT	_	16	det
16	experiment	experiment	NN	_	5	nmod
17	published	publish	VBN	_	16	acl
18	in	in	IN	_	19	case
19	1989	1989	CD	_	17	nmod
20	by	by	IN	_	24	case
21	the	the	DT	_	24	det
22	same	same	JJ	_	24	amod
23	two	two	CD	_	24	nummod
24	scientists	scientist	NNS	_	17	nmod
25	that	that	WDT	_	26	nsubj
26	tried	try	VBD	_	24	acl:relcl
27	and	and	CC	_	26	cc
28	failed	fail	VBD	_	26	conj
29	to	to	TO	_	30	mark
30	elucidate	elucidate	VB	_	28	xcomp
31	the	the	DT	_	32	det
32	mechanism	mechanism	NN	_	30	dobj
33	behind	behind	IN	_	35	case
34	this	this	DT	_	35	det
35	interaction	interaction	NN	_	32	nmod
36	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	sedative	sedative	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	including	include	VBG	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug6	drug6	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug7	drug7	NN	_	10	conj
19	,	,	,	_	10	punct
20	and	and	CC	_	10	cc
21	drug8	drug8	NN	_	10	conj
22	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	13	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug2	drug2	NN	_	4	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	enhanced	enhance	VBN	_	0	ROOT
14	by	by	IN	_	17	case
15	the	the	DT	_	17	det
16	concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	13	nmod
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	.	.	.	_	13	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	effect	effect	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	metabolism	metabolism	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	liver	liver	NN	_	3	nmod
11	.	.	.	_	3	punct

1	Interactions	interaction	NNS	_	11	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	conj
7	have	have	VBP	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	fully	fully	RB	_	11	advmod
11	evaluated	evaluate	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	8	compound
8	therapy	therapy	NN	_	6	dobj
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	nmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	10	nmod
14	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	mixed	mix	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	any	any	DT	_	9	det
8	other	other	JJ	_	9	amod
9	drug	drug	NN	_	5	nmod
10	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	cardioactive	cardioactive	JJ	_	8	amod
8	drugs	drug	NNS	_	2	nmod
9	has	have	VBZ	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	27	nmod
3	to	to	TO	_	4	case
4	bleeding	bleeding	NN	_	2	nmod
5	associated	associate	VBN	_	4	acl
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drugs	drug	NNS	_	7	conj
12	that	that	WDT	_	13	nsubj
13	alter	alter	VBP	_	11	acl:relcl
14	platelet	platelet	NN	_	15	compound
15	function	function	NN	_	13	dobj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug3	drug3	NN	_	11	nmod
20	,	,	,	_	19	punct
21	drug4	drug4	NN	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	drug5	drug5	NN	_	19	conj
25	-RRB-	-rrb-	-RRB-	_	19	punct
26	may	may	MD	_	27	aux
27	increase	increase	VB	_	0	ROOT
28	the	the	DT	_	29	det
29	risk	risk	NN	_	27	dobj
30	of	of	IN	_	31	case
31	bleeding	bleed	VBG	_	29	nmod
32	if	if	IN	_	33	mark
33	administered	administer	VBN	_	27	advcl
34	prior	prior	RB	_	39	advmod
35	to	to	TO	_	39	nmod
36	or	or	CC	_	35	cc
37	after	after	IN	_	35	conj
38	drug6	drug6	NN	_	39	compound
39	therapy	therapy	NN	_	33	nmod
40	.	.	.	_	27	punct

1	The	the	DT	_	2	det
2	occurrence	occurrence	NN	_	17	nsubjpass
3	of	of	IN	_	4	case
4	stupor	stupor	NN	_	2	nmod
5	,	,	,	_	4	punct
6	muscular	muscular	JJ	_	7	amod
7	rigidity	rigidity	NN	_	4	conj
8	,	,	,	_	4	punct
9	severe	severe	JJ	_	10	amod
10	agitation	agitation	NN	_	4	conj
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	elevated	elevated	JJ	_	14	amod
14	temperature	temperature	NN	_	4	conj
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	reported	report	VBN	_	0	ROOT
18	in	in	IN	_	20	case
19	some	some	DT	_	20	det
20	patients	patient	NNS	_	17	nmod
21	receiving	receive	VBG	_	20	acl
22	the	the	DT	_	23	det
23	combination	combination	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	drug2	drug2	NN	_	25	conj
28	.	.	.	_	17	punct

1	Symptoms	symptom	NNS	_	3	nsubj
2	usually	usually	RB	_	3	advmod
3	resolve	resolve	VBP	_	0	ROOT
4	over	over	IN	_	5	case
5	days	day	NNS	_	3	nmod
6	when	when	WRB	_	10	advmod
7	the	the	DT	_	8	det
8	combination	combination	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	discontinued	discontinue	VBN	_	5	acl:relcl
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	typical	typical	JJ	_	0	ROOT
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	.	.	.	_	3	punct

1	Other	other	JJ	_	3	amod
2	serious	serious	JJ	_	3	amod
3	reactions	reaction	NNS	_	16	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	including	include	VBG	_	7	case
6	severe	severe	JJ	_	7	amod
7	agitation	agitation	NN	_	3	nmod
8	,	,	,	_	7	punct
9	hallucinations	hallucination	NNS	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	death	death	NN	_	7	conj
13	-RRB-	-rrb-	-RRB-	_	7	punct
14	have	have	VBP	_	16	aux
15	been	be	VBN	_	16	auxpass
16	reported	report	VBN	_	0	ROOT
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	this	this	DT	_	21	det
21	combination	combination	NN	_	19	dobj
22	.	.	.	_	16	punct

1	Severe	severe	JJ	_	2	amod
2	toxicity	toxicity	NN	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	also	also	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	the	the	DT	_	11	det
11	combination	combination	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	and	and	CC	_	13	cc
17	drug3	drug3	NN	_	13	conj
18	and	and	CC	_	17	cc
19	drug4	drug4	NN	_	17	conj
20	.	.	.	_	6	punct

1	One	one	CD	_	2	nummod
2	case	case	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	hypertensive	hypertensive	JJ	_	5	amod
5	crisis	crisis	NN	_	2	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	a	a	DT	_	11	det
11	patient	patient	NN	_	8	nmod
12	taking	take	VBG	_	11	acl
13	the	the	DT	_	15	det
14	recommended	recommend	VBN	_	15	amod
15	doses	dose	NNS	_	12	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	a	a	DT	_	17	conj
20	drug2	drug2	NN	_	19	dep
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug3	drug3	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	.	.	.	_	8	punct

1	When	when	WRB	_	6	advmod
2	drug1	drug1	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	are	be	VBP	_	6	auxpass
6	used	use	VBN	_	28	advcl
7	together	together	RB	_	6	advmod
8	,	,	,	_	28	punct
9	the	the	DT	_	10	det
10	signs	sign	NNS	_	28	nsubj
11	of	of	IN	_	12	case
12	atropinization	atropinization	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	flushing	flushing	NN	_	12	dep
15	,	,	,	_	14	punct
16	mydriasis	mydriasis	NN	_	14	conj
17	,	,	,	_	14	punct
18	tachycardia	tachycardia	NN	_	14	conj
19	,	,	,	_	14	punct
20	dryness	dryness	NN	_	14	appos
21	of	of	IN	_	23	case
22	the	the	DT	_	23	det
23	mouth	mouth	NN	_	20	nmod
24	and	and	CC	_	23	cc
25	nose	nose	NN	_	23	conj
26	-RRB-	-rrb-	-RRB-	_	14	punct
27	may	may	MD	_	28	aux
28	occur	occur	VB	_	0	ROOT
29	earlier	earlier	JJR	_	28	advmod
30	than	than	IN	_	33	mark
31	might	might	MD	_	33	aux
32	be	be	VB	_	33	auxpass
33	expected	expect	VBN	_	29	advcl
34	when	when	WRB	_	37	advmod
35	drug3	drug3	NN	_	37	nsubjpass
36	is	be	VBZ	_	37	auxpass
37	used	use	VBN	_	33	advcl
38	alone	alone	RB	_	37	advmod
39	.	.	.	_	28	punct

1	This	this	DT	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	especially	especially	RB	_	4	advmod
4	true	true	JJ	_	0	ROOT
5	if	if	IN	_	13	mark
6	the	the	DT	_	8	det
7	total	total	JJ	_	8	amod
8	dose	dose	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	cop
13	large	large	JJ	_	4	advcl
14	and	and	CC	_	13	cc
15	the	the	DT	_	16	det
16	administration	administration	NN	_	21	nsubjpass
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	delayed	delay	VBN	_	13	conj
22	.	.	.	_	4	punct

1	2	2	LS	_	0	ROOT
2	-	-	:	_	1	punct
3	4	4	CD	_	6	nummod
4	The	the	DT	_	6	det
5	following	follow	VBG	_	6	amod
6	precautions	precaution	NNS	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	kept	keep	VBN	_	1	dep
10	in	in	IN	_	11	case
11	mind	mind	NN	_	9	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	treatment	treatment	NN	_	9	nmod
15	of	of	IN	_	17	case
16	anticholinesterase	anticholinesterase	JJ	_	17	amod
17	poisoning	poisoning	NN	_	14	nmod
18	,	,	,	_	9	punct
19	although	although	IN	_	23	mark
20	they	they	PRP	_	23	nsubj
21	do	do	VBP	_	23	aux
22	not	not	RB	_	23	neg
23	bear	bear	VB	_	9	advcl
24	directly	directly	RB	_	23	advmod
25	on	on	IN	_	27	case
26	the	the	DT	_	27	det
27	use	use	NN	_	23	nmod
28	of	of	IN	_	29	case
29	drug1	drug1	NN	_	27	nmod
30	:	:	:	_	9	punct
31	since	since	IN	_	34	mark
32	drug2	drug2	NN	_	34	nsubjpass
33	are	be	VBP	_	34	auxpass
34	potentiated	potentiate	VBN	_	42	advcl
35	by	by	IN	_	37	case
36	the	the	DT	_	37	det
37	drug3	drug3	NN	_	34	nmod
38	,	,	,	_	42	punct
39	they	they	PRP	_	42	nsubjpass
40	should	should	MD	_	42	aux
41	be	be	VB	_	42	auxpass
42	used	use	VBN	_	9	parataxis
43	cautiously	cautiously	RB	_	42	advmod
44	in	in	IN	_	46	case
45	the	the	DT	_	46	det
46	treatment	treatment	NN	_	42	nmod
47	of	of	IN	_	48	case
48	convulsions	convulsion	NNS	_	46	nmod
49	;	;	:	_	1	punct

1	drug1	drug1	NN	_	15	nsubjpass
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	drug4	drug4	NN	_	1	conj
8	,	,	,	_	1	punct
9	drug5	drug5	NN	_	1	conj
10	,	,	,	_	1	punct
11	and	and	CC	_	1	cc
12	drug6	drug6	NN	_	1	conj
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	avoided	avoid	VBN	_	0	ROOT
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	with	with	IN	_	20	case
19	organophosphate	organophosphate	NN	_	20	compound
20	poisoning	poisoning	NN	_	17	nmod
21	.	.	.	_	15	punct

1	No	no	DT	_	4	neg
2	drug-drug	drug-drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	conducted	conduct	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	nsubj
2	administered	administer	VBN	_	8	csubj
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	significantly	significantly	RB	_	8	advmod
8	decrease	decrease	VB	_	0	ROOT
9	the	the	DT	_	11	det
10	serum	serum	NN	_	11	compound
11	concentrations	concentration	NNS	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	8	punct

1	Laboratory	laboratory	NN	_	2	compound
2	Tests	test	NNS	_	0	ROOT
3	The	the	DT	_	4	det
4	pathologist	pathologist	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	advised	advise	VBN	_	2	acl:relcl
8	of	of	IN	_	10	case
9	progestin	progestin	NN	_	10	compound
10	therapy	therapy	NN	_	7	nmod
11	when	when	WRB	_	15	advmod
12	relevant	relevant	JJ	_	13	amod
13	specimens	specimen	NNS	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	submitted	submit	VBN	_	7	advcl
16	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	physician	physician	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	informed	inform	VBN	_	0	ROOT
6	that	that	IN	_	19	mark
7	certain	certain	JJ	_	12	amod
8	endocrine	endocrine	JJ	_	12	amod
9	and	and	CC	_	8	cc
10	liver	liver	NN	_	8	conj
11	function	function	NN	_	12	compound
12	tests	test	NNS	_	19	nsubjpass
13	,	,	,	_	12	punct
14	and	and	CC	_	12	cc
15	blood	blood	NN	_	16	compound
16	components	component	NNS	_	12	conj
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	affected	affect	VBN	_	5	ccomp
20	by	by	IN	_	22	case
21	progestin	progestin	NN	_	22	compound
22	therapy	therapy	NN	_	19	nmod
23	:	:	:	_	5	punct
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	a	a	LS	_	33	dep
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	Plasma	plasma	NN	_	31	amod
28	and	and	CC	_	27	cc
29	urinary	urinary	JJ	_	27	conj
30	steroid	steroid	NN	_	31	compound
31	levels	level	NNS	_	33	nsubjpass
32	are	be	VBP	_	33	auxpass
33	decreased	decrease	VBN	_	5	parataxis
34	-LRB-	-lrb-	-LRB-	_	37	punct
35	e.g.	e.g.	FW	_	37	dep
36	,	,	,	_	37	punct
37	progesterone	progesterone	NN	_	33	dep
38	,	,	,	_	37	punct
39	estradiol	estradiol	NN	_	37	conj
40	,	,	,	_	37	punct
41	pregnanediol	pregnanediol	NN	_	37	conj
42	,	,	,	_	37	punct
43	testosterone	testosterone	NN	_	37	conj
44	,	,	,	_	37	punct
45	cortisol	cortisol	NN	_	37	appos
46	-RRB-	-rrb-	-RRB-	_	37	punct
47	.	.	.	_	5	punct

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	b	b	NN	_	4	compound
3	-RRB-	-rrb-	-RRB-	_	4	punct
4	Plasma	plasma	NN	_	10	nsubjpass
5	and	and	CC	_	4	cc
6	urinary	urinary	JJ	_	8	amod
7	gonadotropin	gonadotropin	NN	_	8	compound
8	levels	level	NNS	_	4	conj
9	are	be	VBP	_	10	auxpass
10	decreased	decrease	VBN	_	0	ROOT
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	LH	lh	NN	_	10	dep
15	,	,	,	_	14	punct
16	FSH	fsh	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	14	punct
18	.	.	.	_	10	punct

1	-LRB-	-lrb-	-LRB-	_	5	punct
2	c	c	NN	_	5	compound
3	-RRB-	-rrb-	-RRB-	_	5	punct
4	SHBG	shbg	NN	_	5	compound
5	concentrations	concentration	NNS	_	7	nsubjpass
6	are	be	VBP	_	7	auxpass
7	decreased	decrease	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	-LRB-	-lrb-	-LRB-	_	5	punct
2	d	d	NN	_	5	compound
3	-RRB-	-rrb-	-RRB-	_	5	punct
4	T3-uptake	t3-uptake	NN	_	5	compound
5	values	value	NNS	_	7	nsubj
6	may	may	MD	_	7	aux
7	decrease	decrease	VB	_	0	ROOT
8	.	.	.	_	7	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	e	e	LS	_	8	dep
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	There	there	EX	_	8	expl
5	may	may	MD	_	8	aux
6	be	be	VB	_	8	cop
7	small	small	JJ	_	8	amod
8	changes	change	NNS	_	0	ROOT
9	in	in	IN	_	11	case
10	coagulation	coagulation	NN	_	11	compound
11	factors	factor	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	f	f	LS	_	13	dep
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	Sulfobromophthalein	sulfobromophthalein	NN	_	13	nsubjpass
5	and	and	CC	_	4	cc
6	other	other	JJ	_	10	amod
7	liver	liver	NN	_	10	compound
8	function	function	NN	_	10	compound
9	test	test	NN	_	10	compound
10	values	value	NNS	_	4	conj
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	increased	increase	VBN	_	0	ROOT
14	slightly	slightly	RB	_	13	advmod
15	.	.	.	_	13	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	g	g	NN	_	8	dep
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	There	there	EX	_	8	expl
5	may	may	MD	_	8	aux
6	be	be	VB	_	8	cop
7	small	small	JJ	_	8	amod
8	changes	change	NNS	_	0	ROOT
9	in	in	IN	_	11	case
10	lipid	lipid	NN	_	11	compound
11	profiles	profile	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	21	nmod
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	21	punct
7	patients	patient	NNS	_	21	nsubj
8	taking	take	VBG	_	7	acl
9	drug2	drug2	NN	_	8	dobj
10	concomitantly	concomitantly	RB	_	8	advmod
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	8	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug4	drug4	NN	_	12	dep
15	,	,	,	_	14	punct
16	Genentech	Genentech	NNP	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	14	punct
18	,	,	,	_	12	punct
19	drug5	drug5	NN	_	12	appos
20	,	,	,	_	21	punct
21	inhaled	inhale	VBD	_	0	ROOT
22	drug6	drug6	NN	_	30	nsubj
23	,	,	,	_	22	punct
24	other	other	JJ	_	25	amod
25	drug7	drug7	NN	_	22	conj
26	,	,	,	_	22	punct
27	or	or	CC	_	22	cc
28	parenteral	parenteral	JJ	_	29	amod
29	drug8	drug8	NN	_	22	conj
30	demonstrated	demonstrate	VBD	_	21	ccomp
31	adverse	adverse	JJ	_	33	amod
32	experience	experience	NN	_	33	compound
33	profiles	profile	NNS	_	30	dobj
34	similar	similar	JJ	_	33	amod
35	to	to	TO	_	38	case
36	the	the	DT	_	38	det
37	study	study	NN	_	38	compound
38	population	population	NN	_	34	nmod
39	as	as	IN	_	41	case
40	a	a	DT	_	41	det
41	whole	whole	NN	_	38	nmod
42	.	.	.	_	21	punct

1	Concurrent	concurrent	JJ	_	4	amod
2	and/or	and/or	CC	_	1	cc
3	sequential	sequential	JJ	_	1	conj
4	use	use	NN	_	17	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	4	nmod
10	with	with	IN	_	14	case
11	neurotoxic	neurotoxic	JJ	_	14	amod
12	or	or	CC	_	11	cc
13	ototoxic	ototoxic	JJ	_	11	conj
14	potential	potential	NN	_	9	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	avoided	avoid	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Some	some	DT	_	2	det
2	drug1	drug1	NN	_	4	nsubj
3	can	can	MD	_	4	aux
4	enhance	enhance	VB	_	0	ROOT
5	drug2	drug2	NN	_	6	compound
6	toxicity	toxicity	NN	_	4	dobj
7	by	by	IN	_	8	mark
8	altering	alter	VBG	_	4	advcl
9	drug3	drug3	NN	_	10	compound
10	concentrations	concentration	NNS	_	8	dobj
11	in	in	IN	_	12	case
12	serum	serum	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	tissue	tissue	NN	_	12	conj
15	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	,	,	,	_	8	punct
14	or	or	CC	_	8	cc
15	drug5	drug5	NN	_	8	conj
16	.	.	.	_	5	punct

1	DRUG	drug	NN	_	2	compound
2	INTERACTIONS	interaction	NNS	_	0	ROOT
3	There	there	EX	_	4	expl
4	are	be	VBP	_	2	acl:relcl
5	no	no	DT	_	8	neg
6	known	known	JJ	_	8	amod
7	drug/drug	drug/drug	NN	_	8	compound
8	interactions	interaction	NNS	_	17	nsubjpass
9	with	with	IN	_	12	case
10	oral	oral	JJ	_	12	amod
11	drug1	drug1	NN	_	12	compound
12	Vaccinations	vaccination	NNS	_	8	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	8	nmod
15	are	be	VBP	_	17	auxpass
16	not	not	RB	_	17	neg
17	recommended	recommend	VBN	_	4	ccomp
18	in	in	IN	_	20	case
19	immunocompromised	immunocompromised	JJ	_	20	amod
20	individuals	individual	NNS	_	17	nmod
21	drug3	drug3	VBN	_	20	acl
22	together	together	RB	_	21	advmod
23	with	with	IN	_	26	case
24	high-dose	high-dose	JJ	_	26	amod
25	intravenous	intravenous	JJ	_	26	amod
26	drug4	drug4	NN	_	21	nmod
27	has	have	VBZ	_	28	aux
28	caused	cause	VBN	_	17	dep
29	deaths	death	NNS	_	28	dobj
30	in	in	IN	_	31	case
31	children	child	NNS	_	29	nmod
32	due	due	JJ	_	28	advmod
33	to	to	TO	_	35	case
34	haemorrhagic	haemorrhagic	JJ	_	35	amod
35	enterocolitis	enterocolitis	NN	_	32	nmod
36	.	.	.	_	2	punct

1	Impaired	impaired	JJ	_	3	amod
2	renal	renal	JJ	_	3	amod
3	function	function	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	described	describe	VBN	_	0	ROOT
7	in	in	IN	_	11	case
8	bone	bone	NN	_	11	compound
9	marrow	marrow	NN	_	11	compound
10	transplant	transplant	NN	_	11	compound
11	patients	patient	NNS	_	6	nmod
12	who	who	WP	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	conditioned	condition	VBN	_	11	acl:relcl
15	with	with	IN	_	18	case
16	high-dose	high-dose	JJ	_	18	amod
17	intravenous	intravenous	JJ	_	18	amod
18	drug1	drug1	NN	_	14	nmod
19	and	and	CC	_	14	cc
20	who	who	WP	_	22	nsubj
21	subsequently	subsequently	RB	_	22	advmod
22	received	receive	VBD	_	14	conj
23	drug2	drug2	NN	_	22	dobj
24	to	to	TO	_	25	mark
25	prevent	prevent	VB	_	22	advcl
26	graft-versus-host	graft-versus-host	JJ	_	27	amod
27	disease	disease	NN	_	25	dobj

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	4	nmod
9	taking	take	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	because	because	IN	_	14	case
12	of	of	IN	_	11	mwe
13	the	the	DT	_	14	det
14	possibility	possibility	NN	_	4	nmod
15	of	of	IN	_	17	case
16	conduction	conduction	NN	_	17	compound
17	disturbances	disturbance	NNS	_	14	nmod
18	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	11	nsubjpass
2	with	with	IN	_	4	case
3	parasympathomimetic	parasympathomimetic	JJ	_	4	amod
4	effects	effect	NNS	_	1	nmod
5	administered	administer	VBN	_	4	acl
6	concurrently	concurrently	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	5	nmod
9	would	would	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	result	result	VB	_	11	xcomp
14	in	in	IN	_	17	case
15	additive	additive	JJ	_	17	amod
16	pharmacologic	pharmacologic	JJ	_	17	amod
17	effects	effect	NNS	_	13	nmod
18	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	might	might	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	anticholinergic	anticholinergic	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	used	use	VBN	_	8	acl
10	concomitantly	concomitantly	RB	_	9	advmod
11	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	when	when	WRB	_	11	advmod
7	anticholinergic	anticholinergic	JJ	_	8	amod
8	properties	property	NNS	_	11	nsubj
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	aux
11	contributing	contribute	VBG	_	5	advcl
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	therapeutic	therapeutic	JJ	_	15	amod
15	effect	effect	NN	_	11	nmod
16	of	of	IN	_	18	case
17	concomitant	concomitant	JJ	_	18	amod
18	medication	medication	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug1	drug1	NN	_	18	dep
23	,	,	,	_	22	punct
24	inhaled	inhale	VBD	_	25	amod
25	drug2	drug2	NN	_	22	appos
26	-RRB-	-rrb-	-RRB-	_	22	punct
27	.	.	.	_	5	punct

1	While	while	IN	_	9	mark
2	no	no	DT	_	6	neg
3	formal	formal	JJ	_	6	amod
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	performed	perform	VBN	_	16	advcl
10	,	,	,	_	16	punct
11	the	the	DT	_	14	det
12	following	follow	VBG	_	14	amod
13	concomitant	concomitant	JJ	_	14	amod
14	drugs	drug	NNS	_	16	nsubjpass
15	were	be	VBD	_	16	auxpass
16	used	use	VBN	_	0	ROOT
17	in	in	IN	_	21	case
18	at	at	IN	_	19	case
19	least	least	JJS	_	20	nmod:npmod
20	10	10	CD	_	21	nummod
21	%	%	NN	_	16	nmod
22	of	of	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	in	in	IN	_	25	case
25	either	either	CC	_	23	nmod
26	or	or	CC	_	25	cc
27	both	both	DT	_	28	det
28	Sj	sj	NN	_	25	conj
29	grens	gren	VBZ	_	16	dep
30	efficacy	efficacy	NN	_	31	compound
31	studies	study	NNS	_	29	dobj
32	:	:	:	_	29	punct
33	drug1	drug1	NN	_	29	dep
34	,	,	,	_	33	punct
35	artificial	artificial	JJ	_	36	amod
36	tears	tear	NNS	_	33	conj
37	,	,	,	_	33	punct
38	drug2	drug2	NN	_	33	conj
39	,	,	,	_	33	punct
40	drug3	drug3	NN	_	33	conj
41	,	,	,	_	33	punct
42	drug4	drug4	NN	_	33	conj
43	,	,	,	_	33	punct
44	drug5	drug5	NN	_	33	conj
45	,	,	,	_	33	punct
46	drug6	drug6	NN	_	33	conj
47	,	,	,	_	33	punct
48	drug7	drug7	NN	_	33	conj
49	,	,	,	_	33	punct
50	drug8	drug8	NN	_	33	conj
51	,	,	,	_	33	punct
52	drug9	drug9	NN	_	33	conj
53	,	,	,	_	33	punct
54	drug10	drug10	NN	_	33	conj
55	,	,	,	_	33	punct
56	drug11	drug11	NN	_	33	conj
57	,	,	,	_	33	punct
58	drug12	drug12	NN	_	33	conj
59	,	,	,	_	33	punct
60	and	and	CC	_	33	cc
61	drug13	drug13	NN	_	33	conj
62	.	.	.	_	16	punct

1	The	the	DT	_	4	det
2	induction	induction	NN	_	4	compound
3	dose	dose	NN	_	4	compound
4	requirements	requirement	NNS	_	11	nsubjpass
5	of	of	IN	_	8	case
6	drug1	drug1	NN	_	8	compound
7	Injectable	injectable	JJ	_	8	amod
8	Emulsion	emulsion	NN	_	4	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	reduced	reduce	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	with	with	IN	_	15	case
15	intramuscular	intramuscular	JJ	_	13	nmod
16	or	or	CC	_	15	cc
17	intravenous	intravenous	JJ	_	15	conj
18	premedication	premedication	NN	_	15	dep
19	,	,	,	_	11	punct
20	particularly	particularly	RB	_	22	advmod
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	11	nmod
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	eg	eg	FW	_	26	compound
25	,	,	,	_	26	punct
26	drug3	drug3	NN	_	22	appos
27	,	,	,	_	26	punct
28	drug4	drug4	NN	_	26	conj
29	,	,	,	_	26	punct
30	and	and	CC	_	26	cc
31	drug5	drug5	NN	_	26	conj
32	,	,	,	_	26	punct
33	etc.	etc.	FW	_	26	dep
34	-RRB-	-rrb-	-RRB-	_	26	punct

1	and	and	CC	_	0	ROOT
2	combinations	combination	NNS	_	1	dep
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	eg	eg	FW	_	10	compound
9	,	,	,	_	10	punct
10	drug3	drug3	NN	_	2	dep
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug6	drug6	NN	_	10	conj
17	,	,	,	_	10	punct
18	etc.	etc.	FW	_	10	dep
19	-RRB-	-rrb-	-RRB-	_	10	punct
20	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	0	ROOT
5	the	the	DT	_	9	det
6	anesthetic	anesthetic	NN	_	9	amod
7	or	or	CC	_	6	cc
8	sedative	sedative	JJ	_	6	conj
9	effects	effect	NNS	_	4	dobj
10	of	of	IN	_	13	case
11	drug1	drug1	NN	_	13	compound
12	Injectable	injectable	JJ	_	13	amod
13	Emulsion	emulsion	NN	_	9	nmod
14	and	and	CC	_	4	cc
15	may	may	MD	_	17	aux
16	also	also	RB	_	17	advmod
17	result	result	VB	_	4	conj
18	in	in	IN	_	21	case
19	more	more	RBR	_	20	advmod
20	pronounced	pronounced	JJ	_	21	amod
21	decreases	decrease	NNS	_	17	nmod
22	in	in	IN	_	21	amod
23	systolic	systolic	JJ	_	22	dep
24	,	,	,	_	23	punct
25	diastolic	diastolic	JJ	_	23	conj
26	,	,	,	_	23	punct
27	and	and	CC	_	23	cc
28	mean	mean	VB	_	23	conj
29	arterial	arterial	JJ	_	30	amod
30	pressures	pressure	NNS	_	28	dobj
31	and	and	CC	_	30	cc
32	cardiac	cardiac	JJ	_	33	amod
33	output	output	NN	_	30	conj
34	.	.	.	_	4	punct

1	During	during	IN	_	2	case
2	maintenance	maintenance	NN	_	17	nmod
3	of	of	IN	_	4	case
4	anesthesia	anesthesia	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	sedation	sedation	NN	_	4	conj
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	rate	rate	NN	_	17	nsubjpass
10	of	of	IN	_	14	case
11	drug1	drug1	NN	_	14	compound
12	Injectable	injectable	JJ	_	14	amod
13	Emulsion	emulsion	NN	_	14	compound
14	administration	administration	NN	_	9	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	adjusted	adjust	VBN	_	0	ROOT
18	according	accord	VBG	_	22	case
19	to	to	TO	_	18	mwe
20	the	the	DT	_	22	det
21	desired	desire	VBN	_	22	amod
22	level	level	NN	_	17	nmod
23	of	of	IN	_	24	case
24	anesthesia	anesthesia	NN	_	22	nmod
25	or	or	CC	_	24	cc
26	sedation	sedation	NN	_	24	conj
27	and	and	CC	_	17	cc
28	may	may	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	reduced	reduce	VBN	_	17	conj
31	in	in	IN	_	36	case
32	the	the	DT	_	36	dep
33	presence	presence	NN	_	36	dep
34	of	of	IN	_	36	case
35	supplemental	supplemental	JJ	_	36	amod
36	drug2	drug2	NN	_	30	nmod
37	-LRB-	-lrb-	-LRB-	_	40	punct
38	eg	eg	FW	_	40	dep
39	,	,	,	_	40	punct
40	drug3	drug3	NN	_	36	dep
41	or	or	CC	_	40	cc
42	drug4	drug4	NN	_	40	conj
43	-RRB-	-rrb-	-RRB-	_	40	punct
44	.	.	.	_	17	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	administration	administration	NN	_	28	nsubjpass
4	of	of	IN	_	7	case
5	potent	potent	JJ	_	7	amod
6	inhalational	inhalational	JJ	_	7	amod
7	agents	agent	NNS	_	3	nmod
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	eg	eg	FW	_	11	compound
10	,	,	,	_	11	punct
11	drug1	drug1	NN	_	7	dep
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	drug3	drug3	NN	_	11	conj
17	-RRB-	-rrb-	-RRB-	_	11	punct
18	during	during	IN	_	19	case
19	maintenance	maintenance	NN	_	3	nmod
20	with	with	IN	_	23	case
21	drug4	drug4	NN	_	23	compound
22	Injectable	injectable	JJ	_	23	amod
23	Emulsion	emulsion	NN	_	19	nmod
24	has	have	VBZ	_	28	aux
25	not	not	RB	_	28	neg
26	been	be	VBN	_	28	auxpass
27	extensively	extensively	RB	_	28	advmod
28	evaluated	evaluate	VBN	_	0	ROOT
29	.	.	.	_	28	punct

1	These	these	DT	_	3	det
2	inhalational	inhalational	JJ	_	3	amod
3	agents	agent	NNS	_	7	nsubjpass
4	can	can	MD	_	7	aux
5	also	also	RB	_	7	advmod
6	be	be	VB	_	7	auxpass
7	expected	expect	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	increase	increase	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	anesthetic	anesthetic	NN	_	9	dobj
12	or	or	CC	_	11	cc
13	sedative	sedative	NN	_	11	conj
14	and	and	CC	_	11	cc
15	cardiorespiratory	cardiorespiratory	JJ	_	16	amod
16	effects	effect	NNS	_	11	conj
17	of	of	IN	_	20	case
18	drug1	drug1	NN	_	20	compound
19	Injectable	injectable	JJ	_	20	amod
20	Emulsion	emulsion	NN	_	11	nmod
21	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	compound
2	Injectable	injectable	JJ	_	3	amod
3	Emulsion	emulsion	NN	_	6	nsubj
4	does	do	VBZ	_	6	aux
5	not	not	RB	_	6	neg
6	cause	cause	VB	_	0	ROOT
7	a	a	DT	_	10	det
8	clinically	clinically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	change	change	NN	_	6	dobj
11	in	in	IN	_	12	case
12	onset	onset	NN	_	10	nmod
13	,	,	,	_	12	punct
14	intensity	intensity	NN	_	12	conj
15	,	,	,	_	12	punct
16	or	or	CC	_	12	cc
17	duration	duration	NN	_	12	conj
18	of	of	IN	_	19	case
19	action	action	NN	_	17	nmod
20	of	of	IN	_	24	case
21	the	the	DT	_	24	det
22	commonly	commonly	RB	_	23	advmod
23	used	use	VBN	_	24	amod
24	drug2	drug2	NN	_	19	nmod
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	eg	eg	FW	_	28	dep
27	,	,	,	_	28	punct
28	drug3	drug3	NN	_	24	dep
29	and	and	CC	_	28	cc
30	drug4	drug4	NN	_	28	conj
31	-RRB-	-rrb-	-RRB-	_	28	punct
32	.	.	.	_	6	punct

1	No	no	DT	_	4	neg
2	significant	significant	JJ	_	4	amod
3	adverse	adverse	JJ	_	4	amod
4	interactions	interaction	NNS	_	34	nsubjpass
5	with	with	IN	_	8	case
6	commonly	commonly	RB	_	7	advmod
7	used	use	VBN	_	8	amod
8	premedications	premedication	NNS	_	4	nmod
9	or	or	CC	_	8	cc
10	drugs	drug	NNS	_	8	conj
11	used	use	VBN	_	4	acl
12	during	during	IN	_	13	case
13	anesthesia	anesthesia	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	sedation	sedation	NN	_	13	conj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	including	include	VBG	_	19	case
18	a	a	DT	_	19	det
19	range	range	NN	_	13	nmod
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	,	,	,	_	19	punct
23	inhalational	inhalational	JJ	_	24	amod
24	agents	agent	NNS	_	19	conj
25	,	,	,	_	19	punct
26	drug2	drug2	NN	_	19	conj
27	,	,	,	_	19	punct
28	and	and	CC	_	19	cc
29	local	local	JJ	_	30	amod
30	drug3	drug3	NN	_	19	conj
31	-RRB-	-rrb-	-RRB-	_	19	punct
32	have	have	VBP	_	34	aux
33	been	be	VBN	_	34	auxpass
34	observed	observe	VBN	_	0	ROOT
35	.	.	.	_	34	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	potentiate	potentiate	VB	_	5	xcomp
8	the	the	DT	_	10	det
9	anticoagulant	anticoagulant	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	7	punct
16	resulting	result	VBG	_	7	advcl
17	in	in	IN	_	19	case
18	a	a	DT	_	19	det
19	prolongation	prolongation	NN	_	16	nmod
20	of	of	IN	_	22	case
21	prothrombin	prothrombin	NN	_	22	compound
22	time	time	NN	_	19	nmod
23	.	.	.	_	5	punct

1	Drug	drug	NN	_	2	compound
2	interactions	interaction	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	kept	keep	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	mind	mind	NN	_	5	nmod
8	when	when	WRB	_	5	dep
9	drug1	drug1	NN	_	8	dep
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	drug2	drug2	NN	_	12	compound
12	gel	gel	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	,	,	,	_	9	punct
15	1	1	CD	_	16	nummod
16	%	%	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	prescribed	prescribe	VBN	_	9	acl:relcl
19	for	for	IN	_	20	case
20	patients	patient	NNS	_	18	nmod
21	who	who	WP	_	23	nsubj
22	are	be	VBP	_	23	aux
23	receiving	receive	VBG	_	20	acl:relcl
24	anticoagulant	anticoagulant	JJ	_	25	amod
25	treatment	treatment	NN	_	23	dobj
26	,	,	,	_	18	punct
27	although	although	IN	_	31	mark
28	they	they	PRP	_	31	nsubj
29	are	be	VBP	_	31	cop
30	less	less	RBR	_	31	advmod
31	likely	likely	JJ	_	18	advcl
32	to	to	TO	_	33	mark
33	occur	occur	VB	_	31	xcomp
34	with	with	IN	_	37	case
35	topical	topical	JJ	_	37	amod
36	drug3	drug3	NN	_	37	compound
37	administration	administration	NN	_	33	nmod
38	because	because	IN	_	41	case
39	of	of	IN	_	38	mwe
40	low	low	JJ	_	41	amod
41	absorption	absorption	NN	_	31	nmod
42	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	on	on	IN	_	11	case
10	steroid	steroid	NN	_	11	compound
11	therapy	therapy	NN	_	8	nmod
12	because	because	IN	_	15	case
13	of	of	IN	_	12	mwe
14	the	the	DT	_	15	det
15	potential	potential	NN	_	4	nmod
16	for	for	IN	_	17	mark
17	developing	develop	VBG	_	15	acl
18	hypokalemia	hypokalemia	NN	_	17	dobj
19	.	.	.	_	4	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	for	for	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	receiving	receive	VBG	_	5	acl
7	high-dose	high-dose	JJ	_	8	amod
8	drug1	drug1	NN	_	6	dobj
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	concomitantly	concomitantly	RB	_	5	advmod
12	,	,	,	_	3	punct
13	as	as	IN	_	14	case
14	anorexia	anorexia	NN	_	3	nmod
15	,	,	,	_	14	punct
16	tachypnea	tachypnea	NN	_	14	conj
17	,	,	,	_	14	punct
18	lethargy	lethargy	NN	_	14	conj
19	,	,	,	_	14	punct
20	coma	coma	NN	_	14	conj
21	and	and	CC	_	14	cc
22	death	death	NN	_	14	conj
23	have	have	VBP	_	25	aux
24	been	be	VBN	_	25	auxpass
25	reported	report	VBN	_	3	dep
26	with	with	IN	_	28	case
27	concomitant	concomitant	JJ	_	28	amod
28	use	use	NN	_	25	nmod
29	of	of	IN	_	31	case
30	high-dose	high-dose	JJ	_	31	amod
31	drug3	drug3	NN	_	28	nmod
32	and	and	CC	_	31	cc
33	drug4	drug4	NN	_	31	conj
34	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	and	and	CC	_	6	cc
10	other	other	JJ	_	11	amod
11	drug4	drug4	NN	_	6	conj
12	,	,	,	_	4	punct
13	and	and	CC	_	4	cc
14	with	with	IN	_	16	case
15	other	other	JJ	_	16	amod
16	drug5	drug5	NN	_	4	conj
17	.	.	.	_	4	punct

1	If	if	IN	_	6	mark
2	signs	sign	NNS	_	6	nsubj
3	of	of	IN	_	5	case
4	folate	folate	NN	_	5	compound
5	deficiency	deficiency	NN	_	2	nmod
6	develop	develop	VB	_	11	advcl
7	,	,	,	_	11	punct
8	drug1	drug1	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	discontinued	discontinue	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	0	ROOT
8	until	until	IN	_	12	mark
9	normal	normal	JJ	_	10	amod
10	hematopoiesis	hematopoiesis	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	restored	restore	VBN	_	7	advcl
13	.	.	.	_	7	punct

1	Mild	mild	JJ	_	2	amod
2	hepatotoxicity	hepatotoxicity	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	some	some	DT	_	8	det
8	patients	patient	NNS	_	5	nmod
9	when	when	WRB	_	14	advmod
10	drug1	drug1	NN	_	14	nsubjpass
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	were	be	VBD	_	14	auxpass
14	administered	administer	VBN	_	5	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	.	.	.	_	5	punct

1	Due	due	JJ	_	4	case
2	to	to	TO	_	4	case
3	its	its	PRP$	_	4	nmod:poss
4	effects	effect	NNS	_	0	ROOT
5	on	on	IN	_	7	case
6	gastric	gastric	JJ	_	7	amod
7	emptying	emptying	NN	_	4	nmod
8	,	,	,	_	7	punct
9	drug1	drug1	NN	_	10	compound
10	therapy	therapy	NN	_	7	appos
11	should	should	MD	_	14	aux
12	not	not	RB	_	14	neg
13	be	be	VB	_	14	auxpass
14	considered	consider	VBN	_	4	dep
15	for	for	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	taking	take	VBG	_	16	acl
18	drugs	drug	NNS	_	17	dobj
19	that	that	WDT	_	20	nsubj
20	alter	alter	VBP	_	18	acl:relcl
21	gastrointestinal	gastrointestinal	JJ	_	22	amod
22	motility	motility	NN	_	20	dobj
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	e.g.	e.g.	FW	_	26	advmod
25	,	,	,	_	26	punct
26	drug2	drug2	NN	_	14	dep
27	such	such	JJ	_	29	case
28	as	as	IN	_	27	mwe
29	drug3	drug3	NN	_	26	nmod
30	-RRB-	-rrb-	-RRB-	_	26	punct
31	and	and	CC	_	14	cc
32	agents	agent	NNS	_	14	conj
33	that	that	WDT	_	34	nsubj
34	slow	slow	VBP	_	32	acl:relcl
35	the	the	DT	_	37	det
36	intestinal	intestinal	JJ	_	37	amod
37	absorption	absorption	NN	_	34	dobj
38	of	of	IN	_	39	case
39	nutrients	nutrient	NNS	_	37	nmod
40	-LRB-	-lrb-	-LRB-	_	43	punct
41	e.g.	e.g.	FW	_	43	dep
42	,	,	,	_	43	punct
43	drug4	drug4	NN	_	32	dep
44	-RRB-	-rrb-	-RRB-	_	43	punct
45	.	.	.	_	4	punct

1	Patients	patient	NNS	_	8	nsubjpass
2	using	use	VBG	_	1	acl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	studied	study	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	trials	trial	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	potential	potential	JJ	_	2	dobj
5	to	to	TO	_	6	mark
6	delay	delay	VB	_	4	acl
7	the	the	DT	_	8	det
8	absorption	absorption	NN	_	6	dobj
9	of	of	IN	_	13	case
10	concomitantly	concomitantly	RB	_	11	advmod
11	administered	administer	VBN	_	13	amod
12	oral	oral	JJ	_	13	amod
13	medications	medication	NNS	_	8	nmod
14	.	.	.	_	2	punct

1	When	when	WRB	_	14	advmod
2	the	the	DT	_	4	det
3	rapid	rapid	JJ	_	4	amod
4	onset	onset	NN	_	14	nsubj
5	of	of	IN	_	10	case
6	a	a	DT	_	10	det
7	concomitant	concomitant	JJ	_	10	amod
8	orally	orally	RB	_	9	advmod
9	administered	administer	VBN	_	10	amod
10	agent	agent	NN	_	4	nmod
11	is	be	VBZ	_	14	cop
12	a	a	DT	_	14	det
13	critical	critical	JJ	_	14	amod
14	determinant	determinant	NN	_	27	advcl
15	of	of	IN	_	16	case
16	effectiveness	effectiveness	NN	_	14	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	drug1	drug1	NN	_	16	nmod
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	27	punct
23	the	the	DT	_	24	det
24	agent	agent	NN	_	27	nsubjpass
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	administered	administer	VBN	_	0	ROOT
28	at	at	IN	_	29	case
29	least	least	JJS	_	30	nmod:npmod
30	1	1	CD	_	31	nummod
31	hour	hour	NN	_	27	dobj
32	prior	prior	RB	_	36	advmod
33	to	to	TO	_	36	case
34	or	or	CC	_	33	cc
35	2	2	CD	_	33	conj
36	hours	hour	NNS	_	27	nmod
37	after	after	IN	_	39	case
38	drug2	drug2	NN	_	39	compound
39	injection	injection	NN	_	36	nmod
40	.	.	.	_	27	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	the	the	DT	_	7	det
6	concomitant	concomitant	JJ	_	7	amod
7	use	use	NN	_	14	nsubj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	did	do	VBD	_	14	aux
13	not	not	RB	_	14	neg
14	alter	alter	VB	_	0	ROOT
15	the	the	DT	_	18	det
16	adverse	adverse	JJ	_	18	amod
17	event	event	NN	_	18	compound
18	profile	profile	NN	_	14	dobj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	.	.	.	_	14	punct

1	No	no	DT	_	4	neg
2	formal	formal	JJ	_	4	amod
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	assess	assess	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	effect	effect	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	kinetics	kinetics	NNS	_	11	nmod
17	of	of	IN	_	19	case
18	oral	oral	JJ	_	19	amod
19	drug2	drug2	NN	_	16	nmod
20	.	.	.	_	7	punct

1	Mixing	mix	VBG	_	11	csubjpass
2	drug1	drug1	NN	_	1	dobj
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	The	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	parameters	parameter	NNS	_	2	dep
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	were	be	VBD	_	11	auxpass
11	altered	alter	VBN	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	mixed	mix	VBN	_	11	advcl
14	with	with	IN	_	13	nmod
15	regular	regular	JJ	_	14	dep
16	,	,	,	_	15	punct
17	NPH	nph	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	70/30	70/30	CD	_	22	nummod
21	premixed	premixed	JJ	_	22	amod
22	formulations	formulation	NNS	_	15	conj
23	of	of	IN	_	25	case
24	recombinant	recombinant	JJ	_	25	amod
25	drug4	drug4	NN	_	22	nmod
26	immediately	immediately	RB	_	27	advmod
27	prior	prior	RB	_	15	advmod
28	to	to	TO	_	29	case
29	injection	injection	NN	_	27	nmod
30	.	.	.	_	11	punct

1	Thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	drug1	drug1	NN	_	9	nsubj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	should	should	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	cop
9	mixed	mixed	JJ	_	0	ROOT
10	and	and	CC	_	9	cc
11	must	must	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	administered	administer	VBN	_	9	conj
14	separately	separately	RB	_	13	advmod
15	.	.	.	_	9	punct

1	Since	since	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	a	a	DT	_	5	det
5	substrate	substrate	NN	_	26	advcl
6	for	for	IN	_	9	case
7	the	the	DT	_	9	det
8	metabolic	metabolic	JJ	_	9	amod
9	pathways	pathway	NNS	_	5	nmod
10	involving	involve	VBG	_	9	acl
11	CYP2D6	cyp2d6	NN	_	14	compound
12	and	and	CC	_	11	cc
13	CYP1A2	cyp1a2	NN	_	11	conj
14	enzymes	enzyme	NNS	_	10	dobj
15	,	,	,	_	14	punct
16	inhibition	inhibition	NN	_	14	conj
17	or	or	CC	_	14	cc
18	induction	induction	NN	_	14	conj
19	of	of	IN	_	20	case
20	either	either	DT	_	18	nmod
21	of	of	IN	_	23	case
22	these	these	DT	_	23	det
23	enzymes	enzyme	NNS	_	20	nmod
24	would	would	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	expected	expect	VBN	_	0	ROOT
27	to	to	TO	_	28	mark
28	alter	alter	VB	_	26	xcomp
29	drug2	drug2	NN	_	31	compound
30	plasma	plasma	NN	_	31	compound
31	concentrations	concentration	NNS	_	28	dobj
32	.	.	.	_	26	punct

1	In	in	IN	_	7	case
2	a	a	DT	_	7	det
3	formal	formal	JJ	_	7	amod
4	,	,	,	_	7	punct
5	single-dose	single-dose	JJ	_	7	amod
6	interaction	interaction	NN	_	7	compound
7	study	study	NN	_	19	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	n	n	NN	_	10	nsubj
10	=	=	JJ	_	7	dep
11	6	6	CD	_	12	nummod
12	males	male	NNS	_	10	dobj
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	the	the	DT	_	15	det
15	clearance	clearance	NN	_	19	nsubjpass
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	was	be	VBD	_	19	auxpass
19	decreased	decrease	VBN	_	0	ROOT
20	by	by	IN	_	22	case
21	38	38	CD	_	22	nummod
22	%	%	NN	_	19	nmod
23	following	follow	VBG	_	25	case
24	the	the	DT	_	25	det
25	coadministration	coadministration	NN	_	19	nmod
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	,	,	,	_	27	punct
29	an	a	DT	_	30	det
30	inhibitor	inhibitor	NN	_	27	appos
31	of	of	IN	_	32	case
32	CYP1A2	cyp1a2	NN	_	30	nmod
33	.	.	.	_	19	punct

1	In	in	IN	_	4	case
2	another	another	DT	_	4	det
3	formal	formal	JJ	_	4	amod
4	study	study	NN	_	25	nmod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	n	n	NN	_	7	nsubj
7	=	=	JJ	_	4	dep
8	8	8	CD	_	9	nummod
9	extensive	extensive	JJ	_	7	dobj
10	and	and	CC	_	9	cc
11	n	n	NN	_	9	conj
12	=	=	JJ	_	9	dep
13	7	7	CD	_	15	nummod
14	poor	poor	JJ	_	15	amod
15	metabolizers	metabolizer	NNS	_	12	dep
16	of	of	IN	_	17	case
17	CYP2D6	cyp2d6	NN	_	15	nmod
18	-RRB-	-rrb-	-RRB-	_	7	punct
19	,	,	,	_	25	punct
20	coadministration	coadministration	NN	_	25	nsubj
21	of	of	IN	_	22	case
22	drug1	drug1	NN	_	20	nmod
23	did	do	VBD	_	25	aux
24	not	not	RB	_	25	neg
25	alter	alter	VB	_	0	ROOT
26	the	the	DT	_	27	det
27	kinetics	kinetics	NNS	_	25	dobj
28	of	of	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod
30	in	in	IN	_	35	case
31	the	the	DT	_	35	det
32	poor	poor	JJ	_	35	amod
33	CYP2D6	cyp2d6	NN	_	35	compound
34	metabolizer	metabolizer	NN	_	35	compound
35	group	group	NN	_	25	nmod
36	.	.	.	_	25	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	5	det
4	metabolic	metabolic	JJ	_	5	amod
5	clearance	clearance	NN	_	2	root
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	12	case
9	the	the	DT	_	12	det
10	extensive	extensive	JJ	_	12	amod
11	metabolizer	metabolizer	NN	_	12	compound
12	phenotype	phenotype	NN	_	5	nmod
13	decreased	decrease	VBN	_	12	acl
14	by	by	IN	_	17	case
15	about	about	RB	_	16	advmod
16	70	70	CD	_	17	nummod
17	%	%	NN	_	13	nmod
18	making	make	VBG	_	12	acl
19	the	the	DT	_	24	det
20	poor	poor	JJ	_	24	amod
21	and	and	CC	_	20	cc
22	extensive	extensive	JJ	_	20	conj
23	metabolizer	metabolizer	NN	_	24	compound
24	groups	group	NNS	_	25	nsubj
25	indistinguishable	indistinguishable	JJ	_	18	xcomp
26	.	.	.	_	5	punct

1	In	in	IN	_	6	case
2	this	this	DT	_	6	det
3	crossover	crossover	NN	_	6	compound
4	steady	steady	JJ	_	6	amod
5	state	state	NN	_	6	compound
6	study	study	NN	_	13	nmod
7	,	,	,	_	13	punct
8	the	the	DT	_	9	det
9	pharmacokinetics	pharmacokinetic	NNS	_	13	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	were	be	VBD	_	13	cop
13	unaffected	unaffected	JJ	_	0	ROOT
14	in	in	IN	_	16	case
15	either	either	CC	_	16	det
16	phenotype	phenotype	NN	_	13	nmod
17	by	by	IN	_	19	case
18	the	the	DT	_	19	det
19	coadministration	coadministration	NN	_	13	nmod
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	13	punct

1	Addition	addition	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	to	to	TO	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	lead	lead	VB	_	0	ROOT
9	to	to	TO	_	13	case
10	further	further	JJ	_	13	amod
11	electrocardiographic	electrocardiographic	JJ	_	13	amod
12	parameters	parameter	NNS	_	13	compound
13	changes	change	NNS	_	8	nmod
14	of	of	IN	_	15	case
15	QRS	QRS	NNP	_	13	nmod
16	,	,	,	_	15	punct
17	QTc	QTc	NNP	_	15	conj
18	,	,	,	_	15	punct
19	RR	RR	NNP	_	15	conj
20	,	,	,	_	15	punct
21	and	and	CC	_	15	cc
22	PR	pr	NN	_	23	compound
23	intervals	interval	NNS	_	15	conj
24	than	than	IN	_	25	case
25	drug3	drug3	NN	_	13	nmod
26	alone	alone	RB	_	25	advmod
27	.	.	.	_	8	punct

1	When	when	WRB	_	13	advmod
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	13	nsubjpass
4	of	of	IN	_	5	case
5	either	either	DT	_	3	nmod
6	of	of	IN	_	9	case
7	these	these	DT	_	9	det
8	two	two	CD	_	9	nummod
9	drugs	drug	NNS	_	5	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	3	nmod
12	is	be	VBZ	_	13	auxpass
13	initiated	initiate	VBN	_	22	advcl
14	,	,	,	_	22	punct
15	the	the	DT	_	16	det
16	dose	dose	NN	_	22	nsubjpass
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	should	should	MD	_	22	aux
20	be	be	VB	_	22	auxpass
21	slowly	slowly	RB	_	22	advmod
22	titrated	titrate	VBN	_	0	ROOT
23	to	to	TO	_	25	case
24	desired	desire	VBN	_	25	amod
25	effect	effect	NN	_	22	nmod
26	.	.	.	_	22	punct

1	In	in	IN	_	7	case
2	a	a	DT	_	7	det
3	large	large	JJ	_	7	amod
4	compassionate	compassionate	JJ	_	7	amod
5	use	use	NN	_	7	compound
6	program	program	NN	_	7	compound
7	drug1	drug1	NN	_	10	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	used	use	VBN	_	0	ROOT
11	concurrently	concurrently	RB	_	10	advmod
12	with	with	IN	_	15	case
13	commonly	commonly	RB	_	14	advmod
14	employed	employ	VBN	_	15	amod
15	antianginal	antianginal	JJ	_	10	nmod
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	drug3	drug3	NN	_	15	conj
21	without	without	IN	_	23	case
22	observed	observe	VBN	_	23	amod
23	interactions	interaction	NNS	_	10	nmod
24	.	.	.	_	10	punct

1	A	a	DT	_	2	det
2	variety	variety	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug2	drug2	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	were	be	VBD	_	12	auxpass
11	also	also	RB	_	12	advmod
12	added	add	VBN	_	0	ROOT
13	,	,	,	_	12	punct
14	sometimes	sometimes	RB	_	12	advmod
15	with	with	IN	_	17	case
16	improved	improve	VBN	_	17	amod
17	control	control	NN	_	14	nmod
18	of	of	IN	_	20	case
19	ventricular	ventricular	JJ	_	20	amod
20	ectopy	ectopy	NN	_	17	nmod
21	.	.	.	_	12	punct

1	When	when	WRB	_	15	advmod
2	drug1	drug1	NN	_	15	nsubjpass
3	or	or	CC	_	2	cc
4	other	other	JJ	_	7	amod
5	hepatic	hepatic	JJ	_	7	amod
6	enzyme	enzyme	NN	_	7	compound
7	inducers	inducer	NNS	_	2	conj
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug2	drug2	NN	_	2	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	taken	take	VBN	_	20	advcl
16	concurrently	concurrently	RB	_	15	advmod
17	with	with	IN	_	18	case
18	drug4	drug4	NN	_	15	nmod
19	,	,	,	_	20	punct
20	lowered	lower	VBD	_	26	csubjpass
21	drug5	drug5	NN	_	23	compound
22	plasma	plasma	NN	_	23	compound
23	levels	level	NNS	_	20	dobj
24	have	have	VBP	_	26	aux
25	been	be	VBN	_	26	auxpass
26	reported	report	VBN	_	0	ROOT
27	.	.	.	_	26	punct

1	Monitoring	monitoring	NN	_	7	nsubjpass
2	of	of	IN	_	5	case
3	drug1	drug1	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	levels	level	NNS	_	1	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	during	during	IN	_	11	case
9	such	such	JJ	_	11	amod
10	concurrent	concurrent	JJ	_	11	amod
11	use	use	NN	_	7	nmod
12	to	to	TO	_	13	mark
13	avoid	avoid	VB	_	11	acl
14	ineffective	ineffective	JJ	_	15	amod
15	therapy	therapy	NN	_	13	dobj
16	.	.	.	_	7	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	formal	formal	JJ	_	4	amod
4	study	study	NN	_	8	nmod
5	,	,	,	_	8	punct
6	drug1	drug1	NN	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	shown	show	VBN	_	0	ROOT
9	not	not	RB	_	11	neg
10	to	to	TO	_	11	mark
11	affect	affect	VB	_	8	xcomp
12	drug2	drug2	NN	_	14	compound
13	plasma	plasma	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	.	.	.	_	8	punct

1	ECG	ecg	NN	_	2	compound
2	intervals	interval	NNS	_	13	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	PR	pr	NN	_	2	dep
5	,	,	,	_	4	punct
6	QRS	QRS	NNP	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	QT	qt	NN	_	4	conj
10	-RRB-	-rrb-	-RRB-	_	4	punct
11	were	be	VBD	_	13	auxpass
12	not	not	RB	_	13	neg
13	affected	affect	VBN	_	0	ROOT
14	by	by	IN	_	16	case
15	concurrent	concurrent	JJ	_	16	amod
16	drug1	drug1	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug3	drug3	NN	_	16	conj
21	,	,	,	_	16	punct
22	or	or	CC	_	16	cc
23	drug4	drug4	NN	_	16	conj
24	.	.	.	_	13	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	increase	increase	VB	_	9	ccomp
12	,	,	,	_	11	punct
13	decrease	decrease	VB	_	11	conj
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	leave	leave	VB	_	11	conj
17	unchanged	unchanged	JJ	_	20	amod
18	drug3	drug3	NN	_	20	compound
19	plasma	plasma	NN	_	20	compound
20	levels	level	NNS	_	16	dobj
21	;	;	:	_	9	punct

1	therefore	therefore	RB	_	5	advmod
2	patients	patient	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	followed	follow	VBN	_	0	ROOT
6	carefully	carefully	RB	_	5	advmod
7	during	during	IN	_	9	case
8	concurrent	concurrent	JJ	_	9	amod
9	therapy	therapy	NN	_	5	nmod
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	alter	alter	VB	_	0	ROOT
5	serum	serum	NN	_	7	compound
6	drug2	drug2	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	but	but	CC	_	4	cc
9	drug3	drug3	NN	_	23	nsubjpass
10	,	,	,	_	9	punct
11	when	when	WRB	_	12	advmod
12	used	use	VBN	_	9	acl:relcl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	gastrointestinal	gastrointestinal	JJ	_	16	amod
16	symptoms	symptom	NNS	_	14	dobj
17	due	due	JJ	_	14	advmod
18	to	to	TO	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	,	,	,	_	9	punct
21	has	have	VBZ	_	23	aux
22	been	be	VBN	_	23	auxpass
23	reported	report	VBN	_	4	conj
24	to	to	TO	_	28	case
25	lower	lower	JJR	_	28	amod
26	serum	serum	NN	_	28	compound
27	drug5	drug5	NN	_	28	compound
28	levels	level	NNS	_	23	nmod
29	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	lead	lead	VB	_	0	ROOT
9	to	to	TO	_	13	case
10	increased	increase	VBN	_	13	amod
11	plasma	plasma	NN	_	13	compound
12	drug3	drug3	NN	_	13	compound
13	levels	level	NNS	_	8	nmod
14	.	.	.	_	8	punct

1	One	one	CD	_	3	nummod
2	controlled	controlled	JJ	_	3	amod
3	study	study	NN	_	8	nsubj
4	in	in	IN	_	7	case
5	eight	eight	CD	_	7	nummod
6	normal	normal	JJ	_	7	amod
7	subjects	subject	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	a	a	DT	_	13	det
10	72	72	CD	_	11	compound
11	%	%	NN	_	13	amod
12	mean	mean	JJ	_	13	amod
13	increase	increase	NN	_	8	dobj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	range	range	NN	_	13	dep
16	35-136	35-136	CD	_	17	nummod
17	%	%	NN	_	15	dep
18	-RRB-	-rrb-	-RRB-	_	15	punct
19	in	in	IN	_	22	case
20	plasma	plasma	NN	_	22	compound
21	drug1	drug1	NN	_	22	compound
22	levels	level	NNS	_	13	nmod
23	.	.	.	_	8	punct

1	This	this	DT	_	2	det
2	increase	increase	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	at	at	IN	_	9	case
6	the	the	DT	_	9	det
7	first	first	JJ	_	9	amod
8	test	test	NN	_	9	compound
9	point	point	NN	_	4	nmod
10	which	which	WDT	_	14	nsubj
11	was	be	VBD	_	14	cop
12	the	the	DT	_	14	det
13	second	second	JJ	_	14	amod
14	day	day	NN	_	9	acl:relcl
15	after	after	IN	_	16	mark
16	starting	start	VBG	_	14	acl
17	drug1	drug1	NN	_	16	dobj
18	.	.	.	_	4	punct
19	drug2	drug2	NN	_	21	compound
20	plasma	plasma	NN	_	21	compound
21	levels	level	NNS	_	22	nsubj
22	returned	return	VBD	_	4	parataxis
23	to	to	TO	_	24	case
24	pre	pre	JJ	_	22	nmod
25	-	-	:	_	22	punct
26	drug3	drug3	NN	_	27	compound
27	values	value	NNS	_	22	dobj
28	within	within	IN	_	30	case
29	48	48	CD	_	30	nummod
30	hours	hour	NNS	_	27	nmod
31	after	after	IN	_	32	mark
32	discontinuing	discontinue	VBG	_	27	acl
33	drug4	drug4	NN	_	32	dobj
34	.	.	.	_	4	punct
35	If	if	IN	_	39	mark
36	drug5	drug5	NN	_	39	nsubj
37	and	and	CC	_	36	cc
38	drug6	drug6	NN	_	36	conj
39	are	be	VBP	_	50	advcl
40	to	to	TO	_	42	mark
41	be	be	VB	_	42	auxpass
42	used	use	VBN	_	39	xcomp
43	concurrently	concurrently	RB	_	42	advmod
44	,	,	,	_	50	punct
45	drug7	drug7	NN	_	47	compound
46	blood	blood	NN	_	47	compound
47	levels	level	NNS	_	50	nsubjpass
48	should	should	MD	_	50	aux
49	be	be	VB	_	50	auxpass
50	monitored	monitor	VBN	_	4	parataxis
51	,	,	,	_	50	punct
52	particularly	particularly	RB	_	58	advmod
53	when	when	WRB	_	58	advmod
54	the	the	DT	_	56	det
55	drug8	drug8	NN	_	56	compound
56	dose	dose	NN	_	58	nsubjpass
57	is	be	VBZ	_	58	auxpass
58	changed	change	VBN	_	50	advcl
59	.	.	.	_	4	punct

1	An	a	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	adjustment	adjustment	NN	_	9	nsubjpass
4	in	in	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	dose	dose	NN	_	3	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Additionally	additionally	RB	_	20	advmod
2	,	,	,	_	20	punct
3	in	in	IN	_	6	case
4	one	one	CD	_	6	nummod
5	controlled	controlled	JJ	_	6	amod
6	study	study	NN	_	20	nmod
7	in	in	IN	_	10	case
8	five	five	CD	_	10	nummod
9	normal	normal	JJ	_	10	amod
10	subjects	subject	NNS	_	6	nmod
11	and	and	CC	_	10	cc
12	seven	seven	CD	_	13	nummod
13	patients	patient	NNS	_	10	conj
14	,	,	,	_	20	punct
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	20	nsubjpass
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	was	be	VBD	_	20	auxpass
20	decreased	decrease	VBN	_	0	ROOT
21	50	50	CD	_	22	nummod
22	%	%	NN	_	20	dobj
23	following	follow	VBG	_	25	case
24	the	the	DT	_	25	det
25	administration	administration	NN	_	20	nmod
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	.	.	.	_	20	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	oral	oral	JJ	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	The	the	DT	_	7	det
7	activity	activity	NN	_	13	nsubjpass
8	of	of	IN	_	10	case
9	oral	oral	JJ	_	10	amod
10	drug2	drug2	NN	_	7	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	potentiated	potentiate	VBN	_	1	dep
14	by	by	IN	_	16	case
15	anti-vitamin-K	anti-vitamin-k	JJ	_	16	amod
16	activity	activity	NN	_	13	nmod
17	attributed	attribute	VBN	_	16	acl
18	to	to	TO	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	1	punct

1	-	-	:	_	6	punct
2	drug1	drug1	NN	_	6	dep
3	:	:	:	_	6	punct
4	Hyperthyroidism	hyperthyroidism	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	cause	cause	VB	_	0	ROOT
7	an	a	DT	_	9	det
8	increased	increase	VBN	_	9	amod
9	clearance	clearance	NN	_	6	dobj
10	of	of	IN	_	12	case
11	beta	beta	NN	_	12	compound
12	ratio	ratio	NN	_	9	nmod
13	.	.	.	_	6	punct

1	A	a	DT	_	3	det
2	dose	dose	NN	_	3	compound
3	reduction	reduction	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	needed	need	VBN	_	0	ROOT
9	when	when	WRB	_	13	advmod
10	a	a	DT	_	12	det
11	hyperthyroid	hyperthyroid	JJ	_	12	amod
12	patient	patient	NN	_	13	nsubj
13	becomes	become	VBZ	_	8	advcl
14	euthyroid	euthyroid	JJ	_	13	xcomp
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Serum	serum	NN	_	5	compound
4	digitalis	digitalis	NN	_	5	compound
5	levels	level	NNS	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	increased	increase	VBN	_	1	appos
9	when	when	WRB	_	17	advmod
10	hyperthyroid	hyperthyroid	JJ	_	11	amod
11	patients	patient	NNS	_	17	nsubj
12	on	on	IN	_	16	case
13	a	a	DT	_	16	det
14	stable	stable	JJ	_	16	amod
15	drug2	drug2	NN	_	16	compound
16	regimen	regimen	NNS	_	11	nmod
17	become	become	VBP	_	8	advcl
18	euthyroid	euthyroid	JJ	_	17	xcomp
19	;	;	:	_	1	punct

1	reduced	reduce	VBN	_	2	amod
2	dosage	dosage	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	required	require	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	clearance	clearance	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	1	parataxis
7	when	when	WRB	_	15	advmod
8	hyperthyroid	hyperthyroid	JJ	_	9	amod
9	patients	patient	NNS	_	15	nsubj
10	on	on	IN	_	14	case
11	a	a	DT	_	14	det
12	stable	stable	JJ	_	14	amod
13	drug3	drug3	NN	_	14	compound
14	regimen	regimen	NNS	_	9	nmod
15	become	become	VBP	_	6	advcl
16	euthyroid	euthyroid	JJ	_	15	xcomp
17	;	;	:	_	1	punct

1	a	a	DT	_	3	det
2	reduced	reduce	VBN	_	3	amod
3	dose	dose	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	needed	need	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	6	advmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	because	because	IN	_	13	mark
11	they	they	PRP	_	13	nsubj
12	may	may	MD	_	13	aux
13	have	have	VB	_	6	advcl
14	additive	additive	JJ	_	15	amod
15	effects	effect	NNS	_	13	dobj
16	.	.	.	_	6	punct

1	Some	some	DT	_	2	det
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	4	punct

1	They	they	PRP	_	4	nsubj
2	can	can	MD	_	4	aux
3	either	either	RB	_	4	advmod
4	increase	increase	VB	_	0	ROOT
5	or	or	CC	_	4	cc
6	decrease	decrease	VB	_	4	conj
7	the	the	DT	_	8	det
8	effect	effect	NN	_	4	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	4	punct

1	Those	those	DT	_	2	det
2	drug1	drug1	NN	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	drug2	drug2	NN	_	3	dobj
5	,	,	,	_	4	punct
6	drug3	drug3	NN	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	drug4	drug4	NN	_	4	conj
10	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	which	which	WDT	_	12	nsubj
12	include	include	VBP	_	9	acl:relcl
13	some	some	DT	_	14	det
14	drug2	drug2	NN	_	12	dobj
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	certain	certain	JJ	_	20	amod
19	heart	heart	NN	_	20	compound
20	medicines	medicine	NNS	_	14	conj
21	,	,	,	_	14	punct
22	birth	birth	NN	_	24	compound
23	control	control	NN	_	24	compound
24	pills	pill	NNS	_	14	conj
25	,	,	,	_	14	punct
26	drug4	drug4	NN	_	14	conj
27	,	,	,	_	14	punct
28	drug5	drug5	NN	_	14	conj
29	and	and	CC	_	14	cc
30	drug6	drug6	NN	_	14	conj
31	Please	please	UH	_	32	discourse
32	note	note	VB	_	4	xcomp
33	that	that	IN	_	36	mark
34	drug7	drug7	NN	_	36	nsubj
35	may	may	MD	_	36	aux
36	interact	interact	VB	_	32	ccomp
37	with	with	IN	_	39	case
38	other	other	JJ	_	39	amod
39	drugs	drug	NNS	_	36	nmod
40	that	that	WDT	_	43	nsubjpass
41	are	be	VBP	_	43	auxpass
42	not	not	RB	_	43	neg
43	listed	list	VBN	_	39	acl:relcl
44	here	here	RB	_	43	advmod
45	.	.	.	_	4	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	:	:	:	_	1	punct
6	The	the	DT	_	8	det
7	depressant	depressant	NN	_	8	compound
8	effects	effect	NNS	_	12	nsubjpass
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	are	be	VBP	_	12	auxpass
12	potentiated	potentiate	VBN	_	1	dep
13	by	by	IN	_	15	case
14	the	the	DT	_	15	det
15	presence	presence	NN	_	12	nmod
16	of	of	IN	_	18	case
17	other	other	JJ	_	18	amod
18	drug3	drug3	NN	_	15	nmod
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	drug4	drug4	NN	_	18	nmod
22	,	,	,	_	21	punct
23	drug5	drug5	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug6	drug6	NN	_	21	conj
26	,	,	,	_	21	punct
27	or	or	CC	_	21	cc
28	drug7	drug7	NN	_	21	conj
29	.	.	.	_	12	punct

1	Use	use	NN	_	10	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	5	case
5	conjunction	conjunction	NN	_	1	nmod
6	with	with	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	may	may	MD	_	10	aux
10	increase	increase	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	respiratory	respiratory	JJ	_	15	amod
15	depression	depression	NN	_	12	nmod
16	,	,	,	_	15	punct
17	hypotension	hypotension	NN	_	15	conj
18	and	and	CC	_	15	cc
19	profound	profound	JJ	_	20	amod
20	sedation	sedation	NN	_	15	conj
21	or	or	CC	_	20	cc
22	coma	coma	NN	_	20	conj
23	.	.	.	_	10	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	drug2	drug2	NN	_	21	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	i.e.	i.e.	FW	_	9	dep
8	,	,	,	_	9	punct
9	drug3	drug3	NN	_	5	dep
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug5	drug5	NN	_	9	conj
14	,	,	,	_	9	punct
15	or	or	CC	_	9	cc
16	drug6	drug6	NN	_	9	conj
17	-RRB-	-rrb-	-RRB-	_	9	punct
18	should	should	MD	_	21	aux
19	NOT	not	RB	_	21	advmod
20	be	be	VB	_	21	auxpass
21	administered	administer	VBN	_	1	dep
22	to	to	TO	_	23	case
23	patients	patient	NNS	_	21	nmod
24	who	who	WP	_	26	nsubj
25	have	have	VBP	_	26	aux
26	received	receive	VBN	_	23	acl:relcl
27	or	or	CC	_	26	cc
28	are	be	VBP	_	29	aux
29	receiving	receive	VBG	_	26	conj
30	a	a	DT	_	31	det
31	course	course	NN	_	26	dobj
32	of	of	IN	_	33	case
33	therapy	therapy	NN	_	31	nmod
34	with	with	IN	_	37	case
35	a	a	DT	_	37	det
36	proof	proof	NN	_	37	compound
37	drug7	drug7	NN	_	26	nmod
38	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	patients	patient	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	the	the	DT	_	7	det
6	mixed	mixed	JJ	_	7	amod
7	agonist/antagonist	agonist/antagonist	NN	_	9	nsubj
8	may	may	MD	_	9	aux
9	alter	alter	VB	_	0	ROOT
10	the	the	DT	_	12	det
11	analgesic	analgesic	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	or	or	CC	_	9	cc
14	may	may	MD	_	15	aux
15	precipitate	precipitate	VB	_	9	conj
16	withdrawal	withdrawal	NN	_	17	compound
17	symptoms	symptom	NNS	_	15	dobj
18	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypotensive	hypotensive	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Use	Use	NNP	_	0	ROOT
2	cautiously	cautiously	RB	_	5	advmod
3	with	with	IN	_	5	case
4	pressor	pressor	NN	_	5	compound
5	agents	agent	NNS	_	1	nmod
6	.	.	.	_	1	punct

1	Human	human	JJ	_	3	amod
2	pharmacologic	pharmacologic	JJ	_	3	amod
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	9	mark
7	drug1	drug1	NN	_	9	nsubj
8	may	may	MD	_	9	aux
9	inhibit	inhibit	VB	_	5	ccomp
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug4	drug4	NN	_	15	dep
18	,	,	,	_	17	punct
19	drug5	drug5	NN	_	17	appos
20	,	,	,	_	17	punct
21	drug6	drug6	NN	_	17	appos
22	-RRB-	-rrb-	-RRB-	_	17	punct
23	,	,	,	_	13	punct
24	drug7	drug7	NN	_	13	conj
25	,	,	,	_	13	punct
26	and	and	CC	_	13	cc
27	drug8	drug8	NN	_	13	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug9	drug9	NN	_	27	dep
30	,	,	,	_	29	punct
31	drug10	drug10	NN	_	29	appos
32	,	,	,	_	29	punct
33	drug11	drug11	NN	_	29	appos
34	-RRB-	-rrb-	-RRB-	_	29	punct
35	.	.	.	_	5	punct

1	Downward	downward	JJ	_	3	amod
2	dosage	dosage	NN	_	3	compound
3	adjustments	adjustment	NNS	_	9	nsubjpass
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	when	when	WRB	_	11	advmod
11	given	give	VBN	_	9	advcl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	11	nmod
15	.	.	.	_	9	punct

1	Serious	serious	JJ	_	3	amod
2	adverse	adverse	JJ	_	3	amod
3	events	event	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	use	use	NN	_	6	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	6	punct
13	although	although	IN	_	21	mark
14	no	no	DT	_	15	neg
15	causality	causality	NN	_	21	nsubjpass
16	for	for	IN	_	18	case
17	the	the	DT	_	18	det
18	combination	combination	NN	_	15	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	established	establish	VBN	_	6	advcl
22	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	safety	safety	NN	_	19	nsubjpass
3	of	of	IN	_	4	mark
4	using	use	VBG	_	2	acl
5	drug1	drug1	NN	_	4	dobj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	other	other	JJ	_	14	amod
12	centrally	centrally	RB	_	13	advmod
13	acting	act	VBG	_	14	amod
14	drug3	drug3	NN	_	9	conj
15	has	have	VBZ	_	19	aux
16	not	not	RB	_	19	neg
17	been	be	VBN	_	19	auxpass
18	systemically	systemically	RB	_	19	advmod
19	evaluated	evaluate	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Co-administration	co-administration	NN	_	37	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	strong	strong	JJ	_	6	amod
6	inhibitors	inhibitor	NNS	_	1	nmod
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	CYP3A4	cyp3a4	NN	_	10	compound
10	family	family	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	drug2	drug2	NN	_	6	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug5	drug5	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug6	drug6	NN	_	14	conj
23	,	,	,	_	14	punct
24	drug7	drug7	NN	_	14	conj
25	,	,	,	_	14	punct
26	drug8	drug8	NN	_	14	conj
27	,	,	,	_	14	punct
28	drug9	drug9	NN	_	14	conj
29	,	,	,	_	14	punct
30	drug10	drug10	NN	_	14	conj
31	,	,	,	_	14	punct
32	drug11	drug11	NN	_	14	conj
33	,	,	,	_	14	punct
34	drug12	drug12	NN	_	14	appos
35	-RRB-	-rrb-	-RRB-	_	14	punct
36	may	may	MD	_	37	aux
37	increases	increase	NNS	_	0	ROOT
38	drug13	drug13	NN	_	39	compound
39	concentrations	concentration	NNS	_	37	dobj
40	.	.	.	_	37	punct

1	Grapefruit	grapefruit	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	increase	increase	VB	_	0	ROOT
5	plasma	plasma	NN	_	6	compound
6	concentrations	concentration	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	4	punct

1	Co-administration	co-administration	NN	_	32	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	inducers	inducer	NNS	_	1	nmod
6	of	of	IN	_	9	case
7	the	the	DT	_	9	det
8	CYP3A4	cyp3a4	NN	_	9	compound
9	family	family	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug2	drug2	NN	_	5	dep
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug5	drug5	NN	_	13	conj
20	,	,	,	_	13	punct
21	drug6	drug6	NN	_	13	conj
22	,	,	,	_	13	punct
23	drug7	drug7	NN	_	13	conj
24	,	,	,	_	13	punct
25	drug8	drug8	NN	_	13	conj
26	,	,	,	_	13	punct
27	St.	St.	NNP	_	29	compound
28	Johns	Johns	NNP	_	29	compound
29	Wort	Wort	NNP	_	13	appos
30	-RRB-	-rrb-	-RRB-	_	13	punct
31	may	may	MD	_	32	aux
32	decrease	decrease	VB	_	0	ROOT
33	drug9	drug9	NN	_	34	compound
34	concentrations	concentration	NNS	_	32	dobj
35	.	.	.	_	32	punct

1	St.	St.	NNP	_	0	ROOT

1	Johns	Johns	NNP	_	2	compound
2	Wort	Wort	NNP	_	4	nsubj
3	may	may	MD	_	4	aux
4	decrease	decrease	VB	_	0	ROOT
5	drug1	drug1	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	unpredictably	unpredictably	RB	_	4	advmod
9	.	.	.	_	4	punct

1	Patients	patient	NNS	_	6	nsubj
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	not	not	RB	_	6	neg
6	take	take	VB	_	0	ROOT
7	St.	St.	NNP	_	6	dobj

1	Johns	Johns	NNP	_	2	compound
2	Wort	Wort	NNP	_	0	ROOT
3	concomitantly	concomitantly	RB	_	2	advmod
4	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	compound
2	dose	dose	NN	_	3	compound
3	modification	modification	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	using	use	VBG	_	7	acl
9	concomitant	concomitant	JJ	_	11	amod
10	CYP3A4	cyp3a4	NN	_	11	compound
11	inhibitors	inhibitor	NNS	_	8	dobj
12	or	or	CC	_	11	cc
13	inducers	inducer	NNS	_	11	conj
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Excessive	excessive	JJ	_	4	amod
4	reductions	reduction	NNS	_	9	nsubj
5	in	in	IN	_	7	case
6	blood	blood	NN	_	7	compound
7	pressure	pressure	NN	_	4	nmod
8	may	may	MD	_	9	aux
9	occur	occur	VB	_	1	dep
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	on	on	IN	_	14	case
13	diuretic	diuretic	JJ	_	14	amod
14	therapy	therapy	NN	_	11	nmod
15	when	when	WRB	_	18	advmod
16	drug2	drug2	NN	_	18	nsubjpass
17	are	be	VBP	_	18	auxpass
18	started	start	VBN	_	9	advcl
19	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	can	can	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	minimized	minimize	VBN	_	0	ROOT
11	by	by	IN	_	12	mark
12	discontinuing	discontinue	VBG	_	10	advcl
13	diuretic	diuretic	JJ	_	14	amod
14	therapy	therapy	NN	_	12	dobj
15	for	for	IN	_	17	case
16	several	several	JJ	_	17	amod
17	days	day	NNS	_	12	nmod
18	or	or	CC	_	12	cc
19	cautiously	cautiously	RB	_	20	advmod
20	increasing	increase	VBG	_	12	conj
21	salt	salt	NN	_	22	compound
22	intake	intake	NN	_	20	dobj
23	before	before	IN	_	24	case
24	initiation	initiation	NN	_	20	nmod
25	of	of	IN	_	26	case
26	treatment	treatment	NN	_	24	nmod
27	with	with	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	.	.	.	_	10	punct
30	If	if	IN	_	34	mark
31	this	this	DT	_	34	nsubj
32	is	be	VBZ	_	34	cop
33	not	not	RB	_	34	neg
34	possible	possible	JJ	_	43	advcl
35	,	,	,	_	43	punct
36	the	the	DT	_	38	det
37	starting	start	VBG	_	38	amod
38	dose	dose	NN	_	43	nsubjpass
39	of	of	IN	_	40	case
40	drug3	drug3	NN	_	38	nmod
41	should	should	MD	_	43	aux
42	be	be	VB	_	43	auxpass
43	reduced	reduce	VBN	_	10	parataxis
44	.	.	.	_	43	punct
45	.	.	.	_	10	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	:	:	:	_	2	punct
6	drug3	drug3	NN	_	8	nsubj
7	can	can	MD	_	8	aux
8	increase	increase	VB	_	2	dep
9	serum	serum	NN	_	10	compound
10	potassium	potassium	NN	_	8	dobj
11	because	because	IN	_	13	mark
12	it	it	PRP	_	13	nsubj
13	decreases	decrease	VBZ	_	8	advcl
14	aldosterone	aldosterone	NN	_	15	compound
15	secretion	secretion	NN	_	13	dobj
16	.	.	.	_	2	punct

1	Use	use	NN	_	18	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	dep
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	appos
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	5	punct
11	or	or	CC	_	3	cc
12	drug5	drug5	NN	_	13	compound
13	supplements	supplement	NNS	_	3	conj
14	concomitantly	concomitantly	RB	_	13	advmod
15	with	with	IN	_	16	case
16	drug6	drug6	NN	_	14	nmod
17	can	can	MD	_	18	aux
18	increase	increase	VB	_	0	ROOT
19	the	the	DT	_	20	det
20	risk	risk	NN	_	18	dobj
21	of	of	IN	_	22	case
22	hyperkalemia	hyperkalemia	NN	_	20	nmod
23	.	.	.	_	18	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	such	such	JJ	_	8	amod
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	they	they	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	given	give	VBN	_	26	csubjpass
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	the	the	DT	_	20	det
20	patient	patient	NN	_	23	nmod:poss
21	's	's	POS	_	20	case
22	serum	serum	NN	_	23	compound
23	potassium	potassium	NN	_	17	conj
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	monitored	monitor	VBN	_	0	ROOT
27	.	.	.	_	26	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubj
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	failed	fail	VBD	_	2	dep
9	to	to	TO	_	10	mark
10	identify	identify	VB	_	8	xcomp
11	any	any	DT	_	14	det
12	clinically	clinically	RB	_	13	advmod
13	important	important	JJ	_	14	amod
14	effect	effect	NN	_	10	dobj
15	on	on	IN	_	18	case
16	the	the	DT	_	18	det
17	serum	serum	NN	_	18	compound
18	concentrations	concentration	NNS	_	14	nmod
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	drug3	drug3	NN	_	18	nmod
22	or	or	CC	_	18	cc
23	on	on	IN	_	26	case
24	its	its	PRP$	_	26	nmod:poss
25	anticoagulant	anticoagulant	JJ	_	26	amod
26	effect	effect	NN	_	18	conj
27	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	6	amod
4	serum	serum	NN	_	6	compound
5	drug2	drug2	NN	_	6	compound
6	levels	level	NNS	_	14	nsubjpass
7	and	and	CC	_	6	cc
8	symptoms	symptom	NNS	_	6	conj
9	of	of	IN	_	11	case
10	drug3	drug3	NN	_	11	compound
11	toxicity	toxicity	NN	_	8	nmod
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	1	appos
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	receiving	receive	VBG	_	16	acl
18	drug4	drug4	NN	_	17	dobj
19	during	during	IN	_	20	case
20	therapy	therapy	NN	_	17	nmod
21	with	with	IN	_	22	case
22	drug5	drug5	NN	_	20	nmod
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	frequent	frequent	JJ	_	11	amod
11	monitoring	monitoring	NN	_	17	nsubjpass
12	of	of	IN	_	15	case
13	serum	serum	NN	_	15	compound
14	drug1	drug1	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	is	be	VBZ	_	17	auxpass
17	recommended	recommend	VBN	_	5	conj
18	.	.	.	_	5	punct

1	If	if	IN	_	6	mark
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	also	also	RB	_	6	advmod
6	used	use	VBN	_	15	advcl
7	,	,	,	_	15	punct
8	the	the	DT	_	9	det
9	risk	risk	NN	_	15	nsubjpass
10	of	of	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	increased	increase	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Other	other	JJ	_	2	amod
2	Agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	No	no	DT	_	8	neg
5	clinically	clinically	RB	_	6	advmod
6	important	important	JJ	_	8	amod
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	interactions	interaction	NNS	_	9	nsubj
9	occurred	occur	VBD	_	2	dep
10	when	when	WRB	_	13	advmod
11	drug1	drug1	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	administered	administer	VBN	_	9	advcl
14	concomitantly	concomitantly	RB	_	13	advmod
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	13	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	or	or	CC	_	16	cc
21	drug4	drug4	NN	_	16	conj
22	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	clinical	clinical	JJ	_	7	amod
7	trials	trial	NNS	_	4	nmod
8	concomitantly	concomitantly	RB	_	10	advmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	7	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug5	drug5	NN	_	10	conj
17	,	,	,	_	10	punct
18	oral	oral	JJ	_	19	amod
19	drug6	drug6	NN	_	10	conj
20	,	,	,	_	10	punct
21	and	and	CC	_	10	cc
22	cholesterol-lowering	cholesterol-lowering	JJ	_	23	amod
23	agents	agent	NNS	_	10	conj
24	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	of	of	IN	_	9	case
6	clinically	clinically	RB	_	7	advmod
7	important	important	JJ	_	9	amod
8	adverse	adverse	JJ	_	9	amod
9	interactions	interaction	NNS	_	4	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	primarily	primarily	RB	_	4	advmod
4	eliminated	eliminate	VBN	_	0	ROOT
5	unchanged	unchanged	JJ	_	4	xcomp
6	renally	renally	RB	_	4	advmod
7	as	as	IN	_	9	case
8	a	a	DT	_	9	det
9	result	result	NN	_	4	nmod
10	of	of	IN	_	12	case
11	glomerular	glomerular	JJ	_	12	amod
12	filtration	filtration	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	tubular	tubular	JJ	_	15	amod
15	secretion	secretion	NN	_	12	conj
16	.	.	.	_	4	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	5	case
4	nephrotoxic	nephrotoxic	JJ	_	5	amod
5	drugs	drug	NNS	_	2	nmod
6	could	could	MD	_	7	aux
7	result	result	VB	_	0	ROOT
8	in	in	IN	_	10	case
9	delayed	delay	VBN	_	10	amod
10	clearance	clearance	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	7	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	17	nsubj
3	of	of	IN	_	4	case
4	substances	substance	NNS	_	2	nmod
5	that	that	WDT	_	9	nsubjpass
6	are	be	VBP	_	9	auxpass
7	also	also	RB	_	9	advmod
8	tubularly	tubularly	RB	_	9	advmod
9	secreted	secrete	VBN	_	4	acl:relcl
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug1	drug1	NN	_	9	dep
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	could	could	MD	_	17	aux
16	potentially	potentially	RB	_	17	advmod
17	result	result	VB	_	0	ROOT
18	in	in	IN	_	20	case
19	delayed	delay	VBN	_	20	amod
20	clearance	clearance	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	17	punct

1	Although	although	IN	_	10	mark
2	drug1	drug1	NN	_	10	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	400	400	CD	_	6	nummod
5	mg	mg	NN	_	6	compound
6	qid	qid	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	can	can	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	administered	administer	VBN	_	29	advcl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	with	with	IN	_	18	case
16	normal	normal	JJ	_	18	amod
17	renal	renal	JJ	_	18	amod
18	function	function	NN	_	14	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	creatinine	creatinine	NN	_	21	compound
21	clearance	clearance	NN	_	18	dep
22	80	80	CD	_	23	nummod
23	mL/min	ml/min	NN	_	21	dep
24	-RRB-	-rrb-	-RRB-	_	21	punct
25	,	,	,	_	29	punct
26	caution	caution	NN	_	29	nsubjpass
27	should	should	MD	_	29	aux
28	be	be	VB	_	29	auxpass
29	used	use	VBN	_	0	ROOT
30	when	when	WRB	_	31	advmod
31	administering	administer	VBG	_	29	advcl
32	drug3	drug3	NN	_	31	dobj
33	concurrently	concurrently	RB	_	32	advmod
34	with	with	IN	_	35	case
35	drug4	drug4	NN	_	31	nmod
36	to	to	TO	_	37	case
37	patients	patient	NNS	_	35	nmod
38	with	with	IN	_	39	case
39	mild	mild	JJ	_	37	nmod
40	to	to	TO	_	43	case
41	moderate	moderate	JJ	_	43	amod
42	renal	renal	JJ	_	43	amod
43	insufficiency	insufficiency	NN	_	39	nmod
44	-LRB-	-lrb-	-LRB-	_	46	punct
45	creatinine	creatinine	NN	_	46	compound
46	clearance	clearance	NN	_	39	dep
47	from	from	IN	_	51	case
48	45	45	CD	_	50	compound
49	to	to	TO	_	50	dep
50	79	79	CD	_	51	nummod
51	mL/min	ml/min	NN	_	46	nmod
52	-RRB-	-rrb-	-RRB-	_	46	punct
53	.	.	.	_	29	punct

1	Patients	patient	NNS	_	9	nsubj
2	with	with	IN	_	3	case
3	mild	mild	JJ	_	1	nmod
4	to	to	TO	_	7	case
5	moderate	moderate	JJ	_	7	amod
6	renal	renal	JJ	_	7	amod
7	insufficiency	insufficiency	NN	_	3	nmod
8	should	should	MD	_	9	aux
9	avoid	avoid	VB	_	0	ROOT
10	taking	take	VBG	_	9	xcomp
11	drug1	drug1	NN	_	10	dobj
12	with	with	IN	_	15	case
13	short	short	JJ	_	15	amod
14	elimination	elimination	NN	_	15	compound
15	half-lives	half-life	NNS	_	10	nmod
16	for	for	IN	_	18	case
17	a	a	DT	_	18	det
18	period	period	NN	_	10	nmod
19	of	of	IN	_	21	case
20	2	2	CD	_	21	nummod
21	days	day	NNS	_	18	nmod
22	before	before	RB	_	10	advmod
23	,	,	,	_	22	punct
24	the	the	DT	_	25	det
25	day	day	NN	_	23	root
26	of	of	IN	_	25	acl
27	,	,	,	_	25	punct
28	and	and	CC	_	25	cc
29	2	2	CD	_	30	nummod
30	days	day	NNS	_	25	conj
31	following	follow	VBG	_	32	case
32	administration	administration	NN	_	30	nmod
33	of	of	IN	_	34	case
34	drug2	drug2	NN	_	32	nmod
35	.	.	.	_	25	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	absence	absence	NN	_	23	nmod
4	of	of	IN	_	5	case
5	data	datum	NNS	_	3	nmod
6	regarding	regard	VBG	_	8	case
7	potential	potential	JJ	_	8	amod
8	interaction	interaction	NN	_	5	nmod
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	with	with	IN	_	15	case
14	longer	longer	JJR	_	15	amod
15	half-lives	half-life	NNS	_	8	nmod
16	,	,	,	_	23	punct
17	all	all	DT	_	18	det
18	patients	patient	NNS	_	23	nsubj
19	taking	take	VBG	_	18	acl
20	these	these	DT	_	21	det
21	drug3	drug3	NN	_	19	dobj
22	should	should	MD	_	23	aux
23	interrupt	interrupt	VB	_	0	ROOT
24	dosing	dosing	NN	_	23	dobj
25	for	for	IN	_	29	case
26	at	at	IN	_	27	case
27	least	least	JJS	_	28	nmod:npmod
28	5	5	CD	_	29	nummod
29	days	day	NNS	_	23	nmod
30	before	before	RB	_	29	advmod
31	,	,	,	_	23	punct
32	the	the	DT	_	33	det
33	day	day	NN	_	31	root
34	of	of	IN	_	33	acl
35	,	,	,	_	33	punct
36	and	and	CC	_	33	cc
37	2	2	CD	_	38	nummod
38	days	day	NNS	_	33	conj
39	following	follow	VBG	_	41	case
40	drug4	drug4	NN	_	41	compound
41	administration	administration	NN	_	38	nmod
42	.	.	.	_	33	punct

1	If	if	IN	_	8	mark
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	an	a	DT	_	6	det
6	drug1	drug1	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	necessary	necessary	JJ	_	13	advcl
9	,	,	,	_	13	punct
10	patients	patient	NNS	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	closely	closely	RB	_	13	advmod
15	for	for	IN	_	16	case
16	toxicity	toxicity	NN	_	13	nmod
17	,	,	,	_	13	punct
18	especially	especially	RB	_	19	advmod
19	myelosuppression	myelosuppression	NN	_	13	dobj
20	,	,	,	_	19	punct
21	renal	renal	JJ	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	gastrointestinal	gastrointestinal	JJ	_	25	amod
25	toxicity	toxicity	NN	_	19	conj
26	.	.	.	_	13	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	None	none	NN	_	0	ROOT
5	known	know	VBN	_	4	acl
6	.	.	.	_	4	punct

1	Prothrombin	Prothrombin	NNP	_	2	compound
2	time	time	NN	_	10	nsubjpass
3	or	or	CC	_	2	cc
4	other	other	JJ	_	7	amod
5	suitable	suitable	JJ	_	7	amod
6	anticoagulation	anticoagulation	JJ	_	7	amod
7	test	test	NN	_	2	conj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	monitored	monitor	VBN	_	0	ROOT
11	if	if	IN	_	14	mark
12	drug1	drug1	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	administered	administer	VBN	_	10	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	10	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	render	render	VB	_	0	ROOT
10	oral	oral	JJ	_	11	amod
11	drug3	drug3	NN	_	13	nsubj
12	less	less	RBR	_	13	advmod
13	effective	effective	JJ	_	9	xcomp
14	.	.	.	_	9	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	There	there	EX	_	5	expl
5	are	be	VBP	_	3	acl:relcl
6	no	no	DT	_	10	neg
7	reported	report	VBN	_	10	amod
8	drug-laboratory	drug-laboratory	JJ	_	10	amod
9	test	test	NN	_	10	compound
10	interactions	interaction	NNS	_	5	nsubj
11	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	following	follow	VBG	_	7	amod
7	drugs	drug	NNS	_	3	nmod
8	:	:	:	_	7	punct
9	drug2	drug2	NN	_	7	dep
10	and	and	CC	_	9	cc
11	other	other	JJ	_	12	amod
12	drug3	drug3	NN	_	9	conj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	may	may	MD	_	15	aux
15	lower	lower	VB	_	7	dep
16	drug4	drug4	NN	_	17	compound
17	levels	level	NNS	_	15	dobj
18	-RRB-	-rrb-	-RRB-	_	15	punct
19	,	,	,	_	7	punct
20	drug5	drug5	NN	_	7	dep
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	bioavailability	bioavailability	NN	_	27	nsubjpass
23	of	of	IN	_	25	case
24	oral	oral	JJ	_	25	amod
25	drug6	drug6	NN	_	22	nmod
26	is	be	VBZ	_	27	auxpass
27	increased	increase	VBN	_	20	acl:relcl
28	with	with	IN	_	29	case
29	coadministration	coadministration	NN	_	27	nmod
30	-RRB-	-rrb-	-RRB-	_	7	punct
31	,	,	,	_	7	punct
32	drug7	drug7	NN	_	7	appos
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	may	may	MD	_	35	aux
35	decrease	decrease	VB	_	32	dep
36	drug8	drug8	NN	_	37	compound
37	levels	level	NNS	_	35	dobj
38	-RRB-	-rrb-	-RRB-	_	35	punct
39	,	,	,	_	32	punct
40	drug9	drug9	NN	_	42	compound
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	reports	report	NNS	_	58	nsubj
43	of	of	IN	_	45	case
44	psychotic	psychotic	JJ	_	45	amod
45	episodes	episode	NNS	_	42	nmod
46	when	when	WRB	_	47	advmod
47	coadministered	coadminister	VBN	_	58	dep
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	,	,	,	_	58	punct
50	drug10	drug10	NN	_	58	dep
51	-LRB-	-lrb-	-LRB-	_	52	punct
52	coadministration	coadministration	NN	_	58	nsubj
53	of	of	IN	_	54	case
54	drug11	drug11	NN	_	52	nmod
55	with	with	IN	_	56	case
56	drug12	drug12	NN	_	52	nmod
57	can	can	MD	_	58	aux
58	inhibit	inhibit	VB	_	32	dep
59	ovarian	ovarian	JJ	_	60	amod
60	function	function	NN	_	58	dobj
61	in	in	IN	_	62	case
62	women	woman	NNS	_	60	nmod
63	-RRB-	-rrb-	-RRB-	_	58	punct
64	,	,	,	_	32	punct
65	drug13	drug13	NN	_	32	conj
66	and	and	CC	_	32	cc
67	other	other	JJ	_	69	amod
68	sedating	sedate	VBG	_	69	amod
69	drugs	drug	NNS	_	32	conj
70	-LRB-	-lrb-	-LRB-	_	72	punct
71	may	may	MD	_	72	aux
72	result	result	VB	_	7	dep
73	in	in	IN	_	75	case
74	additive	additive	JJ	_	75	amod
75	sedation	sedation	NN	_	72	nmod
76	and	and	CC	_	72	cc
77	an	a	DT	_	79	det
78	increased	increase	VBN	_	79	amod
79	incidence	incidence	NN	_	72	conj
80	of	of	IN	_	82	case
81	adverse	adverse	JJ	_	82	amod
82	effects	effect	NNS	_	79	nmod
83	-RRB-	-rrb-	-RRB-	_	72	punct
84	,	,	,	_	3	punct
85	and	and	CC	_	3	cc
86	drug14	drug14	NN	_	88	compound
87	-LRB-	-lrb-	-LRB-	_	88	punct
88	coadministration	coadministration	NN	_	94	nsubj
89	of	of	IN	_	90	case
90	drug15	drug15	NN	_	88	nmod
91	and	and	CC	_	90	cc
92	drug16	drug16	NN	_	90	conj
93	may	may	MD	_	94	aux
94	interfere	interfere	VB	_	3	conj
95	with	with	IN	_	97	case
96	the	the	DT	_	97	det
97	efficacy	efficacy	NN	_	94	nmod
98	of	of	IN	_	100	case
99	the	the	DT	_	100	det
100	drug17	drug17	NN	_	97	nmod
101	-RRB-	-rrb-	-RRB-	_	3	punct
102	.	.	.	_	3	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	with	with	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	that	that	IN	_	13	mark
10	drug1	drug1	NN	_	13	nsubj
11	does	do	VBZ	_	13	aux
12	not	not	RB	_	13	neg
13	inhibit	inhibit	VB	_	8	ccomp
14	the	the	DT	_	15	det
15	metabolism	metabolism	NN	_	13	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug4	drug4	NN	_	17	conj
22	,	,	,	_	17	punct
23	and	and	CC	_	17	cc
24	drug5	drug5	NN	_	17	conj
25	.	.	.	_	8	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	6	nsubj
4	have	have	VBP	_	6	aux
5	also	also	RB	_	6	advmod
6	shown	show	VBN	_	0	ROOT
7	that	that	IN	_	9	mark
8	drug1	drug1	NN	_	9	nsubj
9	inhibits	inhibit	VBZ	_	6	ccomp
10	CYP2D6-mediated	cyp2d6-mediated	JJ	_	11	amod
11	metabolism	metabolism	NN	_	9	dobj
12	.	.	.	_	6	punct

1	This	this	DT	_	6	nsubj
2	may	may	MD	_	6	aux
3	be	be	VB	_	6	cop
4	of	of	IN	_	6	case
5	clinical	clinical	JJ	_	6	amod
6	relevance	relevance	NN	_	0	ROOT
7	for	for	IN	_	8	case
8	compounds	compound	NNS	_	6	nmod
9	predominantly	predominantly	RB	_	10	advmod
10	metabolized	metabolize	VBN	_	8	acl
11	by	by	IN	_	13	case
12	this	this	DT	_	13	det
13	enzyme	enzyme	NN	_	10	nmod
14	,	,	,	_	8	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug1	drug1	NN	_	8	nmod
18	,	,	,	_	17	punct
19	-	-	:	_	17	punct
20	blockers	blocker	NNS	_	17	dep
21	,	,	,	_	17	punct
22	drug2	drug2	NN	_	17	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug3	drug3	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	17	punct
27	and	and	CC	_	17	cc
28	drug4	drug4	NN	_	17	conj
29	,	,	,	_	6	punct
30	if	if	IN	_	32	mark
31	they	they	PRP	_	32	nsubj
32	have	have	VBP	_	6	advcl
33	a	a	DT	_	36	det
34	narrow	narrow	JJ	_	36	amod
35	therapeutic	therapeutic	JJ	_	36	amod
36	window	window	NN	_	32	dobj
37	.	.	.	_	6	punct

1	In	in	FW	_	5	amod
2	vivo	vivo	FW	_	1	dep
3	drug-drug	drug-drug	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	11	nsubj
6	conducted	conduct	VBN	_	5	acl
7	in	in	IN	_	10	case
8	normal	normal	JJ	_	10	amod
9	volunteer	volunteer	NN	_	10	compound
10	subjects	subject	NNS	_	6	nmod
11	showed	show	VBD	_	0	ROOT
12	that	that	IN	_	16	mark
13	drug1	drug1	NN	_	16	nsubj
14	does	do	VBZ	_	16	aux
15	not	not	RB	_	16	neg
16	affect	affect	VB	_	11	ccomp
17	the	the	DT	_	18	det
18	clearance	clearance	NN	_	16	dobj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	or	or	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	.	.	.	_	11	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreases	decrease	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	clearance	clearance	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	by	by	IN	_	9	case
8	19	19	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	increases	increase	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	clearance	clearance	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	by	by	IN	_	9	case
8	15	15	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	.	.	.	_	2	punct

1	There	there	EX	_	5	expl
2	have	have	VBP	_	5	aux
3	been	be	VBN	_	5	cop
4	spontaneous	spontaneous	JJ	_	5	amod
5	reports	report	NNS	_	0	ROOT
6	of	of	IN	_	7	case
7	increase	increase	NN	_	5	nmod
8	or	or	CC	_	5	cc
9	decrease	decrease	VB	_	5	conj
10	in	in	IN	_	12	case
11	prothrombin	prothrombin	NN	_	12	compound
12	times	time	NNS	_	9	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	concomitantly	concomitantly	RB	_	16	advmod
16	taking	take	VBG	_	14	acl
17	oral	oral	JJ	_	18	amod
18	drug1	drug1	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	5	punct
22	however	however	RB	_	5	advmod
23	,	,	,	_	5	punct
24	a	a	DT	_	26	det
25	causal	causal	JJ	_	26	amod
26	relationship	relationship	NN	_	36	nsubjpass
27	between	between	IN	_	29	case
28	drug3	drug3	NN	_	29	compound
29	Tablets	tablet	NNS	_	26	nmod
30	and	and	CC	_	29	cc
31	these	these	DT	_	32	det
32	changes	change	NNS	_	29	conj
33	has	have	VBZ	_	36	aux
34	not	not	RB	_	36	neg
35	been	be	VBN	_	36	auxpass
36	established	establish	VBN	_	5	dep
37	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	compound
2	clearance	clearance	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	increased	increase	VBN	_	25	dep
5	100	100	CD	_	6	nummod
6	%	%	NN	_	4	dobj
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	,	,	,	_	8	punct
10	a	a	DT	_	13	det
11	CyP450	cyp450	NN	_	13	compound
12	enzyme	enzyme	NN	_	13	compound
13	inducer	inducer	NN	_	8	appos
14	,	,	,	_	4	punct
15	and	and	CC	_	4	cc
16	decreased	decrease	VBD	_	4	conj
17	33	33	CD	_	18	nummod
18	%	%	NN	_	16	dobj
19	by	by	IN	_	20	case
20	drug3	drug3	NN	_	16	nmod
21	,	,	,	_	25	punct
22	a	a	DT	_	25	det
23	CyP450	cyp450	NN	_	25	compound
24	enzyme	enzyme	NN	_	25	compound
25	inhibitor	inhibitor	NN	_	0	ROOT
26	.	.	.	_	25	punct

1	drug1	drug1	NN	_	2	compound
2	clearance	clearance	NN	_	4	nsubj
3	is	be	VBZ	_	4	aux
4	unaffected	unaffected	JJ	_	0	ROOT
5	by	by	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	information	information	NN	_	2	nsubj
5	available	available	JJ	_	4	amod
6	from	from	IN	_	10	case
7	adequate	adequate	JJ	_	10	amod
8	drug-drug	drug-drug	JJ	_	10	amod
9	interaction	interaction	NN	_	10	compound
10	studies	study	NNS	_	5	nmod
11	with	with	IN	_	14	case
12	the	the	DT	_	14	det
13	following	follow	VBG	_	14	amod
14	classes	class	NNS	_	10	nmod
15	of	of	IN	_	16	case
16	drugs	drug	NNS	_	14	nmod
17	:	:	:	_	2	punct
18	oral	oral	JJ	_	19	amod
19	drug1	drug1	NN	_	2	dep
20	,	,	,	_	19	punct
21	hormone	hormone	NN	_	23	compound
22	replacement	replacement	NN	_	23	compound
23	therapies	therapy	NNS	_	19	conj
24	,	,	,	_	19	punct
25	drug2	drug2	NN	_	19	conj
26	,	,	,	_	19	punct
27	drug3	drug3	NN	_	19	conj
28	,	,	,	_	19	punct
29	drug4	drug4	NN	_	19	conj
30	,	,	,	_	19	punct
31	drug5	drug5	NN	_	19	conj
32	,	,	,	_	19	punct
33	drug6	drug6	NN	_	19	conj
34	,	,	,	_	19	punct
35	and	and	CC	_	19	cc
36	drug7	drug7	NN	_	19	conj
37	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	demonstrate	demonstrate	VB	_	0	ROOT
4	additive	additive	JJ	_	5	amod
5	toxicity	toxicity	NN	_	3	dobj
6	when	when	WRB	_	7	advmod
7	used	use	VBN	_	5	acl:relcl
8	in	in	IN	_	9	case
9	combination	combination	NN	_	7	nmod
10	with	with	IN	_	13	case
11	other	other	JJ	_	13	amod
12	cytotoxic	cytotoxic	JJ	_	13	amod
13	drugs	drug	NNS	_	9	nmod
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	prolong	prolong	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	elimination	elimination	NN	_	9	compound
9	half-life	half-life	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	4	cc
13	may	may	MD	_	14	aux
14	lead	lead	VB	_	4	conj
15	to	to	TO	_	19	case
16	severe	severe	JJ	_	19	amod
17	bone	bone	NN	_	19	compound
18	marrow	marrow	NN	_	19	compound
19	suppression	suppression	NN	_	14	nmod
20	;	;	:	_	4	punct

1	a	a	DT	_	2	det
2	reduction	reduction	NN	_	9	nsubjpass
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	drug1	drug1	NN	_	6	compound
6	dosage	dosage	NN	_	2	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	receiving	receive	VBG	_	11	acl
13	drug2	drug2	NN	_	12	dobj
14	concurrently	concurrently	RB	_	12	advmod
15	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	in	in	IN	_	13	case
12	one	one	CD	_	13	nummod
13	case	case	NN	_	10	nmod
14	to	to	TO	_	15	mark
15	result	result	VB	_	10	xcomp
16	in	in	IN	_	19	case
17	reduced	reduce	VBN	_	19	amod
18	drug3	drug3	NN	_	19	compound
19	cytotoxicity	cytotoxicity	NN	_	15	nmod
20	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	causes	cause	VBZ	_	1	dep
5	a	a	DT	_	8	det
6	60	60	CD	_	7	compound
7	%	%	NN	_	8	amod
8	reduction	reduction	NN	_	4	dobj
9	in	in	IN	_	14	case
10	the	the	DT	_	14	det
11	absorption	absorption	NN	_	14	amod
12	and	and	CC	_	11	cc
13	enterohepatic	enterohepatic	JJ	_	11	conj
14	cycling	cycling	NN	_	8	nmod
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	and	and	CC	_	4	cc
18	should	should	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	coadministered	coadminister	VBN	_	4	conj
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	coadministration	coadministration	NN	_	12	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	has	have	VBZ	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	assessed	assess	VBN	_	1	appos
13	under	under	IN	_	15	case
14	chronic	chronic	JJ	_	15	amod
15	conditions	condition	NNS	_	12	nmod
16	.	.	.	_	1	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	10	10	CD	_	4	nummod
4	%	%	NN	_	5	nsubj
5	decreases	decrease	VBZ	_	0	ROOT
6	in	in	IN	_	8	case
7	prothrombin	prothrombin	NN	_	8	compound
8	time	time	NN	_	5	nmod
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	observed	observe	VBN	_	5	ccomp
12	in	in	IN	_	14	case
13	single-dose	single-dose	JJ	_	14	amod
14	studies	study	NNS	_	11	nmod
15	.	.	.	_	5	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	given	give	VBN	_	13	advcl
5	concurrently	concurrently	RB	_	4	advmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	13	punct
9	prothrombin	prothrombin	NN	_	10	compound
10	time	time	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Other	other	JJ	_	4	amod
2	Highly	Highly	NNP	_	4	compound
3	Protein-Bound	Protein-Bound	NNP	_	4	compound
4	Drugs	Drugs	NNPS	_	0	ROOT
5	:	:	:	_	4	punct
6	drug1	drug1	NN	_	12	nsubjpass
7	is	be	VBZ	_	12	auxpass
8	more	more	JJR	_	10	advmod
9	than	than	IN	_	8	mwe
10	95	95	CD	_	11	nummod
11	%	%	NN	_	12	dep
12	bound	bind	VBD	_	4	dep
13	to	to	TO	_	15	case
14	plasma	plasma	NN	_	15	compound
15	proteins	protein	NNS	_	12	nmod
16	.	.	.	_	4	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	7	advmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	affect	affect	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	binding	binding	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	drug4	drug4	NN	_	11	conj
17	.	.	.	_	7	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	coadministered	coadminister	VBN	_	4	advcl
9	with	with	IN	_	13	case
10	other	other	JJ	_	13	amod
11	highly	highly	RB	_	12	advmod
12	protein-bound	protein-bound	JJ	_	13	amod
13	drugs	drug	NNS	_	8	nmod
14	,	,	,	_	13	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug2	drug2	NN	_	13	nmod
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug4	drug4	NN	_	17	conj
22	,	,	,	_	17	punct
23	drug5	drug5	NN	_	17	conj
24	,	,	,	_	17	punct
25	drug6	drug6	NN	_	17	conj
26	,	,	,	_	17	punct
27	and	and	CC	_	17	cc
28	drug7	drug7	NN	_	17	conj
29	.	.	.	_	4	punct

1	See	see	VB	_	0	ROOT
2	also	also	RB	_	3	advmod
3	CLINICAL	clinical	JJ	_	4	amod
4	PHARMACOLOGY	pharmacology	NN	_	1	dobj
5	,	,	,	_	1	punct
6	Drug-Drug	Drug-Drug	NNP	_	7	compound
7	Interactions	interaction	NNS	_	5	root

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug4	drug4	NN	_	7	conj
13	.	.	.	_	3	punct

1	It	it	PRP	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	increased	increase	VBN	_	9	amod
9	thrombocytopenia	thrombocytopenia	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	6	punct
12	drug2	drug2	NN	_	6	conj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	increased	increase	VBN	_	15	amod
15	nephrotoxicity	nephrotoxicity	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	6	punct
18	drug3	drug3	NN	_	6	conj
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	increased	increase	VBN	_	22	amod
21	hypoglycemic	hypoglycemic	JJ	_	22	amod
22	response	response	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	6	punct
25	drug4	drug4	NN	_	6	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	increased	increase	VBN	_	29	amod
28	anticoagulant	anticoagulant	JJ	_	29	amod
29	effect	effect	NN	_	25	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	6	punct
32	drug5	drug5	NN	_	6	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	decreased	decrease	VBN	_	36	amod
35	renal	renal	JJ	_	36	amod
36	excretion	excretion	NN	_	32	dep
37	of	of	IN	_	38	case
38	drug6	drug6	NN	_	36	nmod
39	-RRB-	-rrb-	-RRB-	_	36	punct
40	,	,	,	_	6	punct
41	drug7	drug7	NN	_	6	conj
42	-LRB-	-lrb-	-LRB-	_	45	punct
43	decreased	decrease	VBN	_	45	amod
44	hepatic	hepatic	JJ	_	45	amod
45	clearance	clearance	NN	_	41	dep
46	of	of	IN	_	47	case
47	drug8	drug8	NN	_	45	nmod
48	-RRB-	-rrb-	-RRB-	_	45	punct
49	.	.	.	_	4	punct

1	drug1	drug1	NN	_	21	nsubjpass
2	,	,	,	_	1	punct
3	such	such	JJ	_	6	case
4	as	as	IN	_	3	mwe
5	the	the	DT	_	6	det
6	drug2	drug2	NN	_	1	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug3	drug3	NN	_	6	dep
9	,	,	,	_	8	punct
10	drug4	drug4	NN	_	8	appos
11	,	,	,	_	8	punct
12	drug5	drug5	NN	_	8	appos
13	-RRB-	-rrb-	-RRB-	_	8	punct
14	or	or	CC	_	6	cc
15	drug6	drug6	NN	_	6	conj
16	,	,	,	_	1	punct
17	ordinarily	ordinarily	RB	_	21	advmod
18	should	should	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	administered	administer	VBN	_	0	ROOT
22	concurrently	concurrently	RB	_	21	advmod
23	with	with	IN	_	24	case
24	drug7	drug7	NN	_	21	nmod
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	a	a	DT	_	27	det
27	drug8	drug8	NN	_	24	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	;	;	:	_	21	punct

1	these	these	DT	_	2	det
2	agents	agent	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	diminish	diminish	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effectiveness	effectiveness	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	4	punct

1	Because	because	IN	_	7	mark
2	drug1	drug1	NN	_	7	nsubjpass
3	is	be	VBZ	_	7	auxpass
4	approximately	approximately	RB	_	5	advmod
5	90	90	CD	_	6	nummod
6	%	%	NN	_	7	nsubjpass
7	bound	bind	VBD	_	15	advcl
8	to	to	TO	_	10	case
9	plasma	plasma	NN	_	10	compound
10	proteins	protein	NNS	_	7	nmod
11	,	,	,	_	15	punct
12	caution	caution	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	exercised	exercise	VBN	_	0	ROOT
16	if	if	IN	_	19	mark
17	drug2	drug2	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	coadministered	coadminister	VBN	_	15	advcl
20	with	with	IN	_	22	case
21	other	other	JJ	_	22	amod
22	drugs	drug	NNS	_	19	nmod
23	known	know	VBN	_	22	acl
24	to	to	TO	_	25	mark
25	affect	affect	VB	_	23	xcomp
26	protein	protein	NN	_	27	compound
27	binding	binding	NN	_	25	dobj
28	.	.	.	_	15	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Women	woman	NNS	_	9	nsubj
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug1	drug1	NN	_	4	nmod
8	have	have	VBP	_	9	aux
9	shown	show	VBN	_	2	dep
10	a	a	DT	_	12	det
11	significant	significant	JJ	_	12	amod
12	increase	increase	NN	_	9	dobj
13	in	in	IN	_	16	case
14	plasma	plasma	NN	_	16	compound
15	drug2	drug2	NN	_	16	compound
16	levels	level	NNS	_	12	nmod
17	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	gastrointestinal	gastrointestinal	JJ	_	7	amod
7	motility	motility	NN	_	2	nmod
8	are	be	VBP	_	9	auxpass
9	antagonized	antagonize	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	.	.	.	_	9	punct

1	Additive	additive	JJ	_	3	amod
2	sedative	sedative	JJ	_	3	amod
3	effects	effect	NNS	_	5	nsubj
4	can	can	MD	_	5	aux
5	occur	occur	VB	_	0	ROOT
6	when	when	WRB	_	9	advmod
7	drug1	drug1	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	given	give	VBN	_	5	advcl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug5	drug5	NN	_	11	conj
18	,	,	,	_	11	punct
19	or	or	CC	_	11	cc
20	drug6	drug6	NN	_	11	conj
21	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	finding	finding	NN	_	0	ROOT
3	that	that	IN	_	12	mark
4	drug1	drug1	NN	_	6	compound
5	releases	release	NNS	_	6	compound
6	catecholamines	catecholamine	NNS	_	12	nsubj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	essential	essential	JJ	_	11	amod
11	hypertension	hypertension	NN	_	8	nmod
12	suggests	suggest	VBZ	_	2	ccomp
13	that	that	IN	_	17	mark
14	it	it	PRP	_	17	nsubjpass
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	used	use	VBN	_	12	ccomp
18	cautiously	cautiously	RB	_	17	advmod
19	,	,	,	_	17	punct
20	if	if	IN	_	22	mark
21	at	at	IN	_	22	case
22	all	all	DT	_	17	advcl
23	,	,	,	_	17	punct
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	17	nmod
26	receiving	receive	VBG	_	25	acl
27	drug2	drug2	NN	_	26	dobj
28	.	.	.	_	2	punct

1	Absorption	absorption	NN	_	9	nsubjpass
2	of	of	IN	_	3	case
3	drugs	drug	NNS	_	1	nmod
4	from	from	IN	_	6	case
5	the	the	DT	_	6	det
6	stomach	stomach	NN	_	1	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	diminished	diminish	VBN	_	0	ROOT
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug1	drug1	NN	_	9	dep
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	by	by	IN	_	16	case
16	drug2	drug2	NN	_	9	nmod
17	,	,	,	_	9	punct
18	whereas	whereas	IN	_	9	dep
19	the	the	DT	_	20	det
20	rate	rate	NN	_	33	nsubjpass
21	and/or	and/or	CC	_	20	cc
22	extent	extent	NN	_	20	conj
23	of	of	IN	_	24	case
24	absorption	absorption	NN	_	20	nmod
25	of	of	IN	_	26	case
26	drugs	drug	NNS	_	24	nmod
27	from	from	IN	_	30	case
28	the	the	DT	_	30	det
29	small	small	JJ	_	30	amod
30	bowel	bowel	NN	_	26	nmod
31	may	may	MD	_	33	aux
32	be	be	VB	_	33	auxpass
33	increased	increase	VBN	_	9	parataxis
34	-LRB-	-lrb-	-LRB-	_	37	punct
35	e.g.	e.g.	FW	_	37	dep
36	,	,	,	_	37	punct
37	drug3	drug3	NN	_	33	dep
38	,	,	,	_	37	punct
39	drug4	drug4	NN	_	37	conj
40	,	,	,	_	37	punct
41	drug5	drug5	NN	_	37	conj
42	,	,	,	_	37	punct
43	drug6	drug6	NN	_	37	conj
44	,	,	,	_	37	punct
45	drug7	drug7	NN	_	37	appos
46	-RRB-	-rrb-	-RRB-	_	37	punct
47	.	.	.	_	9	punct

1	Gastroparesis	gastroparesis	NN	_	8	nsubj
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	gastric	gastric	JJ	_	4	amod
4	stasis	stasis	NN	_	1	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	responsible	responsible	JJ	_	0	ROOT
9	for	for	IN	_	12	case
10	poor	poor	JJ	_	12	amod
11	diabetic	diabetic	JJ	_	12	amod
12	control	control	NN	_	8	nmod
13	in	in	IN	_	15	case
14	some	some	DT	_	15	det
15	patients	patient	NNS	_	12	nmod
16	.	.	.	_	8	punct

1	Exogenously	exogenously	RB	_	2	advmod
2	administered	administer	VBN	_	3	amod
3	drug1	drug1	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	begin	begin	VB	_	0	ROOT
6	to	to	TO	_	7	mark
7	act	act	VB	_	5	xcomp
8	before	before	IN	_	11	mark
9	food	food	NN	_	11	nsubj
10	has	have	VBZ	_	11	aux
11	left	leave	VBN	_	7	advcl
12	the	the	DT	_	13	det
13	stomach	stomach	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	lead	lead	VB	_	11	conj
16	to	to	TO	_	17	case
17	hypoglycemia	hypoglycemia	NN	_	15	nmod
18	.	.	.	_	5	punct

1	Because	because	IN	_	7	mark
2	the	the	DT	_	3	det
3	action	action	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	will	will	MD	_	7	aux
7	influence	influence	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	delivery	delivery	NN	_	7	dobj
10	of	of	IN	_	11	case
11	food	food	NN	_	9	nmod
12	to	to	TO	_	14	case
13	the	the	DT	_	14	det
14	intestines	intestine	NNS	_	9	nmod
15	and	and	CC	_	7	cc
16	thus	thus	RB	_	29	advmod
17	the	the	DT	_	18	det
18	rate	rate	NN	_	29	nsubj
19	of	of	IN	_	20	case
20	absorption	absorption	NN	_	18	nmod
21	,	,	,	_	18	punct
22	drug2	drug2	NN	_	23	compound
23	dosage	dosage	NN	_	18	appos
24	or	or	CC	_	23	cc
25	timing	timing	NN	_	23	conj
26	of	of	IN	_	27	case
27	dosage	dosage	NN	_	23	nmod
28	may	may	MD	_	29	aux
29	require	require	VB	_	7	conj
30	adjustment	adjustment	NN	_	29	dobj
31	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	9	nsubj
4	listed	list	VBN	_	3	acl
5	below	below	RB	_	4	advmod
6	are	be	VBP	_	9	cop
7	potentially	potentially	RB	_	9	advmod
8	clinically	clinically	RB	_	9	advmod
9	important	important	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Drugs	drug	NNS	_	14	nsubj
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	hepatic	hepatic	JJ	_	5	amod
5	enzymes	enzyme	NNS	_	3	dobj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	and	and	CC	_	8	cc
12	drug3	drug3	NN	_	8	conj
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	and	and	CC	_	14	cc
20	may	may	MD	_	21	aux
21	require	require	VB	_	14	conj
22	increases	increase	NNS	_	21	dobj
23	in	in	IN	_	25	case
24	drug5	drug5	NN	_	25	compound
25	dose	dose	NN	_	22	nmod
26	to	to	TO	_	27	mark
27	achieve	achieve	VB	_	21	xcomp
28	the	the	DT	_	30	det
29	desired	desire	VBN	_	30	amod
30	response	response	NN	_	27	dobj
31	.	.	.	_	14	punct

1	Drugs	drug	NNS	_	8	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	inhibit	inhibit	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	8	cc
14	thus	thus	RB	_	15	advmod
15	decrease	decrease	VB	_	8	conj
16	their	they	PRP$	_	17	nmod:poss
17	clearance	clearance	NN	_	15	dobj
18	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	titrated	titrate	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	avoid	avoid	VB	_	9	xcomp
12	steroid	steroid	NN	_	13	compound
13	toxicity	toxicity	NN	_	11	dobj
14	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	clearance	clearance	NN	_	3	dobj
6	of	of	IN	_	10	case
7	chronic	chronic	JJ	_	10	amod
8	high	high	JJ	_	10	amod
9	dose	dose	NN	_	10	compound
10	drug2	drug2	NN	_	5	nmod
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	decreased	decrease	VBN	_	8	amod
6	drug1	drug1	NN	_	8	compound
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	3	nmod
9	or	or	CC	_	3	cc
10	increase	increase	VB	_	3	conj
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	when	when	WRB	_	19	advmod
17	drug3	drug3	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	withdrawn	withdraw	VBN	_	10	advcl
20	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	cautiously	cautiously	RB	_	4	advmod
6	in	in	IN	_	7	case
7	conjunction	conjunction	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	suffering	suffer	VBG	_	11	acl
13	from	from	IN	_	14	case
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	12	nmod
15	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	is	be	VBZ	_	9	cop
9	variable	variable	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	reports	report	NNS	_	2	nsubj
4	of	of	IN	_	10	case
5	enhanced	enhance	VBN	_	10	amod
6	as	as	RB	_	5	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	diminished	diminished	JJ	_	5	conj
10	effects	effect	NNS	_	3	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	2	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	coagulation	coagulation	NN	_	4	compound
4	indices	index	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	maintain	maintain	VB	_	7	xcomp
10	the	the	DT	_	13	det
11	desired	desire	VBN	_	13	amod
12	anticoagulant	anticoagulant	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	.	.	.	_	7	punct

1	Co-administration	co-administration	NN	_	9	nsubj
2	of	of	IN	_	6	case
3	oral	oral	JJ	_	6	amod
4	drug1	drug1	NN	_	6	compound
5	200	200	CD	_	6	nummod
6	mg	mg	NN	_	1	nmod
7	twice	twice	RB	_	9	advmod
8	daily	daily	RB	_	9	advmod
9	increased	increase	VBN	_	0	ROOT
10	drug2	drug2	NN	_	13	compound
11	geometric	geometric	JJ	_	13	amod
12	mean	mean	NN	_	13	compound
13	AUC	auc	NN	_	9	dobj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	0-24	0-24	CD	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	and	and	CC	_	13	cc
18	Cmax	cmax	NN	_	13	conj
19	by	by	IN	_	21	case
20	81	81	CD	_	21	nummod
21	%	%	NN	_	18	nmod
22	after	after	IN	_	24	case
23	topical	topical	JJ	_	24	amod
24	application	application	NN	_	9	nmod
25	of	of	IN	_	27	case
26	drug3	drug3	NN	_	27	compound
27	ointment	ointment	NN	_	24	nmod
28	,	,	,	_	9	punct
29	1	1	CD	_	30	nummod
30	%	%	NN	_	9	dobj
31	on	on	IN	_	34	case
32	the	the	DT	_	34	det
33	abraded	abraded	JJ	_	34	amod
34	skin	skin	NN	_	30	nmod
35	of	of	IN	_	38	case
36	healthy	healthy	JJ	_	38	amod
37	adult	adult	JJ	_	38	amod
38	males	male	NNS	_	34	nmod
39	.	.	.	_	9	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	low	low	JJ	_	4	amod
4	systemic	systemic	JJ	_	5	amod
5	exposure	exposure	NN	_	19	nmod
6	to	to	TO	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	following	follow	VBG	_	10	case
9	topical	topical	JJ	_	10	amod
10	application	application	NN	_	5	nmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	,	,	,	_	19	punct
14	dosage	dosage	NN	_	15	compound
15	adjustments	adjustment	NNS	_	19	nsubj
16	for	for	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	are	be	VBP	_	19	cop
19	unnecessary	unnecessary	JJ	_	0	ROOT
20	when	when	WRB	_	21	advmod
21	co-administered	co-administer	VBN	_	19	advcl
22	with	with	IN	_	24	case
23	CYP3A4	cyp3a4	NN	_	24	compound
24	inhibitors	inhibitor	NNS	_	21	nmod
25	,	,	,	_	24	punct
26	such	such	JJ	_	28	case
27	as	as	IN	_	26	mwe
28	drug3	drug3	NN	_	24	nmod
29	.	.	.	_	19	punct

1	Based	base	VBN	_	7	case
2	on	on	IN	_	7	case
3	in	in	FW	_	7	amod
4	vitro	vitro	FW	_	3	dep
5	P450	p450	NN	_	7	compound
6	inhibition	inhibition	NN	_	7	compound
7	studies	study	NNS	_	22	advcl
8	and	and	CC	_	7	cc
9	the	the	DT	_	12	det
10	low	low	JJ	_	12	amod
11	systemic	systemic	JJ	_	12	amod
12	exposure	exposure	NN	_	7	conj
13	observed	observe	VBN	_	12	acl
14	following	follow	VBG	_	16	case
15	topical	topical	JJ	_	16	amod
16	application	application	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	,	,	,	_	22	punct
20	drug2	drug2	NN	_	22	nsubj
21	is	be	VBZ	_	22	cop
22	unlikely	unlikely	JJ	_	0	ROOT
23	to	to	TO	_	24	mark
24	affect	affect	VB	_	22	xcomp
25	the	the	DT	_	26	det
26	metabolism	metabolism	NN	_	24	dobj
27	of	of	IN	_	30	case
28	other	other	JJ	_	30	amod
29	P450	p450	NN	_	30	compound
30	substrates	substrate	NNS	_	26	nmod
31	.	.	.	_	22	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	21	nsubjpass
3	of	of	IN	_	5	case
4	concurrent	concurrent	JJ	_	5	amod
5	application	application	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	11	amod
10	topical	topical	JJ	_	11	amod
11	products	product	NNS	_	7	conj
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	same	same	JJ	_	15	amod
15	area	area	NN	_	2	nmod
16	of	of	IN	_	17	case
17	skin	skin	NN	_	15	nmod
18	has	have	VBZ	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	studied	study	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	drug3	drug3	NN	_	8	compound
8	type	type	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	,	,	,	_	5	punct
11	drug4	drug4	NN	_	5	conj
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	e.g.	e.g.	FW	_	15	dep
14	,	,	,	_	15	punct
15	drug5	drug5	NN	_	11	dep
16	,	,	,	_	15	punct
17	drug6	drug6	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug7	drug7	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug8	drug8	NN	_	15	conj
22	,	,	,	_	15	punct
23	drug9	drug9	NN	_	15	conj
24	,	,	,	_	15	punct
25	drug10	drug10	NN	_	15	appos
26	-RRB-	-rrb-	-RRB-	_	15	punct
27	,	,	,	_	5	punct
28	drug11	drug11	NN	_	5	conj
29	,	,	,	_	5	punct
30	drug12	drug12	NN	_	5	conj
31	,	,	,	_	5	punct
32	drug13	drug13	NN	_	5	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	e.g.	e.g.	FW	_	36	dep
35	,	,	,	_	36	punct
36	drug14	drug14	NN	_	32	dep
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	,	,	,	_	5	punct
39	other	other	JJ	_	40	amod
40	drug15	drug15	NN	_	5	conj
41	,	,	,	_	5	punct
42	drug16	drug16	NN	_	43	compound
43	supplements	supplement	NNS	_	5	conj
44	,	,	,	_	5	punct
45	drug17	drug17	NN	_	5	conj
46	,	,	,	_	5	punct
47	drug18	drug18	NN	_	5	conj
48	-LRB-	-lrb-	-LRB-	_	51	punct
49	e.g.	e.g.	FW	_	51	dep
50	,	,	,	_	51	punct
51	drug19	drug19	NN	_	47	dep
52	-	-	:	_	51	punct
53	drug20	drug20	NN	_	51	dep
54	-RRB-	-rrb-	-RRB-	_	51	punct
55	,	,	,	_	5	punct
56	drug21	drug21	NN	_	5	conj
57	-LRB-	-lrb-	-LRB-	_	60	punct
58	e.g.	e.g.	FW	_	60	dep
59	,	,	,	_	60	punct
60	drug22	drug22	NN	_	56	dep
61	,	,	,	_	60	punct
62	drug23	drug23	NN	_	60	appos
63	-RRB-	-rrb-	-RRB-	_	60	punct
64	.	.	.	_	3	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	highly	highly	RB	_	5	advmod
4	protein	protein	NN	_	5	nmod:npmod
5	bound	bind	VBD	_	0	ROOT
6	,	,	,	_	5	punct
7	and	and	CC	_	5	cc
8	therefore	therefore	RB	_	5	advmod
9	,	,	,	_	5	punct
10	might	might	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	expected	expect	VBN	_	5	ccomp
13	to	to	TO	_	14	mark
14	displace	displace	VB	_	12	xcomp
15	other	other	JJ	_	17	amod
16	protein-bound	protein-bound	JJ	_	17	amod
17	drugs	drug	NNS	_	14	dobj
18	.	.	.	_	5	punct

1	Although	although	IN	_	5	mark
2	this	this	DT	_	5	nsubj
3	has	have	VBZ	_	5	aux
4	not	not	RB	_	5	neg
5	occurred	occur	VBN	_	18	advcl
6	in	in	IN	_	9	case
7	in	in	FW	_	9	amod
8	vitro	vitro	FW	_	7	dep
9	studies	study	NNS	_	5	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	11	punct
13	interactions	interaction	NNS	_	11	appos
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	have	have	VBP	_	18	aux
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	0	ROOT
19	with	with	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	since	since	IN	_	22	case
22	marketing	marketing	NN	_	20	nmod
23	,	,	,	_	20	punct
24	therefore	therefore	RB	_	20	advmod
25	,	,	,	_	20	punct
26	physicians	physician	NNS	_	29	nsubj
27	should	should	MD	_	29	aux
28	closely	closely	RB	_	29	advmod
29	monitor	monitor	VB	_	20	dep
30	patients	patient	NNS	_	29	dobj
31	for	for	IN	_	33	case
32	a	a	DT	_	33	det
33	change	change	NN	_	29	nmod
34	in	in	IN	_	36	case
35	dosage	dosage	NN	_	36	compound
36	requirements	requirement	NNS	_	33	nmod
37	when	when	WRB	_	38	advmod
38	administering	administer	VBG	_	29	advcl
39	drug4	drug4	NN	_	38	dobj
40	to	to	TO	_	41	case
41	patients	patient	NNS	_	38	nmod
42	on	on	IN	_	43	case
43	drug5	drug5	NN	_	41	nmod
44	and	and	CC	_	43	cc
45	other	other	JJ	_	48	amod
46	highly	highly	RB	_	47	advmod
47	protein-bound	protein-bound	JJ	_	48	amod
48	drugs	drug	NNS	_	43	conj
49	.	.	.	_	18	punct

1	Plasma	plasma	NN	_	2	compound
2	levels	level	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	6	auxpass
6	depressed	depress	VBN	_	0	ROOT
7	to	to	TO	_	10	case
8	approximately	approximately	RB	_	9	advmod
9	80	80	CD	_	10	nummod
10	%	%	NN	_	6	nmod
11	of	of	IN	_	14	case
12	their	they	PRP$	_	14	nmod:poss
13	normal	normal	JJ	_	14	amod
14	values	value	NNS	_	10	nmod
15	when	when	WRB	_	18	advmod
16	drug2	drug2	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	administered	administer	VBN	_	6	advcl
19	in	in	IN	_	20	case
20	conjunction	conjunction	NN	_	18	nmod
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	3900	3900	CD	_	25	nummod
25	mg/day	mg/day	NN	_	22	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	,	,	,	_	6	punct
28	but	but	CC	_	6	cc
29	concomitant	concomitant	JJ	_	30	amod
30	administration	administration	NN	_	33	nsubj
31	of	of	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	has	have	VBZ	_	6	conj
34	no	no	DT	_	35	neg
35	effect	effect	NN	_	33	dobj
36	on	on	IN	_	39	case
37	drug5	drug5	NN	_	39	compound
38	plasma	plasma	NN	_	39	compound
39	levels	level	NNS	_	33	nmod
40	.	.	.	_	6	punct
41	drug6	drug6	NN	_	48	nsubjpass
42	,	,	,	_	41	punct
43	including	include	VBG	_	44	case
44	drug7	drug7	NN	_	41	nmod
45	,	,	,	_	41	punct
46	have	have	VBP	_	48	aux
47	been	be	VBN	_	48	auxpass
48	reported	report	VBN	_	6	parataxis
49	to	to	TO	_	50	mark
50	increase	increase	VB	_	48	xcomp
51	steady	steady	JJ	_	55	amod
52	state	state	NN	_	55	compound
53	plasma	plasma	NN	_	55	compound
54	drug8	drug8	NN	_	55	compound
55	levels	level	NNS	_	50	dobj
56	.	.	.	_	6	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	9	mark
5	plasma	plasma	NN	_	7	compound
6	drug1	drug1	NN	_	7	compound
7	levels	level	NNS	_	9	nsubjpass
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	3	ccomp
10	when	when	WRB	_	11	advmod
11	initiating	initiate	VBG	_	9	advcl
12	,	,	,	_	11	punct
13	adjusting	adjust	VBG	_	11	conj
14	and	and	CC	_	11	cc
15	discontinuing	discontinue	VBG	_	11	conj
16	drug2	drug2	NN	_	15	dobj
17	.	.	.	_	3	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	7	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	,	,	,	_	7	punct
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	increase	increase	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	12	case
11	oral	oral	JJ	_	12	amod
12	drug2	drug2	NN	_	9	nmod
13	;	;	:	_	7	punct

1	monitor	monitor	NN	_	5	compound
2	and	and	CC	_	1	cc
3	adjust	adjust	VBP	_	1	conj
4	drug1	drug1	NN	_	5	compound
5	dosage	dosage	NN	_	0	ROOT
6	accordingly	accordingly	RB	_	5	advmod
7	.	.	.	_	5	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Physiologic	physiologic	JJ	_	6	amod
6	effects	effect	NNS	_	10	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	may	may	MD	_	10	aux
10	result	result	VB	_	3	dep
11	in	in	IN	_	14	case
12	decreased	decrease	VBN	_	14	amod
13	estradiol	estradiol	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	nmod
15	with	with	IN	_	16	case
16	radioimmunoassays	radioimmunoassay	NNS	_	14	nmod
17	for	for	IN	_	18	case
18	estradiol	estradiol	NN	_	16	nmod
19	,	,	,	_	10	punct
20	increased	increase	VBN	_	23	amod
21	plasma	plasma	NN	_	23	compound
22	calcium	calcium	NN	_	23	compound
23	concentrations	concentration	NNS	_	10	dobj
24	,	,	,	_	10	punct
25	and	and	CC	_	10	cc
26	increased	increase	VBD	_	10	conj
27	24-hour	24-hour	JJ	_	29	amod
28	urinary	urinary	JJ	_	29	amod
29	excretion	excretion	NN	_	26	dobj
30	of	of	IN	_	31	case
31	creatine	creatine	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	17-ketosteroids	17-ketosteroid	NNS	_	31	conj
34	.	.	.	_	3	punct

1	Although	although	IN	_	8	mark
2	a	a	DT	_	4	det
3	causal	causal	JJ	_	4	amod
4	relationship	relationship	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	established	establish	VBN	_	13	advcl
9	,	,	,	_	13	punct
10	there	there	EX	_	13	expl
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	cop
13	reports	report	NNS	_	0	ROOT
14	of	of	IN	_	15	case
15	bleeding	bleeding	NN	_	13	nmod
16	and/or	and/or	CC	_	15	cc
17	prolonged	prolonged	JJ	_	19	amod
18	prothrombin	prothrombin	NN	_	19	compound
19	time	time	NN	_	15	conj
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	13	nmod
22	treated	treat	VBN	_	21	acl
23	with	with	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	with	with	IN	_	28	case
26	and	and	CC	_	25	cc
27	without	without	IN	_	25	conj
28	drug2	drug2	NN	_	24	nmod
29	or	or	CC	_	28	cc
30	drug3	drug3	NN	_	28	conj
31	.	.	.	_	13	punct

1	Patients	patient	NNS	_	5	nsubj
2	on	on	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	should	should	MD	_	5	aux
5	have	have	VB	_	0	ROOT
6	more	more	RBR	_	7	advmod
7	frequent	frequent	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	dobj
9	of	of	IN	_	11	case
10	prothrombin	prothrombin	NN	_	11	compound
11	times	time	NNS	_	8	nmod
12	,	,	,	_	5	punct
13	while	while	IN	_	32	mark
14	patients	patient	NNS	_	32	nsubj
15	with	with	IN	_	18	case
16	other	other	JJ	_	18	amod
17	risk	risk	NN	_	18	compound
18	factors	factor	NNS	_	14	nmod
19	complicated	complicate	VBN	_	18	acl
20	by	by	IN	_	21	case
21	hemorrhage	hemorrhage	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	26	punct
23	e.g.	e.g.	FW	_	26	dep
24	,	,	,	_	26	punct
25	recent	recent	JJ	_	26	amod
26	surgery	surgery	NN	_	21	dep
27	,	,	,	_	26	punct
28	peptic	peptic	JJ	_	29	amod
29	ulceration	ulceration	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	26	punct
31	should	should	MD	_	32	aux
32	have	have	VB	_	5	advcl
33	periodic	periodic	JJ	_	34	amod
34	examinations	examination	NNS	_	32	dobj
35	for	for	IN	_	36	case
36	bleeding	bleed	VBG	_	34	nmod
37	including	include	VBG	_	38	case
38	hematocrit	hematocrit	NN	_	36	nmod
39	and/or	and/or	CC	_	38	cc
40	hemoglobin	hemoglobin	NN	_	38	conj
41	.	.	.	_	5	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	10	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-	-	:	_	2	punct
8	containing	contain	VBG	_	2	acl
9	drugs	drug	NNS	_	8	dobj
10	leads	lead	VBZ	_	0	ROOT
11	to	to	TO	_	14	case
12	increased	increase	VBN	_	14	amod
13	drug3	drug3	NN	_	14	compound
14	levels	level	NNS	_	10	nmod
15	and	and	CC	_	14	cc
16	drug4	drug4	NN	_	17	compound
17	toxicity	toxicity	NN	_	14	conj
18	in	in	IN	_	20	case
19	some	some	DT	_	20	det
20	individuals	individual	NNS	_	14	nmod
21	.	.	.	_	10	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	be	be	VB	_	6	auxpass
5	closely	closely	RB	_	6	advmod
6	monitored	monitor	VBN	_	0	ROOT
7	for	for	IN	_	8	case
8	signs	sign	NNS	_	6	nmod
9	of	of	IN	_	10	case
10	toxicity	toxicity	NN	_	8	nmod
11	and	and	CC	_	6	cc
12	have	have	VBP	_	16	aux
13	their	they	PRP$	_	15	nmod:poss
14	drug1	drug1	NN	_	15	compound
15	dosage	dosage	NN	_	16	nsubj
16	adjusted	adjust	VBN	_	6	conj
17	as	as	RB	_	18	advmod
18	necessary	necessary	JJ	_	16	xcomp
19	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	concurrently	concurrently	RB	_	4	advmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug4	drug4	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug5	drug5	NN	_	7	conj
14	,	,	,	_	7	punct
15	drug6	drug6	NN	_	7	conj
16	,	,	,	_	7	punct
17	and	and	CC	_	7	cc
18	drug7	drug7	NN	_	7	conj
19	,	,	,	_	4	punct
20	without	without	IN	_	22	case
21	observed	observe	VBN	_	22	amod
22	problems	problem	NNS	_	4	nmod
23	.	.	.	_	4	punct

1	Small	small	JJ	_	2	amod
2	decreases	decrease	NNS	_	8	nsubjpass
3	in	in	IN	_	5	case
4	blood	blood	NN	_	5	compound
5	pressure	pressure	NN	_	2	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	some	some	DT	_	11	det
11	patients	patient	NNS	_	8	nmod
12	treated	treat	VBN	_	11	acl
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	;	;	:	_	8	punct

1	periodic	periodic	JJ	_	5	amod
2	systemic	systemic	JJ	_	5	amod
3	blood	blood	NN	_	5	compound
4	pressure	pressure	NN	_	5	compound
5	monitoring	monitoring	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	for	for	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	concomitant	concomitant	JJ	_	13	amod
12	antihypertensive	antihypertensive	JJ	_	13	amod
13	therapy	therapy	NN	_	10	dobj
14	.	.	.	_	7	punct

1	If	if	IN	_	2	mark
2	indicated	indicate	VBN	_	10	advcl
3	,	,	,	_	10	punct
4	dosage	dosage	NN	_	10	nsubjpass
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	drug1	drug1	NN	_	4	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	reduced	reduce	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	5	det
5	use	use	NN	_	31	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug2	drug2	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	Injection	injection	NN	_	7	dep
12	before	before	IN	_	13	case
13	drug3	drug3	NN	_	5	nmod
14	,	,	,	_	5	punct
15	for	for	IN	_	17	case
16	the	the	DT	_	17	det
17	purpose	purpose	NN	_	5	nmod
18	of	of	IN	_	19	mark
19	attenuating	attenuate	VBG	_	17	acl
20	some	some	DT	_	19	dobj
21	of	of	IN	_	24	case
22	the	the	DT	_	24	det
23	side	side	JJ	_	24	amod
24	effects	effect	NNS	_	20	nmod
25	of	of	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	,	,	,	_	5	punct
28	has	have	VBZ	_	31	aux
29	not	not	RB	_	31	neg
30	been	be	VBN	_	31	auxpass
31	studied	study	VBN	_	2	dep
32	.	.	.	_	31	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	14	advcl
5	following	follow	VBG	_	6	case
6	administration	administration	NN	_	4	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	14	punct
10	it	it	PRP	_	14	nsubjpass
11	should	should	MD	_	14	aux
12	not	not	RB	_	14	neg
13	be	be	VB	_	14	auxpass
14	given	give	VBN	_	0	ROOT
15	until	until	IN	_	21	mark
16	recovery	recovery	NN	_	21	nsubjpass
17	from	from	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	observed	observe	VBN	_	14	advcl
22	.	.	.	_	14	punct

1	The	the	DT	_	3	det
2	median	median	JJ	_	3	amod
3	duration	duration	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	action	action	NN	_	3	nmod
6	of	of	IN	_	9	case
7	drug1	drug1	NN	_	9	compound
8	0.6	0.6	CD	_	9	nummod
9	mg/kg	mg/kg	NN	_	5	nmod
10	administered	administer	VBN	_	0	ROOT
11	after	after	IN	_	15	case
12	a	a	DT	_	15	det
13	1	1	CD	_	15	nummod
14	mg/kg	mg/kg	NN	_	15	compound
15	dose	dose	NN	_	10	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	when	when	WRB	_	21	advmod
19	T	t	NN	_	21	nsubj
20	1	1	CD	_	19	nummod
21	returned	return	VBD	_	10	advcl
22	to	to	TO	_	24	case
23	75	75	CD	_	24	nummod
24	%	%	NN	_	21	nmod
25	of	of	IN	_	26	case
26	control	control	NN	_	24	nmod
27	was	be	VBD	_	29	cop
28	36	36	CD	_	29	nummod
29	minutes	minute	NNS	_	21	dep
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	range	range	NN	_	29	dep
32	14-57	14-57	CD	_	31	nummod
33	,	,	,	_	31	punct
34	n	n	NN	_	35	nsubj
35	=	=	JJ	_	31	dep
36	12	12	CD	_	35	dobj
37	-RRB-	-rrb-	-RRB-	_	31	punct
38	vs.	vs.	CC	_	29	cc

1	28	28	CD	_	2	nummod
2	minutes	minute	NNS	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	7	punct
4	17-51	17-51	CD	_	7	dep
5	,	,	,	_	7	punct
6	n	n	NN	_	7	nsubj
7	=	=	JJ	_	2	dep
8	12	12	CD	_	7	dobj
9	-RRB-	-rrb-	-RRB-	_	7	punct
10	without	without	IN	_	11	case
11	drug1	drug1	NN	_	2	nmod
12	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	5	neg
4	controlled	controlled	JJ	_	5	amod
5	studies	study	NNS	_	2	nsubj
6	documenting	document	VBG	_	5	acl
7	the	the	DT	_	8	det
8	use	use	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	before	before	IN	_	15	nmod
12	or	or	CC	_	11	cc
13	after	after	IN	_	11	conj
14	other	other	JJ	_	15	amod
15	drug2	drug2	NN	_	6	nmod
16	.	.	.	_	2	punct

1	Interactions	interaction	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	when	when	WRB	_	10	advmod
6	other	other	JJ	_	7	amod
7	drug1	drug1	NN	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	administered	administer	VBN	_	4	advcl
11	in	in	IN	_	12	case
12	succession	succession	NN	_	10	nmod
13	.	.	.	_	4	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	None	none	NN	_	3	dep
6	known	know	VBN	_	5	acl
7	.	.	.	_	3	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug2	drug2	NN	_	4	dep
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	may	may	MD	_	13	aux
13	diminish	diminish	VB	_	0	ROOT
14	the	the	DT	_	16	det
15	bactericidal	bactericidal	JJ	_	16	amod
16	effects	effect	NNS	_	13	dobj
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	by	by	IN	_	20	mark
20	slowing	slow	VBG	_	13	advcl
21	the	the	DT	_	22	det
22	rate	rate	NN	_	20	dobj
23	of	of	IN	_	25	case
24	bacterial	bacterial	JJ	_	25	amod
25	growth	growth	NN	_	22	nmod
26	.	.	.	_	13	punct

1	Bactericidal	bactericidal	JJ	_	2	amod
2	agents	agent	NNS	_	3	nsubj
3	work	work	VBP	_	0	ROOT
4	most	most	RBS	_	5	advmod
5	effectively	effectively	RB	_	3	advmod
6	against	against	IN	_	10	case
7	the	the	DT	_	10	det
8	immature	immature	JJ	_	10	amod
9	cell	cell	NN	_	10	compound
10	wall	wall	NN	_	3	nmod
11	of	of	IN	_	14	case
12	rapidly	rapidly	RB	_	13	advmod
13	proliferating	proliferate	VBG	_	14	amod
14	microorganisms	microorganism	NNS	_	10	nmod
15	.	.	.	_	3	punct

1	This	this	DT	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	in	in	FW	_	6	compound
6	vitro	vitro	FW	_	4	advmod
7	;	;	:	_	4	punct

1	however	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	the	the	DT	_	5	det
4	clinical	clinical	JJ	_	5	amod
5	significance	significance	NN	_	12	nsubjpass
6	of	of	IN	_	8	case
7	this	this	DT	_	8	det
8	interaction	interaction	NN	_	5	nmod
9	is	be	VBZ	_	12	auxpass
10	not	not	RB	_	12	neg
11	well	well	RB	_	12	advmod
12	documented	document	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	few	few	JJ	_	5	amod
4	clinical	clinical	JJ	_	5	amod
5	situations	situation	NNS	_	2	nsubj
6	in	in	IN	_	7	case
7	which	which	WDT	_	21	nmod
8	the	the	DT	_	10	det
9	concurrent	concurrent	JJ	_	10	amod
10	use	use	NN	_	21	nsubjpass
11	of	of	IN	_	13	case
12	''	''	''	_	13	punct
13	static	static	JJ	_	10	nmod
14	''	''	''	_	13	punct
15	and	and	CC	_	13	cc
16	''	''	''	_	13	punct
17	cidal	cidal	JJ	_	19	amod
18	''	''	''	_	19	punct
19	drug1	drug1	NN	_	13	conj
20	are	be	VBP	_	21	auxpass
21	indicated	indicate	VBN	_	5	acl:relcl
22	.	.	.	_	2	punct

1	However	however	RB	_	26	advmod
2	,	,	,	_	26	punct
3	in	in	IN	_	5	case
4	selected	select	VBN	_	5	amod
5	circumstances	circumstance	NNS	_	26	nmod
6	in	in	IN	_	7	case
7	which	which	WDT	_	11	nmod
8	such	such	JJ	_	9	amod
9	therapy	therapy	NN	_	11	nsubj
10	is	be	VBZ	_	11	cop
11	appropriate	appropriate	JJ	_	5	acl:relcl
12	,	,	,	_	11	punct
13	using	use	VBG	_	11	conj
14	adequate	adequate	JJ	_	15	amod
15	doses	dose	NNS	_	13	dobj
16	of	of	IN	_	18	case
17	drug1	drug1	NN	_	18	compound
18	agents	agent	NNS	_	15	nmod
19	and	and	CC	_	11	cc
20	beginning	begin	VBG	_	22	amod
21	penicillin	penicillin	NN	_	22	compound
22	therapy	therapy	NN	_	11	conj
23	first	first	RB	_	22	advmod
24	,	,	,	_	26	punct
25	should	should	MD	_	26	aux
26	minimize	minimize	VB	_	0	ROOT
27	the	the	DT	_	28	det
28	potential	potential	NN	_	26	dobj
29	for	for	IN	_	30	case
30	interaction	interaction	NN	_	28	nmod
31	.	.	.	_	26	punct

1	drug1	drug1	NN	_	3	compound
2	blood	blood	NN	_	3	compound
3	levels	level	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	prolonged	prolong	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	concurrent	concurrent	JJ	_	9	amod
9	administration	administration	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	which	which	WDT	_	13	nsubj
13	blocks	block	VBZ	_	9	acl:relcl
14	the	the	DT	_	17	det
15	renal	renal	JJ	_	17	amod
16	tubular	tubular	JJ	_	17	amod
17	secretion	secretion	NN	_	13	dobj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	6	punct

1	Displacement	displacement	NN	_	10	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	from	from	IN	_	8	case
5	plasma	plasma	NN	_	8	compound
6	protein	protein	NN	_	8	compound
7	binding	binding	NN	_	8	compound
8	sites	site	NNS	_	1	nmod
9	will	will	MD	_	10	aux
10	elevate	elevate	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	level	level	NN	_	10	dobj
13	of	of	IN	_	15	case
14	free	free	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	serum	serum	NN	_	10	nmod
19	.	.	.	_	10	punct

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	amod
2	drugs	drug	NNS	_	9	nsubj
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	may	may	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	9	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	9	punct

1	Patients	patient	NNS	_	14	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	plus	plus	CC	_	3	cc
5	a	a	DT	_	7	det
6	catecholamine-depleting	catecholamine-depleting	JJ	_	7	amod
7	agent	agent	NN	_	3	conj
8	should	should	MD	_	14	aux
9	,	,	,	_	14	punct
10	therefore	therefore	RB	_	14	advmod
11	,	,	,	_	14	punct
12	be	be	VB	_	14	auxpass
13	closely	closely	RB	_	14	advmod
14	observed	observe	VBN	_	0	ROOT
15	for	for	IN	_	16	case
16	evidence	evidence	NN	_	14	nmod
17	of	of	IN	_	18	case
18	hypotension	hypotension	NN	_	16	nmod
19	and/or	and/or	CC	_	18	cc
20	marked	marked	JJ	_	21	amod
21	bradycardia	bradycardia	NN	_	18	conj
22	which	which	WDT	_	24	nsubj
23	may	may	MD	_	24	aux
24	produce	produce	VB	_	16	acl:relcl
25	vertigo	vertigo	NN	_	24	dobj
26	,	,	,	_	25	punct
27	syncope	syncope	NN	_	25	conj
28	,	,	,	_	25	punct
29	or	or	CC	_	25	cc
30	postural	postural	JJ	_	31	amod
31	hypotension	hypotension	NN	_	25	conj
32	.	.	.	_	14	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	a	a	DT	_	7	det
7	variety	variety	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	7	punct
11	including	include	VBG	_	12	case
12	drug3	drug3	NN	_	7	nmod
13	,	,	,	_	12	punct
14	drug4	drug4	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	drug5	drug5	NN	_	12	conj
18	without	without	IN	_	21	case
19	unexpected	unexpected	JJ	_	21	amod
20	adverse	adverse	JJ	_	21	amod
21	interactions	interaction	NNS	_	12	nmod
22	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	increase	increase	VB	_	4	xcomp
7	serum	serum	NN	_	9	compound
8	drug2	drug2	NN	_	9	compound
9	levels	level	NNS	_	6	dobj
10	when	when	WRB	_	14	advmod
11	both	both	DT	_	12	det
12	drugs	drug	NNS	_	14	nsubj
13	are	be	VBP	_	14	cop
14	co-administered	co-administered	JJ	_	6	advcl
15	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	levels	level	NNS	_	6	nsubjpass
3	may	may	MD	_	6	aux
4	also	also	RB	_	6	advmod
5	be	be	VB	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	this	this	DT	_	9	det
9	combination	combination	NN	_	6	nmod
10	.	.	.	_	6	punct

1	Risk	risk	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	anaphylactic	anaphylactic	JJ	_	4	amod
4	reaction	reaction	NN	_	1	nmod
5	:	:	:	_	1	punct
6	While	while	IN	_	7	mark
7	taking	take	VBG	_	26	advcl
8	drug1	drug1	NN	_	7	dobj
9	,	,	,	_	26	punct
10	patients	patient	NNS	_	26	nsubj
11	with	with	IN	_	13	case
12	a	a	DT	_	13	det
13	history	history	NN	_	10	nmod
14	of	of	IN	_	17	case
15	severe	severe	JJ	_	17	amod
16	anaphylactic	anaphylactic	JJ	_	17	amod
17	reaction	reaction	NN	_	13	nmod
18	to	to	TO	_	20	case
19	a	a	DT	_	20	det
20	variety	variety	NN	_	17	nmod
21	of	of	IN	_	22	case
22	allergens	allergen	NNS	_	20	nmod
23	may	may	MD	_	26	aux
24	be	be	VB	_	26	cop
25	more	more	RBR	_	26	advmod
26	reactive	reactive	JJ	_	1	dep
27	to	to	TO	_	29	case
28	repeated	repeat	VBN	_	29	amod
29	challenge	challenge	NN	_	26	nmod
30	,	,	,	_	26	punct
31	either	either	CC	_	32	cc:preconj
32	accidental	accidental	JJ	_	26	dep
33	,	,	,	_	32	punct
34	diagnostic	diagnostic	JJ	_	32	conj
35	,	,	,	_	32	punct
36	or	or	CC	_	32	cc
37	therapeutic	therapeutic	JJ	_	32	conj
38	.	.	.	_	1	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	unresponsive	unresponsive	JJ	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	usual	usual	JJ	_	9	amod
9	doses	dose	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	used	use	VBN	_	9	acl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	allergic	allergic	JJ	_	16	amod
16	reactions	reaction	NNS	_	14	dobj
17	.	.	.	_	5	punct

1	Although	although	IN	_	12	mark
2	specific	specific	JJ	_	3	amod
3	drug	drug	NN	_	12	nsubjpass
4	or	or	CC	_	3	cc
5	food	food	NN	_	6	compound
6	interactions	interaction	NNS	_	3	conj
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	3	nmod
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	28	advcl
13	,	,	,	_	28	punct
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	basis	basis	NN	_	28	nmod
17	of	of	IN	_	21	case
18	this	this	DT	_	21	det
19	drug	drug	NN	_	21	compound
20	s	s	NNS	_	21	compound
21	metabolism	metabolism	NN	_	16	nmod
22	by	by	IN	_	24	case
23	CYP	cyp	NN	_	24	compound
24	3A4	3a4	NN	_	16	nmod
25	,	,	,	_	28	punct
26	it	it	PRP	_	28	nsubj
27	is	be	VBZ	_	28	cop
28	possible	possible	JJ	_	0	ROOT
29	that	that	IN	_	40	mark
30	drug2	drug2	NN	_	40	nsubj
31	,	,	,	_	30	punct
32	drug3	drug3	NN	_	30	conj
33	,	,	,	_	30	punct
34	drug4	drug4	NN	_	30	conj
35	,	,	,	_	30	punct
36	and	and	CC	_	30	cc
37	grapefruit	grapefruit	NN	_	38	compound
38	juice	juice	NN	_	30	conj
39	may	may	MD	_	40	aux
40	inhibit	inhibit	VB	_	28	ccomp
41	its	its	PRP$	_	42	nmod:poss
42	metabolism	metabolism	NN	_	40	dobj
43	-LRB-	-lrb-	-LRB-	_	46	punct
44	increasing	increase	VBG	_	46	amod
45	serum	serum	NN	_	46	compound
46	levels	level	NNS	_	40	dep
47	of	of	IN	_	48	case
48	drug5	drug5	NN	_	46	nmod
49	-RRB-	-rrb-	-RRB-	_	46	punct
50	.	.	.	_	28	punct

1	Furthermore	furthermore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	compound
4	,	,	,	_	7	punct
5	drug2	drug2	NN	_	7	appos
6	,	,	,	_	7	punct
7	St.	St.	NNP	_	0	ROOT

1	John	John	NNP	_	3	compound
2	s	be	VBZ	_	3	compound
3	Wort	Wort	NNP	_	16	nsubj
4	,	,	,	_	3	punct
5	and	and	CC	_	3	cc
6	certain	certain	JJ	_	7	amod
7	drug1	drug1	NN	_	3	conj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug2	drug2	NN	_	7	dep
10	,	,	,	_	9	punct
11	drug3	drug3	NN	_	9	appos
12	,	,	,	_	9	punct
13	drug4	drug4	NN	_	9	appos
14	-RRB-	-rrb-	-RRB-	_	9	punct
15	may	may	MD	_	16	aux
16	induce	induce	VB	_	0	ROOT
17	drug5	drug5	NN	_	18	compound
18	metabolism	metabolism	NN	_	16	dobj
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	lowering	lower	VBG	_	18	dep
21	serum	serum	NN	_	22	compound
22	levels	level	NNS	_	20	dobj
23	of	of	IN	_	24	case
24	drug6	drug6	NN	_	22	nmod
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	.	.	.	_	16	punct

1	Based	base	VBN	_	6	case
2	on	on	IN	_	6	case
3	in	in	FW	_	6	amod
4	vitro	vitro	FW	_	3	dep
5	inhibition	inhibition	NN	_	6	compound
6	information	information	NN	_	12	advcl
7	,	,	,	_	12	punct
8	coadministration	coadministration	NN	_	12	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	may	may	MD	_	12	aux
12	lead	lead	VB	_	0	ROOT
13	to	to	TO	_	15	case
14	an	a	DT	_	15	det
15	increase	increase	NN	_	12	nmod
16	in	in	IN	_	18	case
17	serum	serum	NN	_	18	compound
18	levels	level	NNS	_	15	nmod
19	of	of	IN	_	20	case
20	drugs	drug	NNS	_	18	nmod
21	that	that	WDT	_	25	nsubj
22	are	be	VBP	_	25	cop
23	CYP	cyp	NN	_	25	compound
24	3A4	3a4	NN	_	25	compound
25	substrates	substrate	NNS	_	20	acl:relcl
26	.	.	.	_	12	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	the	the	DT	_	5	det
4	slow	slow	JJ	_	5	amod
5	elimination	elimination	NN	_	16	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	from	from	IN	_	10	case
9	the	the	DT	_	10	det
10	body	body	NN	_	5	nmod
11	,	,	,	_	16	punct
12	such	such	JJ	_	13	amod
13	interaction	interaction	NN	_	16	nsubjpass
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	for	for	IN	_	20	case
18	a	a	DT	_	20	det
19	prolonged	prolonged	JJ	_	20	amod
20	period	period	NN	_	16	nmod
21	after	after	IN	_	23	case
22	its	its	PRP$	_	23	nmod:poss
23	administration	administration	NN	_	20	nmod
24	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	drug1	drug1	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	administered	administer	VBN	_	6	advcl
11	with	with	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	that	that	WDT	_	17	nsubj
14	are	be	VBP	_	17	cop
15	CYP	cyp	NN	_	17	compound
16	3A4	3a4	NN	_	17	compound
17	substrates	substrate	NNS	_	12	acl:relcl
18	and	and	CC	_	17	cc
19	have	have	VBP	_	17	conj
20	narrow	narrow	JJ	_	22	amod
21	therapeutic	therapeutic	JJ	_	22	amod
22	range	range	NN	_	19	dobj
23	,	,	,	_	22	punct
24	including	include	VBG	_	26	case
25	some	some	DT	_	26	det
26	agents	agent	NNS	_	22	nmod
27	used	use	VBN	_	26	acl
28	during	during	IN	_	30	case
29	general	general	JJ	_	30	amod
30	anesthesia	anesthesia	NN	_	27	nmod
31	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	erythema	erythema	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	histamine-like	histamine-like	JJ	_	14	amod
14	flushing	flushing	NN	_	11	conj
15	and	and	CC	_	11	cc
16	anaphylactoid	anaphylactoid	JJ	_	17	amod
17	reactions	reaction	NNS	_	11	conj
18	.	.	.	_	9	punct

1	Concurrent	concurrent	JJ	_	7	amod
2	and/or	and/or	CC	_	1	cc
3	sequential	sequential	JJ	_	1	conj
4	systemic	systemic	JJ	_	7	amod
5	or	or	CC	_	4	cc
6	topical	topical	JJ	_	4	conj
7	use	use	NN	_	36	nsubj
8	of	of	IN	_	14	case
9	other	other	JJ	_	14	amod
10	potentially	potentially	RB	_	11	advmod
11	neurotoxic	neurotoxic	JJ	_	14	amod
12	and/or	and/or	CC	_	11	cc
13	nephrotoxic	nephrotoxic	JJ	_	11	conj
14	drugs	drug	NNS	_	7	nmod
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug1	drug1	NN	_	14	nmod
19	,	,	,	_	18	punct
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	18	punct
22	drug3	drug3	NN	_	18	conj
23	,	,	,	_	18	punct
24	drug4	drug4	NN	_	18	conj
25	,	,	,	_	18	punct
26	drug5	drug5	NN	_	18	conj
27	,	,	,	_	18	punct
28	drug6	drug6	NN	_	18	conj
29	,	,	,	_	18	punct
30	or	or	CC	_	18	cc
31	drug7	drug7	NN	_	18	conj
32	,	,	,	_	14	punct
33	when	when	WRB	_	34	advmod
34	indicated	indicate	VBN	_	14	acl:relcl
35	,	,	,	_	14	punct
36	requires	require	VBZ	_	0	ROOT
37	careful	careful	JJ	_	38	amod
38	monitoring	monitoring	NN	_	36	dobj
39	.	.	.	_	36	punct

1	Potential	potential	JJ	_	11	nsubjpass
2	for	for	IN	_	5	mark
3	drug1	drug1	NN	_	5	nsubj
4	to	to	TO	_	5	mark
5	Affect	affect	VB	_	1	advcl
6	Other	other	JJ	_	8	amod
7	Drugs	drug	NNS	_	8	compound
8	drug2	drug2	NN	_	5	dobj
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	cause	cause	VB	_	11	xcomp
14	clinically	clinically	RB	_	15	advmod
15	important	important	JJ	_	17	amod
16	pharmacokinetic	pharmacokinetic	JJ	_	17	amod
17	interactions	interaction	NNS	_	13	dobj
18	with	with	IN	_	19	case
19	drugs	drug	NNS	_	17	nmod
20	that	that	WDT	_	22	nsubjpass
21	are	be	VBP	_	22	auxpass
22	metabolized	metabolize	VBN	_	19	acl:relcl
23	by	by	IN	_	26	case
24	cytochrome	cytochrome	NN	_	26	compound
25	P450	p450	NN	_	26	compound
26	isozymes	isozyme	NNS	_	22	nmod
27	.	.	.	_	11	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	in	in	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	that	that	IN	_	14	mark
10	drug1	drug1	NN	_	14	nsubj
11	does	do	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	substantially	substantially	RB	_	14	advmod
14	inhibit	inhibit	VB	_	8	ccomp
15	the	the	DT	_	16	det
16	metabolism	metabolism	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	metabolized	metabolize	VBN	_	18	acl
20	by	by	IN	_	23	case
21	cytochrome	cytochrome	NN	_	23	compound
22	P450	p450	NN	_	23	compound
23	isozymes	isozyme	NNS	_	19	nmod
24	,	,	,	_	23	punct
25	including	include	VBG	_	26	case
26	CYP1A2	cyp1a2	NN	_	23	nmod
27	,	,	,	_	26	punct
28	CYP2A6	cyp2a6	NN	_	26	conj
29	,	,	,	_	26	punct
30	CYP2C8/9/10	cyp2c8/9/10	NN	_	26	conj
31	,	,	,	_	26	punct
32	CYP2D6	cyp2d6	NN	_	26	conj
33	,	,	,	_	26	punct
34	CYP2E1	cyp2e1	NN	_	26	conj
35	,	,	,	_	26	punct
36	CYP3A4	cyp3a4	NN	_	26	conj
37	,	,	,	_	26	punct
38	and	and	CC	_	26	cc
39	CYP3A5	cyp3a5	NN	_	26	conj
40	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	not	not	RB	_	6	neg
6	expected	expect	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	inhibit	inhibit	VB	_	6	xcomp
9	clearance	clearance	NN	_	8	dobj
10	of	of	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	that	that	WDT	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	metabolized	metabolize	VBN	_	11	acl:relcl
15	by	by	IN	_	18	case
16	these	these	DT	_	18	det
17	metabolic	metabolic	JJ	_	18	amod
18	pathways	pathway	NNS	_	14	nmod
19	in	in	IN	_	23	case
20	a	a	DT	_	23	det
21	clinically	clinically	RB	_	22	advmod
22	relevant	relevant	JJ	_	23	amod
23	manner	manner	NN	_	14	nmod
24	.	.	.	_	6	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	also	also	RB	_	5	advmod
4	not	not	RB	_	5	neg
5	expected	expect	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	have	have	VB	_	5	xcomp
8	enzyme	enzyme	NN	_	7	dobj
9	inducing	induce	VBG	_	8	acl
10	properties	property	NNS	_	9	dobj
11	.	.	.	_	5	punct

1	At	at	IN	_	3	case
2	therapeutic	therapeutic	JJ	_	3	amod
3	concentrations	concentration	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	inhibit	inhibit	VB	_	0	ROOT
9	P-glycoprotein	p-glycoprotein	NN	_	8	dobj
10	.	.	.	_	8	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	therefore	therefore	RB	_	5	advmod
4	not	not	RB	_	5	neg
5	expected	expect	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	inhibit	inhibit	VB	_	5	xcomp
8	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	9	amod
9	transport	transport	NN	_	7	dobj
10	of	of	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drugs	drug	NNS	_	9	nmod
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	clinically	clinically	RB	_	16	advmod
16	relevant	relevant	JJ	_	17	amod
17	manner	manner	NN	_	7	nmod
18	.	.	.	_	5	punct

1	Given	give	VBN	_	5	case
2	the	the	DT	_	5	det
3	primary	primary	JJ	_	5	amod
4	CNS	cns	NN	_	5	compound
5	effects	effect	NNS	_	12	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	12	punct
9	drug2	drug2	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	used	use	VBN	_	0	ROOT
13	with	with	IN	_	14	case
14	caution	caution	NN	_	12	nmod
15	in	in	IN	_	16	case
16	combination	combination	NN	_	12	nmod
17	with	with	IN	_	19	case
18	other	other	JJ	_	19	amod
19	drug3	drug3	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effect	effect	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drug3	drug3	NN	_	7	conj
11	.	.	.	_	3	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	its	its	PRP$	_	4	nmod:poss
4	potential	potential	NN	_	15	nmod
5	for	for	IN	_	6	mark
6	inducing	induce	VBG	_	4	acl
7	orthostatic	orthostatic	JJ	_	8	amod
8	hypotension	hypotension	NN	_	6	dobj
9	,	,	,	_	8	punct
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	8	appos
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	when	when	WRB	_	19	advmod
17	drug1	drug1	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	administered	administer	VBN	_	15	advcl
20	with	with	IN	_	23	case
21	other	other	JJ	_	23	amod
22	therapeutic	therapeutic	JJ	_	23	amod
23	agents	agent	NNS	_	19	nmod
24	that	that	WDT	_	25	nsubj
25	have	have	VBP	_	23	acl:relcl
26	this	this	DT	_	27	det
27	potential	potential	NN	_	25	dobj
28	.	.	.	_	15	punct

1	Potential	potential	JJ	_	12	nsubj
2	for	for	IN	_	6	mark
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	6	nsubj
5	to	to	TO	_	6	mark
6	Affect	affect	VB	_	1	advcl
7	drug1	drug1	NN	_	8	compound
8	drug2	drug2	NN	_	6	dobj
9	is	be	VBZ	_	12	cop
10	not	not	RB	_	12	neg
11	a	a	DT	_	12	det
12	substrate	substrate	NN	_	0	ROOT
13	of	of	IN	_	14	case
14	CYP1A2	cyp1a2	NN	_	12	nmod
15	,	,	,	_	14	punct
16	CYP2A6	cyp2a6	NN	_	14	conj
17	,	,	,	_	14	punct
18	CYP2C9	cyp2c9	NN	_	14	conj
19	,	,	,	_	14	punct
20	and	and	CC	_	14	cc
21	CYP2C19	cyp2c19	NN	_	14	conj
22	,	,	,	_	12	punct
23	so	so	RB	_	35	mark
24	that	that	IN	_	23	mwe
25	an	a	DT	_	26	det
26	interaction	interaction	NN	_	35	nsubj
27	with	with	IN	_	28	case
28	inhibitors	inhibitor	NNS	_	26	nmod
29	or	or	CC	_	28	cc
30	inducers	inducer	NNS	_	28	conj
31	of	of	IN	_	33	case
32	these	these	DT	_	33	det
33	isozymes	isozyme	NNS	_	28	nmod
34	is	be	VBZ	_	35	cop
35	unlikely	unlikely	JJ	_	12	advcl
36	.	.	.	_	12	punct

1	While	while	IN	_	5	mark
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	studies	study	NNS	_	5	nsubj
5	indicate	indicate	VBP	_	0	ROOT
6	that	that	IN	_	13	mark
7	CYP2D6	cyp2d6	NN	_	13	nsubjpass
8	and	and	CC	_	7	cc
9	CYP3A4	cyp3a4	NN	_	7	conj
10	may	may	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	minimally	minimally	RB	_	13	advmod
13	involved	involve	VBN	_	5	ccomp
14	in	in	IN	_	16	case
15	drug1	drug1	NN	_	16	compound
16	metabolism	metabolism	NN	_	13	nmod
17	,	,	,	_	16	punct
18	in	in	FW	_	20	amod
19	vivo	vivo	FW	_	18	dep
20	studies	study	NNS	_	23	nsubj
21	do	do	VBP	_	23	aux
22	not	not	RB	_	23	neg
23	show	show	VB	_	16	acl:relcl
24	decreased	decrease	VBN	_	25	amod
25	elimination	elimination	NN	_	23	dobj
26	by	by	IN	_	28	case
27	these	these	DT	_	28	det
28	isozymes	isozyme	NNS	_	25	nmod
29	and	and	CC	_	23	cc
30	they	they	PRP	_	31	nsubj
31	contribute	contribute	VBP	_	23	conj
32	to	to	TO	_	36	case
33	only	only	RB	_	36	advmod
34	a	a	DT	_	36	det
35	small	small	JJ	_	36	amod
36	fraction	fraction	NN	_	31	nmod
37	of	of	IN	_	40	case
38	total	total	JJ	_	40	amod
39	body	body	NN	_	40	compound
40	clearance	clearance	NN	_	36	nmod
41	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	14	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	2	nmod
11	has	have	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	studied	study	VBN	_	0	ROOT
15	in	in	IN	_	16	case
16	humans	human	NNS	_	14	nmod
17	.	.	.	_	14	punct

1	Patients	patient	NNS	_	19	nsubjpass
2	who	who	WP	_	4	nsubj
3	are	be	VBP	_	4	aux
4	receiving	receive	VBG	_	1	acl:relcl
5	drug1	drug1	NN	_	4	dobj
6	concurrently	concurrently	RB	_	4	advmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	4	nmod
10	,	,	,	_	9	punct
11	especially	especially	RB	_	12	advmod
12	drugs	drug	NNS	_	9	appos
13	with	with	IN	_	15	case
14	CNS	cns	NN	_	15	compound
15	activity	activity	NN	_	12	nmod
16	,	,	,	_	19	punct
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	monitored	monitor	VBN	_	0	ROOT
20	carefully	carefully	RB	_	19	advmod
21	.	.	.	_	19	punct

1	Decreased	decrease	VBN	_	3	amod
2	seizure	seizure	NN	_	3	compound
3	threshold	threshold	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	6	punct

1	CYP	cyp	NN	_	3	compound
2	3A4	3a4	NN	_	3	compound
3	Inhibitors	inhibitor	NNS	_	14	nsubj
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	e.g.	e.g.	FW	_	6	dep
6	drug1	drug1	NN	_	3	dep
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	-RRB-	-rrb-	-RRB-	_	6	punct
10	There	there	EX	_	14	expl
11	have	have	VBP	_	14	aux
12	been	be	VBN	_	14	cop
13	rare	rare	JJ	_	14	amod
14	reports	report	NNS	_	0	ROOT
15	of	of	IN	_	18	case
16	serious	serious	JJ	_	18	amod
17	adverse	adverse	JJ	_	18	amod
18	events	event	NNS	_	14	nmod
19	in	in	IN	_	20	case
20	connection	connection	NN	_	18	nmod
21	with	with	IN	_	23	case
22	the	the	DT	_	23	det
23	coadministration	coadministration	NN	_	20	nmod
24	of	of	IN	_	26	case
25	certain	certain	JJ	_	26	amod
26	drug3	drug3	NN	_	23	nmod
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	e.g.	e.g.	FW	_	29	dep
29	drug4	drug4	NN	_	26	dep
30	and	and	CC	_	29	cc
31	drug5	drug5	NN	_	29	conj
32	-RRB-	-rrb-	-RRB-	_	29	punct
33	and	and	CC	_	26	cc
34	potent	potent	JJ	_	37	amod
35	CYP	cyp	NN	_	37	compound
36	3A4	3a4	NN	_	37	compound
37	inhibitors	inhibitor	NNS	_	26	conj
38	,	,	,	_	14	punct
39	resulting	result	VBG	_	14	advcl
40	in	in	IN	_	41	case
41	vasospasm	vasospasm	NN	_	39	nmod
42	leading	lead	VBG	_	41	acl
43	to	to	TO	_	45	case
44	cerebral	cerebral	JJ	_	45	amod
45	ischemia	ischemia	NN	_	42	nmod
46	and/or	and/or	CC	_	45	cc
47	ischemia	ischemia	NN	_	45	conj
48	of	of	IN	_	50	case
49	the	the	DT	_	50	det
50	extremities	extremity	NNS	_	45	nmod
51	.	.	.	_	14	punct

1	Although	although	IN	_	6	mark
2	there	there	EX	_	6	expl
3	have	have	VBP	_	6	aux
4	been	be	VBN	_	6	cop
5	no	no	DT	_	6	neg
6	reports	report	NNS	_	0	ROOT
7	of	of	IN	_	9	case
8	such	such	JJ	_	9	amod
9	interactions	interaction	NNS	_	6	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	alone	alone	RB	_	11	advmod
13	,	,	,	_	11	punct
14	potent	potent	JJ	_	17	amod
15	CYP	cyp	NN	_	17	compound
16	3A4	3a4	NN	_	17	compound
17	inhibitors	inhibitor	NNS	_	21	nsubjpass
18	should	should	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	coadministered	coadminister	VBN	_	11	acl:relcl
22	with	with	IN	_	23	case
23	methylergonovine	methylergonovine	NN	_	21	nmod
24	.	.	.	_	6	punct

1	Examples	example	NNS	_	11	nsubj
2	of	of	IN	_	3	case
3	some	some	DT	_	1	nmod
4	of	of	IN	_	10	case
5	the	the	DT	_	10	det
6	more	more	RBR	_	7	advmod
7	potent	potent	JJ	_	10	amod
8	CYP	cyp	NN	_	10	compound
9	3A4	3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	3	nmod
11	include	include	VBP	_	0	ROOT
12	drug1	drug1	NN	_	11	dobj
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	e.g.	e.g.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug2	drug2	NN	_	12	dep
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	appos
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	appos
21	-RRB-	-rrb-	-RRB-	_	16	punct
22	,	,	,	_	12	punct
23	drug5	drug5	NN	_	12	conj
24	or	or	CC	_	12	cc
25	drug6	drug6	NN	_	12	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	e.g.	e.g.	FW	_	29	dep
28	,	,	,	_	29	punct
29	drug7	drug7	NN	_	25	dep
30	,	,	,	_	29	punct
31	drug8	drug8	NN	_	29	conj
32	,	,	,	_	29	punct
33	drug9	drug9	NN	_	29	conj
34	,	,	,	_	29	punct
35	drug10	drug10	NN	_	29	conj
36	-RRB-	-rrb-	-RRB-	_	29	punct
37	or	or	CC	_	12	cc
38	drug11	drug11	NN	_	12	conj
39	-LRB-	-lrb-	-LRB-	_	42	punct
40	e.g.	e.g.	FW	_	42	dep
41	,	,	,	_	42	punct
42	drug12	drug12	NN	_	38	dep
43	,	,	,	_	42	punct
44	drug13	drug13	NN	_	42	appos
45	,	,	,	_	42	punct
46	drug14	drug14	NN	_	42	appos
47	-RRB-	-rrb-	-RRB-	_	42	punct
48	.	.	.	_	11	punct

1	Less	less	RBR	_	5	advmod
2	potent	potent	JJ	_	5	amod
3	CYP	cyp	NN	_	5	compound
4	3A4	3a4	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	administered	administer	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	caution	caution	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Less	less	RBR	_	3	amod
2	potent	potent	JJ	_	3	amod
3	inhibitors	inhibitor	NNS	_	4	nsubj
4	include	include	VBP	_	0	ROOT
5	drug1	drug1	NN	_	4	dobj
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug3	drug3	NN	_	5	conj
10	,	,	,	_	5	punct
11	grapefruit	grapefruit	NN	_	12	compound
12	juice	juice	NN	_	5	conj
13	,	,	,	_	5	punct
14	drug4	drug4	NN	_	5	conj
15	,	,	,	_	5	punct
16	drug5	drug5	NN	_	5	conj
17	,	,	,	_	5	punct
18	drug6	drug6	NN	_	5	conj
19	,	,	,	_	5	punct
20	and	and	CC	_	5	cc
21	drug7	drug7	NN	_	5	conj
22	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	lists	list	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	not	not	RB	_	5	neg
5	exhaustive	exhaustive	JJ	_	0	ROOT
6	,	,	,	_	5	punct
7	and	and	CC	_	5	cc
8	the	the	DT	_	9	det
9	prescriber	prescriber	NN	_	11	nsubj
10	should	should	MD	_	11	aux
11	consider	consider	VB	_	5	conj
12	the	the	DT	_	13	det
13	effects	effect	NNS	_	11	dobj
14	on	on	IN	_	16	case
15	CYP	cyp	NN	_	16	compound
16	3A4	3a4	NN	_	13	nmod
17	of	of	IN	_	19	case
18	other	other	JJ	_	19	amod
19	agents	agent	NNS	_	16	nmod
20	being	be	VBG	_	21	auxpass
21	considered	consider	VBN	_	19	acl
22	for	for	IN	_	24	case
23	concomitant	concomitant	JJ	_	24	amod
24	use	use	NN	_	21	nmod
25	with	with	IN	_	26	case
26	drug1	drug1	NN	_	24	nmod
27	.	.	.	_	5	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	10	nsubjpass
4	involving	involve	VBG	_	3	acl
5	other	other	JJ	_	8	amod
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	isoenzymes	isoenzyme	NNS	_	4	dobj
9	are	be	VBP	_	10	auxpass
10	known	know	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	11	advmod
6	drug1	drug1	NN	_	11	nsubjpass
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug2	drug2	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	is	be	VBZ	_	11	auxpass
11	used	use	VBN	_	4	advcl
12	concurrently	concurrently	RB	_	11	advmod
13	with	with	IN	_	15	case
14	other	other	JJ	_	15	amod
15	drug3	drug3	NN	_	11	nmod
16	or	or	CC	_	15	cc
17	drug4	drug4	NN	_	15	conj
18	.	.	.	_	4	punct

1	To	to	TO	_	2	mark
2	minimize	minimize	VB	_	0	ROOT
3	CNS	cns	NN	_	4	compound
4	depression	depression	NN	_	2	dobj
5	and	and	CC	_	4	cc
6	possible	possible	JJ	_	7	amod
7	potentiation	potentiation	NN	_	4	conj
8	,	,	,	_	7	punct
9	drug1	drug1	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug2	drug2	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug3	drug3	NN	_	7	conj
14	,	,	,	_	7	punct
15	drug4	drug4	NN	_	7	conj
16	or	or	CC	_	7	cc
17	drug5	drug5	NN	_	7	conj
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	used	use	VBN	_	2	dep
21	with	with	IN	_	22	case
22	caution	caution	NN	_	20	nmod
23	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	since	since	IN	_	13	mark
7	there	there	EX	_	13	expl
8	may	may	MD	_	13	aux
9	be	be	VB	_	13	cop
10	an	a	DT	_	13	det
11	Antabuse	antabuse	NN	_	13	compound
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	disulfiram	disulfiram	NN	_	5	advcl
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	-	-	:	_	5	punct
16	like	like	IN	_	17	case
17	reaction	reaction	NN	_	5	nmod
18	.	.	.	_	5	punct

1	Because	because	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	exhibits	exhibit	VBZ	_	45	advcl
4	some	some	DT	_	8	det
5	monoamine	monoamine	NN	_	8	compound
6	oxidase	oxidase	NN	_	8	compound
7	inhibitory	inhibitory	JJ	_	8	amod
8	activity	activity	NN	_	3	dobj
9	,	,	,	_	45	punct
10	drug2	drug2	NN	_	45	dep
11	,	,	,	_	45	punct
12	drug3	drug3	NN	_	13	compound
13	drugs	drug	NNS	_	45	nsubjpass
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	e.g.	e.g.	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug4	drug4	NN	_	13	dep
18	,	,	,	_	17	punct
19	drug5	drug5	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	and	and	CC	_	13	cc
22	other	other	JJ	_	23	amod
23	drugs	drug	NNS	_	13	conj
24	and	and	CC	_	23	cc
25	foods	food	NNS	_	23	conj
26	with	with	IN	_	30	case
27	known	known	JJ	_	30	amod
28	high	high	JJ	_	30	amod
29	drug6	drug6	NN	_	30	compound
30	content	content	NN	_	23	nmod
31	,	,	,	_	13	punct
32	such	such	JJ	_	34	case
33	as	as	IN	_	32	mwe
34	wine	wine	NN	_	13	nmod
35	,	,	,	_	34	punct
36	yogurt	yogurt	NN	_	34	conj
37	,	,	,	_	34	punct
38	ripe	ripe	JJ	_	39	amod
39	cheese	cheese	NN	_	34	conj
40	and	and	CC	_	34	cc
41	bananas	banana	NNS	_	34	conj
42	,	,	,	_	13	punct
43	should	should	MD	_	45	aux
44	be	be	VB	_	45	auxpass
45	avoided	avoid	VBN	_	0	ROOT
46	.	.	.	_	45	punct

1	A	a	DT	_	3	det
2	further	further	JJ	_	3	amod
3	phenomenon	phenomenon	NN	_	11	nsubj
4	of	of	IN	_	5	case
5	toxicity	toxicity	NN	_	3	nmod
6	common	common	JJ	_	5	amod
7	to	to	TO	_	9	case
8	many	many	JJ	_	9	amod
9	drug1	drug1	NN	_	6	nmod
10	is	be	VBZ	_	11	cop
11	hemolysis	hemolysis	NN	_	0	ROOT
12	and	and	CC	_	11	cc
13	the	the	DT	_	14	det
14	appearance	appearance	NN	_	11	conj
15	of	of	IN	_	18	case
16	Heinz-Ehrlich	heinz-ehrlich	JJ	_	18	amod
17	inclusion	inclusion	NN	_	18	compound
18	bodies	body	NNS	_	14	nmod
19	in	in	IN	_	20	case
20	erythrocytes	erythrocyte	NNS	_	14	nmod
21	.	.	.	_	11	punct

1	No	no	DT	_	2	neg
2	cross-resistance	cross-resistance	NN	_	12	nsubjpass
3	with	with	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	5	punct
7	radiotherapy	radiotherapy	NN	_	5	conj
8	or	or	CC	_	5	cc
9	drug2	drug2	NN	_	5	conj
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	demonstrated	demonstrate	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	nsubj
2	are	be	VBP	_	3	cop
3	capable	capable	JJ	_	0	ROOT
4	of	of	IN	_	5	mark
5	potentiating	potentiate	VBG	_	3	advcl
6	drug2	drug2	NN	_	5	dobj
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	e.g.	e.g.	FW	_	10	dep
9	,	,	,	_	10	punct
10	drug3	drug3	NN	_	6	dep
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug6	drug6	NN	_	10	conj
17	,	,	,	_	10	punct
18	etc.	etc.	FW	_	10	dep
19	-RRB-	-rrb-	-RRB-	_	10	punct

1	as	as	RB	_	4	cc
2	well	well	RB	_	1	mwe
3	as	as	IN	_	1	mwe
4	drug1	drug1	NN	_	0	ROOT
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	15	nsubjpass
2	affecting	affect	VBG	_	1	acl
3	pituitary	pituitary	JJ	_	6	amod
4	or	or	CC	_	3	cc
5	adrenocortical	adrenocortical	JJ	_	3	conj
6	function	function	NN	_	2	dobj
7	,	,	,	_	1	punct
8	including	include	VBG	_	11	case
9	all	all	DT	_	11	det
10	corticosteroid	corticosteroid	NN	_	11	compound
11	therapy	therapy	NN	_	1	nmod
12	,	,	,	_	1	punct
13	must	must	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	discontinued	discontinue	VBN	_	0	ROOT
16	prior	prior	RB	_	20	advmod
17	to	to	TO	_	20	case
18	and	and	CC	_	17	cc
19	during	during	IN	_	17	conj
20	testing	testing	NN	_	15	nmod
21	with	with	IN	_	22	case
22	drug1	drug1	NN	_	20	nmod
23	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	metabolism	metabolism	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	accelerated	accelerate	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	;	;	:	_	6	punct

1	therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	results	result	NNS	_	9	nsubj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	test	test	NN	_	3	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	cop
9	inaccurate	inaccurate	JJ	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	taking	take	VBG	_	11	acl
13	drug1	drug1	NN	_	12	dobj
14	within	within	IN	_	16	case
15	two	two	CD	_	16	nummod
16	weeks	week	NNS	_	12	nmod
17	before	before	RB	_	16	advmod
18	.	.	.	_	9	punct

1	Asubnormal	asubnormal	JJ	_	2	amod
2	response	response	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	occur	occur	VB	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	on	on	IN	_	9	case
8	estrogen	estrogen	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod
10	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	glucuronidation	glucuronidation	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	2	cc
8	could	could	MD	_	10	aux
9	possibly	possibly	RB	_	10	advmod
10	potentiate	potentiate	VB	_	2	conj
11	drug3	drug3	NN	_	12	compound
12	toxicity	toxicity	NN	_	10	dobj
13	.	.	.	_	2	punct

1	Preliminary	preliminary	JJ	_	2	amod
2	evidence	evidence	NN	_	3	nsubj
3	suggests	suggest	VBZ	_	0	ROOT
4	that	that	IN	_	6	mark
5	drug1	drug1	NN	_	6	nsubj
6	inhibits	inhibit	VBZ	_	3	ccomp
7	drug2	drug2	NN	_	8	compound
8	metabolism	metabolism	NN	_	6	dobj
9	and	and	CC	_	6	cc
10	may	may	MD	_	11	aux
11	result	result	VB	_	6	conj
12	in	in	IN	_	14	case
13	an	a	DT	_	14	det
14	increase	increase	NN	_	11	nmod
15	in	in	IN	_	17	case
16	plasma	plasma	NN	_	17	compound
17	concentrations	concentration	NNS	_	14	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	through	through	IN	_	8	case
5	the	the	DT	_	8	det
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	system	system	NN	_	3	nmod
9	,	,	,	_	3	punct
10	primarily	primarily	RB	_	15	advmod
11	the	the	DT	_	15	det
12	CYP2C19	cyp2c19	NN	_	15	compound
13	and	and	CC	_	12	cc
14	CYP3A4	cyp3a4	NN	_	12	conj
15	isozymes	isozyme	NNS	_	3	dep
16	,	,	,	_	15	punct
17	and	and	CC	_	15	cc
18	subsequently	subsequently	RB	_	19	advmod
19	undergoes	undergo	VBZ	_	15	conj
20	Phase	phase	NN	_	22	compound
21	II	ii	CD	_	22	nummod
22	conjugation	conjugation	NN	_	19	dobj
23	.	.	.	_	3	punct

1	Based	base	VBN	_	3	case
2	on	on	IN	_	3	case
3	studies	study	NNS	_	17	advcl
4	evaluating	evaluate	VBG	_	3	acl
5	possible	possible	JJ	_	6	amod
6	interactions	interaction	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	with	with	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	6	nmod
12	,	,	,	_	17	punct
13	no	no	DT	_	15	neg
14	dosage	dosage	NN	_	15	compound
15	adjustment	adjustment	NN	_	17	nsubjpass
16	is	be	VBZ	_	17	auxpass
17	needed	need	VBN	_	0	ROOT
18	with	with	IN	_	20	case
19	concomitant	concomitant	JJ	_	20	amod
20	use	use	NN	_	17	nmod
21	of	of	IN	_	23	case
22	the	the	DT	_	23	det
23	following	following	NN	_	20	nmod
24	:	:	:	_	17	punct
25	drug2	drug2	NN	_	17	dep
26	,	,	,	_	25	punct
27	drug3	drug3	NN	_	25	conj
28	,	,	,	_	25	punct
29	drug4	drug4	NN	_	25	conj
30	,	,	,	_	25	punct
31	drug5	drug5	NN	_	25	conj
32	,	,	,	_	25	punct
33	drug6	drug6	NN	_	25	conj
34	,	,	,	_	25	punct
35	drug7	drug7	NN	_	25	conj
36	-LRB-	-lrb-	-LRB-	_	40	punct
37	and	and	CC	_	40	cc
38	its	its	PRP$	_	40	nmod:poss
39	active	active	JJ	_	40	amod
40	metabolite	metabolite	NN	_	35	dep
41	,	,	,	_	40	punct
42	drug8	drug8	NN	_	40	appos
43	-RRB-	-rrb-	-RRB-	_	40	punct
44	,	,	,	_	25	punct
45	drug9	drug9	NN	_	25	conj
46	,	,	,	_	25	punct
47	drug10	drug10	NN	_	25	conj
48	,	,	,	_	25	punct
49	drug11	drug11	NN	_	25	conj
50	,	,	,	_	25	punct
51	drug12	drug12	NN	_	25	conj
52	,	,	,	_	25	punct
53	drug13	drug13	NN	_	25	conj
54	,	,	,	_	25	punct
55	drug14	drug14	NN	_	25	conj
56	,	,	,	_	25	punct
57	an	a	DT	_	59	det
58	oral	oral	JJ	_	59	amod
59	drug15	drug15	NN	_	25	conj
60	-LRB-	-lrb-	-LRB-	_	61	punct
61	drug16	drug16	NN	_	59	appos
62	/	/	:	_	61	punct
63	drug17	drug17	NN	_	61	dep
64	-RRB-	-rrb-	-RRB-	_	61	punct
65	,	,	,	_	25	punct
66	drug18	drug18	NN	_	25	conj
67	,	,	,	_	25	punct
68	drug19	drug19	NN	_	25	conj
69	,	,	,	_	25	punct
70	drug20	drug20	NN	_	25	conj
71	,	,	,	_	25	punct
72	drug21	drug21	NN	_	25	conj
73	,	,	,	_	25	punct
74	drug22	drug22	NN	_	25	conj
75	,	,	,	_	25	punct
76	drug23	drug23	NN	_	25	conj
77	,	,	,	_	25	punct
78	drug24	drug24	NN	_	25	conj
79	,	,	,	_	25	punct
80	or	or	CC	_	25	cc
81	drug25	drug25	NN	_	25	conj
82	.	.	.	_	17	punct

1	Clinically	clinically	RB	_	2	advmod
2	relevant	relevant	JJ	_	3	amod
3	interactions	interaction	NNS	_	16	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	3	nmod
9	with	with	IN	_	13	case
10	the	the	DT	_	13	det
11	same	same	JJ	_	13	amod
12	metabolic	metabolic	JJ	_	13	amod
13	pathways	pathway	NNS	_	8	nmod
14	are	be	VBP	_	16	auxpass
15	not	not	RB	_	16	neg
16	expected	expect	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	21	advmod
2	,	,	,	_	21	punct
3	when	when	WRB	_	4	advmod
4	coadministered	coadminister	VBN	_	21	advcl
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	21	punct
8	adjustment	adjustment	NN	_	21	nsubj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	dosage	dosage	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	of	of	IN	_	17	case
16	such	such	JJ	_	17	amod
17	drugs	drug	NNS	_	13	conj
18	may	may	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	cop
21	necessary	necessary	JJ	_	0	ROOT
22	.	.	.	_	21	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	also	also	RB	_	2	advmod
4	no	no	DT	_	5	neg
5	interaction	interaction	NN	_	2	nsubj
6	with	with	IN	_	9	case
7	concomitantly	concomitantly	RB	_	8	advmod
8	administered	administer	VBN	_	9	amod
9	drug1	drug1	NN	_	5	nmod
10	.	.	.	_	2	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	aux
4	postmarketing	postmarket	VBG	_	0	ROOT
5	reports	report	NNS	_	4	dobj
6	of	of	IN	_	8	case
7	increased	increase	VBN	_	8	amod
8	INR	inr	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	prothrombin	prothrombin	NN	_	8	conj
11	time	time	NN	_	8	dep
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	8	nmod
14	receiving	receive	VBG	_	13	acl
15	drug1	drug1	NN	_	14	dobj
16	,	,	,	_	13	punct
17	including	include	VBG	_	18	case
18	drug2	drug2	NN	_	13	nmod
19	,	,	,	_	13	punct
20	and	and	CC	_	13	cc
21	drug3	drug3	NN	_	13	conj
22	concomitantly	concomitantly	RB	_	21	advmod
23	.	.	.	_	4	punct

1	Increases	increase	NNS	_	0	ROOT
2	in	in	IN	_	3	case
3	INR	inr	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	prothrombin	prothrombin	NN	_	3	conj
6	time	time	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	lead	lead	VB	_	1	acl:relcl
9	to	to	TO	_	11	case
10	abnormal	abnormal	JJ	_	11	amod
11	bleeding	bleeding	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	even	even	RB	_	14	advmod
14	death	death	NN	_	11	conj
15	.	.	.	_	1	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	concomitantly	concomitantly	RB	_	10	advmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	monitored	monitor	VBN	_	0	ROOT
11	for	for	IN	_	12	case
12	increases	increase	NNS	_	10	nmod
13	in	in	IN	_	14	case
14	INR	inr	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	prothrombin	prothrombin	NN	_	17	compound
17	time	time	NN	_	14	conj
18	.	.	.	_	10	punct

1	Because	because	IN	_	7	case
2	of	of	IN	_	1	mwe
3	profound	profound	JJ	_	7	amod
4	and	and	CC	_	3	cc
5	long	long	JJ	_	3	conj
6	lasting	lasting	JJ	_	7	amod
7	inhibition	inhibition	NN	_	15	nmod
8	of	of	IN	_	11	case
9	gastric	gastric	JJ	_	11	amod
10	acid	acid	NN	_	11	compound
11	secretion	secretion	NN	_	7	nmod
12	,	,	,	_	15	punct
13	drug1	drug1	NN	_	15	nsubj
14	may	may	MD	_	15	aux
15	interfere	interfere	VB	_	0	ROOT
16	with	with	IN	_	17	case
17	absorption	absorption	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drugs	drug	NNS	_	17	nmod
20	where	where	WRB	_	26	advmod
21	gastric	gastric	JJ	_	22	amod
22	pH	ph	NN	_	26	nsubj
23	is	be	VBZ	_	26	cop
24	an	a	DT	_	26	det
25	important	important	JJ	_	26	amod
26	determinant	determinant	NN	_	19	acl:relcl
27	of	of	IN	_	29	case
28	their	they	PRP$	_	29	nmod:poss
29	bioavailability	bioavailability	NN	_	26	nmod
30	-LRB-	-lrb-	-LRB-	_	33	punct
31	eg	eg	FW	_	33	compound
32	,	,	,	_	33	punct
33	drug2	drug2	NN	_	15	dep
34	,	,	,	_	33	punct
35	drug3	drug3	NN	_	36	compound
36	esters	ester	NNS	_	33	conj
37	,	,	,	_	33	punct
38	and	and	CC	_	33	cc
39	drug4	drug4	NN	_	40	compound
40	salts	salt	NNS	_	33	conj
41	-RRB-	-rrb-	-RRB-	_	33	punct
42	.	.	.	_	15	punct

1	Laboratory	Laboratory	NNP	_	2	compound
2	Tests	Tests	NNP	_	6	nsubj
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	0	ROOT
7	of	of	IN	_	11	case
8	false-positive	false-positive	JJ	_	11	amod
9	urine	urine	NN	_	11	compound
10	screening	screening	NN	_	11	compound
11	tests	test	NNS	_	6	nmod
12	for	for	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug2	drug2	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	13	nmod
19	receiving	receive	VBG	_	18	acl
20	most	most	RBS	_	21	advmod
21	drug3	drug3	RB	_	19	advmod
22	,	,	,	_	18	punct
23	including	include	VBG	_	24	case
24	drug4	drug4	NN	_	18	nmod
25	.	.	.	_	6	punct

1	An	a	DT	_	4	det
2	alternative	alternative	JJ	_	4	amod
3	confirmatory	confirmatory	JJ	_	4	amod
4	method	method	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	considered	consider	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	verify	verify	VB	_	7	xcomp
10	positive	positive	JJ	_	11	amod
11	results	result	NNS	_	9	dobj
12	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug4	drug4	NN	_	7	conj
13	.	.	.	_	3	punct

1	It	it	PRP	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	increased	increase	VBN	_	9	amod
9	thrombocytopenia	thrombocytopenia	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	6	punct
12	drug2	drug2	NN	_	6	conj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	increased	increase	VBN	_	15	amod
15	nephrotoxicity	nephrotoxicity	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	6	punct
18	drug3	drug3	NN	_	6	conj
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	increased	increase	VBN	_	22	amod
21	hypoglycemic	hypoglycemic	JJ	_	22	amod
22	response	response	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	6	punct
25	drug4	drug4	NN	_	6	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	increased	increase	VBN	_	29	amod
28	anticoagulant	anticoagulant	JJ	_	29	amod
29	effect	effect	NN	_	25	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	6	punct
32	drug5	drug5	NN	_	6	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	decreased	decrease	VBN	_	36	amod
35	renal	renal	JJ	_	36	amod
36	excretion	excretion	NN	_	32	dep
37	of	of	IN	_	38	case
38	drug6	drug6	NN	_	36	nmod
39	-RRB-	-rrb-	-RRB-	_	36	punct
40	,	,	,	_	6	punct
41	drug7	drug7	NN	_	6	conj
42	-LRB-	-lrb-	-LRB-	_	45	punct
43	decreased	decrease	VBN	_	45	amod
44	hepatic	hepatic	JJ	_	45	amod
45	clearance	clearance	NN	_	41	dep
46	of	of	IN	_	47	case
47	drug8	drug8	NN	_	45	nmod
48	-RRB-	-rrb-	-RRB-	_	45	punct
49	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	compete	compete	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	nmod
7	,	,	,	_	6	punct
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug2	drug2	NN	_	6	nmod
11	,	,	,	_	6	punct
12	for	for	IN	_	13	case
13	sites	site	NNS	_	6	nmod
14	of	of	IN	_	15	case
15	metabolism	metabolism	NN	_	13	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	liver	liver	NN	_	13	nmod
19	,	,	,	_	6	punct
20	thus	thus	RB	_	21	advmod
21	elevating	elevate	VBG	_	6	acl
22	the	the	DT	_	24	det
23	serum	serum	NN	_	24	compound
24	levels	level	NNS	_	21	dobj
25	of	of	IN	_	27	case
26	such	such	JJ	_	27	amod
27	compounds	compound	NNS	_	24	nmod
28	to	to	TO	_	31	case
29	potentially	potentially	RB	_	30	advmod
30	toxic	toxic	JJ	_	31	amod
31	levels	level	NNS	_	21	nmod
32	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	when	when	WRB	_	11	advmod
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	11	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	is	be	VBZ	_	11	auxpass
11	anticipated	anticipate	VBN	_	16	advcl
12	,	,	,	_	16	punct
13	it	it	PRP	_	16	nsubj
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	cop
16	necessary	necessary	JJ	_	0	ROOT
17	to	to	TO	_	18	mark
18	monitor	monitor	VB	_	16	ccomp
19	blood	blood	NN	_	20	compound
20	levels	level	NNS	_	18	dobj
21	and/or	and/or	CC	_	18	cc
22	reduce	reduce	VB	_	18	conj
23	the	the	DT	_	24	det
24	dosage	dosage	NN	_	22	dobj
25	of	of	IN	_	27	case
26	such	such	JJ	_	27	amod
27	compounds	compound	NNS	_	24	nmod
28	.	.	.	_	16	punct

1	Such	such	JJ	_	3	amod
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	administered	administer	VBN	_	0	ROOT
7	under	under	IN	_	10	case
8	careful	careful	JJ	_	10	amod
9	medical	medical	JJ	_	10	amod
10	supervision	supervision	NN	_	6	nmod
11	.	.	.	_	6	punct

1	Administration	administration	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	decreases	decrease	VBZ	_	0	ROOT
5	oral	oral	JJ	_	6	amod
6	clearance	clearance	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	by	by	IN	_	12	case
10	about	about	IN	_	11	advmod
11	5	5	CD	_	12	nummod
12	%	%	NN	_	4	nmod
13	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	implication	implication	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	effect	effect	NN	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	with	with	IN	_	4	case
3	Severe	severe	JJ	_	4	amod
4	Hepatic	hepatic	JJ	_	1	nmod
5	or	or	CC	_	4	cc
6	Renal	renal	JJ	_	4	conj
7	Impairment	impairment	NN	_	8	compound
8	Caution	caution	NN	_	4	dep
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	exercised	exercise	VBN	_	0	ROOT
12	when	when	WRB	_	16	advmod
13	drug1	drug1	NN	_	14	compound
14	Capsules	capsule	NNS	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	administered	administer	VBN	_	11	advcl
17	to	to	TO	_	18	case
18	patients	patient	NNS	_	16	nmod
19	with	with	IN	_	21	case
20	severe	severe	JJ	_	21	amod
21	hepatic	hepatic	JJ	_	18	nmod
22	or	or	CC	_	21	cc
23	renal	renal	JJ	_	24	amod
24	impairment	impairment	NN	_	21	conj
25	.	.	.	_	11	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	show	show	VBP	_	0	ROOT
4	that	that	IN	_	6	mark
5	there	there	EX	_	6	expl
6	are	be	VBP	_	3	ccomp
7	no	no	DT	_	9	neg
8	significant	significant	JJ	_	9	amod
9	alterations	alteration	NNS	_	6	nsubj
10	in	in	IN	_	12	case
11	pharmacokinetic	pharmacokinetic	JJ	_	12	amod
12	parameters	parameter	NNS	_	9	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	to	to	TO	_	18	mark
18	warrant	warrant	VB	_	9	acl
19	dosage	dosage	NN	_	20	compound
20	adjustment	adjustment	NN	_	18	dobj
21	when	when	WRB	_	24	advmod
22	drug3	drug3	NN	_	24	nsubjpass
23	is	be	VBZ	_	24	auxpass
24	administered	administer	VBN	_	18	advcl
25	with	with	IN	_	27	case
26	these	these	DT	_	27	det
27	drugs	drug	NNS	_	24	nmod
28	.	.	.	_	3	punct

1	A	a	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	demonstrated	demonstrate	VBD	_	0	ROOT
5	that	that	IN	_	11	mark
6	coadministration	coadministration	NN	_	11	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	results	result	NNS	_	4	ccomp
12	in	in	IN	_	15	case
13	a	a	DT	_	15	det
14	significant	significant	JJ	_	15	amod
15	decrease	decrease	NN	_	11	nmod
16	in	in	IN	_	19	case
17	the	the	DT	_	19	det
18	pharmacokinetic	pharmacokinetic	JJ	_	19	amod
19	parameters	parameter	NNS	_	15	nmod
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	~	~	CD	_	22	compound
22	36	36	CD	_	23	nummod
23	%	%	NN	_	15	dep
24	for	for	IN	_	25	case
25	Cmax	cmax	NN	_	23	nmod
26	and	and	CC	_	23	cc
27	~	~	NN	_	29	compound
28	28	28	CD	_	29	nummod
29	%	%	NN	_	23	conj
30	for	for	IN	_	31	case
31	AUC	auc	NN	_	29	nmod
32	-RRB-	-rrb-	-RRB-	_	23	punct
33	of	of	IN	_	34	case
34	drug3	drug3	NN	_	15	nmod
35	.	.	.	_	4	punct

1	Administration	administration	NN	_	10	nsubjpass
2	of	of	IN	_	5	case
3	a	a	DT	_	5	det
4	higher	higher	JJR	_	5	amod
5	dose	dose	NN	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	when	when	WRB	_	12	advmod
12	coadministering	coadminister	VBG	_	10	advcl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	16	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	or	or	CC	_	4	cc
8	drug3	drug3	NN	_	4	conj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
12	of	of	IN	_	13	case
13	drug4	drug4	NN	_	11	nmod
14	were	be	VBD	_	16	auxpass
15	not	not	RB	_	16	neg
16	studied	study	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	particularly	particularly	RB	_	4	advmod
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	cause	cause	VB	_	0	ROOT
8	serious	serious	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	arrhythmias	arrhythmia	NNS	_	7	dobj
11	during	during	IN	_	13	case
12	drug3	drug3	NN	_	13	compound
13	anesthesia	anesthesia	NN	_	7	nmod
14	and	and	CC	_	7	cc
15	therefore	therefore	RB	_	18	advmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	7	conj
19	only	only	RB	_	22	advmod
20	with	with	IN	_	22	case
21	great	great	JJ	_	22	amod
22	caution	caution	NN	_	18	nmod
23	or	or	CC	_	22	cc
24	not	not	RB	_	26	neg
25	at	at	IN	_	26	case
26	all	all	DT	_	22	conj
27	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	The	the	DT	_	5	det
4	pressor	pressor	NN	_	5	compound
5	effect	effect	NN	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	is	be	VBZ	_	10	auxpass
9	markedly	markedly	RB	_	10	advmod
10	potentiated	potentiate	VBN	_	1	dep
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	drug3	drug3	NN	_	13	dobj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug4	drug4	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	when	when	WRB	_	4	advmod
4	initiating	initiate	VBG	_	16	advcl
5	pressor	pressor	NN	_	6	compound
6	therapy	therapy	NN	_	4	dobj
7	in	in	IN	_	9	case
8	these	these	DT	_	9	det
9	patients	patient	NNS	_	6	nmod
10	,	,	,	_	16	punct
11	the	the	DT	_	13	det
12	initial	initial	JJ	_	13	amod
13	dose	dose	NN	_	16	nsubj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	cop
16	small	small	JJ	_	0	ROOT
17	and	and	CC	_	16	cc
18	used	use	VBN	_	16	conj
19	with	with	IN	_	21	case
20	due	due	JJ	_	21	amod
21	caution	caution	NN	_	18	nmod
22	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	pressor	pressor	NN	_	3	compound
3	response	response	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	9	aux
7	also	also	RB	_	9	advmod
8	be	be	VB	_	9	auxpass
9	potentiated	potentiate	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	CNS-depressant	cns-depressant	JJ	_	3	amod
3	effect	effect	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	cop
7	additive	additive	JJ	_	0	ROOT
8	with	with	IN	_	9	case
9	that	that	DT	_	7	nmod
10	of	of	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drug2	drug2	NN	_	9	nmod
13	,	,	,	_	12	punct
14	including	include	VBG	_	15	case
15	drug3	drug3	NN	_	12	nmod
16	.	.	.	_	7	punct

1	As	as	IN	_	4	mark
2	is	be	VBZ	_	4	cop
3	the	the	DT	_	4	det
4	case	case	NN	_	12	advcl
5	with	with	IN	_	8	case
6	many	many	JJ	_	8	amod
7	medicinal	medicinal	JJ	_	8	amod
8	agents	agent	NNS	_	4	nmod
9	,	,	,	_	12	punct
10	drug1	drug1	NN	_	12	nsubj
11	may	may	MD	_	12	aux
12	slow	slow	VB	_	0	ROOT
13	the	the	DT	_	14	det
14	metabolism	metabolism	NN	_	12	dobj
15	of	of	IN	_	19	case
16	a	a	DT	_	19	det
17	concomitantly	concomitantly	RB	_	18	advmod
18	administered	administer	VBN	_	19	amod
19	drug	drug	NN	_	14	nmod
20	.	.	.	_	12	punct

1	Should	should	MD	_	3	aux
2	this	this	DT	_	3	nsubj
3	occur	occur	VB	_	0	ROOT
4	,	,	,	_	3	punct
5	the	the	DT	_	8	det
6	higher	higher	JJR	_	8	amod
7	serum	serum	NN	_	8	compound
8	concentrations	concentration	NNS	_	13	nsubj
9	of	of	IN	_	11	case
10	that	that	DT	_	11	det
11	drug	drug	NN	_	8	nmod
12	may	may	MD	_	13	aux
13	result	result	VB	_	3	ccomp
14	in	in	IN	_	19	case
15	increased	increase	VBN	_	19	amod
16	pharmacologic	pharmacologic	JJ	_	19	amod
17	or	or	CC	_	16	cc
18	adverse	adverse	JJ	_	16	conj
19	effects	effect	NNS	_	13	nmod
20	of	of	IN	_	22	case
21	that	that	DT	_	22	det
22	drug	drug	NN	_	19	nmod
23	.	.	.	_	3	punct

1	Such	such	JJ	_	2	amod
2	occurrences	occurrence	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	when	when	WRB	_	9	advmod
7	drug1	drug1	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	administered	administer	VBN	_	5	advcl
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	9	nmod
12	on	on	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	or	or	CC	_	13	cc
18	drug4	drug4	NN	_	13	conj
19	-	-	:	_	9	punct
20	like	like	IN	_	21	case
21	drugs	drug	NNS	_	9	nmod
22	.	.	.	_	5	punct

1	Sever	sever	VB	_	0	ROOT
2	neurologic	neurologic	JJ	_	3	amod
3	signs	sign	NNS	_	9	nsubj
4	,	,	,	_	3	punct
5	including	include	VBG	_	6	case
6	coma	coma	NN	_	3	nmod
7	,	,	,	_	3	punct
8	have	have	VBP	_	9	aux
9	occurred	occur	VBN	_	1	ccomp
10	with	with	IN	_	12	case
11	concurrent	concurrent	JJ	_	12	amod
12	use	use	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	.	.	.	_	1	punct

1	Reduced	reduce	VBN	_	2	amod
2	absorption	absorption	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	when	when	WRB	_	14	advmod
11	those	those	DT	_	12	det
12	agents	agent	NNS	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	administered	administer	VBN	_	9	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	14	nmod
18	.	.	.	_	9	punct

1	When	when	WRB	_	16	advmod
2	daily	daily	JJ	_	3	amod
3	doses	dose	NNS	_	16	nsubjpass
4	of	of	IN	_	7	case
5	drug1	drug1	NN	_	7	compound
6	2	2	CD	_	7	nummod
7	g	g	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	weekly	weekly	JJ	_	10	amod
10	doses	dose	NNS	_	7	conj
11	of	of	IN	_	14	case
12	drug2	drug2	NN	_	14	compound
13	7.5	7.5	CD	_	14	nummod
14	mg	mg	NN	_	10	nmod
15	were	be	VBD	_	16	auxpass
16	coadministered	coadminister	VBN	_	36	advcl
17	to	to	TO	_	21	case
18	15	15	CD	_	21	nummod
19	rheumatoid	rheumatoid	JJ	_	21	amod
20	arthritis	arthritis	NN	_	21	compound
21	patients	patient	NNS	_	16	nmod
22	in	in	IN	_	26	case
23	a	a	DT	_	26	det
24	drug-drug	drug-drug	JJ	_	26	amod
25	interaction	interaction	NN	_	26	compound
26	study	study	NN	_	21	nmod
27	,	,	,	_	36	punct
28	the	the	DT	_	30	det
29	pharmacokinetic	pharmacokinetic	JJ	_	30	amod
30	disposition	disposition	NN	_	36	nsubjpass
31	of	of	IN	_	33	case
32	the	the	DT	_	33	det
33	drugs	drug	NNS	_	30	nmod
34	was	be	VBD	_	36	auxpass
35	not	not	RB	_	36	neg
36	altered	alter	VBN	_	0	ROOT
37	.	.	.	_	36	punct

1	Daily	Daily	NNP	_	2	compound
2	doses	dose	NNS	_	25	nsubjpass
3	of	of	IN	_	6	case
4	drug1	drug1	NN	_	6	compound
5	2	2	CD	_	6	nummod
6	g	g	NN	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	maximum	maximum	NN	_	10	compound
9	3	3	CD	_	10	nummod
10	g	g	NN	_	6	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	and	and	CC	_	6	cc
13	weekly	weekly	JJ	_	14	amod
14	doses	dose	NNS	_	6	conj
15	of	of	IN	_	18	case
16	drug2	drug2	NN	_	18	compound
17	7.5	7.5	CD	_	18	nummod
18	mg	mg	NN	_	14	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	maximum	maximum	NN	_	22	compound
21	15	15	CD	_	22	nummod
22	mg	mg	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	were	be	VBD	_	25	auxpass
25	administered	administer	VBN	_	0	ROOT
26	alone	alone	RB	_	25	advmod
27	or	or	CC	_	25	cc
28	in	in	IN	_	29	case
29	combination	combination	NN	_	25	conj
30	to	to	TO	_	34	case
31	310	310	CD	_	34	nummod
32	rheumatoid	rheumatoid	JJ	_	34	amod
33	arthritis	arthritis	NN	_	34	compound
34	patients	patient	NNS	_	29	nmod
35	in	in	IN	_	40	case
36	two	two	CD	_	40	nummod
37	controlled	controlled	JJ	_	40	amod
38	52-week	52-week	JJ	_	40	amod
39	clinical	clinical	JJ	_	40	amod
40	studies	study	NNS	_	34	nmod
41	.	.	.	_	25	punct

1	The	the	DT	_	4	det
2	overall	overall	JJ	_	4	amod
3	toxicity	toxicity	NN	_	4	compound
4	profile	profile	NN	_	8	nsubj
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	combination	combination	NN	_	4	nmod
8	revealed	reveal	VBD	_	0	ROOT
9	an	a	DT	_	11	det
10	increased	increase	VBN	_	11	amod
11	incidence	incidence	NN	_	8	dobj
12	of	of	IN	_	15	case
13	gastrointestinal	gastrointestinal	JJ	_	15	amod
14	adverse	adverse	JJ	_	15	amod
15	events	event	NNS	_	11	nmod
16	,	,	,	_	15	punct
17	especially	especially	RB	_	18	advmod
18	nausea	nausea	NN	_	15	appos
19	,	,	,	_	15	punct
20	when	when	WRB	_	21	advmod
21	compared	compare	VBN	_	8	advcl
22	to	to	TO	_	24	case
23	the	the	DT	_	24	det
24	incidence	incidence	NN	_	21	nmod
25	associated	associate	VBN	_	24	acl
26	with	with	IN	_	28	case
27	either	either	CC	_	28	det
28	drug	drug	NN	_	25	nmod
29	administered	administer	VBN	_	28	acl
30	alone	alone	RB	_	29	advmod
31	.	.	.	_	8	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	The	the	DT	_	6	det
6	presence	presence	NN	_	18	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	its	its	PRP$	_	11	nmod:poss
11	metabolites	metabolite	NNS	_	8	conj
12	in	in	IN	_	14	case
13	body	body	NN	_	14	compound
14	fluids	fluid	NNS	_	6	nmod
15	has	have	VBZ	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	3	appos
19	to	to	TO	_	20	mark
20	interfere	interfere	VB	_	18	xcomp
21	with	with	IN	_	24	case
22	laboratory	laboratory	NN	_	24	compound
23	test	test	NN	_	24	compound
24	procedures	procedure	NNS	_	20	nmod
25	.	.	.	_	3	punct

1	REFERENCES	reference	NNS	_	0	ROOT
2	7	7	CD	_	1	nummod
3	.	.	.	_	1	punct
4	Farr	Farr	NNP	_	5	compound
5	M	m	NN	_	1	dep
6	,	,	,	_	5	punct
7	et	et	FW	_	8	compound
8	al.	al.	FW	_	5	appos
9	.	.	.	_	1	punct

1	Immunodeficiencies	immunodeficiency	NNS	_	0	ROOT
2	associated	associate	VBN	_	1	acl
3	with	with	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	therapy	therapy	NN	_	2	nmod
6	in	in	IN	_	8	case
7	inflammatory	inflammatory	JJ	_	8	amod
8	arthritis	arthritis	NN	_	5	nmod
9	.	.	.	_	1	punct

1	British	british	JJ	_	3	amod
2	Jnl	jnl	NN	_	3	compound
3	Rheum	Rheum	NNP	_	0	ROOT
4	1991	1991	CD	_	3	nummod
5	;	;	:	_	3	punct
6	30:413	30:413	CD	_	7	compound
7	-417	-417	CD	_	3	dep
8	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	4	expl
4	was	be	VBD	_	1	dep
5	a	a	DT	_	7	det
6	slight	slight	JJ	_	7	amod
7	increase	increase	NN	_	4	nsubj
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	area	area	NN	_	7	nmod
11	under	under	IN	_	13	case
12	the	the	DT	_	13	det
13	curve	curve	NN	_	7	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	AUC	auc	NN	_	13	dep
16	,	,	,	_	15	punct
17	11	11	CD	_	18	nummod
18	%	%	NN	_	15	appos
19	-RRB-	-rrb-	-RRB-	_	15	punct
20	and	and	CC	_	4	cc
21	mean	mean	VB	_	4	conj
22	peak	peak	JJ	_	24	amod
23	drug	drug	NN	_	24	compound
24	concentration	concentration	NN	_	21	dobj
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	Cmax	cmax	NN	_	24	dep
27	,	,	,	_	26	punct
28	18	18	CD	_	29	nummod
29	%	%	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	26	punct
31	of	of	IN	_	32	case
32	drug2	drug2	NN	_	24	nmod
33	with	with	IN	_	35	case
34	the	the	DT	_	35	det
35	co-administration	co-administration	NN	_	32	nmod
36	of	of	IN	_	39	case
37	100	100	CD	_	38	compound
38	mg	mg	NN	_	39	amod
39	drug3	drug3	NN	_	35	nmod
40	for	for	IN	_	42	case
41	10	10	CD	_	42	nummod
42	days	day	NNS	_	21	nmod
43	.	.	.	_	1	punct

1	Patients	patient	NNS	_	6	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	appropriately	appropriately	RB	_	6	advmod
8	.	.	.	_	6	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	is	be	VBZ	_	9	auxpass
9	recommended	recommend	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	While	while	IN	_	5	mark
2	co-administration	co-administration	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	appeared	appear	VBD	_	20	advcl
6	to	to	TO	_	7	mark
7	increase	increase	VB	_	5	xcomp
8	the	the	DT	_	9	det
9	clearance	clearance	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	by	by	IN	_	14	case
13	70	70	CD	_	14	nummod
14	%	%	NN	_	7	nmod
15	,	,	,	_	20	punct
16	these	these	DT	_	17	det
17	results	result	NNS	_	20	nsubj
18	are	be	VBP	_	20	cop
19	not	not	RB	_	20	neg
20	conclusive	conclusive	JJ	_	0	ROOT
21	because	because	IN	_	25	case
22	of	of	IN	_	21	mwe
23	the	the	DT	_	25	det
24	small	small	JJ	_	25	amod
25	number	number	NN	_	20	nmod
26	of	of	IN	_	27	case
27	subjects	subject	NNS	_	25	nmod
28	studied	study	VBN	_	27	acl
29	and	and	CC	_	20	cc
30	because	because	IN	_	32	mark
31	patients	patient	NNS	_	32	nsubj
32	took	take	VBD	_	20	conj
33	variable	variable	JJ	_	34	amod
34	doses	dose	NNS	_	32	dobj
35	of	of	IN	_	36	case
36	drug3	drug3	NN	_	34	nmod
37	.	.	.	_	20	punct

1	Combination	combination	NN	_	2	compound
2	therapy	therapy	NN	_	12	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	and	and	CC	_	4	cc
9	drug3	drug3	NN	_	4	conj
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	indicated	indicate	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	reverse	reverse	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	analgesic	analgesic	JJ	_	6	amod
6	activity	activity	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	17	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	including	include	VBG	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	drug4	drug4	NN	_	6	conj
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	e.g.	e.g.	FW	_	14	dep
14	smoking	smoking	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	may	may	MD	_	17	aux
17	result	result	VB	_	0	ROOT
18	in	in	IN	_	20	case
19	enhanced	enhance	VBN	_	20	amod
20	vasoconstriction	vasoconstriction	NN	_	17	nmod
21	.	.	.	_	17	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	for	for	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	1	punct
8	drug3	drug3	NN	_	1	dep
9	,	,	,	_	8	punct
10	Oral	oral	JJ	_	11	amod
11	drug4	drug4	NN	_	8	conj
12	,	,	,	_	8	punct
13	drug5	drug5	NN	_	8	conj
14	,	,	,	_	8	punct
15	drug6	drug6	NN	_	8	conj

1	Interactions	interaction	NNS	_	0	ROOT
2	for	for	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	1	punct
8	drug3	drug3	NN	_	1	dep
9	-	-	:	_	8	punct
10	impairs	impair	VBZ	_	8	dep
11	the	the	DT	_	13	det
12	intestinal	intestinal	JJ	_	13	amod
13	absorption	absorption	NN	_	10	dobj
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod

1	drug1	drug1	NN	_	4	compound
2	-	-	:	_	4	punct
3	concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	5	nsubj
5	decreases	decrease	VBZ	_	0	ROOT
6	gastrointestinal	gastrointestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	;	;	:	_	5	punct

1	requirements	requirement	NNS	_	6	nsubjpass
2	for	for	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug5	drug5	NN	_	5	conj
12	,	,	,	_	5	punct
13	and	and	CC	_	5	cc
14	drug6	drug6	NN	_	5	conj
15	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Absorption	absorption	NN	_	11	nsubjpass
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	single	single	JJ	_	7	amod
7	dose	dose	NN	_	3	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	decreased	decrease	VBN	_	1	appos
12	when	when	WRB	_	13	advmod
13	administered	administer	VBN	_	11	advcl
14	to	to	TO	_	19	case
15	12	12	CD	_	19	nummod
16	stable	stable	JJ	_	19	amod
17	renal	renal	JJ	_	19	amod
18	transplant	transplant	NN	_	19	compound
19	patients	patient	NNS	_	13	nmod
20	also	also	RB	_	21	advmod
21	taking	take	VBG	_	13	dep
22	drug3	drug3	NN	_	21	dobj
23	-	-	:	_	22	punct
24	drug4	drug4	NN	_	23	root
25	containing	contain	VBG	_	24	acl
26	drug5	drug5	NN	_	25	dobj
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	30	30	CD	_	29	nummod
29	mL	ml	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	:	:	:	_	24	punct
32	the	the	DT	_	34	det
33	mean	mean	NN	_	34	compound
34	Cmax	cmax	NN	_	45	nsubj
35	and	and	CC	_	34	cc
36	AUC	auc	NN	_	40	compound
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	0-t	0-t	NN	_	36	appos
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	values	value	NNS	_	34	conj
41	for	for	IN	_	42	case
42	MPA	MPA	NNP	_	34	nmod
43	were	be	VBD	_	45	cop
44	25	25	CD	_	45	nummod
45	%	%	NN	_	24	dep
46	and	and	CC	_	45	cc
47	37	37	CD	_	48	nummod
48	%	%	NN	_	45	conj
49	lower	lower	JJR	_	45	advmod
50	,	,	,	_	45	punct
51	respectively	respectively	RB	_	45	advmod
52	,	,	,	_	45	punct
53	than	than	IN	_	57	mark
54	when	when	WRB	_	57	advmod
55	drug6	drug6	NN	_	57	nsubjpass
56	was	be	VBD	_	57	auxpass
57	administered	administer	VBN	_	45	advcl
58	alone	alone	RB	_	57	advmod
59	under	under	IN	_	61	case
60	fasting	fasting	NN	_	61	compound
61	conditions	condition	NNS	_	57	nmod
62	.	.	.	_	24	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	10	mark
5	drug1	drug1	NN	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	administered	administer	VBN	_	3	ccomp
11	simultaneously	simultaneously	RB	_	10	advmod
12	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	4	advmod
4	studied	study	VBN	_	19	advcl
5	in	in	IN	_	9	case
6	stable	stable	JJ	_	9	amod
7	renal	renal	JJ	_	9	amod
8	transplant	transplant	NN	_	9	compound
9	patients	patient	NNS	_	4	nmod
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	9	punct
13	USP	usp	NN	_	17	compound
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	MODIFIED	modify	VBN	_	13	dep
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	pharmacokinetics	pharmacokinetic	NNS	_	9	conj
18	were	be	VBD	_	19	aux
19	unaffected	unaffected	JJ	_	1	dep
20	by	by	IN	_	23	case
21	steady	steady	JJ	_	23	amod
22	state	state	NN	_	23	compound
23	dosing	dosing	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	taken	take	VBN	_	3	dep
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	;	;	:	_	7	punct

1	however	however	RB	_	11	advmod
2	,	,	,	_	11	punct
3	during	during	IN	_	5	case
4	the	the	DT	_	5	det
5	period	period	NN	_	11	nmod
6	of	of	IN	_	7	case
7	treatment	treatment	NN	_	5	nmod
8	,	,	,	_	11	punct
9	physicians	physician	NNS	_	11	nsubj
10	should	should	MD	_	11	aux
11	monitor	monitor	VB	_	0	ROOT
12	blood	blood	NN	_	14	compound
13	cell	cell	NN	_	14	compound
14	counts	count	NNS	_	11	dobj
15	.	.	.	_	11	punct

1	Both	both	DT	_	2	cc:preconj
2	drug1	drug1	NN	_	0	ROOT
3	/	/	:	_	2	punct
4	drug2	drug2	NN	_	7	compound
5	and	and	CC	_	4	cc
6	drug3	drug3	NN	_	4	conj
7	concentrations	concentration	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	increased	increase	VBN	_	2	dep
10	in	in	IN	_	15	case
11	the	the	DT	_	15	dep
12	presence	presence	NN	_	15	dep
13	of	of	IN	_	15	case
14	renal	renal	JJ	_	15	amod
15	impairment	impairment	NN	_	9	nmod
16	,	,	,	_	9	punct
17	their	they	PRP$	_	18	nmod:poss
18	coexistence	coexistence	NN	_	20	nsubj
19	may	may	MD	_	20	aux
20	compete	compete	VB	_	9	parataxis
21	for	for	IN	_	23	case
22	tubular	tubular	JJ	_	23	amod
23	secretion	secretion	NN	_	20	nmod
24	and	and	CC	_	20	cc
25	further	further	JJ	_	26	amod
26	increase	increase	NN	_	20	conj
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	concentrations	concentration	NNS	_	26	nmod
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	two	two	CD	_	29	nmod
33	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	Given	give	VBN	_	10	mark
6	that	that	IN	_	10	mark
7	drug3	drug3	NN	_	10	nsubj
8	and	and	CC	_	7	cc
9	drug4	drug4	NN	_	7	conj
10	inhibit	inhibit	VBP	_	16	advcl
11	purine	purine	NN	_	12	compound
12	metabolism	metabolism	NN	_	10	dobj
13	,	,	,	_	16	punct
14	it	it	PRP	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	3	dep
17	that	that	IN	_	21	mark
18	drug5	drug5	NN	_	21	nsubjpass
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	administered	administer	VBN	_	16	ccomp
22	concomitantly	concomitantly	RB	_	21	advmod
23	with	with	IN	_	24	case
24	drug6	drug6	NN	_	21	nmod
25	or	or	CC	_	24	cc
26	drug7	drug7	NN	_	24	conj
27	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	Drugs	drug	NNS	_	1	conj
4	that	that	WDT	_	5	nsubj
5	Bind	bind	VB	_	1	acl:relcl
6	Bile	Bile	NNP	_	7	compound
7	Acids	Acids	NNPS	_	5	dobj
8	:	:	:	_	1	punct
9	These	these	DT	_	10	det
10	drugs	drug	NNS	_	11	nsubj
11	interrupt	interrupt	VBP	_	1	dep
12	enterohepatic	enterohepatic	JJ	_	13	amod
13	recirculation	recirculation	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	reduce	reduce	VB	_	11	conj
16	drug2	drug2	NN	_	17	compound
17	exposure	exposure	NN	_	15	dobj
18	when	when	WRB	_	19	advmod
19	coadministered	coadminister	VBN	_	11	advcl
20	with	with	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	do	do	VBP	_	5	aux
4	not	not	RB	_	5	neg
5	administer	administer	VB	_	0	ROOT
6	drug1	drug1	NN	_	5	dobj
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	or	or	CC	_	8	cc
10	other	other	JJ	_	11	amod
11	agents	agent	NNS	_	8	conj
12	that	that	WDT	_	14	nsubj
13	may	may	MD	_	14	aux
14	interfere	interfere	VB	_	11	acl:relcl
15	with	with	IN	_	17	case
16	enterohepatic	enterohepatic	JJ	_	17	amod
17	recirculation	recirculation	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	drugs	drug	NNS	_	17	conj
20	that	that	WDT	_	22	nsubj
21	may	may	MD	_	22	aux
22	bind	bind	VB	_	17	acl:relcl
23	bile	bile	NN	_	24	compound
24	acids	acid	NNS	_	22	dobj
25	,	,	,	_	5	punct
26	for	for	IN	_	30	case
27	example	example	NN	_	30	compound
28	bile	bile	NN	_	30	compound
29	acid	acid	NN	_	30	compound
30	sequestrates	sequestrate	NNS	_	5	nmod
31	or	or	CC	_	30	cc
32	oral	oral	JJ	_	33	amod
33	drug3	drug3	NN	_	30	conj
34	,	,	,	_	5	punct
35	because	because	IN	_	38	case
36	of	of	IN	_	35	mwe
37	the	the	DT	_	38	det
38	potential	potential	JJ	_	5	nmod
39	to	to	TO	_	40	mark
40	reduce	reduce	VB	_	38	acl
41	the	the	DT	_	42	det
42	efficacy	efficacy	NN	_	40	dobj
43	of	of	IN	_	44	case
44	drug4	drug4	NN	_	42	nmod
45	.	.	.	_	5	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Given	give	VBN	_	7	case
5	the	the	DT	_	7	det
6	different	different	JJ	_	7	amod
7	metabolism	metabolism	NN	_	24	nsubjpass
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	oral	oral	JJ	_	12	amod
12	drug3	drug3	NN	_	9	conj
13	,	,	,	_	7	punct
14	no	no	DT	_	16	neg
15	drug	drug	NN	_	16	compound
16	interaction	interaction	NN	_	7	appos
17	between	between	IN	_	20	case
18	these	these	DT	_	20	det
19	two	two	CD	_	20	nummod
20	classes	class	NNS	_	16	nmod
21	of	of	IN	_	22	case
22	drug	drug	NN	_	20	nmod
23	is	be	VBZ	_	24	auxpass
24	expected	expect	VBN	_	2	dep
25	.	.	.	_	2	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	in	in	IN	_	7	case
4	a	a	DT	_	7	det
5	drug-drug	drug-drug	JJ	_	7	amod
6	interaction	interaction	NN	_	7	compound
7	study	study	NN	_	9	nmod
8	,	,	,	_	9	punct
9	mean	mean	VB	_	0	ROOT
10	drug1	drug1	NN	_	11	compound
11	AUC	auc	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	decreased	decrease	VBN	_	9	ccomp
14	by	by	IN	_	16	case
15	15	15	CD	_	16	nummod
16	%	%	NN	_	13	nmod
17	when	when	WRB	_	18	advmod
18	coadministered	coadminister	VBN	_	13	advcl
19	with	with	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	.	.	.	_	9	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	that	that	IN	_	10	mark
7	oral	oral	JJ	_	8	amod
8	drug1	drug1	NN	_	10	nsubj
9	are	be	VBP	_	10	cop
10	co	co	SYM	_	5	ccomp
11	-	-	:	_	10	punct
12	administered	administer	VBN	_	23	csubjpass
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	additional	additional	JJ	_	21	amod
19	birth	birth	NN	_	21	compound
20	control	control	NN	_	21	compound
21	methods	method	NNS	_	16	conj
22	be	be	VB	_	23	auxpass
23	considered	consider	VBN	_	10	parataxis
24	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	During	during	IN	_	4	case
4	treatment	treatment	NN	_	1	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	4	punct
8	the	the	DT	_	9	det
9	use	use	NN	_	14	nsubjpass
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	avoided	avoid	VBN	_	4	acl:relcl
15	and	and	CC	_	14	cc
16	patients	patient	NNS	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	advised	advise	VBN	_	14	conj
20	that	that	IN	_	25	mark
21	vaccinations	vaccination	NNS	_	25	nsubj
22	may	may	MD	_	25	aux
23	be	be	VB	_	25	cop
24	less	less	RBR	_	25	advmod
25	effective	effective	JJ	_	14	ccomp
26	.	.	.	_	1	punct

1	Influenza	influenza	NN	_	2	compound
2	vaccination	vaccination	NN	_	6	nsubj
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	of	of	IN	_	6	case
6	value	value	NN	_	0	ROOT
7	.	.	.	_	6	punct

1	Prescribers	prescriber	NNS	_	3	nsubj
2	should	should	MD	_	3	aux
3	refer	refer	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	national	national	JJ	_	6	amod
6	guidelines	guideline	NNS	_	3	nmod
7	for	for	IN	_	9	case
8	influenza	influenza	NN	_	9	compound
9	vaccination	vaccination	NN	_	6	nmod
10	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	8	nsubj
2	that	that	WDT	_	3	nsubj
3	alter	alter	VBP	_	1	acl:relcl
4	the	the	DT	_	6	det
5	gastrointestinal	gastrointestinal	JJ	_	6	amod
6	flora	flora	NN	_	3	dobj
7	may	may	MD	_	8	aux
8	interact	interact	VB	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	by	by	IN	_	12	mark
12	disrupting	disrupt	VBG	_	8	advcl
13	enterohepatic	enterohepatic	JJ	_	14	amod
14	recirculation	recirculation	NN	_	12	dobj
15	.	.	.	_	8	punct

1	Interference	interference	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	hydrolysis	hydrolysis	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	lead	lead	VB	_	0	ROOT
7	to	to	TO	_	9	case
8	less	less	JJR	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	available	available	JJ	_	9	amod
11	for	for	IN	_	12	case
12	absorption	absorption	NN	_	10	nmod
13	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	commonly	commonly	RB	_	10	advmod
10	used	use	VBN	_	8	acl
11	in	in	IN	_	12	case
12	COPD	copd	NN	_	10	nmod
13	without	without	IN	_	14	case
14	increases	increase	NNS	_	10	nmod
15	in	in	IN	_	18	case
16	adverse	adverse	JJ	_	18	amod
17	drug	drug	NN	_	18	compound
18	reactions	reaction	NNS	_	14	nmod
19	.	.	.	_	4	punct

1	These	these	DT	_	2	nsubj
2	include	include	VBP	_	0	ROOT
3	drug1	drug1	NN	_	2	dobj
4	,	,	,	_	3	punct
5	drug2	drug2	NN	_	3	conj
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	oral	oral	JJ	_	3	conj
9	and	and	CC	_	2	cc
10	inhaled	inhale	VBD	_	2	conj
11	drug3	drug3	NN	_	10	dobj
12	.	.	.	_	2	punct

1	However	however	RB	_	21	advmod
2	,	,	,	_	21	punct
3	the	the	DT	_	5	det
4	co	co	NN	_	5	compound
5	administration	administration	NN	_	21	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drug2	drug2	NN	_	5	nmod
11	containing	contain	VBG	_	10	acl
12	drugs	drug	NNS	_	11	dobj
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	e.g.	e.g.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug3	drug3	NN	_	10	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	has	have	VBZ	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	studied	study	VBN	_	0	ROOT
22	and	and	CC	_	21	cc
23	is	be	VBZ	_	26	auxpass
24	therefore	therefore	RB	_	26	advmod
25	not	not	RB	_	26	neg
26	recommended	recommend	VBN	_	21	conj
27	.	.	.	_	21	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	:	:	:	_	1	punct
6	drug2	drug2	NN	_	8	nsubj
7	SHOULD	should	MD	_	8	aux
8	BE	be	VB	_	1	parataxis
9	USED	USED	NNP	_	8	dobj
10	WITH	with	IN	_	12	case
11	GREAT	great	JJ	_	12	amod
12	CAUTION	caution	NN	_	9	nmod
13	AND	and	CC	_	9	cc
14	IN	in	IN	_	16	case
15	REDUCED	REDUCED	NNP	_	16	compound
16	DOSAGE	DOSAGE	NNP	_	9	conj
17	IN	in	IN	_	18	case
18	PATIENTS	patient	NNS	_	16	nmod
19	WHO	who	WP	_	22	nsubj
20	ARE	be	VBP	_	22	aux
21	CONCURRENTLY	concurrently	RB	_	22	advmod
22	RECEIVING	receive	VBG	_	18	acl:relcl
23	OTHER	other	JJ	_	24	amod
24	drug3	drug3	NN	_	22	dobj
25	,	,	,	_	9	punct
26	GENERAL	GENERAL	NNP	_	27	compound
27	drug4	drug4	NN	_	9	conj
28	,	,	,	_	9	punct
29	drug5	drug5	NN	_	9	conj
30	,	,	,	_	9	punct
31	OTHER	other	NN	_	32	compound
32	drug6	drug6	NN	_	9	conj
33	,	,	,	_	9	punct
34	drug7	drug7	NN	_	9	conj
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	INCLUDING	include	VBG	_	34	dep
37	drug8	drug8	NN	_	36	dobj
38	-RRB-	-rrb-	-RRB-	_	36	punct
39	,	,	,	_	9	punct
40	drug9	drug9	NN	_	9	conj
41	AND	and	CC	_	9	cc
42	OTHER	other	NN	_	43	compound
43	drug10	drug10	NN	_	9	conj
44	-LRB-	-lrb-	-LRB-	_	45	punct
45	INCLUDING	include	VBG	_	8	parataxis
46	drug11	drug11	NN	_	45	dobj
47	-RRB-	-rrb-	-RRB-	_	45	punct
48	.	.	.	_	1	punct

1	RESPIRATORY	respiratory	JJ	_	2	amod
2	DEPRESSION	depression	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	HYPOTENSION	hypotension	NN	_	2	conj
5	,	,	,	_	2	punct
6	AND	and	CC	_	2	cc
7	PROFOUND	profound	JJ	_	12	amod
8	SEDATION	sedation	NN	_	12	compound
9	OR	or	NN	_	12	compound
10	COMA	COMA	NNP	_	12	compound
11	MAY	MAY	NNP	_	12	compound
12	RESULT	RESULT	NNP	_	2	conj
13	.	.	.	_	2	punct

1	Drug-Drug	Drug-Drug	NNP	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	8	det
5	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
6	and	and	CC	_	5	cc
7	pharmacodynamic	pharmacodynamic	JJ	_	5	conj
8	interactions	interaction	NNS	_	18	nsubjpass
9	between	between	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	capsules	capsule	NNS	_	8	nmod
12	and	and	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	11	conj
15	have	have	VBP	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	determined	determine	VBN	_	2	dep
19	.	.	.	_	2	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	interactions	interaction	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	expected	expect	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	drug1	drug1	NN	_	9	compound
9	capsules	capsule	NNS	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	NOT	not	RB	_	13	advmod
12	be	be	VB	_	13	auxpass
13	used	use	VBN	_	6	conj
14	in	in	IN	_	15	case
15	combination	combination	NN	_	13	nmod
16	with	with	IN	_	18	case
17	other	other	JJ	_	18	amod
18	drug2	drug2	NN	_	15	nmod
19	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	10	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	8	compound
8	capsules	capsule	NNS	_	5	conj
9	was	be	VBD	_	10	auxpass
10	investigated	investigate	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	significant	significant	JJ	_	5	amod
5	changes	change	NNS	_	3	dobj
6	in	in	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	clearance	clearance	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	26	26	CD	_	11	compound
11	%	%	NN	_	12	amod
12	decrease	decrease	NN	_	5	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	and	and	CC	_	5	cc
15	AUC	auc	NN	_	5	conj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	44	44	CD	_	18	compound
18	%	%	NN	_	19	amod
19	increase	increase	NN	_	15	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	4	compound
4	capsules	capsule	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	caution	caution	NN	_	7	nmod
10	in	in	IN	_	11	case
11	combination	combination	NN	_	7	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	7	punct
15	particularly	particularly	RB	_	17	advmod
16	at	at	IN	_	17	case
17	doses	dose	NNS	_	7	nmod
18	higher	higher	JJR	_	17	amod
19	than	than	IN	_	21	case
20	0.4	0.4	CD	_	21	nummod
21	mg	mg	NN	_	18	nmod
22	.	.	.	_	7	punct

1	Results	result	NNS	_	0	ROOT
2	from	from	IN	_	17	case
3	limited	limit	VBN	_	17	dep
4	in	in	FW	_	5	compound
5	vitro	vitro	FW	_	6	advmod
6	and	and	CC	_	17	cc
7	in	in	FW	_	11	amod
8	vivo	vivo	FW	_	7	dep
9	drug-drug	drug-drug	JJ	_	11	amod
10	interaction	interaction	NN	_	11	compound
11	studies	study	NNS	_	17	nsubj
12	between	between	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	are	be	VBP	_	17	cop
17	inconclusive	inconclusive	JJ	_	1	nmod
18	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	14	compound
14	capsules	capsule	NNS	_	11	conj
15	.	.	.	_	6	punct

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	amod
2	drugs	drug	NNS	_	9	nsubj
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	may	may	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	9	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	9	punct

1	Patients	patient	NNS	_	15	nsubjpass
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	6	case
4	extended	extended	JJ	_	6	amod
5	release	release	NN	_	6	compound
6	drug1	drug1	NN	_	2	nmod
7	plus	plus	CC	_	6	cc
8	a	a	DT	_	10	det
9	catecholamine	catecholamine	NN	_	10	compound
10	depletor	depletor	NN	_	6	conj
11	should	should	MD	_	15	aux
12	therefore	therefore	RB	_	15	advmod
13	be	be	VB	_	15	auxpass
14	closely	closely	RB	_	15	advmod
15	observed	observe	VBN	_	0	ROOT
16	for	for	IN	_	17	case
17	evidence	evidence	NN	_	15	nmod
18	of	of	IN	_	19	case
19	hypotension	hypotension	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	marked	marked	JJ	_	22	amod
22	bradycardia	bradycardia	NN	_	19	conj
23	,	,	,	_	17	punct
24	which	which	WDT	_	26	nsubj
25	may	may	MD	_	26	aux
26	produce	produce	VB	_	17	acl:relcl
27	vertigo	vertigo	NN	_	26	dobj
28	,	,	,	_	27	punct
29	syncope	syncope	NN	_	27	conj
30	,	,	,	_	27	punct
31	or	or	CC	_	27	cc
32	postural	postural	JJ	_	33	amod
33	hypotension	hypotension	NN	_	27	conj
34	.	.	.	_	15	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	3	nsubj
3	contra-indicated	contra-indicate	VBN	_	0	ROOT
4	:	:	:	_	3	punct
5	-	-	:	_	3	punct
6	Vasoconstrictive	vasoconstrictive	JJ	_	7	amod
7	drug1	drug1	NN	_	3	dobj
8	.	.	.	_	3	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administrations	administration	NNS	_	0	ROOT
3	not	not	RB	_	4	neg
4	recommended	recommend	VBN	_	2	acl
5	:	:	:	_	2	punct
6	-	-	:	_	2	punct
7	drug1	drug1	NN	_	2	dep
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	:	:	:	_	2	punct
11	Certain	certain	JJ	_	12	amod
12	drug3	drug3	NN	_	13	nsubj
13	interact	interact	VBP	_	2	dep
14	with	with	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug5	drug5	NN	_	15	conj
18	leading	lead	VBG	_	15	acl
19	to	to	TO	_	22	case
20	increased	increase	VBN	_	22	amod
21	serum	serum	NN	_	22	compound
22	concentrations	concentration	NNS	_	18	nmod
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	latter	latter	JJ	_	22	nmod
26	.	.	.	_	2	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	result	result	VB	_	0	ROOT
4	in	in	IN	_	7	case
5	severe	severe	JJ	_	7	amod
6	ventricular	ventricular	JJ	_	7	amod
7	arrhythmia	arrhythmia	NN	_	3	nmod
8	,	,	,	_	7	punct
9	typically	typically	RB	_	12	advmod
10	torsades	torsades	FW	_	12	compound
11	de	de	FW	_	12	compound
12	pointe	pointe	FW	_	7	appos
13	.	.	.	_	3	punct

1	Although	although	IN	_	8	mark
2	such	such	PDT	_	4	det:predet
3	a	a	DT	_	4	det
4	reaction	reaction	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	demonstrated	demonstrate	VBN	_	22	advcl
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	22	punct
12	concomitant	concomitant	JJ	_	13	amod
13	administration	administration	NN	_	22	nsubjpass
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	13	nmod
18	or	or	CC	_	17	cc
19	drug4	drug4	NN	_	17	conj
20	is	be	VBZ	_	22	auxpass
21	not	not	RB	_	22	neg
22	recommended	recommend	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	,	,	,	_	2	punct
4	drug2	drug2	NN	_	3	root
5	:	:	:	_	4	punct
6	Other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	23	nsubjpass
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug3	drug3	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	7	punct
14	which	which	WDT	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	metabolised	metabolise	VBN	_	7	acl:relcl
17	by	by	IN	_	20	case
18	hepatic	hepatic	JJ	_	20	amod
19	CYP3A	cyp3a	NN	_	20	compound
20	isozymes	isozyme	NNS	_	16	nmod
21	have	have	VBP	_	23	aux
22	been	be	VBN	_	23	auxpass
23	associated	associate	VBN	_	4	dep
24	with	with	IN	_	27	case
25	QT	qt	NN	_	27	compound
26	interval	interval	NN	_	27	compound
27	prolongation	prolongation	NN	_	23	nmod
28	and/or	and/or	CC	_	27	cc
29	cardiac	cardiac	JJ	_	30	amod
30	arrythmias	arrythmia	NNS	_	27	conj
31	-LRB-	-lrb-	-LRB-	_	35	punct
32	typically	typically	RB	_	35	advmod
33	torsades	torsades	FW	_	35	compound
34	de	de	FW	_	35	compound
35	pointe	pointe	FW	_	30	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	as	as	IN	_	39	case
38	a	a	DT	_	39	det
39	result	result	NN	_	23	nmod
40	of	of	IN	_	41	case
41	increase	increase	NN	_	39	nmod
42	in	in	IN	_	45	case
43	their	they	PRP$	_	45	nmod:poss
44	serum	serum	NN	_	45	compound
45	level	level	NN	_	41	nmod
46	subsequent	subsequent	JJ	_	41	amod
47	to	to	TO	_	48	case
48	interaction	interaction	NN	_	46	nmod
49	with	with	IN	_	51	case
50	significant	significant	JJ	_	51	amod
51	inhibitors	inhibitor	NNS	_	48	nmod
52	of	of	IN	_	54	case
53	the	the	DT	_	54	det
54	isozyme	isozyme	NN	_	51	nmod
55	,	,	,	_	51	punct
56	including	include	VBG	_	58	case
57	some	some	DT	_	58	det
58	drug5	drug5	NN	_	51	nmod
59	.	.	.	_	4	punct

1	Although	although	IN	_	7	mark
2	such	such	PDT	_	4	det:predet
3	a	a	DT	_	4	det
4	risk	risk	NN	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	verified	verify	VBN	_	19	advcl
8	for	for	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	19	punct
11	combination	combination	NN	_	19	nsubjpass
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	with	with	IN	_	16	case
15	such	such	JJ	_	16	amod
16	drugs	drug	NNS	_	11	nmod
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	recommended	recommend	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effects	effect	NNS	_	16	nsubjpass
5	of	of	IN	_	8	case
6	chronic	chronic	JJ	_	8	amod
7	drug2	drug2	NN	_	8	compound
8	use	use	NN	_	4	nmod
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	4	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	are	be	VBP	_	16	auxpass
15	not	not	RB	_	16	neg
16	known	know	VBN	_	1	appos
17	.	.	.	_	1	punct

1	When	when	WRB	_	10	advmod
2	a	a	DT	_	6	det
3	single	single	JJ	_	6	amod
4	100	100	CD	_	5	compound
5	mg	mg	NN	_	6	amod
6	dose	dose	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	administered	administer	VBN	_	41	advcl
11	one	one	CD	_	12	nummod
12	hour	hour	NN	_	10	nmod
13	after	after	IN	_	12	case
14	the	the	DT	_	15	det
15	initiation	initiation	NN	_	12	dep
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	300	300	CD	_	20	nummod
20	mg	mg	NN	_	17	dep
21	four	four	CD	_	22	nummod
22	times	time	NNS	_	20	nmod:tmod
23	a	a	DT	_	24	det
24	day	day	NN	_	22	nmod:npmod
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	,	,	,	_	41	punct
27	the	the	DT	_	31	det
28	apparent	apparent	JJ	_	31	amod
29	total	total	JJ	_	31	amod
30	drug3	drug3	NN	_	31	compound
31	clearance	clearance	NN	_	41	nsubjpass
32	of	of	IN	_	35	case
33	this	this	DT	_	35	det
34	single	single	JJ	_	35	amod
35	dose	dose	NN	_	31	nmod
36	in	in	IN	_	39	case
37	normal	normal	JJ	_	39	amod
38	healthy	healthy	JJ	_	39	amod
39	adults	adult	NNS	_	31	nmod
40	was	be	VBD	_	41	auxpass
41	reduced	reduce	VBN	_	0	ROOT
42	by	by	IN	_	44	case
43	18	18	CD	_	44	nummod
44	%	%	NN	_	41	nmod
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	compared	compare	VBN	_	41	dep
47	to	to	TO	_	52	case
48	the	the	DT	_	52	det
49	apparent	apparent	JJ	_	52	amod
50	total	total	JJ	_	52	amod
51	drug4	drug4	NN	_	52	compound
52	clearance	clearance	NN	_	46	nmod
53	in	in	IN	_	56	case
54	the	the	DT	_	56	det
55	same	same	JJ	_	56	amod
56	subjects	subject	NNS	_	52	nmod
57	in	in	IN	_	61	case
58	the	the	DT	_	61	dep
59	absence	absence	NN	_	61	dep
60	of	of	IN	_	61	case
61	drug5	drug5	NN	_	52	nmod
62	-RRB-	-rrb-	-RRB-	_	46	punct
63	.	.	.	_	41	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	9	nsubjpass
4	,	,	,	_	3	punct
5	100	100	CD	_	6	nummod
6	mg	mg	NN	_	3	appos
7	,	,	,	_	3	punct
8	was	be	VBD	_	9	auxpass
9	given	give	VBN	_	1	appos
10	twice	twice	RB	_	11	advmod
11	daily	daily	RB	_	9	advmod
12	for	for	IN	_	14	case
13	13	13	CD	_	14	nummod
14	days	day	NNS	_	9	nmod
15	to	to	TO	_	18	case
16	12	12	CD	_	18	nummod
17	healthy	healthy	JJ	_	18	amod
18	volunteers	volunteer	NNS	_	9	nmod
19	.	.	.	_	1	punct

1	On	on	IN	_	2	case
2	day	day	NN	_	14	nmod
3	11	11	CD	_	2	nummod
4	,	,	,	_	14	punct
5	drug1	drug1	NN	_	14	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	650	650	CD	_	8	nummod
8	mg	mg	NN	_	5	dep
9	four	four	CD	_	10	compound
10	times	time	NNS	_	8	dep
11	daily	daily	JJ	_	10	advmod
12	-RRB-	-rrb-	-RRB-	_	8	punct
13	was	be	VBD	_	14	auxpass
14	started	start	VBN	_	0	ROOT
15	and	and	CC	_	14	cc
16	continued	continue	VBN	_	14	conj
17	for	for	IN	_	19	case
18	8	8	CD	_	19	nummod
19	days	day	NNS	_	16	nmod
20	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	6	auxpass
6	assessed	assess	VBN	_	0	ROOT
7	on	on	IN	_	8	case
8	days	day	NNS	_	6	nmod
9	11	11	CD	_	8	dep
10	and	and	CC	_	9	cc
11	13	13	CD	_	9	conj
12	.	.	.	_	6	punct

1	Coadministration	coadministration	NN	_	4	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	reduced	reduce	VBD	_	0	ROOT
5	the	the	DT	_	7	det
6	peak	peak	NN	_	7	compound
7	concentration	concentration	NN	_	4	dobj
8	and	and	CC	_	7	cc
9	AUC	auc	NN	_	10	compound
10	values	value	NNS	_	7	conj
11	for	for	IN	_	12	case
12	drug2	drug2	NN	_	7	nmod
13	by	by	IN	_	16	case
14	approximately	approximately	RB	_	15	advmod
15	11	11	CD	_	16	nummod
16	%	%	NN	_	4	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	9	nsubjpass
4	,	,	,	_	3	punct
5	100	100	CD	_	6	nummod
6	mg	mg	NN	_	3	appos
7	,	,	,	_	3	punct
8	was	be	VBD	_	9	auxpass
9	given	give	VBN	_	1	appos
10	twice	twice	RB	_	12	advmod
11	daily	daily	JJ	_	12	amod
12	fro	fro	NN	_	9	dobj
13	13	13	CD	_	14	nummod
14	days	day	NNS	_	12	nmod:npmod
15	to	to	TO	_	14	dep
16	12	12	CD	_	18	nummod
17	healthy	healthy	JJ	_	18	amod
18	volunteers	volunteer	NNS	_	14	dep
19	.	.	.	_	1	punct

1	On	on	IN	_	2	case
2	day	day	NN	_	15	nmod
3	11	11	CD	_	2	nummod
4	,	,	,	_	15	punct
5	drug1	drug1	NN	_	15	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	650	650	CD	_	8	nummod
8	mg	mg	NN	_	5	dep
9	,	,	,	_	8	punct
10	four	four	CD	_	11	compound
11	times	time	NNS	_	8	appos
12	daily	daily	JJ	_	11	advmod
13	-RRB-	-rrb-	-RRB-	_	8	punct
14	was	be	VBD	_	15	auxpass
15	started	start	VBN	_	0	ROOT
16	and	and	CC	_	15	cc
17	continued	continue	VBN	_	15	conj
18	for	for	IN	_	20	case
19	8	8	CD	_	20	nummod
20	days	day	NNS	_	17	nmod
21	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	6	auxpass
6	assessed	assess	VBN	_	0	ROOT
7	on	on	IN	_	8	case
8	days	day	NNS	_	6	nmod
9	11	11	CD	_	8	dep
10	and	and	CC	_	9	cc
11	13	13	CD	_	9	conj
12	.	.	.	_	6	punct

1	Peak	peak	JJ	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	concentrations	concentration	NNS	_	9	nsubjpass
4	and	and	CC	_	3	cc
5	AUC	auc	NN	_	3	conj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	were	be	VBD	_	9	auxpass
9	reduced	reduce	VBN	_	0	ROOT
10	approximately	approximately	RB	_	11	advmod
11	10	10	CD	_	12	nummod
12	%	%	NN	_	9	dobj
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	presence	presence	NN	_	9	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	9	punct

1	Because	because	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	shown	show	VBN	_	19	advcl
6	to	to	TO	_	7	mark
7	depress	depress	VB	_	5	xcomp
8	plasma	plasma	NN	_	10	compound
9	prothrombin	prothrombin	NN	_	10	compound
10	activity	activity	NN	_	7	dobj
11	,	,	,	_	19	punct
12	patients	patient	NNS	_	19	nsubj
13	who	who	WP	_	17	nsubj
14	are	be	VBP	_	17	cop
15	on	on	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	therapy	therapy	NN	_	12	acl:relcl
18	may	may	MD	_	19	aux
19	require	require	VB	_	0	ROOT
20	downward	downward	JJ	_	21	amod
21	adjustment	adjustment	NN	_	19	dobj
22	of	of	IN	_	25	case
23	their	they	PRP$	_	25	nmod:poss
24	drug3	drug3	NN	_	25	compound
25	dosage	dosage	NN	_	21	nmod
26	.	.	.	_	19	punct

1	Since	since	IN	_	5	mark
2	bacteriostatic	bacteriostatic	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	interfere	interfere	VB	_	15	advcl
6	with	with	IN	_	9	case
7	the	the	DT	_	9	det
8	bactericidal	bactericidal	JJ	_	9	amod
9	action	action	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	15	punct
13	it	it	PRP	_	15	nsubj
14	is	be	VBZ	_	15	cop
15	advisable	advisable	JJ	_	0	ROOT
16	to	to	TO	_	17	mark
17	avoid	avoid	VB	_	15	xcomp
18	giving	give	VBG	_	17	xcomp
19	drug2	drug2	NN	_	18	dobj
20	in	in	IN	_	21	case
21	conjunction	conjunction	NN	_	18	nmod
22	with	with	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	.	.	.	_	15	punct

1	Absorption	absorption	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	is	be	VBZ	_	5	auxpass
5	impaired	impair	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	containing	contain	VBG	_	7	acl
9	drug3	drug3	NN	_	8	dobj
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	or	or	CC	_	9	cc
13	drug5	drug5	NN	_	9	conj
14	,	,	,	_	5	punct
15	and	and	CC	_	5	cc
16	drug6	drug6	NN	_	5	conj
17	-	-	:	_	16	punct
18	containing	contain	VBG	_	16	acl
19	preparations	preparation	NNS	_	18	dobj
20	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	result	result	VB	_	10	xcomp
13	in	in	IN	_	16	case
14	fatal	fatal	JJ	_	16	amod
15	renal	renal	JJ	_	16	amod
16	toxicity	toxicity	NN	_	12	nmod
17	.	.	.	_	10	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	render	render	VB	_	0	ROOT
10	oral	oral	JJ	_	11	amod
11	drug3	drug3	NN	_	13	nsubj
12	less	less	RBR	_	13	advmod
13	effective	effective	JJ	_	9	xcomp
14	.	.	.	_	9	punct

1	There	there	EX	_	8	expl
2	have	have	VBP	_	8	aux
3	been	be	VBN	_	8	cop
4	no	no	DT	_	8	neg
5	formal	formal	JJ	_	8	amod
6	drug	drug	NN	_	8	compound
7	interaction	interaction	NN	_	8	compound
8	studies	study	NNS	_	0	ROOT
9	performed	perform	VBN	_	8	acl
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	in	in	IN	_	13	case
13	humans	human	NNS	_	11	nmod
14	.	.	.	_	8	punct

1	Administration	administration	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	5	case
5	combination	combination	NN	_	1	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	resulted	result	VBD	_	0	ROOT
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	two-fold	two-fold	JJ	_	12	amod
12	decrease	decrease	NN	_	8	nmod
13	in	in	IN	_	15	case
14	drug3	drug3	NN	_	15	compound
15	clearance	clearance	NN	_	12	nmod
16	in	in	IN	_	20	case
17	a	a	DT	_	20	det
18	non-human	non-human	JJ	_	20	amod
19	primate	primate	JJ	_	20	amod
20	study	study	NN	_	12	nmod
21	and	and	CC	_	12	cc
22	in	in	IN	_	25	case
23	a	a	DT	_	25	det
24	1.5-fold	1.5-fold	JJ	_	25	amod
25	increase	increase	NN	_	12	conj
26	in	in	IN	_	29	case
27	drug4	drug4	NN	_	29	compound
28	serum	serum	NN	_	29	compound
29	levels	level	NNS	_	25	nmod
30	in	in	IN	_	32	case
31	clinical	clinical	JJ	_	32	amod
32	studies	study	NNS	_	25	nmod
33	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	22	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	3	nmod
9	that	that	WDT	_	10	nsubj
10	produce	produce	VBP	_	8	acl:relcl
11	dry	dry	JJ	_	12	amod
12	mouth	mouth	NN	_	10	dobj
13	,	,	,	_	12	punct
14	constipation	constipation	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	other	other	JJ	_	20	amod
18	anticholinergic	anticholinergic	JJ	_	20	amod
19	pharmacological	pharmacological	JJ	_	20	amod
20	effects	effect	NNS	_	12	conj
21	may	may	MD	_	22	aux
22	increase	increase	VB	_	0	ROOT
23	the	the	DT	_	24	det
24	frequency	frequency	NN	_	22	dobj
25	and/or	and/or	CC	_	24	cc
26	severity	severity	NN	_	24	conj
27	of	of	IN	_	29	case
28	such	such	JJ	_	29	amod
29	effects	effect	NNS	_	24	nmod
30	.	.	.	_	22	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	potentially	potentially	RB	_	4	advmod
4	alter	alter	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	11	case
8	some	some	DT	_	11	det
9	concomitantly	concomitantly	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drugs	drug	NNS	_	6	nmod
12	due	due	JJ	_	6	amod
13	to	to	TO	_	15	case
14	anticholinergic	anticholinergic	JJ	_	15	amod
15	effects	effect	NNS	_	12	nmod
16	on	on	IN	_	18	case
17	gastrointestinal	gastrointestinal	JJ	_	18	amod
18	motility	motility	NN	_	15	nmod
19	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Eliminated	eliminate	VBN	_	1	acl
3	by	by	IN	_	6	case
4	Active	active	JJ	_	6	amod
5	Tubular	tubular	JJ	_	6	amod
6	Secretion	secretion	NN	_	2	nmod
7	:	:	:	_	1	punct
8	Although	although	IN	_	19	mark
9	studies	study	NNS	_	19	nsubjpass
10	to	to	TO	_	11	mark
11	assess	assess	VB	_	9	acl
12	drug-drug	drug-drug	JJ	_	13	amod
13	interactions	interaction	NNS	_	11	dobj
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	have	have	VBP	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	conducted	conduct	VBN	_	22	advcl
20	,	,	,	_	22	punct
21	drug2	drug2	NN	_	22	nsubj
22	has	have	VBZ	_	1	dep
23	the	the	DT	_	24	det
24	potential	potential	NN	_	22	dobj
25	for	for	IN	_	27	case
26	pharmacokinetic	pharmacokinetic	JJ	_	27	amod
27	interactions	interaction	NNS	_	24	nmod
28	with	with	IN	_	30	case
29	other	other	JJ	_	30	amod
30	drugs	drug	NNS	_	27	nmod
31	that	that	WDT	_	33	nsubjpass
32	are	be	VBP	_	33	auxpass
33	eliminated	eliminate	VBN	_	30	acl:relcl
34	by	by	IN	_	37	case
35	active	active	JJ	_	37	amod
36	tubular	tubular	JJ	_	37	amod
37	secretion	secretion	NN	_	33	nmod
38	-LRB-	-lrb-	-LRB-	_	22	punct
39	e.g.	e.g.	FW	_	38	root
40	drug3	drug3	FW	_	39	dep
41	,	,	,	_	40	punct
42	drug4	drug4	NN	_	40	conj
43	,	,	,	_	40	punct
44	drug5	drug5	NN	_	40	conj
45	,	,	,	_	40	punct
46	drug6	drug6	NN	_	40	conj
47	,	,	,	_	40	punct
48	drug7	drug7	NN	_	40	conj
49	,	,	,	_	40	punct
50	drug8	drug8	NN	_	40	conj
51	and	and	CC	_	40	cc
52	drug9	drug9	NN	_	40	conj
53	-RRB-	-rrb-	-RRB-	_	39	punct
54	.	.	.	_	39	punct

1	Coadministration	coadministration	NN	_	15	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drugs	drug	NNS	_	1	nmod
6	that	that	WDT	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	eliminated	eliminate	VBN	_	5	acl:relcl
9	by	by	IN	_	13	case
10	active	active	JJ	_	13	amod
11	renal	renal	JJ	_	13	amod
12	tubular	tubular	JJ	_	13	amod
13	secretion	secretion	NN	_	8	nmod
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	0	ROOT
16	the	the	DT	_	18	det
17	serum	serum	NN	_	18	compound
18	concentration	concentration	NN	_	15	dobj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	and/or	and/or	CC	_	20	cc
22	the	the	DT	_	24	det
23	coadministered	coadminister	VBN	_	24	amod
24	drug	drug	NN	_	20	conj
25	due	due	JJ	_	27	case
26	to	to	TO	_	25	mwe
27	competition	competition	NN	_	24	nmod
28	for	for	IN	_	31	case
29	this	this	DT	_	31	det
30	elimination	elimination	NN	_	31	compound
31	pathway	pathway	NN	_	27	nmod
32	.	.	.	_	15	punct

1	Careful	careful	JJ	_	3	amod
2	patient	patient	NN	_	3	compound
3	monitoring	monitoring	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	such	such	JJ	_	10	amod
10	drugs	drug	NNS	_	8	dobj
11	.	.	.	_	5	punct

1	Drug-Laboratory-Test	Drug-Laboratory-Test	NNP	_	3	compound
2	Interactions	interaction	NNS	_	3	compound
3	Interactions	interaction	NNS	_	12	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	laboratory	laboratory	NN	_	8	compound
8	tests	test	NNS	_	5	conj
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	in	in	IN	_	6	mark
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	6	dobj
8	to	to	TO	_	9	case
9	patients	patient	NNS	_	6	nmod
10	receiving	receive	VBG	_	9	acl
11	drug2	drug2	NN	_	10	dobj
12	or	or	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	because	because	IN	_	23	mark
15	the	the	DT	_	17	det
16	extrapyramidal	extrapyramidal	JJ	_	17	amod
17	effects	effect	NNS	_	23	nsubjpass
18	of	of	IN	_	20	case
19	these	these	DT	_	20	det
20	drugs	drug	NNS	_	17	nmod
21	can	can	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	expected	expect	VBN	_	4	advcl
24	to	to	TO	_	26	mark
25	be	be	VB	_	26	auxpass
26	potentiated	potentiate	VBN	_	23	xcomp
27	by	by	IN	_	28	case
28	inhibition	inhibition	NN	_	26	nmod
29	of	of	IN	_	31	case
30	catecholamine	catecholamine	NN	_	31	compound
31	synthesis	synthesis	NN	_	28	nmod
32	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	or	or	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drug3	drug3	NN	_	6	conj
10	can	can	MD	_	11	aux
11	increase	increase	VB	_	0	ROOT
12	their	they	PRP$	_	14	nmod:poss
13	sedative	sedative	JJ	_	14	amod
14	effects	effect	NNS	_	11	dobj
15	.	.	.	_	11	punct

1	You	you	PRP	_	4	nsubj
2	can	can	MD	_	4	aux
3	not	not	RB	_	4	neg
4	take	take	VB	_	0	ROOT
5	drug1	drug1	NN	_	4	dobj
6	if	if	IN	_	9	mark
7	you	you	PRP	_	9	nsubj
8	have	have	VBP	_	9	aux
9	taken	take	VBN	_	4	advcl
10	a	a	DT	_	9	dobj
11	drug2	drug2	NN	_	10	amod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug3	drug3	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug4	drug4	NN	_	11	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug5	drug5	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	17	punct
22	drug6	drug6	NN	_	17	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug7	drug7	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	17	punct
27	or	or	CC	_	17	cc
28	drug8	drug8	NN	_	17	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	drug9	drug9	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	in	in	IN	_	36	case
33	the	the	DT	_	36	det
34	last	last	JJ	_	36	amod
35	14	14	CD	_	36	nummod
36	days	day	NNS	_	11	nmod
37	.	.	.	_	4	punct

1	Changes	change	NNS	_	11	nsubj
2	in	in	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	8	amod
6	diabetes	diabetes	NN	_	8	compound
7	drug	drug	NN	_	8	compound
8	therapies	therapy	NNS	_	3	conj
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	cop
11	necessary	necessary	JJ	_	0	ROOT
12	during	during	IN	_	13	case
13	treatment	treatment	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	reduce	reduce	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug3	drug3	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	an	a	DT	_	6	det
6	increase	increase	NN	_	3	nmod
7	in	in	IN	_	9	case
8	blood	blood	NN	_	9	compound
9	pressure	pressure	NN	_	6	nmod
10	.	.	.	_	3	punct

1	Tell	tell	VB	_	0	ROOT
2	your	you	PRP$	_	3	nmod:poss
3	doctor	doctor	NN	_	1	dobj
4	if	if	IN	_	7	mark
5	you	you	PRP	_	7	nsubj
6	are	be	VBP	_	7	aux
7	taking	take	VBG	_	1	advcl
8	drug1	drug1	NN	_	7	dobj
9	.	.	.	_	1	punct

1	Before	before	IN	_	2	mark
2	taking	take	VBG	_	6	advcl
3	this	this	DT	_	4	det
4	medication	medication	NN	_	2	dobj
5	,	,	,	_	6	punct
6	tell	tell	VB	_	0	ROOT
7	your	you	PRP$	_	8	nmod:poss
8	doctor	doctor	NN	_	6	dobj
9	if	if	IN	_	12	mark
10	you	you	PRP	_	12	nsubj
11	are	be	VBP	_	12	aux
12	taking	take	VBG	_	6	advcl
13	a	a	DT	_	14	det
14	drug1	drug1	NN	_	12	dobj
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug2	drug2	NN	_	14	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug3	drug3	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	17	punct
22	drug4	drug4	NN	_	17	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug5	drug5	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	17	punct
27	drug6	drug6	NN	_	17	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug7	drug7	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	17	punct
32	drug8	drug8	NN	_	17	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	drug9	drug9	NN	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	,	,	,	_	17	punct
37	drug10	drug10	NN	_	17	conj
38	-LRB-	-lrb-	-LRB-	_	39	punct
39	drug11	drug11	NN	_	37	appos
40	-RRB-	-rrb-	-RRB-	_	39	punct
41	,	,	,	_	17	punct
42	drug12	drug12	NN	_	17	conj
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	drug13	drug13	NN	_	42	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	,	,	,	_	17	punct
47	drug14	drug14	NN	_	17	conj
48	-LRB-	-lrb-	-LRB-	_	49	punct
49	drug15	drug15	NN	_	47	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	,	,	,	_	17	punct
52	or	or	CC	_	17	cc
53	drug16	drug16	NN	_	17	conj
54	-LRB-	-lrb-	-LRB-	_	55	punct
55	drug17	drug17	NN	_	53	appos
56	-RRB-	-rrb-	-RRB-	_	55	punct
57	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	decrease	decrease	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	accelerate	accelerate	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	by	by	IN	_	13	case
12	the	the	DT	_	13	det
13	mechanism	mechanism	NN	_	6	nmod
14	of	of	IN	_	18	case
15	hepatic	hepatic	JJ	_	18	amod
16	microsomal	microsomal	JJ	_	18	amod
17	enzyme	enzyme	NN	_	18	compound
18	induction	induction	NN	_	13	nmod
19	,	,	,	_	6	punct
20	leading	lead	VBG	_	6	advcl
21	to	to	TO	_	23	case
22	an	a	DT	_	23	det
23	increase	increase	NN	_	20	nmod
24	in	in	IN	_	26	case
25	dosage	dosage	NN	_	26	compound
26	requirements	requirement	NNS	_	23	nmod
27	for	for	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	physicians	physician	NNS	_	6	nsubj
4	should	should	MD	_	6	aux
5	closely	closely	RB	_	6	advmod
6	monitor	monitor	VB	_	0	ROOT
7	patients	patient	NNS	_	6	dobj
8	for	for	IN	_	10	case
9	a	a	DT	_	10	det
10	change	change	NN	_	7	nmod
11	in	in	IN	_	14	case
12	drug1	drug1	NN	_	14	compound
13	dosage	dosage	NN	_	14	compound
14	requirements	requirement	NNS	_	10	nmod
15	when	when	WRB	_	16	advmod
16	administering	administer	VBG	_	6	advcl
17	drug2	drug2	NN	_	16	dobj
18	to	to	TO	_	19	case
19	patients	patient	NNS	_	16	nmod
20	on	on	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	given	give	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	caution	caution	NN	_	7	nmod
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	9	nmod
12	receiving	receive	VBG	_	11	acl
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	15	nsubj
15	susceptible	susceptible	JJ	_	12	xcomp
16	to	to	TO	_	18	case
17	the	the	DT	_	18	det
18	influence	influence	NN	_	15	nmod
19	of	of	IN	_	22	case
20	hepatic	hepatic	JJ	_	22	amod
21	enzyme	enzyme	NN	_	22	compound
22	induction	induction	NN	_	18	nmod
23	.	.	.	_	7	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-	-	:	_	7	punct
3	containing	contain	VBG	_	7	csubjpass
4	drugs	drug	NNS	_	3	dobj
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	cause	cause	VB	_	7	xcomp
10	prolonged	prolonged	JJ	_	12	amod
11	vasospastic	vasospastic	JJ	_	12	amod
12	reactions	reaction	NNS	_	9	dobj
13	.	.	.	_	7	punct

1	Because	because	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	0	ROOT
4	a	a	DT	_	6	det
5	theoretical	theoretical	JJ	_	6	amod
6	basis	basis	NN	_	3	nsubj
7	that	that	IN	_	12	mark
8	these	these	DT	_	9	det
9	effects	effect	NNS	_	12	nsubj
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	additive	additive	JJ	_	6	ccomp
13	,	,	,	_	12	punct
14	use	use	NN	_	37	nsubjpass
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	-	-	:	_	14	punct
18	containing	contain	VBG	_	14	dep
19	or	or	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	like	like	IN	_	23	case
23	drug3	drug3	NN	_	18	nmod
24	or	or	CC	_	23	cc
25	drug4	drug4	NN	_	23	conj
26	-RRB-	-rrb-	-RRB-	_	23	punct
27	and	and	CC	_	18	cc
28	drug5	drug5	NN	_	18	conj
29	within	within	IN	_	31	case
30	24	24	CD	_	31	nummod
31	hours	hour	NNS	_	28	nmod
32	of	of	IN	_	34	case
33	each	each	DT	_	34	det
34	other	other	JJ	_	31	nmod
35	should	should	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	avoided	avoid	VBN	_	12	parataxis
38	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduce	reduce	VB	_	0	ROOT
3	drug2	drug2	NN	_	4	compound
4	clearance	clearance	NN	_	2	dobj
5	,	,	,	_	2	punct
6	significantly	significantly	RB	_	7	advmod
7	increasing	increase	VBG	_	2	advcl
8	systemic	systemic	JJ	_	9	amod
9	exposure	exposure	NN	_	7	dobj
10	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	the	the	DT	_	4	det
4	use	use	NN	_	13	nsubjpass
5	of	of	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	tablets	tablet	NNS	_	4	nmod
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	4	nmod
10	receiving	receive	VBG	_	9	acl
11	drug2	drug2	NN	_	10	dobj
12	is	be	VBZ	_	13	auxpass
13	contraindicated	contraindicate	VBN	_	0	ROOT
14	.	.	.	_	13	punct
15	drug3	drug3	NN	_	32	nsubjpass
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug4	drug4	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug5	drug5	NN	_	15	dep
23	,	,	,	_	22	punct
24	drug6	drug6	NN	_	22	conj
25	,	,	,	_	22	punct
26	drug7	drug7	NN	_	22	conj
27	,	,	,	_	22	punct
28	drug8	drug8	NN	_	22	appos
29	-RRB-	-rrb-	-RRB-	_	22	punct
30	have	have	VBP	_	32	aux
31	been	be	VBN	_	32	auxpass
32	reported	report	VBN	_	13	parataxis
33	,	,	,	_	32	punct
34	rarely	rarely	RB	_	32	advmod
35	,	,	,	_	32	punct
36	to	to	TO	_	37	mark
37	cause	cause	VB	_	32	xcomp
38	weakness	weakness	NN	_	37	dobj
39	,	,	,	_	38	punct
40	hyperreflexia	hyperreflexia	NN	_	38	conj
41	,	,	,	_	38	punct
42	and	and	CC	_	38	cc
43	incoordination	incoordination	NN	_	38	conj
44	when	when	WRB	_	45	advmod
45	coadministered	coadminister	VBN	_	37	advcl
46	with	with	IN	_	47	case
47	drug9	drug9	NN	_	45	nmod
48	.	.	.	_	13	punct

1	If	if	IN	_	11	mark
2	concomitant	concomitant	JJ	_	3	amod
3	treatment	treatment	NN	_	11	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	an	a	DT	_	8	det
8	drug2	drug2	NN	_	5	conj
9	is	be	VBZ	_	11	auxpass
10	clinically	clinically	RB	_	11	advmod
11	warranted	warrant	VBN	_	19	advcl
12	,	,	,	_	19	punct
13	appropriate	appropriate	JJ	_	14	amod
14	observation	observation	NN	_	19	nsubjpass
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	patient	patient	NN	_	14	nmod
18	is	be	VBZ	_	19	auxpass
19	advised	advise	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	80	80	CD	_	8	nummod
8	%	%	NN	_	6	dobj
9	by	by	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	,	,	,	_	10	punct
12	when	when	WRB	_	17	advmod
13	drug3	drug3	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	drug4	drug4	NN	_	13	conj
16	are	be	VBP	_	17	auxpass
17	administered	administer	VBN	_	10	acl:relcl
18	at	at	IN	_	21	case
19	the	the	DT	_	21	det
20	same	same	JJ	_	21	amod
21	time	time	NN	_	17	nmod
22	,	,	,	_	10	punct
23	and	and	CC	_	10	cc
24	60	60	CD	_	25	nummod
25	%	%	NN	_	10	conj
26	by	by	IN	_	28	case
27	some	some	DT	_	28	det
28	drug5	drug5	NN	_	6	nmod
29	-	-	:	_	28	punct
30	or	or	CC	_	28	cc
31	drug6	drug6	NN	_	28	conj
32	-	-	:	_	28	punct
33	containing	contain	VBG	_	28	acl
34	drug7	drug7	NN	_	33	dobj
35	,	,	,	_	28	punct
36	when	when	WRB	_	37	advmod
37	administered	administer	VBN	_	28	acl:relcl
38	1	1	CD	_	39	nummod
39	hour	hour	NN	_	37	nmod
40	before	before	IN	_	39	case
41	drug8	drug8	NN	_	39	dep
42	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	bioavailability	bioavailability	NN	_	3	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	by	by	IN	_	11	case
8	up	up	RB	_	10	dep
9	to	to	TO	_	8	mwe
10	50	50	CD	_	11	nummod
11	%	%	NN	_	3	nmod
12	when	when	WRB	_	13	advmod
13	taken	take	VBN	_	3	advcl
14	2	2	CD	_	15	nummod
15	hours	hour	NNS	_	13	nmod
16	after	after	IN	_	15	case
17	drug3	drug3	NN	_	15	dep
18	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	2-4	2-4	CD	_	8	nummod
8	fold	fold	NN	_	6	dobj
9	by	by	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	but	but	CC	_	6	cc
12	is	be	VBZ	_	15	auxpass
13	not	not	RB	_	15	neg
14	significantly	significantly	RB	_	15	advmod
15	altered	alter	VBN	_	6	conj
16	by	by	IN	_	17	case
17	coadministration	coadministration	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	parameters	parameter	NNS	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	are	be	VBP	_	9	auxpass
7	not	not	RB	_	9	neg
8	significantly	significantly	RB	_	9	advmod
9	modified	modify	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	coadministration	coadministration	NN	_	9	nmod
13	.	.	.	_	9	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	show	show	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	drug1	drug1	NN	_	9	nsubj
7	does	do	VBZ	_	9	aux
8	not	not	RB	_	9	neg
9	displace	displace	VB	_	4	ccomp
10	drug2	drug2	NN	_	9	dobj
11	from	from	IN	_	14	case
12	its	its	PRP$	_	14	nmod:poss
13	binding	binding	NN	_	14	amod
14	site	site	NN	_	9	nmod
15	on	on	IN	_	16	case
16	protein	protein	NN	_	14	nmod
17	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	usually	usually	RB	_	2	advmod
4	complete	complete	JJ	_	5	amod
5	cross-resistance	cross-resistance	NN	_	2	nsubj
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug2	drug2	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	and	and	CC	_	7	cc
12	drug3	drug3	NN	_	14	compound
13	brand	brand	NN	_	14	compound
14	drug4	drug4	NN	_	7	conj
15	.	.	.	_	2	punct

1	As	as	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	27	advcl
4	in	in	FW	_	6	amod
5	vitro	vitro	FW	_	4	dep
6	evidence	evidence	NN	_	3	nsubj
7	that	that	IN	_	19	mark
8	drug1	drug1	NN	_	19	nsubj
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	e.g.	e.g.	FW	_	12	dep
11	,	,	,	_	12	punct
12	drug2	drug2	NN	_	8	dep
13	,	,	,	_	12	punct
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	12	punct
16	or	or	CC	_	12	cc
17	drug4	drug4	NN	_	12	conj
18	-RRB-	-rrb-	-RRB-	_	12	punct
19	inhibit	inhibit	VBP	_	6	ccomp
20	the	the	DT	_	22	det
21	TPMT	tpmt	NN	_	22	compound
22	enzyme	enzyme	NN	_	19	dobj
23	,	,	,	_	27	punct
24	they	they	PRP	_	27	nsubjpass
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	administered	administer	VBN	_	0	ROOT
28	with	with	IN	_	29	case
29	caution	caution	NN	_	27	nmod
30	to	to	TO	_	31	case
31	patients	patient	NNS	_	29	nmod
32	receiving	receive	VBG	_	31	acl
33	concurrent	concurrent	JJ	_	35	amod
34	drug5	drug5	NN	_	35	compound
35	therapy	therapy	NN	_	32	dobj
36	.	.	.	_	27	punct

1	Other	other	JJ	_	3	amod
2	eye	eye	NN	_	3	compound
3	drops	drop	NNS	_	20	nsubj
4	or	or	CC	_	3	cc
5	medications	medication	NNS	_	3	conj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug2	drug2	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	and	and	CC	_	8	cc
13	drug3	drug3	NN	_	8	conj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug4	drug4	NN	_	13	dep
16	,	,	,	_	15	punct
17	drug5	drug5	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	15	punct
19	may	may	MD	_	20	aux
20	decrease	decrease	VB	_	0	ROOT
21	the	the	DT	_	22	det
22	effects	effect	NNS	_	20	dobj
23	of	of	IN	_	25	case
24	drug6	drug6	NN	_	25	compound
25	ophthalmic	ophthalmic	JJ	_	22	nmod
26	.	.	.	_	20	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	particularly	particularly	RB	_	4	advmod
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	cause	cause	VB	_	0	ROOT
8	serious	serious	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	arrhythmias	arrhythmia	NNS	_	7	dobj
11	during	during	IN	_	13	case
12	drug3	drug3	NN	_	13	compound
13	anesthesia	anesthesia	NN	_	7	nmod
14	and	and	CC	_	7	cc
15	therefore	therefore	RB	_	18	advmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	7	conj
19	only	only	RB	_	22	advmod
20	with	with	IN	_	22	case
21	great	great	JJ	_	22	amod
22	caution	caution	NN	_	18	nmod
23	or	or	CC	_	22	cc
24	not	not	RB	_	26	neg
25	at	at	IN	_	26	case
26	all	all	DT	_	22	conj
27	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	pressor	pressor	NN	_	5	compound
5	effect	effect	NN	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	is	be	VBZ	_	10	auxpass
9	markedly	markedly	RB	_	10	advmod
10	potentiated	potentiate	VBN	_	1	appos
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	drug3	drug3	NN	_	13	dobj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug4	drug4	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	when	when	WRB	_	4	advmod
4	initiating	initiate	VBG	_	16	advcl
5	pressor	pressor	NN	_	6	compound
6	therapy	therapy	NN	_	4	dobj
7	in	in	IN	_	9	case
8	these	these	DT	_	9	det
9	patients	patient	NNS	_	6	nmod
10	,	,	,	_	16	punct
11	the	the	DT	_	13	det
12	initial	initial	JJ	_	13	amod
13	dose	dose	NN	_	16	nsubj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	cop
16	small	small	JJ	_	0	ROOT
17	and	and	CC	_	16	cc
18	used	use	VBN	_	16	conj
19	with	with	IN	_	21	case
20	due	due	JJ	_	21	amod
21	caution	caution	NN	_	18	nmod
22	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	pressor	pressor	NN	_	3	compound
3	response	response	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	9	aux
7	also	also	RB	_	9	advmod
8	be	be	VB	_	9	auxpass
9	potentiated	potentiate	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	9	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	expected	expect	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	inhibit	inhibit	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	clearance	clearance	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	metabolized	metabolize	VBN	_	10	acl
12	by	by	IN	_	16	case
13	cytochrome	cytochrome	NN	_	16	compound
14	P450	p450	NN	_	16	compound
15	enzymes	enzyme	NNS	_	16	compound
16	CYP1A2	cyp1a2	NN	_	11	nmod
17	,	,	,	_	16	punct
18	CYP2A6	cyp2a6	NN	_	16	conj
19	,	,	,	_	16	punct
20	CYP2B6	cyp2b6	NN	_	16	conj
21	,	,	,	_	16	punct
22	CYP2C8	cyp2c8	NN	_	16	conj
23	,	,	,	_	16	punct
24	CYP2C9	cyp2c9	NN	_	16	conj
25	,	,	,	_	16	punct
26	CYP2C19	cyp2c19	NN	_	16	conj
27	,	,	,	_	16	punct
28	CYP2D6	cyp2d6	NN	_	29	compound
29	CYP2E1	cyp2e1	NN	_	16	conj
30	or	or	CC	_	16	cc
31	CYP3A	cyp3a	NN	_	16	conj
32	nor	nor	CC	_	6	cc
33	induce	induce	VB	_	6	conj
34	the	the	DT	_	35	det
35	clearance	clearance	NN	_	33	dobj
36	of	of	IN	_	37	case
37	drugs	drug	NNS	_	35	nmod
38	metabolized	metabolize	VBN	_	37	acl
39	by	by	IN	_	40	case
40	CYP2B6	cyp2b6	NN	_	38	nmod
41	,	,	,	_	40	punct
42	CYP2C9	cyp2c9	NN	_	40	conj
43	or	or	CC	_	40	cc
44	CYP3A	cyp3a	NN	_	40	conj
45	.	.	.	_	4	punct

1	A	a	DT	_	6	det
2	multiple	multiple	JJ	_	6	amod
3	dose	dose	NN	_	6	compound
4	drug-drug	drug-drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	study	study	NN	_	7	nsubj
7	demonstrated	demonstrate	VBD	_	0	ROOT
8	that	that	IN	_	11	mark
9	drug1	drug1	NN	_	11	nsubj
10	approximately	approximately	RB	_	11	advmod
11	doubled	double	VBD	_	7	ccomp
12	drug2	drug2	NN	_	13	compound
13	AUC0	auc0	NN	_	11	dobj
14	-	-	:	_	11	punct
15	.	.	.	_	11	punct
16	Since	since	IN	_	20	mark
17	drug3	drug3	NN	_	20	nsubjpass
18	is	be	VBZ	_	20	auxpass
19	partially	partially	RB	_	20	advmod
20	metabolized	metabolize	VBN	_	27	advcl
21	by	by	IN	_	22	case
22	CYP3A	cyp3a	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	le	le	DT	_	22	dep
26	is	be	VBZ	_	27	auxpass
27	known	know	VBN	_	11	parataxis
28	to	to	TO	_	32	mark
29	be	be	VB	_	32	cop
30	a	a	DT	_	32	det
31	strong	strong	JJ	_	32	amod
32	inhibitor	inhibitor	NN	_	27	xcomp
33	of	of	IN	_	37	case
34	cytochrome	cytochrome	NN	_	37	compound
35	P450	p450	NN	_	37	compound
36	3A	3a	NN	_	37	compound
37	enzyme	enzyme	NN	_	32	nmod
38	,	,	,	_	32	punct
39	care	care	NN	_	42	nsubjpass
40	should	should	MD	_	42	aux
41	be	be	VB	_	42	auxpass
42	taken	take	VBN	_	32	parataxis
43	while	while	IN	_	42	xcomp
44	dosing	dosing	NN	_	45	compound
45	drug5	drug5	NN	_	43	dep
46	with	with	IN	_	47	case
47	drug6	drug6	NN	_	45	nmod
48	and	and	CC	_	47	cc
49	other	other	JJ	_	53	amod
50	strong	strong	JJ	_	53	amod
51	P450	p450	NN	_	53	compound
52	3A	3a	NN	_	53	compound
53	inhibitors	inhibitor	NNS	_	47	conj
54	including	include	VBG	_	55	case
55	drug7	drug7	NN	_	53	nmod
56	,	,	,	_	55	punct
57	drug8	drug8	NN	_	55	conj
58	,	,	,	_	55	punct
59	drug9	drug9	NN	_	55	conj
60	,	,	,	_	55	punct
61	drug10	drug10	NN	_	55	conj
62	,	,	,	_	55	punct
63	drug11	drug11	NN	_	55	conj
64	,	,	,	_	55	punct
65	drug12	drug12	NN	_	55	conj
66	,	,	,	_	55	punct
67	drug13	drug13	NN	_	55	conj
68	,	,	,	_	55	punct
69	drug14	drug14	NN	_	55	conj
70	,	,	,	_	55	punct
71	drug15	drug15	NN	_	55	conj
72	or	or	CC	_	55	cc
73	drug16	drug16	NN	_	55	conj
74	.	.	.	_	7	punct

1	Dose	dose	NN	_	2	compound
2	adjustment	adjustment	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	Capsules	capsule	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	required	require	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	and	and	CC	_	8	cc
11	iPTH	ipth	NN	_	15	compound
12	and	and	CC	_	11	cc
13	serum	serum	NN	_	11	conj
14	calcium	calcium	NN	_	15	compound
15	concentrations	concentration	NNS	_	19	nsubjpass
16	should	should	MD	_	19	aux
17	be	be	VB	_	19	auxpass
18	closely	closely	RB	_	19	advmod
19	monitored	monitor	VBN	_	8	conj
20	if	if	IN	_	23	mark
21	a	a	DT	_	22	det
22	patient	patient	NN	_	23	nsubj
23	initiates	initiate	VBZ	_	19	advcl
24	or	or	CC	_	23	cc
25	discontinues	discontinue	VBZ	_	23	conj
26	therapy	therapy	NN	_	23	dobj
27	with	with	IN	_	31	case
28	a	a	DT	_	31	det
29	strong	strong	JJ	_	31	amod
30	CYP3A4	cyp3a4	NN	_	31	compound
31	inhibitor	inhibitor	NN	_	26	nmod
32	such	such	JJ	_	34	case
33	as	as	IN	_	32	mwe
34	drug2	drug2	NN	_	31	nmod
35	.	.	.	_	8	punct

1	Drugs	drug	NNS	_	14	nsubj
2	that	that	WDT	_	3	nsubj
3	impair	impair	VBP	_	1	acl:relcl
4	intestinal	intestinal	JJ	_	5	amod
5	absorption	absorption	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	5	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug2	drug2	NN	_	5	nmod
12	,	,	,	_	14	punct
13	may	may	MD	_	14	aux
14	interfere	interfere	VB	_	0	ROOT
15	with	with	IN	_	17	case
16	the	the	DT	_	17	det
17	absorption	absorption	NN	_	14	nmod
18	of	of	IN	_	20	case
19	drug3	drug3	NN	_	20	compound
20	Capsules	capsule	NNS	_	17	nmod
21	.	.	.	_	14	punct

1	drug1	drug1	NN	_	3	nsubj
2	competitively	competitively	RB	_	3	advmod
3	inhibits	inhibit	VBZ	_	0	ROOT
4	the	the	DT	_	6	det
5	intracellular	intracellular	JJ	_	6	amod
6	phosphorylation	phosphorylation	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	use	use	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	in	in	IN	_	7	case
7	combination	combination	NN	_	3	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	avoided	avoid	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	data	datum	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	12	mark
6	the	the	DT	_	7	det
7	phosphorylation	phosphorylation	NN	_	12	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	is	be	VBZ	_	12	auxpass
11	also	also	RB	_	12	advmod
12	inhibited	inhibit	VBN	_	4	ccomp
13	at	at	IN	_	15	case
14	relevant	relevant	JJ	_	15	amod
15	concentrations	concentration	NNS	_	12	nmod
16	by	by	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	10	nsubj
4	of	of	IN	_	8	case
5	these	these	DT	_	8	det
6	in	in	FW	_	8	amod
7	vitro	vitro	FW	_	6	dep
8	interactions	interaction	NNS	_	3	nmod
9	is	be	VBZ	_	10	cop
10	unknown	unknown	JJ	_	0	ROOT
11	;	;	:	_	10	punct

1	therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	14	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	either	either	DT	_	4	nmod
9	of	of	IN	_	11	case
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	8	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	undertaken	undertake	VBN	_	0	ROOT
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	.	.	.	_	14	punct

1	No	no	DT	_	7	neg
2	specific	specific	JJ	_	7	amod
3	cytochrome	cytochrome	NN	_	7	compound
4	P450-based	p450-based	JJ	_	7	amod
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	conducted	conduct	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	13	nsubjpass
4	between	between	IN	_	7	case
5	85	85	CD	_	7	nummod
6	mg/m2	mg/m2	NN	_	7	compound
7	drug1	drug1	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	infusional	infusional	JJ	_	10	amod
10	drug2	drug2	NN	_	7	conj
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	treated	treat	VBN	_	15	acl
17	every	every	DT	_	19	det
18	2	2	CD	_	19	nummod
19	weeks	week	NNS	_	16	nmod:tmod
20	.	.	.	_	13	punct

1	Increases	increase	NNS	_	12	nsubjpass
2	of	of	IN	_	5	case
3	drug1	drug1	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	1	nmod
6	by	by	IN	_	9	case
7	approximately	approximately	RB	_	8	advmod
8	20	20	CD	_	9	nummod
9	%	%	NN	_	1	nmod
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	observed	observe	VBN	_	0	ROOT
13	with	with	IN	_	14	case
14	doses	dose	NNS	_	12	nmod
15	of	of	IN	_	18	case
16	130	130	CD	_	18	nummod
17	mg/m2	mg/m2	NN	_	18	compound
18	drug2	drug2	NN	_	14	nmod
19	dosed	dose	VBD	_	14	acl
20	every	every	DT	_	22	det
21	3	3	CD	_	22	nummod
22	weeks	week	NNS	_	19	nmod:tmod
23	.	.	.	_	12	punct

1	Since	since	IN	_	6	mark
2	platinum	platinum	NN	_	6	nsubjpass
3	containing	contain	VBG	_	2	acl
4	species	species	NNS	_	3	dobj
5	are	be	VBP	_	6	auxpass
6	eliminated	eliminate	VBN	_	18	advcl
7	primarily	primarily	RB	_	6	advmod
8	through	through	IN	_	10	case
9	the	the	DT	_	10	det
10	kidney	kidney	NN	_	6	nmod
11	,	,	,	_	18	punct
12	clearance	clearance	NN	_	18	nsubjpass
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	products	product	NNS	_	12	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	decreased	decrease	VBN	_	0	ROOT
19	by	by	IN	_	20	case
20	coadministration	coadministration	NN	_	18	nmod
21	of	of	IN	_	24	case
22	potentially	potentially	RB	_	23	advmod
23	nephrotoxic	nephrotoxic	JJ	_	24	amod
24	compounds	compound	NNS	_	20	nmod
25	;	;	:	_	18	punct

1	although	although	IN	_	8	mark
2	,	,	,	_	8	punct
3	this	this	DT	_	8	nsubjpass
4	has	have	VBZ	_	8	aux
5	not	not	RB	_	8	neg
6	been	be	VBN	_	8	auxpass
7	specifically	specifically	RB	_	8	advmod
8	studied	study	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	interact	interact	VB	_	4	xcomp
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	including	include	VBG	_	12	case
11	drug2	drug2	NN	_	12	compound
12	supplements	supplement	NNS	_	9	nmod
13	;	;	:	_	4	punct

1	interactions	interaction	NNS	_	6	nsubjpass
2	have	have	VBP	_	6	aux
3	not	not	RB	_	6	neg
4	been	be	VBN	_	6	auxpass
5	systematically	systematically	RB	_	6	advmod
6	studied	study	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	chelation	chelation	NN	_	8	compound
8	therapy	therapy	NN	_	2	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug2	drug2	NN	_	8	nmod
13	is	be	VBZ	_	15	auxpass
14	not	not	RB	_	15	neg
15	recommended	recommend	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Drug/Laboratory	Drug/Laboratory	NNP	_	3	compound
2	Tests	Tests	NNP	_	3	compound
3	Interaction	interaction	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	interfere	interfere	VB	_	3	dep
8	with	with	IN	_	9	case
9	serum	serum	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	urinary	urinary	JJ	_	13	amod
12	laboratory	laboratory	NN	_	13	compound
13	tests	test	NNS	_	9	conj
14	.	.	.	_	3	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	drug1	drug1	NN	_	5	dobj
7	to	to	TO	_	8	mark
8	cause	cause	VB	_	6	acl
9	false	false	JJ	_	11	amod
10	positive	positive	JJ	_	11	amod
11	results	result	NNS	_	8	dobj
12	for	for	IN	_	13	case
13	ketones	ketone	NNS	_	11	nmod
14	in	in	IN	_	15	case
15	urine	urine	NN	_	13	nmod
16	using	use	VBG	_	8	xcomp
17	nitroprusside	nitroprusside	NN	_	18	compound
18	reagents	reagent	NNS	_	16	dobj
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	Ketostix	Ketostix	NNP	_	18	nmod
22	and	and	CC	_	5	cc
23	falsely	falsely	RB	_	24	advmod
24	decreased	decrease	VBD	_	25	amod
25	measurements	measurement	NNS	_	5	conj
26	of	of	IN	_	29	case
27	serum	serum	NN	_	29	compound
28	uric	uric	JJ	_	29	amod
29	acid	acid	NN	_	25	nmod
30	and	and	CC	_	29	cc
31	CPK	cpk	NN	_	29	conj
32	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	accentuate	accentuate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	orthostatic	orthostatic	JJ	_	6	amod
6	hypotension	hypotension	NN	_	3	dobj
7	that	that	WDT	_	9	nsubj
8	may	may	MD	_	9	aux
9	occur	occur	VB	_	6	acl:relcl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	3	punct

1	Antihypertensive	antihypertensive	JJ	_	2	amod
2	effects	effect	NNS	_	10	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	related	related	JJ	_	7	amod
7	compounds	compound	NNS	_	4	conj
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	counteracted	counteract	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	drug2	drug2	NN	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	used	use	VBN	_	10	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	.	.	.	_	10	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	results	result	VBZ	_	0	ROOT
8	in	in	IN	_	11	case
9	increased	increase	VBN	_	11	amod
10	plasma	plasma	NN	_	11	compound
11	levels	level	NNS	_	7	nmod
12	of	of	IN	_	14	case
13	both	both	DT	_	14	det
14	drugs	drug	NNS	_	11	nmod
15	.	.	.	_	7	punct

1	A	a	DT	_	2	det
2	total	total	NN	_	10	nsubjpass
3	of	of	IN	_	8	case
4	11	11	CD	_	8	nummod
5	clinical	clinical	JJ	_	8	amod
6	drug-drug	drug-drug	JJ	_	8	amod
7	interaction	interaction	NN	_	8	compound
8	studies	study	NNS	_	2	nmod
9	were	be	VBD	_	10	auxpass
10	conducted	conduct	VBN	_	0	ROOT
11	in	in	IN	_	13	case
12	healthy	healthy	JJ	_	13	amod
13	volunteers	volunteer	NNS	_	10	nmod
14	to	to	TO	_	15	mark
15	evaluate	evaluate	VB	_	10	xcomp
16	the	the	DT	_	17	det
17	potential	potential	NN	_	15	dobj
18	for	for	IN	_	19	case
19	interaction	interaction	NN	_	17	nmod
20	between	between	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	drug2	drug2	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug3	drug3	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug4	drug4	NN	_	21	conj
28	,	,	,	_	21	punct
29	drug5	drug5	NN	_	21	conj
30	,	,	,	_	21	punct
31	drug6	drug6	NN	_	21	conj
32	,	,	,	_	21	punct
33	drug7	drug7	NN	_	21	conj
34	,	,	,	_	21	punct
35	drug8	drug8	NN	_	21	conj
36	,	,	,	_	21	punct
37	drug9	drug9	NN	_	21	conj
38	,	,	,	_	21	punct
39	and	and	CC	_	21	cc
40	drug10	drug10	NN	_	21	conj
41	.	.	.	_	10	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	studies	study	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	no	no	DT	_	6	neg
6	interaction	interaction	NN	_	14	nsubjpass
7	that	that	WDT	_	8	nsubj
8	altered	alter	VBD	_	6	acl:relcl
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	8	dobj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	was	be	VBD	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	of	of	IN	_	8	case
6	a	a	DT	_	8	det
7	single	single	JJ	_	8	amod
8	dose	dose	NN	_	4	nmod
9	or	or	CC	_	8	cc
10	multiple	multiple	JJ	_	11	amod
11	doses	dose	NNS	_	8	conj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	8	nmod
14	on	on	IN	_	15	case
15	drug2	drug2	NN	_	4	nmod
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug4	drug4	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug5	drug5	NN	_	15	conj
22	,	,	,	_	15	punct
23	and	and	CC	_	15	cc
24	drug6	drug6	NN	_	25	compound
25	pharmacokinetics	pharmacokinetic	NNS	_	15	conj
26	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	compound
2	AUC	auc	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	increased	increase	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	21	21	CD	_	7	nummod
7	%	%	NN	_	4	nmod
8	with	with	IN	_	10	case
9	no	no	DT	_	10	neg
10	effect	effect	NN	_	4	nmod
11	on	on	IN	_	12	case
12	Cmax	Cmax	NNP	_	10	nmod
13	in	in	IN	_	18	case
14	the	the	DT	_	18	dep
15	presence	presence	NN	_	18	dep
16	of	of	IN	_	18	case
17	steady-state	steady-state	JJ	_	18	amod
18	drug2	drug2	NN	_	10	nmod
19	compared	compare	VBN	_	21	case
20	with	with	IN	_	21	case
21	drug3	drug3	NN	_	10	nmod
22	alone	alone	RB	_	21	advmod
23	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	AUC	auc	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	Cmax	cmax	NN	_	2	conj
5	were	be	VBD	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	18	18	CD	_	9	nummod
9	%	%	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	42	42	CD	_	12	nummod
12	%	%	NN	_	9	conj
13	,	,	,	_	6	punct
14	respectively	respectively	RB	_	6	advmod
15	,	,	,	_	6	punct
16	in	in	IN	_	21	case
17	the	the	DT	_	21	dep
18	presence	presence	NN	_	21	dep
19	of	of	IN	_	21	case
20	steady-state	steady-state	JJ	_	21	amod
21	drug2	drug2	NN	_	6	nmod
22	compared	compare	VBN	_	24	case
23	with	with	IN	_	24	case
24	drug3	drug3	NN	_	21	nmod
25	alone	alone	RB	_	24	advmod
26	.	.	.	_	6	punct

1	Patients	patient	NNS	_	12	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	or	or	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	2	nmod
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	monitored	monitor	VBN	_	0	ROOT
13	for	for	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	drug5	drug5	NN	_	17	compound
17	toxicity	toxicity	NN	_	14	conj
18	and	and	CC	_	14	cc
19	drug6	drug6	NN	_	22	compound
20	or	or	CC	_	19	cc
21	drug7	drug7	NN	_	19	conj
22	dosage	dosage	NN	_	14	conj
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	reduced	reduce	VBN	_	12	ccomp
26	if	if	IN	_	27	mark
27	necessary	necessary	JJ	_	25	advcl
28	.	.	.	_	12	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	not	not	RB	_	5	neg
4	an	a	DT	_	5	det
5	inhibitor	inhibitor	NN	_	0	ROOT
6	of	of	IN	_	7	case
7	P-glycoprotein	p-glycoprotein	NN	_	5	nmod
8	and	and	CC	_	5	cc
9	,	,	,	_	5	punct
10	therefore	therefore	RB	_	15	advmod
11	,	,	,	_	15	punct
12	would	would	MD	_	15	aux
13	not	not	RB	_	15	neg
14	be	be	VB	_	15	auxpass
15	expected	expect	VBN	_	5	conj
16	to	to	TO	_	17	mark
17	alter	alter	VB	_	15	xcomp
18	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	21	amod
19	drug	drug	NN	_	21	compound
20	transport	transport	NN	_	21	compound
21	activity	activity	NN	_	17	dobj
22	.	.	.	_	5	punct

1	Hypokalemia	hypokalemia	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	sensitize	sensitize	VB	_	0	ROOT
4	or	or	CC	_	3	cc
5	exaggerate	exaggerate	VB	_	3	conj
6	the	the	DT	_	7	det
7	response	response	NN	_	3	dobj
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	heart	heart	NN	_	7	nmod
11	to	to	TO	_	14	case
12	the	the	DT	_	14	det
13	toxic	toxic	JJ	_	14	amod
14	effects	effect	NNS	_	7	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	e.g.	e.g.	FW	_	16	dep
19	,	,	,	_	18	punct
20	increased	increase	VBD	_	22	amod
21	ventricular	ventricular	JJ	_	22	amod
22	irritability	irritability	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	18	punct
24	.	.	.	_	3	punct

1	Hypokalemia	hypokalemia	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	develop	develop	VB	_	0	ROOT
4	during	during	IN	_	6	case
5	concomitant	concomitant	JJ	_	6	amod
6	use	use	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	compound
2	requirements	requirement	NNS	_	8	nsubjpass
3	in	in	IN	_	5	case
4	diabetic	diabetic	JJ	_	5	amod
5	patients	patient	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	increased	increase	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	decreased	decrease	VBN	_	8	conj
11	,	,	,	_	8	punct
12	or	or	CC	_	8	cc
13	unchanged	unchanged	JJ	_	8	conj
14	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	arterial	arterial	JJ	_	5	amod
5	responsiveness	responsiveness	NN	_	3	dobj
6	to	to	TO	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	diminution	diminution	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	sufficient	sufficient	JJ	_	0	ROOT
6	to	to	TO	_	7	mark
7	preclude	preclude	VB	_	5	xcomp
8	effectiveness	effectiveness	NN	_	7	dobj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	pressor	pressor	NN	_	12	compound
12	agent	agent	NN	_	8	nmod
13	for	for	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	use	use	NN	_	7	nmod
16	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	responsiveness	responsiveness	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	compound
2	renal	renal	JJ	_	3	amod
3	clearance	clearance	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	reduced	reduce	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	5	punct
9	increasing	increase	VBG	_	5	xcomp
10	the	the	DT	_	11	det
11	risk	risk	NN	_	9	dobj
12	of	of	IN	_	14	case
13	drug3	drug3	NN	_	14	compound
14	toxicity	toxicity	NN	_	11	nmod
15	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	add	add	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	or	or	CC	_	4	cc
6	potentiate	potentiate	VB	_	4	conj
7	the	the	DT	_	8	det
8	action	action	NN	_	3	nmod
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	3	punct

1	Potentiation	potentiation	NN	_	2	nsubj
2	occurs	occur	VBZ	_	0	ROOT
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug3	drug3	NN	_	7	compound
6	/	/	:	_	7	punct
7	drug4	drug4	NN	_	10	nsubj
8	does	do	VBZ	_	10	aux
9	not	not	RB	_	10	neg
10	influence	influence	VB	_	3	dep
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	10	dobj
13	of	of	IN	_	14	case
14	drug5	drug5	NN	_	12	nmod
15	in	in	IN	_	17	case
16	healthy	healthy	JJ	_	17	amod
17	volunteers	volunteer	NNS	_	10	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	N	n	NN	_	17	dep
20	=	=	JJ	_	19	amod
21	10	10	CD	_	20	dep
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	.	.	.	_	3	punct

1	5	5	CD	_	2	nummod
2	hours	hour	NNS	_	0	ROOT
3	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	healthy	healthy	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	15	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	N	n	NN	_	5	dep
8	=	=	JJ	_	7	amod
9	11	11	CD	_	8	dep
10	-RRB-	-rrb-	-RRB-	_	7	punct
11	,	,	,	_	15	punct
12	drug2	drug2	NN	_	15	nsubj
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	influence	influence	VB	_	1	appos
16	the	the	DT	_	17	det
17	pharmacokinetics	pharmacokinetic	NNS	_	15	dobj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Population	Population	NNP	_	5	compound
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	analysis	analysis	NN	_	6	nsubj
6	suggests	suggest	VBZ	_	1	appos
7	that	that	IN	_	10	mark
8	drug2	drug2	NN	_	10	nsubj
9	is	be	VBZ	_	10	cop
10	unlikely	unlikely	JJ	_	6	ccomp
11	to	to	TO	_	12	mark
12	alter	alter	VB	_	10	xcomp
13	the	the	DT	_	15	det
14	oral	oral	JJ	_	15	amod
15	clearance	clearance	NN	_	12	dobj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	N	n	NN	_	20	nsubj
20	=	=	JJ	_	17	dep
21	54	54	CD	_	20	dobj
22	-RRB-	-rrb-	-RRB-	_	20	punct
23	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	21	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	known	known	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	tubular	tubular	JJ	_	11	amod
11	secretion	secretion	NN	_	7	nmod
12	of	of	IN	_	14	case
13	organic	organic	JJ	_	14	amod
14	bases	basis	NNS	_	11	nmod
15	via	via	IN	_	19	case
16	the	the	DT	_	19	det
17	cationic	cationic	JJ	_	19	amod
18	transport	transport	NN	_	19	compound
19	system	system	NN	_	7	nmod
20	,	,	,	_	3	punct
21	caused	cause	VBD	_	1	appos
22	a	a	DT	_	25	det
23	50	50	CD	_	24	compound
24	%	%	NN	_	25	amod
25	increase	increase	NN	_	21	dobj
26	in	in	IN	_	28	case
27	drug3	drug3	NN	_	28	compound
28	AUC	auc	NN	_	25	nmod
29	and	and	CC	_	25	cc
30	a	a	DT	_	33	det
31	40	40	CD	_	32	compound
32	%	%	NN	_	33	amod
33	increase	increase	NN	_	25	conj
34	in	in	IN	_	35	case
35	half-life	half-life	NN	_	33	nmod
36	-LRB-	-lrb-	-LRB-	_	38	punct
37	N	n	NN	_	38	nsubj
38	=	=	JJ	_	33	dep
39	12	12	CD	_	38	dobj
40	-RRB-	-rrb-	-RRB-	_	38	punct
41	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	23	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	known	known	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	tubular	tubular	JJ	_	11	amod
11	secretion	secretion	NN	_	7	nmod
12	of	of	IN	_	14	case
13	organic	organic	JJ	_	14	amod
14	acids	acid	NNS	_	11	nmod
15	via	via	IN	_	18	case
16	the	the	DT	_	18	det
17	aruonic	aruonic	JJ	_	18	amod
18	transporter	transporter	NN	_	7	nmod
19	,	,	,	_	3	punct
20	did	do	VBD	_	23	aux
21	not	not	RB	_	23	neg
22	noticeably	noticeably	RB	_	23	advmod
23	influence	influence	VB	_	1	appos
24	drug3	drug3	NN	_	25	compound
25	pharmacokinetics	pharmacokinetic	NNS	_	23	dobj
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	N	n	NN	_	25	dep
28	=	=	JJ	_	27	amod
29	12	12	CD	_	28	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	0	ROOT
3	eliminated	eliminate	VBN	_	2	acl
4	via	via	IN	_	6	case
5	renal	renal	JJ	_	6	amod
6	secretion	secretion	NN	_	3	nmod
7	:	:	:	_	2	punct
8	Population	Population	NNP	_	10	compound
9	pharmacokinetic	pharmacokinetic	JJ	_	10	amod
10	analysis	analysis	NN	_	11	nsubj
11	suggests	suggest	VBZ	_	2	dep
12	that	that	IN	_	42	mark
13	coadministration	coadministration	NN	_	42	nsubj
14	of	of	IN	_	15	case
15	drugs	drug	NNS	_	13	nmod
16	that	that	WDT	_	18	nsubjpass
17	are	be	VBP	_	18	auxpass
18	secreted	secrete	VBN	_	15	acl:relcl
19	by	by	IN	_	23	case
20	the	the	DT	_	23	det
21	cationic	cationic	JJ	_	23	amod
22	transport	transport	NN	_	23	compound
23	system	system	NN	_	18	nmod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	e.g.	e.g.	FW	_	27	dep
26	,	,	,	_	27	punct
27	drug1	drug1	NN	_	18	dep
28	,	,	,	_	27	punct
29	drug2	drug2	NN	_	27	conj
30	,	,	,	_	27	punct
31	drug3	drug3	NN	_	27	conj
32	,	,	,	_	27	punct
33	drug4	drug4	NN	_	27	conj
34	,	,	,	_	27	punct
35	drug5	drug5	NN	_	27	conj
36	,	,	,	_	27	punct
37	drug6	drug6	NN	_	27	conj
38	,	,	,	_	27	punct
39	and	and	CC	_	27	cc
40	drug7	drug7	NN	_	27	conj
41	-RRB-	-rrb-	-RRB-	_	27	punct
42	decreases	decrease	VBZ	_	11	ccomp
43	the	the	DT	_	45	det
44	oral	oral	JJ	_	45	amod
45	clearance	clearance	NN	_	42	dobj
46	of	of	IN	_	47	case
47	drug8	drug8	NN	_	45	nmod
48	by	by	IN	_	51	case
49	about	about	RB	_	50	advmod
50	20	20	CD	_	51	nummod
51	%	%	NN	_	42	nmod
52	,	,	,	_	42	punct
53	while	while	IN	_	76	mark
54	those	those	DT	_	76	nsubj
55	secreted	secrete	VBN	_	54	acl
56	by	by	IN	_	60	case
57	the	the	DT	_	60	det
58	anionic	anionic	JJ	_	60	amod
59	transport	transport	NN	_	60	compound
60	system	system	NN	_	55	nmod
61	-LRB-	-lrb-	-LRB-	_	64	punct
62	e.g.	e.g.	FW	_	64	dep
63	,	,	,	_	64	punct
64	drug9	drug9	NN	_	54	dep
65	,	,	,	_	64	punct
66	drug10	drug10	NN	_	64	conj
67	,	,	,	_	64	punct
68	drug11	drug11	NN	_	64	conj
69	,	,	,	_	64	punct
70	drug12	drug12	NN	_	64	conj
71	,	,	,	_	64	punct
72	and	and	CC	_	64	cc
73	drug13	drug13	NN	_	64	conj
74	-RRB-	-rrb-	-RRB-	_	64	punct
75	are	be	VBP	_	76	cop
76	likely	likely	JJ	_	42	advcl
77	to	to	TO	_	78	mark
78	have	have	VB	_	76	xcomp
79	little	little	JJ	_	80	amod
80	effect	effect	NN	_	78	dobj
81	on	on	IN	_	84	case
82	the	the	DT	_	84	det
83	oral	oral	JJ	_	84	amod
84	clearance	clearance	NN	_	78	nmod
85	of	of	IN	_	86	case
86	drug14	drug14	NN	_	84	nmod
87	.	.	.	_	2	punct

1	CYP	cyp	NN	_	2	compound
2	interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Inhibitors	inhibitor	NNS	_	12	nsubjpass
5	of	of	IN	_	8	case
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	enzymes	enzyme	NNS	_	4	nmod
9	would	would	MD	_	12	aux
10	not	not	RB	_	12	neg
11	be	be	VB	_	12	auxpass
12	expected	expect	VBN	_	2	dep
13	to	to	TO	_	14	mark
14	affect	affect	VB	_	12	xcomp
15	drug1	drug1	NN	_	16	compound
16	elimination	elimination	NN	_	14	dobj
17	because	because	IN	_	22	mark
18	drug2	drug2	NN	_	22	nsubjpass
19	is	be	VBZ	_	22	auxpass
20	not	not	RB	_	22	neg
21	appreciably	appreciably	RB	_	22	advmod
22	metabolized	metabolize	VBN	_	12	advcl
23	by	by	IN	_	25	case
24	these	these	DT	_	25	det
25	enzymes	enzyme	NNS	_	22	nmod
26	in	in	FW	_	27	compound
27	vivo	vivo	FW	_	28	advmod
28	or	or	CC	_	22	advmod
29	in	in	FW	_	30	compound
30	vitro	vitro	FW	_	28	advmod
31	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	CYP	cyp	NN	_	7	compound
6	enzymes	enzyme	NNS	_	7	compound
7	CYPIA2	cypia2	NN	_	4	dobj
8	,	,	,	_	7	punct
9	CYP2C9	cyp2c9	NN	_	7	conj
10	,	,	,	_	7	punct
11	CYP2CI9	cyp2ci9	NN	_	7	conj
12	,	,	,	_	7	punct
13	CYP2EI	cyp2ei	NN	_	7	conj
14	,	,	,	_	7	punct
15	and	and	CC	_	7	cc
16	CYP3A4	cyp3a4	NN	_	7	conj
17	.	.	.	_	4	punct

1	Inhibition	inhibition	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	CYP2D6	cyp2d6	NN	_	1	nmod
4	was	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	an	a	DT	_	9	det
8	apparent	apparent	JJ	_	9	amod
9	Ki	ki	NN	_	5	nmod
10	of	of	IN	_	12	case
11	30	30	CD	_	12	nummod
12	uM	um	NN	_	9	nmod
13	,	,	,	_	5	punct
14	indicating	indicate	VBG	_	5	xcomp
15	that	that	IN	_	19	mark
16	drug1	drug1	NN	_	19	nsubj
17	will	will	MD	_	19	aux
18	not	not	RB	_	19	neg
19	inhibit	inhibit	VB	_	14	ccomp
20	CYP	cyp	NN	_	21	compound
21	enzymes	enzyme	NNS	_	19	dobj
22	at	at	IN	_	24	case
23	plasma	plasma	NN	_	24	compound
24	concentrations	concentration	NNS	_	19	nmod
25	observed	observe	VBN	_	24	acl
26	following	follow	VBG	_	31	case
27	the	the	DT	_	31	det
28	highest	highest	JJS	_	31	amod
29	recommended	recommend	VBN	_	31	amod
30	clinical	clinical	JJ	_	31	amod
31	dose	dose	NN	_	25	nmod
32	-LRB-	-lrb-	-LRB-	_	35	punct
33	1.5	1.5	CD	_	35	nummod
34	mg	mg	NN	_	35	compound
35	tid	tid	NN	_	31	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Since	since	IN	_	7	mark
4	drug2	drug2	NN	_	7	nsubj
5	is	be	VBZ	_	7	cop
6	a	a	DT	_	7	det
7	drug3	drug3	NN	_	11	advcl
8	,	,	,	_	11	punct
9	it	it	PRP	_	11	nsubj
10	is	be	VBZ	_	11	cop
11	possible	possible	JJ	_	1	dep
12	that	that	IN	_	30	mark
13	drug4	drug4	NN	_	30	nsubj
14	,	,	,	_	13	punct
15	such	such	JJ	_	18	case
16	as	as	IN	_	15	mwe
17	the	the	DT	_	18	det
18	drug5	drug5	NN	_	13	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug6	drug6	NN	_	18	dep
21	,	,	,	_	20	punct
22	drug7	drug7	NN	_	20	appos
23	,	,	,	_	20	punct
24	drug8	drug8	NN	_	20	appos
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	or	or	CC	_	18	cc
27	drug9	drug9	NN	_	18	conj
28	,	,	,	_	13	punct
29	may	may	MD	_	30	aux
30	diminish	diminish	VB	_	11	ccomp
31	the	the	DT	_	32	det
32	effectiveness	effectiveness	NN	_	30	dobj
33	of	of	IN	_	34	case
34	drug10	drug10	NN	_	32	nmod
35	.	.	.	_	1	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	There	there	EX	_	7	expl
7	are	be	VBP	_	5	acl:relcl
8	no	no	DT	_	10	neg
9	known	known	JJ	_	10	amod
10	interactions	interaction	NNS	_	7	nsubj
11	between	between	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	laboratory	laboratory	NN	_	15	compound
15	tests	test	NNS	_	12	conj
16	.	.	.	_	5	punct

1	Do	do	VB	_	3	aux
2	not	not	RB	_	3	neg
3	exceed	exceed	VB	_	0	ROOT
4	a	a	DT	_	8	det
5	5	5	CD	_	6	compound
6	mg	mg	NN	_	8	amod
7	daily	daily	JJ	_	8	amod
8	dose	dose	NN	_	3	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	when	when	WRB	_	12	advmod
12	administered	administer	VBN	_	3	advcl
13	with	with	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	doses	dose	NNS	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	or	or	CC	_	17	cc
19	other	other	JJ	_	22	amod
20	potent	potent	JJ	_	22	amod
21	CYP3A4	cyp3a4	NN	_	22	compound
22	inhibitors	inhibitor	NNS	_	17	conj
23	.	.	.	_	3	punct

1	Patients	patient	NNS	_	29	dep
2	with	with	IN	_	3	case
3	Congenital	congenital	JJ	_	1	nmod
4	or	or	CC	_	3	cc
5	Acquired	acquire	VBN	_	3	conj
6	QT	QT	NNP	_	7	compound
7	Prolongation	Prolongation	NNP	_	3	dep
8	In	in	IN	_	10	case
9	a	a	DT	_	10	det
10	study	study	NN	_	1	nmod
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	effect	effect	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	on	on	IN	_	19	case
17	the	the	DT	_	19	det
18	QT	QT	NNP	_	19	compound
19	interval	interval	NN	_	13	nmod
20	in	in	IN	_	23	case
21	76	76	CD	_	23	nummod
22	healthy	healthy	JJ	_	23	amod
23	women	woman	NNS	_	13	nmod
24	,	,	,	_	29	punct
25	the	the	DT	_	28	det
26	QT	QT	NNP	_	28	compound
27	prolonging	prolong	VBG	_	28	compound
28	effect	effect	NN	_	29	nsubj
29	appeared	appear	VBD	_	0	ROOT
30	less	less	RBR	_	29	advmod
31	with	with	IN	_	34	case
32	drug2	drug2	NN	_	34	compound
33	10	10	CD	_	34	nummod
34	mg	mg	NN	_	30	nmod
35	than	than	IN	_	38	case
36	with	with	IN	_	38	case
37	30	30	CD	_	38	nummod
38	mg	mg	NN	_	30	nmod
39	-LRB-	-lrb-	-LRB-	_	57	punct
40	three	three	CD	_	41	nummod
41	times	time	NNS	_	57	nsubj
42	the	the	DT	_	43	det
43	maximum	maximum	NN	_	44	nsubj
44	recommended	recommend	VBD	_	41	acl:relcl
45	dose	dose	NN	_	44	dobj
46	-RRB-	-rrb-	-RRB-	_	41	punct
47	,	,	,	_	41	punct
48	and	and	CC	_	41	cc
49	the	the	DT	_	50	det
50	effect	effect	NN	_	41	conj
51	of	of	IN	_	52	case
52	drug3	drug3	NN	_	50	nmod
53	30	30	CD	_	54	nummod
54	mg	mg	NN	_	52	dep
55	did	do	VBD	_	57	aux
56	not	not	RB	_	57	neg
57	appear	appear	VB	_	38	acl:relcl
58	as	as	IN	_	59	advmod
59	large	large	JJ	_	57	xcomp
60	as	as	IN	_	61	case
61	that	that	DT	_	59	nmod
62	of	of	IN	_	66	case
63	the	the	DT	_	66	det
64	positive	positive	JJ	_	66	amod
65	control	control	NN	_	66	compound
66	drug4	drug4	NN	_	61	nmod
67	at	at	IN	_	70	case
68	its	its	PRP$	_	70	nmod:poss
69	therapeutic	therapeutic	JJ	_	70	amod
70	dose	dose	NN	_	66	nmod
71	.	.	.	_	29	punct

1	This	this	DT	_	2	det
2	observation	observation	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	clinical	clinical	JJ	_	8	amod
8	decisions	decision	NNS	_	5	nmod
9	to	to	TO	_	10	mark
10	prescribe	prescribe	VB	_	8	acl
11	drug1	drug1	NN	_	10	dobj
12	for	for	IN	_	13	case
13	patients	patient	NNS	_	10	nmod
14	with	with	IN	_	17	case
15	a	a	DT	_	17	det
16	known	known	JJ	_	17	amod
17	history	history	NN	_	13	nmod
18	of	of	IN	_	20	case
19	QT	QT	NNP	_	20	compound
20	prolongation	prolongation	NN	_	17	nmod
21	or	or	CC	_	20	cc
22	patients	patient	NNS	_	20	conj
23	who	who	WP	_	25	nsubj
24	are	be	VBP	_	25	aux
25	taking	take	VBG	_	13	acl:relcl
26	medications	medication	NNS	_	25	dobj
27	known	know	VBN	_	26	acl
28	to	to	TO	_	29	mark
29	prolong	prolong	VB	_	27	xcomp
30	the	the	DT	_	32	det
31	QT	QT	NNP	_	32	compound
32	interval	interval	NN	_	29	dobj
33	.	.	.	_	5	punct

1	drug1	drug1	NN	_	10	nsubj
2	at	at	IN	_	4	case
3	a	a	DT	_	4	det
4	Dose	dose	NN	_	1	nmod
5	of	of	IN	_	7	case
6	10	10	CD	_	7	nummod
7	mg	mg	NN	_	4	nmod
8	Once	once	RB	_	9	advmod
9	Daily	daily	JJ	_	10	advmod
10	Dosed	dose	VBN	_	0	ROOT
11	to	to	TO	_	14	case
12	Pharmacokinetic	pharmacokinetic	JJ	_	14	amod
13	Steady	steady	JJ	_	14	amod
14	State	state	NN	_	10	nmod
15	-	-	:	_	10	punct
16	did	do	VBD	_	18	aux
17	not	not	RB	_	18	neg
18	cause	cause	VB	_	10	parataxis
19	clinically	clinically	RB	_	20	advmod
20	significant	significant	JJ	_	21	amod
21	changes	change	NNS	_	18	dobj
22	in	in	IN	_	24	case
23	the	the	DT	_	24	det
24	kinetics	kinetics	NNS	_	21	nmod
25	of	of	IN	_	29	case
26	a	a	DT	_	29	det
27	single	single	JJ	_	29	amod
28	intravenous	intravenous	JJ	_	29	amod
29	dose	dose	NN	_	24	nmod
30	of	of	IN	_	31	case
31	drug2	drug2	NN	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	38	punct
33	predominantly	predominantly	RB	_	38	advmod
34	a	a	DT	_	38	det
35	cytochrome	cytochrome	NN	_	38	compound
36	P450	p450	NN	_	38	compound
37	1A2	1a2	NN	_	38	compound
38	substrate	substrate	NN	_	29	appos
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	.	.	.	_	10	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	change	change	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	profile	profile	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	a	a	DT	_	12	det
12	substrate	substrate	NN	_	9	dep
13	of	of	IN	_	16	case
14	cytochromes	cytochrome	NNS	_	16	compound
15	P450	p450	NN	_	16	compound
16	2A6	2a6	NN	_	12	nmod
17	and	and	CC	_	16	cc
18	2C9	2c9	NN	_	16	conj
19	-RRB-	-rrb-	-RRB-	_	12	punct
20	or	or	CC	_	4	cc
21	influence	influence	VB	_	4	conj
22	the	the	DT	_	23	det
23	effect	effect	NN	_	21	dobj
24	of	of	IN	_	29	case
25	a	a	DT	_	29	det
26	single	single	JJ	_	29	amod
27	30-mg	30-mg	JJ	_	29	amod
28	oral	oral	JJ	_	29	amod
29	dose	dose	NN	_	23	nmod
30	of	of	IN	_	31	case
31	drug2	drug2	NN	_	29	nmod
32	on	on	IN	_	34	case
33	prothrombin	prothrombin	NN	_	34	compound
34	time	time	NN	_	23	nmod
35	or	or	CC	_	34	cc
36	the	the	DT	_	37	det
37	INR	inr	NN	_	34	conj
38	-LRB-	-lrb-	-LRB-	_	41	punct
39	International	International	NNP	_	41	compound
40	Normalized	Normalized	NNP	_	41	compound
41	Ratio	Ratio	NNP	_	37	appos
42	-RRB-	-rrb-	-RRB-	_	41	punct
43	.	.	.	_	4	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	change	change	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	profile	profile	NN	_	4	dobj
8	or	or	CC	_	7	cc
9	urinary	urinary	JJ	_	10	amod
10	excretion	excretion	NN	_	7	conj
11	of	of	IN	_	13	case
12	immunoreactive	immunoreactive	JJ	_	13	amod
13	drug1	drug1	NN	_	7	nmod
14	.	.	.	_	4	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	change	change	VB	_	0	ROOT
5	the	the	DT	_	8	det
6	plasma	plasma	NN	_	8	compound
7	concentration	concentration	NN	_	8	compound
8	profile	profile	NN	_	4	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	a	a	DT	_	13	det
13	substrate	substrate	NN	_	10	dep
14	of	of	IN	_	17	case
15	cytochrome	cytochrome	NN	_	17	compound
16	P450	p450	NN	_	17	compound
17	3A4	3a4	NN	_	13	nmod
18	-RRB-	-rrb-	-RRB-	_	13	punct
19	or	or	CC	_	10	cc
20	drug2	drug2	NN	_	10	conj
21	,	,	,	_	4	punct
22	its	its	PRP$	_	24	nmod:poss
23	carboxylated	carboxylate	VBN	_	24	amod
24	metabolite	metabolite	NN	_	4	dobj
25	,	,	,	_	4	punct
26	and	and	CC	_	4	cc
27	did	do	VBD	_	29	aux
28	not	not	RB	_	29	neg
29	prolong	prolong	VB	_	4	conj
30	the	the	DT	_	32	det
31	QTc	qtc	NN	_	32	compound
32	interval	interval	NN	_	29	dobj
33	following	follow	VBG	_	34	case
34	co-administration	co-administration	NN	_	29	nmod
35	with	with	IN	_	38	case
36	drug3	drug3	NN	_	38	compound
37	60	60	CD	_	38	nummod
38	mg	mg	NN	_	34	nmod
39	twice	twice	RB	_	40	advmod
40	daily	daily	RB	_	34	advmod
41	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	at	at	IN	_	3	case
3	Doses	dose	NNS	_	1	nmod
4	of	of	IN	_	8	case
5	100	100	CD	_	8	nummod
6	mg	mg	NN	_	8	compound
7	Daily	Daily	NNP	_	8	compound
8	Dosed	Dosed	NNP	_	3	nmod
9	to	to	TO	_	12	case
10	Pharmacokinetic	pharmacokinetic	JJ	_	12	amod
11	Steady	steady	JJ	_	12	amod
12	State	state	NN	_	1	nmod
13	:	:	:	_	1	punct
14	-	-	:	_	1	punct
15	did	do	VBD	_	18	aux
16	not	not	RB	_	18	neg
17	significantly	significantly	RB	_	18	advmod
18	alter	alter	VB	_	1	dep
19	the	the	DT	_	21	det
20	plasma	plasma	NN	_	21	compound
21	concentrations	concentration	NNS	_	18	dobj
22	of	of	IN	_	24	case
23	either	either	CC	_	24	det
24	component	component	NN	_	21	nmod
25	of	of	IN	_	28	case
26	an	a	DT	_	28	det
27	oral	oral	JJ	_	28	amod
28	drug2	drug2	NN	_	24	nmod
29	containing	contain	VBG	_	28	acl
30	drug3	drug3	NN	_	35	compound
31	1	1	CD	_	35	nummod
32	mg/ethinyl	mg/ethinyl	NN	_	35	compound
33	drug4	drug4	NN	_	35	compound
34	35	35	CD	_	35	nummod
35	mcg	mcg	NN	_	29	dobj
36	.	.	.	_	1	punct

1	-	-	:	_	4	punct
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	cause	cause	VB	_	0	ROOT
5	any	any	DT	_	8	det
6	clinically	clinically	RB	_	7	advmod
7	significant	significant	JJ	_	8	amod
8	change	change	NN	_	4	dobj
9	in	in	IN	_	11	case
10	plasma	plasma	NN	_	11	compound
11	profiles	profile	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	following	follow	VBG	_	17	case
17	administration	administration	NN	_	4	nmod
18	of	of	IN	_	21	case
19	either	either	CC	_	21	cc:preconj
20	oral	oral	JJ	_	21	amod
21	drug3	drug3	NN	_	17	nmod
22	or	or	CC	_	21	cc
23	intravenous	intravenous	JJ	_	24	amod
24	drug4	drug4	NN	_	21	conj
25	.	.	.	_	4	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	which	which	WDT	_	4	nsubj
4	induces	induce	VBZ	_	1	acl:relcl
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	4	dobj
7	,	,	,	_	1	punct
8	decreased	decrease	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	AUC	auc	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	approximately	approximately	RB	_	14	advmod
14	40	40	CD	_	15	nummod
15	%	%	NN	_	8	nmod:npmod
16	following	follow	VBG	_	20	case
17	a	a	DT	_	20	det
18	single	single	JJ	_	20	amod
19	10-mg	10-mg	JJ	_	20	amod
20	dose	dose	NN	_	8	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	7	nsubjpass
4	for	for	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	reasonable	reasonable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	employ	employ	VB	_	3	xcomp
6	appropriate	appropriate	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	dobj
9	when	when	WRB	_	23	advmod
10	potent	potent	JJ	_	14	amod
11	cytochrome	cytochrome	NN	_	14	compound
12	P450	p450	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	inducers	inducer	NNS	_	23	nsubjpass
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug1	drug1	NN	_	14	nmod
19	or	or	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	14	punct
22	are	be	VBP	_	23	auxpass
23	co-administered	co-administer	VBN	_	5	advcl
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	therapies	therapy	NNS	_	4	nmod
8	routinely	routinely	RB	_	9	advmod
9	used	use	VBN	_	7	acl
10	in	in	IN	_	15	case
11	the	the	DT	_	15	det
12	prophylaxis	prophylaxis	NN	_	15	amod
13	and	and	CC	_	12	cc
14	chronic	chronic	JJ	_	12	conj
15	treatment	treatment	NN	_	9	nmod
16	of	of	IN	_	17	case
17	asthma	asthma	NN	_	15	nmod
18	with	with	IN	_	21	case
19	no	no	DT	_	21	neg
20	apparent	apparent	JJ	_	21	amod
21	increase	increase	NN	_	9	nmod
22	in	in	IN	_	24	case
23	adverse	adverse	JJ	_	24	amod
24	reactions	reaction	NNS	_	21	nmod
25	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	drug-interaction	drug-interaction	JJ	_	3	amod
3	studies	study	NNS	_	13	nmod
4	,	,	,	_	13	punct
5	the	the	DT	_	8	det
6	recommended	recommend	VBN	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	dose	dose	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	did	do	VBD	_	13	aux
12	not	not	RB	_	13	neg
13	have	have	VB	_	0	ROOT
14	clinically	clinically	RB	_	15	advmod
15	important	important	JJ	_	16	amod
16	effects	effect	NNS	_	13	dobj
17	on	on	IN	_	19	case
18	the	the	DT	_	19	det
19	pharmacokinetics	pharmacokinetic	NNS	_	13	nmod
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	following	follow	VBG	_	23	amod
23	drugs	drug	NNS	_	19	nmod
24	:	:	:	_	19	punct
25	drug2	drug2	NN	_	19	dep
26	,	,	,	_	25	punct
27	drug3	drug3	NN	_	25	conj
28	,	,	,	_	25	punct
29	drug4	drug4	NN	_	25	conj
30	,	,	,	_	25	punct
31	oral	oral	JJ	_	32	amod
32	drug5	drug5	NN	_	25	conj
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	drug6	drug6	NN	_	36	compound
35	1	1	CD	_	36	nummod
36	mg	mg	NN	_	32	appos
37	/	/	:	_	36	punct
38	drug7	drug7	NN	_	40	compound
39	35	35	CD	_	40	nummod
40	mcg	mcg	NN	_	36	dep
41	-RRB-	-rrb-	-RRB-	_	36	punct
42	,	,	,	_	25	punct
43	drug8	drug8	NN	_	25	conj
44	,	,	,	_	25	punct
45	drug9	drug9	NN	_	25	conj
46	,	,	,	_	25	punct
47	and	and	CC	_	25	cc
48	drug10	drug10	NN	_	25	conj
49	.	.	.	_	13	punct

1	Although	although	IN	_	8	mark
2	additional	additional	JJ	_	5	amod
3	specific	specific	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	were	be	VBD	_	8	auxpass
7	not	not	RB	_	8	neg
8	performed	perform	VBN	_	12	advcl
9	,	,	,	_	12	punct
10	drug1	drug1	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	used	use	VBN	_	0	ROOT
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	17	case
15	a	a	DT	_	17	det
16	wide	wide	JJ	_	17	amod
17	range	range	NN	_	12	nmod
18	of	of	IN	_	21	case
19	commonly	commonly	RB	_	20	advmod
20	prescribed	prescribe	VBN	_	21	amod
21	drugs	drug	NNS	_	17	nmod
22	in	in	IN	_	24	case
23	clinical	clinical	JJ	_	24	amod
24	studies	study	NNS	_	12	nmod
25	without	without	IN	_	26	case
26	evidence	evidence	NN	_	12	nmod
27	of	of	IN	_	30	case
28	clinical	clinical	JJ	_	30	amod
29	adverse	adverse	JJ	_	30	amod
30	interactions	interaction	NNS	_	26	nmod
31	.	.	.	_	12	punct

1	These	these	DT	_	2	det
2	medications	medication	NNS	_	3	nsubj
3	included	include	VBD	_	0	ROOT
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	drug5	drug5	NN	_	4	conj
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	which	which	WDT	_	4	nsubj
4	induces	induce	VBZ	_	1	acl:relcl
5	hepatic	hepatic	JJ	_	6	amod
6	metabolism	metabolism	NN	_	4	dobj
7	,	,	,	_	1	punct
8	decreased	decrease	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	AUC	auc	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	approximately	approximately	RB	_	14	advmod
14	40	40	CD	_	15	nummod
15	%	%	NN	_	8	nmod:npmod
16	following	follow	VBG	_	20	case
17	a	a	DT	_	20	det
18	single	single	JJ	_	20	amod
19	10-mg	10-mg	JJ	_	20	amod
20	dose	dose	NN	_	8	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	7	nsubjpass
4	for	for	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	reasonable	reasonable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	employ	employ	VB	_	3	xcomp
6	appropriate	appropriate	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	dobj
9	when	when	WRB	_	23	advmod
10	potent	potent	JJ	_	14	amod
11	cytochrome	cytochrome	NN	_	14	compound
12	P450	p450	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	inducers	inducer	NNS	_	23	nsubjpass
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug1	drug1	NN	_	14	nmod
19	or	or	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	14	punct
22	are	be	VBP	_	23	auxpass
23	co-administered	co-administer	VBN	_	5	advcl
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	study	study	NN	_	24	nmod
5	of	of	IN	_	10	case
6	18	18	CD	_	10	nummod
7	chronic	chronic	JJ	_	10	amod
8	hepatitis	hepatitis	NN	_	10	compound
9	C	c	NN	_	10	compound
10	patients	patient	NNS	_	4	nmod
11	concomitantly	concomitantly	RB	_	12	advmod
12	receiving	receive	VBG	_	10	acl
13	drug1	drug1	NN	_	12	dobj
14	,	,	,	_	24	punct
15	treatment	treatment	NN	_	24	nsubjpass
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	once	once	RB	_	19	advmod
19	weekly	weekly	JJ	_	15	amod
20	for	for	IN	_	22	case
21	4	4	CD	_	22	nummod
22	weeks	week	NNS	_	19	nmod
23	was	be	VBD	_	24	auxpass
24	associated	associate	VBN	_	0	ROOT
25	with	with	IN	_	28	case
26	a	a	DT	_	28	det
27	mean	mean	JJ	_	28	amod
28	increase	increase	NN	_	24	nmod
29	of	of	IN	_	31	case
30	16	16	CD	_	31	nummod
31	%	%	NN	_	28	nmod
32	in	in	IN	_	34	case
33	drug3	drug3	NN	_	34	compound
34	AUC	auc	NN	_	28	nmod
35	;	;	:	_	24	punct

1	in	in	IN	_	2	case
2	2	2	CD	_	10	nmod
3	out	out	IN	_	6	case
4	of	of	IN	_	6	case
5	18	18	CD	_	6	nummod
6	patients	patient	NNS	_	2	nmod
7	,	,	,	_	10	punct
8	drug1	drug1	NN	_	9	compound
9	AUC	auc	NN	_	10	nsubj
10	doubled	double	VBD	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	finding	finding	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	;	;	:	_	8	punct

1	however	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	for	for	IN	_	9	case
8	the	the	DT	_	9	det
9	signs	sign	NNS	_	6	nmod
10	and	and	CC	_	9	cc
11	symptoms	symptom	NNS	_	9	conj
12	of	of	IN	_	15	case
13	increased	increase	VBN	_	15	amod
14	narcotic	narcotic	JJ	_	15	amod
15	effect	effect	NN	_	9	nmod
16	.	.	.	_	6	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	0	ROOT
5	,	,	,	_	4	punct
6	the	the	DT	_	7	det
7	potential	potential	NN	_	5	root
8	for	for	IN	_	9	case
9	interaction	interaction	NN	_	7	nmod
10	by	by	IN	_	12	case
11	a	a	DT	_	12	det
12	variety	variety	NN	_	9	nmod
13	of	of	IN	_	14	case
14	mechanisms	mechanism	NNS	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	21	punct
16	e.g.	e.g.	FW	_	21	dep
17	,	,	,	_	21	punct
18	pharmacodynamic	pharmacodynamic	JJ	_	21	amod
19	,	,	,	_	21	punct
20	pharmacokinetic	pharmacokinetic	JJ	_	21	amod
21	inhibition	inhibition	NN	_	7	dep
22	or	or	CC	_	21	cc
23	enhancement	enhancement	NN	_	21	conj
24	,	,	,	_	21	punct
25	etc.	etc.	FW	_	21	dep
26	-RRB-	-rrb-	-RRB-	_	21	punct

1	is	be	VBZ	_	3	cop
2	a	a	DT	_	3	det
3	possibility	possibility	NN	_	0	ROOT
4	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Affecting	affect	VBG	_	1	acl
3	Hepatic	hepatic	JJ	_	4	amod
4	Metabolism	metabolism	NN	_	2	dobj
5	The	the	DT	_	6	det
6	metabolism	metabolism	NN	_	19	nsubjpass
7	and	and	CC	_	6	cc
8	pharmacokinetics	pharmacokinetic	NNS	_	6	conj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	Orally	orally	RB	_	15	advmod
15	Disintegrating	disintegrate	VBG	_	16	amod
16	Tablets	tablet	NNS	_	10	dep
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	affected	affect	VBN	_	4	acl:relcl
20	by	by	IN	_	22	case
21	the	the	DT	_	22	det
22	induction	induction	NN	_	19	nmod
23	or	or	CC	_	22	cc
24	inhibition	inhibition	NN	_	22	conj
25	of	of	IN	_	27	case
26	drug-metab-olizing	drug-metab-olizing	JJ	_	27	amod
27	enzymes	enzyme	NNS	_	22	nmod
28	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	14	nsubjpass
2	that	that	WDT	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	Metabolized	metabolize	VBN	_	1	acl:relcl
5	by	by	IN	_	12	case
6	and/or	and/or	CC	_	5	cc
7	Inhibit	inhibit	VB	_	5	conj
8	Cytochrome	cytochrome	NN	_	12	compound
9	P450	p450	NN	_	12	compound
10	Enzymes	enzyme	NNS	_	12	compound
11	Many	many	JJ	_	12	amod
12	drugs	drug	NNS	_	4	nmod
13	are	be	VBP	_	14	auxpass
14	metabolized	metabolize	VBN	_	0	ROOT
15	by	by	IN	_	21	case
16	and/or	and/or	CC	_	15	cc
17	inhibit	inhibit	VB	_	15	conj
18	various	various	JJ	_	21	amod
19	cytochrome	cytochrome	NN	_	21	compound
20	P450	p450	NN	_	21	compound
21	enzymes	enzyme	NNS	_	14	nmod
22	,	,	,	_	21	punct
23	e.g.	e.g.	FW	_	25	dep
24	,	,	,	_	25	punct
25	2D6	2d6	NN	_	21	nmod
26	,	,	,	_	25	punct
27	1A2	1a2	NN	_	25	conj
28	,	,	,	_	25	punct
29	3A4	3a4	NN	_	25	conj
30	,	,	,	_	25	punct
31	etc.	etc.	FW	_	25	dep
32	.	.	.	_	14	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	10	mark
7	drug1	drug1	NN	_	10	nsubj
8	is	be	VBZ	_	10	cop
9	a	a	DT	_	10	det
10	substrate	substrate	NN	_	5	ccomp
11	for	for	IN	_	12	case
12	several	several	JJ	_	10	nmod
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	enzymes	enzyme	NNS	_	12	nmod
16	,	,	,	_	12	punct
17	including	include	VBG	_	18	case
18	2D6	2d6	NN	_	12	nmod
19	,	,	,	_	18	punct
20	1A2	1a2	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	3A4	3a4	NN	_	18	conj
24	.	.	.	_	5	punct

1	While	while	IN	_	6	mark
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	studies	study	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	shown	show	VBN	_	66	advcl
7	that	that	IN	_	13	mark
8	drug1	drug1	NN	_	13	nsubj
9	is	be	VBZ	_	13	cop
10	not	not	RB	_	13	neg
11	a	a	DT	_	13	det
12	potent	potent	JJ	_	13	amod
13	inhibitor	inhibitor	NN	_	6	ccomp
14	of	of	IN	_	15	case
15	any	any	DT	_	13	nmod
16	of	of	IN	_	18	case
17	these	these	DT	_	18	det
18	enzymes	enzyme	NNS	_	15	nmod
19	,	,	,	_	66	punct
20	an	a	DT	_	21	det
21	indication	indication	NN	_	66	ccomp
22	that	that	WDT	_	26	mark
23	drug2	drug2	NN	_	26	nsubj
24	is	be	VBZ	_	26	cop
25	not	not	RB	_	26	neg
26	likely	likely	JJ	_	21	ccomp
27	to	to	TO	_	28	mark
28	have	have	VB	_	26	xcomp
29	a	a	DT	_	33	det
30	clinically	clinically	RB	_	31	advmod
31	significant	significant	JJ	_	33	amod
32	inhibitory	inhibitory	JJ	_	33	amod
33	effect	effect	NN	_	28	dobj
34	on	on	IN	_	36	case
35	the	the	DT	_	36	det
36	metabolism	metabolism	NN	_	28	nmod
37	of	of	IN	_	39	case
38	other	other	JJ	_	39	amod
39	drugs	drug	NNS	_	36	nmod
40	that	that	WDT	_	42	nsubj
41	are	be	VBP	_	42	cop
42	substrates	substrate	NNS	_	39	acl:relcl
43	for	for	IN	_	47	case
44	these	these	DT	_	47	det
45	cytochrome	cytochrome	NN	_	47	compound
46	P450	p450	NN	_	47	compound
47	enzymes	enzyme	NNS	_	42	nmod
48	,	,	,	_	66	punct
49	the	the	DT	_	51	det
50	concomitant	concomitant	JJ	_	51	amod
51	use	use	NN	_	66	nsubjpass
52	of	of	IN	_	53	case
53	drug3	drug3	NN	_	51	nmod
54	with	with	IN	_	57	case
55	most	most	JJS	_	57	amod
56	other	other	JJ	_	57	amod
57	drugs	drug	NNS	_	51	nmod
58	metabolized	metabolize	VBN	_	57	acl
59	by	by	IN	_	61	case
60	these	these	DT	_	61	det
61	enzymes	enzyme	NNS	_	58	nmod
62	has	have	VBZ	_	66	aux
63	not	not	RB	_	66	neg
64	been	be	VBN	_	66	auxpass
65	formally	formally	RB	_	66	advmod
66	studied	study	VBN	_	0	ROOT
67	.	.	.	_	66	punct

1	Consequently	consequently	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubj
4	is	be	VBZ	_	6	cop
5	not	not	RB	_	6	neg
6	possible	possible	JJ	_	0	ROOT
7	to	to	TO	_	8	mark
8	make	make	VB	_	6	xcomp
9	any	any	DT	_	11	det
10	definitive	definitive	JJ	_	11	amod
11	statements	statement	NNS	_	8	dobj
12	about	about	IN	_	14	case
13	the	the	DT	_	14	det
14	risks	risk	NNS	_	11	nmod
15	of	of	IN	_	16	case
16	coadministration	coadministration	NN	_	14	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	with	with	IN	_	21	case
20	such	such	JJ	_	21	amod
21	drugs	drug	NNS	_	16	nmod
22	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	1	dep
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	13	punct
8	equivalent	equivalent	JJ	_	13	dep
9	to	to	TO	_	11	case
10	60	60	CD	_	11	nummod
11	g	g	NN	_	8	nmod
12	-RRB-	-rrb-	-RRB-	_	13	punct
13	had	have	VBD	_	4	dep
14	a	a	DT	_	16	det
15	minimal	minimal	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	on	on	IN	_	19	case
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	13	nmod
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	15	15	CD	_	24	nummod
24	mg	mg	NN	_	21	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	in	in	IN	_	30	case
27	6	6	CD	_	30	nummod
28	healthy	healthy	JJ	_	30	amod
29	male	male	JJ	_	30	amod
30	subjects	subject	NNS	_	13	nmod
31	.	.	.	_	13	punct

1	However	however	RB	_	14	advmod
2	,	,	,	_	14	punct
3	the	the	DT	_	4	det
4	impairment	impairment	NN	_	14	nsubjpass
5	of	of	IN	_	9	case
6	cognitive	cognitive	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	motor	motor	NN	_	6	conj
9	skills	skill	NNS	_	4	nmod
10	produced	produce	VBN	_	9	acl
11	by	by	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	were	be	VBD	_	14	auxpass
14	shown	show	VBN	_	0	ROOT
15	to	to	TO	_	17	mark
16	be	be	VB	_	17	cop
17	additive	additive	JJ	_	14	xcomp
18	with	with	IN	_	19	case
19	those	those	DT	_	17	nmod
20	produced	produce	VBN	_	19	acl
21	by	by	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	14	punct

1	Accordingly	accordingly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	avoid	avoid	VB	_	6	xcomp
9	drug1	drug1	NN	_	8	dobj
10	while	while	IN	_	11	mark
11	taking	take	VBG	_	8	advcl
12	drug2	drug2	NN	_	11	dobj
13	.	.	.	_	6	punct
14	drug3	drug3	NN	_	6	dep
15	:	:	:	_	14	punct
16	Concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	24	nsubj
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	15	15	CD	_	22	nummod
22	mg	mg	NN	_	19	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	had	have	VBD	_	14	appos
25	a	a	DT	_	27	det
26	minimal	minimal	JJ	_	27	amod
27	effect	effect	NN	_	24	dobj
28	on	on	IN	_	30	case
29	plasma	plasma	NN	_	30	compound
30	levels	level	NNS	_	27	nmod
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	30	nmod
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	15	15	CD	_	35	nummod
35	mg	mg	NN	_	32	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	in	in	IN	_	40	case
38	12	12	CD	_	40	nummod
39	healthy	healthy	JJ	_	40	amod
40	subjects	subject	NNS	_	24	nmod
41	.	.	.	_	6	punct

1	However	however	RB	_	13	advmod
2	,	,	,	_	13	punct
3	the	the	DT	_	4	det
4	impairment	impairment	NN	_	13	nsubjpass
5	of	of	IN	_	7	case
6	motor	motor	NN	_	7	compound
7	skills	skill	NNS	_	4	nmod
8	produced	produce	VBN	_	7	acl
9	by	by	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	shown	show	VBN	_	0	ROOT
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	cop
16	additive	additive	JJ	_	13	xcomp
17	with	with	IN	_	18	case
18	those	those	DT	_	16	nmod
19	caused	cause	VBN	_	18	acl
20	by	by	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	13	punct

1	Accordingly	accordingly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	avoid	avoid	VB	_	6	xcomp
9	drug1	drug1	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	other	other	JJ	_	13	amod
12	similar	similar	JJ	_	13	amod
13	drugs	drug	NNS	_	9	conj
14	while	while	IN	_	15	mark
15	taking	take	VBG	_	8	advcl
16	drug2	drug2	NN	_	15	dobj
17	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Spontaneous	spontaneous	JJ	_	6	amod
4	adverse	adverse	JJ	_	6	amod
5	reaction	reaction	NN	_	6	compound
6	reports	report	NNS	_	17	nsubj
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	concomitant	concomitant	JJ	_	11	amod
11	drug2	drug2	NN	_	9	dobj
12	with	with	IN	_	14	case
13	recommended	recommend	VBN	_	14	amod
14	doses	dose	NNS	_	9	nmod
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	demonstrate	demonstrate	VBP	_	1	dep
18	QT	qt	NN	_	20	compound
19	interval	interval	NN	_	20	compound
20	prolongation	prolongation	NN	_	17	dobj
21	and	and	CC	_	20	cc
22	rare	rare	JJ	_	25	amod
23	serious	serious	JJ	_	25	amod
24	cardiac	cardiac	JJ	_	25	amod
25	events	event	NNS	_	20	conj
26	,	,	,	_	17	punct
27	e.g.	e.g.	FW	_	17	dep

1	death	death	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	cardiac	cardiac	JJ	_	4	amod
4	arrest	arrest	NN	_	1	conj
5	,	,	,	_	1	punct
6	and	and	CC	_	1	cc
7	ventricular	ventricular	JJ	_	8	amod
8	arrhythmia	arrhythmia	NN	_	1	conj
9	including	include	VBG	_	12	case
10	torsades	torsade	NNS	_	12	compound
11	de	de	IN	_	12	amod
12	pointes	pointe	NNS	_	8	nmod
13	.	.	.	_	1	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	data	datum	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	markedly	markedly	RB	_	7	advmod
7	inhibits	inhibit	VBZ	_	3	ccomp
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	7	punct
13	resulting	result	VBG	_	7	advcl
14	in	in	IN	_	18	case
15	elevated	elevated	JJ	_	18	amod
16	plasma	plasma	NN	_	18	compound
17	drug3	drug3	NN	_	18	compound
18	levels	level	NNS	_	13	nmod
19	.	.	.	_	3	punct

1	Presence	presence	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	unchanged	unchanged	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	10	case
8	statistically	statistically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	prolongation	prolongation	NN	_	6	nmod
11	of	of	IN	_	16	case
12	the	the	DT	_	16	det
13	QT	QT	NNP	_	16	compound
14	and	and	CC	_	13	cc
15	QTc	QTc	NNP	_	13	conj
16	intervals	interval	NNS	_	10	nmod
17	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Torsades	Torsades	NNP	_	5	compound
4	de	de	NNP	_	5	compound
5	pointes	pointes	NNP	_	13	nsubjpass
6	and	and	CC	_	5	cc
7	elevated	elevated	JJ	_	10	amod
8	parent	parent	NN	_	10	compound
9	drug2	drug2	NN	_	10	compound
10	levels	level	NNS	_	5	conj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	1	appos
14	during	during	IN	_	16	case
15	concomitant	concomitant	JJ	_	16	amod
16	use	use	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug4	drug4	NN	_	18	conj
21	in	in	IN	_	23	case
22	clinical	clinical	JJ	_	23	amod
23	trials	trial	NNS	_	16	nmod
24	of	of	IN	_	25	case
25	drug5	drug5	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	from	from	IN	_	30	case
28	foreign	foreign	JJ	_	30	amod
29	post-marketing	post-marketing	JJ	_	30	amod
30	sources	source	NNS	_	25	conj
31	.	.	.	_	1	punct

1	One	one	CD	_	2	nummod
2	death	death	NN	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	also	also	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	from	from	IN	_	9	case
8	foreign	foreign	JJ	_	9	amod
9	post	post	NN	_	6	nmod
10	-	-	:	_	9	punct
11	marketing	marketing	NN	_	12	compound
12	sources	source	NNS	_	9	dep
13	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	the	the	DT	_	5	det
4	chemical	chemical	NN	_	5	compound
5	similarity	similarity	NN	_	0	ROOT
6	of	of	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	8	punct
10	including	include	VBG	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	drug4	drug4	NN	_	11	conj
17	-RRB-	-rrb-	-RRB-	_	8	punct
18	to	to	TO	_	19	mark
19	drug5	drug5	VB	_	5	acl
20	,	,	,	_	19	punct
21	and	and	CC	_	19	cc
22	drug6	drug6	NN	_	33	nsubjpass
23	,	,	,	_	22	punct
24	concomitant	concomitant	JJ	_	25	amod
25	use	use	NN	_	22	appos
26	of	of	IN	_	28	case
27	these	these	DT	_	28	det
28	products	product	NNS	_	25	nmod
29	with	with	IN	_	30	case
30	drug7	drug7	NN	_	25	nmod
31	is	be	VBZ	_	33	auxpass
32	not	not	RB	_	33	neg
33	recommended	recommend	VBN	_	19	conj
34	pending	pend	VBG	_	36	case
35	full	full	JJ	_	36	amod
36	examination	examination	NN	_	33	nmod
37	of	of	IN	_	39	case
38	potential	potential	JJ	_	39	amod
39	interactions	interaction	NNS	_	36	nmod
40	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	6	amod
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	7	nsubj
7	indicate	indicate	VBP	_	1	appos
8	that	that	IN	_	13	mark
9	drug2	drug2	NN	_	13	nsubj
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	can	can	MD	_	13	aux
13	exert	exert	VB	_	7	ccomp
14	an	a	DT	_	15	det
15	effect	effect	NN	_	13	dobj
16	on	on	IN	_	18	case
17	drug4	drug4	NN	_	18	compound
18	metabolism	metabolism	NN	_	15	nmod
19	by	by	IN	_	21	case
20	a	a	DT	_	21	det
21	mechanism	mechanism	NN	_	13	nmod
22	which	which	WDT	_	25	nsubj
23	may	may	MD	_	25	aux
24	be	be	VB	_	25	cop
25	similar	similar	JJ	_	21	acl:relcl
26	to	to	TO	_	27	case
27	that	that	DT	_	25	nmod
28	of	of	IN	_	29	case
29	drug5	drug5	NN	_	27	nmod
30	,	,	,	_	13	punct
31	but	but	CC	_	13	cc
32	to	to	TO	_	35	case
33	a	a	DT	_	35	det
34	lesser	lesser	JJR	_	35	amod
35	extent	extent	NN	_	13	conj
36	.	.	.	_	1	punct

1	Although	although	IN	_	4	mark
2	erythromycin	erythromycin	NN	_	4	nsubj
3	measurably	measurably	RB	_	4	advmod
4	decreases	decrease	VBZ	_	22	advcl
5	the	the	DT	_	6	det
6	clearance	clearance	NN	_	4	dobj
7	of	of	IN	_	11	case
8	the	the	DT	_	11	det
9	drug1	drug1	NN	_	11	compound
10	acid	acid	NN	_	11	compound
11	metabolite	metabolite	NN	_	6	nmod
12	,	,	,	_	22	punct
13	its	its	PRP$	_	14	nmod:poss
14	influence	influence	NN	_	22	nsubj
15	on	on	IN	_	18	case
16	terfenadine	terfenadine	NN	_	18	compound
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	14	nmod
19	is	be	VBZ	_	22	cop
20	still	still	RB	_	22	advmod
21	under	under	IN	_	22	case
22	investigation	investigation	NN	_	0	ROOT
23	.	.	.	_	22	punct

1	A	a	DT	_	4	det
2	few	few	JJ	_	4	amod
3	spontaneous	spontaneous	JJ	_	4	amod
4	accounts	account	NNS	_	19	nsubjpass
5	of	of	IN	_	8	case
6	QT	qt	NN	_	8	compound
7	interval	interval	NN	_	8	compound
8	prolongation	prolongation	NN	_	4	nmod
9	with	with	IN	_	11	case
10	ventricular	ventricular	JJ	_	11	amod
11	arrhythmia	arrhythmia	NN	_	8	nmod
12	including	include	VBG	_	15	case
13	torsades	torsade	NNS	_	15	compound
14	de	de	IN	_	15	amod
15	pointes	pointe	NNS	_	11	nmod
16	,	,	,	_	4	punct
17	have	have	VBP	_	19	aux
18	been	be	VBN	_	19	auxpass
19	reported	report	VBN	_	0	ROOT
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	receiving	receive	VBG	_	21	acl
23	drug1	drug1	NN	_	22	dobj
24	or	or	CC	_	23	cc
25	drug2	drug2	NN	_	23	conj
26	.	.	.	_	19	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	13	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	or	or	CC	_	6	cc
11	drug4	drug4	NN	_	6	conj
12	is	be	VBZ	_	13	auxpass
13	contraindicated	contraindicate	VBN	_	0	ROOT
14	:	:	:	_	13	punct
15	Pending	pend	VBG	_	35	advcl
16	full	full	JJ	_	17	amod
17	characterization	characterization	NN	_	15	dobj
18	of	of	IN	_	20	case
19	potential	potential	JJ	_	20	amod
20	interactions	interaction	NNS	_	17	nmod
21	,	,	,	_	35	punct
22	concomitant	concomitant	JJ	_	23	amod
23	administration	administration	NN	_	35	nsubjpass
24	of	of	IN	_	25	case
25	drug5	drug5	NN	_	23	nmod
26	with	with	IN	_	28	case
27	other	other	JJ	_	28	amod
28	drug6	drug6	NN	_	23	nmod
29	,	,	,	_	28	punct
30	including	include	VBG	_	31	case
31	drug7	drug7	NN	_	28	nmod
32	,	,	,	_	28	punct
33	is	be	VBZ	_	35	auxpass
34	not	not	RB	_	35	neg
35	recommended	recommend	VBN	_	13	parataxis
36	.	.	.	_	13	punct

1	Studies	study	NNS	_	12	nsubj
2	to	to	TO	_	3	mark
3	evaluate	evaluate	VB	_	1	acl
4	potential	potential	JJ	_	5	amod
5	interactions	interaction	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	5	nmod
10	are	be	VBP	_	12	cop
11	in	in	IN	_	12	case
12	progress	progress	NN	_	0	ROOT
13	.	.	.	_	12	punct

1	Acromegalic	acromegalic	JJ	_	2	amod
2	patients	patient	NNS	_	7	nsubjpass
3	with	with	IN	_	5	case
4	diabetes	diabetes	NN	_	5	compound
5	mellitus	mellitus	NN	_	2	nmod
6	being	be	VBG	_	7	auxpass
7	treated	treat	VBN	_	15	csubj
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and/or	and/or	CC	_	9	cc
11	oral	oral	JJ	_	13	amod
12	drug2	drug2	NN	_	13	compound
13	agents	agent	NNS	_	9	conj
14	may	may	MD	_	15	aux
15	require	require	VB	_	0	ROOT
16	dose	dose	NN	_	17	compound
17	reductions	reduction	NNS	_	15	dobj
18	of	of	IN	_	21	case
19	these	these	DT	_	21	det
20	therapeutic	therapeutic	JJ	_	21	amod
21	agents	agent	NNS	_	17	nmod
22	after	after	IN	_	24	case
23	the	the	DT	_	24	det
24	initiation	initiation	NN	_	15	nmod
25	of	of	IN	_	26	case
26	therapy	therapy	NN	_	24	nmod
27	with	with	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	.	.	.	_	15	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	patients	patient	NNS	_	9	nsubj
6	on	on	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	often	often	RB	_	9	advmod
9	needed	need	VBD	_	0	ROOT
10	higher	higher	JJR	_	13	amod
11	serum	serum	NN	_	13	compound
12	drug2	drug2	NN	_	13	compound
13	concentrations	concentration	NNS	_	9	dobj
14	to	to	TO	_	15	mark
15	achieve	achieve	VB	_	9	advcl
16	appropriate	appropriate	JJ	_	18	amod
17	IGF-I	igf-i	NN	_	18	compound
18	suppression	suppression	NN	_	15	dobj
19	compared	compare	VBN	_	21	case
20	with	with	IN	_	21	case
21	patients	patient	NNS	_	15	advcl
22	not	not	RB	_	23	neg
23	receiving	receive	VBG	_	21	acl
24	drug3	drug3	NN	_	23	dobj
25	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	interaction	interaction	NN	_	2	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	known	know	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	19	csubj
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	9	case
8	digitalized	digitalized	JJ	_	9	amod
9	patients	patient	NNS	_	6	nmod
10	,	,	,	_	4	punct
11	since	since	IN	_	13	case
12	the	the	DT	_	13	det
13	combination	combination	NN	_	4	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug3	drug3	NN	_	15	conj
18	may	may	MD	_	19	aux
19	cause	cause	VB	_	0	ROOT
20	ectopic	ectopic	JJ	_	21	amod
21	arrhythmias	arrhythmia	NNS	_	19	dobj
22	.	.	.	_	19	punct

1	drug1	drug1	NN	_	5	nsubj
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	may	may	MD	_	5	aux
5	potentiate	potentiate	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	action	action	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	18	advmod
2	,	,	,	_	18	punct
3	when	when	WRB	_	4	advmod
4	initiating	initiate	VBG	_	18	advcl
5	pressor	pressor	NN	_	6	compound
6	therapy	therapy	NN	_	4	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	9	dobj
12	,	,	,	_	18	punct
13	the	the	DT	_	15	det
14	initial	initial	JJ	_	15	amod
15	dose	dose	NN	_	18	nsubj
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	cop
18	small	small	JJ	_	0	ROOT
19	and	and	CC	_	18	cc
20	given	give	VBN	_	22	case
21	with	with	IN	_	22	case
22	caution	caution	NN	_	18	conj
23	.	.	.	_	18	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	a	a	DT	_	5	det
4	bacteriostatic	bacteriostatic	JJ	_	5	amod
5	drug2	drug2	NN	_	1	appos
6	,	,	,	_	1	punct
7	may	may	MD	_	8	aux
8	antagonize	antagonize	VB	_	22	csubjpass
9	the	the	DT	_	11	det
10	bactericidal	bactericidal	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	concurrent	concurrent	JJ	_	16	amod
16	use	use	NN	_	13	conj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	drugs	drug	NNS	_	13	nmod
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	avoided	avoid	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	may	may	MD	_	8	aux
8	result	result	VB	_	0	ROOT
9	in	in	IN	_	13	case
10	an	a	DT	_	13	det
11	adverse	adverse	JJ	_	13	amod
12	drug	drug	NN	_	13	compound
13	interaction	interaction	NN	_	8	nmod
14	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	studied	study	VBN	_	0	ROOT
5	on	on	IN	_	7	case
6	a	a	DT	_	7	det
7	background	background	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	2	punct
6	in	in	IN	_	7	case
7	combination	combination	NN	_	2	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	,	,	,	_	2	punct
13	has	have	VBZ	_	15	aux
14	been	be	VBN	_	15	auxpass
15	associated	associate	VBN	_	28	ccomp
16	with	with	IN	_	18	case
17	an	a	DT	_	18	det
18	increase	increase	NN	_	15	nmod
19	in	in	IN	_	20	mark
20	bleeding	bleed	VBG	_	18	acl
21	compared	compare	VBN	_	23	case
22	to	to	TO	_	23	case
23	drug4	drug4	NN	_	20	advcl
24	and	and	CC	_	23	cc
25	drug5	drug5	NN	_	23	conj
26	alone	alone	RB	_	23	advmod
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	see	see	VB	_	0	ROOT

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Inhibitors	inhibitor	NNS	_	2	dep
5	of	of	IN	_	7	case
6	CYP3A4	cyp3a4	NN	_	7	compound
7	Isozymes	isozyme	NNS	_	4	nmod
8	:	:	:	_	4	punct
9	Caution	caution	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	advised	advise	VBN	_	4	dep
12	when	when	WRB	_	15	advmod
13	drug1	drug1	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	administered	administer	VBN	_	11	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	with	with	IN	_	18	case
18	drugs	drug	NNS	_	15	nmod
19	that	that	WDT	_	21	nsubjpass
20	are	be	VBP	_	21	auxpass
21	known	know	VBN	_	18	acl:relcl
22	to	to	TO	_	23	mark
23	inhibit	inhibit	VB	_	21	xcomp
24	the	the	DT	_	29	det
25	cytochrome	cytochrome	NN	_	29	compound
26	P450	p450	NN	_	29	compound
27	3A4	3a4	NN	_	29	compound
28	enzyme	enzyme	NN	_	29	compound
29	system	system	NN	_	23	dobj
30	-LRB-	-lrb-	-LRB-	_	29	punct
31	ie	ie	FW	_	30	root
32	,	,	,	_	31	punct
33	some	some	DT	_	34	det
34	drugs	drug	NNS	_	32	root
35	in	in	IN	_	38	case
36	the	the	DT	_	38	det
37	drug	drug	NN	_	38	compound
38	classes	class	NNS	_	34	nmod
39	of	of	IN	_	40	case
40	drug2	drug2	NN	_	38	nmod
41	,	,	,	_	40	punct
42	drug3	drug3	NN	_	40	conj
43	,	,	,	_	40	punct
44	drug4	drug4	NN	_	40	conj
45	,	,	,	_	40	punct
46	and	and	CC	_	40	cc
47	drug5	drug5	NN	_	40	conj
48	-RRB-	-rrb-	-RRB-	_	34	punct
49	.	.	.	_	34	punct

1	Drugs	drug	NNS	_	16	nsubjpass
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	drug5	drug5	NN	_	4	conj
13	and	and	CC	_	4	cc
14	drug6	drug6	NN	_	4	conj
15	were	be	VBD	_	16	auxpass
16	shown	show	VBN	_	0	ROOT
17	to	to	TO	_	19	mark
18	significantly	significantly	RB	_	19	advmod
19	increase	increase	VB	_	16	xcomp
20	the	the	DT	_	22	det
21	C	c	NN	_	22	compound
22	max	max	NN	_	19	dobj
23	and	and	CC	_	22	cc
24	AUC	auc	NN	_	22	conj
25	of	of	IN	_	28	case
26	orally	orally	RB	_	27	advmod
27	administered	administer	VBN	_	28	amod
28	drug7	drug7	NN	_	22	nmod
29	.	.	.	_	16	punct

1	These	these	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	result	result	VB	_	0	ROOT
6	in	in	IN	_	10	case
7	increased	increase	VBN	_	10	amod
8	and	and	CC	_	7	cc
9	prolonged	prolong	VBN	_	7	conj
10	sedation	sedation	NN	_	5	nmod
11	due	due	JJ	_	14	case
12	to	to	TO	_	11	mwe
13	a	a	DT	_	14	det
14	decrease	decrease	NN	_	10	nmod
15	in	in	IN	_	17	case
16	plasma	plasma	NN	_	17	compound
17	clearance	clearance	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	.	.	.	_	5	punct

1	Although	although	IN	_	3	mark
2	not	not	RB	_	3	neg
3	studied	study	VBN	_	15	advcl
4	,	,	,	_	15	punct
5	the	the	DT	_	10	det
6	potent	potent	JJ	_	10	amod
7	cytochrome	cytochrome	NN	_	10	compound
8	P450	p450	NN	_	10	compound
9	3A4	3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	15	nsubj
11	drug1	drug1	NN	_	10	dep
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	may	may	MD	_	15	aux
15	cause	cause	VB	_	0	ROOT
16	intense	intense	JJ	_	19	amod
17	and	and	CC	_	16	cc
18	prolonged	prolonged	JJ	_	16	conj
19	sedation	sedation	NN	_	15	dobj
20	and	and	CC	_	19	cc
21	respiratory	respiratory	JJ	_	22	amod
22	depression	depression	NN	_	19	conj
23	due	due	JJ	_	26	case
24	to	to	TO	_	23	mwe
25	a	a	DT	_	26	det
26	decrease	decrease	NN	_	19	nmod
27	in	in	IN	_	29	case
28	plasma	plasma	NN	_	29	compound
29	clearance	clearance	NN	_	26	nmod
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	.	.	.	_	15	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	when	when	WRB	_	7	advmod
5	drug1	drug1	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	used	use	VBN	_	3	advcl
8	concomitantly	concomitantly	RB	_	7	advmod
9	with	with	IN	_	11	case
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	7	nmod
12	.	.	.	_	3	punct

1	Dose	dose	NN	_	2	compound
2	adjustments	adjustment	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	and	and	CC	_	5	cc
7	possible	possible	JJ	_	8	amod
8	prolongation	prolongation	NN	_	15	nsubjpass
9	and	and	CC	_	8	cc
10	intensity	intensity	NN	_	8	conj
11	of	of	IN	_	12	case
12	effect	effect	NN	_	8	nmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	anticipated	anticipate	VBN	_	5	conj
16	.	.	.	_	5	punct

1	Inducers	inducer	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	CYP3A4	cyp3a4	NN	_	4	compound
4	Isozymes	isozyme	NNS	_	1	nmod
5	:	:	:	_	1	punct
6	Cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	inducers	inducer	NNS	_	19	nsubj
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug1	drug1	NN	_	8	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	drug3	drug3	NN	_	12	conj
18	,	,	,	_	8	punct
19	induce	induce	VBP	_	1	dep
20	metabolism	metabolism	NN	_	19	dobj
21	and	and	CC	_	19	cc
22	caused	cause	VBD	_	19	conj
23	a	a	DT	_	27	det
24	markedly	markedly	RB	_	25	advmod
25	decreased	decrease	VBN	_	27	amod
26	C	c	NN	_	27	compound
27	max	max	NN	_	22	dobj
28	and	and	CC	_	27	cc
29	AUC	auc	NN	_	27	conj
30	of	of	IN	_	32	case
31	oral	oral	JJ	_	32	amod
32	drug4	drug4	NN	_	27	nmod
33	in	in	IN	_	35	case
34	adult	adult	JJ	_	35	amod
35	studies	study	NNS	_	27	nmod
36	.	.	.	_	1	punct

1	Although	although	IN	_	7	mark
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	7	nsubjpass
4	have	have	VBP	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	11	advcl
8	,	,	,	_	11	punct
9	drug1	drug1	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	have	have	VB	_	11	xcomp
14	the	the	DT	_	16	det
15	same	same	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	.	.	.	_	11	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	administering	administer	VBG	_	3	advcl
6	drug1	drug1	NN	_	5	dobj
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	these	these	DT	_	11	det
11	medications	medication	NNS	_	9	dobj
12	and	and	CC	_	5	cc
13	if	if	IN	_	19	mark
14	necessary	necessary	JJ	_	16	amod
15	dose	dose	NN	_	16	compound
16	adjustments	adjustment	NNS	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	considered	consider	VBN	_	5	conj
20	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	difficulty	difficulty	NN	_	11	nsubj
3	in	in	IN	_	4	mark
4	achieving	achieve	VBG	_	2	acl
5	adequate	adequate	JJ	_	6	amod
6	sedation	sedation	NN	_	4	dobj
7	may	may	MD	_	11	aux
8	have	have	VB	_	11	aux
9	been	be	VBN	_	11	cop
10	the	the	DT	_	11	det
11	result	result	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	decreased	decrease	VBN	_	14	amod
14	absorption	absorption	NN	_	11	nmod
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	drug1	drug1	NN	_	14	nmod
18	due	due	JJ	_	23	case
19	to	to	TO	_	18	mwe
20	both	both	CC	_	23	cc:preconj
21	the	the	DT	_	23	det
22	gastrointestinal	gastrointestinal	JJ	_	23	amod
23	effects	effect	NNS	_	14	nmod
24	and	and	CC	_	23	cc
25	stimulant	stimulant	NN	_	26	compound
26	effects	effect	NNS	_	23	conj
27	of	of	IN	_	28	case
28	drug2	drug2	NN	_	23	nmod
29	.	.	.	_	11	punct

1	The	the	DT	_	3	det
2	sedative	sedative	JJ	_	3	amod
3	effect	effect	NN	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	accentuated	accentuate	VBN	_	0	ROOT
8	by	by	IN	_	12	case
9	any	any	DT	_	12	det
10	concomitantly	concomitantly	RB	_	11	advmod
11	administered	administer	VBN	_	12	amod
12	medication	medication	NN	_	7	nmod
13	which	which	WDT	_	14	nsubj
14	depresses	depress	VBZ	_	12	acl:relcl
15	the	the	DT	_	18	det
16	central	central	JJ	_	18	amod
17	nervous	nervous	JJ	_	18	amod
18	system	system	NN	_	14	dobj
19	,	,	,	_	12	punct
20	particularly	particularly	RB	_	21	advmod
21	drug2	drug2	NN	_	12	appos
22	-LRB-	-lrb-	-LRB-	_	25	punct
23	eg	eg	FW	_	25	compound
24	,	,	,	_	25	punct
25	drug3	drug3	NN	_	21	dep
26	,	,	,	_	25	punct
27	drug4	drug4	NN	_	25	conj
28	and	and	CC	_	25	cc
29	drug5	drug5	NN	_	25	conj
30	-RRB-	-rrb-	-RRB-	_	25	punct
31	,	,	,	_	21	punct
32	drug6	drug6	NN	_	21	conj
33	,	,	,	_	21	punct
34	drug7	drug7	NN	_	21	conj
35	,	,	,	_	21	punct
36	drug8	drug8	NN	_	21	conj
37	,	,	,	_	21	punct
38	drug9	drug9	NN	_	21	conj
39	and	and	CC	_	21	cc
40	drug10	drug10	NN	_	21	conj
41	.	.	.	_	7	punct

1	Consequently	consequently	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	adjusted	adjust	VBN	_	0	ROOT
10	according	accord	VBG	_	13	case
11	to	to	TO	_	10	mwe
12	the	the	DT	_	13	det
13	type	type	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	amount	amount	NN	_	13	conj
16	of	of	IN	_	18	case
17	concomitant	concomitant	JJ	_	18	amod
18	medications	medication	NNS	_	13	nmod
19	administered	administer	VBN	_	18	acl
20	and	and	CC	_	13	cc
21	the	the	DT	_	24	det
22	desired	desire	VBN	_	24	amod
23	clinical	clinical	JJ	_	24	amod
24	response	response	NN	_	13	conj
25	.	.	.	_	9	punct

1	No	no	DT	_	4	neg
2	significant	significant	JJ	_	4	amod
3	adverse	adverse	JJ	_	4	amod
4	interactions	interaction	NNS	_	30	nsubjpass
5	with	with	IN	_	7	case
6	common	common	JJ	_	7	amod
7	premedications	premedication	NNS	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug1	drug1	NN	_	7	dep
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug3	drug3	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug4	drug4	NN	_	11	conj
18	,	,	,	_	11	punct
19	drug5	drug5	NN	_	11	conj
20	,	,	,	_	11	punct
21	and	and	CC	_	11	cc
22	other	other	JJ	_	23	amod
23	drug6	drug6	NN	_	11	conj
24	-RRB-	-rrb-	-RRB-	_	11	punct
25	or	or	CC	_	7	cc
26	local	local	JJ	_	27	amod
27	drug7	drug7	NN	_	7	conj
28	have	have	VBP	_	30	aux
29	been	be	VBN	_	30	auxpass
30	observed	observe	VBN	_	0	ROOT
31	.	.	.	_	30	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	29	nsubj
4	of	of	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	including	include	VBG	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	,	,	,	_	8	punct
14	general	general	JJ	_	15	amod
15	drug5	drug5	NN	_	8	conj
16	,	,	,	_	8	punct
17	drug6	drug6	NN	_	8	conj
18	,	,	,	_	8	punct
19	other	other	JJ	_	20	amod
20	drug7	drug7	NN	_	8	conj
21	,	,	,	_	8	punct
22	drug8	drug8	NN	_	8	conj
23	,	,	,	_	8	punct
24	drug9	drug9	NN	_	8	conj
25	,	,	,	_	8	punct
26	and	and	CC	_	8	cc
27	drug10	drug10	NN	_	8	conj
28	may	may	MD	_	29	aux
29	produce	produce	VB	_	0	ROOT
30	additive	additive	JJ	_	33	amod
31	CNS	cn	NNS	_	33	compound
32	depressant	depressant	NN	_	33	compound
33	effects	effect	NNS	_	29	dobj
34	.	.	.	_	29	punct

1	When	when	WRB	_	6	advmod
2	such	such	JJ	_	4	amod
3	combined	combined	JJ	_	4	amod
4	therapy	therapy	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	contemplated	contemplate	VBN	_	17	advcl
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	one	one	CD	_	9	nmod
12	or	or	CC	_	11	cc
13	both	both	DT	_	14	det
14	agents	agent	NNS	_	11	conj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	reduced	reduce	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	drug1	drug1	NN	_	14	nsubj
2	or	or	CC	_	1	cc
3	other	other	JJ	_	4	amod
4	medications	medication	NNS	_	1	conj
5	with	with	IN	_	7	case
6	anticholinergic	anticholinergic	JJ	_	7	amod
7	activity	activity	NN	_	1	nmod
8	when	when	WRB	_	9	advmod
9	used	use	VBN	_	1	acl:relcl
10	concurrently	concurrently	RB	_	9	advmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	9	nmod
13	may	may	MD	_	14	aux
14	result	result	VB	_	0	ROOT
15	in	in	IN	_	17	case
16	increased	increase	VBN	_	17	amod
17	risk	risk	NN	_	14	nmod
18	of	of	IN	_	20	case
19	urinary	urinary	JJ	_	20	amod
20	retention	retention	NN	_	17	nmod
21	and/or	and/or	CC	_	20	cc
22	severe	severe	JJ	_	23	amod
23	constipation	constipation	NN	_	20	conj
24	,	,	,	_	17	punct
25	which	which	WDT	_	27	nsubj
26	may	may	MD	_	27	aux
27	lead	lead	VB	_	17	acl:relcl
28	to	to	TO	_	30	case
29	paralytic	paralytic	JJ	_	30	amod
30	ileus	ileus	NN	_	27	nmod
31	.	.	.	_	14	punct

1	It	it	PRP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	that	that	IN	_	11	mark
6	the	the	DT	_	7	det
7	incidence	incidence	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	bradycardia	bradycardia	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	increased	increase	VBN	_	4	ccomp
12	when	when	WRB	_	15	advmod
13	drug1	drug1	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	combined	combine	VBN	_	11	advcl
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	for	for	IN	_	19	case
19	induction	induction	NN	_	17	nmod
20	of	of	IN	_	21	case
21	anesthesia	anesthesia	NN	_	19	nmod
22	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	,	,	,	_	8	punct
4	CNS	cns	NN	_	5	compound
5	toxicity	toxicity	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	confusion	confusion	NN	_	8	dep
11	,	,	,	_	10	punct
12	disorientation	disorientation	NN	_	10	conj
13	,	,	,	_	10	punct
14	respiratory	respiratory	JJ	_	15	amod
15	depression	depression	NN	_	10	conj
16	,	,	,	_	10	punct
17	apnea	apnea	NN	_	10	conj
18	,	,	,	_	10	punct
19	seizures	seizure	NNS	_	10	appos
20	-RRB-	-rrb-	-RRB-	_	10	punct
21	following	follow	VBG	_	22	case
22	coadministration	coadministration	NN	_	8	nmod
23	of	of	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	with	with	IN	_	26	case
26	drug2	drug2	NN	_	22	nmod
27	;	;	:	_	8	punct

1	no	no	DT	_	3	neg
2	clear-cut	clear-cut	JJ	_	3	amod
3	cause	cause	NN	_	8	nsubjpass
4	and	and	CC	_	3	cc
5	effect	effect	NN	_	6	compound
6	relationship	relationship	NN	_	3	conj
7	was	be	VBD	_	8	auxpass
8	established	establish	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Dosages	dosage	NNS	_	8	nsubjpass
2	of	of	IN	_	5	case
3	concomitantly	concomitantly	RB	_	4	advmod
4	administered	administer	VBN	_	5	amod
5	drug1	drug1	NN	_	1	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	reduced	reduce	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	approximately	approximately	RB	_	11	advmod
11	half	half	RB	_	8	nmod
12	,	,	,	_	8	punct
13	because	because	IN	_	15	mark
14	drug2	drug2	NN	_	15	nsubj
15	amplifies	amplify	VBZ	_	8	advcl
16	the	the	DT	_	18	det
17	therapeutic	therapeutic	JJ	_	18	amod
18	actions	action	NNS	_	15	dobj
19	and	and	CC	_	18	cc
20	side-effects	side-effect	NNS	_	18	conj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	8	punct

1	Combination	combination	NN	_	8	nsubjpass
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	is	be	VBZ	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	increased	increase	VBN	_	11	amod
11	risk	risk	NN	_	8	nmod
12	of	of	IN	_	13	case
13	seizures	seizure	NNS	_	11	nmod
14	.	.	.	_	8	punct

1	Additive	additive	JJ	_	3	amod
2	sedative	sedative	JJ	_	3	amod
3	effects	effect	NNS	_	8	nsubj
4	and	and	CC	_	3	cc
5	confusional	confusional	JJ	_	6	amod
6	states	state	NNS	_	3	conj
7	may	may	MD	_	8	aux
8	emerge	emerge	VB	_	0	ROOT
9	if	if	IN	_	12	mark
10	drug1	drug1	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	given	give	VBN	_	8	advcl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	.	.	.	_	8	punct

1	This	this	DT	_	4	nsubjpass
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	avoided	avoid	VBN	_	0	ROOT
5	by	by	IN	_	6	mark
6	using	use	VBG	_	4	advcl
7	the	the	DT	_	9	det
8	lowest	lowest	JJS	_	9	amod
9	dose	dose	NN	_	6	dobj
10	possible	possible	JJ	_	9	amod
11	with	with	IN	_	13	case
12	the	the	DT	_	13	det
13	substances	substance	NNS	_	10	nmod
14	in	in	IN	_	15	case
15	question	question	NN	_	13	nmod
16	.	.	.	_	4	punct

1	Exert	exert	VB	_	0	ROOT
2	particular	particular	JJ	_	3	amod
3	caution	caution	NN	_	1	dobj
4	in	in	IN	_	5	mark
5	combining	combine	VBG	_	1	advcl
6	drug1	drug1	NN	_	5	dobj
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	dep
12	and	and	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	-RRB-	-rrb-	-RRB-	_	11	punct
15	:	:	:	_	1	punct
16	Particularly	particularly	RB	_	18	advmod
17	the	the	DT	_	18	det
18	elderly	elderly	JJ	_	20	nsubj
19	may	may	MD	_	20	aux
20	develop	develop	VB	_	1	parataxis
21	delirium	delirium	NN	_	20	dobj
22	,	,	,	_	21	punct
23	high	high	JJ	_	24	amod
24	fever	fever	NN	_	21	conj
25	,	,	,	_	21	punct
26	severe	severe	JJ	_	27	amod
27	obstipation	obstipation	NN	_	21	conj
28	,	,	,	_	21	punct
29	even	even	RB	_	30	advmod
30	ileus	ileus	NN	_	21	conj
31	and	and	CC	_	21	cc
32	glaucoma	glaucoma	NN	_	21	conj
33	.	.	.	_	1	punct

1	Reduce	reduce	VB	_	0	ROOT
2	both	both	CC	_	4	cc:preconj
3	the	the	DT	_	4	det
4	dose	dose	NN	_	1	dobj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	4	cc
8	the	the	DT	_	9	det
9	dose	dose	NN	_	4	conj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	other	other	JJ	_	13	amod
13	drug	drug	NN	_	9	nmod
14	.	.	.	_	1	punct

1	If	if	IN	_	2	mark
2	possible	possible	JJ	_	4	advcl
3	,	,	,	_	4	punct
4	avoid	avoid	VB	_	0	ROOT
5	such	such	JJ	_	6	amod
6	combinations	combination	NNS	_	4	dobj
7	.	.	.	_	4	punct

1	drug1	drug1	NN	_	11	nsubj
2	and/or	and/or	CC	_	1	cc
3	stimulantes	stimulante	NNS	_	1	conj
4	of	of	IN	_	9	case
5	the	the	DT	_	9	det
6	drug2	drug2	NN	_	9	compound
7	/	/	:	_	9	punct
8	drug3	drug3	NN	_	9	compound
9	type	type	NN	_	1	nmod
10	may	may	MD	_	11	aux
11	counteract	counteract	VB	_	0	ROOT
12	the	the	DT	_	14	det
13	specific	specific	JJ	_	14	amod
14	actions	action	NNS	_	11	dobj
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	11	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	substances	substance	NNS	_	2	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	avoided	avoid	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Coffee	Coffee	NNP	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	black	black	JJ	_	4	amod
4	tea	tea	NN	_	1	conj
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	avoided	avoid	VBN	_	0	ROOT
8	because	because	IN	_	10	mark
9	they	they	PRP	_	10	nsubj
10	decrease	decrease	VBP	_	7	advcl
11	the	the	DT	_	12	det
12	absorption	absorption	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	considerably	considerably	RB	_	10	advmod
16	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	same	same	JJ	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	true	true	JJ	_	0	ROOT
5	for	for	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	;	;	:	_	4	punct

1	these	these	DT	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	given	give	VBN	_	0	ROOT
5	1	1	CD	_	7	compound
6	to	to	TO	_	7	dep
7	2	2	CD	_	8	nummod
8	hours	hour	NNS	_	4	dobj
9	before	before	IN	_	13	nmod
10	or	or	CC	_	9	cc
11	after	after	IN	_	9	conj
12	oral	oral	JJ	_	13	amod
13	administration	administration	NN	_	8	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	.	.	.	_	4	punct

1	Usage	usage	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Due	due	JJ	_	18	advmod
6	to	to	TO	_	8	case
7	the	the	DT	_	8	det
8	potential	potential	NN	_	5	nmod
9	for	for	IN	_	13	case
10	increased	increase	VBN	_	13	amod
11	CNS	cns	NN	_	13	compound
12	depressants	depressant	NNS	_	13	compound
13	effects	effect	NNS	_	8	nmod
14	,	,	,	_	18	punct
15	drug2	drug2	NN	_	18	nsubjpass
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	1	dep
19	with	with	IN	_	20	case
20	caution	caution	NN	_	18	nmod
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	who	who	WP	_	26	nsubj
24	are	be	VBP	_	26	aux
25	currently	currently	RB	_	26	advmod
26	receiving	receive	VBG	_	22	acl:relcl
27	drug3	drug3	NN	_	26	dobj
28	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	CNS	cns	NN	_	4	compound
3	depressant	depressant	NN	_	4	compound
4	effects	effect	NNS	_	9	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	cop
9	additive	additive	JJ	_	0	ROOT
10	with	with	IN	_	11	case
11	that	that	DT	_	9	nmod
12	of	of	IN	_	14	case
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	11	nmod
15	.	.	.	_	9	punct
16	.	.	.	_	9	punct

1	Limited	limited	JJ	_	2	amod
2	evidence	evidence	NN	_	3	nsubj
3	suggests	suggest	VBZ	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	influence	influence	VB	_	3	ccomp
8	the	the	DT	_	9	det
9	intensity	intensity	NN	_	7	dobj
10	and	and	CC	_	9	cc
11	duration	duration	NN	_	9	conj
12	of	of	IN	_	13	case
13	action	action	NN	_	9	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	multiple-dose	multiple-dose	JJ	_	6	amod
6	study	study	NN	_	32	nmod
7	in	in	IN	_	11	case
8	30	30	CD	_	11	nummod
9	normal	normal	JJ	_	11	amod
10	weight	weight	NN	_	11	compound
11	subjects	subject	NNS	_	6	nmod
12	,	,	,	_	6	punct
13	coadministration	coadministration	NN	_	32	nsubj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	40	40	CD	_	18	nummod
18	grams	gram	NNS	_	15	conj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	15	nmod
21	-LRB-	-lrb-	-LRB-	_	26	punct
22	e.g.	e.g.	FW	_	26	dep
23	,	,	,	_	26	punct
24	approximately	approximately	RB	_	25	advmod
25	3	3	CD	_	26	nummod
26	glasses	glass	NNS	_	20	dep
27	of	of	IN	_	28	case
28	wine	wine	NN	_	26	nmod
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	did	do	VBD	_	32	aux
31	not	not	RB	_	32	neg
32	result	result	VB	_	1	appos
33	in	in	IN	_	34	case
34	alteration	alteration	NN	_	32	nmod
35	of	of	IN	_	37	case
36	drug4	drug4	NN	_	37	compound
37	pharmacokinetics	pharmacokinetic	NNS	_	34	nmod
38	,	,	,	_	34	punct
39	drug5	drug5	NN	_	40	compound
40	pharmacodynamics	pharmacodynamic	NNS	_	34	conj
41	-LRB-	-lrb-	-LRB-	_	44	punct
42	fecal	fecal	JJ	_	44	amod
43	fat	fat	JJ	_	44	amod
44	excretion	excretion	NN	_	40	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	,	,	,	_	34	punct
47	or	or	CC	_	34	cc
48	systemic	systemic	JJ	_	49	amod
49	exposure	exposure	NN	_	34	conj
50	to	to	TO	_	51	case
51	drug6	drug6	NN	_	49	nmod
52	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Preliminary	preliminary	JJ	_	4	amod
4	data	datum	NNS	_	13	nsubj
5	from	from	IN	_	12	case
6	a	a	DT	_	12	det
7	drug2	drug2	NN	_	12	compound
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	drug	drug	NN	_	12	compound
11	interaction	interaction	NN	_	12	compound
12	study	study	NN	_	4	nmod
13	indicate	indicate	VBP	_	1	appos
14	a	a	DT	_	15	det
15	reduction	reduction	NN	_	13	dobj
16	in	in	IN	_	19	case
17	drug4	drug4	NN	_	19	compound
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	15	nmod
20	when	when	WRB	_	23	advmod
21	drug5	drug5	NN	_	23	nsubjpass
22	was	be	VBD	_	23	auxpass
23	coadministered	coadminister	VBN	_	13	advcl
24	with	with	IN	_	25	case
25	drug6	drug6	NN	_	23	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	12	12	CD	_	6	nummod
5	normal-weight	normal-weight	JJ	_	6	amod
6	subjects	subject	NNS	_	22	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	10	compound
9	120	120	CD	_	10	nummod
10	mg	mg	NN	_	7	dobj
11	three	three	CD	_	12	nummod
12	times	time	NNS	_	7	nmod:tmod
13	a	a	DT	_	14	det
14	day	day	NN	_	12	nmod:npmod
15	for	for	IN	_	17	case
16	6	6	CD	_	17	nummod
17	days	day	NNS	_	7	nmod
18	,	,	,	_	22	punct
19	drug3	drug3	NN	_	22	nsubj
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	alter	alter	VB	_	1	appos
23	the	the	DT	_	24	det
24	pharmacokinetics	pharmacokinetic	NNS	_	22	dobj
25	of	of	IN	_	28	case
26	a	a	DT	_	28	det
27	single	single	JJ	_	28	amod
28	dose	dose	NN	_	24	nmod
29	of	of	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	Analogues	analogue	NNS	_	1	conj
4	:	:	:	_	1	punct
5	A	a	DT	_	8	det
6	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
7	interaction	interaction	NN	_	8	compound
8	study	study	NN	_	9	nsubj
9	showed	show	VBD	_	1	dep
10	a	a	DT	_	13	det
11	30	30	CD	_	12	compound
12	%	%	NN	_	13	amod
13	reduction	reduction	NN	_	9	dobj
14	in	in	IN	_	17	case
15	drug2	drug2	NN	_	17	compound
16	supplement	supplement	NN	_	17	compound
17	absorption	absorption	NN	_	13	nmod
18	when	when	WRB	_	20	advmod
19	concomitantly	concomitantly	RB	_	20	advmod
20	administered	administer	VBN	_	9	advcl
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibited	inhibit	VBD	_	0	ROOT
3	absorption	absorption	NN	_	2	dobj
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	drug2	drug2	NN	_	7	compound
7	supplement	supplement	NN	_	3	nmod
8	by	by	IN	_	11	case
9	approximately	approximately	RB	_	10	advmod
10	60	60	CD	_	11	nummod
11	%	%	NN	_	2	nmod
12	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	19	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	2	nmod
8	of	of	IN	_	10	case
9	supplemental	supplemental	JJ	_	10	amod
10	drug2	drug2	NN	_	7	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	and	and	CC	_	10	cc
15	nutritionally-derived	nutritionally-derived	JJ	_	16	amod
16	drug4	drug4	NN	_	10	conj
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	known	know	VBN	_	0	ROOT
20	at	at	IN	_	22	case
21	this	this	DT	_	22	det
22	time	time	NN	_	19	nmod
23	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	12	12	CD	_	6	nummod
5	normal-weight	normal-weight	JJ	_	6	amod
6	subjects	subject	NNS	_	22	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	10	compound
9	80	80	CD	_	10	nummod
10	mg	mg	NN	_	7	dobj
11	three	three	CD	_	12	nummod
12	times	time	NNS	_	7	nmod:tmod
13	a	a	DT	_	14	det
14	day	day	NN	_	12	nmod:npmod
15	for	for	IN	_	17	case
16	5	5	CD	_	17	nummod
17	days	day	NNS	_	7	nmod
18	,	,	,	_	22	punct
19	drug3	drug3	NN	_	22	nsubj
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	alter	alter	VB	_	1	appos
23	the	the	DT	_	24	det
24	pharmacokinetics	pharmacokinetic	NNS	_	22	dobj
25	or	or	CC	_	24	cc
26	pharmacodynamics	pharmacodynamic	NNS	_	24	conj
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	blood	blood	NN	_	29	compound
29	glucose-lowering	glucose-lowering	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	of	of	IN	_	32	case
32	drug4	drug4	NN	_	24	nmod
33	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	extended-release	extended-release	JJ	_	4	amod
4	tablets	tablet	NNS	_	1	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	:	:	:	_	1	punct
7	In	in	IN	_	10	case
8	17	17	CD	_	10	nummod
9	normal-weight	normal-weight	JJ	_	10	amod
10	subjects	subject	NNS	_	26	nmod
11	receiving	receive	VBG	_	10	acl
12	drug2	drug2	NN	_	14	compound
13	120	120	CD	_	14	nummod
14	mg	mg	NN	_	11	dobj
15	three	three	CD	_	16	nummod
16	times	time	NNS	_	11	nmod:tmod
17	a	a	DT	_	18	det
18	day	day	NN	_	16	nmod:npmod
19	for	for	IN	_	21	case
20	6	6	CD	_	21	nummod
21	days	day	NNS	_	11	nmod
22	,	,	,	_	26	punct
23	drug3	drug3	NN	_	26	nsubj
24	did	do	VBD	_	26	aux
25	not	not	RB	_	26	neg
26	alter	alter	VB	_	1	dep
27	the	the	DT	_	28	det
28	bioavailability	bioavailability	NN	_	26	dobj
29	of	of	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	extended-release	extended-release	JJ	_	33	amod
33	tablets	tablet	NNS	_	30	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	.	.	.	_	1	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	8	case
5	20	20	CD	_	8	nummod
6	normal-weight	normal-weight	JJ	_	8	amod
7	female	female	JJ	_	8	amod
8	subjects	subject	NNS	_	2	nmod
9	,	,	,	_	8	punct
10	the	the	DT	_	11	det
11	treatment	treatment	NN	_	23	nsubj
12	of	of	IN	_	15	case
13	drug2	drug2	NN	_	15	compound
14	120	120	CD	_	15	nummod
15	mg	mg	NN	_	11	nmod
16	three	three	CD	_	17	nummod
17	times	time	NNS	_	11	nmod:tmod
18	a	a	DT	_	19	det
19	day	day	NN	_	17	nmod:npmod
20	for	for	IN	_	22	case
21	23	23	CD	_	22	nummod
22	days	day	NNS	_	11	nmod
23	resulted	result	VBD	_	8	acl:relcl
24	in	in	IN	_	26	case
25	no	no	DT	_	26	neg
26	changes	change	NNS	_	23	nmod
27	in	in	IN	_	30	case
28	the	the	DT	_	30	det
29	ovulation-suppressing	ovulation-suppressing	JJ	_	30	amod
30	action	action	NN	_	26	nmod
31	of	of	IN	_	33	case
32	oral	oral	JJ	_	33	amod
33	drug3	drug3	NN	_	30	nmod
34	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	12	12	CD	_	6	nummod
5	normal-weight	normal-weight	JJ	_	6	amod
6	subjects	subject	NNS	_	22	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	10	compound
9	120	120	CD	_	10	nummod
10	mg	mg	NN	_	7	dobj
11	three	three	CD	_	12	nummod
12	times	time	NNS	_	7	nmod:tmod
13	a	a	DT	_	14	det
14	day	day	NN	_	12	nmod:npmod
15	for	for	IN	_	17	case
16	7	7	CD	_	17	nummod
17	days	day	NNS	_	7	nmod
18	,	,	,	_	22	punct
19	drug3	drug3	NN	_	22	nsubj
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	alter	alter	VB	_	1	appos
23	the	the	DT	_	24	det
24	pharmacokinetics	pharmacokinetic	NNS	_	22	dobj
25	of	of	IN	_	29	case
26	a	a	DT	_	29	det
27	single	single	JJ	_	29	amod
28	300-mg	300-mg	JJ	_	29	amod
29	dose	dose	NN	_	24	nmod
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	7	case
4	a	a	DT	_	7	det
5	2-way	2-way	JJ	_	7	amod
6	crossover	crossover	NN	_	7	compound
7	study	study	NN	_	1	nmod
8	of	of	IN	_	10	case
9	24	24	CD	_	10	nummod
10	normal-weight	normal-weight	JJ	_	7	nmod
11	,	,	,	_	10	punct
12	mildly	mildly	RB	_	13	advmod
13	hypercholesterolemic	hypercholesterolemic	JJ	_	14	amod
14	patients	patient	NNS	_	10	appos
15	receiving	receive	VBG	_	14	acl
16	drug2	drug2	NN	_	18	compound
17	120	120	CD	_	18	nummod
18	mg	mg	NN	_	15	dobj
19	three	three	CD	_	20	nummod
20	times	time	NNS	_	14	dep
21	a	a	DT	_	22	det
22	day	day	NN	_	20	nmod:npmod
23	for	for	IN	_	25	case
24	6	6	CD	_	25	nummod
25	days	day	NNS	_	20	nmod
26	,	,	,	_	14	punct
27	drug3	drug3	NN	_	30	nsubj
28	did	do	VBD	_	30	aux
29	not	not	RB	_	30	neg
30	affect	affect	VB	_	14	acl:relcl
31	the	the	DT	_	32	det
32	pharmacokinetics	pharmacokinetic	NNS	_	30	dobj
33	of	of	IN	_	34	case
34	drug4	drug4	NN	_	32	nmod
35	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	12	12	CD	_	6	nummod
5	normal-weight	normal-weight	JJ	_	6	amod
6	subjects	subject	NNS	_	22	nmod
7	,	,	,	_	6	punct
8	administration	administration	NN	_	22	nsubj
9	of	of	IN	_	12	case
10	drug2	drug2	NN	_	12	compound
11	120	120	CD	_	12	nummod
12	mg	mg	NN	_	8	nmod
13	three	three	CD	_	14	nummod
14	times	time	NNS	_	8	nmod:tmod
15	a	a	DT	_	16	det
16	day	day	NN	_	14	nmod:npmod
17	for	for	IN	_	19	case
18	16	16	CD	_	19	nummod
19	days	day	NNS	_	8	nmod
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	result	result	VB	_	1	appos
23	in	in	IN	_	25	case
24	any	any	DT	_	25	det
25	change	change	NN	_	22	nmod
26	in	in	IN	_	29	case
27	either	either	CC	_	29	cc:preconj
28	drug3	drug3	NN	_	29	compound
29	pharmacokinetics	pharmacokinetic	NNS	_	25	nmod
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	both	both	CC	_	32	cc:preconj
32	R	r	NN	_	29	dep
33	-	-	:	_	32	punct
34	and	and	CC	_	32	cc
35	S-enantiomers	s-enantiomer	NNS	_	32	conj
36	-RRB-	-rrb-	-RRB-	_	32	punct
37	or	or	CC	_	29	cc
38	pharmacodynamics	pharmacodynamic	NNS	_	29	conj
39	-LRB-	-lrb-	-LRB-	_	41	punct
40	prothrombin	prothrombin	NN	_	41	compound
41	time	time	NN	_	38	dep
42	and	and	CC	_	41	cc
43	serum	serum	NN	_	45	compound
44	Factor	factor	NN	_	45	compound
45	VII	vii	NN	_	41	conj
46	-RRB-	-rrb-	-RRB-	_	41	punct
47	.	.	.	_	1	punct

1	Although	although	IN	_	14	mark
2	undercarboxylated	undercarboxylated	JJ	_	3	amod
3	osteocalcin	osteocalcin	NN	_	14	nsubj
4	,	,	,	_	3	punct
5	a	a	DT	_	6	det
6	marker	marker	NN	_	3	appos
7	of	of	IN	_	11	case
8	vitamin	vitamin	NN	_	11	compound
9	K	k	NN	_	11	compound
10	nutritional	nutritional	JJ	_	11	amod
11	status	status	NN	_	6	nmod
12	,	,	,	_	3	punct
13	was	be	VBD	_	14	cop
14	unaltered	unaltered	JJ	_	22	advcl
15	with	with	IN	_	17	case
16	drug1	drug1	NN	_	17	compound
17	administration	administration	NN	_	14	nmod
18	,	,	,	_	22	punct
19	vitamin	vitamin	NN	_	21	compound
20	K	k	NN	_	21	compound
21	levels	level	NNS	_	22	nsubj
22	tended	tend	VBD	_	0	ROOT
23	to	to	TO	_	24	mark
24	decline	decline	VB	_	22	xcomp
25	in	in	IN	_	26	case
26	subjects	subject	NNS	_	24	nmod
27	taking	take	VBG	_	26	acl
28	drug2	drug2	NN	_	27	dobj
29	.	.	.	_	22	punct

1	Therefore	therefore	RB	_	25	advmod
2	,	,	,	_	25	punct
3	as	as	IN	_	8	mark
4	drug1	drug1	NN	_	5	compound
5	absorption	absorption	NN	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	decreased	decrease	VBN	_	25	advcl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	25	punct
12	patients	patient	NNS	_	25	nsubjpass
13	on	on	IN	_	16	case
14	chronic	chronic	JJ	_	16	amod
15	stable	stable	JJ	_	16	amod
16	doses	dose	NNS	_	12	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	who	who	WP	_	21	nsubjpass
20	are	be	VBP	_	21	auxpass
21	prescribed	prescribe	VBN	_	16	acl:relcl
22	drug4	drug4	NN	_	21	dobj
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	monitored	monitor	VBN	_	0	ROOT
26	closely	closely	RB	_	25	advmod
27	for	for	IN	_	28	case
28	changes	change	NNS	_	25	nmod
29	in	in	IN	_	31	case
30	coagulation	coagulation	NN	_	31	compound
31	parameters	parameter	NNS	_	28	nmod
32	.	.	.	_	25	punct

1	drug1	drug1	NN	_	2	nsubj
2	competes	compete	VBZ	_	0	ROOT
3	with	with	IN	_	4	case
4	drug2	drug2	NN	_	2	nmod
5	for	for	IN	_	8	case
6	active	active	JJ	_	8	amod
7	tubular	tubular	JJ	_	8	amod
8	secretion	secretion	NN	_	2	nmod
9	and	and	CC	_	2	cc
10	thus	thus	RB	_	11	advmod
11	inhibits	inhibit	VBZ	_	2	conj
12	the	the	DT	_	14	det
13	renal	renal	JJ	_	14	amod
14	excretion	excretion	NN	_	11	dobj
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	2	punct

1	This	this	DT	_	2	nsubj
2	led	lead	VBD	_	0	ROOT
3	to	to	TO	_	6	case
4	statistically	statistically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	increases	increase	NNS	_	2	nmod
7	in	in	IN	_	10	case
8	the	the	DT	_	10	det
9	elimination	elimination	NN	_	10	compound
10	half-life	half-life	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	38	38	CD	_	13	nummod
13	%	%	NN	_	6	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	and	and	CC	_	6	cc
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	extent	extent	NN	_	6	conj
19	of	of	IN	_	21	case
20	systemic	systemic	JJ	_	21	amod
21	exposure	exposure	NN	_	18	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	56	56	CD	_	24	nummod
24	%	%	NN	_	18	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	4	det
4	coadministration	coadministration	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	evidence	evidence	NN	_	2	nsubj
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	reduce	reduce	VB	_	3	ccomp
8	serum	serum	NN	_	9	compound
9	levels	level	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	to	to	TO	_	14	case
13	subtherapeutic	subtherapeutic	JJ	_	14	amod
14	levels	level	NNS	_	7	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	therapeutic	therapeutic	JJ	_	17	amod
17	range	range	NN	_	14	dep
18	considered	consider	VBN	_	17	acl
19	to	to	TO	_	26	mark
20	be	be	VB	_	26	cop
21	50	50	CD	_	23	compound
22	to	to	TO	_	23	dep
23	100	100	CD	_	26	nummod
24	g/mL	g/ml	NN	_	26	compound
25	total	total	JJ	_	26	amod
26	drug3	drug3	NN	_	18	xcomp
27	-RRB-	-rrb-	-RRB-	_	17	punct
28	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	nsubj
2	does	do	VBZ	_	5	aux
3	not	not	RB	_	5	neg
4	itself	itself	PRP	_	5	nsubj
5	appear	appear	VB	_	0	ROOT
6	to	to	TO	_	7	mark
7	induce	induce	VB	_	5	xcomp
8	or	or	CC	_	7	cc
9	inhibit	inhibit	VB	_	7	conj
10	the	the	DT	_	15	det
11	cytochrome	cytochrome	NN	_	15	compound
12	P-450	p-450	NN	_	15	compound
13	drug-metabolizing	drug-metabolizing	JJ	_	15	amod
14	enzyme	enzyme	NN	_	15	compound
15	system	system	NN	_	7	dobj
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	liver	liver	NN	_	15	nmod
19	.	.	.	_	5	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	26	csubj
5	by	by	IN	_	10	case
6	hepatic	hepatic	JJ	_	10	amod
7	cytochrome	cytochrome	NN	_	10	compound
8	P-450	p-450	NN	_	10	compound
9	drug-metabolizing	drug-metabolizing	JJ	_	10	amod
10	enzymes	enzyme	NNS	_	4	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	CYP3A4	cyp3a4	NN	_	10	dep
13	,	,	,	_	12	punct
14	CYP2D6	cyp2d6	NN	_	12	appos
15	,	,	,	_	12	punct
16	CYP1A2	cyp1a2	NN	_	12	appos
17	-RRB-	-rrb-	-RRB-	_	12	punct
18	,	,	,	_	10	punct
19	inducers	inducer	NNS	_	10	conj
20	or	or	CC	_	10	cc
21	inhibitors	inhibitor	NNS	_	10	conj
22	of	of	IN	_	24	case
23	these	these	DT	_	24	det
24	enzymes	enzyme	NNS	_	21	nmod
25	may	may	MD	_	26	aux
26	change	change	VB	_	0	ROOT
27	the	the	DT	_	28	det
28	clearance	clearance	NN	_	26	dobj
29	and	and	CC	_	26	cc
30	,	,	,	_	26	punct
31	hence	hence	RB	_	26	advmod
32	,	,	,	_	26	punct
33	the	the	DT	_	34	det
34	half-life	half-life	NN	_	26	dobj
35	of	of	IN	_	36	case
36	drug2	drug2	NN	_	34	nmod
37	.	.	.	_	26	punct

1	On	on	IN	_	3	case
2	the	the	DT	_	3	det
3	basis	basis	NN	_	13	nmod
4	of	of	IN	_	7	case
5	limited	limited	JJ	_	7	amod
6	available	available	JJ	_	7	amod
7	data	datum	NNS	_	3	nmod
8	,	,	,	_	13	punct
9	no	no	DT	_	11	neg
10	dosage	dosage	NN	_	11	compound
11	adjustment	adjustment	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	for	for	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	on	on	IN	_	18	case
17	these	these	DT	_	18	det
18	drugs	drug	NNS	_	15	nmod
19	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	:	:	:	_	1	punct
8	In	in	IN	_	9	case
9	patients	patient	NNS	_	33	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	13	case
12	potent	potent	JJ	_	13	amod
13	inducers	inducer	NNS	_	10	nmod
14	of	of	IN	_	15	case
15	CYP3A4	cyp3a4	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	i.e.	i.e.	FW	_	19	dep
18	,	,	,	_	19	punct
19	drug4	drug4	NN	_	9	dep
20	,	,	,	_	19	punct
21	drug5	drug5	NN	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	drug6	drug6	NN	_	19	conj
25	-RRB-	-rrb-	-RRB-	_	19	punct
26	,	,	,	_	9	punct
27	the	the	DT	_	28	det
28	clearance	clearance	NN	_	33	nsubjpass
29	of	of	IN	_	30	case
30	drug7	drug7	NN	_	28	nmod
31	was	be	VBD	_	33	auxpass
32	significantly	significantly	RB	_	33	advmod
33	increased	increase	VBN	_	1	dep
34	and	and	CC	_	33	cc
35	drug8	drug8	VBN	_	37	amod
36	blood	blood	NN	_	37	compound
37	concentrations	concentration	NNS	_	39	nsubjpass
38	were	be	VBD	_	39	auxpass
39	decreased	decrease	VBN	_	33	conj
40	.	.	.	_	1	punct

1	However	however	RB	_	16	advmod
2	,	,	,	_	16	punct
3	on	on	IN	_	5	case
4	the	the	DT	_	5	det
5	basis	basis	NN	_	16	nmod
6	of	of	IN	_	8	case
7	available	available	JJ	_	8	amod
8	data	datum	NNS	_	5	nmod
9	,	,	,	_	16	punct
10	no	no	DT	_	12	neg
11	dosage	dosage	NN	_	12	compound
12	adjustment	adjustment	NN	_	16	nsubjpass
13	for	for	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	for	for	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	on	on	IN	_	21	case
20	these	these	DT	_	21	det
21	drugs	drug	NNS	_	18	nmod
22	.1,3	.1,3	CD	_	23	nummod
23	drug2	drug2	NN	_	21	dep
24	:	:	:	_	16	punct
25	Although	although	IN	_	36	mark
26	no	no	DT	_	29	neg
27	pharmacokinetic	pharmacokinetic	JJ	_	29	amod
28	drug	drug	NN	_	29	compound
29	interaction	interaction	NN	_	36	nsubjpass
30	between	between	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	drug4	drug4	NN	_	31	conj
34	has	have	VBZ	_	36	aux
35	been	be	VBN	_	36	auxpass
36	observed	observe	VBN	_	43	advcl
37	,	,	,	_	43	punct
38	data	datum	NNS	_	43	nsubj
39	from	from	IN	_	42	case
40	2	2	CD	_	42	nummod
41	small	small	JJ	_	42	amod
42	studies	study	NNS	_	38	nmod
43	indicate	indicate	VBP	_	16	parataxis
44	that	that	IN	_	48	mark
45	drug5	drug5	NN	_	48	nsubjpass
46	may	may	MD	_	48	aux
47	be	be	VB	_	48	auxpass
48	associated	associate	VBN	_	43	ccomp
49	with	with	IN	_	51	case
50	an	a	DT	_	51	det
51	increase	increase	NN	_	48	nmod
52	in	in	IN	_	55	case
53	patient	patient	NN	_	55	compound
54	controlled	controlled	JJ	_	55	amod
55	administration	administration	NN	_	51	nmod
56	of	of	IN	_	57	case
57	drug6	drug6	NN	_	55	nmod
58	.4,5	.4,5	CD	_	59	nummod
59	Chemotherapy	Chemotherapy	NNP	_	57	dep
60	:	:	:	_	48	punct
61	Tumor	tumor	NN	_	62	compound
62	response	response	NN	_	74	nsubjpass
63	to	to	TO	_	64	case
64	chemotherapy	chemotherapy	NN	_	62	nmod
65	in	in	IN	_	71	case
66	the	the	DT	_	71	det
67	P	p	NN	_	71	compound
68	388	388	CD	_	71	nummod
69	mouse	mouse	NN	_	71	compound
70	leukemia	leukemia	NN	_	71	compound
71	model	model	NN	_	64	nmod
72	is	be	VBZ	_	74	auxpass
73	not	not	RB	_	74	neg
74	affected	affect	VBN	_	48	parataxis
75	by	by	IN	_	76	case
76	drug7	drug7	NN	_	74	nmod
77	.	.	.	_	16	punct

1	In	in	IN	_	2	case
2	humans	human	NNS	_	12	nmod
3	,	,	,	_	12	punct
4	drug1	drug1	NN	_	12	nsubj
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	drug3	drug3	NN	_	4	conj
10	do	do	VBP	_	12	aux
11	not	not	RB	_	12	neg
12	affect	affect	VB	_	0	ROOT
13	the	the	DT	_	14	det
14	pharmacokinetics	pharmacokinetic	NNS	_	12	dobj
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	12	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	crossover	crossover	NN	_	4	compound
4	study	study	NN	_	10	nmod
5	in	in	IN	_	8	case
6	76	76	CD	_	8	nummod
7	pediatric	pediatric	JJ	_	8	amod
8	patients	patient	NNS	_	4	nmod
9	,	,	,	_	10	punct
10	I.V.	I.V.	NNP	_	0	ROOT

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	increase	increase	VB	_	0	ROOT
5	blood	blood	NN	_	6	compound
6	levels	level	NNS	_	4	dobj
7	of	of	IN	_	9	case
8	high-dose	high-dose	JJ	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	.	.	.	_	4	punct

1	CYP3A4	cyp3a4	NN	_	2	compound
2	Inhibitors	inhibitor	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug1	drug1	NN	_	2	dep
5	,	,	,	_	4	punct
6	an	a	DT	_	7	det
7	inhibitor	inhibitor	NN	_	4	appos
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	drug	drug	NN	_	7	nmod
11	metabolizing	metabolize	VBG	_	10	acl
12	enzyme	enzyme	NN	_	13	compound
13	CYP3A4	cyp3a4	NN	_	11	dobj
14	,	,	,	_	4	punct
15	significantly	significantly	RB	_	16	advmod
16	increased	increase	VBN	_	18	amod
17	plasma	plasma	NN	_	18	compound
18	concentrations	concentration	NNS	_	4	appos
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	when	when	WRB	_	22	advmod
22	coadministered	coadminister	VBN	_	18	acl:relcl
23	to	to	TO	_	24	case
24	subjects	subject	NNS	_	22	nmod
25	who	who	WP	_	28	nsubj
26	were	be	VBD	_	28	cop
27	poor	poor	JJ	_	28	amod
28	metabolizers	metabolizer	NNS	_	24	acl:relcl
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	see	see	VB	_	28	dep
31	CLINICAL	CLINICAL	NNP	_	32	compound
32	PHARMACOLOGY	PHARMACOLOGY	NNP	_	30	dobj
33	,	,	,	_	32	punct
34	Variability	variability	NN	_	32	appos
35	in	in	IN	_	36	case
36	Metabolism	metabolism	NN	_	34	nmod
37	and	and	CC	_	36	cc
38	Drug-Drug	Drug-Drug	NNP	_	39	compound
39	Interactions	interaction	NNS	_	36	conj
40	-RRB-	-rrb-	-RRB-	_	30	punct
41	.	.	.	_	2	punct

1	For	for	IN	_	2	case
2	patients	patient	NNS	_	42	nmod
3	receiving	receive	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	or	or	CC	_	4	cc
6	other	other	JJ	_	9	amod
7	potent	potent	JJ	_	9	amod
8	CYP3A4	cyp3a4	NN	_	9	compound
9	inhibitors	inhibitor	NNS	_	4	conj
10	such	such	JJ	_	13	case
11	as	as	IN	_	10	mwe
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	2	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	eg	eg	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug3	drug3	NN	_	13	dep
18	,	,	,	_	17	punct
19	drug4	drug4	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	or	or	CC	_	13	cc
22	drug5	drug5	NN	_	13	conj
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	eg	eg	FW	_	26	dep
25	,	,	,	_	26	punct
26	drug6	drug6	NN	_	22	dep
27	,	,	,	_	26	punct
28	drug7	drug7	NN	_	26	appos
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	or	or	CC	_	13	cc
31	drug8	drug8	NN	_	13	conj
32	or	or	CC	_	31	cc
33	drug9	drug9	NN	_	31	conj
34	,	,	,	_	42	punct
35	the	the	DT	_	37	det
36	recommended	recommend	VBN	_	37	amod
37	dose	dose	NN	_	42	nsubj
38	of	of	IN	_	39	case
39	drug10	drug10	NN	_	37	nmod
40	is	be	VBZ	_	42	cop
41	2	2	CD	_	42	nummod
42	mg	mg	NN	_	0	ROOT
43	daily	daily	RB	_	42	advmod
44	.	.	.	_	42	punct

1	Drug-Laboratory-Test	Drug-Laboratory-Test	NNP	_	3	compound
2	Interactions	interaction	NNS	_	3	compound
3	Interactions	interaction	NNS	_	12	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	laboratory	laboratory	NN	_	8	compound
8	tests	test	NNS	_	5	conj
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Since	since	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	22	advcl
5	by	by	IN	_	9	case
6	a	a	DT	_	9	det
7	P450	p450	NN	_	9	compound
8	enzyme	enzyme	NN	_	9	compound
9	system	system	NN	_	4	nmod
10	,	,	,	_	22	punct
11	drugs	drug	NNS	_	22	nsubj
12	that	that	WDT	_	13	nsubj
13	induce	induce	VBP	_	11	acl:relcl
14	or	or	CC	_	13	cc
15	inhibit	inhibit	VBP	_	13	conj
16	this	this	DT	_	17	det
17	drug	drug	NN	_	20	compound
18	metabolizing	metabolize	VBG	_	20	amod
19	enzyme	enzyme	NN	_	20	compound
20	system	system	NN	_	13	dobj
21	may	may	MD	_	22	aux
22	elicit	elicit	VB	_	0	ROOT
23	important	important	JJ	_	25	amod
24	drug-drug	drug-drug	JJ	_	25	amod
25	interactions	interaction	NNS	_	22	dobj
26	that	that	WDT	_	28	nsubj
27	may	may	MD	_	28	aux
28	alter	alter	VB	_	25	acl:relcl
29	drug2	drug2	NN	_	31	compound
30	plasma	plasma	NN	_	31	compound
31	concentrations	concentration	NNS	_	28	dobj
32	.	.	.	_	22	punct

1	Agents	agent	NNS	_	19	nsubj
2	that	that	WDT	_	5	nsubjpass
3	might	might	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	1	acl:relcl
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	10	case
9	AIDS	aids	NN	_	10	compound
10	patients	patient	NNS	_	7	nmod
11	for	for	IN	_	13	case
12	other	other	JJ	_	13	amod
13	indications	indication	NNS	_	10	nmod
14	that	that	WDT	_	16	nsubj
15	could	could	MD	_	16	aux
16	elicit	elicit	VB	_	13	acl:relcl
17	this	this	DT	_	18	det
18	activity	activity	NN	_	16	dobj
19	include	include	VBP	_	0	ROOT
20	drug2	drug2	NN	_	19	dobj
21	,	,	,	_	20	punct
22	drug3	drug3	NN	_	20	conj
23	,	,	,	_	20	punct
24	drug4	drug4	NN	_	20	conj
25	,	,	,	_	20	punct
26	drug5	drug5	NN	_	20	conj
27	,	,	,	_	20	punct
28	and	and	CC	_	20	cc
29	drug6	drug6	NN	_	20	conj
30	.	.	.	_	19	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	perfusion	perfusion	NN	_	9	nsubj
4	of	of	IN	_	7	case
5	isolated	isolate	VBN	_	7	amod
6	rat	rat	NN	_	7	compound
7	liver	liver	NN	_	3	nmod
8	has	have	VBZ	_	9	aux
9	shown	show	VBN	_	0	ROOT
10	that	that	IN	_	12	mark
11	drug1	drug1	NN	_	12	nsubj
12	caused	cause	VBD	_	9	ccomp
13	a	a	DT	_	15	det
14	significant	significant	JJ	_	15	amod
15	reduction	reduction	NN	_	12	dobj
16	in	in	IN	_	18	case
17	drug2	drug2	NN	_	18	compound
18	metabolism	metabolism	NN	_	15	nmod
19	and	and	CC	_	12	cc
20	that	that	IN	_	22	mark
21	drug3	drug3	NN	_	22	nsubj
22	altered	alter	VBD	_	12	conj
23	the	the	DT	_	25	det
24	relative	relative	JJ	_	25	amod
25	concentration	concentration	NN	_	22	dobj
26	of	of	IN	_	28	case
27	trimetrexate	trimetrexate	NN	_	28	compound
28	metabolites	metabolite	NNS	_	25	nmod
29	possibly	possibly	RB	_	22	advmod
30	by	by	IN	_	31	mark
31	competing	compete	VBG	_	22	advcl
32	for	for	IN	_	34	case
33	sulfate	sulfate	NN	_	34	compound
34	metabolites	metabolite	NNS	_	31	nmod
35	.	.	.	_	9	punct

1	Based	base	VBN	_	8	case
2	on	on	IN	_	8	case
3	an	a	DT	_	8	det
4	in	in	FW	_	8	amod
5	vitro	vitro	FW	_	4	dep
6	rat	rat	NN	_	8	compound
7	liver	liver	NN	_	8	compound
8	model	model	NN	_	11	advcl
9	,	,	,	_	11	punct
10	nitrogen	nitrogen	NN	_	11	nsubj
11	substituted	substitute	VBN	_	0	ROOT
12	drug1	drug1	NN	_	21	nsubj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug2	drug2	NN	_	12	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	appos
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	appos
19	-RRB-	-rrb-	-RRB-	_	14	punct
20	were	be	VBD	_	21	cop
21	potent	potent	JJ	_	11	ccomp
22	,	,	,	_	21	punct
23	non-competitive	non-competitive	JJ	_	24	amod
24	inhibitors	inhibitor	NNS	_	21	appos
25	of	of	IN	_	27	case
26	drug5	drug5	NN	_	27	compound
27	metabolism	metabolism	NN	_	24	nmod
28	.	.	.	_	11	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	medicated	medicate	VBN	_	1	acl
3	with	with	IN	_	5	case
4	these	these	DT	_	5	det
5	drugs	drug	NNS	_	2	nmod
6	and	and	CC	_	5	cc
7	drug1	drug1	NN	_	5	conj
8	should	should	MD	_	11	aux
9	be	be	VB	_	11	auxpass
10	carefully	carefully	RB	_	11	advmod
11	monitored	monitor	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Prolongation	prolongation	NN	_	18	nsubjpass
4	of	of	IN	_	6	case
5	prothrombin	prothrombin	NN	_	6	compound
6	time	time	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	PT	pt	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	and	and	CC	_	6	cc
11	International	International	NNP	_	13	compound
12	Normalized	Normalized	NNP	_	13	compound
13	Ratio	Ratio	NNP	_	6	conj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	INR	INR	NNP	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	were	be	VBD	_	18	auxpass
18	observed	observe	VBN	_	1	appos
19	in	in	IN	_	20	case
20	patients	patient	NNS	_	18	nmod
21	receiving	receive	VBG	_	20	acl
22	drug2	drug2	NN	_	21	dobj
23	concomitantly	concomitantly	RB	_	21	advmod
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	21	nmod
26	.	.	.	_	1	punct

1	Physicians	Physicians	NNP	_	4	nsubj
2	should	should	MD	_	4	aux
3	carefully	carefully	RB	_	4	advmod
4	monitor	monitor	VB	_	0	ROOT
5	PT	pt	NN	_	4	dobj
6	and	and	CC	_	5	cc
7	INR	inr	NN	_	5	conj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	4	nmod
10	concurrently	concurrently	RB	_	11	advmod
11	administered	administer	VBN	_	12	amod
12	drug1	drug1	NN	_	9	dep
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	.	.	.	_	4	punct

1	Other	other	JJ	_	4	amod
2	drug1	drug1	NN	_	4	compound
3	Severe	severe	JJ	_	4	amod
4	thrombocytopenia	thrombocytopenia	NN	_	10	nsubjpass
5	and	and	CC	_	4	cc
6	gastrointestinal	gastrointestinal	JJ	_	7	amod
7	bleeding	bleeding	NN	_	4	conj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	with	with	IN	_	13	case
12	concomitant	concomitant	JJ	_	13	amod
13	use	use	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	other	other	JJ	_	18	amod
18	drug3	drug3	NN	_	15	conj
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug4	drug4	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	.	.	.	_	10	punct

1	Monitor	Monitor	NNP	_	3	compound
2	platelet	platelet	NN	_	3	compound
3	count	count	NN	_	0	ROOT
4	every	every	DT	_	6	det
5	2	2	CD	_	6	nummod
6	weeks	week	NNS	_	3	nmod:tmod
7	for	for	IN	_	11	case
8	the	the	DT	_	11	det
9	first	first	JJ	_	11	amod
10	2	2	CD	_	11	nummod
11	months	month	NNS	_	3	nmod
12	.	.	.	_	3	punct

1	Nasal	nasal	JJ	_	2	amod
2	Spray	spray	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Formal	formal	JJ	_	5	amod
5	studies	study	NNS	_	16	nsubjpass
6	designed	design	VBN	_	5	acl
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	8	dobj
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	have	have	VBP	_	16	aux
14	not	not	RB	_	16	neg
15	been	be	VBN	_	16	auxpass
16	done	do	VBN	_	2	dep
17	.	.	.	_	2	punct

1	No	no	DT	_	4	neg
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	with	with	IN	_	12	case
9	drug1	drug1	NN	_	12	compound
10	nasal	nasal	JJ	_	12	amod
11	spray	spray	NN	_	12	compound
12	ingredients	ingredient	NNS	_	7	nmod
13	.	.	.	_	7	punct

1	Currently	currently	RB	_	10	advmod
2	,	,	,	_	10	punct
3	no	no	DT	_	5	neg
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	10	nsubjpass
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	observed	observe	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	15	nsubjpass
3	of	of	IN	_	5	case
4	prior	prior	JJ	_	5	amod
5	use	use	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	11	case
9	postmenopausal	postmenopausal	JJ	_	11	amod
10	osteoporosis	osteoporosis	NN	_	11	compound
11	patients	patient	NNS	_	2	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	assessed	assess	VBN	_	0	ROOT
16	;	;	:	_	15	punct

1	however	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	12	nmod
5	with	with	IN	_	8	case
6	Paget	paget	NN	_	8	nmod:poss
7	's	's	POS	_	6	case
8	Disease	disease	NN	_	4	nmod
9	prior	prior	RB	_	11	advmod
10	drug1	drug1	NN	_	11	compound
11	use	use	NN	_	12	nsubj
12	appears	appear	VBZ	_	0	ROOT
13	to	to	TO	_	14	mark
14	reduce	reduce	VB	_	12	xcomp
15	the	the	DT	_	17	det
16	anti-resorptive	anti-resorptive	JJ	_	17	amod
17	response	response	NN	_	14	dobj
18	to	to	TO	_	21	case
19	drug2	drug2	NN	_	21	compound
20	nasal	nasal	JJ	_	21	amod
21	spray	spray	NN	_	17	nmod
22	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	absorption	absorption	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	oral	oral	JJ	_	5	amod
5	medications	medication	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	decreased	decrease	VBN	_	0	ROOT
9	during	during	IN	_	12	case
10	the	the	DT	_	12	det
11	concurrent	concurrent	JJ	_	12	amod
12	use	use	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	because	because	IN	_	19	case
16	of	of	IN	_	15	mwe
17	decreased	decrease	VBN	_	19	amod
18	gastric	gastric	JJ	_	19	amod
19	motility	motility	NN	_	8	nmod
20	and	and	CC	_	19	cc
21	delayed	delay	VBN	_	23	amod
22	gastric	gastric	JJ	_	23	amod
23	emptying	emptying	NN	_	19	conj
24	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	care	care	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	4	nmod
9	taking	take	VBG	_	8	acl
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	9	dobj
12	that	that	WDT	_	14	nsubj
13	are	be	VBP	_	14	cop
14	capable	capable	JJ	_	11	acl:relcl
15	of	of	IN	_	16	mark
16	causing	cause	VBG	_	14	advcl
17	CNS	cns	NN	_	18	compound
18	effects	effect	NNS	_	16	dobj
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	drug2	drug2	NN	_	18	nmod
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	conj
24	,	,	,	_	21	punct
25	or	or	CC	_	21	cc
26	drug4	drug4	NN	_	21	conj
27	.	.	.	_	4	punct

1	Special	special	JJ	_	2	amod
2	attention	attention	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	paid	pay	VBN	_	0	ROOT
6	to	to	TO	_	8	case
7	potential	potential	JJ	_	8	amod
8	interactions	interaction	NNS	_	5	nmod
9	with	with	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	having	have	VBG	_	10	acl
12	anticholinergic	anticholinergic	JJ	_	13	amod
13	properties	property	NNS	_	11	dobj
14	;	;	:	_	5	punct

1	e.g.	e.g.	FW	_	4	dep
2	,	,	,	_	4	punct
3	other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	0	ROOT
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	including	include	VBG	_	9	case
9	drug3	drug3	NN	_	6	nmod
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	4	punct
12	drug4	drug4	NN	_	4	conj
13	,	,	,	_	4	punct
14	and	and	CC	_	4	cc
15	drug5	drug5	NN	_	4	conj
16	.	.	.	_	4	punct

1	Laboratory	Laboratory	NNP	_	4	compound
2	Test	Test	NNP	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	will	will	MD	_	6	aux
6	interfere	interfere	VB	_	0	ROOT
7	with	with	IN	_	11	case
8	the	the	DT	_	11	det
9	gastric	gastric	JJ	_	11	amod
10	secretion	secretion	NN	_	11	compound
11	test	test	NN	_	6	nmod
12	.	.	.	_	6	punct

1	Formal	formal	JJ	_	3	amod
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	performed	perform	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	studied	study	VBN	_	1	acl
3	in	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	trials	trial	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	were	be	VBD	_	10	auxpass
9	routinely	routinely	RB	_	10	advmod
10	treated	treat	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	.	.	.	_	10	punct

1	drug1	drug1	NN	_	28	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	dep
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	and	and	CC	_	1	cc
10	drugs	drug	NNS	_	1	conj
11	that	that	WDT	_	12	nsubj
12	alter	alter	VBP	_	1	acl:relcl
13	platelet	platelet	NN	_	14	compound
14	function	function	NN	_	12	dobj
15	-LRB-	-lrb-	-LRB-	_	18	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug4	drug4	NN	_	14	nmod
19	,	,	,	_	18	punct
20	drug5	drug5	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	GP	gp	NN	_	25	compound
24	IIb/IIIa	iib/iiia	NN	_	25	compound
25	inhibitors	inhibitor	NNS	_	18	conj
26	-RRB-	-rrb-	-RRB-	_	18	punct
27	may	may	MD	_	28	aux
28	increase	increase	VB	_	0	ROOT
29	the	the	DT	_	30	det
30	risk	risk	NN	_	28	dobj
31	of	of	IN	_	32	case
32	bleeding	bleed	VBG	_	30	nmod
33	if	if	IN	_	34	mark
34	administered	administer	VBN	_	28	advcl
35	prior	prior	RB	_	34	advmod
36	to	to	TO	_	43	nmod
37	,	,	,	_	43	punct
38	during	during	IN	_	43	conj
39	,	,	,	_	43	punct
40	or	or	CC	_	43	cc
41	after	after	IN	_	43	conj
42	drug6	drug6	NN	_	43	compound
43	therapy	therapy	NN	_	34	nmod
44	.	.	.	_	28	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	19	nsubj
4	During	during	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	therapy	therapy	NN	_	3	nmod
7	,	,	,	_	3	punct
8	results	result	NNS	_	3	appos
9	of	of	IN	_	11	case
10	coagulation	coagulation	NN	_	11	compound
11	tests	test	NNS	_	8	nmod
12	and/or	and/or	CC	_	11	cc
13	measures	measure	NNS	_	11	conj
14	of	of	IN	_	16	case
15	fibrinolytic	fibrinolytic	JJ	_	16	amod
16	activity	activity	NN	_	13	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	cop
19	unreliable	unreliable	JJ	_	0	ROOT
20	unless	unless	IN	_	24	mark
21	specific	specific	JJ	_	22	amod
22	precautions	precaution	NNS	_	24	nsubjpass
23	are	be	VBP	_	24	auxpass
24	taken	take	VBN	_	19	advcl
25	to	to	TO	_	26	mark
26	prevent	prevent	VB	_	24	xcomp
27	in	in	FW	_	29	amod
28	vitro	vitro	FW	_	27	dep
29	artifacts	artifact	NNS	_	26	dobj
30	.	.	.	_	19	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	an	a	DT	_	4	det
4	enzyme	enzyme	NN	_	0	ROOT
5	that	that	IN	_	15	nsubj
6	,	,	,	_	15	punct
7	when	when	WRB	_	8	advmod
8	present	present	JJ	_	15	dep
9	in	in	IN	_	10	case
10	blood	blood	NN	_	8	nmod
11	in	in	IN	_	13	case
12	pharmacologic	pharmacologic	JJ	_	13	amod
13	concentrations	concentration	NNS	_	8	nmod
14	,	,	,	_	15	punct
15	remains	remain	VBZ	_	4	acl:relcl
16	active	active	JJ	_	15	xcomp
17	under	under	IN	_	20	case
18	in	in	FW	_	20	amod
19	vitro	vitro	FW	_	18	dep
20	conditions	condition	NNS	_	16	nmod
21	.	.	.	_	4	punct

1	This	this	DT	_	3	nsubj
2	can	can	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	5	case
5	degradation	degradation	NN	_	3	nmod
6	of	of	IN	_	7	case
7	fibrinogen	fibrinogen	NN	_	5	nmod
8	in	in	IN	_	10	case
9	blood	blood	NN	_	10	compound
10	samples	sample	NNS	_	5	nmod
11	removed	remove	VBD	_	3	xcomp
12	for	for	IN	_	13	case
13	analysis	analysis	NN	_	11	nmod
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	causing	cause	VBG	_	3	dep
10	too	too	RB	_	11	advmod
11	great	great	JJ	_	13	amod
12	a	a	DT	_	13	det
13	decrease	decrease	NN	_	9	dobj
14	in	in	IN	_	16	case
15	adrenal	adrenal	JJ	_	16	amod
16	function	function	NN	_	13	nmod
17	-RRB-	-rrb-	-RRB-	_	9	punct
18	.	.	.	_	3	punct

1	Although	although	IN	_	12	mark
2	drug1	drug1	NN	_	12	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	a	a	DT	_	5	det
5	mixture	mixture	NN	_	2	dep
6	of	of	IN	_	8	case
7	three	three	CD	_	8	nummod
8	stereoisomers	stereoisomer	NNS	_	5	nmod
9	-RRB-	-rrb-	-RRB-	_	5	punct
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	administered	administer	VBN	_	29	advcl
13	safely	safely	RB	_	12	advmod
14	following	follow	VBG	_	17	case
15	succinylcholine-facilitated	succinylcholine-facilitated	JJ	_	17	amod
16	tracheal	tracheal	NN	_	17	compound
17	intubation	intubation	NN	_	12	nmod
18	,	,	,	_	29	punct
19	the	the	DT	_	20	det
20	interaction	interaction	NN	_	29	nsubjpass
21	between	between	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	has	have	VBZ	_	29	aux
26	not	not	RB	_	29	neg
27	been	be	VBN	_	29	auxpass
28	systematically	systematically	RB	_	29	advmod
29	studied	study	VBN	_	0	ROOT
30	.	.	.	_	29	punct

1	Prior	prior	RB	_	6	advmod
2	administration	administration	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	can	can	MD	_	6	aux
6	potentiate	potentiate	VB	_	0	ROOT
7	the	the	DT	_	10	det
8	neuromuscular	neuromuscular	JJ	_	10	amod
9	blocking	blocking	NN	_	10	compound
10	effects	effect	NNS	_	6	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	6	punct

1	Evidence	evidence	NN	_	9	nsubjpass
2	of	of	IN	_	4	case
3	spontaneous	spontaneous	JJ	_	4	amod
4	recovery	recovery	NN	_	1	nmod
5	from	from	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	before	before	IN	_	12	case
11	the	the	DT	_	12	det
12	administration	administration	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	19	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	before	before	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	to	to	TO	_	8	mark
8	attenuate	attenuate	VB	_	2	acl
9	some	some	DT	_	8	dobj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	side	side	JJ	_	13	amod
13	effects	effect	NNS	_	9	nmod
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	has	have	VBZ	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	studied	study	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	5	neg
4	clinical	clinical	JJ	_	5	amod
5	data	datum	NNS	_	2	nsubj
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	use	use	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	8	nmod
14	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	administered	administer	VBN	_	1	dep
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	5	nmod
8	/	/	:	_	5	punct
9	drug4	drug4	NN	_	5	dep
10	to	to	TO	_	11	mark
11	achieve	achieve	VB	_	9	acl
12	1.25	1.25	CD	_	13	nummod
13	M.C.	M.C.	NNP	_	11	dobj

1	decrease	decrease	VB	_	0	ROOT
2	the	the	DT	_	3	det
3	ED50	ed50	NN	_	1	dobj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	by	by	IN	_	11	case
7	as	as	RB	_	10	advmod
8	much	much	JJ	_	10	advmod
9	as	as	IN	_	10	advmod
10	25	25	CD	_	11	nummod
11	%	%	NN	_	1	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	see	see	VB	_	1	dep
14	CLINICAL	CLINICAL	NNP	_	15	compound
15	PHARMACOLOGY	PHARMACOLOGY	NNP	_	13	dobj
16	:	:	:	_	15	punct
17	Pharmacodynamics	pharmacodynamic	NNS	_	15	dep
18	and	and	CC	_	17	cc
19	Individualization	individualization	NN	_	17	conj
20	of	of	IN	_	21	case
21	Dosages	dosage	NNS	_	17	nmod
22	-RRB-	-rrb-	-RRB-	_	13	punct
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	also	also	RB	_	5	advmod
5	prolong	prolong	VB	_	0	ROOT
6	the	the	DT	_	9	det
7	clinically	clinically	RB	_	8	advmod
8	effective	effective	JJ	_	9	amod
9	duration	duration	NN	_	5	dobj
10	of	of	IN	_	11	case
11	action	action	NN	_	9	nmod
12	and	and	CC	_	5	cc
13	decrease	decrease	VB	_	5	conj
14	the	the	DT	_	17	det
15	average	average	JJ	_	17	amod
16	infusion	infusion	NN	_	17	compound
17	requirement	requirement	NN	_	13	dobj
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	by	by	IN	_	25	case
21	as	as	RB	_	24	advmod
22	much	much	JJ	_	24	advmod
23	as	as	IN	_	24	advmod
24	35	35	CD	_	25	nummod
25	%	%	NN	_	13	nmod
26	to	to	TO	_	28	case
27	40	40	CD	_	28	nummod
28	%	%	NN	_	13	nmod
29	.	.	.	_	5	punct

1	A	a	DT	_	3	det
2	greater	greater	JJR	_	3	amod
3	potentiation	potentiation	NN	_	13	nsubjpass
4	of	of	IN	_	8	case
5	the	the	DT	_	8	det
6	neuromuscular	neuromuscular	JJ	_	8	amod
7	blocking	blocking	NN	_	8	compound
8	effects	effect	NNS	_	3	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	expected	expect	VBN	_	0	ROOT
14	with	with	IN	_	16	case
15	higher	higher	JJR	_	16	amod
16	concentrations	concentration	NNS	_	13	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	or	or	CC	_	18	cc
20	drug3	drug3	NN	_	18	conj
21	.	.	.	_	13	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	little	little	JJ	_	2	dobj
4	or	or	CC	_	3	cc
5	no	no	DT	_	3	conj
6	effect	effect	NN	_	3	dep
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	ED50	ed50	NN	_	2	nmod
10	,	,	,	_	2	punct
11	but	but	CC	_	2	cc
12	may	may	MD	_	13	aux
13	prolong	prolong	VB	_	2	conj
14	the	the	DT	_	15	det
15	duration	duration	NN	_	13	dobj
16	of	of	IN	_	17	case
17	action	action	NN	_	15	nmod
18	and	and	CC	_	13	cc
19	decrease	decrease	VB	_	13	conj
20	the	the	DT	_	23	det
21	average	average	JJ	_	23	amod
22	infusion	infusion	NN	_	23	compound
23	requirement	requirement	NN	_	19	dobj
24	by	by	IN	_	29	case
25	as	as	RB	_	28	advmod
26	much	much	JJ	_	28	advmod
27	as	as	IN	_	28	advmod
28	20	20	CD	_	29	nummod
29	%	%	NN	_	19	nmod
30	.	.	.	_	2	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	15	nsubj
3	which	which	WDT	_	5	nsubj
4	may	may	MD	_	5	aux
5	enhance	enhance	VB	_	2	acl:relcl
6	the	the	DT	_	9	det
7	neuromuscular	neuromuscular	JJ	_	9	amod
8	blocking	block	VBG	_	9	amod
9	action	action	NN	_	5	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug2	drug2	NN	_	11	nmod
15	include	include	VBP	_	0	ROOT
16	certain	certain	JJ	_	17	amod
17	drug3	drug3	NN	_	15	dobj
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	e.g.	e.g.	FW	_	21	dep
20	,	,	,	_	21	punct
21	drug4	drug4	NN	_	17	dep
22	,	,	,	_	21	punct
23	drug5	drug5	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug6	drug6	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug7	drug7	NN	_	21	conj
28	,	,	,	_	21	punct
29	drug8	drug8	NN	_	21	conj
30	,	,	,	_	21	punct
31	drug9	drug9	NN	_	21	conj
32	,	,	,	_	21	punct
33	drug10	drug10	NN	_	21	conj
34	,	,	,	_	21	punct
35	and	and	CC	_	21	cc
36	drug11	drug11	NN	_	21	conj
37	-RRB-	-rrb-	-RRB-	_	21	punct
38	,	,	,	_	17	punct
39	drug12	drug12	NN	_	40	compound
40	salts	salt	NNS	_	17	conj
41	,	,	,	_	17	punct
42	drug13	drug13	NN	_	17	conj
43	,	,	,	_	17	punct
44	local	local	JJ	_	45	amod
45	drug14	drug14	NN	_	17	conj
46	,	,	,	_	17	punct
47	drug15	drug15	NN	_	17	conj
48	,	,	,	_	17	punct
49	and	and	CC	_	17	cc
50	drug16	drug16	NN	_	17	conj
51	.	.	.	_	15	punct

1	The	the	DT	_	4	det
2	neuromuscular	neuromuscular	JJ	_	4	amod
3	blocking	blocking	NN	_	4	compound
4	effect	effect	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	enhanced	enhance	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	that	that	WDT	_	13	nsubj
13	reduce	reduce	VBP	_	11	acl:relcl
14	plasma	plasma	NN	_	16	compound
15	cholinesterase	cholinesterase	NN	_	16	compound
16	activity	activity	NN	_	13	dobj
17	-LRB-	-lrb-	-LRB-	_	23	punct
18	e.g.	e.g.	FW	_	23	dep
19	,	,	,	_	23	punct
20	chronically	chronically	RB	_	21	advmod
21	administered	administer	VBN	_	23	amod
22	oral	oral	JJ	_	23	amod
23	drug2	drug2	NN	_	11	dep
24	,	,	,	_	23	punct
25	drug3	drug3	NN	_	23	conj
26	,	,	,	_	23	punct
27	or	or	CC	_	23	cc
28	certain	certain	JJ	_	29	amod
29	drug4	drug4	NN	_	23	conj
30	-RRB-	-rrb-	-RRB-	_	23	punct
31	or	or	CC	_	11	cc
32	by	by	IN	_	33	case
33	drugs	drug	NNS	_	11	conj
34	that	that	WDT	_	36	nsubj
35	irreversibly	irreversibly	RB	_	36	advmod
36	inhibit	inhibit	VBP	_	33	acl:relcl
37	plasma	plasma	NN	_	38	compound
38	cholinesterase	cholinesterase	NN	_	36	dobj
39	.	.	.	_	9	punct
40	Resistance	resistance	NN	_	51	nsubjpass
41	to	to	TO	_	45	case
42	the	the	DT	_	45	det
43	neuromuscular	neuromuscular	JJ	_	45	amod
44	blocking	block	VBG	_	45	amod
45	action	action	NN	_	40	nmod
46	of	of	IN	_	48	case
47	nondepolarizing	nondepolarizing	JJ	_	48	amod
48	drug5	drug5	NN	_	45	nmod
49	has	have	VBZ	_	51	aux
50	been	be	VBN	_	51	auxpass
51	demonstrated	demonstrate	VBN	_	9	parataxis
52	in	in	IN	_	53	case
53	patients	patient	NNS	_	51	nmod
54	chronically	chronically	RB	_	55	advmod
55	administered	administer	VBN	_	53	acl
56	drug6	drug6	NN	_	55	dobj
57	or	or	CC	_	56	cc
58	drug7	drug7	NN	_	56	conj
59	.	.	.	_	9	punct

1	While	while	IN	_	16	mark
2	the	the	DT	_	3	det
3	effects	effect	NNS	_	16	nsubj
4	of	of	IN	_	6	case
5	chronic	chronic	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	or	or	CC	_	6	cc
8	drug2	drug2	NN	_	9	compound
9	therapy	therapy	NN	_	6	conj
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	action	action	NN	_	3	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	are	be	VBP	_	16	cop
16	unknown	unknown	JJ	_	20	advcl
17	,	,	,	_	20	punct
18	slightly	slightly	RB	_	19	advmod
19	shorter	shorter	JJR	_	20	amod
20	durations	duration	NNS	_	33	nmod
21	of	of	IN	_	23	case
22	neuromuscular	neuromuscular	JJ	_	23	amod
23	block	block	NN	_	20	nmod
24	may	may	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	anticipated	anticipate	VBN	_	33	csubj
27	and	and	CC	_	26	cc
28	infusion	infusion	NN	_	30	compound
29	rate	rate	NN	_	30	compound
30	requirements	requirement	NNS	_	26	conj
31	may	may	MD	_	33	aux
32	be	be	VB	_	33	cop
33	higher	higher	JJR	_	0	ROOT
34	.	.	.	_	33	punct

1	Some	some	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	9	nsubj
4	are	be	VBP	_	9	cop
5	:	:	:	_	9	punct
6	-	-	:	_	9	punct
7	birth	birth	NN	_	9	compound
8	control	control	NN	_	9	compound
9	pills	pill	NNS	_	0	ROOT
10	-	-	:	_	9	punct
11	drug1	drug1	NN	_	13	compound
12	-	-	:	_	13	punct
13	medicines	medicine	NNS	_	9	dep
14	for	for	IN	_	15	case
15	angina	angina	NN	_	13	nmod
16	or	or	CC	_	15	cc
17	high	high	JJ	_	19	amod
18	blood	blood	NN	_	19	compound
19	pressure	pressure	NN	_	15	conj
20	-	-	:	_	13	punct
21	medicines	medicine	NNS	_	13	dep
22	for	for	IN	_	23	case
23	pain	pain	NN	_	21	nmod
24	-	-	:	_	13	punct
25	medicines	medicine	NNS	_	13	dep
26	to	to	TO	_	27	mark
27	control	control	VB	_	25	acl
28	seizures	seizure	NNS	_	27	dobj
29	such	such	JJ	_	31	case
30	as	as	IN	_	29	mwe
31	drug2	drug2	NN	_	28	nmod
32	or	or	CC	_	31	cc
33	drug3	drug3	NN	_	31	conj
34	-	-	:	_	13	punct
35	certain	certain	JJ	_	36	amod
36	drug4	drug4	NN	_	13	dep
37	given	give	VBN	_	36	acl
38	by	by	IN	_	39	case
39	injection	injection	NN	_	37	nmod
40	-	-	:	_	39	punct
41	drug5	drug5	NN	_	39	dep
42	-	-	:	_	39	punct
43	drug6	drug6	NN	_	39	dep
44	-	-	:	_	39	punct
45	drug7	drug7	NN	_	39	dep
46	-	-	:	_	45	punct
47	drug8	drug8	NN	_	45	dep
48	or	or	CC	_	47	cc
49	drug9	drug9	NN	_	47	conj
50	-	-	:	_	39	punct
51	local	local	JJ	_	52	amod
52	drug10	drug10	NN	_	39	dep
53	such	such	JJ	_	55	case
54	as	as	IN	_	53	mwe
55	drug11	drug11	NN	_	52	nmod
56	-	-	:	_	55	punct
57	general	general	JJ	_	58	amod
58	drug12	drug12	NN	_	55	dep
59	-	-	:	_	58	punct
60	drug13	drug13	NN	_	58	dep
61	or	or	CC	_	60	cc
62	other	other	JJ	_	63	amod
63	drug14	drug14	NN	_	60	conj

1	Clinically	clinically	RB	_	4	advmod
2	or	or	CC	_	1	cc
3	potentially	potentially	RB	_	1	conj
4	significant	significant	JJ	_	6	amod
5	drug	drug	NN	_	6	compound
6	interactions	interaction	NNS	_	15	nsubjpass
7	between	between	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	12	det
11	following	follow	VBG	_	12	amod
12	agents/classes	agents/classes	NNS	_	8	conj
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	These	these	DT	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	described	describe	VBN	_	0	ROOT
4	in	in	IN	_	6	case
5	greater	greater	JJR	_	6	amod
6	detail	detail	NN	_	3	nmod
7	below	below	IN	_	6	advmod
8	:	:	:	_	3	punct
9	drug1	drug1	NN	_	16	nsubjpass
10	and	and	CC	_	9	cc
11	the	the	DT	_	13	det
12	following	follow	VBG	_	13	amod
13	agents/classes	agents/classes	NNS	_	9	conj
14	have	have	VBP	_	16	aux
15	been	be	VBN	_	16	auxpass
16	observed	observe	VBN	_	3	parataxis
17	.	.	.	_	3	punct

1	These	these	DT	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	described	describe	VBN	_	0	ROOT
4	in	in	IN	_	6	case
5	greater	greater	JJR	_	6	amod
6	detail	detail	NN	_	3	nmod
7	below	below	IN	_	6	advmod
8	:	:	:	_	3	punct
9	Oral	oral	JJ	_	10	amod
10	drug1	drug1	NN	_	3	dep
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug3	drug3	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug4	drug4	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug5	drug5	NN	_	10	conj
19	,	,	,	_	10	punct
20	drug6	drug6	NN	_	10	conj
21	,	,	,	_	10	punct
22	drug7	drug7	NN	_	10	conj
23	,	,	,	_	10	punct
24	drug8	drug8	NN	_	10	conj
25	,	,	,	_	10	punct
26	drug9	drug9	NN	_	10	conj
27	,	,	,	_	10	punct
28	drug10	drug10	NN	_	10	conj
29	,	,	,	_	10	punct
30	drug11	drug11	NN	_	10	conj
31	,	,	,	_	10	punct
32	drug12	drug12	NN	_	10	conj
33	,	,	,	_	10	punct
34	Oral	oral	JJ	_	35	amod
35	drug13	drug13	NN	_	10	conj
36	:	:	:	_	10	punct
37	Clinically	clinically	RB	_	39	advmod
38	significant	significant	JJ	_	39	amod
39	hypoglycemia	hypoglycemia	NN	_	42	nsubjpass
40	may	may	MD	_	42	aux
41	be	be	VB	_	42	auxpass
42	precipitated	precipitate	VBN	_	10	dep
43	by	by	IN	_	45	case
44	the	the	DT	_	45	det
45	use	use	NN	_	42	nmod
46	of	of	IN	_	47	case
47	drug14	drug14	NN	_	45	nmod
48	with	with	IN	_	50	case
49	oral	oral	JJ	_	50	amod
50	drug15	drug15	NN	_	45	nmod
51	;	;	:	_	42	punct

1	one	one	CD	_	2	nummod
2	fatality	fatality	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	from	from	IN	_	7	case
7	hypoglycemia	hypoglycemia	NN	_	5	nmod
8	in	in	IN	_	9	case
9	association	association	NN	_	5	nmod
10	with	with	IN	_	12	case
11	combined	combined	JJ	_	12	amod
12	drug1	drug1	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	15	compound
15	use	use	NN	_	12	conj
16	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduces	reduce	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	metabolism	metabolism	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	drug4	drug4	NN	_	6	conj
12	and	and	CC	_	2	cc
13	increases	increase	VBZ	_	2	conj
14	the	the	DT	_	16	det
15	plasma	plasma	NN	_	16	compound
16	concentration	concentration	NN	_	13	dobj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	agents	agent	NNS	_	16	nmod
20	.	.	.	_	2	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	used	use	VBN	_	18	csubjpass
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	7	case
7	these	these	DT	_	4	nmod
8	or	or	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drug2	drug2	NN	_	7	conj
11	,	,	,	_	10	punct
12	blood	blood	NN	_	14	compound
13	glucose	glucose	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	appos
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	carefully	carefully	RB	_	18	advmod
18	monitored	monitor	VBN	_	0	ROOT
19	and	and	CC	_	18	cc
20	the	the	DT	_	21	det
21	dose	dose	NN	_	27	nsubjpass
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	drug3	drug3	NN	_	21	nmod
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	adjusted	adjust	VBN	_	18	conj
28	as	as	RB	_	29	advmod
29	necessary	necessary	JJ	_	27	xcomp
30	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Prothrombin	Prothrombin	NNP	_	4	compound
4	time	time	NN	_	7	nsubjpass
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	increased	increase	VBN	_	1	dep
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	concomitant	concomitant	JJ	_	12	amod
12	drug2	drug2	NN	_	10	dobj
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	post-marketing	post-marketing	JJ	_	3	amod
3	experience	experience	NN	_	27	nmod
4	,	,	,	_	27	punct
5	as	as	IN	_	8	case
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug1	drug1	NN	_	27	nmod
9	,	,	,	_	27	punct
10	bleeding	bleed	VBG	_	11	amod
11	events	event	NNS	_	27	nsubjpass
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	bruising	bruise	VBG	_	11	dep
14	,	,	,	_	13	punct
15	epistaxis	epistaxis	NN	_	13	conj
16	,	,	,	_	13	punct
17	gastrointestinal	gastrointestinal	JJ	_	18	amod
18	bleeding	bleeding	NN	_	13	conj
19	,	,	,	_	13	punct
20	hematuria	hematuria	NN	_	13	conj
21	,	,	,	_	13	punct
22	and	and	CC	_	13	cc
23	melena	melena	NN	_	13	conj
24	-RRB-	-rrb-	-RRB-	_	13	punct
25	have	have	VBP	_	27	aux
26	been	be	VBN	_	27	auxpass
27	reported	report	VBN	_	0	ROOT
28	in	in	IN	_	29	case
29	association	association	NN	_	27	nmod
30	with	with	IN	_	31	case
31	increases	increase	NNS	_	29	nmod
32	in	in	IN	_	34	case
33	prothrombin	prothrombin	NN	_	34	compound
34	time	time	NN	_	31	nmod
35	in	in	IN	_	36	case
36	patients	patient	NNS	_	34	nmod
37	receiving	receive	VBG	_	36	acl
38	drug2	drug2	NN	_	37	dobj
39	concurrently	concurrently	RB	_	37	advmod
40	with	with	IN	_	41	case
41	drug3	drug3	NN	_	37	nmod
42	.	.	.	_	27	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	13	nsubjpass
3	of	of	IN	_	5	case
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	2	nmod
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	drug1	drug1	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	See	see	VB	_	0	ROOT
3	<	<	JJR	_	6	advmod
4	a	a	DT	_	5	det
5	href	href	NN	_	6	nsubj
6	=	=	JJ	_	2	ccomp
7	``	``	``	_	6	punct
8	flucon_cp	flucon_cp	NN	_	6	dobj
9	.	.	.	_	2	punct
10	htm	htm	NN	_	11	compound
11	#CP	#cp	NN	_	2	dep
12	''	''	''	_	11	punct
13	>	>	JJR	_	15	dep
14	CLINICAL	CLINICAL	NNP	_	15	compound
15	PHARMACOLOGY	PHARMACOLOGY	NNP	_	11	nmod
16	:	:	:	_	15	punct
17	Drug	Drug	NNP	_	19	compound
18	Interaction	interaction	NN	_	19	compound
19	Studies	study	NNS	_	15	dep
20	.	.	.	_	2	punct
21	-RRB-	-rrb-	-RRB-	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	increases	increase	VBZ	_	1	appos
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	13	nsubjpass
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	nmod
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	drug2	drug2	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	See	see	VB	_	0	ROOT
3	<	<	JJR	_	6	advmod
4	a	a	DT	_	5	det
5	href	href	NN	_	6	nsubj
6	=	=	JJ	_	2	ccomp
7	``	``	``	_	6	punct
8	flucon_cp	flucon_cp	NN	_	6	dobj
9	.	.	.	_	2	punct
10	htm	htm	NN	_	11	compound
11	#CP	#cp	NN	_	2	dep
12	''	''	''	_	11	punct
13	>	>	JJR	_	15	dep
14	CLINICAL	CLINICAL	NNP	_	15	compound
15	PHARMACOLOGY	PHARMACOLOGY	NNP	_	11	nmod
16	:	:	:	_	15	punct
17	Drug	Drug	NNP	_	19	compound
18	Interaction	interaction	NN	_	19	compound
19	Studies	study	NNS	_	15	dep
20	.	.	.	_	2	punct
21	-RRB-	-rrb-	-RRB-	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubj
4	may	may	MD	_	6	aux
5	significantly	significantly	RB	_	6	advmod
6	increase	increase	VB	_	1	dep
7	drug3	drug3	NN	_	8	compound
8	levels	level	NNS	_	6	dobj
9	in	in	IN	_	12	case
10	renal	renal	JJ	_	12	amod
11	transplant	transplant	NN	_	12	compound
12	patients	patient	NNS	_	6	nmod
13	with	with	IN	_	17	nmod
14	or	or	CC	_	13	cc
15	without	without	IN	_	13	conj
16	renal	renal	JJ	_	17	amod
17	impairment	impairment	NN	_	12	nmod
18	.	.	.	_	1	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	nmod
6	and	and	CC	_	5	cc
7	serum	serum	NN	_	8	compound
8	creatinine	creatinine	NN	_	5	conj
9	is	be	VBZ	_	10	auxpass
10	recommended	recommend	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	drug2	drug2	NN	_	13	dobj
15	and	and	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	.	.	.	_	10	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	See	see	VB	_	0	ROOT
3	CLINICAL	CLINICAL	NNP	_	4	compound
4	PHARMACOLOGY	PHARMACOLOGY	NNP	_	2	dobj
5	:	:	:	_	4	punct
6	Drug	Drug	NNP	_	8	compound
7	Interaction	interaction	NN	_	8	compound
8	Studies	study	NNS	_	4	dep
9	.	.	.	_	2	punct
10	-RRB-	-rrb-	-RRB-	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	enhances	enhance	VBZ	_	1	appos
5	the	the	DT	_	6	det
6	metabolism	metabolism	NN	_	4	dobj
7	of	of	IN	_	10	case
8	concurrently	concurrently	RB	_	9	advmod
9	administered	administer	VBN	_	10	amod
10	drug3	drug3	NN	_	6	nmod
11	.	.	.	_	1	punct

1	Depending	depend	VBG	_	4	case
2	on	on	IN	_	4	case
3	clinical	clinical	JJ	_	4	amod
4	circumstances	circumstance	NNS	_	9	advcl
5	,	,	,	_	9	punct
6	consideration	consideration	NN	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	given	give	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	increasing	increase	VBG	_	9	advcl
12	the	the	DT	_	13	det
13	dose	dose	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	when	when	WRB	_	19	advmod
17	it	it	PRP	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	administered	administer	VBN	_	11	advcl
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	increases	increase	VBZ	_	1	appos
5	the	the	DT	_	7	det
6	serum	serum	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Careful	careful	JJ	_	2	amod
2	monitoring	monitoring	NN	_	14	nsubjpass
3	of	of	IN	_	6	case
4	serum	serum	NN	_	6	compound
5	drug1	drug1	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	is	be	VBZ	_	14	auxpass
14	recommended	recommend	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Because	because	IN	_	6	case
4	of	of	IN	_	3	mwe
5	the	the	DT	_	6	det
6	occurrence	occurrence	NN	_	31	nmod
7	of	of	IN	_	10	case
8	serious	serious	JJ	_	10	amod
9	cardiac	cardiac	JJ	_	10	amod
10	dysrhythmias	dysrhythmia	NNS	_	6	nmod
11	secondary	secondary	JJ	_	10	amod
12	to	to	TO	_	13	case
13	prolongation	prolongation	NN	_	11	nmod
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	QTc	qtc	NN	_	17	compound
17	interval	interval	NN	_	13	nmod
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	receiving	receive	VBG	_	19	acl
21	drug2	drug2	NN	_	20	dobj
22	in	in	IN	_	23	case
23	conjunction	conjunction	NN	_	20	nmod
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	,	,	,	_	31	punct
27	interaction	interaction	NN	_	28	compound
28	studies	study	NNS	_	31	nsubjpass
29	have	have	VBP	_	31	aux
30	been	be	VBN	_	31	auxpass
31	performed	perform	VBN	_	1	appos
32	.	.	.	_	1	punct

1	One	one	CD	_	2	nummod
2	study	study	NN	_	10	nsubj
3	at	at	IN	_	7	case
4	a	a	DT	_	7	det
5	200-mg	200-mg	JJ	_	7	amod
6	daily	daily	JJ	_	7	amod
7	dose	dose	NN	_	2	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	failed	fail	VBD	_	0	ROOT
11	to	to	TO	_	12	mark
12	demonstrate	demonstrate	VB	_	10	xcomp
13	a	a	DT	_	14	det
14	prolongation	prolongation	NN	_	12	dobj
15	in	in	IN	_	17	case
16	QTc	qtc	NN	_	17	compound
17	interval	interval	NN	_	14	nmod
18	.	.	.	_	10	punct

1	Another	another	DT	_	2	det
2	study	study	NN	_	12	nsubj
3	at	at	IN	_	9	case
4	a	a	DT	_	9	det
5	400-mg	400-mg	JJ	_	9	amod
6	and	and	CC	_	5	cc
7	800-mg	800-mg	JJ	_	5	conj
8	daily	daily	JJ	_	9	amod
9	dose	dose	NN	_	2	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	demonstrated	demonstrate	VBD	_	0	ROOT
13	that	that	IN	_	12	dobj
14	drug2	drug2	NN	_	13	dep
15	taken	take	VBN	_	14	acl
16	in	in	IN	_	17	case
17	doses	dose	NNS	_	15	nmod
18	of	of	IN	_	20	case
19	400	400	CD	_	20	nummod
20	mg	mg	NN	_	17	nmod
21	per	per	IN	_	22	case
22	day	day	NN	_	20	nmod
23	or	or	CC	_	20	cc
24	greater	greater	JJR	_	26	dep
25	significantly	significantly	RB	_	26	advmod
26	increases	increase	VBZ	_	20	conj
27	plasma	plasma	NN	_	28	compound
28	levels	level	NNS	_	26	dobj
29	of	of	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	when	when	WRB	_	32	advmod
32	taken	take	VBN	_	15	advcl
33	concomitantly	concomitantly	RB	_	32	advmod
34	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	combined	combine	VBN	_	3	amod
3	use	use	NN	_	16	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	at	at	IN	_	7	case
7	doses	dose	NNS	_	3	nmod
8	of	of	IN	_	10	case
9	400	400	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	greater	greater	JJR	_	10	conj
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	3	nmod
15	is	be	VBZ	_	16	auxpass
16	contraindicated	contraindicate	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	coadministration	coadministration	NN	_	16	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	at	at	IN	_	6	case
6	doses	dose	NNS	_	2	nmod
7	lower	lower	JJR	_	6	amod
8	than	than	IN	_	10	case
9	400	400	CD	_	10	nummod
10	mg/day	mg/day	NN	_	7	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	should	should	MD	_	16	aux
14	be	be	VB	_	16	auxpass
15	carefully	carefully	RB	_	16	advmod
16	monitored	monitor	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	appos
7	of	of	IN	_	9	case
8	cardiac	cardiac	JJ	_	9	amod
9	events	event	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	including	include	VBG	_	14	case
12	torsade	torsade	NN	_	14	compound
13	de	de	IN	_	14	amod
14	pointes	pointe	NNS	_	9	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	to	to	TO	_	18	case
18	whom	whom	WP	_	23	nmod
19	drug2	drug2	NN	_	23	nsubjpass
20	and	and	CC	_	19	cc
21	drug3	drug3	NN	_	19	conj
22	were	be	VBD	_	23	auxpass
23	coadministered	coadminister	VBN	_	16	acl:relcl
24	.	.	.	_	1	punct

1	A	a	DT	_	3	det
2	controlled	controlled	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	found	find	VBD	_	0	ROOT
5	that	that	IN	_	20	mark
6	concomitant	concomitant	JJ	_	9	amod
7	drug1	drug1	NN	_	9	compound
8	200	200	CD	_	9	nummod
9	mg	mg	NN	_	20	nsubj
10	once	once	RB	_	11	advmod
11	daily	daily	JJ	_	9	amod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	15	compound
14	20	20	CD	_	15	nummod
15	mg	mg	NN	_	11	conj
16	four	four	CD	_	17	nummod
17	times	time	NNS	_	11	nmod:tmod
18	a	a	DT	_	19	det
19	day	day	NN	_	17	nmod:npmod
20	yielded	yield	VBD	_	4	ccomp
21	a	a	DT	_	23	det
22	significant	significant	JJ	_	23	amod
23	increase	increase	NN	_	20	dobj
24	in	in	IN	_	27	case
25	drug3	drug3	NN	_	27	compound
26	plasma	plasma	NN	_	27	compound
27	levels	level	NNS	_	23	nmod
28	and	and	CC	_	23	cc
29	prolongation	prolongation	NN	_	23	conj
30	of	of	IN	_	32	case
31	QTc	qtc	NN	_	32	compound
32	interval	interval	NN	_	29	nmod
33	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	combined	combine	VBN	_	3	amod
3	use	use	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	is	be	VBZ	_	9	auxpass
9	contraindicated	contraindicate	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	use	use	NN	_	23	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	4	nmod
9	concurrently	concurrently	RB	_	10	advmod
10	taking	take	VBG	_	8	acl
11	drug3	drug3	NN	_	10	dobj
12	or	or	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	conj
15	metabolized	metabolize	VBN	_	11	acl
16	by	by	IN	_	20	case
17	the	the	DT	_	20	det
18	cytochrome	cytochrome	NN	_	20	compound
19	P450	p450	NN	_	20	compound
20	system	system	NN	_	15	nmod
21	may	may	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	associated	associate	VBN	_	1	appos
24	with	with	IN	_	25	case
25	elevations	elevation	NNS	_	23	nmod
26	in	in	IN	_	28	case
27	serum	serum	NN	_	28	compound
28	levels	level	NNS	_	25	nmod
29	of	of	IN	_	31	case
30	these	these	DT	_	31	det
31	drugs	drug	NNS	_	28	nmod
32	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	absence	absence	NN	_	11	nmod
4	of	of	IN	_	6	case
5	definitive	definitive	JJ	_	6	amod
6	information	information	NN	_	3	nmod
7	,	,	,	_	11	punct
8	caution	caution	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	used	use	VBN	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	coadministering	coadminister	VBG	_	11	advcl
14	drug1	drug1	NN	_	13	dobj
15	.	.	.	_	11	punct

1	Patients	patient	NNS	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	be	be	VB	_	5	auxpass
4	carefully	carefully	RB	_	5	advmod
5	monitored	monitor	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	dep
7	of	of	IN	_	8	case
8	uveitis	uveitis	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	6	nmod
11	to	to	TO	_	12	case
12	whom	whom	WP	_	17	nmod
13	drug2	drug2	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	were	be	VBD	_	17	auxpass
17	coadministered	coadminister	VBN	_	10	acl:relcl
18	.	.	.	_	1	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	concomitantly	concomitantly	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	carefully	carefully	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	dep
7	of	of	IN	_	8	case
8	nephrotoxicity	nephrotoxicity	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	6	nmod
11	to	to	TO	_	12	case
12	whom	whom	WP	_	17	nmod
13	drug2	drug2	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	were	be	VBD	_	17	auxpass
17	coadministered	coadminister	VBN	_	10	acl:relcl
18	.	.	.	_	1	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	concomitantly	concomitantly	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	carefully	carefully	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Following	follow	VBG	_	5	case
4	oral	oral	JJ	_	5	amod
5	administration	administration	NN	_	10	nmod
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	10	punct
9	drug3	drug3	NN	_	10	nsubj
10	resulted	result	VBD	_	1	appos
11	in	in	IN	_	13	case
12	substantial	substantial	JJ	_	13	amod
13	increases	increase	NNS	_	10	nmod
14	in	in	IN	_	16	case
15	drug4	drug4	NN	_	16	compound
16	concentrations	concentration	NNS	_	13	nmod
17	and	and	CC	_	16	cc
18	psychomotor	psychomotor	JJ	_	19	amod
19	effects	effect	NNS	_	16	conj
20	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubj
3	on	on	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	appears	appear	VBZ	_	0	ROOT
6	to	to	TO	_	9	mark
7	be	be	VB	_	9	cop
8	more	more	RBR	_	9	advmod
9	pronounced	pronounced	JJ	_	5	xcomp
10	following	follow	VBG	_	12	case
11	oral	oral	JJ	_	12	amod
12	administration	administration	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	than	than	IN	_	17	case
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	9	nmod
18	administered	administer	VBN	_	17	acl
19	intravenously	intravenously	RB	_	18	advmod
20	.	.	.	_	5	punct

1	If	if	IN	_	15	mark
2	drug1	drug1	NN	_	15	nsubjpass
3	,	,	,	_	2	punct
4	which	which	WDT	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	metabolized	metabolize	VBN	_	2	acl:relcl
7	by	by	IN	_	11	case
8	the	the	DT	_	11	det
9	cytochrome	cytochrome	NN	_	11	compound
10	P450	p450	NN	_	11	compound
11	system	system	NN	_	6	nmod
12	,	,	,	_	2	punct
13	are	be	VBP	_	15	auxpass
14	concomitantly	concomitantly	RB	_	15	advmod
15	administered	administer	VBN	_	22	advcl
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	22	punct
19	consideration	consideration	NN	_	22	nsubjpass
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	given	give	VBN	_	0	ROOT
23	to	to	TO	_	24	mark
24	decreasing	decrease	VBG	_	22	advcl
25	the	the	DT	_	27	det
26	drug3	drug3	NN	_	27	compound
27	dosage	dosage	NN	_	24	dobj
28	,	,	,	_	22	punct
29	and	and	CC	_	22	cc
30	the	the	DT	_	31	det
31	patients	patient	NNS	_	35	nsubjpass
32	should	should	MD	_	35	aux
33	be	be	VB	_	35	auxpass
34	appropriately	appropriately	RB	_	35	advmod
35	monitored	monitor	VBN	_	22	conj
36	.	.	.	_	22	punct

1	drug1	drug1	NN	_	2	compound
2	tablets	tablet	NNS	_	13	nsubj
3	coadministered	coadminister	VBN	_	2	acl
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-	-	:	_	2	punct
7	and	and	CC	_	2	cc
8	drug3	drug3	NN	_	2	conj
9	-	-	:	_	8	punct
10	containing	contain	VBG	_	8	acl
11	oral	oral	JJ	_	12	amod
12	drug4	drug4	NN	_	10	dobj
13	produced	produce	VBD	_	0	ROOT
14	an	a	DT	_	17	det
15	overall	overall	JJ	_	17	amod
16	mean	mean	JJ	_	17	amod
17	increase	increase	NN	_	13	dobj
18	in	in	IN	_	22	case
19	drug5	drug5	NN	_	22	compound
20	and	and	CC	_	19	cc
21	drug6	drug6	NN	_	19	conj
22	levels	level	NNS	_	17	nmod
23	;	;	:	_	13	punct

1	however	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	in	in	IN	_	5	case
4	some	some	DT	_	5	det
5	patients	patient	NNS	_	8	nmod
6	there	there	EX	_	8	expl
7	were	be	VBD	_	8	auxpass
8	decreases	decrease	VBZ	_	0	ROOT
9	up	up	RP	_	11	dep
10	to	to	TO	_	9	mwe
11	47	47	CD	_	12	nummod
12	%	%	NN	_	8	dobj
13	and	and	CC	_	12	cc
14	33	33	CD	_	15	nummod
15	%	%	NN	_	12	conj
16	of	of	IN	_	20	case
17	drug1	drug1	NN	_	20	compound
18	and	and	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	levels	level	NNS	_	12	nmod
21	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	data	datum	NNS	_	5	nsubj
3	presently	presently	RB	_	4	advmod
4	available	available	JJ	_	2	amod
5	indicate	indicate	VBP	_	0	ROOT
6	that	that	IN	_	21	mark
7	the	the	DT	_	8	det
8	decreases	decrease	NNS	_	21	nsubj
9	in	in	IN	_	12	case
10	some	some	DT	_	12	det
11	individual	individual	JJ	_	12	amod
12	drug1	drug1	NN	_	8	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	16	compound
15	AUC	auc	NN	_	16	compound
16	values	value	NNS	_	12	conj
17	with	with	IN	_	19	case
18	drug3	drug3	NN	_	19	compound
19	treatment	treatment	NN	_	8	nmod
20	are	be	VBP	_	21	cop
21	likely	likely	JJ	_	5	ccomp
22	the	the	DT	_	23	det
23	result	result	NN	_	21	dobj
24	of	of	IN	_	26	case
25	random	random	JJ	_	26	amod
26	variation	variation	NN	_	23	nmod
27	.	.	.	_	5	punct

1	While	while	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	17	advcl
4	evidence	evidence	NN	_	3	nsubj
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubj
7	can	can	MD	_	8	aux
8	inhibit	inhibit	VB	_	4	ccomp
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	17	punct
16	there	there	EX	_	17	expl
17	is	be	VBZ	_	0	ROOT
18	no	no	DT	_	19	neg
19	evidence	evidence	NN	_	17	nsubj
20	that	that	IN	_	25	mark
21	drug4	drug4	NN	_	25	nsubj
22	is	be	VBZ	_	25	cop
23	a	a	DT	_	25	det
24	net	net	JJ	_	25	amod
25	inducer	inducer	NN	_	19	ccomp
26	of	of	IN	_	27	case
27	drug5	drug5	NN	_	25	nmod
28	or	or	CC	_	27	cc
29	drug6	drug6	NN	_	30	compound
30	metabolism	metabolism	NN	_	27	conj
31	.	.	.	_	17	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	9	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	effects	effect	NNS	_	3	nmod
7	is	be	VBZ	_	9	cop
8	presently	presently	RB	_	9	advmod
9	unknown	unknown	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Physicians	Physicians	NNP	_	4	nsubj
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	cop
4	aware	aware	JJ	_	0	ROOT
5	that	that	IN	_	19	mark
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	19	nsubj
8	with	with	IN	_	9	case
9	medications	medication	NNS	_	7	nmod
10	other	other	JJ	_	9	amod
11	than	than	IN	_	12	case
12	those	those	DT	_	10	nmod
13	listed	list	VBN	_	12	acl
14	in	in	IN	_	18	case
15	the	the	DT	_	18	det
16	<	<	JJR	_	18	amod
17	a	a	DT	_	18	det
18	href	href	NN	_	13	nmod
19	=	=	JJ	_	4	ccomp
20	``	``	``	_	19	punct
21	flucon_cp	flucon_cp	NN	_	19	dobj
22	.	.	.	_	4	punct
23	htm	htm	NN	_	24	compound
24	#CP	#cp	NN	_	33	dep
25	''	''	''	_	24	punct
26	>	>	JJR	_	29	amod
27	CLINICAL	CLINICAL	NNP	_	29	compound
28	PHARMACOLOGY	PHARMACOLOGY	NNP	_	29	compound
29	section	section	NN	_	33	nsubjpass
30	have	have	VBP	_	33	aux
31	not	not	RB	_	33	neg
32	been	be	VBN	_	33	auxpass
33	conducted	conduct	VBN	_	4	parataxis
34	,	,	,	_	33	punct
35	but	but	CC	_	33	cc
36	such	such	JJ	_	37	amod
37	interactions	interaction	NNS	_	39	nsubj
38	may	may	MD	_	39	aux
39	occur	occur	VB	_	33	conj
40	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	appos
7	,	,	,	_	4	punct
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	2	nmod
11	has	have	VBZ	_	15	aux
12	not	not	RB	_	15	neg
13	been	be	VBN	_	15	auxpass
14	well	well	RB	_	15	advmod
15	studied	study	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Use	use	NN	_	21	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	--	--	:	_	1	punct
7	drug3	drug3	NN	_	1	dep
8	,	,	,	_	7	punct
9	drug4	drug4	NN	_	7	conj
10	,	,	,	_	7	punct
11	alone	alone	RB	_	7	conj
12	or	or	CC	_	7	cc
13	in	in	IN	_	14	case
14	combination	combination	NN	_	7	conj
15	with	with	IN	_	16	case
16	drug5	drug5	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug6	drug6	NN	_	16	conj
19	,	,	,	_	1	punct
20	may	may	MD	_	21	aux
21	cause	cause	VB	_	0	ROOT
22	bleeding	bleeding	JJ	_	23	amod
23	complications	complication	NNS	_	21	dobj
24	.	.	.	_	21	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	careful	careful	JJ	_	4	amod
4	monitoring	monitoring	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	treatment	treatment	NN	_	17	nmod
4	of	of	IN	_	6	case
5	acute	acute	JJ	_	6	amod
6	MI	MI	NNP	_	3	nmod
7	,	,	,	_	6	punct
8	drug1	drug1	NN	_	6	appos
9	,	,	,	_	6	punct
10	when	when	WRB	_	13	advmod
11	not	not	RB	_	13	neg
12	otherwise	otherwise	RB	_	13	advmod
13	contraindicated	contraindicate	VBN	_	17	dep
14	,	,	,	_	17	punct
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	administered	administer	VBN	_	0	ROOT
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	see	see	VB	_	17	dep
22	below	below	IN	_	21	advmod
23	-RRB-	-rrb-	-RRB-	_	21	punct
24	.	.	.	_	17	punct

1	Anticoagulation	anticoagulation	NN	_	24	nsubjpass
2	and	and	CC	_	1	cc
3	drug1	drug1	NN	_	1	conj
4	After	after	IN	_	5	case
5	Treatment	treatment	NN	_	1	nmod
6	for	for	IN	_	8	case
7	Myocardial	myocardial	JJ	_	8	amod
8	Infarction	infarction	NN	_	5	nmod
9	--	--	:	_	1	punct
10	In	in	IN	_	12	case
11	the	the	DT	_	12	det
12	treatment	treatment	NN	_	24	nmod
13	of	of	IN	_	16	case
14	acute	acute	JJ	_	16	amod
15	myocardial	myocardial	JJ	_	16	amod
16	infarction	infarction	NN	_	12	nmod
17	,	,	,	_	24	punct
18	the	the	DT	_	19	det
19	use	use	NN	_	24	nsubjpass
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	has	have	VBZ	_	24	aux
23	been	be	VBN	_	24	auxpass
24	shown	show	VBN	_	0	ROOT
25	to	to	TO	_	26	mark
26	reduce	reduce	VB	_	24	xcomp
27	the	the	DT	_	28	det
28	incidence	incidence	NN	_	26	dobj
29	of	of	IN	_	30	case
30	reinfarction	reinfarction	NN	_	28	nmod
31	and	and	CC	_	30	cc
32	stroke	stroke	NN	_	30	conj
33	.	.	.	_	24	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	causes	cause	VBZ	_	0	ROOT
8	a	a	DT	_	10	det
9	minimal	minimal	JJ	_	10	amod
10	increase	increase	NN	_	37	nsubj
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	risk	risk	NN	_	10	nmod
14	of	of	IN	_	16	case
15	minor	minor	JJ	_	16	amod
16	bleeding	bleeding	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	37	punct
18	3.9	3.9	CD	_	19	nummod
19	%	%	NN	_	37	dep
20	vs.	vs.	CC	_	19	cc
21	3.1	3.1	CD	_	22	nummod
22	%	%	NN	_	19	conj
23	-RRB-	-rrb-	-RRB-	_	19	punct
24	,	,	,	_	19	punct
25	but	but	CC	_	19	cc
26	does	do	VBZ	_	28	aux
27	not	not	RB	_	28	neg
28	appear	appear	VB	_	19	conj
29	to	to	TO	_	30	mark
30	increase	increase	VB	_	28	xcomp
31	the	the	DT	_	32	det
32	incidence	incidence	NN	_	30	dobj
33	of	of	IN	_	35	case
34	major	major	JJ	_	35	amod
35	bleeding	bleeding	NN	_	32	nmod
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	see	see	VB	_	7	ccomp

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	used	use	VBN	_	14	advcl
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	14	punct
9	potentiation	potentiation	NN	_	14	nsubj
10	of	of	IN	_	12	case
11	antihypertensive	antihypertensive	JJ	_	12	amod
12	effect	effect	NN	_	9	nmod
13	may	may	MD	_	14	aux
14	occur	occur	VB	_	0	ROOT
15	.	.	.	_	14	punct

1	Patients	patient	NNS	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	followed	follow	VBN	_	0	ROOT
5	carefully	carefully	RB	_	4	advmod
6	to	to	TO	_	7	mark
7	detect	detect	VB	_	4	xcomp
8	side	side	JJ	_	9	amod
9	reactions	reaction	NNS	_	7	dobj
10	or	or	CC	_	9	cc
11	unusual	unusual	JJ	_	12	amod
12	manifestations	manifestation	NNS	_	9	conj
13	of	of	IN	_	15	case
14	drug	drug	NN	_	15	compound
15	idiosyncrasy	idiosyncrasy	NN	_	12	nmod
16	.	.	.	_	4	punct

1	Patients	patient	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	require	require	VB	_	0	ROOT
4	reduced	reduced	JJ	_	5	amod
5	doses	dose	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	when	when	WRB	_	10	advmod
9	on	on	IN	_	10	case
10	drug2	drug2	NN	_	3	advcl
11	.	.	.	_	3	punct

1	If	if	IN	_	4	mark
2	hypotension	hypotension	NN	_	4	nsubj
3	does	do	VBZ	_	4	aux
4	occur	occur	VB	_	12	advcl
5	during	during	IN	_	6	case
6	anesthesia	anesthesia	NN	_	4	nmod
7	,	,	,	_	12	punct
8	it	it	PRP	_	12	nsubjpass
9	usually	usually	RB	_	12	advmod
10	can	can	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	controlled	control	VBN	_	0	ROOT
13	by	by	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	adrenergic	adrenergic	JJ	_	3	amod
3	receptors	receptor	NNS	_	4	nsubj
4	remain	remain	VBP	_	0	ROOT
5	sensitive	sensitive	JJ	_	4	xcomp
6	during	during	IN	_	7	case
7	treatment	treatment	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	4	punct

1	When	when	WRB	_	6	advmod
2	drug1	drug1	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	are	be	VBP	_	6	auxpass
6	given	give	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	13	advmod
8	the	the	DT	_	9	det
9	patient	patient	NN	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	carefully	carefully	RB	_	13	advmod
13	monitored	monitor	VBN	_	6	ccomp
14	for	for	IN	_	15	case
15	symptoms	symptom	NNS	_	13	nmod
16	of	of	IN	_	18	case
17	drug3	drug3	NN	_	18	compound
18	toxicity	toxicity	NN	_	15	nmod
19	.	.	.	_	6	punct

1	Read	read	VB	_	0	ROOT
2	the	the	DT	_	3	det
3	circular	circular	JJ	_	1	dobj
4	for	for	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	preparations	preparation	NNS	_	3	nmod
7	.	.	.	_	1	punct

1	Several	several	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	demonstrate	demonstrate	VBP	_	0	ROOT
4	a	a	DT	_	5	det
5	decrease	decrease	NN	_	3	dobj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	bioavailability	bioavailability	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	when	when	WRB	_	14	advmod
12	it	it	PRP	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	ingested	ingest	VBN	_	3	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	or	or	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	.	.	.	_	3	punct

1	This	this	DT	_	4	nsubj
2	may	may	MD	_	4	aux
3	adversely	adversely	RB	_	4	advmod
4	affect	affect	VB	_	0	ROOT
5	blood	blood	NN	_	7	compound
6	pressure	pressure	NN	_	7	compound
7	control	control	NN	_	4	dobj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	10	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	or	or	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	recommended	recommend	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	See	see	VB	_	1	dep
4	CONTRAINDICATIONS	contraindication	NNS	_	3	dobj
5	.	.	.	_	1	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	interfere	interfere	VB	_	0	ROOT
7	with	with	IN	_	8	case
8	measurement	measurement	NN	_	6	nmod
9	of	of	IN	_	13	case
10	:	:	:	_	13	punct
11	urinary	urinary	JJ	_	13	amod
12	uric	uric	JJ	_	13	amod
13	acid	acid	NN	_	8	nmod
14	by	by	IN	_	17	case
15	the	the	DT	_	17	det
16	phosphotungstate	phosphotungstate	NN	_	17	compound
17	method	method	NN	_	6	nmod
18	,	,	,	_	17	punct
19	serum	serum	NN	_	20	compound
20	creatinine	creatinine	NN	_	17	conj
21	by	by	IN	_	25	case
22	the	the	DT	_	25	det
23	alkaline	alkaline	NN	_	25	compound
24	picrate	picrate	NN	_	25	compound
25	method	method	NN	_	20	nmod
26	,	,	,	_	17	punct
27	and	and	CC	_	17	cc
28	SGOT	sgot	NN	_	17	conj
29	by	by	IN	_	31	case
30	colorimetric	colorimetric	JJ	_	31	amod
31	methods	method	NNS	_	28	nmod
32	.	.	.	_	6	punct

1	Interference	interference	NN	_	11	nsubjpass
2	with	with	IN	_	4	case
3	spectrophotometric	spectrophotometric	JJ	_	4	amod
4	methods	method	NNS	_	1	nmod
5	for	for	IN	_	7	case
6	SGOT	sgot	NN	_	7	compound
7	analysis	analysis	NN	_	4	nmod
8	has	have	VBZ	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Since	since	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	causes	cause	VBZ	_	24	advcl
4	fluorescence	fluorescence	NN	_	3	dobj
5	in	in	IN	_	7	case
6	urine	urine	NN	_	7	compound
7	samples	sample	NNS	_	4	nmod
8	at	at	IN	_	12	case
9	the	the	DT	_	12	det
10	same	same	JJ	_	12	amod
11	wave	wave	NN	_	12	compound
12	lengths	length	NNS	_	3	nmod
13	as	as	IN	_	14	case
14	catecholamines	catecholamine	NNS	_	12	nmod
15	,	,	,	_	24	punct
16	falsely	falsely	RB	_	17	advmod
17	high	high	JJ	_	18	amod
18	levels	level	NNS	_	24	nsubjpass
19	of	of	IN	_	21	case
20	urinary	urinary	JJ	_	21	amod
21	catecholamines	catecholamine	NNS	_	18	nmod
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	reported	report	VBN	_	0	ROOT
25	.	.	.	_	24	punct

1	This	this	DT	_	3	nsubj
2	will	will	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	the	the	DT	_	6	det
6	diagnosis	diagnosis	NN	_	3	nmod
7	of	of	IN	_	8	case
8	pheochromocytoma	pheochromocytoma	NN	_	6	nmod
9	.	.	.	_	3	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	important	important	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	recognize	recognize	VB	_	3	xcomp
6	this	this	DT	_	7	det
7	phenomenon	phenomenon	NN	_	5	dobj
8	before	before	IN	_	10	case
9	a	a	DT	_	10	det
10	patient	patient	NN	_	5	nmod
11	with	with	IN	_	14	case
12	a	a	DT	_	14	det
13	possible	possible	JJ	_	14	amod
14	pheochromocytoma	pheochromocytoma	NN	_	10	nmod
15	is	be	VBZ	_	16	auxpass
16	subjected	subject	VBN	_	3	dep
17	to	to	TO	_	18	case
18	surgery	surgery	NN	_	16	nmod
19	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	measurement	measurement	NN	_	4	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug3	drug3	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	8	punct
13	a	a	DT	_	14	det
14	test	test	NN	_	8	appos
15	for	for	IN	_	16	case
16	pheochromocytoma	pheochromocytoma	NN	_	14	nmod
17	,	,	,	_	8	punct
18	by	by	IN	_	20	case
19	those	those	DT	_	20	det
20	methods	method	NNS	_	6	nmod
21	which	which	WDT	_	22	nsubj
22	convert	convert	VBP	_	20	acl:relcl
23	drug4	drug4	NN	_	22	dobj
24	to	to	TO	_	25	case
25	drug5	drug5	NN	_	22	nmod
26	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	recommended	recommend	VBN	_	0	ROOT
5	for	for	IN	_	7	case
6	the	the	DT	_	7	det
7	treatment	treatment	NN	_	4	nmod
8	of	of	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	with	with	IN	_	11	case
11	pheochromocytoma	pheochromocytoma	NN	_	9	nmod
12	.	.	.	_	4	punct

1	Rarely	rarely	RB	_	14	advmod
2	,	,	,	_	14	punct
3	when	when	WRB	_	6	advmod
4	urine	urine	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	exposed	expose	VBN	_	14	advcl
7	to	to	TO	_	8	case
8	air	air	NN	_	6	nmod
9	after	after	IN	_	10	mark
10	voiding	void	VBG	_	6	advcl
11	,	,	,	_	14	punct
12	it	it	PRP	_	14	nsubj
13	may	may	MD	_	14	aux
14	darken	darken	VB	_	0	ROOT
15	because	because	IN	_	17	case
16	of	of	IN	_	15	mwe
17	breakdown	breakdown	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	its	its	PRP$	_	22	nmod:poss
22	metabolites	metabolite	NNS	_	19	conj
23	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	result	result	VB	_	1	dep
11	in	in	IN	_	14	case
12	increased	increase	VBN	_	14	amod
13	systemic	systemic	JJ	_	14	amod
14	toxicity	toxicity	NN	_	10	nmod
15	since	since	IN	_	17	mark
16	drug4	drug4	NN	_	17	nsubj
17	inhibit	inhibit	VBP	_	10	advcl
18	the	the	DT	_	19	det
19	breakdown	breakdown	NN	_	17	dobj
20	of	of	IN	_	21	case
21	drug5	drug5	NN	_	19	nmod
22	.	.	.	_	1	punct

1	Antimyasthenics	Antimyasthenics	NNP	_	3	compound
2	Concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	antimyasthenics	antimyasthenic	NNS	_	5	conj
8	may	may	MD	_	9	aux
9	result	result	VB	_	0	ROOT
10	in	in	IN	_	11	case
11	loss	loss	NN	_	9	nmod
12	of	of	IN	_	13	case
13	control	control	NN	_	11	nmod
14	of	of	IN	_	15	case
15	symptoms	symptom	NNS	_	13	nmod
16	of	of	IN	_	18	case
17	myasthenia	myasthenia	NN	_	18	compound
18	gravis	gravis	NN	_	15	nmod
19	due	due	JJ	_	21	case
20	to	to	TO	_	19	mwe
21	antagonism	antagonism	NN	_	11	nmod
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	effects	effect	NNS	_	21	nmod
25	of	of	IN	_	26	case
26	antimyasthenics	antimyasthenic	NNS	_	24	nmod
27	on	on	IN	_	29	case
28	skeletal	skeletal	JJ	_	29	amod
29	muscle	muscle	NN	_	24	nmod
30	.	.	.	_	9	punct

1	Temporary	temporary	JJ	_	3	amod
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	antimyasthenics	antimyasthenic	NNS	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	required	require	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Also	also	RB	_	4	advmod
2	antimyasthenics	antimyasthenic	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	have	have	VB	_	0	ROOT
5	anticholinesterase	anticholinesterase	JJ	_	6	amod
6	activity	activity	NN	_	4	dobj
7	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	medications	medication	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Concurrent	concurrent	JJ	_	5	amod
5	use	use	NN	_	11	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	may	may	MD	_	11	aux
11	result	result	VB	_	2	dep
12	in	in	IN	_	15	case
13	additive	additive	JJ	_	15	amod
14	depressant	depressant	NN	_	15	compound
15	effects	effect	NNS	_	11	nmod
16	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	1	dep
6	the	the	DT	_	8	det
7	diffusion	diffusion	NN	_	8	compound
8	rate	rate	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	,	,	,	_	5	punct
12	resulting	result	VBG	_	5	advcl
13	in	in	IN	_	16	case
14	a	a	DT	_	16	det
15	decreased	decrease	VBN	_	16	amod
16	time	time	NN	_	12	nmod
17	of	of	IN	_	18	case
18	onset	onset	NN	_	16	nmod
19	,	,	,	_	5	punct
20	but	but	CC	_	5	cc
21	an	a	DT	_	22	det
22	increase	increase	NN	_	5	conj
23	in	in	IN	_	25	case
24	systemic	systemic	JJ	_	25	amod
25	toxicity	toxicity	NN	_	22	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	nmod
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	1	punct
8	Concurrent	concurrent	JJ	_	9	amod
9	use	use	NN	_	15	nsubj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	may	may	MD	_	15	aux
15	result	result	VB	_	1	dep
16	in	in	IN	_	17	case
17	prolongation	prolongation	NN	_	15	nmod
18	or	or	CC	_	17	cc
19	enhancement	enhancement	NN	_	17	conj
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	neuromuscular	neuromuscular	JJ	_	23	amod
23	blockade	blockade	NN	_	17	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	result	result	VB	_	1	dep
11	in	in	IN	_	13	case
12	a	a	DT	_	13	det
13	reduction	reduction	NN	_	10	nmod
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	antibacterial	antibacterial	JJ	_	17	amod
17	action	action	NN	_	13	nmod
18	of	of	IN	_	20	case
19	the	the	DT	_	20	det
20	drug4	drug4	NN	_	17	nmod
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	extend	extend	VB	_	1	dep
11	the	the	DT	_	13	det
12	plasma	plasma	NN	_	13	compound
13	half-life	half-life	NN	_	10	dobj
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Patients	patient	NNS	_	15	nsubj
4	on	on	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	especially	especially	RB	_	9	advmod
9	those	those	DT	_	3	conj
10	started	start	VBN	_	9	acl
11	recently	recently	RB	_	10	advmod
12	,	,	,	_	3	punct
13	may	may	MD	_	15	aux
14	occasionally	occasionally	RB	_	15	advmod
15	experience	experience	VB	_	1	dep
16	an	a	DT	_	18	det
17	excessive	excessive	JJ	_	18	amod
18	reduction	reduction	NN	_	15	dobj
19	of	of	IN	_	21	case
20	blood	blood	NN	_	21	compound
21	pressure	pressure	NN	_	18	nmod
22	after	after	IN	_	23	case
23	initiation	initiation	NN	_	15	nmod
24	of	of	IN	_	27	case
25	drug3	drug3	NN	_	27	compound
26	Tablets	tablet	NNS	_	27	compound
27	therapy	therapy	NN	_	23	nmod
28	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	can	can	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	minimized	minimize	VBN	_	0	ROOT
9	by	by	IN	_	11	mark
10	either	either	CC	_	11	cc:preconj
11	discontinuing	discontinue	VBG	_	8	advcl
12	the	the	DT	_	13	det
13	drug1	drug1	NN	_	11	dobj
14	or	or	CC	_	11	cc
15	increasing	increase	VBG	_	11	conj
16	the	the	DT	_	18	det
17	salt	salt	NN	_	18	compound
18	intake	intake	NN	_	15	dobj
19	prior	prior	RB	_	15	advmod
20	to	to	TO	_	21	case
21	initiation	initiation	NN	_	19	nmod
22	of	of	IN	_	23	case
23	treatment	treatment	NN	_	21	nmod
24	with	with	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	.	.	.	_	8	punct

1	If	if	IN	_	6	mark
2	drug1	drug1	NN	_	6	nsubj
3	can	can	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	cop
6	interrupted	interrupted	JJ	_	13	advcl
7	,	,	,	_	13	punct
8	close	close	JJ	_	10	amod
9	medical	medical	JJ	_	10	amod
10	supervision	supervision	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	provided	provide	VBN	_	0	ROOT
14	with	with	IN	_	17	case
15	the	the	DT	_	17	det
16	first	first	JJ	_	17	amod
17	dose	dose	NN	_	13	nmod
18	of	of	IN	_	20	case
19	drug2	drug2	NN	_	20	compound
20	Tablets	tablet	NNS	_	17	nmod
21	,	,	,	_	17	punct
22	for	for	IN	_	26	case
23	at	at	IN	_	24	case
24	least	least	JJS	_	25	nmod:npmod
25	two	two	CD	_	26	nummod
26	hours	hour	NNS	_	17	nmod
27	and	and	CC	_	26	cc
28	until	until	IN	_	32	mark
29	blood	blood	NN	_	30	compound
30	pressure	pressure	NN	_	32	nsubj
31	has	have	VBZ	_	32	aux
32	stabilized	stabilize	VBN	_	26	conj
33	for	for	IN	_	35	case
34	another	another	DT	_	35	det
35	hour	hour	NN	_	32	nmod
36	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	rate	rate	NN	_	12	nsubjpass
3	and	and	CC	_	2	cc
4	extent	extent	NN	_	2	conj
5	of	of	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	absorption	absorption	NN	_	2	nmod
8	and	and	CC	_	7	cc
9	elimination	elimination	NN	_	7	conj
10	are	be	VBP	_	12	auxpass
11	not	not	RB	_	12	neg
12	affected	affect	VBN	_	0	ROOT
13	by	by	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	reduced	reduce	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	6	punct
10	however	however	RB	_	6	advmod
11	,	,	,	_	6	punct
12	and	and	CC	_	6	cc
13	this	this	DT	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	associated	associate	VBN	_	6	conj
16	with	with	IN	_	18	case
17	a	a	DT	_	18	det
18	decrease	decrease	NN	_	15	nmod
19	in	in	IN	_	22	case
20	plasma	plasma	NN	_	22	compound
21	ACE	ace	NN	_	22	compound
22	inhibition	inhibition	NN	_	18	nmod
23	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	:	:	:	_	2	punct
6	drug3	drug3	NN	_	7	compound
7	Tablets	tablet	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	2	dep
10	serum	serum	NN	_	11	compound
11	potassium	potassium	NN	_	9	dobj
12	because	because	IN	_	15	case
13	of	of	IN	_	12	mwe
14	its	its	PRP$	_	15	nmod:poss
15	potential	potential	JJ	_	9	nmod
16	to	to	TO	_	17	mark
17	decrease	decrease	VB	_	15	acl
18	aldosterone	aldosterone	NN	_	19	compound
19	production	production	NN	_	17	dobj
20	.	.	.	_	2	punct

1	Use	use	NN	_	34	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	dep
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	and	and	CC	_	5	cc
11	others	other	NNS	_	5	conj
12	-RRB-	-rrb-	-RRB-	_	5	punct
13	,	,	,	_	3	punct
14	drug5	drug5	NN	_	15	compound
15	supplements	supplement	NNS	_	3	conj
16	or	or	CC	_	3	cc
17	other	other	JJ	_	18	amod
18	drugs	drug	NNS	_	3	conj
19	capable	capable	JJ	_	3	amod
20	of	of	IN	_	21	mark
21	increasing	increase	VBG	_	19	advcl
22	serum	serum	NN	_	23	compound
23	potassium	potassium	NN	_	21	dobj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	drug6	drug6	NN	_	23	dep
26	,	,	,	_	25	punct
27	drug7	drug7	NN	_	25	conj
28	,	,	,	_	25	punct
29	drug8	drug8	NN	_	25	conj
30	and	and	CC	_	25	cc
31	others	other	NNS	_	25	conj
32	-RRB-	-rrb-	-RRB-	_	25	punct
33	can	can	MD	_	34	aux
34	increase	increase	VB	_	0	ROOT
35	the	the	DT	_	36	det
36	risk	risk	NN	_	34	dobj
37	of	of	IN	_	38	case
38	hyperkalemia	hyperkalemia	NN	_	36	nmod
39	.	.	.	_	34	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	such	such	JJ	_	8	amod
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	they	they	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	given	give	VBN	_	0	ROOT
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	the	the	DT	_	20	det
20	patient	patient	NN	_	23	nmod:poss
21	's	's	POS	_	20	case
22	serum	serum	NN	_	23	compound
23	potassium	potassium	NN	_	17	conj
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	monitored	monitor	VBN	_	15	dep
27	frequently	frequently	RB	_	26	advmod
28	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	5	amod
4	serum	serum	NN	_	5	compound
5	drug2	drug2	NN	_	13	nsubjpass
6	and	and	CC	_	5	cc
7	symptoms	symptom	NNS	_	5	conj
8	of	of	IN	_	10	case
9	drug3	drug3	NN	_	10	compound
10	toxicity	toxicity	NN	_	7	nmod
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	1	dep
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	concomitant	concomitant	JJ	_	18	amod
18	drug4	drug4	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	ACE	ace	NN	_	22	compound
21	inhibitor	inhibitor	NN	_	22	compound
22	therapy	therapy	NN	_	18	conj
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	16	csubjpass
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	frequent	frequent	JJ	_	10	amod
10	monitoring	monitoring	NN	_	7	conj
11	of	of	IN	_	14	case
12	serum	serum	NN	_	14	compound
13	drug1	drug1	NN	_	14	compound
14	concentration	concentration	NN	_	10	nmod
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Use	use	NN	_	7	nsubj
2	of	of	IN	_	4	case
3	a	a	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	may	may	MD	_	7	aux
6	further	further	RB	_	7	advmod
7	increase	increase	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	risk	risk	NN	_	7	dobj
10	of	of	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	6	det
4	controlled	controlled	JJ	_	6	amod
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	8	nsubj
7	has	have	VBZ	_	8	aux
8	shown	show	VBN	_	1	dep
9	no	no	DT	_	10	neg
10	effect	effect	NN	_	8	dobj
11	on	on	IN	_	14	case
12	plasma	plasma	NN	_	14	compound
13	drug2	drug2	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	nmod
15	when	when	WRB	_	16	advmod
16	coadministered	coadminister	VBN	_	8	advcl
17	with	with	IN	_	19	case
18	drug3	drug3	NN	_	19	compound
19	Tablets	tablet	NNS	_	16	nmod
20	,	,	,	_	8	punct
21	but	but	CC	_	8	cc
22	an	a	DT	_	23	det
23	effect	effect	NN	_	8	conj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	on	on	IN	_	29	case
27	the	the	DT	_	29	det
28	plasma	plasma	NN	_	29	compound
29	concentration	concentration	NN	_	23	nmod
30	of	of	IN	_	31	case
31	drug5	drug5	NN	_	29	nmod
32	/	/	:	_	23	punct
33	drug6	drug6	NN	_	37	nsubjpass
34	has	have	VBZ	_	37	aux
35	not	not	RB	_	37	neg
36	been	be	VBN	_	37	auxpass
37	excluded	exclude	VBN	_	23	acl:relcl
38	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Animal	Animal	NNP	_	4	compound
4	data	datum	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	suggested	suggest	VBN	_	1	appos
7	the	the	DT	_	8	det
8	possibility	possibility	NN	_	6	dobj
9	of	of	IN	_	10	case
10	interaction	interaction	NN	_	8	nmod
11	between	between	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	.	.	.	_	1	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	this	this	DT	_	7	nsubjpass
4	has	have	VBZ	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	investigated	investigate	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	human	human	JJ	_	10	amod
10	studies	study	NNS	_	7	nmod
11	.	.	.	_	7	punct

1	Coadministration	Coadministration	NNP	_	6	nsubj
2	of	of	IN	_	4	case
3	both	both	DT	_	4	det
4	drugs	drug	NNS	_	1	nmod
5	should	should	MD	_	6	aux
6	proceed	proceed	VB	_	0	ROOT
7	with	with	IN	_	8	case
8	caution	caution	NN	_	6	nmod
9	.	.	.	_	6	punct

1	Food	Food	NNP	_	2	compound
2	Interaction	interaction	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Oral	oral	JJ	_	5	amod
5	administration	administration	NN	_	14	nsubj
6	of	of	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	Tablets	tablet	NNS	_	5	nmod
9	with	with	IN	_	10	case
10	food	food	NN	_	5	nmod
11	does	do	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	significantly	significantly	RB	_	14	advmod
14	lower	lower	JJR	_	2	dep
15	the	the	DT	_	16	det
16	rate	rate	NN	_	14	dobj
17	or	or	CC	_	16	cc
18	extent	extent	NN	_	16	conj
19	of	of	IN	_	21	case
20	drug2	drug2	NN	_	21	compound
21	absorption	absorption	NN	_	16	nmod
22	relative	relative	JJ	_	16	amod
23	to	to	TO	_	26	case
24	the	the	DT	_	26	det
25	fasted	fasted	JJ	_	26	amod
26	state	state	NN	_	22	nmod
27	.	.	.	_	2	punct

1	However	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	the	the	DT	_	4	det
4	extent	extent	NN	_	17	nsubjpass
5	of	of	IN	_	6	case
6	biotransformation	biotransformation	NN	_	4	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	to	to	TO	_	12	case
10	the	the	DT	_	12	det
11	active	active	JJ	_	12	amod
12	metabolite	metabolite	NN	_	4	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	12	appos
15	,	,	,	_	12	punct
16	is	be	VBZ	_	17	auxpass
17	reduced	reduce	VBN	_	0	ROOT
18	approximately	approximately	RB	_	19	advmod
19	43	43	CD	_	20	nummod
20	%	%	NN	_	17	dobj
21	,	,	,	_	17	punct
22	resulting	result	VBG	_	17	advcl
23	in	in	IN	_	25	case
24	a	a	DT	_	25	det
25	reduction	reduction	NN	_	22	nmod
26	in	in	IN	_	31	case
27	the	the	DT	_	31	det
28	plasma	plasma	NN	_	31	compound
29	ACE	ace	NN	_	31	compound
30	inhibition	inhibition	NN	_	31	compound
31	curve	curve	NN	_	25	nmod
32	of	of	IN	_	35	case
33	approximately	approximately	RB	_	34	advmod
34	20	20	CD	_	35	nummod
35	%	%	NN	_	31	nmod
36	,	,	,	_	17	punct
37	probably	probably	RB	_	39	advmod
38	clinically	clinically	RB	_	39	advmod
39	insignificant	insignificant	JJ	_	17	dep
40	.	.	.	_	17	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubjpass
6	was	be	VBD	_	8	auxpass
7	generally	generally	RB	_	8	advmod
8	administered	administer	VBN	_	0	ROOT
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	non-fasting	non-fasting	JJ	_	12	amod
12	state	state	NN	_	8	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	the	the	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	following	follow	VBG	_	10	amod
10	categories	category	NNS	_	6	nmod
11	:	:	:	_	3	punct
12	-	-	:	_	3	punct
13	Blood	blood	NN	_	14	compound
14	dyscrasia	dyscrasia	NN	_	26	nsubj
15	:	:	:	_	14	punct
16	can	can	MD	_	17	aux
17	cause	cause	VB	_	14	dep
18	unpredictable	unpredictable	JJ	_	19	amod
19	myelotoxicity	myelotoxicity	NN	_	17	dobj
20	-	-	:	_	19	punct
21	Bone	bone	NN	_	23	compound
22	marrow	marrow	NN	_	23	compound
23	depressants	depressant	NNS	_	19	dep
24	:	:	:	_	14	punct
25	can	can	MD	_	26	aux
26	cause	cause	VB	_	3	parataxis
27	a	a	DT	_	30	det
28	predictable	predictable	JJ	_	30	amod
29	dose-related	dose-related	JJ	_	30	amod
30	myelotoxicity	myelotoxicity	NN	_	26	dobj
31	-	-	:	_	30	punct
32	Radiation	Radiation	NNP	_	33	compound
33	therapy	therapy	NN	_	30	dep
34	:	:	:	_	26	punct
35	may	may	MD	_	36	aux
36	cause	cause	VB	_	26	dep
37	marrow	marrow	NN	_	38	compound
38	depression	depression	NN	_	36	dobj
39	-	-	:	_	38	punct
40	Neurotoxic	neurotoxic	JJ	_	41	amod
41	medications	medication	NNS	_	38	dep
42	:	:	:	_	36	punct
43	can	can	MD	_	44	aux
44	cause	cause	VB	_	36	parataxis
45	neurologic	neurologic	JJ	_	46	amod
46	toxicity	toxicity	NN	_	44	dobj
47	-	-	:	_	46	punct
48	drug2	drug2	NN	_	46	dep
49	:	:	:	_	44	punct
50	can	can	MD	_	51	aux
51	increase	increase	VB	_	44	parataxis
52	seizure	seizure	NN	_	53	compound
53	activity	activity	NN	_	51	dobj
54	-	-	:	_	51	punct
55	drug3	drug3	NN	_	51	dep
56	:	:	:	_	51	punct
57	may	may	MD	_	58	aux
58	potentiate	potentiate	VB	_	51	dep
59	the	the	DT	_	60	det
60	replication	replication	NN	_	58	dobj
61	of	of	IN	_	64	case
62	the	the	DT	_	64	det
63	drug4	drug4	NN	_	64	compound
64	virus	virus	NN	_	60	nmod
65	,	,	,	_	58	punct
66	may	may	MD	_	67	aux
67	increase	increase	VB	_	58	conj
68	the	the	DT	_	70	det
69	side	side	JJ	_	70	amod
70	effects	effect	NNS	_	67	dobj
71	of	of	IN	_	73	case
72	the	the	DT	_	73	det
73	vaccination	vaccination	NN	_	70	nmod
74	,	,	,	_	58	punct
75	and	and	CC	_	58	cc
76	decrease	decrease	VB	_	58	conj
77	patient	patient	NN	_	79	nmod:poss
78	's	's	POS	_	77	case
79	response	response	NN	_	76	dobj
80	to	to	TO	_	82	case
81	the	the	DT	_	82	det
82	vaccine	vaccine	NN	_	79	nmod
83	-	-	:	_	82	punct
84	drug5	drug5	NN	_	82	dep
85	:	:	:	_	51	punct
86	may	may	MD	_	87	aux
87	cause	cause	VB	_	51	dep
88	shortness	shortness	NN	_	87	dobj
89	of	of	IN	_	90	case
90	breath	breath	NN	_	88	nmod
91	and	and	CC	_	90	cc
92	bronchospasm	bronchospasm	NN	_	90	conj
93	-	-	:	_	87	punct
94	drug6	drug6	NN	_	87	dep
95	:	:	:	_	94	punct
96	may	may	MD	_	97	aux
97	decrease	decrease	VB	_	94	dep
98	patient	patient	NN	_	100	nmod:poss
99	's	's	POS	_	98	case
100	response	response	NN	_	97	dobj
101	to	to	TO	_	103	case
102	the	the	DT	_	103	det
103	drug7	drug7	NN	_	100	nmod

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	some	some	DT	_	2	dobj
4	of	of	IN	_	8	case
5	the	the	DT	_	6	det
6	liver	liver	NN	_	8	nmod:poss
7	's	's	POS	_	6	case
8	ability	ability	NN	_	3	nmod
9	to	to	TO	_	10	mark
10	metabolize	metabolize	VB	_	8	acl
11	some	some	DT	_	13	det
12	other	other	JJ	_	13	amod
13	drugs	drug	NNS	_	10	dobj
14	-	-	:	_	13	punct
15	drug2	drug2	NN	_	13	dep
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug4	drug4	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug5	drug5	NN	_	15	conj
22	,	,	,	_	15	punct
23	and	and	CC	_	15	cc
24	drug6	drug6	NN	_	15	conj
25	.	.	.	_	2	punct

1	Thus	thus	RB	_	8	advmod
2	the	the	DT	_	3	det
3	concentrations	concentration	NNS	_	8	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	would	would	MD	_	8	aux
8	increase	increase	VB	_	14	csubjpass
9	meaning	mean	VBG	_	8	xcomp
10	side	side	JJ	_	11	amod
11	effects	effect	NNS	_	9	dobj
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	seen	see	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	A	a	DT	_	3	det
2	dose	dose	NN	_	3	compound
3	adjustment	adjustment	NN	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	required	require	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	30	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	3	nmod
9	or	or	CC	_	8	cc
10	with	with	IN	_	12	case
11	other	other	JJ	_	12	amod
12	agents	agent	NNS	_	8	conj
13	which	which	WDT	_	14	nsubj
14	produce	produce	VBP	_	12	acl:relcl
15	dry	dry	JJ	_	16	amod
16	mouth	mouth	NN	_	14	dobj
17	,	,	,	_	16	punct
18	constipation	constipation	NN	_	16	conj
19	,	,	,	_	16	punct
20	somnolence	somnolence	NN	_	16	conj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drowsiness	drowsiness	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	16	punct
25	and/or	and/or	CC	_	16	cc
26	other	other	JJ	_	28	amod
27	anticholinergic-like	anticholinergic-like	JJ	_	28	amod
28	effects	effect	NNS	_	16	conj
29	may	may	MD	_	30	aux
30	increase	increase	VB	_	0	ROOT
31	the	the	DT	_	32	det
32	frequency	frequency	NN	_	30	dobj
33	and/or	and/or	CC	_	32	cc
34	severity	severity	NN	_	32	conj
35	of	of	IN	_	37	case
36	such	such	JJ	_	37	amod
37	effects	effect	NNS	_	32	nmod
38	.	.	.	_	30	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	potentially	potentially	RB	_	4	advmod
4	alter	alter	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	11	case
8	some	some	DT	_	11	det
9	concomitantly	concomitantly	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drugs	drug	NNS	_	6	nmod
12	due	due	JJ	_	6	amod
13	to	to	TO	_	15	case
14	anticholinergic	anticholinergic	JJ	_	15	amod
15	effects	effect	NNS	_	12	nmod
16	on	on	IN	_	18	case
17	gastrointestinal	gastrointestinal	JJ	_	18	amod
18	motility	motility	NN	_	15	nmod
19	.	.	.	_	4	punct

1	This	this	DT	_	5	nsubj
2	may	may	MD	_	5	aux
3	be	be	VB	_	5	cop
4	of	of	IN	_	5	case
5	concern	concern	NN	_	0	ROOT
6	for	for	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	with	with	IN	_	12	case
9	a	a	DT	_	12	det
10	narrow	narrow	JJ	_	12	amod
11	therapeutic	therapeutic	JJ	_	12	amod
12	index	index	NN	_	7	nmod
13	.	.	.	_	5	punct

1	Mean	mean	NN	_	4	compound
2	drug1	drug1	NN	_	4	compound
3	plasma	plasma	NN	_	4	compound
4	concentrations	concentration	NNS	_	9	nsubj
5	were	be	VBD	_	9	cop
6	approximately	approximately	RB	_	7	advmod
7	2	2	CD	_	8	nummod
8	fold	fold	NN	_	9	nmod:npmod
9	higher	higher	JJR	_	0	ROOT
10	when	when	WRB	_	13	advmod
11	drug2	drug2	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	administered	administer	VBN	_	9	advcl
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	,	,	,	_	15	punct
17	a	a	DT	_	20	det
18	potent	potent	JJ	_	20	amod
19	CYP3A4	cyp3a4	NN	_	20	compound
20	inhibitor	inhibitor	NN	_	15	appos
21	.	.	.	_	9	punct

1	Other	other	JJ	_	2	amod
2	inhibitors	inhibitor	NNS	_	32	nsubj
3	of	of	IN	_	9	case
4	the	the	DT	_	9	det
5	cytochrome	cytochrome	NN	_	9	compound
6	P450	p450	NN	_	9	compound
7	3A4	3a4	NN	_	9	compound
8	enzyme	enzyme	NN	_	9	compound
9	system	system	NN	_	2	nmod
10	,	,	,	_	2	punct
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug1	drug1	NN	_	2	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	e.g.	e.g.	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug2	drug2	NN	_	13	dep
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	or	or	CC	_	13	cc
22	drug4	drug4	NN	_	13	conj
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	e.g.	e.g.	FW	_	26	dep
25	,	,	,	_	26	punct
26	drug5	drug5	NN	_	22	dep
27	and	and	CC	_	26	cc
28	drug6	drug6	NN	_	26	conj
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	,	,	,	_	2	punct
31	may	may	MD	_	32	aux
32	alter	alter	VB	_	0	ROOT
33	drug7	drug7	NN	_	34	nsubj
34	mean	mean	VB	_	32	ccomp
35	pharmacokinetic	pharmacokinetic	JJ	_	36	amod
36	parameters	parameter	NNS	_	34	dobj
37	-LRB-	-lrb-	-LRB-	_	40	punct
38	i.e.	i.e.	FW	_	40	dep
39	,	,	,	_	40	punct
40	Cmax	cmax	NN	_	36	dep
41	and	and	CC	_	40	cc
42	AUC	auc	NN	_	40	conj
43	-RRB-	-rrb-	-RRB-	_	40	punct
44	.	.	.	_	32	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	10	nsubjpass
4	of	of	IN	_	7	case
5	such	such	JJ	_	7	amod
6	potential	potential	JJ	_	7	amod
7	interactions	interaction	NNS	_	3	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	known	know	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	9	advmod
6	such	such	JJ	_	7	amod
7	drugs	drug	NNS	_	9	nsubj
8	are	be	VBP	_	9	cop
9	co-administered	co-administered	JJ	_	4	advcl
10	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	ingestion	ingestion	NN	_	21	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	20	20	CD	_	7	nummod
7	mL	ml	NN	_	4	dep
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	containing	contain	VBG	_	9	acl
11	drug3	drug3	NN	_	10	dobj
12	,	,	,	_	11	punct
13	drug4	drug4	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	drug5	drug5	NN	_	11	conj
17	-RRB-	-rrb-	-RRB-	_	7	punct
18	did	do	VBD	_	21	aux
19	not	not	RB	_	21	neg
20	significantly	significantly	RB	_	21	advmod
21	affect	affect	VB	_	0	ROOT
22	the	the	DT	_	23	det
23	exposure	exposure	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug6	drug6	NN	_	23	nmod
26	or	or	CC	_	25	cc
27	drug7	drug7	NN	_	25	conj
28	.	.	.	_	21	punct

1	-LSB-	-lsb-	-LRB-	_	2	punct
2	Interaction	interaction	NN	_	0	ROOT
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-RSB-	-rsb-	-RRB-	_	2	punct
8	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	drug	drug	NN	_	3	compound
3	interaction	interaction	NN	_	11	nsubj
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	11	aux
9	been	be	VBN	_	11	cop
10	the	the	DT	_	11	det
11	subject	subject	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	much	much	JJ	_	14	amod
14	study	study	NN	_	11	nmod
15	in	in	IN	_	17	case
16	recent	recent	JJ	_	17	amod
17	years	year	NNS	_	11	nmod
18	.	.	.	_	11	punct

1	Contradictory	contradictory	JJ	_	2	amod
2	results	result	NNS	_	0	ROOT
3	regarding	regard	VBG	_	5	case
4	the	the	DT	_	5	det
5	effect	effect	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	on	on	IN	_	10	case
9	platelet	platelet	NN	_	10	compound
10	reactivity	reactivity	NN	_	5	nmod
11	and	and	CC	_	5	cc
12	on	on	IN	_	14	case
13	clinical	clinical	JJ	_	14	amod
14	outcome	outcome	NN	_	5	conj
15	in	in	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	-	-	:	_	5	punct
18	treated	treated	JJ	_	19	amod
19	patients	patient	NNS	_	22	nsubjpass
20	have	have	VBP	_	22	aux
21	been	be	VBN	_	22	auxpass
22	reported	report	VBN	_	5	acl:relcl
23	in	in	IN	_	24	case
24	literature	literature	NN	_	22	nmod
25	.	.	.	_	2	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	was	be	VBD	_	8	auxpass
8	found	find	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	decrease	decrease	VB	_	8	xcomp
11	the	the	DT	_	12	det
12	exposure	exposure	NN	_	10	dobj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	AUC	auc	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	to	to	TO	_	20	case
17	clopidogrel	clopidogrel	NN	_	20	nmod:poss
18	's	's	POS	_	17	case
19	active	active	JJ	_	20	amod
20	metabolite	metabolite	NN	_	12	nmod
21	by	by	IN	_	23	case
22	50	50	CD	_	23	nummod
23	%	%	NN	_	10	nmod
24	and	and	CC	_	10	cc
25	to	to	TO	_	27	mark
26	sharply	sharply	RB	_	27	advmod
27	increase	increase	VB	_	10	conj
28	platelet	platelet	NN	_	29	compound
29	reactivity	reactivity	NN	_	27	dobj
30	,	,	,	_	10	punct
31	as	as	IN	_	33	case
32	a	a	DT	_	33	det
33	result	result	NN	_	10	nmod
34	of	of	IN	_	35	case
35	inhibition	inhibition	NN	_	33	nmod
36	by	by	IN	_	37	case
37	drug3	drug3	NN	_	35	nmod
38	of	of	IN	_	39	case
39	CYP2C19	cyp2c19	NN	_	37	nmod
40	,	,	,	_	39	punct
41	a	a	DT	_	43	det
42	cytochrome	cytochrome	NN	_	43	compound
43	P450	p450	NN	_	47	compound
44	-LRB-	-lrb-	-LRB-	_	45	punct
45	CYP	cyp	NN	_	43	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	enzyme	enzyme	NN	_	39	appos
48	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	a	a	DT	_	6	det
4	much	much	JJ	_	6	amod
5	weaker	weaker	JJR	_	6	amod
6	effect	effect	NN	_	2	dobj
7	on	on	IN	_	10	case
8	drug2	drug2	NN	_	10	nmod:poss
9	's	's	POS	_	8	case
10	pharmacokinetics	pharmacokinetic	NNS	_	6	nmod
11	and	and	CC	_	10	cc
12	on	on	IN	_	14	case
13	platelet	platelet	NN	_	14	compound
14	reactivity	reactivity	NN	_	10	conj
15	during	during	IN	_	17	case
16	concomitant	concomitant	JJ	_	17	amod
17	use	use	NN	_	14	nmod
18	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	influence	influence	NN	_	16	nsubjpass
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	other	other	JJ	_	6	amod
6	drug1	drug1	NN	_	2	nmod
7	when	when	WRB	_	8	advmod
8	used	use	VBN	_	2	acl:relcl
9	simultaneously	simultaneously	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	has	have	VBZ	_	16	aux
13	not	not	RB	_	16	neg
14	yet	yet	RB	_	16	advmod
15	been	be	VBN	_	16	auxpass
16	investigated	investigate	VBN	_	0	ROOT
17	in	in	IN	_	20	case
18	adequately	adequately	RB	_	19	advmod
19	randomized	randomize	VBN	_	20	amod
20	studies	study	NNS	_	16	nmod
21	.	.	.	_	16	punct

1	Regulatory	regulatory	JJ	_	2	amod
2	agencies	agency	NNS	_	3	nsubj
3	state	state	VBP	_	0	ROOT
4	that	that	IN	_	18	mark
5	the	the	DT	_	6	det
6	combination	combination	NN	_	18	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	12	det
11	CYP2C19	cyp2c19	NN	_	12	compound
12	inhibitors	inhibitor	NNS	_	8	conj
13	drug2	drug2	NN	_	12	dep
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	avoided	avoid	VBN	_	3	ccomp
19	.	.	.	_	3	punct

1	To	to	TO	_	2	case
2	date	date	NN	_	5	nmod
3	,	,	,	_	5	punct
4	there	there	EX	_	5	expl
5	is	be	VBZ	_	0	ROOT
6	no	no	DT	_	8	neg
7	conclusive	conclusive	JJ	_	8	amod
8	evidence	evidence	NN	_	5	nsubj
9	of	of	IN	_	12	case
10	a	a	DT	_	12	det
11	clinically-relevant	clinically-relevant	JJ	_	12	amod
12	interaction	interaction	NN	_	8	nmod
13	between	between	IN	_	14	case
14	any	any	DT	_	12	nmod
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	drug1	drug1	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	.	.	.	_	5	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	,	,	,	_	1	punct
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	9	advmod
9	and	and	CC	_	1	advmod
10	in	in	FW	_	11	compound
11	vivo	vivo	FW	_	9	advmod
12	,	,	,	_	1	punct
13	in	in	IN	_	17	case
14	human	human	JJ	_	17	amod
15	A375	a375	NN	_	17	compound
16	melanoma	melanoma	NN	_	17	compound
17	cells	cell	NNS	_	1	nmod
18	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	mechanisms	mechanism	NNS	_	2	dobj
4	of	of	IN	_	5	case
5	interaction	interaction	NN	_	3	nmod
6	between	between	IN	_	10	case
7	the	the	DT	_	10	det
8	alkyating	alkyating	JJ	_	10	amod
9	agent	agent	NN	_	10	compound
10	drug1	drug1	NN	_	5	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	and	and	CC	_	10	cc
15	the	the	DT	_	18	det
16	pro-oxidant	pro-oxidant	JJ	_	18	amod
17	,	,	,	_	18	punct
18	drug3	drug3	NN	_	10	conj
19	,	,	,	_	2	punct
20	in	in	IN	_	26	case
21	the	the	DT	_	26	det
22	human	human	JJ	_	26	amod
23	A375	a375	NN	_	26	compound
24	melanoma	melanoma	NN	_	26	compound
25	cell	cell	NN	_	26	compound
26	line	line	NN	_	2	nmod
27	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	14	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	alone	alone	RB	_	4	conj
9	and	and	CC	_	4	cc
10	in	in	IN	_	11	case
11	combination	combination	NN	_	4	conj
12	,	,	,	_	2	punct
13	was	be	VBD	_	14	auxpass
14	evaluated	evaluate	VBN	_	0	ROOT
15	for	for	IN	_	17	case
16	growth	growth	NN	_	17	compound
17	inhibition	inhibition	NN	_	14	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	MTT	mtt	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	17	punct
22	radiolabeled	radiolabele	VBN	_	24	amod
23	drug	drug	NN	_	24	compound
24	uptake	uptake	NN	_	17	conj
25	,	,	,	_	17	punct
26	cellular	cellular	JJ	_	28	amod
27	thiol	thiol	NN	_	28	compound
28	content	content	NN	_	17	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	HPLC	hplc	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	,	,	,	_	17	punct
33	and	and	CC	_	17	cc
34	DNA	dna	NN	_	36	compound
35	strand	strand	NN	_	36	compound
36	breaks	break	NNS	_	17	conj
37	-LRB-	-lrb-	-LRB-	_	39	punct
38	Comet	comet	NN	_	39	compound
39	assay	assay	NN	_	36	appos
40	-RRB-	-rrb-	-RRB-	_	39	punct
41	.	.	.	_	14	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	6	nsubjpass
2	and	and	CC	_	1	cc
3	antitumor	antitumor	JJ	_	1	conj
4	effects	effect	NNS	_	1	dep
5	were	be	VBD	_	6	auxpass
6	evaluated	evaluate	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	mice	mouse	NNS	_	6	nmod
9	.	.	.	_	6	punct

1	Growth	growth	NN	_	2	compound
2	inhibition	inhibition	NN	_	6	nsubj
3	in	in	FW	_	4	compound
4	vitro	vitro	FW	_	2	advmod
5	was	be	VBD	_	6	cop
6	additive	additive	JJ	_	0	ROOT
7	with	with	IN	_	10	case
8	the	the	DT	_	10	det
9	two	two	CD	_	10	nummod
10	drugs	drug	NNS	_	6	nmod
11	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	on	on	IN	_	7	case
6	drug	drug	NN	_	7	compound
7	uptake	uptake	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	number	number	NN	_	7	conj
12	of	of	IN	_	15	case
13	DNA	dna	NN	_	15	compound
14	strand	strand	NN	_	15	compound
15	breaks	break	NNS	_	11	nmod
16	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	a	a	DT	_	7	det
4	>	>	JJR	_	5	advmod
5	75	75	CD	_	6	dep
6	%	%	NN	_	7	dep
7	reduction	reduction	NN	_	2	nsubj
8	in	in	IN	_	10	case
9	cellular	cellular	JJ	_	10	amod
10	glutathione	glutathione	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	cysteine	cysteine	NN	_	10	conj
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	7	nmod
15	but	but	CC	_	16	cc
16	not	not	RB	_	14	cc
17	drug2	drug2	NN	_	14	conj
18	.	.	.	_	2	punct

1	Co-administration	co-administration	NN	_	8	nsubj
2	of	of	IN	_	5	case
3	the	the	DT	_	5	det
4	two	two	CD	_	5	nummod
5	drugs	drug	NNS	_	1	nmod
6	in	in	IN	_	7	case
7	mice	mouse	NNS	_	5	nmod
8	caused	cause	VBD	_	0	ROOT
9	an	a	DT	_	10	det
10	increase	increase	NN	_	8	dobj
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	area	area	NN	_	10	nmod
14	under	under	IN	_	16	case
15	the	the	DT	_	16	det
16	curve	curve	NN	_	10	nmod
17	of	of	IN	_	19	case
18	both	both	CC	_	19	det
19	drugs	drug	NNS	_	16	nmod
20	,	,	,	_	8	punct
21	but	but	CC	_	8	cc
22	the	the	DT	_	23	det
23	combination	combination	NN	_	26	nsubj
24	was	be	VBD	_	26	cop
25	not	not	RB	_	26	neg
26	effective	effective	JJ	_	8	conj
27	in	in	IN	_	28	mark
28	reducing	reduce	VBG	_	26	advcl
29	human	human	JJ	_	32	amod
30	A375	a375	NN	_	32	compound
31	melanoma	melanoma	NN	_	32	compound
32	tumors	tumor	NNS	_	28	dobj
33	in	in	FW	_	34	compound
34	vivo	vivo	FW	_	28	advmod
35	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	show	show	VBP	_	0	ROOT
5	additive	additive	JJ	_	6	amod
6	effects	effect	NNS	_	4	dobj
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	4	advmod
9	but	but	CC	_	10	cc
10	not	not	RB	_	8	cc
11	in	in	FW	_	12	compound
12	vivo	vivo	FW	_	8	conj
13	in	in	IN	_	17	case
14	human	human	JJ	_	17	amod
15	A375	a375	NN	_	17	compound
16	melanoma	melanoma	NN	_	17	compound
17	cells	cell	NNS	_	4	nmod
18	.	.	.	_	4	punct

1	Enhancement	enhancement	NN	_	0	ROOT
2	of	of	IN	_	5	case
3	humoral	humoral	JJ	_	5	amod
4	immune	immune	JJ	_	5	amod
5	responses	response	NNS	_	1	nmod
6	to	to	TO	_	9	case
7	inactivated	inactivate	VBN	_	9	amod
8	Newcastle	Newcastle	NNP	_	9	compound
9	disease	disease	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	drug1	drug1	NN	_	9	conj
12	by	by	IN	_	14	case
13	oral	oral	JJ	_	14	amod
14	administration	administration	NN	_	1	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	in	in	IN	_	18	case
18	chickens	chicken	NNS	_	14	nmod
19	.	.	.	_	1	punct

1	Newcastle	newcastle	JJ	_	2	amod
2	disease	disease	NN	_	13	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	ND	nd	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	and	and	CC	_	2	cc
7	avian	avian	JJ	_	8	amod
8	influenza	influenza	NN	_	2	conj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	AI	ai	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	are	be	VBP	_	13	cop
13	common	common	JJ	_	0	ROOT
14	in	in	IN	_	17	case
15	the	the	DT	_	17	det
16	poultry	poultry	NN	_	17	compound
17	industry	industry	NN	_	13	nmod
18	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	objective	objective	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	effect	effect	NN	_	8	dobj
11	of	of	IN	_	13	case
12	oral	oral	JJ	_	13	amod
13	administration	administration	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug2	drug2	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	on	on	IN	_	23	case
20	the	the	DT	_	23	det
21	humoral	humoral	JJ	_	23	amod
22	immune	immune	JJ	_	23	amod
23	responses	response	NNS	_	10	nmod
24	of	of	IN	_	25	case
25	chickens	chicken	NNS	_	23	nmod
26	to	to	TO	_	27	case
27	drug3	drug3	NN	_	23	nmod
28	and	and	CC	_	27	cc
29	drug4	drug4	NN	_	30	compound
30	drug4	drug4	NN	_	27	conj
31	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	experiment	experiment	NN	_	31	nmod
3	1	1	CD	_	2	nummod
4	,	,	,	_	31	punct
5	oral	oral	JJ	_	6	amod
6	administration	administration	NN	_	31	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	at	at	IN	_	11	case
10	a	a	DT	_	11	det
11	dose	dose	NN	_	6	nmod
12	of	of	IN	_	14	case
13	5	5	CD	_	14	nummod
14	mg/kg	mg/kg	NN	_	11	nmod
15	of	of	IN	_	16	case
16	BW	bw	NN	_	14	nmod
17	for	for	IN	_	19	case
18	7	7	CD	_	19	nummod
19	d	d	NN	_	6	nmod
20	on	on	IN	_	23	case
21	the	the	DT	_	23	det
22	immune	immune	JJ	_	23	amod
23	response	response	NN	_	19	nmod
24	in	in	IN	_	25	case
25	chickens	chicken	NNS	_	23	nmod
26	intramuscularly	intramuscularly	RB	_	27	advmod
27	injected	inject	VBN	_	25	acl
28	with	with	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod
30	was	be	VBD	_	31	auxpass
31	evaluated	evaluate	VBN	_	0	ROOT
32	.	.	.	_	31	punct

1	Results	result	NNS	_	2	nsubj
2	showed	show	VBD	_	0	ROOT
3	that	that	IN	_	6	mark
4	drug1	drug1	NN	_	6	nsubj
5	significantly	significantly	RB	_	6	advmod
6	increased	increase	VBD	_	2	ccomp
7	the	the	DT	_	9	det
8	antibody	antibody	NN	_	9	compound
9	level	level	NN	_	6	dobj
10	against	against	IN	_	11	case
11	ND	nd	NN	_	9	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	serum	serum	NN	_	9	nmod
15	of	of	IN	_	16	case
16	chickens	chicken	NNS	_	14	nmod
17	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	experiment	experiment	NN	_	11	nmod
3	2	2	CD	_	2	nummod
4	,	,	,	_	11	punct
5	the	the	DT	_	7	det
6	same	same	JJ	_	7	amod
7	regimen	regimen	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	0	ROOT
12	to	to	TO	_	13	case
13	chickens	chicken	NNS	_	11	nmod
14	inoculated	inoculate	VBN	_	13	acl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	11	punct
18	and	and	CC	_	11	cc
19	an	a	DT	_	23	det
20	enhanced	enhance	VBN	_	23	amod
21	serum	serum	NN	_	23	compound
22	antibody	antibody	NN	_	23	compound
23	response	response	NN	_	29	nsubjpass
24	to	to	TO	_	26	case
25	AI	AI	NNP	_	26	compound
26	vaccination	vaccination	NN	_	23	nmod
27	was	be	VBD	_	29	auxpass
28	also	also	RB	_	29	advmod
29	observed	observe	VBN	_	11	conj
30	.	.	.	_	11	punct

1	Considering	consider	VBG	_	23	advcl
2	the	the	DT	_	3	det
3	safety	safety	NN	_	1	dobj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	1	punct
7	because	because	IN	_	12	mark
8	no	no	DT	_	10	neg
9	adverse	adverse	JJ	_	10	amod
10	effect	effect	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	found	find	VBN	_	1	advcl
13	throughout	throughout	IN	_	15	case
14	the	the	DT	_	15	det
15	experiments	experiment	NNS	_	12	nmod
16	,	,	,	_	23	punct
17	drug2	drug2	NN	_	23	nsubj
18	may	may	MD	_	23	aux
19	be	be	VB	_	23	cop
20	a	a	DT	_	23	det
21	promising	promising	JJ	_	23	amod
22	oral	oral	JJ	_	23	amod
23	adjuvant	adjuvant	JJ	_	0	ROOT
24	to	to	TO	_	25	mark
25	improve	improve	VB	_	23	xcomp
26	immunization	immunization	NN	_	25	dobj
27	in	in	IN	_	28	case
28	poultry	poultry	NN	_	26	nmod
29	.	.	.	_	23	punct

1	Protective	protective	JJ	_	2	amod
2	effect	effect	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	against	against	IN	_	10	case
8	the	the	DT	_	10	det
9	acute	acute	JJ	_	10	amod
10	toxicity	toxicity	NN	_	2	nmod
11	of	of	IN	_	12	case
12	diepoxybutane	diepoxybutane	NN	_	10	nmod
13	to	to	TO	_	15	case
14	human	human	JJ	_	15	amod
15	lymphocytes	lymphocyte	NNS	_	10	nmod
16	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	biotransformation	biotransformation	NN	_	7	nsubj
3	and	and	CC	_	2	cc
4	oxidative	oxidative	JJ	_	5	amod
5	stress	stress	NN	_	2	conj
6	may	may	MD	_	7	aux
7	contribute	contribute	VB	_	0	ROOT
8	to	to	TO	_	9	case
9	1,2:3,4	1,2:3,4	CD	_	7	nmod
10	-	-	:	_	9	punct
11	diepoxybutane	diepoxybutane	NN	_	9	dep
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	DEB	deb	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	-	-	:	_	9	punct
16	induced	induce	VBN	_	17	amod
17	toxicity	toxicity	NN	_	9	dep
18	to	to	TO	_	20	case
19	human	human	JJ	_	20	amod
20	lymphocytes	lymphocyte	NNS	_	17	nmod
21	of	of	IN	_	23	case
22	Fanconi	Fanconi	NNP	_	23	compound
23	Anemia	Anemia	NNP	_	20	nmod
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	FA	FA	NNP	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	patients	patient	NNS	_	23	dep
28	.	.	.	_	7	punct

1	Thus	thus	RB	_	29	advmod
2	,	,	,	_	29	punct
3	the	the	DT	_	4	det
4	identification	identification	NN	_	29	nsubj
5	of	of	IN	_	7	case
6	putative	putative	JJ	_	7	amod
7	inhibitors	inhibitor	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	bioactivation	bioactivation	NN	_	7	nmod
10	,	,	,	_	7	punct
11	as	as	RB	_	7	cc
12	well	well	RB	_	11	mwe
13	as	as	IN	_	11	mwe
14	the	the	DT	_	15	det
15	determination	determination	NN	_	7	conj
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	protective	protective	JJ	_	19	amod
19	role	role	NN	_	15	nmod
20	of	of	IN	_	22	case
21	oxidant	oxidant	JJ	_	22	amod
22	defenses	defens	NNS	_	19	nmod
23	,	,	,	_	4	punct
24	on	on	IN	_	26	case
25	DEB-induced	deb-induced	JJ	_	26	amod
26	toxicity	toxicity	NN	_	4	nmod
27	,	,	,	_	4	punct
28	can	can	MD	_	29	aux
29	help	help	VB	_	0	ROOT
30	to	to	TO	_	31	mark
31	understand	understand	VB	_	29	xcomp
32	what	what	WP	_	34	nsubj
33	is	be	VBZ	_	34	aux
34	failing	fail	VBG	_	31	ccomp
35	in	in	IN	_	37	case
36	FA	fa	NN	_	37	compound
37	cells	cell	NNS	_	34	nmod
38	.	.	.	_	29	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	work	work	NN	_	6	nmod
5	we	we	PRP	_	6	nsubj
6	studied	study	VBD	_	0	ROOT
7	the	the	DT	_	8	det
8	contribution	contribution	NN	_	6	dobj
9	of	of	IN	_	12	case
10	several	several	JJ	_	12	amod
11	biochemical	biochemical	JJ	_	12	amod
12	pathways	pathway	NNS	_	8	nmod
13	for	for	IN	_	16	case
14	DEB-induced	deb-induced	JJ	_	16	amod
15	acute	acute	JJ	_	16	amod
16	toxicity	toxicity	NN	_	12	nmod
17	in	in	IN	_	20	case
18	human	human	JJ	_	20	amod
19	lymphocyte	lymphocyte	NN	_	20	compound
20	suspensions	suspension	NNS	_	16	nmod
21	,	,	,	_	6	punct
22	by	by	IN	_	23	mark
23	using	use	VBG	_	6	advcl
24	inhibitors	inhibitor	NNS	_	23	dobj
25	of	of	IN	_	27	case
26	epoxide	epoxide	NN	_	27	compound
27	hydrolases	hydrolase	NNS	_	24	nmod
28	,	,	,	_	24	punct
29	inhibitors	inhibitor	NNS	_	24	conj
30	of	of	IN	_	32	case
31	protective	protective	JJ	_	32	amod
32	enzymes	enzyme	NNS	_	29	nmod
33	as	as	IN	_	35	case
34	glutathione	glutathione	NN	_	35	compound
35	S-transferase	s-transferase	NN	_	29	nmod
36	and	and	CC	_	35	cc
37	catalase	catalase	NN	_	35	conj
38	,	,	,	_	24	punct
39	the	the	DT	_	40	det
40	depletion	depletion	NN	_	24	conj
41	of	of	IN	_	42	case
42	glutathione	glutathione	NN	_	40	nmod
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	GSH	gsh	NN	_	42	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	,	,	,	_	24	punct
47	and	and	CC	_	24	cc
48	the	the	DT	_	49	det
49	inhibition	inhibition	NN	_	24	conj
50	of	of	IN	_	52	case
51	protein	protein	NN	_	52	compound
52	synthesis	synthesis	NN	_	49	nmod
53	;	;	:	_	6	punct

1	and	and	CC	_	0	ROOT
2	a	a	DT	_	3	det
3	variety	variety	NN	_	1	dep
4	of	of	IN	_	7	case
5	putative	putative	JJ	_	7	amod
6	protective	protective	JJ	_	7	amod
7	compounds	compound	NNS	_	3	nmod
8	,	,	,	_	7	punct
9	including	include	VBG	_	10	case
10	antioxidants	antioxidant	NNS	_	7	nmod
11	,	,	,	_	7	punct
12	and	and	CC	_	7	cc
13	mitochondrial	mitochondrial	JJ	_	15	amod
14	protective	protective	JJ	_	15	amod
15	agents	agent	NNS	_	7	conj
16	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	present	present	JJ	_	3	amod
3	study	study	NN	_	4	nsubj
4	reports	report	VBZ	_	0	ROOT
5	two	two	CD	_	7	nummod
6	novel	novel	JJ	_	7	amod
7	findings	finding	NNS	_	4	dobj
8	:	:	:	_	7	punct
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	i	i	LS	_	15	dep
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	it	it	PRP	_	15	nsubjpass
13	was	be	VBD	_	15	auxpass
14	clearly	clearly	RB	_	15	advmod
15	evidenced	evidence	VBN	_	7	dep
16	,	,	,	_	15	punct
17	for	for	IN	_	20	case
18	the	the	DT	_	20	det
19	first	first	JJ	_	20	amod
20	time	time	NN	_	15	nmod
21	,	,	,	_	15	punct
22	that	that	IN	_	33	mark
23	the	the	DT	_	25	det
24	acute	acute	JJ	_	25	amod
25	exposure	exposure	NN	_	33	nsubj
26	of	of	IN	_	30	case
27	freshly	freshly	RB	_	28	advmod
28	isolated	isolate	VBN	_	30	amod
29	human	human	JJ	_	30	amod
30	lymphocytes	lymphocyte	NNS	_	25	nmod
31	to	to	TO	_	32	case
32	DEB	DEB	NNP	_	25	nmod
33	results	result	VBZ	_	15	ccomp
34	in	in	IN	_	37	case
35	severe	severe	JJ	_	37	amod
36	GSH	gsh	NN	_	37	compound
37	depletion	depletion	NN	_	33	nmod
38	and	and	CC	_	37	cc
39	loss	loss	NN	_	37	conj
40	of	of	IN	_	41	case
41	ATP	atp	NN	_	39	nmod
42	,	,	,	_	33	punct
43	followed	follow	VBN	_	33	dep
44	by	by	IN	_	46	case
45	cell	cell	NN	_	46	compound
46	death	death	NN	_	43	nmod
47	;	;	:	_	15	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	ii	ii	LS	_	5	dep
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	drug1	drug1	NN	_	5	nsubj
5	elicits	elicit	VBZ	_	0	ROOT
6	a	a	DT	_	9	det
7	significant	significant	JJ	_	9	amod
8	protective	protective	JJ	_	9	amod
9	effect	effect	NN	_	5	dobj
10	on	on	IN	_	13	case
11	DEB	deb	NN	_	13	compound
12	induced	induce	VBD	_	13	amod
13	toxicity	toxicity	NN	_	9	nmod
14	,	,	,	_	13	punct
15	which	which	WDT	_	17	nsubjpass
16	was	be	VBD	_	17	auxpass
17	potentiated	potentiate	VBN	_	13	acl:relcl
18	by	by	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	5	punct

1	Collectively	collectively	RB	_	5	advmod
2	,	,	,	_	5	punct
3	these	these	DT	_	4	det
4	findings	finding	NNS	_	5	nsubj
5	contribute	contribute	VBP	_	0	ROOT
6	to	to	TO	_	7	mark
7	increase	increase	VB	_	5	xcomp
8	our	we	PRP$	_	9	nmod:poss
9	knowledge	knowledge	NN	_	7	dobj
10	of	of	IN	_	12	case
11	DEB-induce	deb-induce	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	and	and	CC	_	5	cc
14	will	will	MD	_	17	aux
15	be	be	VB	_	17	cop
16	very	very	RB	_	17	advmod
17	useful	useful	JJ	_	5	conj
18	when	when	WRB	_	19	advmod
19	applied	apply	VBN	_	17	advcl
20	in	in	IN	_	21	case
21	studies	study	NNS	_	19	nmod
22	with	with	IN	_	23	case
23	lymphocytes	lymphocyte	NNS	_	21	nmod
24	from	from	IN	_	26	case
25	FA	fa	NN	_	26	compound
26	patients	patient	NNS	_	23	nmod
27	,	,	,	_	5	punct
28	in	in	IN	_	31	mark
29	order	order	NN	_	28	mwe
30	to	to	TO	_	31	mark
31	find	find	VB	_	5	advcl
32	out	out	RP	_	31	compound:prt
33	a	a	DT	_	35	det
34	protective	protective	JJ	_	35	amod
35	agent	agent	NN	_	31	dobj
36	against	against	IN	_	41	case
37	spontaneous	spontaneous	JJ	_	41	amod
38	and	and	CC	_	37	cc
39	DEB-induced	deb-induced	JJ	_	37	conj
40	chromosome	chromosome	NN	_	41	compound
41	instability	instability	NN	_	35	nmod
42	.	.	.	_	5	punct

1	Metabotropic	metabotropic	JJ	_	5	amod
2	glutamate	glutamate	NN	_	5	compound
3	receptor	receptor	NN	_	5	compound
4	5	5	CD	_	5	nummod
5	antagonist	antagonist	NN	_	6	nsubj
6	protects	protect	VBZ	_	0	ROOT
7	dopaminergic	dopaminergic	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	noradrenergic	noradrenergic	JJ	_	7	conj
10	neurons	neuron	NNS	_	6	dobj
11	from	from	IN	_	12	case
12	degeneration	degeneration	NN	_	6	nmod
13	in	in	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	-	-	:	_	6	punct
16	treated	treat	VBN	_	17	amod
17	monkeys	monkey	NNS	_	6	dobj
18	.	.	.	_	6	punct

1	Degeneration	Degeneration	NNP	_	18	nsubj
2	of	of	IN	_	6	case
3	the	the	DT	_	6	det
4	dopaminergic	dopaminergic	JJ	_	6	amod
5	nigrostriatal	nigrostriatal	JJ	_	6	amod
6	system	system	NN	_	1	nmod
7	and	and	CC	_	1	cc
8	of	of	IN	_	10	case
9	noradrenergic	noradrenergic	JJ	_	10	amod
10	neurons	neuron	NNS	_	1	conj
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	locus	locus	NN	_	14	compound
14	coeruleus	coeruleus	NN	_	10	nmod
15	are	be	VBP	_	18	cop
16	important	important	JJ	_	18	amod
17	pathological	pathological	JJ	_	18	amod
18	features	feature	NNS	_	0	ROOT
19	of	of	IN	_	22	case
20	Parkinson	Parkinson	NNP	_	22	nmod:poss
21	's	's	POS	_	20	case
22	disease	disease	NN	_	18	nmod
23	.	.	.	_	18	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	an	a	DT	_	5	det
4	urgent	urgent	JJ	_	5	amod
5	need	need	NN	_	2	nsubj
6	to	to	TO	_	7	mark
7	develop	develop	VB	_	5	acl
8	therapies	therapy	NNS	_	7	dobj
9	that	that	WDT	_	10	nsubj
10	slow	slow	VBP	_	8	acl:relcl
11	down	down	RP	_	10	compound:prt
12	the	the	DT	_	13	det
13	progression	progression	NN	_	10	dobj
14	of	of	IN	_	15	case
15	neurodegeneration	neurodegeneration	NN	_	13	nmod
16	in	in	IN	_	19	case
17	Parkinson	Parkinson	NNP	_	19	nmod:poss
18	's	's	POS	_	17	case
19	disease	disease	NN	_	13	nmod
20	.	.	.	_	2	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	7	nmod
5	,	,	,	_	7	punct
6	we	we	PRP	_	7	nsubj
7	tested	test	VBD	_	0	ROOT
8	whether	whether	IN	_	20	mark
9	the	the	DT	_	14	det
10	highly	highly	RB	_	11	advmod
11	specific	specific	JJ	_	14	amod
12	metabotropic	metabotropic	JJ	_	14	amod
13	glutamate	glutamate	NN	_	14	compound
14	receptor	receptor	NN	_	20	nsubj
15	5	5	CD	_	14	nummod
16	antagonist	antagonist	NN	_	14	dep
17	,	,	,	_	14	punct
18	drug1	drug1	NN	_	14	appos
19	,	,	,	_	14	punct
20	reduces	reduce	VBZ	_	7	ccomp
21	dopaminergic	dopaminergic	JJ	_	25	amod
22	and	and	CC	_	21	cc
23	noradrenergic	noradrenergic	JJ	_	21	conj
24	neuronal	neuronal	JJ	_	25	amod
25	loss	loss	NN	_	20	dobj
26	in	in	IN	_	27	case
27	monkeys	monkey	NNS	_	25	nmod
28	rendered	render	VBN	_	27	acl
29	parkinsonian	parkinsonian	JJ	_	28	xcomp
30	by	by	IN	_	32	case
31	chronic	chronic	JJ	_	32	amod
32	treatment	treatment	NN	_	28	nmod
33	with	with	IN	_	35	case
34	low	low	JJ	_	35	amod
35	doses	dose	NNS	_	32	nmod
36	of	of	IN	_	37	case
37	drug2	drug2	NN	_	35	nmod
38	.	.	.	_	7	punct

1	Weekly	Weekly	NNP	_	4	compound
2	intramuscular	intramuscular	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	injections	injection	NNS	_	24	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	10	punct
6	0.2-0	0.2-0	CD	_	10	nummod
7	.5	.5	CD	_	10	nummod
8	mg/kg	mg/kg	NN	_	10	compound
9	body	body	NN	_	10	compound
10	weight	weight	NN	_	4	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	4	punct
13	in	in	IN	_	14	case
14	combination	combination	NN	_	4	nmod
15	with	with	IN	_	17	case
16	daily	daily	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	vehicle	vehicle	NN	_	19	conj
22	,	,	,	_	4	punct
23	were	be	VBD	_	24	auxpass
24	performed	perform	VBN	_	0	ROOT
25	until	until	IN	_	27	case
26	the	the	DT	_	27	det
27	development	development	NN	_	24	nmod
28	of	of	IN	_	31	case
29	parkinsonian	parkinsonian	JJ	_	31	amod
30	motor	motor	NN	_	31	compound
31	symptoms	symptom	NNS	_	27	nmod
32	in	in	IN	_	33	case
33	either	either	DT	_	31	nmod
34	of	of	IN	_	38	case
35	the	the	DT	_	38	det
36	two	two	CD	_	38	nummod
37	experimental	experimental	JJ	_	38	amod
38	groups	group	NNS	_	33	nmod
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	drug3	drug3	NN	_	38	dep
41	/	/	:	_	40	punct
42	drug4	drug4	NN	_	40	dep
43	versus	versus	CC	_	42	cc
44	drug5	drug5	NN	_	42	conj
45	/	/	:	_	40	punct
46	vehicle	vehicle	NN	_	40	dep
47	-RRB-	-rrb-	-RRB-	_	40	punct
48	.	.	.	_	24	punct

1	After	after	IN	_	3	case
2	21	21	CD	_	3	nummod
3	weeks	week	NNS	_	13	nmod
4	of	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	treatment	treatment	NN	_	3	nmod
7	,	,	,	_	13	punct
8	all	all	DT	_	9	det
9	drug2	drug2	NN	_	12	dep
10	/	/	:	_	12	punct
11	vehicle-treated	vehicle-treated	JJ	_	12	amod
12	animals	animal	NNS	_	13	nsubj
13	displayed	display	VBD	_	0	ROOT
14	parkinsonian	parkinsonian	JJ	_	15	amod
15	symptoms	symptom	NNS	_	13	dobj
16	,	,	,	_	13	punct
17	whereas	whereas	IN	_	13	dep
18	none	none	NN	_	29	nsubjpass
19	of	of	IN	_	23	case
20	the	the	DT	_	23	det
21	drug3	drug3	NN	_	23	compound
22	/	/	:	_	23	punct
23	drug4	drug4	NN	_	18	nmod
24	-	-	:	_	23	punct
25	treated	treat	VBN	_	26	amod
26	monkeys	monkey	NNS	_	23	dep
27	were	be	VBD	_	29	auxpass
28	significantly	significantly	RB	_	29	advmod
29	affected	affect	VBN	_	13	parataxis
30	.	.	.	_	13	punct

1	These	these	DT	_	3	det
2	behavioural	behavioural	JJ	_	3	amod
3	observations	observation	NNS	_	5	nsubj
4	were	be	VBD	_	5	cop
5	consistent	consistent	JJ	_	0	ROOT
6	with	with	IN	_	15	case
7	in	in	FW	_	15	amod
8	vivo	vivo	FW	_	7	dep
9	positron	positron	FW	_	15	compound
10	emission	emission	NN	_	15	compound
11	tomography	tomography	NN	_	15	compound
12	dopamine	dopamine	NN	_	15	compound
13	transporter	transporter	NN	_	15	compound
14	imaging	imaging	NN	_	15	compound
15	data	datum	NNS	_	5	nmod
16	,	,	,	_	5	punct
17	and	and	CC	_	5	cc
18	with	with	IN	_	21	case
19	post-mortem	post-mortem	NN	_	21	compound
20	stereological	stereological	JJ	_	21	amod
21	counts	count	NNS	_	5	conj
22	of	of	IN	_	25	case
23	midbrain	midbrain	JJ	_	25	amod
24	dopaminergic	dopaminergic	JJ	_	25	amod
25	neurons	neuron	NNS	_	21	nmod
26	,	,	,	_	21	punct
27	as	as	RB	_	21	cc
28	well	well	RB	_	27	mwe
29	as	as	IN	_	27	mwe
30	striatal	striatal	JJ	_	32	amod
31	intensity	intensity	NN	_	32	compound
32	measurements	measurement	NNS	_	21	conj
33	of	of	IN	_	35	case
34	dopamine	dopamine	NN	_	35	compound
35	transporter	transporter	NN	_	32	nmod
36	and	and	CC	_	35	cc
37	tyrosine	tyrosine	NN	_	39	compound
38	hydroxylase	hydroxylase	NN	_	39	compound
39	immunoreactivity	immunoreactivity	NN	_	35	conj
40	,	,	,	_	32	punct
41	which	which	WDT	_	45	nsubj
42	were	be	VBD	_	45	cop
43	all	all	DT	_	45	advmod
44	significantly	significantly	RB	_	45	advmod
45	higher	higher	JJR	_	32	acl:relcl
46	in	in	IN	_	47	case
47	drug1	drug1	NN	_	45	nmod
48	/	/	:	_	47	punct
49	drug2	drug2	NN	_	47	dep
50	-	-	:	_	47	punct
51	treated	treat	VBN	_	52	amod
52	animals	animal	NNS	_	47	dep
53	than	than	IN	_	55	case
54	in	in	IN	_	55	case
55	drug3	drug3	NN	_	52	nmod
56	/	/	:	_	47	punct
57	vehicle-treated	vehicle-treated	JJ	_	58	amod
58	monkeys	monkey	NNS	_	47	dep
59	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	treatment	treatment	NN	_	5	nsubj
4	also	also	RB	_	5	advmod
5	had	have	VBD	_	0	ROOT
6	a	a	DT	_	8	det
7	significant	significant	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	drug2	drug2	NN	_	8	nmod
12	-	-	:	_	8	punct
13	induced	induced	JJ	_	14	amod
14	loss	loss	NN	_	8	dep
15	of	of	IN	_	17	case
16	norepinephrine	norepinephrine	NN	_	17	compound
17	neurons	neuron	NNS	_	14	nmod
18	in	in	IN	_	21	case
19	the	the	DT	_	21	det
20	locus	locus	NN	_	21	compound
21	coeruleus	coeruleus	NN	_	14	nmod
22	and	and	CC	_	21	cc
23	adjoining	adjoining	JJ	_	24	amod
24	A5	a5	NN	_	21	conj
25	and	and	CC	_	24	cc
26	A7	a7	NN	_	29	compound
27	noradrenaline	noradrenaline	NN	_	29	compound
28	cell	cell	NN	_	29	compound
29	groups	group	NNS	_	24	conj
30	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	drug1	drug1	NN	_	17	nmod
3	/	/	:	_	5	punct
4	vehicle-treated	vehicle-treated	JJ	_	5	amod
5	animals	animal	NNS	_	17	nsubjpass
6	,	,	,	_	5	punct
7	almost	almost	RB	_	8	advmod
8	40	40	CD	_	9	dep
9	%	%	NN	_	10	dep
10	loss	loss	NN	_	5	appos
11	of	of	IN	_	15	case
12	tyrosine	tyrosine	NN	_	15	compound
13	hydroxylase-positive	hydroxylase-positive	JJ	_	15	amod
14	norepinephrine	norepinephrine	NN	_	15	compound
15	neurons	neuron	NNS	_	10	nmod
16	was	be	VBD	_	17	auxpass
17	found	find	VBN	_	0	ROOT
18	in	in	IN	_	23	case
19	locus	locus	NN	_	23	compound
20	coeruleus/A5/A7	coeruleus/a5/a7	NN	_	23	compound
21	noradrenaline	noradrenaline	NN	_	23	compound
22	cell	cell	NN	_	23	compound
23	groups	group	NNS	_	17	nmod
24	,	,	,	_	17	punct
25	whereas	whereas	IN	_	17	dep
26	the	the	DT	_	27	det
27	extent	extent	NN	_	32	nsubj
28	of	of	IN	_	30	case
29	neuronal	neuronal	JJ	_	30	amod
30	loss	loss	NN	_	27	nmod
31	was	be	VBD	_	32	cop
32	lower	lower	JJR	_	17	parataxis
33	than	than	IN	_	35	case
34	15	15	CD	_	35	nummod
35	%	%	NN	_	32	nmod
36	of	of	IN	_	38	case
37	control	control	NN	_	38	compound
38	values	value	NNS	_	35	nmod
39	in	in	IN	_	40	case
40	drug2	drug2	NN	_	38	nmod
41	/	/	:	_	32	punct
42	drug3	drug3	NN	_	45	compound
43	-	-	:	_	45	punct
44	treated	treat	VBN	_	45	amod
45	monkeys	monkey	NNS	_	32	dep
46	.	.	.	_	17	punct

1	Our	we	PRP$	_	2	nmod:poss
2	data	datum	NNS	_	3	nsubj
3	demonstrate	demonstrate	VBP	_	0	ROOT
4	that	that	IN	_	18	mark
5	chronic	chronic	JJ	_	6	amod
6	treatment	treatment	NN	_	18	nsubj
7	with	with	IN	_	11	case
8	the	the	DT	_	11	det
9	metabotropic	metabotropic	JJ	_	11	amod
10	glutamate	glutamate	NN	_	11	compound
11	receptor	receptor	NN	_	6	nmod
12	5	5	CD	_	13	nummod
13	antagonist	antagonist	NN	_	11	dep
14	,	,	,	_	11	punct
15	drug1	drug1	NN	_	11	appos
16	,	,	,	_	11	punct
17	significantly	significantly	RB	_	18	advmod
18	reduces	reduce	VBZ	_	3	ccomp
19	drug2	drug2	NN	_	20	compound
20	toxicity	toxicity	NN	_	18	dobj
21	towards	towards	IN	_	26	case
22	dopaminergic	dopaminergic	JJ	_	26	amod
23	and	and	CC	_	22	cc
24	noradrenergic	noradrenergic	JJ	_	22	conj
25	cell	cell	NN	_	26	compound
26	groups	group	NNS	_	18	nmod
27	in	in	IN	_	29	case
28	non-human	non-human	JJ	_	29	amod
29	primates	primate	NNS	_	26	nmod
30	.	.	.	_	3	punct

1	This	this	DT	_	2	nsubj
2	suggests	suggest	VBZ	_	0	ROOT
3	that	that	IN	_	16	mark
4	the	the	DT	_	5	det
5	use	use	NN	_	16	nsubj
6	of	of	IN	_	11	case
7	metabotropic	metabotropic	JJ	_	11	amod
8	glutamate	glutamate	NN	_	11	compound
9	receptor	receptor	NN	_	11	compound
10	5	5	CD	_	11	nummod
11	antagonists	antagonist	NNS	_	5	nmod
12	may	may	MD	_	16	aux
13	be	be	VB	_	16	cop
14	a	a	DT	_	16	det
15	useful	useful	JJ	_	16	amod
16	strategy	strategy	NN	_	2	ccomp
17	to	to	TO	_	18	mark
18	reduce	reduce	VB	_	16	acl
19	degeneration	degeneration	NN	_	18	dobj
20	of	of	IN	_	22	case
21	catecholaminergic	catecholaminergic	JJ	_	22	amod
22	neurons	neuron	NNS	_	19	nmod
23	in	in	IN	_	26	case
24	Parkinson	Parkinson	NNP	_	26	nmod:poss
25	's	's	POS	_	24	case
26	disease	disease	NN	_	18	nmod
27	.	.	.	_	2	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	activity	activity	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	combined	combine	VBN	_	3	acl
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	against	against	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	isolates	isolate	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	-	-	:	_	3	punct
15	resistant	resistant	JJ	_	17	amod
16	Staphylococcus	staphylococcus	FW	_	17	compound
17	aureus	aureus	FW	_	3	dep
18	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	0	ROOT
3	aimed	aim	VBN	_	2	acl
4	to	to	TO	_	5	mark
5	evaluate	evaluate	VB	_	3	xcomp
6	the	the	DT	_	9	det
7	in	in	FW	_	9	amod
8	vitro	vitro	FW	_	7	dep
9	activity	activity	NN	_	5	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	combined	combine	VBN	_	11	acl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	against	against	IN	_	16	case
16	isolates	isolate	NNS	_	14	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	-	-	:	_	2	punct
20	resistant	resistant	JJ	_	22	amod
21	Staphylococcus	staphylococcus	FW	_	22	compound
22	aureus	aureus	FW	_	2	dep
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	MRSA	mrsa	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	.	.	.	_	2	punct

1	A	a	DT	_	2	det
2	total	total	NN	_	15	nsubjpass
3	of	of	IN	_	6	case
4	87	87	CD	_	6	nummod
5	clinical	clinical	JJ	_	6	amod
6	isolates	isolate	NNS	_	2	nmod
7	of	of	IN	_	8	case
8	MRSA	MRSA	NNP	_	6	nmod
9	collected	collect	VBN	_	2	acl
10	from	from	IN	_	13	case
11	three	three	CD	_	13	nummod
12	Chinese	chinese	JJ	_	13	amod
13	hospitals	hospital	NNS	_	9	nmod
14	were	be	VBD	_	15	auxpass
15	included	include	VBN	_	0	ROOT
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	study	study	NN	_	15	nmod
19	.	.	.	_	15	punct

1	The	the	DT	_	3	det
2	checkerboard	checkerboard	NN	_	3	compound
3	method	method	NN	_	15	nsubjpass
4	with	with	IN	_	5	case
5	determination	determination	NN	_	3	nmod
6	of	of	IN	_	10	case
7	the	the	DT	_	10	det
8	fractional	fractional	JJ	_	10	amod
9	IC	ic	NN	_	10	compound
10	index	index	NN	_	5	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	FICI	fici	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	was	be	VBD	_	15	auxpass
15	used	use	VBN	_	0	ROOT
16	to	to	TO	_	17	mark
17	determine	determine	VB	_	15	xcomp
18	whether	whether	IN	_	21	mark
19	drug1	drug1	NN	_	20	compound
20	combinations	combination	NNS	_	21	nsubj
21	act	act	VBP	_	17	ccomp
22	synergistically	synergistically	RB	_	21	advmod
23	against	against	IN	_	25	case
24	these	these	DT	_	25	det
25	isolates	isolate	NNS	_	21	nmod
26	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	susceptibility	susceptibility	NN	_	3	nsubj
3	results	result	VBZ	_	9	csubjpass
4	for	for	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	were	be	VBD	_	9	auxpass
9	interpreted	interpret	VBN	_	0	ROOT
10	according	accord	VBG	_	15	case
11	to	to	TO	_	10	mwe
12	the	the	DT	_	15	det
13	most	most	RBS	_	14	advmod
14	relevant	relevant	JJ	_	15	amod
15	criteria	criterion	NNS	_	9	nmod
16	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	demonstrated	demonstrate	VBD	_	0	ROOT
4	the	the	DT	_	6	det
5	following	following	JJ	_	6	amod
6	interactions	interaction	NNS	_	3	dobj
7	:	:	:	_	6	punct
8	76	76	CD	_	9	nummod
9	isolates	isolate	NNS	_	14	nsubj
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	87.4	87.4	CD	_	12	nummod
12	%	%	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	showed	show	VBD	_	6	dep
15	synergistic	synergistic	JJ	_	16	amod
16	interactions	interaction	NNS	_	14	dobj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	FICI	fici	NN	_	16	appos
19	0.5	0.5	CD	_	18	nummod
20	-RRB-	-rrb-	-RRB-	_	18	punct
21	and	and	CC	_	16	cc
22	11	11	CD	_	23	nummod
23	isolates	isolate	NNS	_	16	conj
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	12.6	12.6	CD	_	26	nummod
26	%	%	NN	_	23	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	showed	show	VBD	_	14	dep
29	indifferent	indifferent	JJ	_	30	amod
30	interactions	interaction	NNS	_	28	dobj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	0.5	0.5	CD	_	30	dep
33	&	&	CC	_	32	cc
34	lt	lt	NN	_	32	conj
35	;	;	:	_	32	punct
36	FICI	FICI	NNP	_	32	conj
37	&	&	CC	_	36	cc
38	lt	lt	NN	_	36	conj
39	;	;	:	_	32	punct
40	4	4	LS	_	32	dep
41	-RRB-	-rrb-	-RRB-	_	32	punct
42	.	.	.	_	3	punct

1	No	no	DT	_	3	neg
2	antagonistic	antagonistic	JJ	_	3	amod
3	interactions	interaction	NNS	_	9	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	FICI	fici	NN	_	3	appos
6	4	4	CD	_	5	nummod
7	-RRB-	-rrb-	-RRB-	_	5	punct
8	were	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	combination	combination	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	can	can	MD	_	9	aux
8	be	be	VB	_	9	cop
9	synergistic	synergistic	JJ	_	0	ROOT
10	against	against	IN	_	11	case
11	MRSA	MRSA	NNP	_	9	nmod
12	.	.	.	_	9	punct

1	Further	further	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	required	require	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	determine	determine	VB	_	4	xcomp
7	the	the	DT	_	10	det
8	potential	potential	JJ	_	10	amod
9	clinical	clinical	JJ	_	10	amod
10	role	role	NN	_	6	dobj
11	of	of	IN	_	14	case
12	this	this	DT	_	14	det
13	combination	combination	NN	_	14	compound
14	regimen	regimen	NN	_	10	nmod
15	as	as	IN	_	18	case
16	a	a	DT	_	18	det
17	therapeutic	therapeutic	JJ	_	18	amod
18	alternative	alternative	NN	_	10	nmod
19	for	for	IN	_	21	case
20	certain	certain	JJ	_	21	amod
21	types	type	NNS	_	18	nmod
22	of	of	IN	_	24	case
23	MRSA	mrsa	NN	_	24	compound
24	infections	infection	NNS	_	21	nmod
25	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	enhances	enhance	VBZ	_	0	ROOT
3	drug2	drug2	NN	_	2	dobj
4	-	-	:	_	3	punct
5	mediated	mediate	VBN	_	8	amod
6	antibody-dependent	antibody-dependent	JJ	_	8	amod
7	cellular	cellular	JJ	_	8	amod
8	cytotoxicity	cytotoxicity	NN	_	3	dep
9	by	by	IN	_	10	case
10	up-regulation	up-regulation	NN	_	8	nmod
11	of	of	IN	_	15	case
12	cell	cell	NN	_	15	compound
13	surface	surface	NN	_	15	compound
14	HER2	her2	NN	_	15	compound
15	expression	expression	NN	_	10	nmod
16	.	.	.	_	2	punct

1	Although	although	IN	_	5	mark
2	it	it	PRP	_	5	nsubjpass
3	was	be	VBD	_	5	auxpass
4	previously	previously	RB	_	5	advmod
5	reported	report	VBN	_	0	ROOT
6	that	that	IN	_	11	mark
7	drug1	drug1	NN	_	11	nsubj
8	combined	combine	VBN	_	7	acl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	improved	improve	VBD	_	5	ccomp
12	the	the	DT	_	15	det
13	progression-free	progression-free	JJ	_	15	amod
14	survival	survival	NN	_	15	compound
15	rate	rate	NN	_	11	dobj
16	compared	compare	VBN	_	18	case
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	11	advcl
19	alone	alone	RB	_	18	advmod
20	for	for	IN	_	21	case
21	patients	patient	NNS	_	18	nmod
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	-	-	:	_	29	punct
25	refractory	refractory	JJ	_	29	amod
26	HER2-positive	her2-positive	JJ	_	29	amod
27	metastatic	metastatic	JJ	_	29	amod
28	breast	breast	NN	_	29	compound
29	cancer	cancer	NN	_	5	dobj
30	,	,	,	_	29	punct
31	the	the	DT	_	32	det
32	mechanism	mechanism	NN	_	34	nsubj
33	is	be	VBZ	_	34	cop
34	purported	purported	JJ	_	29	acl:relcl
35	to	to	TO	_	39	mark
36	be	be	VB	_	39	cop
37	an	a	DT	_	39	det
38	antiproliferative	antiproliferative	JJ	_	39	amod
39	effect	effect	NN	_	34	xcomp
40	relating	relate	VBG	_	39	acl
41	to	to	TO	_	43	case
42	the	the	DT	_	43	det
43	synergism	synergism	NN	_	40	nmod
44	of	of	IN	_	47	case
45	these	these	DT	_	47	det
46	two	two	CD	_	47	nummod
47	agents	agent	NNS	_	43	nmod
48	.	.	.	_	5	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	how	how	WRB	_	5	advmod
4	drug1	drug1	NN	_	5	nsubj
5	interacts	interact	VBZ	_	2	ccomp
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	in	in	IN	_	11	case
9	HER2-positive	her2-positive	JJ	_	11	amod
10	breast	breast	NN	_	11	compound
11	cancer	cancer	NN	_	5	nmod
12	,	,	,	_	5	punct
13	with	with	IN	_	16	case
14	a	a	DT	_	16	det
15	particular	particular	JJ	_	16	amod
16	focus	focus	NN	_	5	nmod
17	on	on	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	-	-	:	_	16	punct
20	mediated	mediate	VBN	_	23	amod
21	antibody-dependent	antibody-dependent	JJ	_	23	amod
22	cellular	cellular	JJ	_	23	amod
23	cytotoxicity	cytotoxicity	NN	_	16	dep
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	ADCC	adcc	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	.	.	.	_	2	punct

1	In	in	IN	_	5	case
2	an	a	DT	_	5	det
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	assay	assay	NN	_	8	nmod
6	,	,	,	_	8	punct
7	drug1	drug1	NN	_	8	nsubj
8	induced	induce	VBD	_	0	ROOT
9	HER2	her2	NN	_	10	compound
10	expression	expression	NN	_	8	dobj
11	at	at	IN	_	14	case
12	the	the	DT	_	14	det
13	cell	cell	NN	_	14	compound
14	surface	surface	NN	_	8	nmod
15	of	of	IN	_	20	case
16	HER2-positive	her2-positive	JJ	_	20	amod
17	breast	breast	NN	_	20	compound
18	cancer	cancer	NN	_	20	compound
19	cell	cell	NN	_	20	compound
20	lines	line	NNS	_	14	nmod
21	,	,	,	_	8	punct
22	leading	lead	VBG	_	8	advcl
23	to	to	TO	_	25	case
24	the	the	DT	_	25	det
25	enhancement	enhancement	NN	_	22	nmod
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	-	-	:	_	25	punct
29	mediated	mediate	VBN	_	30	amod
30	ADCC	adcc	NN	_	25	dep
31	.	.	.	_	8	punct

1	Furthermore	furthermore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	present	present	VBP	_	0	ROOT
5	a	a	DT	_	7	det
6	case	case	NN	_	7	compound
7	report	report	NN	_	4	dobj
8	in	in	IN	_	9	case
9	which	which	WDT	_	16	nmod
10	a	a	DT	_	13	det
11	second	second	JJ	_	13	amod
12	drug1	drug1	NN	_	13	compound
13	treatment	treatment	NN	_	16	nsubj
14	following	follow	VBG	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	resulted	result	VBD	_	7	acl:relcl
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	marked	marked	JJ	_	20	amod
20	shrinkage	shrinkage	NN	_	16	nmod
21	of	of	IN	_	24	case
22	multiple	multiple	JJ	_	24	amod
23	metastatic	metastatic	JJ	_	24	amod
24	tumors	tumor	NNS	_	20	nmod
25	in	in	IN	_	28	case
26	HER2-positive	her2-positive	JJ	_	28	amod
27	breast	breast	NN	_	28	compound
28	cancer	cancer	NN	_	24	nmod
29	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	have	have	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	potential	potential	JJ	_	3	dobj
6	to	to	TO	_	7	mark
7	convert	convert	VB	_	5	acl
8	drug2	drug2	NN	_	7	dobj
9	-	-	:	_	8	punct
10	refractory	refractory	JJ	_	8	amod
11	to	to	TO	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	-	-	:	_	8	punct
14	sensitive	sensitive	JJ	_	15	amod
15	tumors	tumor	NNS	_	8	dep
16	in	in	IN	_	19	case
17	HER2-positive	her2-positive	JJ	_	19	amod
18	breast	breast	NN	_	19	compound
19	cancer	cancer	NN	_	15	nmod
20	by	by	IN	_	21	case
21	up-regulation	up-regulation	NN	_	15	nmod
22	of	of	IN	_	26	case
23	the	the	DT	_	26	det
24	cell	cell	NN	_	26	compound
25	surface	surface	NN	_	26	compound
26	expression	expression	NN	_	21	nmod
27	of	of	IN	_	28	case
28	HER2	her2	NN	_	26	nmod
29	.	.	.	_	3	punct

1	Improved	improve	VBN	_	4	amod
2	parathyroid	parathyroid	JJ	_	4	amod
3	hormone	hormone	NN	_	4	compound
4	control	control	NN	_	8	nsubjpass
5	by	by	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	reduction	reduction	NN	_	8	nmod
11	in	in	IN	_	13	case
12	drug2	drug2	NN	_	13	compound
13	requirement	requirement	NN	_	10	nmod
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	with	with	IN	_	19	case
17	end-stage	end-stage	JJ	_	19	amod
18	renal	renal	JJ	_	19	amod
19	disease	disease	NN	_	15	nmod
20	.	.	.	_	8	punct

1	Uncontrolled	uncontrolled	JJ	_	2	amod
2	hy-per-parathyroidism	hy-per-parathyroidism	NN	_	3	nsubj
3	causes	cause	VBZ	_	0	ROOT
4	bone	bone	NN	_	6	compound
5	marrow	marrow	NN	_	6	compound
6	fibrosis	fibrosis	NN	_	3	dobj
7	,	,	,	_	3	punct
8	leading	lead	VBG	_	3	advcl
9	to	to	TO	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	resistance	resistance	NN	_	10	dep
15	.	.	.	_	3	punct

1	Medical	medical	JJ	_	2	amod
2	treatment	treatment	NN	_	6	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	cop
6	effective	effective	JJ	_	0	ROOT
7	in	in	IN	_	8	mark
8	reducing	reduce	VBG	_	6	advcl
9	plasma	plasma	NN	_	11	compound
10	parathyroid	parathyroid	JJ	_	11	amod
11	hormone	hormone	NN	_	15	compound
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	PTH	pth	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	levels	level	NNS	_	8	dobj
16	,	,	,	_	6	punct
17	but	but	CC	_	6	cc
18	its	its	PRP$	_	19	nmod:poss
19	effect	effect	NN	_	24	nsubj
20	on	on	IN	_	22	case
21	drug2	drug2	NN	_	22	compound
22	dosing	dosing	NN	_	19	nmod
23	is	be	VBZ	_	24	cop
24	unknown	unknown	JJ	_	6	conj
25	.	.	.	_	6	punct

1	METHODS	method	NNS	_	0	ROOT
2	AND	and	CC	_	1	cc
3	AIMS	aim	NNS	_	1	conj
4	:	:	:	_	1	punct
5	We	we	PRP	_	6	nsubj
6	conducted	conduct	VBD	_	1	dep
7	a	a	DT	_	10	det
8	retrospective	retrospective	JJ	_	10	amod
9	cohort	cohort	NN	_	10	compound
10	study	study	NN	_	6	dobj
11	of	of	IN	_	15	case
12	40	40	CD	_	15	nummod
13	end-stage	end-stage	JJ	_	15	amod
14	renal	renal	JJ	_	15	amod
15	disease	disease	NN	_	10	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	ESRD	esrd	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	patients	patient	NNS	_	15	dep
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	age	age	NN	_	19	dep
22	:	:	:	_	21	punct
23	55	55	CD	_	24	compound
24	14	14	CD	_	21	dep
25	;	;	:	_	21	punct
26	mean	mean	VB	_	21	dep
27	SD	sd	NN	_	26	dobj
28	;	;	:	_	21	punct
29	21	21	CD	_	31	nummod
30	:	:	:	_	31	punct
31	male	male	NN	_	21	dep
32	-RRB-	-rrb-	-RRB-	_	21	punct
33	who	who	WP	_	34	nsubj
34	had	have	VBD	_	10	acl:relcl
35	at	at	IN	_	36	case
36	least	least	JJS	_	37	nmod:npmod
37	12	12	CD	_	38	nummod
38	months	month	NNS	_	34	dobj
39	of	of	IN	_	41	case
40	drug1	drug1	NN	_	41	compound
41	therapy	therapy	NN	_	38	nmod
42	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	distribution	distribution	NN	_	11	nsubj
3	of	of	IN	_	6	case
4	renal	renal	JJ	_	6	amod
5	replacement	replacement	NN	_	6	compound
6	therapies	therapy	NNS	_	2	nmod
7	were	be	VBD	_	11	cop
8	:	:	:	_	11	punct
9	14	14	CD	_	11	nummod
10	peritoneal	peritoneal	JJ	_	11	amod
11	dialysis	dialysis	NN	_	0	ROOT
12	,	,	,	_	11	punct
13	18	18	CD	_	15	nummod
14	conventional	conventional	JJ	_	15	amod
15	hemodialysis	hemodialysis	NN	_	11	conj
16	and	and	CC	_	11	cc
17	8	8	CD	_	19	nummod
18	nocturnal	nocturnal	JJ	_	19	amod
19	hemodialysis	hemodialysis	NN	_	11	conj
20	.	.	.	_	11	punct

1	Standard	Standard	NNP	_	5	compound
2	dialysis	dialysis	NN	_	5	compound
3	related	related	JJ	_	5	amod
4	biochemical	biochemical	JJ	_	5	amod
5	indices	index	NNS	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	medications	medication	NNS	_	5	conj
8	used	use	VBN	_	5	acl
9	were	be	VBD	_	10	auxpass
10	recorded	record	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	primary	primary	JJ	_	3	amod
3	objective	objective	NN	_	7	nsubj
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	study	study	NN	_	3	nmod
7	was	be	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	ascertain	ascertain	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	difference	difference	NN	_	9	dobj
12	in	in	IN	_	14	case
13	drug1	drug1	NN	_	14	compound
14	responsiveness	responsiveness	NN	_	11	nmod
15	before	before	IN	_	19	case
16	and	and	CC	_	15	cc
17	after	after	IN	_	15	conj
18	12	12	CD	_	19	nummod
19	months	month	NNS	_	9	nmod
20	of	of	IN	_	22	case
21	drug2	drug2	NN	_	22	compound
22	therapy	therapy	NN	_	19	nmod
23	.	.	.	_	7	punct

1	Our	we	PRP$	_	3	nmod:poss
2	secondary	secondary	JJ	_	3	amod
3	objective	objective	NN	_	4	nsubj
4	was	be	VBD	_	0	ROOT
5	to	to	TO	_	6	mark
6	determine	determine	VB	_	4	xcomp
7	if	if	IN	_	9	mark
8	there	there	EX	_	9	expl
9	was	be	VBD	_	6	advcl
10	a	a	DT	_	11	det
11	relationship	relationship	NN	_	9	nsubj
12	between	between	IN	_	14	case
13	the	the	DT	_	14	det
14	changes	change	NNS	_	11	nmod
15	in	in	IN	_	16	case
16	PTH	pth	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug1	drug1	NN	_	19	compound
19	requirement	requirement	NN	_	16	conj
20	.	.	.	_	4	punct

1	Overall	overall	RB	_	5	advmod
2	,	,	,	_	5	punct
3	PTH	pth	NN	_	4	compound
4	levels	level	NNS	_	5	nsubj
5	decreased	decrease	VBD	_	0	ROOT
6	from	from	IN	_	7	case
7	197.5	197.5	CD	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	151.8	151.8	CD	_	7	dep
10	;	;	:	_	9	punct
11	249.2	249.2	CD	_	9	dep
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	to	to	TO	_	14	case
14	66.1	66.1	CD	_	5	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	41.2	41.2	CD	_	14	dep
17	;	;	:	_	16	punct
18	136.5	136.5	CD	_	16	dep
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	median	median	NN	_	14	dep
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	25th	25th	JJ	_	21	dep
24	;	;	:	_	23	punct
25	75th	75th	JJ	_	26	amod
26	percentile	percentile	NN	_	23	dep
27	-RRB-	-rrb-	-RRB-	_	23	punct
28	-RRB-	-rrb-	-RRB-	_	21	punct
29	pmol/l	pmol/l	NN	_	14	dep
30	;	;	:	_	5	punct

1	p	p	NN	_	0	ROOT
2	&	&	CC	_	1	cc
3	lt	lt	NN	_	1	conj
4	;	;	:	_	1	punct

1	0.001	0.001	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	dose	dose	NN	_	3	nsubj
3	increased	increase	VBN	_	0	ROOT
4	from	from	IN	_	6	case
5	30.0	30.0	CD	_	6	compound
6	6	6	CD	_	3	nmod
7	to	to	TO	_	10	case
8	63	63	CD	_	9	compound
9	25	25	CD	_	10	nummod
10	mg/day	mg/day	NN	_	3	nmod
11	,	,	,	_	3	punct
12	p	p	NN	_	3	parataxis
13	<	<	JJR	_	12	dep

1	0.05	0.05	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Hemoglobin	hemoglobin	NN	_	2	nsubj
2	remained	remain	VBD	_	0	ROOT
3	unchanged	unchanged	JJ	_	2	xcomp
4	-LRB-	-lrb-	-LRB-	_	10	punct
5	116	116	CD	_	6	compound
6	13	13	CD	_	10	nummod
7	to	to	TO	_	6	dep
8	116	116	CD	_	9	compound
9	13	13	CD	_	6	dep
10	g/l	g/l	NN	_	2	dep
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	2	punct
13	while	while	IN	_	16	mark
14	drug1	drug1	NN	_	15	compound
15	requirement	requirement	NN	_	16	nsubj
16	decreased	decrease	VBD	_	2	advcl
17	from	from	IN	_	18	case
18	40	40	CD	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	20	20	CD	_	18	dep
21	;	;	:	_	20	punct
22	60	60	CD	_	20	dep
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	to	to	TO	_	25	dep
25	24	24	CD	_	18	nmod
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	19	19	CD	_	25	dep
28	;	;	:	_	27	punct
29	59	59	CD	_	27	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	g/week	g/week	NN	_	25	dep
32	,	,	,	_	16	punct
33	p	p	NN	_	34	nsubj
34	=	=	JJ	_	16	dep
35	0.02	0.02	CD	_	34	dobj
36	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	remainder	remainder	NN	_	21	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	dialysis-related	dialysis-related	JJ	_	6	amod
6	biochemistry	biochemistry	NN	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	electrolytes	electrolyte	NNS	_	6	dep
9	,	,	,	_	8	punct
10	calcium	calcium	NN	_	8	conj
11	,	,	,	_	8	punct
12	phosphate	phosphate	NN	_	8	conj
13	,	,	,	_	8	punct
14	iron	iron	NN	_	15	compound
15	status	status	NN	_	8	conj
16	-RRB-	-rrb-	-RRB-	_	8	punct
17	and	and	CC	_	6	cc
18	vitamin	vitamin	NN	_	20	compound
19	D	d	NN	_	20	compound
20	use	use	NN	_	6	conj
21	remained	remain	VBD	_	0	ROOT
22	unchanged	unchanged	JJ	_	21	xcomp
23	.	.	.	_	21	punct

1	A	a	DT	_	2	det
2	reduction	reduction	NN	_	12	nsubjpass
3	in	in	IN	_	5	case
4	PTH	pth	NN	_	5	compound
5	level	level	NN	_	2	nmod
6	of	of	IN	_	10	case
7	greater	greater	JJR	_	9	advmod
8	than	than	IN	_	9	advmod
9	30	30	CD	_	10	nummod
10	%	%	NN	_	5	nmod
11	was	be	VBD	_	12	auxpass
12	experienced	experience	VBN	_	0	ROOT
13	by	by	IN	_	15	case
14	82.5	82.5	CD	_	15	nummod
15	%	%	NN	_	12	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	33/40	33/40	CD	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	of	of	IN	_	21	case
20	our	we	PRP$	_	21	nmod:poss
21	cohort	cohort	NN	_	15	nmod
22	.	.	.	_	12	punct

1	Among	among	IN	_	3	case
2	the	the	DT	_	3	det
3	responders	responder	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	the	the	DT	_	6	det
6	fall	fall	NN	_	14	nsubj
7	in	in	IN	_	8	case
8	PTH	pth	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	reduction	reduction	NN	_	12	compound
11	drug1	drug1	NN	_	12	compound
12	requirement	requirement	NN	_	8	conj
13	were	be	VBD	_	14	cop
14	related	related	JJ	_	0	ROOT
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	R	r	NN	_	17	nsubj
17	=	=	JJ	_	14	dep
18	-0.48	-0.48	CD	_	17	dobj
19	,	,	,	_	17	punct
20	p	p	NN	_	21	nsubj
21	=	=	JJ	_	17	parataxis
22	0.004	0.004	CD	_	21	dobj
23	-RRB-	-rrb-	-RRB-	_	17	punct
24	.	.	.	_	14	punct

1	Reduction	reduction	NN	_	7	nsubjpass
2	of	of	IN	_	3	case
3	PTH	pth	NN	_	1	nmod
4	by	by	IN	_	5	case
5	drug1	drug1	NN	_	1	nmod
6	is	be	VBZ	_	7	auxpass
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	a	a	DT	_	10	det
10	decrease	decrease	NN	_	7	nmod
11	in	in	IN	_	13	case
12	drug2	drug2	NN	_	13	compound
13	requirement	requirement	NN	_	10	nmod
14	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	interface	interface	NN	_	10	nsubj
3	between	between	IN	_	4	case
4	bone	bone	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	bone	bone	NN	_	7	compound
7	marrow	marrow	NN	_	4	conj
8	in	in	IN	_	9	case
9	uremia	uremia	NN	_	2	nmod
10	represents	represent	VBZ	_	0	ROOT
11	a	a	DT	_	13	det
12	critical	critical	JJ	_	13	amod
13	step	step	NN	_	10	dobj
14	in	in	IN	_	18	case
15	red	red	JJ	_	18	amod
16	blood	blood	NN	_	18	compound
17	cell	cell	NN	_	18	compound
18	production	production	NN	_	13	nmod
19	which	which	WDT	_	20	det
20	merits	merit	NNS	_	22	nsubj
21	further	further	RB	_	22	advmod
22	investigation	investigation	NN	_	13	acl:relcl
23	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	9	case
8	5	5	CD	_	9	nummod
9	milligrams	milligram	NNS	_	6	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	at	at	IN	_	15	case
15	doses	dose	NNS	_	6	nmod
16	less	less	JJR	_	18	advmod
17	than	than	IN	_	16	mwe
18	800	800	CD	_	19	nummod
19	milligrams	milligram	NNS	_	15	dep
20	in	in	IN	_	22	case
21	nonpregnant	nonpregnant	JJ	_	22	amod
22	women	woman	NNS	_	19	nmod
23	.	.	.	_	4	punct

1	drug1	drug1	NN	_	6	nsubj
2	is	be	VBZ	_	6	cop
3	the	the	DT	_	6	det
4	only	only	RB	_	5	advmod
5	known	known	JJ	_	6	amod
6	component	component	NN	_	0	ROOT
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	diet	diet	NN	_	6	nmod
10	that	that	WDT	_	12	nsubj
11	may	may	MD	_	12	aux
12	affect	affect	VB	_	6	acl:relcl
13	absorption	absorption	NN	_	12	dobj
14	of	of	IN	_	16	case
15	both	both	CC	_	16	cc:preconj
16	drug2	drug2	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	.	.	.	_	6	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	4	det
4	evidence	evidence	NN	_	2	root
5	for	for	IN	_	8	case
6	a	a	DT	_	8	det
7	drug1	drug1	NN	_	8	compound
8	effect	effect	NN	_	4	nmod
9	on	on	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	absorption	absorption	NN	_	8	nmod
12	mainly	mainly	RB	_	13	advmod
13	comes	come	VBZ	_	8	acl
14	from	from	IN	_	15	case
15	studies	study	NNS	_	13	nmod
16	that	that	WDT	_	19	nsubj
17	did	do	VBD	_	19	aux
18	not	not	RB	_	19	neg
19	isolate	isolate	VB	_	15	acl:relcl
20	the	the	DT	_	21	det
21	effect	effect	NN	_	19	dobj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	from	from	IN	_	25	case
25	that	that	DT	_	19	nmod
26	of	of	IN	_	29	case
27	other	other	JJ	_	29	amod
28	dietary	dietary	JJ	_	29	amod
29	components	component	NNS	_	25	nmod
30	,	,	,	_	4	punct
31	because	because	IN	_	34	mark
32	it	it	PRP	_	34	nsubjpass
33	was	be	VBD	_	34	auxpass
34	detected	detect	VBN	_	30	root
35	in	in	IN	_	37	case
36	single-meal	single-meal	JJ	_	37	amod
37	studies	study	NNS	_	34	nmod
38	.	.	.	_	34	punct

1	Our	we	PRP$	_	2	nmod:poss
2	objective	objective	NN	_	3	nsubj
3	was	be	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	establish	establish	VB	_	3	xcomp
6	potential	potential	JJ	_	7	amod
7	effects	effect	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	on	on	IN	_	11	case
11	absorption	absorption	NN	_	7	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	and	and	CC	_	11	cc
17	the	the	DT	_	19	det
18	dose	dose	NN	_	19	compound
19	response	response	NN	_	11	conj
20	for	for	IN	_	22	case
21	this	this	DT	_	22	det
22	effect	effect	NN	_	19	nmod
23	in	in	IN	_	25	case
24	the	the	DT	_	25	det
25	absence	absence	NN	_	22	nmod
26	of	of	IN	_	28	case
27	a	a	DT	_	28	det
28	meal	meal	NN	_	25	nmod
29	.	.	.	_	3	punct

1	Fifty-four	fifty-four	CD	_	7	dep
2	healthy	healthy	JJ	_	7	dep
3	,	,	,	_	7	punct
4	nonpregnant	nonpregnant	JJ	_	5	amod
5	women	woman	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	selected	select	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	participate	participate	VB	_	7	xcomp
10	in	in	IN	_	14	case
11	4	4	CD	_	14	nummod
12	drug1	drug1	NN	_	14	compound
13	absorption	absorption	NN	_	14	compound
14	studies	study	NNS	_	9	nmod
15	using	use	VBG	_	14	acl
16	iron	iron	NN	_	18	compound
17	radioactive	radioactive	JJ	_	18	amod
18	tracers	tracer	NNS	_	15	dobj
19	.	.	.	_	7	punct

1	We	we	PRP	_	2	nsubj
2	evaluated	evaluate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	dobj
5	of	of	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	doses	dose	NNS	_	4	nmod
8	between	between	IN	_	12	case
9	200	200	CD	_	12	nummod
10	and	and	CC	_	9	cc
11	1500	1500	CD	_	9	conj
12	mg	mg	NN	_	4	nmod
13	on	on	IN	_	14	case
14	absorption	absorption	NN	_	4	nmod
15	of	of	IN	_	18	case
16	5	5	CD	_	18	nummod
17	mg	mg	NN	_	18	compound
18	drug2	drug2	NN	_	14	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	as	as	IN	_	21	case
21	drug3	drug3	NN	_	14	nmod
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	.	.	.	_	2	punct

1	We	we	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	evaluated	evaluate	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	doses	dose	NNS	_	5	nmod
9	between	between	IN	_	13	case
10	200	200	CD	_	13	nummod
11	and	and	CC	_	10	cc
12	800	800	CD	_	10	conj
13	mg	mg	NN	_	5	nmod
14	on	on	IN	_	15	case
15	absorption	absorption	NN	_	5	nmod
16	of	of	IN	_	19	case
17	5	5	CD	_	19	nummod
18	mg	mg	NN	_	19	compound
19	drug2	drug2	NN	_	15	nmod
20	-LSB-	-lsb-	-LRB-	_	23	punct
21	as	as	IN	_	23	case
22	concentrated	concentrated	JJ	_	23	amod
23	RBC	rbc	NNS	_	5	nmod
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	CRBC	crbc	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	-RSB-	-rsb-	-RRB-	_	23	punct
28	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	administered	administer	VBN	_	12	csubjpass
4	as	as	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	in	in	IN	_	8	case
7	all	all	DT	_	8	det
8	studies	study	NNS	_	3	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	were	be	VBD	_	12	auxpass
12	ingested	ingest	VBN	_	0	ROOT
13	on	on	IN	_	16	case
14	an	a	DT	_	16	det
15	empty	empty	JJ	_	16	amod
16	stomach	stomach	NN	_	12	nmod
17	.	.	.	_	12	punct

1	drug1	drug1	NN	_	2	compound
2	doses	dose	NNS	_	5	nsubj
3	1000	1000	CD	_	4	nummod
4	mg	mg	NN	_	2	dep
5	diminished	diminish	VBD	_	0	ROOT
6	drug2	drug2	NN	_	7	compound
7	absorption	absorption	NN	_	5	dobj
8	by	by	IN	_	10	case
9	an	a	DT	_	10	det
10	average	average	NN	_	5	nmod
11	of	of	IN	_	13	case
12	49.6	49.6	CD	_	13	nummod
13	%	%	NN	_	10	nmod
14	.	.	.	_	5	punct

1	A	a	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	dose	dose	NN	_	7	nsubj
4	of	of	IN	_	6	case
5	800	800	CD	_	6	nummod
6	mg	mg	NN	_	3	nmod
7	diminished	diminish	VBD	_	0	ROOT
8	absorption	absorption	NN	_	7	dobj
9	of	of	IN	_	12	case
10	5	5	CD	_	11	compound
11	mg	mg	NN	_	12	amod
12	drug2	drug2	NN	_	8	nmod
13	by	by	IN	_	15	case
14	37.7	37.7	CD	_	15	nummod
15	%	%	NN	_	7	nmod
16	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	conclusion	conclusion	NN	_	5	nmod
3	,	,	,	_	5	punct
4	we	we	PRP	_	5	nsubj
5	demonstrated	demonstrate	VBD	_	0	ROOT
6	an	a	DT	_	8	det
7	isolated	isolate	VBN	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	as	as	IN	_	13	case
13	chloride	chloride	NN	_	8	nmod
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	on	on	IN	_	16	case
16	absorption	absorption	NN	_	8	nmod
17	of	of	IN	_	19	case
18	5	5	CD	_	19	nummod
19	mg	mg	NN	_	16	nmod
20	of	of	IN	_	21	case
21	iron	iron	NN	_	19	nmod
22	provided	provide	VBN	_	8	acl
23	as	as	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	as	as	IN	_	27	case
27	sulfate	sulfate	NN	_	24	nmod
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	and	and	CC	_	24	cc
30	drug3	drug3	NN	_	35	compound
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	as	as	IN	_	33	case
33	CRBC	crbc	NN	_	35	dep
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	drug3	drug3	NN	_	24	conj
36	.	.	.	_	5	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	at	at	IN	_	6	case
6	doses	dose	NNS	_	4	nmod
7	higher	higher	JJR	_	6	amod
8	than	than	IN	_	10	mark
9	previously	previously	RB	_	10	advmod
10	reported	report	VBN	_	7	advcl
11	from	from	IN	_	13	case
12	single-meal	single-meal	JJ	_	13	amod
13	studies	study	NNS	_	10	nmod
14	,	,	,	_	4	punct
15	starting	start	VBG	_	4	xcomp
16	at	at	IN	_	19	case
17	~	~	CD	_	18	compound
18	800	800	CD	_	19	nummod
19	mg	mg	NN	_	15	nmod
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	.	.	.	_	4	punct

1	Synergistic	synergistic	JJ	_	2	amod
2	interaction	interaction	NN	_	9	nsubj
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	9	cop
8	sequence	sequence	NN	_	9	nmod:npmod
9	dependent	dependent	JJ	_	0	ROOT
10	in	in	IN	_	14	case
11	human	human	JJ	_	14	amod
12	non-small	non-small	JJ	_	14	amod
13	lung	lung	NN	_	14	compound
14	cancer	cancer	NN	_	9	nmod
15	with	with	IN	_	18	case
16	EGFR	egfr	NN	_	18	compound
17	TKIs-resistant	tkis-resistant	JJ	_	18	amod
18	mutation	mutation	NN	_	14	nmod
19	.	.	.	_	9	punct

1	Previous	previous	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	that	that	IN	_	7	mark
6	drug1	drug1	NN	_	7	nsubj
7	has	have	VBZ	_	4	ccomp
8	the	the	DT	_	10	det
9	anti-tumor	anti-tumor	JJ	_	10	amod
10	activity	activity	NN	_	7	dobj
11	in	in	IN	_	16	case
12	human	human	JJ	_	16	amod
13	non-small	non-small	JJ	_	16	amod
14	cell	cell	NN	_	16	compound
15	lung	lung	NN	_	16	compound
16	cancer	cancer	NN	_	10	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	NSCLC	nsclc	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	aimed	aim	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	investigate	investigate	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	efficacy	efficacy	NN	_	6	dobj
9	of	of	IN	_	11	case
10	single	single	JJ	_	11	amod
11	use	use	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	4	cc
15	that	that	IN	_	4	conj
16	of	of	IN	_	20	case
17	concurrent	concurrent	JJ	_	20	amod
18	or	or	CC	_	17	cc
19	sequential	sequential	JJ	_	17	conj
20	administration	administration	NN	_	15	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	in	in	IN	_	28	case
26	NSCLC	nsclc	NN	_	28	compound
27	cell	cell	NN	_	28	compound
28	lines	line	NNS	_	20	nmod
29	that	that	WDT	_	31	nsubj
30	are	be	VBP	_	31	cop
31	resistant	resistant	JJ	_	28	acl:relcl
32	to	to	TO	_	34	case
33	EGFR	egfr	NN	_	34	compound
34	TKIs	tki	NNS	_	31	nmod
35	.	.	.	_	4	punct

1	NSCLC	nsclc	NN	_	3	compound
2	cell	cell	NN	_	3	compound
3	lines	line	NNS	_	12	nsubjpass
4	with	with	IN	_	7	case
5	EGFR	egfr	NN	_	7	compound
6	T790M	t790m	NN	_	7	compound
7	mutation	mutation	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	K-ras	k-ras	NN	_	10	compound
10	mutation	mutation	NN	_	7	conj
11	were	be	VBD	_	12	auxpass
12	exposed	expose	VBN	_	0	ROOT
13	to	to	TO	_	15	case
14	either	either	CC	_	15	cc:preconj
15	drug1	drug1	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	or	or	CC	_	15	cc
19	both	both	DT	_	15	conj
20	based	base	VBN	_	24	case
21	on	on	IN	_	24	case
22	various	various	JJ	_	24	amod
23	sequential	sequential	JJ	_	24	amod
24	administrations	administration	NNS	_	19	nmod
25	.	.	.	_	12	punct

1	After	after	IN	_	2	case
2	exposure	exposure	NN	_	8	nmod
3	,	,	,	_	8	punct
4	the	the	DT	_	6	det
5	cell	cell	NN	_	6	compound
6	viability	viability	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	measured	measure	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	MTT	MTT	NNP	_	11	compound
11	assay	assay	NN	_	8	nmod
12	,	,	,	_	11	punct
13	cell	cell	NN	_	15	compound
14	cycle	cycle	NN	_	15	compound
15	distribution	distribution	NN	_	11	appos
16	was	be	VBD	_	17	auxpass
17	analyzed	analyze	VBN	_	28	csubjpass
18	by	by	IN	_	20	case
19	flow	flow	NN	_	20	compound
20	cytometry	cytometry	NN	_	17	nmod
21	,	,	,	_	20	punct
22	and	and	CC	_	20	cc
23	alterations	alteration	NNS	_	20	conj
24	in	in	IN	_	26	case
25	signaling	signaling	NN	_	26	compound
26	pathway	pathway	NN	_	20	nmod
27	were	be	VBD	_	28	auxpass
28	determined	determine	VBN	_	8	ccomp
29	by	by	IN	_	30	case
30	immunoblotting	immunoblotting	NN	_	28	nmod
31	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	exhibited	exhibit	VBD	_	0	ROOT
3	dose-dependent	dose-dependent	JJ	_	5	amod
4	growth	growth	NN	_	5	compound
5	inhibition	inhibition	NN	_	2	dobj
6	in	in	IN	_	9	case
7	NSCLC	nsclc	NN	_	9	compound
8	cell	cell	NN	_	9	compound
9	lines	line	NNS	_	5	nmod
10	and	and	CC	_	2	cc
11	arrested	arrest	VBN	_	13	amod
12	cell	cell	NN	_	13	compound
13	cycle	cycle	NN	_	2	conj
14	at	at	IN	_	16	case
15	G1	g1	NN	_	16	compound
16	phase	phase	NN	_	13	nmod
17	,	,	,	_	2	punct
18	whereas	whereas	IN	_	2	dep
19	drug2	drug2	NN	_	2	dep
20	arrested	arrest	VBN	_	19	acl
21	at	at	IN	_	23	case
22	S	s	NN	_	23	compound
23	phase	phase	NN	_	20	nmod
24	.	.	.	_	2	punct

1	Although	although	IN	_	10	mark
2	single	single	JJ	_	5	amod
3	or	or	CC	_	2	cc
4	concurrent	concurrent	JJ	_	2	conj
5	use	use	NN	_	10	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	has	have	VBZ	_	22	advcl
11	some	some	DT	_	13	det
12	anti-proliferative	anti-proliferative	JJ	_	13	amod
13	effects	effect	NNS	_	10	dobj
14	,	,	,	_	22	punct
15	the	the	DT	_	17	det
16	sequential	sequential	JJ	_	17	amod
17	administrations	administration	NNS	_	22	nsubj
18	of	of	IN	_	20	case
19	both	both	DT	_	20	det
20	drugs	drug	NNS	_	17	nmod
21	remarkably	remarkably	RB	_	22	advmod
22	enhanced	enhance	VBD	_	0	ROOT
23	anti-tumor	anti-tumor	JJ	_	24	amod
24	activity	activity	NN	_	22	dobj
25	.	.	.	_	22	punct

1	When	when	WRB	_	4	advmod
2	cells	cell	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	exposed	expose	VBN	_	13	advcl
5	to	to	TO	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	followed	follow	VBN	_	4	dep
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	13	punct
11	synergism	synergism	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	The	the	DT	_	3	det
2	molecular	molecular	JJ	_	3	amod
3	basis	basis	NN	_	7	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	synergism	synergism	NN	_	3	nmod
7	is	be	VBZ	_	0	ROOT
8	that	that	IN	_	21	mark
9	the	the	DT	_	11	det
10	signaling	signaling	NN	_	11	compound
11	pathways	pathway	NNS	_	21	nsubjpass
12	that	that	WDT	_	15	nsubjpass
13	were	be	VBD	_	15	auxpass
14	initially	initially	RB	_	15	advmod
15	activated	activate	VBN	_	11	acl:relcl
16	by	by	IN	_	18	case
17	drug1	drug1	NN	_	18	compound
18	exposure	exposure	NN	_	15	nmod
19	were	be	VBD	_	21	auxpass
20	efficiently	efficiently	RB	_	21	advmod
21	suppressed	suppress	VBN	_	7	ccomp
22	by	by	IN	_	25	case
23	the	the	DT	_	25	det
24	subsequent	subsequent	JJ	_	25	amod
25	exposure	exposure	NN	_	21	nmod
26	to	to	TO	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	10	nmod
3	,	,	,	_	10	punct
4	the	the	DT	_	5	det
5	reverse	reverse	NN	_	10	nsubj
6	of	of	IN	_	9	case
7	this	this	DT	_	9	det
8	sequential	sequential	JJ	_	9	amod
9	administration	administration	NN	_	5	nmod
10	resulted	result	VBD	_	0	ROOT
11	in	in	IN	_	12	case
12	antagonism	antagonism	NN	_	10	nmod
13	,	,	,	_	12	punct
14	which	which	WDT	_	20	nsubj
15	may	may	MD	_	20	aux
16	be	be	VB	_	20	cop
17	due	due	JJ	_	20	case
18	to	to	TO	_	17	mwe
19	differential	differential	JJ	_	20	amod
20	effects	effect	NNS	_	12	acl:relcl
21	on	on	IN	_	24	case
22	cell	cell	NN	_	24	compound
23	cycle	cycle	NN	_	24	compound
24	arrest	arrest	NN	_	20	nmod
25	.	.	.	_	10	punct

1	drug1	drug1	NN	_	6	nsubj
2	as	as	IN	_	5	case
3	a	a	DT	_	5	det
4	single	single	JJ	_	5	amod
5	agent	agent	NN	_	1	nmod
6	exhibits	exhibit	VBZ	_	0	ROOT
7	anti-proliferative	anti-proliferative	JJ	_	8	amod
8	effects	effect	NNS	_	6	dobj
9	in	in	FW	_	10	compound
10	vitro	vitro	FW	_	6	advmod
11	in	in	IN	_	14	case
12	NSCLC	nsclc	NN	_	14	compound
13	cell	cell	NN	_	14	compound
14	lines	line	NNS	_	6	nmod
15	with	with	IN	_	17	case
16	EGFR	egfr	NN	_	17	compound
17	T790M	t790m	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	K-ras	k-ras	NN	_	20	compound
20	mutations	mutation	NNS	_	17	conj
21	but	but	CC	_	6	cc
22	the	the	DT	_	24	det
23	sequential	sequential	JJ	_	24	amod
24	administration	administration	NN	_	31	nsubj
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	followed	follow	VBN	_	24	acl
28	by	by	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	is	be	VBZ	_	31	cop
31	superior	superior	JJ	_	6	conj
32	to	to	TO	_	33	case
33	drug4	drug4	NN	_	31	nmod
34	followed	follow	VBN	_	33	acl
35	by	by	IN	_	36	case
36	drug5	drug5	NN	_	34	nmod
37	and	and	CC	_	36	cc
38	concurrent	concurrent	JJ	_	39	amod
39	administration	administration	NN	_	36	conj
40	.	.	.	_	6	punct

1	Determinants	determinant	NNS	_	6	nsubj
2	of	of	IN	_	3	case
3	sensitivity	sensitivity	NN	_	1	nmod
4	to	to	TO	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	induced	induce	VBD	_	0	ROOT
7	apoptosis	apoptosis	NN	_	6	dobj
8	in	in	IN	_	11	case
9	multiple	multiple	JJ	_	11	amod
10	myeloma	myeloma	NN	_	11	compound
11	cells	cell	NNS	_	6	nmod
12	.	.	.	_	6	punct

1	The	the	DT	_	0	ROOT
2	drug1	drug1	NN	_	17	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	,	,	,	_	2	punct
7	one	one	CD	_	2	appos
8	of	of	IN	_	9	case
9	S-adenosylhomocysteine	s-adenosylhomocysteine	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	AdoHcy	adohcy	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	hydrolase	hydrolase	NN	_	14	compound
14	inhibitors	inhibitor	NNS	_	9	dep
15	,	,	,	_	2	punct
16	has	have	VBZ	_	17	aux
17	shown	show	VBN	_	1	acl:relcl
18	antitumor	antitumor	NN	_	19	compound
19	activities	activity	NNS	_	17	dobj
20	in	in	IN	_	23	case
21	a	a	DT	_	23	det
22	broad	broad	JJ	_	23	amod
23	range	range	NN	_	17	nmod
24	of	of	IN	_	26	case
25	solid	solid	JJ	_	26	amod
26	tumors	tumor	NNS	_	23	nmod
27	and	and	CC	_	26	cc
28	acute	acute	JJ	_	30	amod
29	myeloid	myeloid	JJ	_	30	amod
30	leukemia	leukemia	NN	_	26	conj
31	.	.	.	_	1	punct

1	Here	here	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	examined	examine	VBD	_	0	ROOT
5	its	its	PRP$	_	6	nmod:poss
6	effects	effect	NNS	_	4	dobj
7	on	on	IN	_	13	case
8	multiple	multiple	JJ	_	9	amod
9	myeloma	myeloma	NN	_	13	compound
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	MM	mm	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	cells	cell	NNS	_	6	nmod
14	and	and	CC	_	4	cc
15	found	find	VBD	_	4	conj
16	that	that	IN	_	24	mark
17	,	,	,	_	24	punct
18	at	at	IN	_	20	case
19	500	500	CD	_	20	nummod
20	nM	nm	NN	_	24	nmod
21	,	,	,	_	24	punct
22	it	it	PRP	_	24	nsubj
23	potently	potently	RB	_	24	advmod
24	inhibited	inhibit	VBD	_	15	ccomp
25	growth	growth	NN	_	24	dobj
26	and	and	CC	_	24	cc
27	induced	induce	VBD	_	24	conj
28	apoptosis	apoptosis	NN	_	27	dobj
29	in	in	IN	_	27	nmod
30	2	2	CD	_	29	dep
31	of	of	IN	_	35	case
32	8	8	CD	_	35	nummod
33	MM	mm	NN	_	35	compound
34	cell	cell	NN	_	35	compound
35	lines	line	NNS	_	30	nmod
36	.	.	.	_	4	punct

1	RNA	rna	NN	_	9	nsubjpass
2	from	from	IN	_	7	case
3	un-treated	un-treated	JJ	_	7	amod
4	and	and	CC	_	3	cc
5	drug1	drug1	NN	_	3	conj
6	treated	treated	JJ	_	7	amod
7	cells	cell	NNS	_	1	nmod
8	was	be	VBD	_	9	auxpass
9	profiled	profile	VBN	_	26	csubjpass
10	by	by	IN	_	13	case
11	Affymetrix	Affymetrix	NNP	_	13	compound
12	HG-U133	HG-U133	NNP	_	13	compound
13	Plus	Plus	NNP	_	9	nmod
14	2.0	2.0	CD	_	15	nummod
15	microarray	microarray	NN	_	13	dep
16	and	and	CC	_	15	cc
17	genes	gene	NNS	_	15	conj
18	with	with	IN	_	21	case
19	a	a	DT	_	21	det
20	significant	significant	JJ	_	21	amod
21	change	change	NN	_	9	nmod
22	in	in	IN	_	24	case
23	gene	gene	NN	_	24	compound
24	expression	expression	NN	_	21	nmod
25	were	be	VBD	_	26	auxpass
26	determined	determine	VBN	_	0	ROOT
27	by	by	IN	_	29	case
28	significance	significance	NN	_	29	compound
29	analysis	analysis	NN	_	26	nmod
30	of	of	IN	_	31	case
31	microarray	microarray	NN	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	SAM	sam	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	testing	testing	NN	_	31	dep
36	.	.	.	_	26	punct

1	ALOX5	alox5	NN	_	6	nsubj
2	was	be	VBD	_	6	cop
3	the	the	DT	_	6	det
4	most	most	RBS	_	5	advmod
5	down-regulated	down-regulate	VBN	_	6	amod
6	gene	gene	NN	_	0	ROOT
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	5.8-fold	5.8-fold	JJ	_	6	dep
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	in	in	IN	_	12	case
11	sensitive	sensitive	JJ	_	12	amod
12	cells	cell	NNS	_	6	nmod
13	and	and	CC	_	6	cc
14	was	be	VBD	_	15	auxpass
15	expressed	express	VBN	_	6	conj
16	at	at	IN	_	18	case
17	low	low	JJ	_	18	amod
18	level	level	NN	_	15	nmod
19	in	in	IN	_	21	case
20	resistant	resistant	JJ	_	21	amod
21	cells	cell	NNS	_	15	nmod
22	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	corroborated	corroborate	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	quantitative	quantitative	JJ	_	7	amod
7	RT-PCR	rt-pcr	NN	_	4	nmod
8	.	.	.	_	4	punct

1	Western-blot	western-blot	JJ	_	2	amod
2	analysis	analysis	NN	_	3	nsubj
3	indicated	indicate	VBD	_	0	ROOT
4	ALOX5	alox5	NN	_	7	nsubjpass
5	was	be	VBD	_	7	auxpass
6	highly	highly	RB	_	7	advmod
7	expressed	express	VBN	_	3	ccomp
8	only	only	RB	_	13	advmod
9	in	in	IN	_	13	case
10	sensitive	sensitive	JJ	_	13	amod
11	cell	cell	NN	_	13	compound
12	line	line	NN	_	13	compound
13	H929	h929	NN	_	7	nmod
14	and	and	CC	_	13	cc
15	greatly	greatly	RB	_	16	advmod
16	decreased	decrease	VBN	_	13	conj
17	upon	upon	IN	_	19	case
18	drug1	drug1	NN	_	19	compound
19	treatment	treatment	NN	_	16	nmod
20	.	.	.	_	3	punct

1	Ectopic	ectopic	JJ	_	2	amod
2	expression	expression	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	ALOX5	alox5	NN	_	2	nmod
5	reduced	reduce	VBD	_	0	ROOT
6	sensitivity	sensitivity	NN	_	5	dobj
7	to	to	TO	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	in	in	IN	_	11	case
10	H929	h929	NN	_	11	compound
11	cells	cell	NNS	_	6	nmod
12	.	.	.	_	5	punct

1	Furthermore	furthermore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	down-regulation	down-regulation	NN	_	11	nsubj
4	of	of	IN	_	5	case
5	ALOX5	alox5	NN	_	3	nmod
6	by	by	IN	_	8	case
7	RNA	rna	NN	_	8	compound
8	interference	interference	NN	_	3	nmod
9	could	could	MD	_	11	aux
10	also	also	RB	_	11	advmod
11	induce	induce	VB	_	0	ROOT
12	apoptosis	apoptosis	NN	_	11	dobj
13	in	in	IN	_	14	case
14	H929	h929	NN	_	11	nmod
15	.	.	.	_	11	punct

1	Gene	gene	NN	_	3	compound
2	expression	expression	NN	_	3	compound
3	analysis	analysis	NN	_	8	nsubj
4	on	on	IN	_	7	case
5	MM	mm	NN	_	7	compound
6	patient	patient	NN	_	7	compound
7	dataset	dataset	NN	_	3	nmod
8	indicated	indicate	VBD	_	0	ROOT
9	ALOX5	alox5	NN	_	10	compound
10	expression	expression	NN	_	13	nsubj
11	was	be	VBD	_	13	cop
12	significantly	significantly	RB	_	13	advmod
13	higher	higher	JJR	_	8	ccomp
14	in	in	IN	_	16	case
15	MM	mm	NN	_	16	compound
16	patients	patient	NNS	_	13	nmod
17	compared	compare	VBN	_	21	case
18	to	to	TO	_	21	case
19	normal	normal	JJ	_	21	amod
20	plasma	plasma	NN	_	21	compound
21	cells	cell	NNS	_	13	advcl
22	.	.	.	_	8	punct

1	We	we	PRP	_	3	nsubj
2	also	also	RB	_	3	advmod
3	found	find	VBD	_	0	ROOT
4	that	that	IN	_	7	mark
5	Bcl-2	bcl-2	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	overexpressed	overexpress	VBN	_	3	ccomp
8	in	in	IN	_	11	case
9	drug1	drug1	NN	_	11	compound
10	insensitive	insensitive	JJ	_	11	amod
11	cells	cell	NNS	_	7	nmod
12	,	,	,	_	7	punct
13	and	and	CC	_	7	cc
14	cotreatment	cotreatment	NN	_	26	nsubj
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	a	a	DT	_	23	det
21	Bcl-2	bcl-2	NN	_	23	compound
22	family	family	NN	_	23	compound
23	inhibitor	inhibitor	NN	_	16	appos
24	,	,	,	_	16	punct
25	synergistically	synergistically	RB	_	26	advmod
26	inhibited	inhibit	VBD	_	7	conj
27	growth	growth	NN	_	26	dobj
28	and	and	CC	_	26	cc
29	induced	induce	VBD	_	26	conj
30	apoptosis	apoptosis	NN	_	29	dobj
31	of	of	IN	_	35	case
32	drug4	drug4	NN	_	35	compound
33	insensitive	insensitive	JJ	_	35	amod
34	MM	mm	NN	_	35	compound
35	cells	cell	NNS	_	30	nmod
36	.	.	.	_	3	punct

1	Taken	take	VBN	_	6	advcl
2	together	together	RB	_	1	advmod
3	,	,	,	_	6	punct
4	this	this	DT	_	5	det
5	study	study	NN	_	6	nsubj
6	shows	show	VBZ	_	0	ROOT
7	one	one	CD	_	16	nsubj
8	of	of	IN	_	9	case
9	mechanisms	mechanism	NNS	_	7	nmod
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	drug1	drug1	NN	_	13	compound
13	efficacy	efficacy	NN	_	9	nmod
14	on	on	IN	_	15	case
15	MM	mm	NN	_	13	nmod
16	correlates	correlate	VBZ	_	6	ccomp
17	with	with	IN	_	19	case
18	its	its	PRP$	_	19	nmod:poss
19	ability	ability	NN	_	16	nmod
20	to	to	TO	_	21	mark
21	down-regulate	down-regulate	VB	_	19	acl
22	the	the	DT	_	24	det
23	ALOX5	alox5	NN	_	24	compound
24	levels	level	NNS	_	21	dobj
25	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	,	,	,	_	8	punct
4	drug1	drug1	NN	_	5	compound
5	insensitivity	insensitivity	NN	_	8	nsubjpass
6	might	might	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	overexpression	overexpression	NN	_	8	nmod
11	of	of	IN	_	12	case
12	Bcl-2	bcl-2	NN	_	10	nmod
13	,	,	,	_	8	punct
14	and	and	CC	_	8	cc
15	the	the	DT	_	16	det
16	combination	combination	NN	_	23	nsubj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug3	drug3	NN	_	18	conj
21	could	could	MD	_	23	aux
22	synergistically	synergistically	RB	_	23	advmod
23	induced	induce	VBN	_	8	conj
24	apoptosis	apoptosis	NN	_	23	dobj
25	.	.	.	_	8	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	drug1	drug1	NN	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	exploited	exploit	VBN	_	3	ccomp
9	therapeutically	therapeutically	RB	_	8	advmod
10	for	for	IN	_	12	case
11	a	a	DT	_	12	det
12	subset	subset	NN	_	8	nmod
13	of	of	IN	_	14	case
14	MM	mm	NN	_	12	nmod
15	.	.	.	_	3	punct

1	Drug	drug	NN	_	2	compound
2	interaction	interaction	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	8	case
6	infant	infant	NN	_	8	compound
7	colic	colic	JJ	_	8	amod
8	drops	drop	NNS	_	2	nmod
9	.	.	.	_	2	punct

1	drug1	drug1	NN	_	16	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	Forest	forest	NN	_	5	compound
4	Laboratories	Laboratories	NNPS	_	5	compound
5	UK	UK	NNP	_	1	dep
6	,	,	,	_	5	punct
7	Kent	Kent	NNP	_	5	appos
8	,	,	,	_	5	punct
9	UK	UK	NNP	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	5	punct
11	is	be	VBZ	_	16	cop
12	a	a	DT	_	16	det
13	widely	widely	RB	_	14	advmod
14	available	available	JJ	_	16	amod
15	over-the-counter	over-the-counter	JJ	_	16	amod
16	preparation	preparation	NN	_	0	ROOT
17	used	use	VBN	_	16	acl
18	to	to	TO	_	19	mark
19	relieve	relieve	VB	_	17	xcomp
20	colic	colic	JJ	_	21	amod
21	symptoms	symptom	NNS	_	19	dobj
22	in	in	IN	_	23	case
23	neonates	neonate	NNS	_	21	nmod
24	and	and	CC	_	23	cc
25	infants	infant	NNS	_	23	conj
26	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	active	active	JJ	_	3	amod
3	ingredient	ingredient	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	drug1	drug1	NN	_	0	ROOT
6	.	.	.	_	5	punct

1	No	no	DT	_	3	neg
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	7	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	are	be	VBP	_	7	auxpass
7	documented	document	VBN	_	0	ROOT
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	current	current	JJ	_	11	amod
11	summary	summary	NN	_	7	nmod
12	of	of	IN	_	14	case
13	product	product	NN	_	14	compound
14	characteristics	characteristic	NNS	_	11	nmod
15	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	authors	author	NNS	_	3	nsubj
3	report	report	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	case	case	NN	_	3	dobj
6	of	of	IN	_	8	case
7	an	a	DT	_	8	det
8	infant	infant	NN	_	5	nmod
9	with	with	IN	_	12	case
10	confirmed	confirm	VBN	_	12	amod
11	congenital	congenital	JJ	_	12	amod
12	hypothyroidism	hypothyroidism	NN	_	8	nmod
13	on	on	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	who	who	WP	_	16	nsubj
16	experienced	experience	VBD	_	8	acl:relcl
17	a	a	DT	_	20	det
18	possible	possible	JJ	_	20	amod
19	drug	drug	NN	_	20	compound
20	interaction	interaction	NN	_	16	dobj
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	3	punct

1	Despite	despite	IN	_	4	case
2	adequate	adequate	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	dosage	dosage	NN	_	13	nmod
5	,	,	,	_	13	punct
6	thyroid	thyroid	NN	_	8	compound
7	stimulating	stimulating	NN	_	8	compound
8	hormone	hormone	NN	_	13	nsubj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	TSH	tsh	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	was	be	VBD	_	13	cop
13	high	high	JJ	_	0	ROOT
14	,	,	,	_	13	punct
15	suggesting	suggest	VBG	_	13	xcomp
16	undertreatment	undertreatment	NN	_	15	dobj
17	.	.	.	_	13	punct

1	Questioning	question	VBG	_	2	nsubj
2	revealed	reveal	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	child	child	NN	_	6	nsubj
5	was	be	VBD	_	6	aux
6	taking	take	VBG	_	2	ccomp
7	drug1	drug1	NN	_	8	compound
8	drops	drop	NNS	_	6	dobj
9	before	before	IN	_	10	mark
10	feeds	feed	VBZ	_	6	advcl
11	while	while	IN	_	13	mark
12	on	on	IN	_	13	case
13	drug2	drug2	NN	_	10	advcl
14	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	colic	colic	JJ	_	3	amod
3	drops	drop	NNS	_	6	nsubjpass
4	were	be	VBD	_	6	auxpass
5	immediately	immediately	RB	_	6	advmod
6	discontinued	discontinue	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	TSH	tsh	NN	_	10	nsubj
9	promptly	promptly	RB	_	10	advmod
10	normalised	normalise	VBD	_	6	conj
11	with	with	IN	_	13	case
12	a	a	DT	_	13	det
13	reduction	reduction	NN	_	10	nmod
14	in	in	IN	_	16	case
15	thyroxine	thyroxine	NN	_	16	compound
16	requirement	requirement	NN	_	13	nmod
17	to	to	TO	_	21	case
18	an	a	DT	_	21	det
19	age	age	NN	_	21	compound
20	appropriate	appropriate	JJ	_	21	amod
21	dosage	dosage	NN	_	13	nmod
22	.	.	.	_	6	punct

1	Drug	drug	NN	_	2	compound
2	interaction	interaction	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	previously	previously	RB	_	10	advmod
12	and	and	CC	_	10	cc
13	is	be	VBZ	_	15	auxpass
14	not	not	RB	_	15	neg
15	listed	list	VBN	_	10	conj
16	in	in	IN	_	20	case
17	the	the	DT	_	20	det
18	British	British	NNP	_	20	compound
19	National	National	NNP	_	20	compound
20	Formulary	Formulary	NNP	_	15	nmod
21	for	for	IN	_	22	case
22	Children	Children	NNP	_	15	nmod
23	.	.	.	_	10	punct

1	Clinicians	clinician	NNS	_	4	nsubj
2	and	and	CC	_	1	cc
3	parents	parent	NNS	_	1	conj
4	need	need	VBP	_	0	ROOT
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	cop
7	aware	aware	JJ	_	4	xcomp
8	of	of	IN	_	10	case
9	this	this	DT	_	10	det
10	interaction	interaction	NN	_	7	nmod
11	to	to	TO	_	12	mark
12	avoid	avoid	VB	_	10	acl
13	unnecessary	unnecessary	JJ	_	14	amod
14	undertreatment	undertreatment	NN	_	12	dobj
15	and	and	CC	_	12	cc
16	prevent	prevent	VB	_	12	conj
17	potential	potential	JJ	_	20	amod
18	long-term	long-term	JJ	_	20	amod
19	neurological	neurological	JJ	_	20	amod
20	sequelae	sequelae	NN	_	16	dobj
21	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	compound
2	locomotor	locomotor	NN	_	3	compound
3	sensitization	sensitization	NN	_	0	ROOT
4	and	and	CC	_	3	cc
5	conditioned	condition	VBN	_	7	amod
6	place	place	NN	_	7	compound
7	preference	preference	NN	_	3	conj
8	in	in	IN	_	10	case
9	adolescent	adolescent	JJ	_	10	amod
10	male	male	NN	_	3	nmod
11	and	and	CC	_	10	cc
12	female	female	JJ	_	13	amod
13	rats	rat	NNS	_	10	conj
14	neonatally	neonatally	RB	_	15	advmod
15	treated	treat	VBN	_	10	acl
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	3	punct

1	Neonatal	neonatal	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	treatment	treatment	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	shown	show	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	produce	produce	VB	_	6	xcomp
9	an	a	DT	_	10	det
10	increase	increase	NN	_	8	dobj
11	in	in	IN	_	15	case
12	dopamine	dopamine	NN	_	15	compound
13	D2-like	d2-like	JJ	_	15	amod
14	receptor	receptor	NN	_	15	compound
15	sensitivity	sensitivity	NN	_	10	nmod
16	that	that	WDT	_	17	nsubj
17	persists	persist	VBZ	_	10	acl:relcl
18	throughout	throughout	IN	_	22	case
19	the	the	DT	_	20	det
20	subject	subject	NN	_	22	nmod:poss
21	's	's	POS	_	20	case
22	lifetime	lifetime	NN	_	17	nmod
23	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	objective	objective	NN	_	3	nsubj
3	was	be	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	analyze	analyze	VB	_	3	xcomp
6	the	the	DT	_	7	det
7	effects	effect	NNS	_	5	dobj
8	of	of	IN	_	11	case
9	neonatal	neonatal	JJ	_	11	amod
10	drug1	drug1	NN	_	11	compound
11	treatment	treatment	NN	_	7	nmod
12	on	on	IN	_	13	case
13	effects	effect	NNS	_	7	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	in	in	IN	_	18	case
17	adolescent	adolescent	JJ	_	18	amod
18	rats	rat	NNS	_	13	nmod
19	using	use	VBG	_	5	xcomp
20	locomotor	locomotor	JJ	_	21	amod
21	sensitization	sensitization	NN	_	19	dobj
22	and	and	CC	_	21	cc
23	conditioned	condition	VBN	_	26	amod
24	place	place	NN	_	26	compound
25	preference	preference	NN	_	26	compound
26	procedures	procedure	NNS	_	21	conj
27	.	.	.	_	3	punct

1	Sprague-Dawley	sprague-dawley	JJ	_	2	amod
2	rats	rat	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	treated	treat	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	1	1	CD	_	9	nummod
9	mg/kg	mg/kg	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	or	or	CC	_	6	cc
12	saline	saline	NN	_	6	conj
13	from	from	IN	_	15	case
14	postnatal	postnatal	JJ	_	15	amod
15	days	day	NNS	_	4	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	P	p	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	1	1	CD	_	15	nummod
20	to	to	TO	_	21	case
21	P11	p11	CD	_	19	nmod
22	and	and	CC	_	4	cc
23	raised	raise	VBD	_	4	conj
24	to	to	TO	_	25	case
25	adolescence	adolescence	NN	_	23	nmod
26	.	.	.	_	4	punct

1	For	for	IN	_	3	case
2	locomotor	locomotor	JJ	_	3	amod
3	sensitization	sensitization	NN	_	7	nmod
4	,	,	,	_	7	punct
5	subjects	subject	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	given	give	VBN	_	0	ROOT
8	drug1	drug1	NN	_	7	dobj
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	1	1	CD	_	11	nummod
11	mg/kg	mg/kg	NN	_	8	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	or	or	CC	_	8	cc
14	saline	saline	NN	_	8	conj
15	every	every	DT	_	17	det
16	second	second	JJ	_	17	amod
17	day	day	NN	_	7	nmod:tmod
18	from	from	IN	_	19	case
19	P35	p35	NN	_	7	nmod
20	to	to	TO	_	21	case
21	P47	p47	NN	_	19	nmod
22	and	and	CC	_	7	cc
23	were	be	VBD	_	24	auxpass
24	placed	place	VBN	_	7	conj
25	into	into	IN	_	28	case
26	a	a	DT	_	28	det
27	locomotor	locomotor	JJ	_	28	amod
28	arena	arena	NN	_	24	nmod
29	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	female	female	JJ	_	3	amod
3	rats	rat	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	neonatal	neonatal	JJ	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	treatment	treatment	NN	_	8	nsubj
8	enhanced	enhance	VBD	_	0	ROOT
9	drug2	drug2	NN	_	11	compound
10	locomotor	locomotor	NN	_	11	compound
11	sensitization	sensitization	NN	_	8	dobj
12	compared	compare	VBN	_	14	case
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	8	advcl
15	-	-	:	_	14	punct
16	free	free	JJ	_	17	amod
17	controls	control	NNS	_	14	dep
18	sensitized	sensitize	VBN	_	17	acl
19	to	to	TO	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	.	.	.	_	8	punct

1	Male	male	JJ	_	2	amod
2	rats	rat	NNS	_	3	nsubj
3	demonstrated	demonstrate	VBD	_	0	ROOT
4	sensitization	sensitization	NN	_	3	dobj
5	to	to	TO	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	3	punct
8	although	although	IN	_	11	mark
9	this	this	DT	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	muted	mute	VBN	_	3	advcl
12	compared	compare	VBN	_	15	case
13	with	with	IN	_	15	case
14	female	female	JJ	_	15	amod
15	rats	rat	NNS	_	11	advcl
16	,	,	,	_	3	punct
17	and	and	CC	_	3	cc
18	were	be	VBD	_	19	aux
19	unaffected	unaffected	JJ	_	3	conj
20	by	by	IN	_	22	case
21	neonatal	neonatal	JJ	_	22	amod
22	drug2	drug2	NN	_	19	nmod
23	.	.	.	_	3	punct

1	For	for	IN	_	4	case
2	conditioned	condition	VBN	_	4	amod
3	place	place	NN	_	4	compound
4	preference	preference	NN	_	8	nmod
5	,	,	,	_	8	punct
6	subjects	subject	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	conditioned	condition	VBN	_	0	ROOT
9	for	for	IN	_	12	case
10	8	8	CD	_	12	nummod
11	consecutive	consecutive	JJ	_	12	amod
12	days	day	NNS	_	8	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	P32-39	p32-39	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	with	with	IN	_	17	case
17	drug1	drug1	NN	_	12	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	1	1	CD	_	20	nummod
20	mg/kg	mg/kg	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	or	or	CC	_	17	cc
23	saline	saline	NN	_	17	conj
24	and	and	CC	_	23	cc
25	a	a	DT	_	28	det
26	drug-free	drug-free	JJ	_	28	amod
27	preference	preference	NN	_	28	compound
28	test	test	NN	_	23	conj
29	was	be	VBD	_	30	auxpass
30	conducted	conduct	VBN	_	8	dep
31	at	at	IN	_	32	case
32	P40	p40	NN	_	30	nmod
33	.	.	.	_	8	punct

1	Rats	rat	NNS	_	6	nsubj
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	5	case
4	neonatal	neonatal	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	enhanced	enhance	VBD	_	0	ROOT
7	time	time	NN	_	6	dobj
8	spent	spend	VBN	_	7	acl
9	in	in	IN	_	14	case
10	the	the	DT	_	14	det
11	drug2	drug2	NN	_	14	compound
12	-	-	:	_	14	punct
13	paired	paired	JJ	_	14	amod
14	context	context	NN	_	8	nmod
15	compared	compare	VBN	_	17	case
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	6	advcl
18	-	-	:	_	17	punct
19	free	free	JJ	_	20	amod
20	controls	control	NNS	_	17	dep
21	conditioned	condition	VBN	_	20	acl
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	,	,	,	_	6	punct
25	but	but	CC	_	6	cc
26	only	only	RB	_	28	advmod
27	female	female	JJ	_	28	amod
28	controls	control	NNS	_	32	nsubj
29	conditioned	condition	VBN	_	28	acl
30	with	with	IN	_	31	case
31	drug5	drug5	NN	_	29	nmod
32	spent	spend	VBD	_	6	conj
33	more	more	JJR	_	34	amod
34	time	time	NN	_	32	dobj
35	in	in	IN	_	38	case
36	the	the	DT	_	38	det
37	drug-paired	drug-paired	JJ	_	38	amod
38	context	context	NN	_	32	nmod
39	compared	compare	VBN	_	42	case
40	with	with	IN	_	42	case
41	saline-treated	saline-treated	JJ	_	42	amod
42	controls	control	NNS	_	32	advcl
43	.	.	.	_	6	punct

1	Increased	increase	VBN	_	2	amod
2	D	d	NN	_	7	nsubj
3	-	-	:	_	2	punct
4	like	like	IN	_	6	case
5	receptor	receptor	NN	_	6	compound
6	sensitivity	sensitivity	NN	_	2	nmod
7	appears	appear	VBZ	_	0	ROOT
8	to	to	TO	_	10	mark
9	have	have	VB	_	10	aux
10	enhanced	enhance	VBN	_	7	xcomp
11	the	the	DT	_	13	det
12	behavioral	behavioral	JJ	_	13	amod
13	effects	effect	NNS	_	10	dobj
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	,	,	,	_	7	punct
17	but	but	CC	_	7	cc
18	these	these	DT	_	19	det
19	effects	effect	NNS	_	22	nsubj
20	were	be	VBD	_	22	cop
21	more	more	RBR	_	22	advmod
22	prevalent	prevalent	JJ	_	7	conj
23	in	in	IN	_	26	case
24	adolescent	adolescent	JJ	_	26	amod
25	female	female	JJ	_	26	amod
26	rats	rat	NNS	_	22	nmod
27	compared	compare	VBN	_	30	case
28	with	with	IN	_	30	case
29	male	male	JJ	_	30	amod
30	rats	rat	NNS	_	22	advcl
31	.	.	.	_	7	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-	-	:	_	1	punct
5	mediated	mediate	VBN	_	7	amod
6	CYP3A4	cyp3a4	NN	_	7	compound
7	inhibition	inhibition	NN	_	1	dep
8	on	on	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug3	drug3	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	12	punct
17	an	a	DT	_	20	det
18	orally	orally	RB	_	19	advmod
19	active	active	JJ	_	20	amod
20	drug4	drug4	NN	_	12	appos
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	partly	partly	RB	_	4	advmod
4	metabolized	metabolize	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	CYP3A4	cyp3a4	NN	_	4	nmod
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	4	advmod
9	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	evaluated	evaluate	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	effect	effect	NN	_	3	dobj
6	of	of	IN	_	10	case
7	a	a	DT	_	10	det
8	potent	potent	JJ	_	10	amod
9	CYP3A	cyp3a	NN	_	10	compound
10	inhibitor	inhibitor	NN	_	5	nmod
11	,	,	,	_	10	punct
12	drug1	drug1	NN	_	10	appos
13	,	,	,	_	10	punct
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	pharmacokinetics	pharmacokinetic	NNS	_	5	nmod
17	and	and	CC	_	16	cc
18	safety	safety	NN	_	16	conj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	16	nmod
21	.	.	.	_	3	punct

1	Patients	patient	NNS	_	2	nsubj
2	received	receive	VBD	_	0	ROOT
3	a	a	DT	_	7	det
4	single	single	JJ	_	7	amod
5	drug1	drug1	NN	_	7	compound
6	oral	oral	JJ	_	7	amod
7	dose	dose	NN	_	2	dobj
8	on	on	IN	_	9	case
9	day	day	NN	_	2	nmod
10	1	1	CD	_	9	nummod
11	,	,	,	_	2	punct
12	followed	follow	VBN	_	2	advcl
13	by	by	IN	_	15	case
14	4	4	CD	_	15	nummod
15	days	day	NNS	_	12	nmod
16	wash-out	wash-out	JJ	_	17	amod
17	period	period	NN	_	15	dep
18	.	.	.	_	2	punct

1	On	on	IN	_	2	case
2	days	day	NNS	_	7	nmod
3	5-9	5-9	CD	_	2	nummod
4	,	,	,	_	7	punct
5	drug1	drug1	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	administered	administer	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	On	on	IN	_	2	case
2	day	day	NN	_	10	nmod
3	8	8	CD	_	2	nummod
4	,	,	,	_	10	punct
5	a	a	DT	_	8	det
6	single	single	JJ	_	8	amod
7	drug1	drug1	NN	_	8	compound
8	dose	dose	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	co-administered	co-administer	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	10	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	administered	administer	VBN	_	0	ROOT
4	as	as	IN	_	6	case
5	single	single	JJ	_	6	amod
6	agent	agent	NN	_	3	nmod
7	three	three	CD	_	8	nummod
8	times	time	NNS	_	3	nmod:tmod
9	a	a	DT	_	10	det
10	week	week	NN	_	8	nmod:npmod
11	on	on	IN	_	12	case
12	day	day	NN	_	3	nmod
13	15	15	CD	_	12	nummod
14	and	and	CC	_	12	cc
15	onward	onward	RB	_	12	conj
16	.	.	.	_	3	punct

1	In	in	IN	_	5	case
2	the	the	DT	_	5	dep
3	presence	presence	NN	_	5	dep
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	8	nmod
6	,	,	,	_	8	punct
7	there	there	EX	_	8	expl
8	was	be	VBD	_	0	ROOT
9	1.6	1.6	CD	_	13	dep
10	-	-	:	_	13	punct
11	and	and	CC	_	13	cc
12	1.8-fold	1.8-fold	JJ	_	13	amod
13	increase	increase	NN	_	8	dep
14	in	in	IN	_	17	case
15	C	c	NN	_	17	compound
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	max	max	NN	_	13	nmod
18	-RRB-	-rrb-	-RRB-	_	13	punct
19	and	and	CC	_	13	cc
20	AUC	auc	NN	_	13	conj
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	,	,	,	_	13	punct
24	respectively	respectively	RB	_	13	advmod
25	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	substantial	substantial	JJ	_	3	amod
3	change	change	NN	_	12	nsubjpass
4	in	in	IN	_	7	case
5	T	t	NN	_	7	compound
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	max	max	NN	_	3	nmod
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	or	or	CC	_	7	cc
10	half-life	half-life	NN	_	7	conj
11	was	be	VBD	_	12	auxpass
12	observed	observe	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	No	no	DT	_	2	neg
2	difference	difference	NN	_	0	ROOT
3	in	in	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-	-	:	_	2	punct
6	pharmacokinetics	pharmacokinetic	NNS	_	2	dep
7	between	between	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	carrying	carry	VBG	_	8	acl
10	CYP3A5	cyp3a5	NN	_	9	dobj
11	*	*	SYM	_	12	dep
12	1	1	CD	_	25	nsubjpass
13	/	/	:	_	12	punct
14	*	*	SYM	_	15	dep
15	3	3	CD	_	12	dep
16	and	and	CC	_	15	cc
17	CYP3A5	cyp3a5	NN	_	19	dep
18	*	*	SYM	_	19	dep
19	3	3	CD	_	15	conj
20	/	/	:	_	12	punct
21	*	*	SYM	_	22	dep
22	3	3	CD	_	23	nummod
23	alleles	allele	NNS	_	12	dep
24	was	be	VBD	_	25	auxpass
25	observed	observe	VBN	_	8	acl:relcl
26	.	.	.	_	2	punct

1	Most	most	JJS	_	3	nsubj
2	frequently	frequently	RB	_	3	advmod
3	reported	report	VBN	_	0	ROOT
4	adverse	adverse	JJ	_	5	amod
5	events	event	NNS	_	8	nsubj
6	were	be	VBD	_	8	cop
7	gastrointestinal	gastrointestinal	JJ	_	8	amod
8	related	related	JJ	_	3	ccomp
9	.	.	.	_	3	punct

1	Patients	patient	NNS	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	asymptomatic	asymptomatic	JJ	_	4	amod
4	hypophosphatemia	hypophosphatemia	NN	_	13	nsubj
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	64	64	CD	_	7	nummod
7	%	%	NN	_	4	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	urine	urine	NN	_	12	compound
12	analysis	analysis	NN	_	4	conj
13	suggested	suggest	VBD	_	2	ccomp
14	renal	renal	JJ	_	15	amod
15	phosphate	phosphate	NN	_	16	nsubj
16	wasting	waste	VBG	_	13	ccomp
17	.	.	.	_	2	punct

1	Co-administration	co-administration	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	CYP3A	cyp3a	NN	_	6	compound
6	inhibitors	inhibitor	NNS	_	1	nmod
7	is	be	VBZ	_	8	cop
8	feasible	feasible	JJ	_	19	csubjpass
9	as	as	IN	_	12	case
10	the	the	DT	_	12	det
11	observed	observe	VBN	_	12	amod
12	increase	increase	NN	_	8	nmod
13	in	in	IN	_	16	case
14	drug2	drug2	NN	_	16	compound
15	PK	pk	NN	_	16	compound
16	parameters	parameter	NNS	_	12	nmod
17	was	be	VBD	_	19	auxpass
18	not	not	RB	_	19	neg
19	considered	consider	VBN	_	0	ROOT
20	clinically	clinically	RB	_	21	advmod
21	relevant	relevant	JJ	_	19	xcomp
22	.	.	.	_	19	punct

1	Considering	consider	VBG	_	0	ROOT
2	the	the	DT	_	3	det
3	variability	variability	NN	_	1	dobj
4	in	in	IN	_	5	case
5	exposure	exposure	NN	_	1	nmod
6	following	follow	VBG	_	8	case
7	enzyme	enzyme	NN	_	8	compound
8	inhibition	inhibition	NN	_	5	nmod
9	and	and	CC	_	1	cc
10	the	the	DT	_	11	det
11	fact	fact	NN	_	1	conj
12	that	that	IN	_	19	mark
13	chronic	chronic	JJ	_	14	amod
14	dosing	dosing	NN	_	19	nsubjpass
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	was	be	VBD	_	19	auxpass
18	not	not	RB	_	19	neg
19	studied	study	VBN	_	11	ccomp
20	with	with	IN	_	22	case
21	CYP3A	cyp3a	NN	_	22	compound
22	inhibitors	inhibitor	NNS	_	33	nmod
23	,	,	,	_	22	punct
24	close	close	JJ	_	25	amod
25	monitoring	monitoring	NN	_	22	appos
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	-	-	:	_	22	punct
29	related	related	JJ	_	31	amod
30	adverse	adverse	JJ	_	31	amod
31	events	event	NNS	_	33	nsubj
32	is	be	VBZ	_	33	cop
33	necessary	necessary	JJ	_	19	ccomp
34	.	.	.	_	1	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	CYP	cyp	NN	_	4	compound
4	inhibitors	inhibitor	NNS	_	1	nmod
5	on	on	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	metabolism	metabolism	NN	_	1	nmod
8	and	and	CC	_	7	cc
9	toxicity	toxicity	NN	_	7	conj
10	in	in	IN	_	13	case
11	rat	rat	NN	_	13	compound
12	liver	liver	NN	_	13	compound
13	slices	slice	NNS	_	7	nmod
14	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	present	present	VBP	_	0	ROOT
3	a	a	DT	_	7	det
4	comprehensive	comprehensive	JJ	_	7	amod
5	in	in	FW	_	7	amod
6	vitro	vitro	FW	_	5	dep
7	approach	approach	NN	_	2	dobj
8	to	to	TO	_	9	mark
9	assessing	assess	VBG	_	7	acl
10	metabolism-mediated	metabolism-mediated	JJ	_	11	amod
11	hepatotoxicity	hepatotoxicity	NN	_	9	dobj
12	using	use	VBG	_	9	xcomp
13	male	male	JJ	_	17	amod
14	Sprague-Dawley	sprague-dawley	JJ	_	17	amod
15	rat	rat	NN	_	17	compound
16	liver	liver	NN	_	17	compound
17	slices	slice	NNS	_	12	dobj
18	incubated	incubate	VBN	_	17	acl
19	with	with	IN	_	23	case
20	the	the	DT	_	23	det
21	well	well	RB	_	22	advmod
22	characterized	characterize	VBN	_	23	amod
23	hepatotoxicant	hepatotoxicant	NN	_	18	nmod
24	,	,	,	_	23	punct
25	drug1	drug1	NN	_	23	conj
26	,	,	,	_	23	punct
27	and	and	CC	_	23	cc
28	inhibitors	inhibitor	NNS	_	23	conj
29	of	of	IN	_	31	case
30	cytochrome	cytochrome	NN	_	31	compound
31	P450	p450	NN	_	28	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	CYP	cyp	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	enzymes	enzyme	NNS	_	31	dep
36	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	approach	approach	NN	_	3	nsubj
3	combines	combine	VBZ	_	0	ROOT
4	liquid	liquid	JJ	_	7	amod
5	chromatography	chromatography	NN	_	7	compound
6	mass	mass	NN	_	7	compound
7	spectrometry	spectrometry	NN	_	13	compound
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	LC	lc	NN	_	10	compound
10	MS	ms	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	detection	detection	NN	_	13	compound
13	methods	method	NNS	_	3	dobj
14	with	with	IN	_	17	case
15	multiple	multiple	JJ	_	17	amod
16	toxicity	toxicity	NN	_	17	compound
17	endpoints	endpoint	NNS	_	13	nmod
18	to	to	TO	_	19	mark
19	enable	enable	VB	_	3	advcl
20	identification	identification	NN	_	19	dobj
21	of	of	IN	_	24	case
22	critical	critical	JJ	_	24	amod
23	metabolic	metabolic	JJ	_	24	amod
24	pathways	pathway	NNS	_	20	nmod
25	for	for	IN	_	26	case
26	hepatotoxicity	hepatotoxicity	NN	_	24	nmod
27	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	incubations	incubation	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	performed	perform	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	dep
7	absence	absence	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	presence	presence	NN	_	7	conj
10	of	of	IN	_	14	case
11	the	the	DT	_	14	det
12	non-specific	non-specific	JJ	_	14	amod
13	CYP	cyp	NN	_	14	compound
14	inhibitor	inhibitor	NN	_	7	nmod
15	,	,	,	_	14	punct
16	drug1	drug1	NN	_	14	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug2	drug2	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	and	and	CC	_	14	cc
21	isoform-specific	isoform-specific	JJ	_	22	amod
22	inhibitors	inhibitor	NNS	_	14	conj
23	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	metabolite	metabolite	NN	_	3	compound
3	profile	profile	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	in	in	IN	_	9	case
7	rat	rat	NN	_	9	compound
8	liver	liver	NN	_	9	compound
9	slices	slice	NNS	_	3	nmod
10	shares	share	VBZ	_	0	ROOT
11	some	some	DT	_	12	det
12	features	feature	NNS	_	10	dobj
13	of	of	IN	_	17	case
14	the	the	DT	_	17	det
15	in	in	FW	_	17	amod
16	vivo	vivo	FW	_	15	dep
17	profile	profile	NN	_	12	nmod
18	,	,	,	_	10	punct
19	but	but	CC	_	10	cc
20	also	also	RB	_	21	advmod
21	had	have	VBD	_	10	conj
22	a	a	DT	_	24	det
23	major	major	JJ	_	24	amod
24	difference	difference	NN	_	21	dobj
25	in	in	IN	_	33	mark
26	that	that	DT	_	33	mark
27	epoxide	epoxide	NN	_	30	compound
28	dihydrodiol	dihydrodiol	NN	_	30	compound
29	hydrolysis	hydrolysis	NN	_	30	compound
30	products	product	NNS	_	33	nsubjpass
31	were	be	VBD	_	33	auxpass
32	not	not	RB	_	33	neg
33	observed	observe	VBN	_	24	acl
34	to	to	TO	_	37	case
35	a	a	DT	_	37	det
36	measurable	measurable	JJ	_	37	amod
37	extent	extent	NN	_	33	nmod
38	.	.	.	_	10	punct

1	As	as	IN	_	2	case
2	examples	example	NNS	_	25	nmod
3	of	of	IN	_	9	case
4	our	we	PRP$	_	9	nmod:poss
5	liver	liver	NN	_	9	compound
6	slice	slice	NN	_	9	compound
7	metabolite	metabolite	NN	_	9	compound
8	identification	identification	NN	_	9	compound
9	procedure	procedure	NN	_	2	nmod
10	,	,	,	_	25	punct
11	a	a	DT	_	14	det
12	minor	minor	JJ	_	14	amod
13	glutathione	glutathione	NN	_	14	compound
14	adduct	adduct	NN	_	25	nsubjpass
15	and	and	CC	_	14	cc
16	previously	previously	RB	_	17	advmod
17	unreported	unreported	JJ	_	18	amod
18	7-O-desmethyl	7-o-desmethyl	NN	_	14	conj
19	and	and	CC	_	14	cc
20	glucuronidated	glucuronidate	VBN	_	21	amod
21	metabolites	metabolite	NNS	_	14	conj
22	of	of	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	are	be	VBP	_	25	auxpass
25	reported	report	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	drug1	drug1	NN	_	2	nsubj
2	induced	induce	VBD	_	0	ROOT
3	hepatocellular	hepatocellular	JJ	_	4	amod
4	necrosis	necrosis	NN	_	2	dobj
5	in	in	IN	_	7	case
6	a	a	DT	_	7	det
7	dose	dose	NN	_	2	nmod
8	-	-	:	_	2	punct
9	and	and	CC	_	2	cc
10	time-dependent	time-dependent	JJ	_	11	amod
11	manner	manner	NN	_	2	conj
12	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreased	decrease	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	toxicity	toxicity	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	2	punct
8	increased	increase	VBD	_	9	amod
9	exposure	exposure	NN	_	2	conj
10	to	to	TO	_	12	case
11	parent	parent	NN	_	12	compound
12	compound	compound	NN	_	9	nmod
13	,	,	,	_	2	punct
14	and	and	CC	_	2	cc
15	decreased	decrease	VBD	_	2	conj
16	metabolite	metabolite	NN	_	17	compound
17	levels	level	NNS	_	15	dobj
18	in	in	IN	_	21	case
19	a	a	DT	_	21	det
20	dose-dependent	dose-dependent	JJ	_	21	amod
21	manner	manner	NN	_	15	nmod
22	.	.	.	_	2	punct

1	Of	of	IN	_	5	case
2	the	the	DT	_	5	det
3	isoform-specific	isoform-specific	JJ	_	5	amod
4	CYP	cyp	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	20	nmod
6	tested	test	VBN	_	5	acl
7	for	for	IN	_	9	case
8	an	a	DT	_	9	det
9	effect	effect	NN	_	6	nmod
10	on	on	IN	_	14	case
11	the	the	DT	_	14	det
12	drug1	drug1	NN	_	14	compound
13	metabolite	metabolite	NN	_	14	compound
14	profile	profile	NN	_	9	nmod
15	,	,	,	_	20	punct
16	only	only	RB	_	17	advmod
17	drug2	drug2	NN	_	20	nsubj
18	was	be	VBD	_	20	cop
19	noticeably	noticeably	RB	_	20	advmod
20	effective	effective	JJ	_	0	ROOT
21	,	,	,	_	20	punct
22	indicating	indicate	VBG	_	20	xcomp
23	a	a	DT	_	24	det
24	role	role	NN	_	22	dobj
25	of	of	IN	_	27	case
26	CYPs	cyp	NNS	_	27	compound
27	2A6	2a6	NN	_	24	nmod
28	,	,	,	_	27	punct
29	2C9	2c9	NN	_	27	conj
30	,	,	,	_	27	punct
31	2Cl9	2cl9	NN	_	27	conj
32	,	,	,	_	27	punct
33	and	and	CC	_	27	cc
34	2E1	2e1	NN	_	27	conj
35	.	.	.	_	20	punct

1	With	with	IN	_	2	case
2	respect	respect	NN	_	0	ROOT
3	to	to	TO	_	4	case
4	toxicity	toxicity	NN	_	2	nmod
5	,	,	,	_	2	punct
6	the	the	DT	_	7	det
7	order	order	NN	_	5	root
8	of	of	IN	_	11	case
9	CYP	cyp	NN	_	11	compound
10	inhibitor	inhibitor	NN	_	11	compound
11	effectiveness	effectiveness	NN	_	7	nmod
12	was	be	VBD	_	7	acl
13	drug1	drug1	CD	_	17	nummod
14	>	>	JJR	_	17	dep
15	drug2	drug2	NN	_	17	compound
16	~	~	CD	_	17	nummod
17	drug3	drug3	NN	_	12	nsubj
18	>	>	JJR	_	19	amod
19	drug4	drug4	NN	_	17	dep
20	.	.	.	_	7	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	had	have	VBD	_	0	ROOT
5	no	no	DT	_	6	neg
6	effect	effect	NN	_	4	dobj
7	,	,	,	_	4	punct
8	while	while	IN	_	10	mark
9	drug3	drug3	NN	_	10	nsubj
10	appeared	appear	VBD	_	4	advcl
11	to	to	TO	_	12	mark
12	augment	augment	VB	_	10	xcomp
13	drug4	drug4	NN	_	14	compound
14	toxicity	toxicity	NN	_	12	dobj
15	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	10	mark
5	rat	rat	NN	_	7	compound
6	liver	liver	NN	_	7	compound
7	slices	slice	NNS	_	10	nsubj
8	do	do	VBP	_	10	aux
9	not	not	RB	_	10	neg
10	reproduce	reproduce	VB	_	3	ccomp
11	the	the	DT	_	15	det
12	reported	report	VBN	_	15	amod
13	in	in	FW	_	15	amod
14	vivo	vivo	FW	_	13	dep
15	biotransformation	biotransformation	NN	_	10	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	and	and	CC	_	10	cc
19	therefore	therefore	RB	_	25	advmod
20	may	may	MD	_	25	aux
21	not	not	RB	_	25	neg
22	be	be	VB	_	25	cop
23	an	a	DT	_	25	det
24	appropriate	appropriate	JJ	_	25	amod
25	model	model	NN	_	10	conj
26	for	for	IN	_	28	case
27	drug2	drug2	NN	_	28	compound
28	metabolism	metabolism	NN	_	25	nmod
29	.	.	.	_	3	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	these	these	DT	_	4	det
4	results	result	NNS	_	5	nsubj
5	provide	provide	VBP	_	0	ROOT
6	an	a	DT	_	7	det
7	example	example	NN	_	5	dobj
8	of	of	IN	_	12	case
9	how	how	WRB	_	10	advmod
10	small	small	JJ	_	12	amod
11	molecule	molecule	NN	_	12	compound
12	manipulation	manipulation	NN	_	7	nmod
13	of	of	IN	_	15	case
14	CYP	cyp	NN	_	15	compound
15	activity	activity	NN	_	12	nmod
16	in	in	IN	_	20	case
17	an	a	DT	_	20	det
18	in	in	FW	_	20	amod
19	vitro	vitro	FW	_	18	dep
20	model	model	NN	_	5	nmod
21	can	can	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	used	use	VBN	_	5	dep
24	to	to	TO	_	25	mark
25	confirm	confirm	VB	_	23	xcomp
26	metabolism-mediated	metabolism-mediated	JJ	_	27	amod
27	toxicity	toxicity	NN	_	25	dobj
28	.	.	.	_	5	punct

1	Glycosidic	glycosidic	JJ	_	2	amod
2	enzymes	enzyme	NNS	_	3	nsubj
3	enhance	enhance	VBP	_	0	ROOT
4	retinal	retinal	JJ	_	5	amod
5	transduction	transduction	NN	_	3	dobj
6	following	follow	VBG	_	8	case
7	intravitreal	intravitreal	JJ	_	8	amod
8	delivery	delivery	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	3	punct

1	To	to	TO	_	2	mark
2	determine	determine	VB	_	0	ROOT
3	whether	whether	IN	_	11	mark
4	the	the	DT	_	5	det
5	co-injection	co-injection	NN	_	11	nsubj
6	of	of	IN	_	10	case
7	extracellular	extracellular	JJ	_	10	amod
8	matrix	matrix	NN	_	10	compound
9	degrading	degrading	JJ	_	10	amod
10	enzymes	enzyme	NNS	_	5	nmod
11	improves	improve	VBZ	_	2	ccomp
12	retinal	retinal	JJ	_	13	amod
13	transduction	transduction	NN	_	11	dobj
14	following	follow	VBG	_	16	case
15	intravitreal	intravitreal	JJ	_	16	amod
16	delivery	delivery	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug2	drug2	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	nsubj
2	containing	contain	VBG	_	1	acl
3	cDNA	cdna	NN	_	4	compound
4	encoding	encoding	NN	_	2	dobj
5	enhanced	enhance	VBD	_	0	ROOT
6	green	green	JJ	_	8	amod
7	fluorescent	fluorescent	JJ	_	8	amod
8	protein	protein	NN	_	5	dobj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	GFP	gfp	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	5	punct
13	under	under	IN	_	15	case
14	the	the	DT	_	15	det
15	control	control	NN	_	5	nmod
16	of	of	IN	_	21	case
17	a	a	DT	_	21	det
18	chicken	chicken	NN	_	21	compound
19	-	-	:	_	21	punct
20	actin	actin	NN	_	21	compound
21	promoter	promoter	NN	_	15	nmod
22	,	,	,	_	5	punct
23	was	be	VBD	_	24	auxpass
24	delivered	deliver	VBN	_	5	dep
25	by	by	IN	_	27	case
26	intravitreal	intravitreal	JJ	_	27	amod
27	injection	injection	NN	_	24	nmod
28	to	to	TO	_	30	case
29	adult	adult	JJ	_	30	amod
30	mice	mouse	NNS	_	27	nmod
31	in	in	IN	_	32	case
32	conjunction	conjunction	NN	_	24	nmod
33	with	with	IN	_	34	case
34	enzymes	enzyme	NNS	_	32	nmod
35	including	include	VBG	_	36	case
36	drug2	drug2	NN	_	34	nmod
37	,	,	,	_	36	punct
38	drug3	drug3	NN	_	36	conj
39	,	,	,	_	36	punct
40	drug4	drug4	NN	_	36	conj
41	,	,	,	_	36	punct
42	or	or	CC	_	36	cc
43	drug5	drug5	NN	_	36	conj
44	.	.	.	_	5	punct

1	Two	two	CD	_	2	nummod
2	weeks	week	NNS	_	3	nmod:npmod
3	later	later	RB	_	8	advmod
4	,	,	,	_	8	punct
5	retinal	retinal	JJ	_	6	amod
6	flatmounts	flatmount	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	examined	examine	VBN	_	0	ROOT
9	for	for	IN	_	11	case
10	GFP	gfp	NN	_	11	compound
11	expression	expression	NN	_	8	nmod
12	using	use	VBG	_	11	acl
13	confocal	confocal	JJ	_	14	amod
14	microscopy	microscopy	NN	_	12	dobj
15	.	.	.	_	8	punct

1	Without	without	IN	_	3	case
2	the	the	DT	_	3	det
3	addition	addition	NN	_	9	nmod
4	of	of	IN	_	5	case
5	enzymes	enzyme	NNS	_	3	nmod
6	,	,	,	_	9	punct
7	transduction	transduction	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	limited	limit	VBN	_	0	ROOT
10	to	to	TO	_	12	case
11	occasional	occasional	JJ	_	12	amod
12	cells	cell	NNS	_	9	nmod
13	in	in	IN	_	18	case
14	the	the	DT	_	18	det
15	retinal	retinal	JJ	_	18	amod
16	ganglion	ganglion	NN	_	18	compound
17	cell	cell	NN	_	18	compound
18	layer	layer	NN	_	12	nmod
19	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	greatly	greatly	RB	_	8	advmod
8	enhanced	enhance	VBD	_	0	ROOT
9	transduction	transduction	NN	_	8	dobj
10	of	of	IN	_	15	case
11	the	the	DT	_	15	det
12	retinal	retinal	JJ	_	15	amod
13	ganglion	ganglion	NN	_	15	compound
14	cell	cell	NN	_	15	compound
15	layer	layer	NN	_	9	nmod
16	and	and	CC	_	8	cc
17	increased	increase	VBD	_	8	conj
18	the	the	DT	_	19	det
19	depth	depth	NN	_	17	dobj
20	of	of	IN	_	21	case
21	transduction	transduction	NN	_	19	nmod
22	into	into	IN	_	25	case
23	the	the	DT	_	25	det
24	outer	outer	JJ	_	25	amod
25	retina	retina	NN	_	17	nmod
26	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	a	a	DT	_	5	det
4	limited	limited	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	and	and	CC	_	2	cc
7	drug2	drug2	NN	_	9	nsubj
8	was	be	VBD	_	9	cop
9	ineffective	ineffective	JJ	_	2	conj
10	.	.	.	_	2	punct

1	Electroretinograms	electroretinograms	NN	_	2	nsubj
2	survived	survive	VBD	_	0	ROOT
3	with	with	IN	_	5	case
4	higher	higher	JJR	_	5	amod
5	concentrations	concentration	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	than	than	IN	_	12	mark
11	were	be	VBD	_	12	auxpass
12	required	require	VBN	_	5	dep
13	for	for	IN	_	16	case
14	optimal	optimal	JJ	_	16	amod
15	retinal	retinal	JJ	_	16	amod
16	transduction	transduction	NN	_	12	nmod
17	.	.	.	_	2	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-	-	:	_	1	punct
3	mediated	mediate	VBN	_	5	amod
4	retinal	retinal	JJ	_	5	amod
5	transduction	transduction	NN	_	1	dep
6	is	be	VBZ	_	7	auxpass
7	improved	improve	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	co-injection	co-injection	NN	_	7	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	.	.	.	_	7	punct

1	Improved	improve	VBN	_	3	amod
2	transduction	transduction	NN	_	3	compound
3	efficiency	efficiency	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	allow	allow	VB	_	0	ROOT
6	intravitreal	intravitreal	JJ	_	7	amod
7	injection	injection	NN	_	5	dobj
8	to	to	TO	_	9	mark
9	become	become	VB	_	5	xcomp
10	the	the	DT	_	12	det
11	preferred	preferred	JJ	_	12	amod
12	route	route	NN	_	9	xcomp
13	for	for	IN	_	14	mark
14	delivering	deliver	VBG	_	12	acl
15	gene	gene	NN	_	16	compound
16	therapy	therapy	NN	_	14	dobj
17	to	to	TO	_	23	case
18	both	both	CC	_	23	cc:preconj
19	the	the	DT	_	23	det
20	inner	inner	JJ	_	23	amod
21	and	and	CC	_	20	cc
22	outer	outer	JJ	_	20	conj
23	retina	retina	NN	_	14	nmod
24	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	--	--	:	_	1	punct
6	better	better	JJR	_	1	dep
7	than	than	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug4	drug4	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct

1	The	the	DT	_	2	det
2	FDA	FDA	NNP	_	4	nsubj
3	has	have	VBZ	_	4	aux
4	approved	approve	VBN	_	0	ROOT
5	drug1	drug1	NN	_	4	dobj
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-	-	:	_	7	punct
9	AstraZeneca	AstraZeneca	NNP	_	7	dep
10	-RRB-	-rrb-	-RRB-	_	7	punct
11	,	,	,	_	5	punct
12	an	a	DT	_	14	det
13	oral	oral	JJ	_	14	amod
14	drug3	drug3	NN	_	5	appos
15	,	,	,	_	5	punct
16	for	for	IN	_	17	case
17	use	use	NN	_	4	nmod
18	with	with	IN	_	20	case
19	low-dose	low-dose	JJ	_	20	amod
20	drug4	drug4	NN	_	17	nmod
21	to	to	TO	_	22	mark
22	reduce	reduce	VB	_	17	acl
23	the	the	DT	_	24	det
24	rate	rate	NN	_	22	dobj
25	of	of	IN	_	28	case
26	thrombotic	thrombotic	JJ	_	28	amod
27	cardiovascular	cardiovascular	JJ	_	28	amod
28	events	event	NNS	_	24	nmod
29	in	in	IN	_	30	case
30	patients	patient	NNS	_	28	nmod
31	with	with	IN	_	34	case
32	acute	acute	JJ	_	34	amod
33	coronary	coronary	JJ	_	34	amod
34	syndrome	syndrome	NN	_	30	nmod
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	ACS	acs	NN	_	34	appos
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	.	.	.	_	4	punct

1	It	it	PRP	_	3	nsubj
2	will	will	MD	_	3	aux
3	compete	compete	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	and	and	CC	_	5	cc
10	drug3	drug3	NN	_	5	conj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug4	drug4	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	for	for	IN	_	16	case
15	such	such	JJ	_	16	amod
16	use	use	NN	_	3	nmod
17	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	expected	expect	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	become	become	VB	_	3	xcomp
6	available	available	JJ	_	5	xcomp
7	generically	generically	RB	_	5	advmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	US	US	NNP	_	7	nmod
11	within	within	IN	_	15	case
12	the	the	DT	_	15	det
13	next	next	JJ	_	15	amod
14	few	few	JJ	_	15	amod
15	months	month	NNS	_	5	nmod
16	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	role	role	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	p27	p27	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	Kip1	kip1	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	in	in	IN	_	9	case
9	drug1	drug1	NN	_	2	nmod
10	-	-	:	_	2	punct
11	enhanced	enhance	VBN	_	13	amod
12	drug2	drug2	NN	_	13	compound
13	cytotoxicity	cytotoxicity	NN	_	2	dep
14	in	in	IN	_	18	case
15	human	human	JJ	_	18	amod
16	ovarian	ovarian	JJ	_	18	amod
17	cancer	cancer	NN	_	18	compound
18	cells	cell	NNS	_	13	nmod
19	.	.	.	_	2	punct

1	Less	less	RBR	_	3	advmod
2	than	than	IN	_	1	mwe
3	50	50	CD	_	4	nummod
4	%	%	NN	_	8	nsubj
5	of	of	IN	_	7	case
6	ovarian	ovarian	JJ	_	7	amod
7	cancers	cancer	NNS	_	4	nmod
8	respond	respond	VBP	_	0	ROOT
9	to	to	TO	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Effective	effective	JJ	_	2	amod
2	strategies	strategy	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	needed	need	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	enhance	enhance	VB	_	4	xcomp
7	drug1	drug1	NN	_	8	compound
8	sensitivity	sensitivity	NN	_	6	dobj
9	.	.	.	_	4	punct

1	A	a	DT	_	2	det
2	library	library	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	silencing	silencing	NN	_	5	compound
5	RNAs	rna	NNS	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	siRNAs	sirna	NNS	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	was	be	VBD	_	10	auxpass
10	used	use	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	identify	identify	VB	_	10	xcomp
13	kinases	kinase	NNS	_	12	dobj
14	that	that	WDT	_	15	nsubj
15	regulate	regulate	VBP	_	13	acl:relcl
16	drug1	drug1	NN	_	17	compound
17	sensitivity	sensitivity	NN	_	15	dobj
18	in	in	IN	_	23	case
19	human	human	JJ	_	23	amod
20	ovarian	ovarian	JJ	_	23	amod
21	cancer	cancer	NN	_	23	compound
22	SKOv3	skov3	NN	_	23	compound
23	cells	cell	NNS	_	17	nmod
24	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	18	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	an	a	DT	_	7	det
7	inhibitor	inhibitor	NN	_	4	appos
8	of	of	IN	_	12	case
9	Src	src	NN	_	12	compound
10	and	and	CC	_	9	cc
11	Abl	abl	NN	_	9	conj
12	kinases	kinase	NNS	_	7	nmod
13	,	,	,	_	4	punct
14	on	on	IN	_	16	case
15	drug2	drug2	NN	_	16	compound
16	sensitivity	sensitivity	NN	_	2	nmod
17	was	be	VBD	_	18	auxpass
18	measured	measure	VBN	_	0	ROOT
19	in	in	IN	_	22	case
20	ovarian	ovarian	JJ	_	22	amod
21	cancer	cancer	NN	_	22	compound
22	cells	cell	NNS	_	18	nmod
23	and	and	CC	_	22	cc
24	HEY	hey	NN	_	25	compound
25	xenografts	xenograft	NNS	_	22	conj
26	.	.	.	_	18	punct

1	The	the	DT	_	2	det
2	roles	role	NNS	_	21	nsubjpass
3	of	of	IN	_	4	case
4	p27	p27	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	Kip1	kip1	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	,	,	,	_	4	punct
9	Bcl-2	bcl-2	NN	_	4	conj
10	,	,	,	_	4	punct
11	and	and	CC	_	4	cc
12	Cdk1	cdk1	NN	_	4	conj
13	in	in	IN	_	14	case
14	apoptosis	apoptosis	NN	_	2	nmod
15	induced	induce	VBN	_	14	acl
16	by	by	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	were	be	VBD	_	21	auxpass
21	assessed	assess	VBN	_	0	ROOT
22	using	use	VBG	_	21	xcomp
23	a	a	DT	_	29	det
24	terminal	terminal	JJ	_	29	amod
25	deoxynucleotidyl	deoxynucleotidyl	NN	_	29	compound
26	transferase-mediated	transferase-mediated	JJ	_	29	amod
27	dUTP	dutp	NN	_	29	compound
28	nick-end	nick-end	JJ	_	29	amod
29	labeling	labeling	NN	_	33	compound
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	TUNEL	tunel	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	assay	assay	NN	_	22	dobj
34	,	,	,	_	21	punct
35	siRNA	sirna	NN	_	36	compound
36	knockdown	knockdown	NN	_	21	dobj
37	of	of	IN	_	39	case
38	gene	gene	NN	_	39	compound
39	expression	expression	NN	_	36	nmod
40	,	,	,	_	36	punct
41	transfection	transfection	NN	_	36	conj
42	with	with	IN	_	43	case
43	Bcl-2	bcl-2	NN	_	41	nmod
44	and	and	CC	_	43	cc
45	Cdk1	cdk1	NN	_	47	compound
46	expression	expression	NN	_	47	compound
47	vectors	vector	NNS	_	43	conj
48	,	,	,	_	36	punct
49	and	and	CC	_	36	cc
50	flow	flow	NN	_	51	compound
51	cytometry	cytometry	NN	_	36	conj
52	.	.	.	_	21	punct

1	All	all	DT	_	3	det
2	statistical	statistical	JJ	_	3	amod
3	tests	test	NNS	_	5	nsubj
4	were	be	VBD	_	5	cop
5	two-sided	two-sided	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	Src	src	NN	_	2	compound
2	family	family	NN	_	7	nsubjpass
3	and	and	CC	_	2	cc
4	Abl	abl	NN	_	5	compound
5	kinases	kinase	NNS	_	2	conj
6	were	be	VBD	_	7	auxpass
7	identified	identify	VBN	_	0	ROOT
8	as	as	IN	_	9	case
9	modulators	modulator	NNS	_	7	nmod
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	sensitivity	sensitivity	NN	_	9	nmod
13	in	in	IN	_	15	case
14	SKOv3	skov3	NN	_	15	compound
15	cells	cell	NNS	_	12	nmod
16	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	siRNA	sirna	NN	_	3	compound
3	knockdown	knockdown	NN	_	11	nsubj
4	of	of	IN	_	5	case
5	Src	src	NN	_	3	nmod
6	,	,	,	_	5	punct
7	Fyn	fyn	NN	_	5	conj
8	,	,	,	_	5	punct
9	or	or	CC	_	5	cc
10	Abl1	abl1	NN	_	5	conj
11	enhanced	enhance	VBD	_	0	ROOT
12	drug1	drug1	NN	_	11	dobj
13	-	-	:	_	12	punct
14	mediated	mediate	VBN	_	16	amod
15	growth	growth	NN	_	16	compound
16	inhibition	inhibition	NN	_	12	dep
17	in	in	IN	_	20	case
18	ovarian	ovarian	JJ	_	20	amod
19	cancer	cancer	NN	_	20	compound
20	cells	cell	NNS	_	16	nmod
21	compared	compare	VBN	_	25	case
22	with	with	IN	_	25	case
23	a	a	DT	_	25	det
24	control	control	NN	_	25	compound
25	siRNA	siRNA	NNP	_	16	nmod
26	.	.	.	_	11	punct

1	HEY	hey	NN	_	2	compound
2	cells	cell	NNS	_	8	nsubj
3	treated	treat	VBN	_	2	acl
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	plus	plus	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	formed	form	VBD	_	0	ROOT
9	fewer	fewer	JJR	_	10	amod
10	colonies	colony	NNS	_	8	dobj
11	than	than	IN	_	12	dep
12	did	do	VBD	_	10	dep
13	cells	cell	NNS	_	12	nsubj
14	treated	treat	VBN	_	13	acl
15	with	with	IN	_	17	case
16	either	either	CC	_	17	det
17	agent	agent	NN	_	14	nmod
18	alone	alone	RB	_	17	advmod
19	.	.	.	_	8	punct

1	Treatment	treatment	NN	_	10	nsubj
2	of	of	IN	_	5	case
3	HEY	hey	NN	_	5	compound
4	xenograft-bearing	xenograft-bearing	JJ	_	5	amod
5	mice	mouse	NNS	_	1	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	1	nmod
8	plus	plus	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	inhibited	inhibit	VBD	_	0	ROOT
11	tumor	tumor	NN	_	12	compound
12	growth	growth	NN	_	10	dobj
13	more	more	JJR	_	10	advmod
14	than	than	IN	_	15	case
15	treatment	treatment	NN	_	13	nmod
16	with	with	IN	_	18	case
17	either	either	CC	_	18	det
18	agent	agent	NN	_	15	nmod
19	alone	alone	RB	_	18	advmod
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	average	average	JJ	_	23	amod
22	tumor	tumor	NN	_	23	compound
23	volume	volume	NN	_	10	dep
24	per	per	IN	_	25	case
25	mouse	mouse	NN	_	23	nmod
26	,	,	,	_	23	punct
27	drug3	drug3	NN	_	23	appos
28	+	+	CC	_	27	cc
29	drug4	drug4	NN	_	27	conj
30	vs	vs	CC	_	27	cc
31	drug5	drug5	NN	_	27	conj
32	:	:	:	_	23	punct
33	0.28	0.28	CD	_	36	nummod
34	vs.	vs.	CC	_	33	cc
35	0.81	0.81	CD	_	33	conj
36	cm3	cm3	NN	_	23	dep
37	,	,	,	_	36	punct
38	difference	difference	NN	_	36	appos
39	=	=	JJ	_	38	amod
40	0.53	0.53	CD	_	41	nummod
41	cm3	cm3	NN	_	39	dep
42	,	,	,	_	36	punct
43	95	95	CD	_	44	compound
44	%	%	NN	_	46	amod
45	confidence	confidence	NN	_	46	compound
46	interval	interval	NN	_	36	appos
47	-LSB-	-lsb-	-LRB-	_	48	punct
48	CI	ci	NN	_	46	appos
49	-RSB-	-rsb-	-RRB-	_	48	punct
50	=	=	JJ	_	46	amod
51	0.44	0.44	CD	_	53	compound
52	to	to	TO	_	53	dep
53	0.62	0.62	CD	_	54	nummod
54	cm3	cm3	NN	_	50	dep
55	,	,	,	_	36	punct
56	P	p	NN	_	57	nsubj
57	=	=	JJ	_	36	dep
58	.014	.014	CD	_	57	dobj
59	-RRB-	-rrb-	-RRB-	_	23	punct
60	;	;	:	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	+	+	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	vs.	vs.	NN	_	1	dep

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	0.28	0.28	CD	_	1	dep
4	vs.	vs.	CC	_	1	dep

1	0.55	0.55	CD	_	2	nummod
2	cm3	cm3	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	difference	difference	NN	_	2	appos
5	=	=	JJ	_	4	amod
6	0.27	0.27	CD	_	7	nummod
7	cm3	cm3	NN	_	5	dep
8	,	,	,	_	2	punct
9	95	95	CD	_	10	compound
10	%	%	NN	_	11	amod
11	CI	ci	NN	_	2	appos
12	=	=	JJ	_	11	amod
13	0.21	0.21	CD	_	15	compound
14	to	to	TO	_	15	dep
15	0.33	0.33	CD	_	16	nummod
16	cm3	cm3	NN	_	12	dep
17	,	,	,	_	2	punct
18	P	p	NN	_	19	nsubj
19	=	=	JJ	_	2	dep
20	.035	.035	CD	_	19	dobj
21	-RRB-	-rrb-	-RRB-	_	19	punct
22	.	.	.	_	2	punct

1	Combined	combined	JJ	_	2	amod
2	treatment	treatment	NN	_	3	nsubj
3	induced	induce	VBD	_	0	ROOT
4	more	more	RBR	_	5	advmod
5	TUNEL-positive	tunel-positive	JJ	_	7	amod
6	apoptotic	apoptotic	JJ	_	7	amod
7	cells	cell	NNS	_	3	dobj
8	than	than	IN	_	9	dep
9	did	do	VBD	_	7	dep
10	either	either	DT	_	11	det
11	agent	agent	NN	_	9	nsubj
12	alone	alone	RB	_	11	advmod
13	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	siRNA	sirna	NN	_	3	compound
3	knockdown	knockdown	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	p27	p27	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	Kip1	kip1	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	decreased	decrease	VBD	_	0	ROOT
10	drug1	drug1	NN	_	9	dobj
11	-	-	:	_	10	punct
12	and	and	CC	_	10	cc
13	drug2	drug2	NN	_	10	conj
14	-	-	:	_	10	punct
15	induced	induced	JJ	_	16	amod
16	apoptosis	apoptosis	NN	_	10	dep
17	compared	compare	VBN	_	22	case
18	with	with	IN	_	22	case
19	a	a	DT	_	22	det
20	negative	negative	JJ	_	22	amod
21	control	control	NN	_	22	compound
22	siRNA	sirna	NN	_	16	nmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	sub-G1	sub-g1	NN	_	25	compound
25	fraction	fraction	NN	_	22	dep
26	,	,	,	_	25	punct
27	control	control	NN	_	28	compound
28	siRNA	siRNA	NNP	_	25	appos
29	vs.	vs.	CC	_	28	cc
30	p27	p27	NN	_	34	compound
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	Kip1	kip1	NN	_	30	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	siRNA	sirna	NN	_	28	conj
35	:	:	:	_	25	punct
36	42.5	42.5	CD	_	37	nummod
37	%	%	NN	_	25	dep
38	vs.	vs.	CC	_	37	cc
39	20.1	20.1	CD	_	40	nummod
40	%	%	NN	_	37	conj
41	,	,	,	_	37	punct
42	difference	difference	NN	_	37	appos
43	=	=	JJ	_	42	amod
44	22.4	22.4	CD	_	45	nummod
45	%	%	NN	_	43	dep
46	,	,	,	_	37	punct
47	95	95	CD	_	48	nummod
48	%	%	NN	_	37	appos
49	CI	ci	NN	_	58	nsubj
50	=	=	JJ	_	58	dep
51	20.1	20.1	CD	_	58	punct
52	%	%	NN	_	58	dep
53	to	to	TO	_	55	case
54	24.7	24.7	CD	_	55	nummod
55	%	%	NN	_	52	nmod
56	,	,	,	_	58	punct
57	P	p	NN	_	58	nsubj
58	=	=	JJ	_	48	acl:relcl
59	.017	.017	CD	_	58	dobj
60	-RRB-	-rrb-	-RRB-	_	25	punct
61	.	.	.	_	9	punct

1	Studies	study	NNS	_	12	nsubj
2	with	with	IN	_	4	case
3	forced	force	VBN	_	4	amod
4	expression	expression	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	siRNA	sirna	NN	_	7	compound
7	knockdown	knockdown	NN	_	4	conj
8	of	of	IN	_	9	case
9	Bcl-2	bcl-2	NN	_	4	nmod
10	and	and	CC	_	9	cc
11	Cdk1	cdk1	NN	_	9	conj
12	suggest	suggest	VBP	_	0	ROOT
13	that	that	IN	_	12	dobj
14	drug1	drug1	NN	_	13	dep
15	-	-	:	_	14	punct
16	mediated	mediated	JJ	_	17	amod
17	induction	induction	NN	_	23	nsubj
18	of	of	IN	_	19	case
19	p27	p27	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	Kip1	kip1	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	enhanced	enhance	VBD	_	14	dep
24	drug2	drug2	NN	_	23	dobj
25	-	-	:	_	24	punct
26	induced	induced	JJ	_	27	amod
27	apoptosis	apoptosis	NN	_	24	dep
28	by	by	IN	_	30	mark
29	negatively	negatively	RB	_	30	advmod
30	regulating	regulate	VBG	_	27	acl
31	Bcl-2	bcl-2	NN	_	34	compound
32	and	and	CC	_	31	cc
33	Cdk1	cdk1	NN	_	31	conj
34	expression	expression	NN	_	30	dobj
35	.	.	.	_	12	punct

1	Inhibition	inhibition	NN	_	13	nsubj
2	of	of	IN	_	4	case
3	Src	src	NN	_	4	compound
4	family	family	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	Abl	abl	NN	_	7	compound
7	kinases	kinase	NNS	_	4	conj
8	with	with	IN	_	10	case
9	either	either	CC	_	10	cc:preconj
10	siRNAs	sirnas	NN	_	1	nmod
11	or	or	CC	_	10	cc
12	drug1	drug1	NN	_	10	conj
13	enhances	enhance	VBZ	_	0	ROOT
14	drug2	drug2	NN	_	15	compound
15	sensitivity	sensitivity	NN	_	13	dobj
16	of	of	IN	_	19	case
17	ovarian	ovarian	JJ	_	19	amod
18	cancer	cancer	NN	_	19	compound
19	cells	cell	NNS	_	15	nmod
20	through	through	IN	_	21	case
21	p27	p27	NN	_	13	nmod
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	Kip1	kip1	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	-	-	:	_	21	punct
26	mediated	mediate	VBN	_	27	amod
27	suppression	suppression	NN	_	21	dep
28	of	of	IN	_	29	case
29	Bcl-2	bcl-2	NN	_	27	nmod
30	and	and	CC	_	29	cc
31	Cdk1	cdk1	NN	_	29	conj
32	expression	expression	NN	_	29	dep
33	.	.	.	_	13	punct

1	Influence	influence	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	induced	induce	VBD	_	0	ROOT
7	antinociception	antinociception	NN	_	6	dobj
8	and	and	CC	_	7	cc
9	its	its	PRP$	_	10	nmod:poss
10	pharmacokinetics	pharmacokinetic	NNS	_	7	conj
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	CAS	cas	NN	_	1	appos
4	94-62-2	94-62-2	CD	_	3	nummod
5	-RRB-	-rrb-	-RRB-	_	3	punct
6	,	,	,	_	1	punct
7	an	a	DT	_	8	det
8	alkaloid	alkaloid	NN	_	1	appos
9	obtained	obtain	VBN	_	8	acl
10	from	from	IN	_	12	case
11	Piper	Piper	NNP	_	12	compound
12	nigrum	nigrum	NNP	_	9	nmod
13	and	and	CC	_	12	cc
14	P.	P.	NNP	_	12	conj

1	longum	longum	NN	_	6	nsubj
2	,	,	,	_	6	punct
3	is	be	VBZ	_	6	cop
4	a	a	DT	_	6	det
5	known	known	JJ	_	6	amod
6	inhibitor	inhibitor	NN	_	0	ROOT
7	of	of	IN	_	9	case
8	various	various	JJ	_	9	amod
9	enzymes	enzyme	NNS	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	CYP	cyp	NN	_	12	compound
12	isozymes	isozyme	NNS	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	responsible	responsible	JJ	_	9	amod
15	for	for	IN	_	16	case
16	biotransformation	biotransformation	NN	_	14	nmod
17	of	of	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	.	.	.	_	6	punct

1	By	by	IN	_	2	mark
2	inhibiting	inhibit	VBG	_	9	advcl
3	the	the	DT	_	4	det
4	metabolism	metabolism	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	,	,	,	_	9	punct
8	drug1	drug1	NN	_	9	nsubj
9	improves	improve	VBZ	_	0	ROOT
10	the	the	DT	_	11	det
11	bioavailability	bioavailability	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drugs	drug	NNS	_	11	nmod
14	.	.	.	_	9	punct

1	In	in	IN	_	5	case
2	the	the	DT	_	5	det
3	present	present	JJ	_	5	amod
4	study	study	NN	_	5	compound
5	drug1	drug1	NN	_	11	nmod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	10	10	CD	_	8	nummod
8	mg/kg	mg/kg	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	significantly	significantly	RB	_	11	advmod
11	increased	increase	VBD	_	0	ROOT
12	the	the	DT	_	15	det
13	dose-dependent	dose-dependent	JJ	_	15	amod
14	antinociceptive	antinociceptive	JJ	_	15	amod
15	activity	activity	NN	_	11	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	evaluated	evaluate	VBN	_	17	acl
19	by	by	IN	_	22	case
20	both	both	CC	_	22	cc:preconj
21	drug3	drug3	NN	_	22	compound
22	writhing	writhe	VBG	_	18	nmod
23	and	and	CC	_	22	cc
24	formalin	formalin	NN	_	25	compound
25	test	test	NN	_	22	conj
26	,	,	,	_	11	punct
27	when	when	WRB	_	30	advmod
28	it	it	PRP	_	30	nsubjpass
29	was	be	VBD	_	30	auxpass
30	administered	administer	VBN	_	11	advcl
31	with	with	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	compound
2	plasma	plasma	NN	_	3	compound
3	concentration	concentration	NN	_	6	nsubjpass
4	was	be	VBD	_	6	auxpass
5	also	also	RB	_	6	advmod
6	increased	increase	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	it	it	PRP	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	administered	administer	VBN	_	6	advcl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	6	punct

1	The	the	DT	_	4	det
2	synergistic	synergistic	JJ	_	4	amod
3	antinociception	antinociception	NN	_	4	compound
4	activity	activity	NN	_	13	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	when	when	WRB	_	8	advmod
8	administered	administer	VBN	_	4	acl:relcl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	can	can	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	attributed	attribute	VBN	_	0	ROOT
14	to	to	TO	_	17	case
15	increased	increase	VBN	_	17	amod
16	plasma	plasma	NN	_	17	compound
17	concentration	concentration	NN	_	13	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	13	punct

1	From	from	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	7	nmod
4	it	it	PRP	_	7	nsubjpass
5	can	can	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	concluded	conclude	VBN	_	0	ROOT
8	that	that	IN	_	12	mark
9	drug1	drug1	NN	_	12	nsubjpass
10	can	can	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	used	use	VBN	_	7	ccomp
13	as	as	IN	_	15	case
14	a	a	DT	_	15	det
15	bioenhancer	bioenhancer	NN	_	12	nmod
16	along	along	IN	_	18	case
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	15	nmod
19	.	.	.	_	7	punct

1	Prevention	Prevention	NNP	_	0	ROOT
2	of	of	IN	_	4	case
3	emergence	emergence	NN	_	4	compound
4	agitation	agitation	NN	_	1	nmod
5	in	in	IN	_	7	case
6	seven	seven	CD	_	7	nummod
7	children	child	NNS	_	1	nmod
8	receiving	receive	VBG	_	7	acl
9	low-dose	low-dose	JJ	_	10	amod
10	drug1	drug1	NN	_	8	dobj
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	15	compound
13	total	total	JJ	_	15	amod
14	intravenous	intravenous	JJ	_	15	amod
15	anesthesia	anesthesia	NN	_	10	conj
16	.	.	.	_	1	punct

1	Emergence	emergence	NN	_	2	compound
2	agitation	agitation	NN	_	11	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	EA	ea	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	can	can	MD	_	11	aux
7	be	be	VB	_	11	cop
8	a	a	DT	_	11	det
9	distressing	distressing	JJ	_	11	amod
10	side	side	NN	_	11	compound
11	effect	effect	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	pediatric	pediatric	JJ	_	14	amod
14	anesthesia	anesthesia	NN	_	11	nmod
15	.	.	.	_	11	punct

1	We	we	PRP	_	3	nsubj
2	retrospectively	retrospectively	RB	_	3	advmod
3	reviewed	review	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	records	record	NNS	_	3	dobj
6	of	of	IN	_	10	case
7	7	7	CD	_	10	nummod
8	pediatric	pediatric	JJ	_	10	amod
9	oncology	oncology	NN	_	10	compound
10	patients	patient	NNS	_	5	nmod
11	who	who	WP	_	12	nsubj
12	received	receive	VBD	_	10	acl:relcl
13	low-dose	low-dose	JJ	_	14	amod
14	drug1	drug1	NN	_	12	dobj
15	in	in	IN	_	16	case
16	conjunction	conjunction	NN	_	12	nmod
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	for	for	IN	_	22	case
20	total	total	JJ	_	22	amod
21	intravenous	intravenous	JJ	_	22	amod
22	anesthesia	anesthesia	NN	_	12	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	TIVA	tiva	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	repeatedly	repeatedly	RB	_	22	advmod
27	for	for	IN	_	29	case
28	radiation	radiation	NN	_	29	compound
29	therapy	therapy	NN	_	22	nmod
30	.	.	.	_	3	punct

1	EA	ea	NN	_	2	compound
2	signs	sign	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	in	in	IN	_	8	case
6	all	all	DT	_	8	det
7	7	7	CD	_	8	nummod
8	patients	patient	NNS	_	4	nmod
9	in	in	IN	_	10	case
10	association	association	NN	_	8	nmod
11	with	with	IN	_	13	case
12	drug1	drug1	NN	_	13	compound
13	TIVA	tiva	NN	_	10	nmod
14	but	but	CC	_	4	cc
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	recur	recur	VB	_	4	conj
18	in	in	IN	_	17	nmod
19	any	any	DT	_	18	dep
20	of	of	IN	_	24	case
21	123	123	CD	_	24	nummod
22	subsequent	subsequent	JJ	_	24	amod
23	anesthetics	anesthetic	NNS	_	24	compound
24	sessions	session	NNS	_	19	nmod
25	during	during	IN	_	26	case
26	which	which	WDT	_	30	nmod
27	low-dose	low-dose	JJ	_	28	amod
28	drug2	drug2	NN	_	30	nsubjpass
29	was	be	VBD	_	30	auxpass
30	added	add	VBN	_	24	acl:relcl
31	to	to	TO	_	32	case
32	drug3	drug3	NN	_	30	nmod
33	.	.	.	_	4	punct

1	Based	base	VBN	_	4	case
2	on	on	IN	_	4	case
3	this	this	DT	_	4	det
4	experience	experience	NN	_	7	advcl
5	,	,	,	_	7	punct
6	we	we	PRP	_	7	nsubj
7	suggest	suggest	VBP	_	0	ROOT
8	that	that	IN	_	11	mark
9	low-dose	low-dose	JJ	_	10	amod
10	drug1	drug1	NN	_	11	nsubj
11	added	add	VBD	_	7	ccomp
12	to	to	TO	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	associated	associate	VBN	_	11	ccomp
17	with	with	IN	_	18	case
18	prevention	prevention	NN	_	16	nmod
19	of	of	IN	_	20	case
20	EA	ea	NN	_	18	nmod
21	in	in	IN	_	22	case
22	children	child	NNS	_	18	nmod
23	with	with	IN	_	25	case
24	a	a	DT	_	25	det
25	history	history	NN	_	22	nmod
26	of	of	IN	_	27	case
27	EA	ea	NN	_	25	nmod
28	with	with	IN	_	30	case
29	drug3	drug3	NN	_	30	compound
30	TIVA	tiva	NN	_	27	nmod
31	.	.	.	_	7	punct

1	-LSB-	-lsb-	-LRB-	_	2	punct
2	Efficacy	efficacy	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	fixed	fix	VBN	_	6	amod
5	combination	combination	NN	_	6	compound
6	drug1	drug1	NN	_	2	nmod
7	/	/	:	_	2	punct
8	drug2	drug2	NN	_	2	dep
9	in	in	IN	_	11	case
10	hospitalized	hospitalize	VBN	_	11	amod
11	patients	patient	NNS	_	8	nmod
12	with	with	IN	_	14	case
13	hypertensive	hypertensive	JJ	_	14	amod
14	disease	disease	NN	_	11	nmod
15	-RSB-	-rsb-	-RRB-	_	2	punct

1	Efficacy	efficacy	NN	_	11	nsubjpass
2	and	and	CC	_	1	cc
3	tolerability	tolerability	NN	_	1	conj
4	of	of	IN	_	6	case
5	fixed	fix	VBN	_	6	amod
6	drug1	drug1	NN	_	1	nmod
7	/	/	:	_	6	punct
8	drug2	drug2	NN	_	9	compound
9	combination	combination	NN	_	6	dep
10	was	be	VBD	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	86	86	CD	_	14	nummod
14	patients	patient	NNS	_	11	nmod
15	with	with	IN	_	17	case
16	hypertensive	hypertensive	JJ	_	17	amod
17	disease	disease	NN	_	14	nmod
18	hospitalized	hospitalize	VBN	_	14	acl
19	in	in	IN	_	20	case
20	departments	department	NNS	_	18	nmod
21	of	of	IN	_	24	case
22	general	general	JJ	_	24	amod
23	internal	internal	JJ	_	24	amod
24	medicine	medicine	NN	_	20	nmod
25	or	or	CC	_	24	cc
26	cardiology	cardiology	NN	_	24	conj
27	.	.	.	_	11	punct

1	All	all	DT	_	2	det
2	patients	patient	NNS	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	indications	indication	NNS	_	3	dobj
5	for	for	IN	_	7	case
6	antihypertensive	antihypertensive	JJ	_	7	amod
7	therapy	therapy	NN	_	4	nmod
8	and	and	CC	_	3	cc
9	were	be	VBD	_	10	auxpass
10	randomized	randomize	VBN	_	3	conj
11	either	either	CC	_	17	cc:preconj
12	to	to	TO	_	17	case
13	fixed	fix	VBN	_	17	amod
14	combination	combination	NN	_	17	compound
15	drug1	drug1	NN	_	17	compound
16	/	/	:	_	17	punct
17	drug2	drug2	NN	_	10	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	n	n	NN	_	17	dep
20	=	=	JJ	_	19	amod
21	43	43	CD	_	20	dep
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	or	or	CC	_	17	cc
24	to	to	TO	_	25	case
25	therapy	therapy	NN	_	17	conj
26	which	which	WDT	_	27	nsubj
27	corresponded	correspond	VBD	_	17	acl:relcl
28	to	to	TO	_	31	case
29	the	the	DT	_	31	det
30	hospital	hospital	NN	_	31	compound
31	formulary	formulary	NN	_	27	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	n	n	NN	_	31	dep
34	=	=	JJ	_	33	amod
35	43	43	CD	_	34	dep
36	-RRB-	-rrb-	-RRB-	_	33	punct
37	.	.	.	_	3	punct

1	Correction	correction	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	therapy	therapy	NN	_	1	nmod
5	was	be	VBD	_	6	auxpass
6	performed	perform	VBN	_	0	ROOT
7	by	by	IN	_	8	mark
8	treating	treat	VBG	_	6	advcl
9	physician	physician	NN	_	8	dobj
10	at	at	IN	_	12	case
11	daily	daily	JJ	_	12	amod
12	rounds	round	NNS	_	8	nmod
13	.	.	.	_	6	punct

1	Self-control	self-control	NN	_	9	nsubjpass
2	of	of	IN	_	4	case
3	blood	blood	NN	_	4	compound
4	pressure	pressure	NN	_	1	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	BP	bp	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	was	be	VBD	_	9	auxpass
9	performed	perform	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	with	with	IN	_	14	case
13	the	the	DT	_	14	det
14	use	use	NN	_	11	nmod
15	of	of	IN	_	17	case
16	UA767PC	ua767pc	NN	_	17	compound
17	apparatus	apparatus	NN	_	14	nmod
18	.	.	.	_	9	punct

1	Results	result	NNS	_	6	nsubjpass
2	of	of	IN	_	4	case
3	BP	BP	NNP	_	4	compound
4	self-control	self-control	NN	_	1	nmod
5	were	be	VBD	_	6	auxpass
6	compared	compare	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	clinical	clinical	JJ	_	9	amod
9	measurements	measurement	NNS	_	6	nmod
10	in	in	IN	_	13	mark
11	order	order	NN	_	10	mwe
12	to	to	TO	_	13	mark
13	detect	detect	VB	_	9	acl
14	concealed	conceal	VBN	_	15	amod
15	inefficacy	inefficacy	NN	_	13	dobj
16	of	of	IN	_	17	case
17	treatment	treatment	NN	_	15	nmod
18	.	.	.	_	6	punct

1	Results	result	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	Rate	rate	NN	_	18	nsubj
2	of	of	IN	_	3	case
3	achievement	achievement	NN	_	1	nmod
4	of	of	IN	_	6	case
5	target	target	NN	_	6	compound
6	BP	bp	NN	_	3	nmod
7	with	with	IN	_	12	case
8	fixed	fix	VBN	_	12	amod
9	combination	combination	NN	_	12	compound
10	drug1	drug1	NN	_	12	compound
11	/	/	:	_	12	punct
12	drug2	drug2	NN	_	1	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	93	93	CD	_	15	nummod
15	%	%	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	was	be	VBD	_	18	cop
18	comparable	comparable	JJ	_	0	ROOT
19	with	with	IN	_	20	case
20	that	that	DT	_	18	nmod
21	on	on	IN	_	23	case
22	traditional	traditional	JJ	_	23	amod
23	therapy	therapy	NN	_	20	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	90	90	CD	_	26	nummod
26	%	%	NN	_	23	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	.	.	.	_	18	punct

1	But	but	CC	_	15	cc
2	the	the	DT	_	3	det
3	use	use	NN	_	15	nsubjpass
4	of	of	IN	_	7	case
5	fixed	fix	VBN	_	7	amod
6	combination	combination	NN	_	7	compound
7	drug1	drug1	NN	_	3	nmod
8	/	/	:	_	7	punct
9	drug2	drug2	NN	_	7	dep
10	compared	compare	VBN	_	13	case
11	with	with	IN	_	13	case
12	traditional	traditional	JJ	_	13	amod
13	therapy	therapy	NN	_	3	nmod
14	was	be	VBD	_	15	auxpass
15	associated	associate	VBN	_	0	ROOT
16	with	with	IN	_	18	case
17	lower	lower	JJR	_	18	dep
18	clinical	clinical	JJ	_	15	nmod
19	and	and	CC	_	18	cc
20	self	self	NN	_	18	conj
21	measured	measure	VBD	_	18	dep
22	BP	BP	NNP	_	21	dobj
23	,	,	,	_	22	punct
24	quicker	quicker	JJR	_	25	amod
25	achievement	achievement	NN	_	22	appos
26	of	of	IN	_	28	case
27	target	target	NN	_	28	compound
28	BP	bp	NN	_	25	nmod
29	-LRB-	-lrb-	-LRB-	_	25	punct
30	5.8	5.8	CD	_	29	root
31	+	+	CC	_	30	cc
32	/	/	:	_	33	punct
33	-2.3	-2.3	CD	_	30	conj
34	and	and	CC	_	33	cc
35	9.2	9.2	CD	_	33	conj
36	+	+	CC	_	30	cc
37	/	/	:	_	39	punct
38	-1.8	-1.8	CD	_	39	nummod
39	days	day	NNS	_	30	conj
40	,	,	,	_	39	punct
41	respectively	respectively	RB	_	39	advmod
42	,	,	,	_	39	punct
43	0.05	0.05	CD	_	39	dep
44	-RRB-	-rrb-	-RRB-	_	39	punct
45	,	,	,	_	30	punct
46	lesser	lesser	JJR	_	47	amod
47	number	number	NN	_	45	root
48	of	of	IN	_	49	case
49	drug3	drug3	NN	_	47	nmod
50	-LRB-	-lrb-	-LRB-	_	49	punct
51	2.5	2.5	CD	_	50	root
52	+	+	CC	_	51	cc
53	/	/	:	_	54	punct
54	-0.6	-0.6	CD	_	51	conj
55	and	and	CC	_	54	cc
56	3.0	3.0	CD	_	54	conj
57	+	+	CC	_	51	cc
58	/	/	:	_	60	punct
59	-0.9	-0.9	CD	_	60	nummod
60	days	day	NNS	_	51	conj
61	,	,	,	_	60	punct
62	respectively	respectively	RB	_	60	advmod
63	-RRB-	-rrb-	-RRB-	_	60	punct
64	,	,	,	_	51	punct
65	lower	lower	JJR	_	66	amod
66	rate	rate	NN	_	64	root
67	of	of	IN	_	69	case
68	concealed	conceal	VBN	_	69	amod
69	inefficacy	inefficacy	NN	_	66	nmod
70	of	of	IN	_	71	case
71	treatment	treatment	NN	_	69	nmod
72	-LRB-	-lrb-	-LRB-	_	76	punct
73	12	12	CD	_	76	nummod
74	and	and	CC	_	73	cc
75	31	31	CD	_	73	conj
76	%	%	NN	_	66	dep
77	,	,	,	_	76	punct
78	respectively	respectively	RB	_	76	advmod
79	,	,	,	_	76	punct
80	0.05	0.05	CD	_	76	dep
81	-RRB-	-rrb-	-RRB-	_	76	punct
82	.	.	.	_	66	punct

1	Conclusions	conclusion	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	We	we	PRP	_	3	nsubj
2	have	have	VBP	_	3	aux
3	demonstrated	demonstrate	VBN	_	0	ROOT
4	appropriateness	appropriateness	NN	_	13	dep
5	of	of	IN	_	7	case
6	inhospital	inhospital	JJ	_	7	amod
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	10	case
9	fixed	fix	VBN	_	10	amod
10	drug1	drug1	NN	_	7	nmod
11	/	/	:	_	13	punct
12	drug2	drug2	NN	_	13	compound
13	combination	combination	NN	_	3	ccomp
14	as	as	IN	_	16	case
15	an	a	DT	_	16	det
16	approach	approach	NN	_	13	nmod
17	allowing	allow	VBG	_	16	acl
18	to	to	TO	_	19	mark
19	achieve	achieve	VB	_	17	xcomp
20	target	target	NN	_	21	compound
21	BP	bp	NN	_	19	dobj
22	in	in	IN	_	24	case
23	shorter	shorter	JJR	_	24	amod
24	time	time	NN	_	19	nmod
25	,	,	,	_	13	punct
26	with	with	IN	_	28	case
27	the	the	DT	_	28	det
28	use	use	NN	_	13	nmod
29	of	of	IN	_	31	case
30	fewer	fewer	JJR	_	31	amod
31	drug3	drug3	NN	_	28	nmod
32	,	,	,	_	13	punct
33	and	and	CC	_	13	cc
34	diminishing	diminish	VBG	_	13	conj
35	concealed	conceal	VBN	_	36	amod
36	inefficacy	inefficacy	NN	_	34	dobj
37	of	of	IN	_	38	case
38	treatment	treatment	NN	_	36	nmod
39	.	.	.	_	3	punct

1	Antitumor	antitumor	JJ	_	2	amod
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	a	a	DT	_	8	det
7	specific	specific	JJ	_	8	amod
8	inhibitor	inhibitor	NN	_	4	appos
9	of	of	IN	_	10	case
10	HB-EGF	hb-egf	NN	_	8	nmod
11	,	,	,	_	4	punct
12	in	in	IN	_	16	case
13	T-cell	t-cell	NN	_	16	compound
14	acute	acute	JJ	_	16	amod
15	lymphoblastic	lymphoblastic	JJ	_	16	amod
16	leukemia	leukemia	NN	_	2	nmod
17	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	therapeutic	therapeutic	JJ	_	3	amod
3	outcome	outcome	NN	_	12	nsubj
4	for	for	IN	_	8	case
5	T-cell	t-cell	NN	_	8	compound
6	acute	acute	JJ	_	8	amod
7	lymphoblastic	lymphoblastic	JJ	_	8	amod
8	leukemia	leukemia	NN	_	3	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	T-ALL	t-all	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	remains	remain	VBZ	_	0	ROOT
13	poor	poor	JJ	_	12	xcomp
14	;	;	:	_	12	punct

1	thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	novel	novel	JJ	_	9	dep
4	,	,	,	_	9	punct
5	targeted	target	VBN	_	6	amod
6	therapies	therapy	NNS	_	9	nsubjpass
7	are	be	VBP	_	9	auxpass
8	urgently	urgently	RB	_	9	advmod
9	needed	need	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Recently	recently	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	showed	show	VBD	_	0	ROOT
5	that	that	IN	_	26	mark
6	heparin-binding	heparin-binding	JJ	_	11	amod
7	epidermal	epidermal	JJ	_	11	amod
8	growth	growth	NN	_	11	compound
9	factor-like	factor-like	JJ	_	11	amod
10	growth	growth	NN	_	11	compound
11	factor	factor	NN	_	26	nsubj
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	HB-EGF	hb-egf	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	,	,	,	_	11	punct
16	a	a	DT	_	17	det
17	member	member	NN	_	11	appos
18	of	of	IN	_	21	case
19	the	the	DT	_	21	det
20	EGF	egf	NN	_	21	compound
21	family	family	NN	_	17	nmod
22	,	,	,	_	11	punct
23	is	be	VBZ	_	26	cop
24	a	a	DT	_	26	det
25	promising	promising	JJ	_	26	amod
26	target	target	NN	_	4	ccomp
27	for	for	IN	_	29	case
28	the	the	DT	_	29	det
29	treatment	treatment	NN	_	26	nmod
30	of	of	IN	_	32	case
31	various	various	JJ	_	32	amod
32	types	type	NNS	_	29	nmod
33	of	of	IN	_	34	case
34	cancer	cancer	NN	_	32	nmod
35	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	aim	aim	NN	_	7	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	present	present	JJ	_	6	amod
6	study	study	NN	_	2	nmod
7	was	be	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	investigate	investigate	VB	_	7	xcomp
10	whether	whether	IN	_	15	mark
11	HB-EGF	hb-egf	NN	_	15	nsubj
12	is	be	VBZ	_	15	cop
13	a	a	DT	_	15	det
14	therapeutic	therapeutic	JJ	_	15	amod
15	target	target	NN	_	9	ccomp
16	for	for	IN	_	17	case
17	T-ALL	t-all	NN	_	15	nmod
18	,	,	,	_	9	punct
19	and	and	CC	_	9	cc
20	to	to	TO	_	22	mark
21	further	further	RB	_	22	advmod
22	elucidate	elucidate	VB	_	9	conj
23	the	the	DT	_	25	det
24	antitumor	antitumor	JJ	_	25	amod
25	effects	effect	NNS	_	22	dobj
26	of	of	IN	_	29	case
27	a	a	DT	_	29	det
28	specific	specific	JJ	_	29	amod
29	inhibitor	inhibitor	NN	_	25	nmod
30	of	of	IN	_	31	case
31	HB-EGF	hb-egf	NN	_	29	nmod
32	,	,	,	_	31	punct
33	drug1	drug1	NN	_	31	appos
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	drug2	drug2	NN	_	33	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	.	.	.	_	7	punct

1	We	we	PRP	_	2	nsubj
2	elucidated	elucidate	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	expression	expression	NN	_	2	dobj
5	of	of	IN	_	6	case
6	HB-EGF	hb-egf	NN	_	4	nmod
7	in	in	IN	_	10	case
8	T-ALL	t-all	NN	_	10	compound
9	cell	cell	NN	_	10	compound
10	lines	line	NNS	_	4	nmod
11	,	,	,	_	2	punct
12	and	and	CC	_	2	cc
13	evaluated	evaluate	VBD	_	2	conj
14	the	the	DT	_	15	det
15	effect	effect	NN	_	13	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	on	on	IN	_	20	case
19	these	these	DT	_	20	det
20	cells	cell	NNS	_	15	nmod
21	alone	alone	RB	_	22	advmod
22	or	or	CC	_	20	advmod
23	in	in	IN	_	24	case
24	combination	combination	NN	_	22	conj
25	with	with	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	expression	expression	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	EGFR	egfr	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	EGFR	egfr	NN	_	4	conj
7	ligands	ligand	NNS	_	4	dep
8	was	be	VBD	_	9	auxpass
9	determined	determine	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	flow	flow	NN	_	12	compound
12	cytometry	cytometry	NN	_	9	nmod
13	,	,	,	_	12	punct
14	RT-PCR	rt-pcr	NN	_	12	conj
15	and	and	CC	_	12	cc
16	real-time	real-time	JJ	_	18	amod
17	quantitative	quantitative	JJ	_	18	amod
18	PCR	pcr	NN	_	12	conj
19	.	.	.	_	9	punct

1	Induction	induction	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	apoptosis	apoptosis	NN	_	1	nmod
4	was	be	VBD	_	5	auxpass
5	assessed	assess	VBN	_	0	ROOT
6	by	by	IN	_	8	case
7	TUNEL	tunel	NN	_	8	compound
8	assay	assay	NN	_	5	nmod
9	.	.	.	_	5	punct

1	HB-EGF	hb-egf	NN	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	strongly	strongly	RB	_	4	advmod
4	expressed	express	VBN	_	0	ROOT
5	by	by	IN	_	8	case
6	T-ALL	t-all	NN	_	8	compound
7	cell	cell	NN	_	8	compound
8	lines	line	NNS	_	4	nmod
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	the	the	DT	_	12	det
12	expression	expression	NN	_	19	nsubjpass
13	of	of	IN	_	15	case
14	both	both	CC	_	15	cc:preconj
15	HB-EGF	hb-egf	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	EGFR	egfr	NN	_	15	conj
18	was	be	VBD	_	19	auxpass
19	enhanced	enhance	VBN	_	4	conj
20	by	by	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	induced	induce	VBD	_	0	ROOT
3	apoptosis	apoptosis	NN	_	2	dobj
4	,	,	,	_	2	punct
5	and	and	CC	_	2	cc
6	furthermore	furthermore	RB	_	14	advmod
7	,	,	,	_	14	punct
8	the	the	DT	_	9	det
9	combination	combination	NN	_	14	nsubj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	plus	plus	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	enhanced	enhance	VBD	_	2	conj
15	cytotoxicity	cytotoxicity	NN	_	14	dobj
16	in	in	IN	_	20	case
17	a	a	DT	_	20	det
18	T-ALL	t-all	NN	_	20	compound
19	cell	cell	NN	_	20	compound
20	line	line	NN	_	14	nmod
21	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	10	mark
5	HB-EGF	hb-egf	NN	_	10	nsubj
6	is	be	VBZ	_	10	cop
7	a	a	DT	_	10	det
8	promising	promising	JJ	_	10	amod
9	therapeutic	therapeutic	JJ	_	10	amod
10	target	target	NN	_	3	ccomp
11	for	for	IN	_	12	case
12	T-ALL	t-all	NN	_	10	nmod
13	.	.	.	_	3	punct

1	Distinct	distinct	JJ	_	3	amod
2	synergistic	synergistic	JJ	_	3	amod
3	action	action	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	against	against	IN	_	10	case
9	Pseudomonas	pseudomonas	FW	_	10	compound
10	aeruginosa	aeruginosa	FW	_	3	nmod
11	.	.	.	_	3	punct

1	The	the	DT	_	4	det
2	dicarbonyl	dicarbonyl	NN	_	4	compound
3	compound	compound	NN	_	4	compound
4	drug1	drug1	NN	_	8	nsubj
5	is	be	VBZ	_	8	cop
6	a	a	DT	_	8	det
7	natural	natural	JJ	_	8	amod
8	constituent	constituent	NN	_	0	ROOT
9	of	of	IN	_	11	case
10	Manuka	Manuka	NNP	_	11	compound
11	honey	honey	NN	_	8	nmod
12	produced	produce	VBD	_	8	acl
13	from	from	IN	_	15	case
14	Manuka	Manuka	NNP	_	15	compound
15	flowers	flower	NNS	_	12	nmod
16	in	in	IN	_	18	case
17	New	New	NNP	_	18	compound
18	Zealand	Zealand	NNP	_	15	nmod
19	.	.	.	_	8	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	possess	possess	VB	_	3	xcomp
6	both	both	CC	_	7	cc:preconj
7	anticancer	anticancer	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	antibacterial	antibacterial	JJ	_	7	conj
10	activity	activity	NN	_	5	dobj
11	.	.	.	_	3	punct

1	Such	such	JJ	_	2	amod
2	observations	observation	NNS	_	3	nsubj
3	prompted	prompt	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	investigate	investigate	VB	_	3	xcomp
6	the	the	DT	_	7	det
7	ability	ability	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	as	as	IN	_	13	case
11	a	a	DT	_	13	det
12	potent	potent	JJ	_	13	amod
13	drug	drug	NN	_	7	nmod
14	against	against	IN	_	18	case
15	multidrug	multidrug	JJ	_	18	amod
16	resistant	resistant	JJ	_	18	amod
17	Pseudomonas	pseudomonas	FW	_	18	compound
18	aeruginosa	aeruginosa	FW	_	13	nmod
19	.	.	.	_	3	punct

1	A	a	DT	_	2	det
2	total	total	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	12	12	CD	_	6	nummod
5	test	test	NN	_	6	compound
6	P.	P.	NNP	_	2	nmod

1	aeruginosa	aeruginosa	FW	_	2	compound
2	strains	strain	NNS	_	8	nsubjpass
3	isolated	isolate	VBN	_	2	acl
4	from	from	IN	_	6	case
5	various	various	JJ	_	6	amod
6	hospitals	hospital	NNS	_	3	nmod
7	were	be	VBD	_	8	auxpass
8	tested	test	VBN	_	0	ROOT
9	for	for	IN	_	11	case
10	their	they	PRP$	_	11	nmod:poss
11	resistances	resistance	NNS	_	8	nmod
12	against	against	IN	_	14	case
13	many	many	JJ	_	14	amod
14	drug1	drug1	NN	_	11	nmod
15	,	,	,	_	14	punct
16	most	most	JJS	_	20	nsubjpass
17	of	of	IN	_	18	case
18	which	which	WDT	_	16	nmod
19	are	be	VBP	_	20	auxpass
20	applied	apply	VBN	_	14	acl:relcl
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	treatment	treatment	NN	_	20	nmod
24	of	of	IN	_	25	case
25	P.	P.	NNP	_	23	nmod

1	aeruginosa	aeruginosa	FW	_	2	compound
2	infections	infection	NNS	_	0	ROOT
3	.	.	.	_	2	punct

1	Results	result	NNS	_	2	nsubj
2	revealed	reveal	VBD	_	0	ROOT
3	that	that	IN	_	7	mark
4	the	the	DT	_	5	det
5	strains	strain	NNS	_	7	nsubj
6	were	be	VBD	_	7	cop
7	resistant	resistant	JJ	_	2	ccomp
8	to	to	TO	_	10	case
9	many	many	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	at	at	IN	_	13	case
12	high	high	JJ	_	13	amod
13	levels	level	NNS	_	7	nmod
14	,	,	,	_	7	punct
15	only	only	RB	_	16	advmod
16	drug1	drug1	NN	_	23	nsubj
17	,	,	,	_	16	punct
18	drug2	drug2	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug3	drug3	NN	_	16	conj
21	and	and	CC	_	16	cc
22	drug4	drug4	NN	_	16	conj
23	showed	show	VBD	_	7	ccomp
24	resistances	resistance	NNS	_	23	dobj
25	at	at	IN	_	28	case
26	comparatively	comparatively	RB	_	27	advmod
27	lower	lower	JJR	_	28	amod
28	levels	level	NNS	_	23	nmod
29	.	.	.	_	2	punct

1	Following	follow	VBG	_	3	case
2	multiple	multiple	JJ	_	3	amod
3	experimentations	experimentation	NNS	_	6	nmod
4	it	it	PRP	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	that	that	IN	_	11	mark
8	drug1	drug1	NN	_	11	nsubj
9	was	be	VBD	_	11	cop
10	also	also	RB	_	11	advmod
11	antimicrobic	antimicrobic	JJ	_	6	ccomp
12	against	against	IN	_	15	case
13	all	all	PDT	_	15	det:predet
14	the	the	DT	_	15	det
15	strains	strain	NNS	_	11	nmod
16	at	at	IN	_	18	case
17	comparable	comparable	JJ	_	18	amod
18	levels	level	NNS	_	11	nmod
19	.	.	.	_	6	punct

1	Distinct	distinct	JJ	_	5	amod
2	and	and	CC	_	1	cc
3	statistically	statistically	RB	_	4	advmod
4	significant	significant	JJ	_	1	conj
5	synergism	synergism	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	0	ROOT
8	between	between	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	by	by	IN	_	15	case
13	disc	disc	NN	_	15	compound
14	diffusion	diffusion	NN	_	15	compound
15	tests	test	NNS	_	7	nmod
16	when	when	WRB	_	17	advmod
17	compared	compare	VBN	_	7	advcl
18	with	with	IN	_	21	case
19	their	they	PRP$	_	21	nmod:poss
20	individual	individual	JJ	_	21	amod
21	effects	effect	NNS	_	17	nmod
22	.	.	.	_	7	punct

1	The	the	DT	_	5	det
2	fractional	fractional	JJ	_	5	amod
3	inhibitory	inhibitory	JJ	_	5	amod
4	concentration	concentration	NN	_	5	compound
5	index	index	NN	_	15	nsubj
6	of	of	IN	_	8	case
7	this	this	DT	_	8	det
8	combination	combination	NN	_	5	nmod
9	evaluated	evaluate	VBN	_	8	acl
10	by	by	IN	_	12	case
11	checkerboard	checkerboard	NN	_	12	compound
12	analysis	analysis	NN	_	9	nmod
13	,	,	,	_	5	punct
14	was	be	VBD	_	15	cop
15	0.5	0.5	CD	_	0	ROOT
16	,	,	,	_	15	punct
17	which	which	WDT	_	18	nsubj
18	confirmed	confirm	VBD	_	15	acl:relcl
19	synergism	synergism	NN	_	18	dobj
20	between	between	IN	_	22	case
21	the	the	DT	_	22	det
22	pair	pair	NN	_	19	nmod
23	.	.	.	_	15	punct

1	Synergism	synergism	NN	_	4	nsubjpass
2	was	be	VBD	_	4	auxpass
3	also	also	RB	_	4	advmod
4	noted	note	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	combined	combine	VBN	_	4	advcl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	failure	failure	NN	_	0	ROOT
3	in	in	IN	_	6	case
4	an	a	DT	_	6	det
5	HIV-positive	hiv-positive	JJ	_	6	amod
6	woman	woman	NN	_	2	nmod
7	on	on	IN	_	9	case
8	drug2	drug2	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod
10	resulting	result	VBG	_	6	acl
11	in	in	IN	_	14	case
12	two	two	CD	_	14	nummod
13	ectopic	ectopic	JJ	_	14	amod
14	pregnancies	pregnancy	NNS	_	10	nmod
15	.	.	.	_	2	punct

1	Since	since	IN	_	3	case
2	its	its	PRP$	_	3	nmod:poss
3	introduction	introduction	NN	_	8	nmod
4	in	in	IN	_	5	case
5	1999	1999	CD	_	3	nmod
6	,	,	,	_	8	punct
7	drug1	drug1	NN	_	8	nsubj
8	remains	remain	VBZ	_	0	ROOT
9	one	one	CD	_	8	xcomp
10	of	of	IN	_	14	case
11	the	the	DT	_	14	det
12	preferred	preferred	JJ	_	14	amod
13	contraceptive	contraceptive	JJ	_	14	amod
14	choices	choice	NNS	_	9	nmod
15	for	for	IN	_	17	case
16	many	many	JJ	_	17	amod
17	women	woman	NNS	_	14	nmod
18	as	as	IN	_	20	mark
19	it	it	PRP	_	20	nsubj
20	offers	offer	VBZ	_	8	advcl
21	a	a	DT	_	24	det
22	highly	highly	RB	_	23	advmod
23	effective	effective	JJ	_	24	amod
24	means	means	NNS	_	20	dobj
25	of	of	IN	_	27	case
26	long-term	long-term	JJ	_	27	amod
27	contraception	contraception	NN	_	24	nmod
28	for	for	IN	_	30	case
29	three	three	CD	_	30	nummod
30	years	year	NNS	_	27	nmod
31	that	that	WDT	_	34	nsubj
32	does	do	VBZ	_	34	aux
33	not	not	RB	_	34	neg
34	rely	rely	VB	_	24	acl:relcl
35	on	on	IN	_	36	case
36	adherence	adherence	NN	_	34	nmod
37	.	.	.	_	8	punct

1	Like	like	IN	_	3	case
2	all	all	DT	_	3	det
3	drug1	drug1	NN	_	10	nmod
4	,	,	,	_	10	punct
5	certain	certain	JJ	_	8	amod
6	hepatic	hepatic	JJ	_	8	amod
7	enzyme-inducing	enzyme-inducing	JJ	_	8	amod
8	drugs	drug	NNS	_	10	nsubj
9	may	may	MD	_	10	aux
10	reduce	reduce	VB	_	0	ROOT
11	its	its	PRP$	_	12	nmod:poss
12	efficacy	efficacy	NN	_	10	dobj
13	.	.	.	_	10	punct

1	We	we	PRP	_	2	nsubj
2	present	present	VBP	_	0	ROOT
3	an	a	DT	_	5	det
4	interesting	interesting	JJ	_	5	amod
5	case	case	NN	_	2	dobj
6	of	of	IN	_	9	case
7	an	a	DT	_	9	det
8	HIV-positive	hiv-positive	JJ	_	9	amod
9	woman	woman	NN	_	5	nmod
10	on	on	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	therapy	therapy	NN	_	9	nmod
13	having	have	VBG	_	9	acl
14	tubal	tubal	JJ	_	15	amod
15	pregnancies	pregnancy	NNS	_	13	dobj
16	on	on	IN	_	19	case
17	two	two	CD	_	19	nummod
18	separate	separate	JJ	_	19	amod
19	occasions	occasion	NNS	_	13	nmod
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	in	in	IN	_	23	case
23	place	place	NN	_	19	nmod
24	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	compound
2	and	and	CC	_	1	cc
3	CYP	cyp	NN	_	1	conj
4	2D6	2d6	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	caution	caution	NN	_	5	dep
8	.	.	.	_	5	punct

1	drug1	drug1	NN	_	10	nsubj
2	,	,	,	_	1	punct
3	an	a	DT	_	4	det
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	is	be	VBZ	_	10	cop
7	the	the	DT	_	10	det
8	standard	standard	JJ	_	10	amod
9	hormone	hormone	NN	_	10	compound
10	treatment	treatment	NN	_	0	ROOT
11	for	for	IN	_	13	case
12	breast	breast	NN	_	13	compound
13	cancer	cancer	NN	_	10	nmod
14	.	.	.	_	10	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	extensively	extensively	RB	_	4	advmod
4	transformed	transform	VBN	_	0	ROOT
5	into	into	IN	_	8	case
6	its	its	PRP$	_	8	nmod:poss
7	active	active	JJ	_	8	amod
8	metabolites	metabolite	NNS	_	4	nmod
9	by	by	IN	_	14	case
10	the	the	DT	_	14	det
11	cytochrome	cytochrome	NN	_	14	compound
12	P450	p450	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	system	system	NN	_	4	nmod
15	,	,	,	_	4	punct
16	especially	especially	RB	_	18	advmod
17	into	into	IN	_	18	case
18	drug1	drug1	NN	_	4	nmod
19	by	by	IN	_	22	case
20	isoenzyme	isoenzyme	NN	_	22	compound
21	CYP	cyp	NN	_	22	compound
22	2D6	2d6	NN	_	18	nmod
23	.	.	.	_	4	punct

1	Co-administration	co-administration	NN	_	9	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	8	case
5	isoenzyme	isoenzyme	NN	_	8	compound
6	CYP	cyp	NN	_	8	compound
7	2D6	2d6	NN	_	8	compound
8	inhibitors	inhibitor	NNS	_	1	nmod
9	reduces	reduce	VBZ	_	0	ROOT
10	this	this	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	.	.	.	_	9	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibit	inhibit	VBP	_	0	ROOT
3	isoenzyme	isoenzyme	NN	_	5	compound
4	CYP	cyp	NN	_	5	compound
5	2D6	2d6	NN	_	2	dobj
6	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	reduce	reduce	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	concentration	concentration	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	by	by	IN	_	13	case
11	about	about	IN	_	12	advmod
12	50	50	CD	_	13	nummod
13	%	%	NN	_	4	nmod
14	.	.	.	_	4	punct

1	Two	two	CD	_	3	nummod
2	epidemiological	epidemiological	JJ	_	3	amod
3	studies	study	NNS	_	9	nsubj
4	involving	involve	VBG	_	3	acl
5	about	about	IN	_	6	advmod
6	3700	3700	CD	_	7	nummod
7	women	woman	NNS	_	4	dobj
8	have	have	VBP	_	9	aux
9	shown	show	VBN	_	0	ROOT
10	a	a	DT	_	11	det
11	link	link	NN	_	9	dobj
12	between	between	IN	_	14	case
13	the	the	DT	_	14	det
14	use	use	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	and	and	CC	_	14	cc
18	an	a	DT	_	20	det
19	increased	increase	VBN	_	20	amod
20	frequency	frequency	NN	_	14	conj
21	of	of	IN	_	24	case
22	breast	breast	NN	_	24	compound
23	cancer	cancer	NN	_	24	compound
24	recurrence	recurrence	NN	_	20	nmod
25	.	.	.	_	9	punct

1	Other	other	JJ	_	2	amod
2	studies	study	NNS	_	13	nsubj
3	,	,	,	_	2	punct
4	with	with	IN	_	7	case
5	a	a	DT	_	7	det
6	lower	lower	JJR	_	7	amod
7	level	level	NN	_	2	nmod
8	of	of	IN	_	9	case
9	evidence	evidence	NN	_	7	nmod
10	,	,	,	_	2	punct
11	were	be	VBD	_	13	cop
12	less	less	RBR	_	13	advmod
13	convincing	convincing	JJ	_	0	ROOT
14	.	.	.	_	13	punct

1	Studies	study	NNS	_	8	nsubj
2	of	of	IN	_	7	case
3	other	other	JJ	_	7	amod
4	isoenzyme	isoenzyme	NN	_	7	compound
5	CYP	cyp	NN	_	7	compound
6	2D6	2d6	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	1	nmod
8	showed	show	VBD	_	0	ROOT
9	no	no	DT	_	10	neg
10	increase	increase	NN	_	8	dobj
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	risk	risk	NN	_	10	nmod
14	of	of	IN	_	17	case
15	breast	breast	NN	_	17	compound
16	cancer	cancer	NN	_	17	compound
17	recurrence	recurrence	NN	_	13	nmod
18	,	,	,	_	8	punct
19	but	but	CC	_	8	cc
20	they	they	PRP	_	21	nsubj
21	lacked	lack	VBD	_	8	conj
22	statistical	statistical	JJ	_	23	amod
23	power	power	NN	_	21	dobj
24	.	.	.	_	8	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	better	better	JJR	_	0	ROOT
4	to	to	TO	_	5	mark
5	avoid	avoid	VB	_	3	xcomp
6	prescribing	prescribe	VBG	_	5	xcomp
7	isoenzyme	isoenzyme	NN	_	10	compound
8	CYP	cyp	NN	_	10	compound
9	2D6	2d6	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	6	dobj
11	to	to	TO	_	12	case
12	women	woman	NNS	_	6	nmod
13	treated	treat	VBN	_	12	acl
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	for	for	IN	_	18	case
17	breast	breast	NN	_	18	compound
18	cancer	cancer	NN	_	15	nmod
19	,	,	,	_	3	punct
20	especially	especially	RB	_	21	advmod
21	drug2	drug2	NN	_	3	dep
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug3	drug3	NN	_	21	nmod
25	and	and	CC	_	24	cc
26	drug4	drug4	NN	_	24	conj
27	.	.	.	_	3	punct

1	Depression	depression	NN	_	5	nsubj
2	does	do	VBZ	_	5	aux
3	not	not	RB	_	5	neg
4	always	always	RB	_	5	advmod
5	require	require	VB	_	0	ROOT
6	drug1	drug1	NN	_	7	compound
7	therapy	therapy	NN	_	5	dobj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	drug2	drug2	NN	_	11	nsubj
11	have	have	VBP	_	5	conj
12	no	no	DT	_	15	neg
13	proven	proven	JJ	_	15	amod
14	preventive	preventive	JJ	_	15	amod
15	impact	impact	NN	_	11	dobj
16	on	on	IN	_	18	case
17	hot	hot	JJ	_	18	amod
18	flushes	flush	NNS	_	15	nmod
19	linked	link	VBN	_	18	acl
20	to	to	TO	_	22	case
21	the	the	DT	_	22	det
22	menopause	menopause	NN	_	19	nmod
23	.	.	.	_	5	punct

1	If	if	IN	_	9	mark
2	in	in	IN	_	4	case
3	certain	certain	JJ	_	4	amod
4	cases	case	NNS	_	9	nmod
5	,	,	,	_	9	punct
6	an	a	DT	_	7	det
7	drug1	drug1	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	considered	consider	VBN	_	15	advcl
10	necessary	necessary	JJ	_	9	xcomp
11	,	,	,	_	15	punct
12	it	it	PRP	_	15	nsubj
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	cop
15	advisable	advisable	JJ	_	0	ROOT
16	to	to	TO	_	17	mark
17	replace	replace	VB	_	15	xcomp
18	drug2	drug2	NN	_	17	dobj
19	with	with	IN	_	20	case
20	drug3	drug3	NN	_	17	nmod
21	.	.	.	_	15	punct

1	Phase	phase	NN	_	3	compound
2	I	i	CD	_	3	nummod
3	trial	trial	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	3	nmod
10	with	with	IN	_	13	case
11	relapsed	relapse	VBN	_	13	amod
12	multiple	multiple	JJ	_	13	amod
13	myeloma	myeloma	NN	_	9	nmod
14	:	:	:	_	3	punct
15	evidence	evidence	NN	_	3	dep
16	for	for	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	-	-	:	_	17	punct
19	drug4	drug4	NN	_	20	compound
20	interaction	interaction	NN	_	17	dep
21	via	via	IN	_	22	case
22	P-glycoprotein	p-glycoprotein	NN	_	20	nmod
23	.	.	.	_	3	punct

1	Multiple	multiple	JJ	_	2	amod
2	myeloma	myeloma	NN	_	10	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	MM	mm	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	is	be	VBZ	_	10	cop
7	an	a	DT	_	10	det
8	incurable	incurable	JJ	_	10	amod
9	plasma-cell	plasma-cell	NN	_	10	compound
10	neoplasm	neoplasm	NN	_	0	ROOT
11	for	for	IN	_	12	case
12	which	which	WDT	_	15	nmod
13	most	most	RBS	_	14	amod
14	treatments	treatment	NNS	_	15	nsubj
15	involve	involve	VBP	_	10	acl:relcl
16	a	a	DT	_	18	det
17	therapeutic	therapeutic	JJ	_	18	amod
18	agent	agent	NN	_	15	dobj
19	combined	combine	VBN	_	18	acl
20	with	with	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	preclinical	preclinical	JJ	_	3	amod
3	combination	combination	NN	_	12	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	10	case
7	the	the	DT	_	10	det
8	mTOR	mtor	NN	_	10	compound
9	inhibitor	inhibitor	NN	_	10	compound
10	drug2	drug2	NN	_	3	nmod
11	has	have	VBZ	_	12	aux
12	displayed	display	VBN	_	0	ROOT
13	synergy	synergy	NN	_	12	dobj
14	in	in	FW	_	15	compound
15	vitro	vitro	FW	_	12	advmod
16	and	and	CC	_	12	cc
17	represents	represent	VBZ	_	12	conj
18	a	a	DT	_	20	det
19	novel	novel	JJ	_	20	amod
20	combination	combination	NN	_	17	dobj
21	in	in	IN	_	22	case
22	MM	mm	NN	_	20	nmod
23	.	.	.	_	12	punct

1	In	in	FW	_	4	amod
2	vivo	vivo	FW	_	1	dep
3	CYP3A	cyp3a	NN	_	4	compound
4	activity	activity	NN	_	7	nsubj
5	is	be	VBZ	_	7	cop
6	significantly	significantly	RB	_	7	advmod
7	lower	lower	JJR	_	0	ROOT
8	in	in	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	-	-	:	_	9	punct
11	treated	treat	VBN	_	9	acl
12	as	as	IN	_	13	mark
13	compared	compare	VBN	_	11	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	-	-	:	_	15	punct
17	treated	treat	VBN	_	20	amod
18	renal	renal	JJ	_	20	amod
19	allograft	allograft	NN	_	20	compound
20	recipients	recipient	NNS	_	15	dep
21	.	.	.	_	7	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	identified	identify	VBN	_	0	ROOT
6	drug1	drug1	NN	_	5	dobj
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	as	as	IN	_	11	case
10	CYP3A	cyp3a	NN	_	11	compound
11	inhibitors	inhibitor	NNS	_	5	nmod
12	.	.	.	_	5	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	current	current	JJ	_	4	amod
4	study	study	NN	_	11	nmod
5	in	in	IN	_	8	case
6	renal	renal	JJ	_	8	amod
7	allograft	allograft	NN	_	8	compound
8	recipients	recipient	NNS	_	4	nmod
9	,	,	,	_	11	punct
10	we	we	PRP	_	11	nsubj
11	used	use	VBD	_	0	ROOT
12	intravenously	intravenously	RB	_	13	advmod
13	and	and	CC	_	15	advmod
14	orally	orally	RB	_	13	advmod
15	administered	administer	VBN	_	11	dep
16	drug1	drug1	NN	_	15	dobj
17	as	as	IN	_	20	case
18	a	a	DT	_	20	det
19	drug	drug	NN	_	20	compound
20	probe	probe	NN	_	15	nmod
21	to	to	TO	_	22	mark
22	assess	assess	VB	_	15	advcl
23	whether	whether	IN	_	26	mark
24	the	the	DT	_	25	det
25	study	study	NN	_	26	nsubj
26	drugs	drug	NNS	_	22	ccomp
27	at	at	IN	_	28	case
28	doses	dose	NNS	_	26	nmod
29	that	that	WDT	_	32	nsubjpass
30	are	be	VBP	_	32	auxpass
31	generally	generally	RB	_	32	advmod
32	used	use	VBN	_	28	acl:relcl
33	in	in	IN	_	35	case
34	clinical	clinical	JJ	_	35	amod
35	practice	practice	NN	_	32	nmod
36	have	have	VBP	_	15	dep
37	differential	differential	JJ	_	38	amod
38	effects	effect	NNS	_	36	dobj
39	on	on	IN	_	42	case
40	in	in	FW	_	42	amod
41	vivo	vivo	FW	_	40	dep
42	hepatic	hepatic	JJ	_	36	nmod
43	and	and	CC	_	42	cc
44	first-pass	first-pass	JJ	_	42	conj
45	CYP3A	cyp3a	NN	_	46	compound
46	activities	activity	NNS	_	42	dep
47	.	.	.	_	11	punct

1	Systemic	systemic	JJ	_	6	amod
2	and	and	CC	_	1	cc
3	apparent	apparent	JJ	_	1	conj
4	oral	oral	JJ	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	clearance	clearance	NN	_	9	nsubj
7	were	be	VBD	_	9	cop
8	24	24	CD	_	9	nummod
9	%	%	NN	_	0	ROOT
10	-LRB-	-lrb-	-LRB-	_	9	punct
11	269	269	CD	_	12	compound
12	73	73	CD	_	10	root
13	vs.	vs.	IN	_	16	case
14	354	354	CD	_	15	compound
15	102	102	CD	_	16	nummod
16	ml/min	ml/min	NN	_	12	nmod
17	,	,	,	_	16	punct
18	P	p	NN	_	19	nsubj
19	=	=	JJ	_	16	dep
20	0.022	0.022	CD	_	19	dobj
21	-RRB-	-rrb-	-RRB-	_	16	punct
22	and	and	CC	_	12	cc
23	31	31	CD	_	24	nummod
24	%	%	NN	_	40	nmod:npmod
25	-LRB-	-lrb-	-LRB-	_	40	punct
26	479	479	CD	_	27	compound
27	190	190	CD	_	40	dep
28	vs.	vs.	IN	_	31	case
29	688	688	CD	_	30	compound
30	265	265	CD	_	31	nummod
31	ml/min	ml/min	NN	_	27	nmod
32	,	,	,	_	31	punct
33	P	p	NN	_	34	nsubj
34	=	=	JJ	_	31	dep
35	0.013	0.013	CD	_	34	dobj
36	-RRB-	-rrb-	-RRB-	_	31	punct
37	,	,	,	_	40	punct
38	respectively	respectively	RB	_	40	advmod
39	,	,	,	_	40	punct
40	lower	lower	JJR	_	12	conj
41	in	in	IN	_	42	case
42	drug2	drug2	NN	_	40	nmod
43	-	-	:	_	12	punct
44	treated	treated	JJ	_	45	amod
45	patients	patient	NNS	_	12	dep
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	n	n	NN	_	45	dep
48	=	=	JJ	_	47	amod
49	20	20	CD	_	48	dep
50	-RRB-	-rrb-	-RRB-	_	47	punct
51	than	than	IN	_	54	case
52	in	in	IN	_	54	case
53	matched	match	VBN	_	54	amod
54	drug3	drug3	NN	_	45	nmod
55	-	-	:	_	45	punct
56	treated	treated	JJ	_	57	amod
57	patients	patient	NNS	_	45	dep
58	-LRB-	-lrb-	-LRB-	_	59	punct
59	n	n	NN	_	57	dep
60	=	=	JJ	_	59	amod
61	20	20	CD	_	60	dep
62	-RRB-	-rrb-	-RRB-	_	59	punct
63	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	latter	latter	JJ	_	3	nsubj
3	displayed	display	VBD	_	0	ROOT
4	drug1	drug1	NN	_	5	compound
5	clearances	clearance	NNS	_	3	dobj
6	similar	similar	JJ	_	5	amod
7	to	to	TO	_	8	case
8	those	those	DT	_	6	nmod
9	in	in	IN	_	12	case
10	two	two	CD	_	12	nummod
11	larger	larger	JJR	_	12	amod
12	cohorts	cohort	NNS	_	8	nmod
13	of	of	IN	_	15	case
14	nonmatched	nonmatched	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	-	-	:	_	12	punct
17	treated	treated	JJ	_	18	amod
18	patients	patient	NNS	_	12	dep
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	n	n	NN	_	18	dep
21	=	=	JJ	_	20	amod
22	58	58	CD	_	21	dep
23	and	and	CC	_	20	cc
24	n	n	NN	_	25	nsubj
25	=	=	JJ	_	20	conj
26	80	80	CD	_	25	dobj
27	-RRB-	-rrb-	-RRB-	_	20	punct
28	and	and	CC	_	18	cc
29	to	to	TO	_	30	case
30	those	those	DT	_	18	conj
31	receiving	receive	VBG	_	30	acl
32	a	a	DT	_	33	det
33	drug3	drug3	NN	_	31	dobj
34	-	-	:	_	18	punct
35	free	free	JJ	_	36	amod
36	regimen	regimen	NN	_	18	dep
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	n	n	NN	_	36	dep
39	=	=	JJ	_	38	amod
40	6	6	CD	_	39	dep
41	-RRB-	-rrb-	-RRB-	_	38	punct
42	.	.	.	_	3	punct

1	This	this	DT	_	2	nsubj
2	implies	imply	VBZ	_	0	ROOT
3	that	that	IN	_	13	mark
4	in	in	FW	_	6	amod
5	vivo	vivo	FW	_	4	dep
6	hepatic	hepatic	JJ	_	13	nsubj
7	and	and	CC	_	6	cc
8	first-pass	first-pass	JJ	_	6	conj
9	CYP3A	cyp3a	NN	_	10	compound
10	activities	activity	NNS	_	6	dep
11	are	be	VBP	_	13	cop
12	significantly	significantly	RB	_	13	advmod
13	lower	lower	JJR	_	2	ccomp
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	drug1	drug1	NN	_	16	dobj
18	than	than	IN	_	20	case
19	in	in	IN	_	20	case
20	those	those	DT	_	13	nmod
21	receiving	receive	VBG	_	20	acl
22	drug2	drug2	NN	_	21	dobj
23	,	,	,	_	13	punct
24	indicating	indicate	VBG	_	13	xcomp
25	that	that	IN	_	39	mark
26	,	,	,	_	39	punct
27	at	at	IN	_	29	case
28	the	the	DT	_	29	det
29	doses	dose	NNS	_	39	nmod
30	generally	generally	RB	_	31	advmod
31	used	use	VBN	_	29	acl
32	in	in	IN	_	34	case
33	clinical	clinical	JJ	_	34	amod
34	practice	practice	NN	_	31	nmod
35	,	,	,	_	39	punct
36	drug3	drug3	NN	_	39	nsubj
37	is	be	VBZ	_	39	cop
38	the	the	DT	_	39	det
39	stronger	stronger	JJR	_	24	ccomp
40	of	of	IN	_	42	case
41	the	the	DT	_	42	det
42	two	two	CD	_	39	nmod
43	with	with	IN	_	44	case
44	respect	respect	NN	_	39	nmod
45	to	to	TO	_	47	case
46	CYP3A	cyp3a	NN	_	47	compound
47	inhibition	inhibition	NN	_	44	nmod
48	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	observation	observation	NN	_	3	nsubj
3	has	have	VBZ	_	0	ROOT
4	important	important	JJ	_	5	amod
5	implications	implication	NNS	_	3	dobj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	context	context	NN	_	5	nmod
9	of	of	IN	_	11	case
10	drug-drug	drug-drug	JJ	_	11	amod
11	interactions	interaction	NNS	_	8	nmod
12	in	in	IN	_	14	case
13	transplant	transplant	NN	_	14	compound
14	recipients	recipient	NNS	_	11	nmod
15	.	.	.	_	3	punct

1	-LSB-	-lsb-	-LRB-	_	2	punct
2	Influence	influence	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	on	on	IN	_	10	case
8	MPTP-evoked	mptp-evoked	JJ	_	10	amod
9	behavior	behavior	NN	_	10	compound
10	violations	violation	NNS	_	2	nmod
11	in	in	IN	_	13	case
12	C57BL/6	c57bl/6	NN	_	13	compound
13	mice	mouse	NNS	_	10	nmod
14	-RSB-	-rsb-	-RRB-	_	2	punct
15	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	drug2	drug2	NN	_	2	nmod
6	-LSB-	-lsb-	-LRB-	_	7	punct
7	drug3	drug3	NN	_	5	appos
8	-RSB-	-rsb-	-RRB-	_	7	punct
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	10	10	CD	_	11	nummod
11	mg/kg	mg/kg	NN	_	5	dep
12	,	,	,	_	11	punct
13	p.	p.	NN	_	14	compound
14	o.	o.	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	11	punct

1	and/or	and/or	CC	_	0	ROOT
2	drug1	drug1	NN	_	3	compound
3	drug2	drug2	NN	_	1	dep
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	100	100	CD	_	6	nummod
6	mg/kg	mg/kg	NN	_	3	dep
7	,	,	,	_	6	punct
8	p.	p.	NN	_	9	compound
9	o.	o.	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	6	punct
11	,	,	,	_	3	punct
12	as	as	RB	_	3	cc
13	well	well	RB	_	12	mwe
14	as	as	IN	_	12	mwe
15	that	that	DT	_	3	conj
16	of	of	IN	_	18	case
17	neurotoxin	neurotoxin	NN	_	18	compound
18	drug3	drug3	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug4	drug4	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	-LRB-	-lrb-	-LRB-	_	26	punct
23	4	4	CD	_	26	nummod
24	x	x	CC	_	23	cc
25	20	20	CD	_	23	conj
26	mg/kg	mg/kg	NN	_	18	dep
27	,	,	,	_	26	punct
28	i.	i.	NN	_	29	compound
29	p.	p.	NN	_	26	appos
30	-RRB-	-rrb-	-RRB-	_	26	punct

1	were	be	VBD	_	2	auxpass
2	studied	study	VBN	_	0	ROOT
3	in	in	IN	_	7	case
4	elevated	elevated	JJ	_	7	amod
5	plus	plus	CC	_	4	cc
6	maze	maze	NN	_	4	conj
7	test	test	NN	_	2	nmod
8	on	on	IN	_	10	case
9	C57BL/6	c57bl/6	NN	_	10	compound
10	mice	mouse	NNS	_	7	nmod
11	.	.	.	_	2	punct

1	On	on	IN	_	3	case
2	second	second	JJ	_	3	amod
3	day	day	NN	_	8	nmod
4	after	after	IN	_	5	case
5	injection	injection	NN	_	3	nmod
6	,	,	,	_	8	punct
7	drug1	drug1	NN	_	8	nsubj
8	decreased	decrease	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	locomot	locomot	NN	_	8	dobj
11	or	or	CC	_	10	cc
12	activity	activity	NN	_	10	conj
13	in	in	IN	_	14	case
14	comparison	comparison	NN	_	8	nmod
15	to	to	TO	_	16	case
16	saline	saline	NN	_	14	nmod
17	.	.	.	_	8	punct

1	Acute	acute	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	failed	fail	VBD	_	0	ROOT
8	to	to	TO	_	9	mark
9	influence	influence	VB	_	7	xcomp
10	locomotion	locomotion	NN	_	9	dobj
11	in	in	IN	_	12	case
12	mice	mouse	NNS	_	10	nmod
13	,	,	,	_	7	punct
14	while	while	IN	_	17	mark
15	their	they	PRP$	_	16	nmod:poss
16	combination	combination	NN	_	17	nsubj
17	normalized	normalize	VBD	_	7	advcl
18	motor	motor	NN	_	19	compound
19	activity	activity	NN	_	17	dobj
20	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	4	nsubj
3	obtained	obtain	VBN	_	2	acl
4	confirm	confirm	VBP	_	0	ROOT
5	the	the	DT	_	6	det
6	role	role	NN	_	4	dobj
7	of	of	IN	_	9	case
8	inflammatory	inflammatory	JJ	_	9	amod
9	processes	process	NNS	_	6	nmod
10	in	in	IN	_	11	case
11	parkinsonism	parkinsonism	NN	_	6	nmod
12	and	and	CC	_	4	cc
13	suggest	suggest	VBP	_	4	conj
14	expediency	expediency	NN	_	13	dobj
15	of	of	IN	_	17	case
16	combined	combined	JJ	_	17	amod
17	pharmacotherapy	pharmacotherapy	NN	_	14	nmod
18	of	of	IN	_	20	case
19	neurodegenerative	neurodegenerative	JJ	_	20	amod
20	diseases	disease	NNS	_	17	nmod
21	.	.	.	_	4	punct

1	Exposure	exposure	NN	_	6	nsubjpass
2	to	to	TO	_	4	case
3	oral	oral	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	unaffected	unaffected	JJ	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	but	but	CC	_	6	cc
10	greatly	greatly	RB	_	11	advmod
11	increased	increase	VBN	_	6	conj
12	by	by	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	6	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	examined	examine	VBD	_	0	ROOT
4	drug-drug	drug-drug	JJ	_	5	amod
5	interactions	interaction	NNS	_	3	dobj
6	of	of	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	with	with	IN	_	12	case
10	the	the	DT	_	12	det
11	cytochrome	cytochrome	NN	_	12	compound
12	P450	p450	NN	_	5	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	CYP	cyp	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	2B6	2b6	NN	_	18	compound
17	inhibitor	inhibitor	NN	_	18	compound
18	drug2	drug2	NN	_	12	dep
19	and	and	CC	_	12	cc
20	the	the	DT	_	23	det
21	CYP3A	cyp3a	NN	_	23	compound
22	inhibitor	inhibitor	NN	_	23	compound
23	drug3	drug3	NN	_	12	conj
24	.	.	.	_	3	punct

1	In	in	IN	_	0	ROOT
2	this	this	DT	_	1	dep
3	randomized	randomize	VBN	_	2	dep
4	,	,	,	_	3	punct
5	blinded	blind	VBN	_	4	root
6	,	,	,	_	5	punct
7	crossover	crossover	NN	_	8	compound
8	study	study	NN	_	6	root
9	,	,	,	_	8	punct
10	11	11	CD	_	12	nummod
11	healthy	healthy	JJ	_	12	amod
12	volunteers	volunteer	NNS	_	13	nsubj
13	ingested	ingest	VBD	_	8	acl:relcl
14	0.2	0.2	CD	_	16	nummod
15	mg/kg	mg/kg	NN	_	16	compound
16	drug1	drug1	NN	_	13	dobj
17	after	after	IN	_	18	case
18	pretreatments	pretreatment	NNS	_	13	nmod
19	with	with	IN	_	21	case
20	oral	oral	JJ	_	21	amod
21	drug2	drug2	NN	_	18	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	250	250	CD	_	24	nummod
24	mg	mg	NN	_	21	appos
25	twice	twice	RB	_	26	advmod
26	daily	daily	RB	_	24	advmod
27	-RRB-	-rrb-	-RRB-	_	24	punct
28	,	,	,	_	21	punct
29	drug3	drug3	NN	_	21	conj
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	200	200	CD	_	32	nummod
32	mg	mg	NN	_	29	dep
33	once	once	RB	_	34	advmod
34	daily	daily	JJ	_	32	amod
35	-RRB-	-rrb-	-RRB-	_	32	punct
36	,	,	,	_	21	punct
37	or	or	CC	_	21	cc
38	placebo	placebo	NN	_	21	conj
39	in	in	IN	_	42	case
40	6-day	6-day	JJ	_	42	amod
41	treatment	treatment	NN	_	42	compound
42	periods	period	NNS	_	18	nmod
43	at	at	IN	_	44	case
44	intervals	interval	NNS	_	42	nmod
45	of	of	IN	_	47	case
46	4	4	CD	_	47	nummod
47	weeks	week	NNS	_	44	nmod
48	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	compound
2	treatment	treatment	NN	_	3	nsubj
3	increased	increase	VBD	_	0	ROOT
4	the	the	DT	_	6	det
5	mean	mean	JJ	_	6	amod
6	area	area	NN	_	3	dobj
7	under	under	IN	_	11	case
8	the	the	DT	_	11	det
9	plasma	plasma	NN	_	11	compound
10	concentration-time	concentration-time	NN	_	11	compound
11	curve	curve	NN	_	3	nmod
12	extrapolated	extrapolate	VBD	_	11	acl
13	to	to	TO	_	14	case
14	infinity	infinity	NN	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	AUC	auc	NN	_	14	dep
17	-LRB-	-lrb-	-LRB-	_	24	punct
18	0	0	CD	_	24	nummod
19	-	-	:	_	24	punct
20	-RRB-	-rrb-	-RRB-	_	24	punct
21	-RRB-	-rrb-	-RRB-	_	24	punct
22	of	of	IN	_	24	case
23	oral	oral	JJ	_	24	amod
24	drug2	drug2	NN	_	16	dep
25	by	by	IN	_	26	case
26	2.4-fold	2.4-fold	JJ	_	24	nmod
27	,	,	,	_	24	punct
28	whereas	whereas	IN	_	33	mark
29	drug3	drug3	NN	_	30	compound
30	treatment	treatment	NN	_	33	nsubj
31	did	do	VBD	_	33	aux
32	not	not	RB	_	33	neg
33	increase	increase	VB	_	24	advcl
34	the	the	DT	_	35	det
35	exposure	exposure	NN	_	33	dobj
36	to	to	TO	_	37	case
37	drug4	drug4	NN	_	35	nmod
38	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	ratio	ratio	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	AUC	auc	NN	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	11	punct
7	0	0	CD	_	11	dep
8	-	-	:	_	11	punct
9	-RRB-	-rrb-	-RRB-	_	11	punct
10	to	to	TO	_	11	mark
11	drug2	drug2	VB	_	5	dep
12	AUC	auc	NN	_	11	dobj
13	-LRB-	-lrb-	-LRB-	_	19	punct
14	0	0	CD	_	19	dep
15	-	-	:	_	19	punct
16	-RRB-	-rrb-	-RRB-	_	19	punct
17	was	be	VBD	_	19	auxpass
18	significantly	significantly	RB	_	19	advmod
19	decreased	decrease	VBN	_	12	dep
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	drug3	drug3	NN	_	19	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	P	p	NN	_	22	dep
25	&	&	CC	_	24	cc
26	lt	lt	NN	_	24	conj
27	;	;	:	_	24	punct
28	0.001	0.001	CD	_	24	dep
29	-RRB-	-rrb-	-RRB-	_	24	punct
30	drug4	drug4	NN	_	32	compound
31	zole	zole	NN	_	32	compound
32	phases	phase	NNS	_	22	dep
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	P	p	NN	_	32	dep
35	=	=	JJ	_	34	amod
36	0.006	0.006	CD	_	35	dep
37	-RRB-	-rrb-	-RRB-	_	34	punct
38	as	as	IN	_	39	mark
39	compared	compare	VBN	_	19	advcl
40	to	to	TO	_	41	case
41	placebo	placebo	NN	_	39	nmod
42	.	.	.	_	2	punct

1	In	in	IN	_	6	case
2	the	the	DT	_	6	det
3	drug1	drug1	NN	_	6	compound
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	phases	phase	NNS	_	22	nmod
7	,	,	,	_	22	punct
8	the	the	DT	_	9	det
9	areas	area	NNS	_	22	nsubj
10	under	under	IN	_	13	case
11	the	the	DT	_	13	det
12	effect-time	effect-time	JJ	_	13	amod
13	curves	curve	NNS	_	9	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	self-reported	self-reported	JJ	_	16	amod
16	drowsiness	drowsiness	NN	_	13	dep
17	and	and	CC	_	16	cc
18	performance	performance	NN	_	16	conj
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	were	be	VBD	_	22	cop
21	significantly	significantly	RB	_	22	advmod
22	higher	higher	JJR	_	0	ROOT
23	than	than	IN	_	24	case
24	those	those	DT	_	22	nmod
25	in	in	IN	_	28	case
26	the	the	DT	_	28	det
27	placebo	placebo	NN	_	28	compound
28	phase	phase	NN	_	24	nmod
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	P	p	NN	_	31	dep
31	<	<	JJR	_	22	parataxis
32	0.05	0.05	CD	_	31	nummod
33	-RRB-	-rrb-	-RRB-	_	31	punct
34	.	.	.	_	22	punct

1	The	the	DT	_	2	det
2	findings	finding	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	11	mark
5	the	the	DT	_	6	det
6	dosage	dosage	NN	_	11	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	reduced	reduce	VBN	_	3	ccomp
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	receiving	receive	VBG	_	13	acl
15	drug2	drug2	NN	_	14	dobj
16	.	.	.	_	3	punct

1	Interaction	interaction	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	different	different	JJ	_	6	amod
6	drug2	drug2	NN	_	1	nmod
7	is	be	VBZ	_	8	cop
8	antagonistic	antagonistic	JJ	_	0	ROOT
9	in	in	IN	_	10	case
10	breast	breast	NN	_	8	nmod
11	but	but	CC	_	10	cc
12	not	not	RB	_	16	neg
13	in	in	IN	_	16	case
14	other	other	JJ	_	16	amod
15	cancer	cancer	NN	_	16	compound
16	cells	cell	NNS	_	10	conj
17	.	.	.	_	8	punct

1	drug1	drug1	NN	_	10	nsubjpass
2	,	,	,	_	1	punct
3	an	a	DT	_	4	det
4	inhibitor	inhibitor	NN	_	1	appos
5	of	of	IN	_	6	case
6	cyclooxygenase-2	cyclooxygenase-2	NN	_	4	nmod
7	,	,	,	_	1	punct
8	is	be	VBZ	_	10	aux
9	being	be	VBG	_	10	auxpass
10	investigated	investigate	VBN	_	0	ROOT
11	for	for	IN	_	12	case
12	enhancement	enhancement	NN	_	10	nmod
13	of	of	IN	_	15	case
14	chemotherapy	chemotherapy	NN	_	15	compound
15	efficacy	efficacy	NN	_	12	nmod
16	in	in	IN	_	19	case
17	cancer	cancer	NN	_	19	compound
18	clinical	clinical	JJ	_	19	amod
19	trials	trial	NNS	_	12	nmod
20	.	.	.	_	10	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	investigates	investigate	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	ability	ability	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	to	to	TO	_	9	mark
9	sensitize	sensitize	VB	_	5	acl
10	cells	cell	NNS	_	9	dobj
11	from	from	IN	_	13	case
12	different	different	JJ	_	13	amod
13	origins	origin	NNS	_	9	nmod
14	to	to	TO	_	16	case
15	several	several	JJ	_	16	amod
16	drug2	drug2	NN	_	9	nmod
17	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	16	nsubjpass
3	of	of	IN	_	7	case
4	the	the	DT	_	5	det
5	drug	drug	NN	_	7	nmod:poss
6	's	's	POS	_	5	case
7	mechanism	mechanism	NN	_	2	nmod
8	of	of	IN	_	9	case
9	action	action	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	sequence	sequence	NN	_	9	conj
12	of	of	IN	_	13	case
13	administration	administration	NN	_	9	nmod
14	are	be	VBP	_	16	auxpass
15	also	also	RB	_	16	advmod
16	investigated	investigate	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	sensitivity	sensitivity	NN	_	42	nsubjpass
3	,	,	,	_	2	punct
4	cell	cell	NN	_	5	compound
5	cycle	cycle	NN	_	2	conj
6	,	,	,	_	2	punct
7	apoptosis	apoptosis	NN	_	2	conj
8	and	and	CC	_	2	cc
9	DNA	dna	NN	_	10	compound
10	damage	damage	NN	_	2	conj
11	of	of	IN	_	16	case
12	five	five	CD	_	16	nummod
13	different	different	JJ	_	16	amod
14	cancer	cancer	NN	_	16	compound
15	cell	cell	NN	_	16	compound
16	lines	line	NNS	_	2	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	HeLa	hela	NN	_	16	dep
19	,	,	,	_	18	punct
20	HCT116	hct116	NN	_	18	conj
21	,	,	,	_	18	punct
22	HepG2	hepg2	NN	_	18	conj
23	,	,	,	_	18	punct
24	MCF7	mcf7	NN	_	18	conj
25	and	and	CC	_	18	cc
26	U251	u251	NN	_	18	conj
27	-RRB-	-rrb-	-RRB-	_	18	punct
28	to	to	TO	_	29	case
29	drug1	drug1	NN	_	2	nmod
30	,	,	,	_	29	punct
31	drug2	drug2	NN	_	29	conj
32	,	,	,	_	29	punct
33	drug3	drug3	NN	_	29	conj
34	and	and	CC	_	29	cc
35	drug4	drug4	NN	_	36	compound
36	drug5	drug5	NN	_	29	conj
37	following	follow	VBG	_	40	case
38	different	different	JJ	_	40	amod
39	incubation	incubation	NN	_	40	compound
40	schedules	schedule	NNS	_	2	nmod
41	were	be	VBD	_	42	auxpass
42	analyzed	analyze	VBN	_	0	ROOT
43	.	.	.	_	42	punct

1	We	we	PRP	_	2	nsubj
2	found	find	VBD	_	0	ROOT
3	antagonism	antagonism	NN	_	2	dobj
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	the	the	DT	_	9	det
8	four	four	CD	_	9	nummod
9	drugs	drug	NNS	_	5	conj
10	in	in	IN	_	14	case
11	the	the	DT	_	14	det
12	breast	breast	NN	_	14	compound
13	cancer	cancer	NN	_	14	compound
14	cells	cell	NNS	_	9	nmod
15	MCF7	mcf7	NN	_	5	dep
16	following	follow	VBG	_	19	case
17	all	all	DT	_	19	det
18	incubation	incubation	NN	_	19	compound
19	schedules	schedule	NNS	_	2	nmod
20	and	and	CC	_	19	cc
21	between	between	IN	_	22	case
22	drug2	drug2	NN	_	19	conj
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	in	in	IN	_	28	case
26	all	all	DT	_	28	det
27	cell	cell	NN	_	28	compound
28	lines	line	NNS	_	22	nmod
29	except	except	IN	_	32	case
30	for	for	IN	_	32	case
31	two	two	CD	_	32	nummod
32	combinations	combination	NNS	_	2	nmod
33	in	in	IN	_	35	case
34	HCT116	hct116	NN	_	35	compound
35	cells	cell	NNS	_	32	nmod
36	.	.	.	_	2	punct

1	drug1	drug1	NN	_	13	nsubj
2	with	with	IN	_	6	case
3	the	the	DT	_	6	det
4	other	other	JJ	_	6	amod
5	three	three	CD	_	6	nummod
6	drugs	drug	NNS	_	1	nmod
7	in	in	IN	_	12	case
8	the	the	DT	_	12	det
9	remaining	remain	VBG	_	12	amod
10	four	four	CD	_	12	nummod
11	cell	cell	NN	_	12	compound
12	lines	line	NNS	_	6	nmod
13	resulted	result	VBD	_	0	ROOT
14	in	in	IN	_	16	case
15	variable	variable	JJ	_	16	amod
16	interactions	interaction	NNS	_	13	nmod
17	.	.	.	_	13	punct

1	Mechanistic	mechanistic	JJ	_	2	amod
2	investigations	investigation	NNS	_	3	nsubj
3	revealed	reveal	VBD	_	0	ROOT
4	that	that	IN	_	6	mark
5	drug1	drug1	NN	_	6	nsubj
6	exerts	exert	VBZ	_	3	ccomp
7	different	different	JJ	_	9	amod
8	molecular	molecular	JJ	_	9	amod
9	effects	effect	NNS	_	6	dobj
10	in	in	IN	_	12	case
11	different	different	JJ	_	12	amod
12	cells	cell	NNS	_	6	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	lines	line	NNS	_	6	nmod
4	,	,	,	_	6	punct
5	it	it	PRP	_	6	nsubj
6	abrogates	abrogate	VBZ	_	0	ROOT
7	the	the	DT	_	10	det
8	drug-induced	drug-induced	JJ	_	10	amod
9	G2/M	g2/m	NN	_	10	compound
10	arrest	arrest	NN	_	6	dobj
11	enhancing	enhance	VBG	_	10	acl
12	pre-mature	pre-mature	JJ	_	13	amod
13	entry	entry	NN	_	11	dobj
14	into	into	IN	_	15	case
15	mitosis	mitosis	NN	_	13	nmod
16	with	with	IN	_	18	case
17	damaged	damaged	JJ	_	18	amod
18	DNA	dna	NN	_	13	nmod
19	thus	thus	RB	_	20	advmod
20	increasing	increase	VBG	_	6	dep
21	apoptosis	apoptosis	NN	_	20	dobj
22	and	and	CC	_	20	cc
23	resulting	result	VBG	_	20	conj
24	in	in	IN	_	25	case
25	synergism	synergism	NN	_	23	nmod
26	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	other	other	JJ	_	3	amod
3	cells	cell	NNS	_	6	nmod
4	,	,	,	_	6	punct
5	it	it	PRP	_	6	nsubj
6	enhances	enhance	VBZ	_	0	ROOT
7	drug-induced	drug-induced	JJ	_	9	amod
8	G2/M	g2/m	NN	_	9	compound
9	arrest	arrest	NN	_	6	dobj
10	allowing	allow	VBG	_	9	acl
11	time	time	NN	_	10	dobj
12	to	to	TO	_	13	mark
13	repair	repair	VB	_	10	xcomp
14	drug-induced	drug-induced	JJ	_	16	amod
15	DNA	dna	NN	_	16	compound
16	damage	damage	NN	_	13	dobj
17	before	before	IN	_	18	case
18	entry	entry	NN	_	13	nmod
19	into	into	IN	_	20	case
20	mitosis	mitosis	NN	_	18	nmod
21	and	and	CC	_	13	cc
22	decreasing	decrease	VBG	_	24	amod
23	cell	cell	NN	_	24	compound
24	death	death	NN	_	13	conj
25	resulting	result	VBG	_	24	acl
26	in	in	IN	_	27	case
27	antagonism	antagonism	NN	_	25	nmod
28	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	some	some	DT	_	4	det
3	synergistic	synergistic	JJ	_	4	amod
4	combinations	combination	NNS	_	13	nmod
5	,	,	,	_	13	punct
6	celecoxib-induced	celecoxib-induced	JJ	_	7	amod
7	abrogation	abrogation	NN	_	13	nsubjpass
8	of	of	IN	_	10	case
9	G2/M	g2/m	NN	_	10	compound
10	arrest	arrest	NN	_	7	nmod
11	was	be	VBD	_	13	auxpass
12	not	not	RB	_	13	neg
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	15	case
15	apoptosis	apoptosis	NN	_	13	nmod
16	but	but	CC	_	15	cc
17	permanent	permanent	JJ	_	18	amod
18	arrest	arrest	NN	_	15	conj
19	in	in	IN	_	21	case
20	G1	g1	NN	_	21	compound
21	phase	phase	NN	_	18	nmod
22	.	.	.	_	13	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	8	nsubj
3	,	,	,	_	8	punct
4	if	if	IN	_	5	mark
5	confirmed	confirm	VBN	_	8	advcl
6	in-vivo	in-vivo	JJ	_	5	xcomp
7	,	,	,	_	8	punct
8	indicate	indicate	VBP	_	0	ROOT
9	that	that	IN	_	15	mark
10	drug1	drug1	NN	_	15	nsubj
11	is	be	VBZ	_	15	cop
12	not	not	RB	_	15	neg
13	a	a	DT	_	15	det
14	suitable	suitable	JJ	_	15	amod
15	chemosensitizer	chemosensitizer	NN	_	8	ccomp
16	for	for	IN	_	18	case
17	breast	breast	NN	_	18	compound
18	cancer	cancer	NN	_	15	nmod
19	or	or	CC	_	18	cc
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	18	conj
22	for	for	IN	_	24	case
23	other	other	JJ	_	24	amod
24	cancers	cancer	NNS	_	21	nmod
25	.	.	.	_	8	punct

1	Moreover	moreover	RB	_	11	advmod
2	,	,	,	_	11	punct
3	combination	combination	NN	_	11	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	tailored	tailor	VBN	_	0	ROOT
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	tumor	tumor	NN	_	15	compound
15	type	type	NN	_	11	nmod
16	,	,	,	_	15	punct
17	drug	drug	NN	_	15	conj
18	and	and	CC	_	15	cc
19	administration	administration	NN	_	20	compound
20	schedule	schedule	NN	_	15	conj
21	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	interaction	interaction	NN	_	1	dep
5	and	and	CC	_	4	cc
6	associated	associate	VBN	_	9	amod
7	gastrointestinal	gastrointestinal	JJ	_	9	amod
8	bleeding	bleeding	NN	_	9	compound
9	risk	risk	NN	_	4	conj
10	in	in	IN	_	13	case
11	a	a	DT	_	13	det
12	case-control	case-control	JJ	_	13	amod
13	study	study	NN	_	1	nmod
14	.	.	.	_	1	punct

1	Bleeding	bleeding	NN	_	9	nsubj
2	is	be	VBZ	_	9	cop
3	the	the	DT	_	9	det
4	most	most	RBS	_	5	advmod
5	common	common	JJ	_	9	amod
6	and	and	CC	_	5	cc
7	worrisome	worrisome	JJ	_	5	conj
8	adverse	adverse	JJ	_	9	amod
9	effect	effect	NN	_	0	ROOT
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	therapy	therapy	NN	_	9	nmod
13	.	.	.	_	9	punct

1	One	one	CD	_	11	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	factors	factor	NNS	_	1	nmod
5	that	that	WDT	_	7	nsubj
6	might	might	MD	_	7	aux
7	increase	increase	VB	_	4	acl:relcl
8	bleeding	bleeding	JJ	_	9	amod
9	risk	risk	NN	_	7	dobj
10	is	be	VBZ	_	11	cop
11	initiation	initiation	NN	_	0	ROOT
12	of	of	IN	_	14	case
13	interacting	interact	VBG	_	14	amod
14	drugs	drug	NNS	_	11	nmod
15	that	that	WDT	_	16	nsubj
16	potentiate	potentiate	VBP	_	14	acl:relcl
17	drug1	drug1	NN	_	16	dobj
18	.	.	.	_	11	punct

1	We	we	PRP	_	2	nsubj
2	sought	seek	VBD	_	0	ROOT
3	to	to	TO	_	4	mark
4	evaluate	evaluate	VB	_	2	xcomp
5	whether	whether	IN	_	10	mark
6	initiation	initiation	NN	_	10	nsubj
7	of	of	IN	_	9	case
8	an	a	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	increases	increase	VBZ	_	4	ccomp
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	14	case
14	hospitalization	hospitalization	NN	_	12	nmod
15	for	for	IN	_	17	case
16	gastrointestinal	gastrointestinal	JJ	_	17	amod
17	bleeding	bleeding	NN	_	12	nmod
18	in	in	IN	_	20	case
19	drug2	drug2	NN	_	20	compound
20	users	user	NNS	_	17	nmod
21	.	.	.	_	2	punct

1	Medicaid	Medicaid	NNP	_	2	nsubj
2	claims	claim	VBZ	_	0	ROOT
3	data	datum	NNS	_	8	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	1999-2005	1999-2005	CD	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	were	be	VBD	_	8	auxpass
8	used	use	VBN	_	2	ccomp
9	to	to	TO	_	10	mark
10	perform	perform	VB	_	8	xcomp
11	an	a	DT	_	14	det
12	observational	observational	JJ	_	14	amod
13	case-control	case-control	JJ	_	14	amod
14	study	study	NN	_	10	dobj
15	nested	nested	JJ	_	14	amod
16	within	within	IN	_	17	case
17	person-time	person-time	JJ	_	15	nmod
18	exposed	expose	VBN	_	17	acl
19	to	to	TO	_	20	mark
20	drug1	drug1	VB	_	18	xcomp
21	in	in	IN	_	24	case
22	those	those	DT	_	24	det
23	18	18	CD	_	24	nummod
24	years	year	NNS	_	20	nmod
25	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	total	total	NN	_	7	nmod
3	,	,	,	_	7	punct
4	430,455	430,455	CD	_	6	nummod
5	drug1	drug1	NN	_	6	compound
6	users	user	NNS	_	7	nsubj
7	contributed	contribute	VBD	_	0	ROOT
8	407,370	407,370	CD	_	9	nummod
9	person-years	person-year	NNS	_	7	dobj
10	of	of	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	use	use	NN	_	9	nmod
13	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	incidence	incidence	NN	_	3	compound
3	rate	rate	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	hospitalization	hospitalization	NN	_	3	nmod
6	for	for	IN	_	8	case
7	GI	gi	NN	_	8	compound
8	bleeding	bleeding	NN	_	3	nmod
9	among	among	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	users	user	NNS	_	8	nmod
12	was	be	VBD	_	3	dep
13	4.48	4.48	CD	_	12	nsubj
14	per	per	IN	_	16	case
15	100	100	CD	_	16	nummod
16	person-years	person-year	NNS	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	95	95	CD	_	19	compound
19	%	%	NN	_	20	amod
20	CI	ci	NN	_	16	dep
21	,	,	,	_	20	punct
22	4.42-4	4.42-4	CD	_	23	nummod
23	.55	.55	CD	_	20	appos
24	-RRB-	-rrb-	-RRB-	_	20	punct
25	.	.	.	_	3	punct

1	Each	each	DT	_	4	det
2	gastrointestinal	gastrointestinal	JJ	_	4	amod
3	bleeding	bleeding	NN	_	4	compound
4	cases	case	NNS	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	matched	match	VBN	_	0	ROOT
7	to	to	TO	_	9	case
8	50	50	CD	_	9	nummod
9	controls	control	NNS	_	6	nmod
10	based	base	VBN	_	13	case
11	on	on	IN	_	13	case
12	index	index	NN	_	13	compound
13	date	date	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	state	state	NN	_	13	conj
16	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	compound
2	users	user	NNS	_	3	nsubj
3	had	have	VBD	_	0	ROOT
4	an	a	DT	_	7	det
5	increased	increase	VBN	_	7	amod
6	odds	odds	NNS	_	7	compound
7	ratio	ratio	NN	_	3	dobj
8	of	of	IN	_	10	case
9	gastrointestinal	gastrointestinal	JJ	_	10	amod
10	bleeding	bleeding	NN	_	7	nmod
11	upon	upon	IN	_	12	case
12	initiation	initiation	NN	_	3	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	OR	or	NN	_	3	dep
17	=	=	JJ	_	16	amod
18	1.73	1.73	CD	_	22	nummod
19	-LSB-	-lsb-	-LRB-	_	22	punct
20	95	95	CD	_	21	compound
21	%	%	NN	_	22	amod
22	CI	ci	NN	_	17	dep
23	,	,	,	_	16	punct
24	1.25-2	1.25-2	CD	_	25	compound
25	.38	.38	CD	_	16	nummod
26	-RSB-	-rsb-	-RRB-	_	16	punct
27	-RRB-	-rrb-	-RRB-	_	16	punct
28	,	,	,	_	3	punct
29	drug3	drug3	NN	_	3	dep
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	OR	or	NN	_	29	appos
32	=	=	JJ	_	31	amod
33	1.63	1.63	CD	_	37	nummod
34	-LSB-	-lsb-	-LRB-	_	37	punct
35	95	95	CD	_	36	compound
36	%	%	NN	_	37	amod
37	CI	ci	NN	_	32	dep
38	,	,	,	_	31	punct
39	1.11-2	1.11-2	CD	_	40	compound
40	.38	.38	CD	_	31	nummod
41	-RSB-	-rsb-	-RRB-	_	31	punct
42	-RRB-	-rrb-	-RRB-	_	31	punct
43	,	,	,	_	29	punct
44	drug4	drug4	NN	_	29	conj
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	OR	or	NN	_	44	appos
47	=	=	JJ	_	46	amod
48	1.64	1.64	CD	_	52	nummod
49	-LSB-	-lsb-	-LRB-	_	52	punct
50	95	95	CD	_	51	compound
51	%	%	NN	_	52	amod
52	CI	ci	NN	_	47	dep
53	,	,	,	_	46	punct
54	1.27-2	1.27-2	CD	_	55	compound
55	.12	.12	CD	_	46	nummod
56	-RSB-	-rsb-	-RRB-	_	46	punct
57	-RRB-	-rrb-	-RRB-	_	46	punct
58	,	,	,	_	29	punct
59	drug5	drug5	NN	_	29	appos
60	-LRB-	-lrb-	-LRB-	_	61	punct
61	OR	or	NN	_	59	dep
62	=	=	JJ	_	61	amod
63	1.47	1.47	CD	_	67	nummod
64	-LSB-	-lsb-	-LRB-	_	67	punct
65	95	95	CD	_	66	compound
66	%	%	NN	_	67	amod
67	CI	ci	NN	_	62	dep
68	,	,	,	_	61	punct
69	1.02-2	1.02-2	CD	_	70	nummod
70	.11	.11	CD	_	61	appos
71	-RSB-	-rsb-	-RRB-	_	61	punct
72	-RRB-	-rrb-	-RRB-	_	29	punct
73	.	.	.	_	3	punct

1	Also	also	RB	_	2	advmod
2	drug1	drug1	NN	_	13	nsubj
3	,	,	,	_	2	punct
4	which	which	WDT	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	believed	believe	VBN	_	2	acl:relcl
8	to	to	TO	_	9	mark
9	interact	interact	VB	_	7	xcomp
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	2	punct
13	increased	increase	VBD	_	0	ROOT
14	the	the	DT	_	15	det
15	risk	risk	NN	_	13	dobj
16	of	of	IN	_	18	case
17	GI	gi	NN	_	18	compound
18	bleeding	bleeding	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	OR	or	NN	_	21	nsubj
21	=	=	JJ	_	13	parataxis
22	1.75	1.75	CD	_	21	dobj
23	-LSB-	-lsb-	-LRB-	_	26	punct
24	95	95	CD	_	25	compound
25	%	%	NN	_	26	amod
26	CI	ci	NN	_	21	dep
27	,	,	,	_	26	punct
28	1.30-2	1.30-2	CD	_	29	nummod
29	.35	.35	CD	_	26	appos
30	-RSB-	-rsb-	-RRB-	_	26	punct
31	-RRB-	-rrb-	-RRB-	_	21	punct
32	.	.	.	_	13	punct

1	drug1	drug1	NN	_	2	compound
2	users	user	NNS	_	15	nsubj
3	who	who	WP	_	4	nsubj
4	initiated	initiate	VBD	_	2	acl:relcl
5	drug2	drug2	NN	_	4	dobj
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug5	drug5	NN	_	5	conj
12	,	,	,	_	5	punct
13	or	or	CC	_	5	cc
14	drug6	drug6	NN	_	5	conj
15	had	have	VBD	_	0	ROOT
16	an	a	DT	_	18	det
17	increased	increase	VBN	_	18	amod
18	risk	risk	NN	_	15	dobj
19	of	of	IN	_	20	case
20	hospitalization	hospitalization	NN	_	18	nmod
21	for	for	IN	_	23	case
22	gastrointestinal	gastrointestinal	JJ	_	23	amod
23	bleeding	bleeding	NN	_	18	nmod
24	.	.	.	_	15	punct

1	However	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	the	the	DT	_	5	det
4	elevated	elevated	JJ	_	5	amod
5	risk	risk	NN	_	8	nsubj
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	suggests	suggest	VBZ	_	0	ROOT
9	that	that	IN	_	17	mark
10	a	a	DT	_	12	det
11	drug-drug	drug-drug	JJ	_	12	amod
12	interaction	interaction	NN	_	17	nsubj
13	may	may	MD	_	17	aux
14	not	not	RB	_	17	neg
15	have	have	VB	_	17	aux
16	been	be	VBN	_	17	cop
17	responsible	responsible	JJ	_	8	ccomp
18	for	for	IN	_	19	case
19	all	all	DT	_	17	nmod
20	of	of	IN	_	22	case
21	the	the	DT	_	22	det
22	observed	observe	VBN	_	19	nmod
23	increased	increase	VBD	_	24	amod
24	risk	risk	NN	_	17	dep
25	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	enhances	enhance	VBZ	_	0	ROOT
3	the	the	DT	_	5	det
4	antinociceptive	antinociceptive	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	in	in	IN	_	9	case
9	mice	mouse	NNS	_	5	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	11	nsubjpass
2	,	,	,	_	1	punct
3	a	a	DT	_	7	det
4	highly	highly	RB	_	5	advmod
5	selective	selective	JJ	_	7	amod
6	alpha-2-adrenoceptor	alpha-2-adrenoceptor	NN	_	7	compound
7	agonist	agonist	NN	_	1	appos
8	,	,	,	_	1	punct
9	was	be	VBD	_	11	auxpass
10	recently	recently	RB	_	11	advmod
11	introduced	introduce	VBN	_	0	ROOT
12	into	into	IN	_	14	case
13	clinical	clinical	JJ	_	14	amod
14	practice	practice	NN	_	11	nmod
15	for	for	IN	_	17	case
16	its	its	PRP$	_	17	nmod:poss
17	sedative	sedative	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	analgesic	analgesic	JJ	_	20	amod
20	properties	property	NNS	_	17	conj
21	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	purpose	purpose	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	xcomp
9	whether	whether	IN	_	14	mark
10	the	the	DT	_	13	det
11	psychostimulant	psychostimulant	NN	_	13	compound
12	drug	drug	NN	_	13	compound
13	drug1	drug1	NN	_	14	nsubj
14	has	have	VBZ	_	8	ccomp
15	any	any	DT	_	16	det
16	effect	effect	NN	_	14	dobj
17	on	on	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	-	-	:	_	8	punct
20	induced	induce	VBN	_	21	amod
21	antinociception	antinociception	NN	_	8	dep
22	and	and	CC	_	21	cc
23	locomotor	locomotor	NN	_	25	compound
24	inhibitor	inhibitor	NN	_	25	compound
25	activity	activity	NN	_	21	conj
26	in	in	IN	_	27	case
27	mice	mouse	NNS	_	21	nmod
28	in	in	IN	_	30	case
29	acute	acute	JJ	_	30	amod
30	application	application	NN	_	21	nmod
31	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	both	both	DT	_	3	det
3	sexes	sex	NNS	_	0	ROOT
4	of	of	IN	_	7	case
5	swiss	swiss	JJ	_	7	amod
6	albino	albino	NN	_	7	compound
7	mice	mouse	NNS	_	3	nmod
8	;	;	:	_	3	punct

1	antinociception	antinociception	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	assessed	assess	VBN	_	14	csubjpass
4	with	with	IN	_	6	case
5	hot-plate	hot-plate	JJ	_	6	amod
6	test	test	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	the	the	DT	_	9	det
9	locomotor	locomotor	NN	_	6	conj
10	,	,	,	_	6	punct
11	exploratory	exploratory	JJ	_	12	amod
12	activities	activity	NNS	_	6	conj
13	were	be	VBD	_	14	auxpass
14	assessed	assess	VBN	_	0	ROOT
15	with	with	IN	_	19	case
16	holed	hole	VBN	_	19	amod
17	open	open	JJ	_	19	amod
18	field	field	NN	_	19	compound
19	test	test	NN	_	14	nmod
20	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	animals	animal	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	received	receive	VBN	_	0	ROOT
5	;	;	:	_	4	punct

1	saline	saline	NN	_	0	ROOT
2	+	+	CC	_	1	cc
3	saline	saline	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug1	drug1	NN	_	1	conj
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	10	10	CD	_	8	nummod
8	mg/kg	mg/kg	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	+	+	CC	_	1	cc
11	saline	saline	NN	_	1	conj
12	,	,	,	_	1	punct
13	saline	saline	NN	_	1	conj
14	+	+	CC	_	1	cc
15	drug2	drug2	NN	_	1	conj
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	15	15	CD	_	18	nummod
18	g/kg	g/kg	NN	_	15	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	and	and	CC	_	1	cc
21	drug3	drug3	NN	_	1	conj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	10	10	CD	_	24	nummod
24	mg/kg	mg/kg	NN	_	21	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	+	+	CC	_	21	cc
27	drug4	drug4	NN	_	21	conj
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	15	15	CD	_	30	nummod
30	g/kg	g/kg	NN	_	27	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	,	,	,	_	1	punct
33	intraperitoneally	intraperitoneally	RB	_	1	dep
34	,	,	,	_	33	punct
35	30	30	CD	_	36	nummod
36	min	min	NN	_	34	root
37	before	before	IN	_	39	case
38	hot	hot	JJ	_	39	amod
39	plate	plate	NN	_	36	nmod
40	or	or	CC	_	36	cc
41	holed	hole	VBD	_	36	conj
42	open	open	JJ	_	44	amod
43	field	field	NN	_	44	compound
44	tests	test	NNS	_	41	dobj
45	.	.	.	_	36	punct

1	In	in	IN	_	5	case
2	the	the	DT	_	5	det
3	hot	hot	JJ	_	5	amod
4	plate	plate	NN	_	5	compound
5	test	test	NN	_	21	nmod
6	in	in	IN	_	7	case
7	mice	mouse	NNS	_	5	nmod
8	,	,	,	_	21	punct
9	co-administration	co-administration	NN	_	21	nsubj
10	of	of	IN	_	13	case
11	15	15	CD	_	13	nummod
12	g/kg	g/kg	NN	_	13	compound
13	drug1	drug1	NN	_	9	nmod
14	with	with	IN	_	17	case
15	10	10	CD	_	17	nummod
16	mg/kg	mg/kg	NN	_	17	compound
17	drug2	drug2	NN	_	9	nmod
18	intraperitoneally	intraperitoneally	RB	_	21	advmod
19	not	not	RB	_	20	neg
20	only	only	RB	_	21	cc:preconj
21	enhanced	enhance	VBN	_	0	ROOT
22	,	,	,	_	21	punct
23	but	but	CC	_	21	cc
24	also	also	RB	_	25	advmod
25	prolonged	prolong	VBD	_	21	conj
26	the	the	DT	_	27	det
27	duration	duration	NN	_	25	dobj
28	of	of	IN	_	29	case
29	antinociception	antinociception	NN	_	27	nmod
30	induced	induce	VBN	_	29	acl
31	by	by	IN	_	32	case
32	drug3	drug3	NN	_	30	nmod
33	.	.	.	_	21	punct

1	At	at	IN	_	4	case
2	the	the	DT	_	4	det
3	same	same	JJ	_	4	amod
4	time	time	NN	_	13	nmod
5	,	,	,	_	13	punct
6	the	the	DT	_	9	det
7	locomotor	locomotor	NN	_	9	compound
8	inhibitory	inhibitory	JJ	_	9	amod
9	effect	effect	NN	_	13	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	was	be	VBD	_	13	auxpass
13	counteracted	counteract	VBN	_	0	ROOT
14	by	by	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	13	punct

1	We	we	PRP	_	2	nsubj
2	concluded	conclude	VBD	_	0	ROOT
3	that	that	IN	_	12	mark
4	the	the	DT	_	6	det
5	combined	combined	JJ	_	6	amod
6	administration	administration	NN	_	12	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	may	may	MD	_	12	aux
12	have	have	VB	_	2	ccomp
13	beneficial	beneficial	JJ	_	14	amod
14	effects	effect	NNS	_	12	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	treatment	treatment	NN	_	12	nmod
18	of	of	IN	_	19	case
19	pain	pain	NN	_	17	nmod
20	without	without	IN	_	21	mark
21	causing	cause	VBG	_	12	advcl
22	sedation	sedation	NN	_	21	dobj
23	,	,	,	_	22	punct
24	which	which	WDT	_	25	nsubj
25	limits	limit	VBZ	_	22	acl:relcl
26	the	the	DT	_	27	det
27	use	use	NN	_	25	dobj
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	as	as	IN	_	32	case
31	an	a	DT	_	32	det
32	drug4	drug4	NN	_	25	nmod
33	in	in	IN	_	34	case
34	humans	human	NNS	_	32	nmod
35	.	.	.	_	2	punct

1	Interaction	interaction	NN	_	2	compound
2	study	study	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	with	with	IN	_	9	case
8	co-administered	co-administered	JJ	_	9	amod
9	drugs	drug	NNS	_	2	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	are	be	VBP	_	5	cop
5	drug3	drug3	NN	_	0	ROOT
6	used	use	VBN	_	5	acl
7	in	in	IN	_	8	mark
8	treating	treat	VBG	_	6	advcl
9	urinary	urinary	JJ	_	13	amod
10	and	and	CC	_	9	cc
11	respiratory	respiratory	JJ	_	9	conj
12	tract	tract	NN	_	13	compound
13	infections	infection	NNS	_	8	dobj
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	have	have	VB	_	3	xcomp
6	interactions	interaction	NNS	_	5	dobj
7	with	with	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	that	that	WDT	_	11	nsubj
10	are	be	VBP	_	11	cop
11	active	active	JJ	_	8	acl:relcl
12	in	in	IN	_	15	case
13	gastro	gastro	NN	_	15	compound
14	intestinal	intestinal	JJ	_	15	amod
15	tract	tract	NN	_	11	nmod
16	.	.	.	_	3	punct

1	Being	be	VBG	_	0	ROOT
2	drug1	drug1	NN	_	8	compound
3	and	and	CC	_	2	cc
4	lomefloxacin	lomefloxacin	NN	_	2	conj
5	drug2	drug2	NN	_	8	compound
6	the	the	DT	_	8	det
7	interaction	interaction	NN	_	8	compound
8	study	study	NN	_	1	dobj
9	of	of	IN	_	11	mark
10	was	be	VBD	_	11	auxpass
11	carried	carry	VBN	_	8	acl
12	out	out	RP	_	11	compound:prt
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	11	nmod
15	,	,	,	_	14	punct
16	drug4	drug4	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug5	drug5	NN	_	14	conj
19	and	and	CC	_	14	cc
20	drug6	drug6	NN	_	14	conj
21	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	studied	study	VBN	_	0	ROOT
5	at	at	IN	_	11	case
6	neutral	neutral	JJ	_	11	amod
7	,	,	,	_	6	punct
8	acidic	acidic	JJ	_	6	conj
9	and	and	CC	_	6	cc
10	basic	basic	JJ	_	6	conj
11	conditions	condition	NNS	_	4	nmod
12	both	both	CC	_	15	cc:preconj
13	at	at	IN	_	15	case
14	room	room	NN	_	15	compound
15	temperature	temperature	NN	_	11	nmod
16	and	and	CC	_	15	cc
17	37	37	CD	_	18	nummod
18	C	c	NN	_	15	conj
19	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	16	nsubjpass
3	of	of	IN	_	5	case
4	dissolution	dissolution	NN	_	5	compound
5	medium	medium	NN	_	2	nmod
6	simulating	simulate	VBG	_	5	acl
7	various	various	JJ	_	9	amod
8	body	body	NN	_	9	compound
9	environments	environment	NNS	_	6	dobj
10	with	with	IN	_	11	case
11	response	response	NN	_	6	nmod
12	to	to	TO	_	13	case
13	pH	ph	NN	_	11	nmod
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	examined	examine	VBN	_	0	ROOT
17	in	in	IN	_	20	mark
18	order	order	NN	_	17	mwe
19	to	to	TO	_	20	mark
20	elucidate	elucidate	VB	_	16	advcl
21	the	the	DT	_	22	det
22	interactions	interaction	NNS	_	20	dobj
23	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	response	response	NN	_	18	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	after	after	IN	_	8	case
8	interaction	interaction	NN	_	2	nmod
9	with	with	IN	_	11	case
10	co-administered	co-administered	JJ	_	11	amod
11	drugs	drug	NNS	_	8	nmod
12	at	at	IN	_	14	case
13	different	different	JJ	_	14	amod
14	conditions	condition	NNS	_	8	nmod
15	and	and	CC	_	14	cc
16	temperature	temperature	NN	_	14	conj
17	were	be	VBD	_	18	auxpass
18	noted	note	VBN	_	0	ROOT
19	using	use	VBG	_	18	xcomp
20	a	a	DT	_	23	det
21	Shimadzu	Shimadzu	NNP	_	23	compound
22	HPLC	hplc	NN	_	23	compound
23	system	system	NN	_	19	dobj
24	with	with	IN	_	26	case
25	PDA	pda	NN	_	26	compound
26	detector	detector	NN	_	23	nmod
27	.	.	.	_	18	punct

1	It	it	PRP	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	seen	see	VBN	_	0	ROOT
4	that	that	IN	_	13	mark
5	interaction	interaction	NN	_	13	nsubj
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	drug1	drug1	NN	_	5	nmod
9	was	be	VBD	_	13	cop
10	more	more	RBR	_	13	advmod
11	at	at	IN	_	13	case
12	37	37	CD	_	13	nummod
13	C	c	NN	_	3	ccomp
14	than	than	IN	_	17	case
15	at	at	IN	_	17	case
16	room	room	NN	_	17	compound
17	temperature	temperature	NN	_	13	nmod
18	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	reacts	react	VBZ	_	0	ROOT
5	faster	faster	RBR	_	4	advmod
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	drug4	drug4	NN	_	7	conj
10	in	in	IN	_	12	case
11	acidic	acidic	JJ	_	12	amod
12	media	media	NNS	_	7	nmod
13	whereas	whereas	IN	_	4	dep
14	with	with	IN	_	15	case
15	drug5	drug5	NN	_	13	nmod
16	in	in	IN	_	18	case
17	basic	basic	JJ	_	18	amod
18	media	media	NNS	_	15	nmod
19	and	and	CC	_	18	cc
20	drug6	drug6	NN	_	18	conj
21	in	in	IN	_	23	case
22	neutral	neutral	JJ	_	23	amod
23	media	media	NNS	_	18	nmod
24	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	ensures	ensure	VBZ	_	0	ROOT
4	the	the	DT	_	5	det
5	interaction	interaction	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	10	case
9	selected	select	VBN	_	10	amod
10	class	class	NN	_	5	nmod
11	of	of	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	achieve	achieve	VB	_	0	ROOT
5	the	the	DT	_	8	det
6	effective	effective	JJ	_	8	amod
7	therapeutic	therapeutic	JJ	_	8	amod
8	effect	effect	NN	_	4	dobj
9	appropriate	appropriate	JJ	_	11	amod
10	time	time	NN	_	11	compound
11	intervals	interval	NNS	_	17	nsubj
12	between	between	IN	_	13	case
13	administrations	administration	NNS	_	11	nmod
14	of	of	IN	_	15	case
15	drugs	drug	NNS	_	13	nmod
16	is	be	VBZ	_	17	cop
17	essential	essential	JJ	_	8	acl:relcl
18	.	.	.	_	4	punct

